CA2785046C - Polynucleotides and polypeptide sequences involved in the process of bone remodeling - Google Patents
Polynucleotides and polypeptide sequences involved in the process of bone remodeling Download PDFInfo
- Publication number
- CA2785046C CA2785046C CA2785046A CA2785046A CA2785046C CA 2785046 C CA2785046 C CA 2785046C CA 2785046 A CA2785046 A CA 2785046A CA 2785046 A CA2785046 A CA 2785046A CA 2785046 C CA2785046 C CA 2785046C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- analog
- osteoclast
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 314
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 304
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 295
- 238000000034 method Methods 0.000 title claims abstract description 168
- 230000010072 bone remodeling Effects 0.000 title claims abstract description 78
- 102000040430 polynucleotide Human genes 0.000 title abstract description 222
- 108091033319 polynucleotide Proteins 0.000 title abstract description 222
- 239000002157 polynucleotide Substances 0.000 title abstract description 221
- 230000008569 process Effects 0.000 title abstract description 23
- 210000002997 osteoclast Anatomy 0.000 claims abstract description 391
- 230000000694 effects Effects 0.000 claims abstract description 54
- 210000004027 cell Anatomy 0.000 claims description 209
- 230000014509 gene expression Effects 0.000 claims description 201
- 239000002243 precursor Substances 0.000 claims description 127
- 230000004069 differentiation Effects 0.000 claims description 111
- 150000001875 compounds Chemical class 0.000 claims description 57
- 230000002401 inhibitory effect Effects 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 27
- 238000000338 in vitro Methods 0.000 claims description 15
- 108020004459 Small interfering RNA Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000009467 reduction Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000001419 dependent effect Effects 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 10
- 206010065687 Bone loss Diseases 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000004055 small Interfering RNA Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 52
- 201000010099 disease Diseases 0.000 abstract description 30
- 230000001225 therapeutic effect Effects 0.000 abstract description 17
- 239000000203 mixture Substances 0.000 abstract description 14
- 230000002068 genetic effect Effects 0.000 abstract description 13
- 238000002955 isolation Methods 0.000 abstract description 8
- 238000010200 validation analysis Methods 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 description 273
- 210000001519 tissue Anatomy 0.000 description 112
- 238000009396 hybridization Methods 0.000 description 100
- 102000004169 proteins and genes Human genes 0.000 description 82
- 235000018102 proteins Nutrition 0.000 description 79
- 239000012634 fragment Substances 0.000 description 64
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 58
- 235000001014 amino acid Nutrition 0.000 description 53
- 239000002299 complementary DNA Substances 0.000 description 52
- 230000006870 function Effects 0.000 description 49
- 239000002773 nucleotide Substances 0.000 description 49
- 125000003729 nucleotide group Chemical group 0.000 description 48
- 108020004414 DNA Proteins 0.000 description 44
- 150000001413 amino acids Chemical class 0.000 description 44
- 230000000295 complement effect Effects 0.000 description 44
- 239000013598 vector Substances 0.000 description 44
- 229940024606 amino acid Drugs 0.000 description 43
- 239000000523 sample Substances 0.000 description 43
- 108020004999 messenger RNA Proteins 0.000 description 42
- 230000003827 upregulation Effects 0.000 description 39
- 238000006467 substitution reaction Methods 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 241000124008 Mammalia Species 0.000 description 26
- 230000027455 binding Effects 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 108700026244 Open Reading Frames Proteins 0.000 description 22
- 210000000988 bone and bone Anatomy 0.000 description 22
- 238000003556 assay Methods 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- 208000020084 Bone disease Diseases 0.000 description 19
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 19
- 208000006386 Bone Resorption Diseases 0.000 description 18
- 230000024279 bone resorption Effects 0.000 description 18
- 230000004048 modification Effects 0.000 description 18
- 238000012986 modification Methods 0.000 description 18
- 102000014128 RANK Ligand Human genes 0.000 description 17
- 108010025832 RANK Ligand Proteins 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- 230000009918 complex formation Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 239000013615 primer Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 208000001132 Osteoporosis Diseases 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 210000004962 mammalian cell Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 108010029485 Protein Isoforms Proteins 0.000 description 11
- 102000001708 Protein Isoforms Human genes 0.000 description 11
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 10
- 208000024883 bone remodeling disease Diseases 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- 230000009368 gene silencing by RNA Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 108020004635 Complementary DNA Proteins 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 206010020850 Hyperthyroidism Diseases 0.000 description 9
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 9
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 9
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 9
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000013610 patient sample Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 230000009261 transgenic effect Effects 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 208000014311 Cushing syndrome Diseases 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 210000003238 esophagus Anatomy 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 208000005368 osteomalacia Diseases 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 7
- -1 queosine Chemical compound 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 208000010191 Osteitis Deformans Diseases 0.000 description 6
- 208000027868 Paget disease Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 208000027202 mammary Paget disease Diseases 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 5
- 102100026897 Cystatin-C Human genes 0.000 description 5
- 238000000018 DNA microarray Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- 102100022297 Integrin alpha-X Human genes 0.000 description 5
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 208000029725 Metabolic bone disease Diseases 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000013614 RNA sample Substances 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000004404 adrenal cortex Anatomy 0.000 description 5
- 230000001919 adrenal effect Effects 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 210000003679 cervix uteri Anatomy 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000002132 lysosomal effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 210000003101 oviduct Anatomy 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108091006112 ATPases Proteins 0.000 description 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 4
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 description 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 4
- 102000055006 Calcitonin Human genes 0.000 description 4
- 108060001064 Calcitonin Proteins 0.000 description 4
- 101710167917 Carbonic anhydrase 2 Proteins 0.000 description 4
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 4
- 208000026019 Fanconi renotubular syndrome Diseases 0.000 description 4
- 101800002068 Galanin Proteins 0.000 description 4
- 102400001370 Galanin Human genes 0.000 description 4
- 208000015872 Gaucher disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 101000844213 Homo sapiens Thioredoxin domain-containing protein 17 Proteins 0.000 description 4
- 206010020564 Hyperadrenocorticism Diseases 0.000 description 4
- 208000037147 Hypercalcaemia Diseases 0.000 description 4
- 201000002980 Hyperparathyroidism Diseases 0.000 description 4
- 208000013038 Hypocalcemia Diseases 0.000 description 4
- 206010058359 Hypogonadism Diseases 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- 208000001826 Marfan syndrome Diseases 0.000 description 4
- 206010027294 Menkes' syndrome Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 4
- 206010049088 Osteopenia Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 4
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 108010039518 Proton-Translocating ATPases Proteins 0.000 description 4
- 102000015176 Proton-Translocating ATPases Human genes 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 102100029608 Sorting nexin-10 Human genes 0.000 description 4
- 101710182523 Sorting nexin-10 Proteins 0.000 description 4
- 201000008736 Systemic mastocytosis Diseases 0.000 description 4
- 102100032035 Thioredoxin domain-containing protein 17 Human genes 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 201000008101 adult hypophosphatasia Diseases 0.000 description 4
- 229940062527 alendronate Drugs 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 4
- 229960004015 calcitonin Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 201000010073 fibrogenesis imperfecta ossium Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000000148 hypercalcaemia Effects 0.000 description 4
- 208000030915 hypercalcemia disease Diseases 0.000 description 4
- 230000000705 hypocalcaemia Effects 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000001630 jejunum Anatomy 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 201000010108 pycnodysostosis Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000003705 ribosome Anatomy 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 208000007442 rickets Diseases 0.000 description 4
- 229940089617 risedronate Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 208000005057 thyrotoxicosis Diseases 0.000 description 4
- 210000003437 trachea Anatomy 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 101710112067 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- 102100028699 C-type lectin domain family 4 member E Human genes 0.000 description 3
- 102000004631 Calcineurin Human genes 0.000 description 3
- 108010042955 Calcineurin Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102100024940 Cathepsin K Human genes 0.000 description 3
- 108010014421 Chemokine CXCL5 Proteins 0.000 description 3
- 102000016948 Chemokine CXCL5 Human genes 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108010005843 Cysteine Proteases Proteins 0.000 description 3
- 102000005927 Cysteine Proteases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100032222 Emopamil-binding protein-like Human genes 0.000 description 3
- 101710094225 Emopamil-binding protein-like Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 3
- 208000005050 Familial Hypophosphatemic Rickets Diseases 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000766921 Homo sapiens C-type lectin domain family 4 member E Proteins 0.000 description 3
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 3
- 101000912205 Homo sapiens Cystatin-C Proteins 0.000 description 3
- 101000835787 Homo sapiens Tudor domain-containing protein 3 Proteins 0.000 description 3
- 244000025221 Humulus lupulus Species 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- 101710117505 Integrin beta-1-binding protein 1 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 101710014005 KIAA0040 Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010083204 Proton Pumps Proteins 0.000 description 3
- 102000006270 Proton Pumps Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000000583 SNARE Proteins Human genes 0.000 description 3
- 108010041948 SNARE Proteins Proteins 0.000 description 3
- 108700015968 Slam family Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 102100026362 Tudor domain-containing protein 3 Human genes 0.000 description 3
- 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 description 3
- 101710178436 Tumor necrosis factor receptor superfamily member 11A Proteins 0.000 description 3
- 208000026928 Turner syndrome Diseases 0.000 description 3
- 102100037162 Uncharacterized protein KIAA0040 Human genes 0.000 description 3
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
- 208000031878 X-linked hypophosphatemia Diseases 0.000 description 3
- 208000035724 X-linked hypophosphatemic rickets Diseases 0.000 description 3
- 101150016810 YKT6 gene Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000123 anti-resoprtive effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 239000002617 bone density conservation agent Substances 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 230000018678 bone mineralization Effects 0.000 description 3
- 208000019664 bone resorption disease Diseases 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000003200 chromosome mapping Methods 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 201000010384 renal tubular acidosis Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000014848 ubiquitin-dependent protein catabolic process Effects 0.000 description 3
- 101150096322 ANKH gene Proteins 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 208000008822 Ankylosis Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100025805 Cadherin-1 Human genes 0.000 description 2
- 102100027557 Calcipressin-1 Human genes 0.000 description 2
- 108010001789 Calcitonin Receptors Proteins 0.000 description 2
- 102100038520 Calcitonin receptor Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 108090000625 Cathepsin K Proteins 0.000 description 2
- 102000004171 Cathepsin K Human genes 0.000 description 2
- 108010061642 Cystatin C Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 101710205374 Extracellular elastase Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101100382253 Homo sapiens CDH1 gene Proteins 0.000 description 2
- 101000580357 Homo sapiens Calcipressin-1 Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 2
- 101000633613 Homo sapiens Probable threonine protease PRSS50 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- 101000948324 Homo sapiens Protein CutA Proteins 0.000 description 2
- 101000594428 Homo sapiens Protein N-lysine methyltransferase METTL21A Proteins 0.000 description 2
- 101000614095 Homo sapiens Proton-activated chloride channel Proteins 0.000 description 2
- 101000744542 Homo sapiens Ras-related protein Rab-33A Proteins 0.000 description 2
- 101000760210 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 12 Proteins 0.000 description 2
- 101000772904 Homo sapiens Ubiquitin-conjugating enzyme E2 D1 Proteins 0.000 description 2
- 101000644655 Homo sapiens Ubiquitin-conjugating enzyme E2 E1 Proteins 0.000 description 2
- 101000644661 Homo sapiens Ubiquitin-conjugating enzyme E2 E3 Proteins 0.000 description 2
- 101000855256 Homo sapiens Uncharacterized protein C16orf74 Proteins 0.000 description 2
- 101000854873 Homo sapiens V-type proton ATPase 116 kDa subunit a 4 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 101710123028 Integrin alpha-X Proteins 0.000 description 2
- 102100033335 Integrin beta-1-binding protein 1 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010023198 Joint ankylosis Diseases 0.000 description 2
- 102000013960 Jun dimerization protein 2 Human genes 0.000 description 2
- 108050003784 Jun dimerization protein 2 Proteins 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102100029523 Probable threonine protease PRSS50 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102100036046 Protein CutA Human genes 0.000 description 2
- 102100035607 Protein N-lysine methyltransferase METTL21A Human genes 0.000 description 2
- 102100040631 Proton-activated chloride channel Human genes 0.000 description 2
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 102100039761 Ras-related protein Rab-33A Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 102000004531 Selenoprotein P Human genes 0.000 description 2
- 102100023843 Selenoprotein P Human genes 0.000 description 2
- 108010042443 Selenoprotein P Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 2
- 102100024662 Ubiquitin carboxyl-terminal hydrolase 12 Human genes 0.000 description 2
- 102100030433 Ubiquitin-conjugating enzyme E2 D1 Human genes 0.000 description 2
- 102100020711 Ubiquitin-conjugating enzyme E2 E1 Human genes 0.000 description 2
- 102100020709 Ubiquitin-conjugating enzyme E2 E3 Human genes 0.000 description 2
- 102100026591 Uncharacterized protein C16orf74 Human genes 0.000 description 2
- 102100020737 V-type proton ATPase 116 kDa subunit a 4 Human genes 0.000 description 2
- 108010037026 Vacuolar Proton-Translocating ATPases Proteins 0.000 description 2
- 102000011731 Vacuolar Proton-Translocating ATPases Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 235000020964 calcitriol Nutrition 0.000 description 2
- 239000011612 calcitriol Substances 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000963 caseinolytic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 208000024637 distal renal tubular acidosis Diseases 0.000 description 2
- 238000007878 drug screening assay Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000012909 foetal bovine serum Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004079 mineral homeostasis Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000001721 multinucleated osteoclast Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 208000002865 osteopetrosis Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 125000006853 reporter group Chemical group 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 229940016590 sarkosyl Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 235000016491 selenocysteine Nutrition 0.000 description 2
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 239000001433 sodium tartrate Substances 0.000 description 2
- 229960002167 sodium tartrate Drugs 0.000 description 2
- 235000011004 sodium tartrates Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000005758 transcription activity Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 230000028973 vesicle-mediated transport Effects 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- 102100031765 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Human genes 0.000 description 1
- IEXIHWCBQMQDHC-KEIUHOJNSA-N 5,9-hexacosadienoic acid Chemical compound CCCCCCCCCCCCCCCC\C=C\CC\C=C\CCCC(O)=O IEXIHWCBQMQDHC-KEIUHOJNSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100034163 Alpha-actinin-1 Human genes 0.000 description 1
- 101710115082 Alpha-actinin-1 Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 101000956243 Arabidopsis thaliana CSC1-like protein HYP1 Proteins 0.000 description 1
- 101000912181 Arabidopsis thaliana Cysteine synthase, mitochondrial Proteins 0.000 description 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100024630 Asc-type amino acid transporter 1 Human genes 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 101150049479 CCNC gene Proteins 0.000 description 1
- 101150002460 COQ4 gene Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 102000000389 Calcipressin-1 Human genes 0.000 description 1
- 108050008834 Calcipressin-1 Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710104415 Cartilage-associated protein Proteins 0.000 description 1
- 102100027848 Cartilage-associated protein Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108030001126 Cholestenol Delta-isomerases Proteins 0.000 description 1
- 102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 102100022874 Dexamethasone-induced Ras-related protein 1 Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 102100038509 E3 ubiquitin-protein ligase ARIH1 Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100039578 ETS translocation variant 4 Human genes 0.000 description 1
- DWAWDSVKAUWFHC-UHFFFAOYSA-N Emopamil Chemical compound C=1C=CC=CC=1C(C(C)C)(C#N)CCCN(C)CCC1=CC=CC=C1 DWAWDSVKAUWFHC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000630879 Guyu Species 0.000 description 1
- 102100039856 Histone H1.1 Human genes 0.000 description 1
- 101000859758 Homo sapiens Cartilage-associated protein Proteins 0.000 description 1
- 101000641221 Homo sapiens Chromaffin granule amine transporter Proteins 0.000 description 1
- 101000620808 Homo sapiens Dexamethasone-induced Ras-related protein 1 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000808922 Homo sapiens E3 ubiquitin-protein ligase ARIH1 Proteins 0.000 description 1
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 101001035402 Homo sapiens Histone H1.1 Proteins 0.000 description 1
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001055216 Homo sapiens Interleukin-9 Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000996935 Homo sapiens Putative oxidoreductase GLYR1 Proteins 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 101000709472 Homo sapiens Sialic acid-binding Ig-like lectin 15 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 102100026871 Interleukin-9 Human genes 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000859702 Mus musculus Cartilage-associated protein Proteins 0.000 description 1
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 1
- 101100017009 Mus musculus Hhat gene Proteins 0.000 description 1
- 101100369238 Mus musculus Tgtp2 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 101150043994 NOS1 gene Proteins 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108700000193 Osteopetrosis with renal tubular acidosis Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- SVXXJYJCRNKDDE-AVGNSLFASA-N Pro-Pro-His Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CN=CN1 SVXXJYJCRNKDDE-AVGNSLFASA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101000798993 Pseudomonas putida (strain ATCC 700007 / DSM 6899 / BCRC 17059 / F1) 2-hydroxy-6-oxo-2,4-heptadienoate hydrolase Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 102100034301 Putative oxidoreductase GLYR1 Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 101001044101 Rattus norvegicus Lipopolysaccharide-induced tumor necrosis factor-alpha factor homolog Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 108091006242 SLC7A10 Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000008114 Selenoproteins Human genes 0.000 description 1
- 108010074686 Selenoproteins Proteins 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 102100034361 Sialic acid-binding Ig-like lectin 15 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000009322 Tudor domains Human genes 0.000 description 1
- 108050000178 Tudor domains Proteins 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- AUYLVPGDOVEOML-UHFFFAOYSA-N [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(piperidin-1-ylmethoxy)phenyl]methanone Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 AUYLVPGDOVEOML-UHFFFAOYSA-N 0.000 description 1
- WCHSQACWYIQTKL-XPWFQUROSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 WCHSQACWYIQTKL-XPWFQUROSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000012082 adaptor molecule Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 201000003294 autosomal recessive osteopetrosis 3 Diseases 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000001126 calcilytic effect Effects 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000006507 cellular pH homeostasis Effects 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 229950009967 emopamil Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000002411 hand bone Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 102000046955 human CRTAP Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108010088383 interleukin-6 receptor alpha Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000865 membrane-inlet mass spectrometry Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000027361 mineral metabolism disease Diseases 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- WWHFPJVBJUJTEA-UHFFFAOYSA-N n'-[3-chloro-4,5-bis(prop-2-ynoxy)phenyl]-n-methoxymethanimidamide Chemical compound CONC=NC1=CC(Cl)=C(OCC#C)C(OCC#C)=C1 WWHFPJVBJUJTEA-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- SBUYBNIDQXQZSZ-UHFFFAOYSA-N p-aminophenylphosphocholine Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC1=CC=C(N)C=C1 SBUYBNIDQXQZSZ-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000005238 principal cell Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 150000003345 selenocysteines Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.
Description
2 POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN THE
PROCESS OF BONE REMODELING
FIELD OF THE INVENTION
This invention relates, in part. to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides polypeptides, variants and derivatives, methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. including but not limited to osteoporosis, osteopenia, osteomalacia. hyperparathyroidism, hypothyroidism, hyperthyroidism, hypogonadism, thyrotoxicosis, systemic mastocytosis, adult hypophosphatasia, hyperadrenocorticism, osteogenesis imperfecta, Paget's disease, Cushing's disease/syndrome, Turner syndrome, Gaucher disease, Ehlers-Danlos syndrome, Marfan's syndrome, Menkes' syndrome, Fanconi's syndrome, multiple myeloma, hypercalcemia, hypocalcemia, arthritides, periodontal disease, rickets (including vitamin D dependent, type I and II, and x-linked hypophosphatemic rickets), fibrogenesis imperfecta ossium, osteosclerotic disorders such as pycnodysostosis and damage caused by macrophage-mediated inflammatory processes.
In particular, this invention relates to polynucleotide expression profiles of active osteoclasts. the isolation and identification of polynucleotides.
polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides. variants and derivatives for the amelioration of disease states and research purposes. as well as in diagnosis of disease states or in the predisposition to .. develop same, BACKGROUND OF THE INVENTION
Bone is a dynamic connective tissue comprised of functionally distinct cell populations required to support the structural, mechanical and biochemical integrity of .. bone and the human body's mineral homeostasis. The principal cell types involved include, osteoblasts responsible for bone formation and maintaining bone mass, and osteoclasts responsible for bone resorption. Osteoblasts and osteoclasts function in a dynamic process termed bone remodeling. The development and proliferation of these cells from their progenitors is governed by networks of growth factors and cytokines produced in the bone microenvironment as well as by systemic hormones. Bone remodeling is ongoing throughout the lifetime of the individual and is necessary for the maintenance of healthy bone tissue and mineral homeostasis. The process remains largely in equilibrium and is governed by a complex interplay of systemic hormones, peptides and downstream signalling pathway proteins, local transcription factors.
cytokines, growth factors and matrix remodeling genes.
Any interference or imbalance arising in the bone remodeling process can produce skeletal disease, with the most common skeletal disorders characterized by a net decrease in bone mass. A primary cause of this reduction in bone mass is an increase in osteoclast number and/or activity, The most common of such disease, and perhaps the best known, is osteoporosis occurring particularly in women after the onset of menopause. In fact osteoporosis is the most significant underlying cause of skeletal fractures in late middle-aged and elderly women. While estrogen deficiency has been strongly implicated as a factor in postmenopausal osteoporosis. there is longstanding evidence that remodeling is a locally controlled process being that it takes place in discrete packets throughout the skeleton as first described by Frost over forty years ago (Frost H.M. 1964).
Since bone remodeling takes place in discrete packets, locally produced hormones and enzymes may be more important than systemic hormones for the initiation of bone resorption and the normal remodeling process. Such local control is mediated by osteoblasts and osteoclasts in the microenvironment in which they operate. For example, osteoclasts attach to the bone matrix and form a separate compartment between themselves and the bone surface delimited by a sealing zone formed by a ring of actin surrounding the ruffled border, Multiple small vesicles transport enzymes toward the bone matrix and internalize partially digested bone matrix_ The microenvironment within the sealing zone is rich with the presence of lysosomal enzymes and is highly acidic compared to the normal physiological pH
of the body, The ruffled border membrane also expresses RANK, the receptor for RANKL, and macrophage-colony stimulating factor (M-CSF) receptor, both of which are responsible for osteoclast differentiation, as well as the calcitonin receptor capable of rapidly inactivating the osteoclast (Baron. R. 2003).
PROCESS OF BONE REMODELING
FIELD OF THE INVENTION
This invention relates, in part. to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides polypeptides, variants and derivatives, methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. including but not limited to osteoporosis, osteopenia, osteomalacia. hyperparathyroidism, hypothyroidism, hyperthyroidism, hypogonadism, thyrotoxicosis, systemic mastocytosis, adult hypophosphatasia, hyperadrenocorticism, osteogenesis imperfecta, Paget's disease, Cushing's disease/syndrome, Turner syndrome, Gaucher disease, Ehlers-Danlos syndrome, Marfan's syndrome, Menkes' syndrome, Fanconi's syndrome, multiple myeloma, hypercalcemia, hypocalcemia, arthritides, periodontal disease, rickets (including vitamin D dependent, type I and II, and x-linked hypophosphatemic rickets), fibrogenesis imperfecta ossium, osteosclerotic disorders such as pycnodysostosis and damage caused by macrophage-mediated inflammatory processes.
In particular, this invention relates to polynucleotide expression profiles of active osteoclasts. the isolation and identification of polynucleotides.
polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides. variants and derivatives for the amelioration of disease states and research purposes. as well as in diagnosis of disease states or in the predisposition to .. develop same, BACKGROUND OF THE INVENTION
Bone is a dynamic connective tissue comprised of functionally distinct cell populations required to support the structural, mechanical and biochemical integrity of .. bone and the human body's mineral homeostasis. The principal cell types involved include, osteoblasts responsible for bone formation and maintaining bone mass, and osteoclasts responsible for bone resorption. Osteoblasts and osteoclasts function in a dynamic process termed bone remodeling. The development and proliferation of these cells from their progenitors is governed by networks of growth factors and cytokines produced in the bone microenvironment as well as by systemic hormones. Bone remodeling is ongoing throughout the lifetime of the individual and is necessary for the maintenance of healthy bone tissue and mineral homeostasis. The process remains largely in equilibrium and is governed by a complex interplay of systemic hormones, peptides and downstream signalling pathway proteins, local transcription factors.
cytokines, growth factors and matrix remodeling genes.
Any interference or imbalance arising in the bone remodeling process can produce skeletal disease, with the most common skeletal disorders characterized by a net decrease in bone mass. A primary cause of this reduction in bone mass is an increase in osteoclast number and/or activity, The most common of such disease, and perhaps the best known, is osteoporosis occurring particularly in women after the onset of menopause. In fact osteoporosis is the most significant underlying cause of skeletal fractures in late middle-aged and elderly women. While estrogen deficiency has been strongly implicated as a factor in postmenopausal osteoporosis. there is longstanding evidence that remodeling is a locally controlled process being that it takes place in discrete packets throughout the skeleton as first described by Frost over forty years ago (Frost H.M. 1964).
Since bone remodeling takes place in discrete packets, locally produced hormones and enzymes may be more important than systemic hormones for the initiation of bone resorption and the normal remodeling process. Such local control is mediated by osteoblasts and osteoclasts in the microenvironment in which they operate. For example, osteoclasts attach to the bone matrix and form a separate compartment between themselves and the bone surface delimited by a sealing zone formed by a ring of actin surrounding the ruffled border, Multiple small vesicles transport enzymes toward the bone matrix and internalize partially digested bone matrix_ The microenvironment within the sealing zone is rich with the presence of lysosomal enzymes and is highly acidic compared to the normal physiological pH
of the body, The ruffled border membrane also expresses RANK, the receptor for RANKL, and macrophage-colony stimulating factor (M-CSF) receptor, both of which are responsible for osteoclast differentiation, as well as the calcitonin receptor capable of rapidly inactivating the osteoclast (Baron. R. 2003).
3 In a complex pattern of inhibition and stimulation not yet fully understood, growth hormone, insulin-like growth factor-1, the sex steroids, thyroid hormone, calciotrophic hormones such as PTH and prostaglandin E2, various cytokines, such as interleukin-1 beta, interleukin-6, and tumour necrosis factor-alpha, and 1,25-dihydroxyvitamin D (calcitriol) act co-ordinately in the bone remodeling process (Jilka et al. 1992; Poli et al. 1994; Srivastava et al. 1998; de Vemejoul 1996).
Thus, it stands to reason that the unique local environments created by these specialized cells is due to the expression of either unique genetic sequences not expressed in other tissues and/or splice variants of polynucleotides and polypeptides expressed in other tissues. The isolation and identification of polynucleotides, polypeptides and their variants and derivatives specific to osteoclast activity will permit a clearer understanding of the remodeling process and offer tissue specific therapeutic targets for the treatment of disease states related to bone remodeling.
Many diseases linked to bone remodeling are poorly understood, generally untreatable or treatable only to a limited extent. For example, osteoarthritis is difficult to treat as there is no cure and treatment focuses on relieving pain and preventing the affected joint from becoming deformed. Non-steroidal anti-inflammatory drugs (NSAIDs) are generally used to relieve pain.
Another example is osteoporosis where the only current medications approved by the FDA for use in the United States are the anti-resorptive agents that prevent bone breakdown. Estrogen replacement therapy is one example of an anti-resorptive agent. Others include alendronate (FosamaxTM- a biphosphonate anti-resorptive), risedronate (ActonelTM - a bisphosphonate anti-resorptive), raloxifene (EvistaTM- selective estrogen receptor modulator (SERM)), calcitonin (CalcimarTM- a hormone), and parathyroid hormone/teriparatide (ForteoTM- a synthetic version of the human hormone, parathyroid hormone, which helps to regulate calcium metabolism).
Bisphosphonates such as alendronate and risedronate bind permanently to the surface of bone and interfere with osteoclast activity. This allows the osteoblasts to outpace the rate of resorption. The most common side effects are nausea, abdominal pain and loose bowel movements. However, alendronate is reported to also cause irritation and inflammation of the esophagus, and in some cases, ulcers of the esophagus. Risedronate is chemically different from alendronate and has less likelihood of causing esophagus irritation. However, certain foods, calcium, iron
Thus, it stands to reason that the unique local environments created by these specialized cells is due to the expression of either unique genetic sequences not expressed in other tissues and/or splice variants of polynucleotides and polypeptides expressed in other tissues. The isolation and identification of polynucleotides, polypeptides and their variants and derivatives specific to osteoclast activity will permit a clearer understanding of the remodeling process and offer tissue specific therapeutic targets for the treatment of disease states related to bone remodeling.
Many diseases linked to bone remodeling are poorly understood, generally untreatable or treatable only to a limited extent. For example, osteoarthritis is difficult to treat as there is no cure and treatment focuses on relieving pain and preventing the affected joint from becoming deformed. Non-steroidal anti-inflammatory drugs (NSAIDs) are generally used to relieve pain.
Another example is osteoporosis where the only current medications approved by the FDA for use in the United States are the anti-resorptive agents that prevent bone breakdown. Estrogen replacement therapy is one example of an anti-resorptive agent. Others include alendronate (FosamaxTM- a biphosphonate anti-resorptive), risedronate (ActonelTM - a bisphosphonate anti-resorptive), raloxifene (EvistaTM- selective estrogen receptor modulator (SERM)), calcitonin (CalcimarTM- a hormone), and parathyroid hormone/teriparatide (ForteoTM- a synthetic version of the human hormone, parathyroid hormone, which helps to regulate calcium metabolism).
Bisphosphonates such as alendronate and risedronate bind permanently to the surface of bone and interfere with osteoclast activity. This allows the osteoblasts to outpace the rate of resorption. The most common side effects are nausea, abdominal pain and loose bowel movements. However, alendronate is reported to also cause irritation and inflammation of the esophagus, and in some cases, ulcers of the esophagus. Risedronate is chemically different from alendronate and has less likelihood of causing esophagus irritation. However, certain foods, calcium, iron
4 supplements, vitamins and minerals, or antacids containing calcium, magnesium, or aluminum can reduce the absorption of risedronate, thereby resulting in loss of effectiveness.
The most common side effect of Raloxifen and other SERMS (such as Tamoxifen) are hot flashes. However, Raloxifene and other hormone replacement therapies have been shown to increase the risk of blood clots, including deep vein thrombosis and pulmonary embolism, cardiovascular disease and cancer.
Calcitonin is not as effective in increasing bone density and strengthening bone as estrogen and the other anti-resorptive agents. Common side effects of either injected or nasal spray calcitonin are nausea and flushing. Patients can develop nasal irritations, a runny nose, or nosebleeds. Injectable calcitonin can cause local skin redness at the site of injection, skin rash, and flushing.
A situation demonstrative of the link between several disorders or disease states involving bone remodeling is that of the use of etidronate (DidronelTM) first approved by the FDA to treat Paget's disease. Paget's disease is a bone disease characterized by a disorderly and accelerated remodeling of the bone, leading to bone weakness and pain. DidronelTM has been used 'off-label' and in some studies shown to increase bone density in postmenopausal women with established osteoporosis. It has also been found effective in preventing bone loss in patients requiring long-term steroid medications (such as Prednisone or Cortisone).
However, high dose or continuous use of DidronelTM can cause another bone disease called osteomalacia. Like osteoporosis, osteomalacia can lead to weak bones with increased risk of fractures. Because of osteomalacia concerns and lack of enough studies yet regarding reduction in the rate of bone fractures, the United States FDA
has not approved DidronelTM for the treatment of osteoporosis.
Osteoporosis therapy has been largely focused on antiresorptive drugs that reduce the rate of bone loss but emerging therapies show promise in increasing bone mineral density instead of merely maintaining it or slowing its deterioration.
The osteoporosis early stage pipeline consists largely of drug candidates in new therapeutic classes, in particular cathepsin K inhibitors, osteoprotegerin and calcilytics as well as novel bisphosphonates. Some of these are examples where novel drugs exploiting genomics programs are being developed based on a deeper understanding of bone biology and have the potential to change the face of treatment of bone disorders in the long term.
There thus remains a need to better understand the bone remodeling process and to provide new compositions that are useful for the diagnosis, prognosis, treatment, prevention and evaluation of therapies for bone remodeling and
The most common side effect of Raloxifen and other SERMS (such as Tamoxifen) are hot flashes. However, Raloxifene and other hormone replacement therapies have been shown to increase the risk of blood clots, including deep vein thrombosis and pulmonary embolism, cardiovascular disease and cancer.
Calcitonin is not as effective in increasing bone density and strengthening bone as estrogen and the other anti-resorptive agents. Common side effects of either injected or nasal spray calcitonin are nausea and flushing. Patients can develop nasal irritations, a runny nose, or nosebleeds. Injectable calcitonin can cause local skin redness at the site of injection, skin rash, and flushing.
A situation demonstrative of the link between several disorders or disease states involving bone remodeling is that of the use of etidronate (DidronelTM) first approved by the FDA to treat Paget's disease. Paget's disease is a bone disease characterized by a disorderly and accelerated remodeling of the bone, leading to bone weakness and pain. DidronelTM has been used 'off-label' and in some studies shown to increase bone density in postmenopausal women with established osteoporosis. It has also been found effective in preventing bone loss in patients requiring long-term steroid medications (such as Prednisone or Cortisone).
However, high dose or continuous use of DidronelTM can cause another bone disease called osteomalacia. Like osteoporosis, osteomalacia can lead to weak bones with increased risk of fractures. Because of osteomalacia concerns and lack of enough studies yet regarding reduction in the rate of bone fractures, the United States FDA
has not approved DidronelTM for the treatment of osteoporosis.
Osteoporosis therapy has been largely focused on antiresorptive drugs that reduce the rate of bone loss but emerging therapies show promise in increasing bone mineral density instead of merely maintaining it or slowing its deterioration.
The osteoporosis early stage pipeline consists largely of drug candidates in new therapeutic classes, in particular cathepsin K inhibitors, osteoprotegerin and calcilytics as well as novel bisphosphonates. Some of these are examples where novel drugs exploiting genomics programs are being developed based on a deeper understanding of bone biology and have the potential to change the face of treatment of bone disorders in the long term.
There thus remains a need to better understand the bone remodeling process and to provide new compositions that are useful for the diagnosis, prognosis, treatment, prevention and evaluation of therapies for bone remodeling and
5 associated disorders. A method for analysing polynucleotide expression patterns has been developed and applied to identify polynucleotides, polypeptides, variants and derivatives specifically involved in bone remodeling.
The present invention seeks to meet these and other needs.
SUMMARY OF THE INVENTION
The present invention relates to polynucleotides comprising sequences involved in the process of bone remodeling, the open reading frame of such sequences, substantially identical sequences (e.g., variants (e.g., allelic variant), non human orthologs), substantially complementary sequences and fragments of any one of the above thereof.
The present invention relates to polypeptide comprising sequences involved in the process of bone remodeling including biologically active analogs and biologically active fragments thereof. The present invention also relates to compositions that are useful for the diagnosis, prognosis, treatment, prevention and/or evaluation of therapies for bone remodeling and associated disorders.
In addition, the present invention relates to a method for analyzing polynucleotide expression patterns, and applied in the identification of polynucleotides, polypeptides, variants and derivatives specifically involved in bone remodeling.
The present invention relates to polynucleotide expression profiles of osteoclasts, the isolation and identification of polynucleotides, their corresponding polypeptides, variants and derivatives involved in osteoclast activity, validation of these identified elements for their potential as therapeutic targets and use of said polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states.
The present invention seeks to meet these and other needs.
SUMMARY OF THE INVENTION
The present invention relates to polynucleotides comprising sequences involved in the process of bone remodeling, the open reading frame of such sequences, substantially identical sequences (e.g., variants (e.g., allelic variant), non human orthologs), substantially complementary sequences and fragments of any one of the above thereof.
The present invention relates to polypeptide comprising sequences involved in the process of bone remodeling including biologically active analogs and biologically active fragments thereof. The present invention also relates to compositions that are useful for the diagnosis, prognosis, treatment, prevention and/or evaluation of therapies for bone remodeling and associated disorders.
In addition, the present invention relates to a method for analyzing polynucleotide expression patterns, and applied in the identification of polynucleotides, polypeptides, variants and derivatives specifically involved in bone remodeling.
The present invention relates to polynucleotide expression profiles of osteoclasts, the isolation and identification of polynucleotides, their corresponding polypeptides, variants and derivatives involved in osteoclast activity, validation of these identified elements for their potential as therapeutic targets and use of said polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states.
6 It is an object of the present invention to provide polynucleotides and/or related polypeptides that have been isolated and identified. More specifically, the invention provides (isolated or substantially purified) polynucleotides comprising or consisting of any one of SEQ. ID. NOs:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86 their coding sequence (open reading frame) substantially identical sequence (e.g., variants, orthologs (e.g., SEQ ID NO.:35)), substantially complementary sequences and related polypeptides comprising any one of SEQ ID NO.: 48-80 and polypeptides encoded by SEQ ID NO .85 or SEQ ID NO :86 which have been shown to be upregulated in a highly specific fashion in osteoclasts. The present invention also relates to polypeptide analogs, variants (e.g., SEQ ID NO .81) and fragments thereof NSEQ refers generally to polynucleotide sequences of the present invention and includes for example, SEQ. ID. NOs:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86 whereas PSEQ refers generally to polypeptide sequences of the present invention and includes, for example. SEQ ID NO. :48 to 82 and polypeptides encoded by SEQ ID
NO.:85 or SEQ ID NO.:86. Of course it will be understood that NSEQ also encompasses polynucleotide sequences which are designed or derived from SEQ.
ID.
NOs:1 to 33 SEQ ID NO.:85 or SEQ ID NO.:86 for example, their coding sequence, complementary sequences. Non-limiting examples of such sequences are disclosed herein (e.g. SEQ ID Nos 42-45).
As used herein the term -NSEQ" refers generally to polynucleotides sequences comprising or consisting of any one of SEQ. ID. NOs:1 to 33, 85 or 86 (e.g..
an isolated form) or comprising or consisting of a fragment of any one of SEQ ID NOs 1 to 33. 85 or 86. The term "NSEQ" more particularly refers to a polynucleotide sequence comprising or consisting of a transcribed portion of any one of SEQ. ID. NOs.1 to 33.
85 or 86, which may be, for example, free of untranslated or untranslatable portion(s) (i.e., a coding portion of any one of SEQ ID Nos.: 1 to 33, 85 or 86). The term "NSEQ"
additionally refers to a sequence substantially identical to any one of the above and more particularly substantially identical to polynucleotide sequence comprising or consisting of a transcribed portion of any one of SEQ. ID. Nos1 to 33, 85 or 86, which may be, for example, free of untranslated or untranslatable portion(s). The term "NSEQ" additionally refers to a polynucleotide sequence region of any one of SEQ. ID.
NOs:1 to 33, 85 or 86 which encodes or is able to encode a polypeptide. The term "NSEQ" also refers to a polynucleotide sequence able of encoding any one of the polypeptides described herein or a polypeptide fragment of any one of the above
NO.:85 or SEQ ID NO.:86. Of course it will be understood that NSEQ also encompasses polynucleotide sequences which are designed or derived from SEQ.
ID.
NOs:1 to 33 SEQ ID NO.:85 or SEQ ID NO.:86 for example, their coding sequence, complementary sequences. Non-limiting examples of such sequences are disclosed herein (e.g. SEQ ID Nos 42-45).
As used herein the term -NSEQ" refers generally to polynucleotides sequences comprising or consisting of any one of SEQ. ID. NOs:1 to 33, 85 or 86 (e.g..
an isolated form) or comprising or consisting of a fragment of any one of SEQ ID NOs 1 to 33. 85 or 86. The term "NSEQ" more particularly refers to a polynucleotide sequence comprising or consisting of a transcribed portion of any one of SEQ. ID. NOs.1 to 33.
85 or 86, which may be, for example, free of untranslated or untranslatable portion(s) (i.e., a coding portion of any one of SEQ ID Nos.: 1 to 33, 85 or 86). The term "NSEQ"
additionally refers to a sequence substantially identical to any one of the above and more particularly substantially identical to polynucleotide sequence comprising or consisting of a transcribed portion of any one of SEQ. ID. Nos1 to 33, 85 or 86, which may be, for example, free of untranslated or untranslatable portion(s). The term "NSEQ" additionally refers to a polynucleotide sequence region of any one of SEQ. ID.
NOs:1 to 33, 85 or 86 which encodes or is able to encode a polypeptide. The term "NSEQ" also refers to a polynucleotide sequence able of encoding any one of the polypeptides described herein or a polypeptide fragment of any one of the above
7 Finally, the term "NSEQ" also comprise a sequence substantially complementary to any one of the above.
The term "inhibitory NSEQ" generally refers to a sequence substantially complementary to any one of SEQ. ID. Nos: 1 to 33, 85 or 86, substantially complementary to a fragment of any one of SEQ. ID. Nos: 1 to 33, 85 or 86, substantially complementary to a sequence substantially identical to SEQ. ID.
NOs:1 to 33, 85 or 86 and more particularly, substantially complementary to a transcribed portion of any one of SEQ. ID. NOs.1 to 33. 85 or 86 (e.g., which may be free of unstranslated or untranslatable portion) and which may have attenuating or even inhibitory action againts the transcription of a mRNA or against expression of a polypeptide encoded by a corresponding SEQ ID NOs..1 to 33, 85 or 86. Suitable "inhibitory NSEQ" may have for example and without limitation from about 10 to about 30 nucleotides. from about 10 to about 25 nucleotides or from about 15 to about 20 nucleotides. As used herein the term "nucleotide" means deoxyribonucleotide or ribonucleotide. In an exemplary embodiment, the use of nucleotide analogues is also encompassed in the present invention.
The present invention relates in one aspect thereof to an isolated polynucleotide sequence having at least from about 80% to about 100% (e.g., 80%, 90%, 95%, etc.) sequence identity to a polynucleotide sequence selected from the group consisting of polynucleotides comprising (a) any one of a SEQ. ID. NOs.1 to 33 or SEQ ID NO
85 or SEQ ID NO. :86, (b) an open reading frame of (a): (c) a full complement of (a) or (b), and ,(d) a fragment of any one of (a) to (c).
As used herein the term "unstranscribable region" may include for example. a promoter region (or portion thereof), silencer region, enhancer region etc of a polynucleotide sequence.
As used herein the term "unstranslatable region" may include for example, an initiator portion of a polynucleotide sequence (upstream of an initiator codon, e.g., AUG), intronic regions, stop codon and/or region downstream of a stop codon (including polyA tail, etc.).
Complements of the isolated polynucleotide sequence encompassed by the present invention may be those, for example, which hybridize under high stringency conditions to any of the nucleotide sequences in (a), or (b). The high stringency conditions may comprise, for example, a hybridization reaction at 65 C in 5X
SSC, 5X
The term "inhibitory NSEQ" generally refers to a sequence substantially complementary to any one of SEQ. ID. Nos: 1 to 33, 85 or 86, substantially complementary to a fragment of any one of SEQ. ID. Nos: 1 to 33, 85 or 86, substantially complementary to a sequence substantially identical to SEQ. ID.
NOs:1 to 33, 85 or 86 and more particularly, substantially complementary to a transcribed portion of any one of SEQ. ID. NOs.1 to 33. 85 or 86 (e.g., which may be free of unstranslated or untranslatable portion) and which may have attenuating or even inhibitory action againts the transcription of a mRNA or against expression of a polypeptide encoded by a corresponding SEQ ID NOs..1 to 33, 85 or 86. Suitable "inhibitory NSEQ" may have for example and without limitation from about 10 to about 30 nucleotides. from about 10 to about 25 nucleotides or from about 15 to about 20 nucleotides. As used herein the term "nucleotide" means deoxyribonucleotide or ribonucleotide. In an exemplary embodiment, the use of nucleotide analogues is also encompassed in the present invention.
The present invention relates in one aspect thereof to an isolated polynucleotide sequence having at least from about 80% to about 100% (e.g., 80%, 90%, 95%, etc.) sequence identity to a polynucleotide sequence selected from the group consisting of polynucleotides comprising (a) any one of a SEQ. ID. NOs.1 to 33 or SEQ ID NO
85 or SEQ ID NO. :86, (b) an open reading frame of (a): (c) a full complement of (a) or (b), and ,(d) a fragment of any one of (a) to (c).
As used herein the term "unstranscribable region" may include for example. a promoter region (or portion thereof), silencer region, enhancer region etc of a polynucleotide sequence.
As used herein the term "unstranslatable region" may include for example, an initiator portion of a polynucleotide sequence (upstream of an initiator codon, e.g., AUG), intronic regions, stop codon and/or region downstream of a stop codon (including polyA tail, etc.).
Complements of the isolated polynucleotide sequence encompassed by the present invention may be those, for example, which hybridize under high stringency conditions to any of the nucleotide sequences in (a), or (b). The high stringency conditions may comprise, for example, a hybridization reaction at 65 C in 5X
SSC, 5X
8 Denhardt's solution. 1% SDS, and 100 pg/ml denatured salmon sperm DNA
In accordance with the present invention, the polynucleotide sequence may be used, for example, in the treatment of diseases or disorders involving bone remodeling.
Fragments of polynucleotides may be used, for example, as probes for determining the presence of the isolated polynucleotide (or its complement or fragments thereof) in a sample, cell, tissue, etc. for experimental purposes or for the purpose of diagnostic of a diseases or disorders involving bone remodeling.
The present invention also relates to a combination comprising a plurality of polynucleotides (substantially purified and/or isolated). The polynucleotides may be co-expressed with one or more genes known to be involved in bone remodeling.
Furthermore, the plurality of polynucleotides may be selected, for example, from the group consisting of a polynucleotide comprising (a) any one of SEQ. ID. NOs:1 to 33.
SEQ ID NO.:85 or SEQ ID NO.:86: (b) an open reading frame (a) (c) a polynucleotide sequence comprising or consisting of a transcribed portion of any one of SEQ.
ID
NOs:1 to 33, 85 or 86, which may be. for example, free of untranslated or untranslatable portion(s) (d) a complementary sequence of any one of (a) to (c); (e) a sequence that hybridizes under high stringency conditions to any one of the nucleotide sequences of (a) to (d) and; (f) fragments of any one of (a) to (e).
The present invention further relates to a polynucleotide encoding any one of the polypeptides described herein. In accordance with the present invention, the polynucleotide (RNA, DNA, etc.) may encode a polypeptide which may be selected from the group consisting of any one of SEQ ID NO. :48 to 80. polypeptides encoded by SEQ ID NO.:85 or 86, analogs or fragments thereof (e.g., biologically active fragments, immunologically active fragments, etc.), The present invention also relates to an isolated nucleic acid molecule comprising the polynucleotides of the present invention, operatively linked to a nucleotide sequence encoding a heterologous polypeptide thereby encoding a fusion polypeptide.
The invention further relates to a polypeptide encoded by a polynucleotide of SEQ. ID. NOs:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86 or more particularly from the open reading frame of any one of SEQ. ID. NOs.1 to 33, SEQ ID NO.:85 or SEQ ID
NO. :86, or a portion thereof. The invention also comprise the product of a gene that is co-expressed with one or more genes known to be involved in bone remodeling.
In accordance with the present invention, the polynucleotide sequence may be used, for example, in the treatment of diseases or disorders involving bone remodeling.
Fragments of polynucleotides may be used, for example, as probes for determining the presence of the isolated polynucleotide (or its complement or fragments thereof) in a sample, cell, tissue, etc. for experimental purposes or for the purpose of diagnostic of a diseases or disorders involving bone remodeling.
The present invention also relates to a combination comprising a plurality of polynucleotides (substantially purified and/or isolated). The polynucleotides may be co-expressed with one or more genes known to be involved in bone remodeling.
Furthermore, the plurality of polynucleotides may be selected, for example, from the group consisting of a polynucleotide comprising (a) any one of SEQ. ID. NOs:1 to 33.
SEQ ID NO.:85 or SEQ ID NO.:86: (b) an open reading frame (a) (c) a polynucleotide sequence comprising or consisting of a transcribed portion of any one of SEQ.
ID
NOs:1 to 33, 85 or 86, which may be. for example, free of untranslated or untranslatable portion(s) (d) a complementary sequence of any one of (a) to (c); (e) a sequence that hybridizes under high stringency conditions to any one of the nucleotide sequences of (a) to (d) and; (f) fragments of any one of (a) to (e).
The present invention further relates to a polynucleotide encoding any one of the polypeptides described herein. In accordance with the present invention, the polynucleotide (RNA, DNA, etc.) may encode a polypeptide which may be selected from the group consisting of any one of SEQ ID NO. :48 to 80. polypeptides encoded by SEQ ID NO.:85 or 86, analogs or fragments thereof (e.g., biologically active fragments, immunologically active fragments, etc.), The present invention also relates to an isolated nucleic acid molecule comprising the polynucleotides of the present invention, operatively linked to a nucleotide sequence encoding a heterologous polypeptide thereby encoding a fusion polypeptide.
The invention further relates to a polypeptide encoded by a polynucleotide of SEQ. ID. NOs:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86 or more particularly from the open reading frame of any one of SEQ. ID. NOs.1 to 33, SEQ ID NO.:85 or SEQ ID
NO. :86, or a portion thereof. The invention also comprise the product of a gene that is co-expressed with one or more genes known to be involved in bone remodeling.
9 Isolated naturally occurring allelic variant are also encompassed by the present invention as well as synthetic variants (e.g., made by recombinant DNA
technology or by chemical synthesis, etc.) such as biologically active variant which may comprise one or more amino acid substitutions (compared to a naturally occurring polypeptide), such as conservative or non conservative amino acid substitution.
The present invention, further provides a vector (mammalian, bacterial, viral, etc.) comprising the polynucleotides described herein or fragments thereof, such as an expression vector. The vector may further comprise a nucleic acid sequence which may help in the regulation of expression of the polynucleotide and/or a nucleotide sequence encoding a tag (e.g., affinity tag; HA, GST, His etc.).
In accordance with the present invention, an expression vector may comprise.
for example. the following operatively linked elements:
a) a transcription promoter:
b) a polynucleotide segment (which may comprise an open reading frame of any one of SEQ ID NOs :1-33. 85 or 86); and c) a transcription terminator.
The invention also relates to an expression vector comprising a polynucleotide described herein, a host cell transformed with the expression vector and a method for producing a polypeptide of the present invention.
The invention further relates to a vector comprising a polynucleotide or polynucleotide fragment. Vectors which may comprise a sequence substantially complementary to the polynucleotides of the present invention (e.g., siRNA, shRNA) are thus encompassed by the present invention. The vector may comprise sequences enabling transcription of the polynucleotide or polynucleotide fragment.
More particularly, the present invention therefore provides a cell which may be genetically engineered to contain and/or to express the polynucleotide (including complements and fragments) and/or polypeptides of the present invention The cell may be. for example. a mammalian cell, an insect cell, a bacteria cell. etc.
The present invention, therefore provides a host cell which may comprise a vector as described herein. The cell may be, for example, a mammalian cell, an insect cell, a bacteria, etc. The cell may be able to express or expresses a polypeptide encoded by the polynucleotide described herein.
Methods of producing the polypeptides of the present invention encompassed herewith includes for example, culturing the cell in conditions allowing the transcription of a gene or expression of the polypeptide. The polypeptide may be recovered, for example, from cell lysate or from the cell supernatant.
5 The invention relates to the use of at least one polynucleotide comprising any one of SEQ. ID. NOs:1 to 33, SEQ ID NO.:85 or SEQ ID NO :86 their coding sequence.
substantially identical sequences, substantially complementary sequences or fragments thereof on an array. The array may be used in a method for diagnosing a bone remodeling disease or disorder by hybridizing the array with a patient sample
technology or by chemical synthesis, etc.) such as biologically active variant which may comprise one or more amino acid substitutions (compared to a naturally occurring polypeptide), such as conservative or non conservative amino acid substitution.
The present invention, further provides a vector (mammalian, bacterial, viral, etc.) comprising the polynucleotides described herein or fragments thereof, such as an expression vector. The vector may further comprise a nucleic acid sequence which may help in the regulation of expression of the polynucleotide and/or a nucleotide sequence encoding a tag (e.g., affinity tag; HA, GST, His etc.).
In accordance with the present invention, an expression vector may comprise.
for example. the following operatively linked elements:
a) a transcription promoter:
b) a polynucleotide segment (which may comprise an open reading frame of any one of SEQ ID NOs :1-33. 85 or 86); and c) a transcription terminator.
The invention also relates to an expression vector comprising a polynucleotide described herein, a host cell transformed with the expression vector and a method for producing a polypeptide of the present invention.
The invention further relates to a vector comprising a polynucleotide or polynucleotide fragment. Vectors which may comprise a sequence substantially complementary to the polynucleotides of the present invention (e.g., siRNA, shRNA) are thus encompassed by the present invention. The vector may comprise sequences enabling transcription of the polynucleotide or polynucleotide fragment.
More particularly, the present invention therefore provides a cell which may be genetically engineered to contain and/or to express the polynucleotide (including complements and fragments) and/or polypeptides of the present invention The cell may be. for example. a mammalian cell, an insect cell, a bacteria cell. etc.
The present invention, therefore provides a host cell which may comprise a vector as described herein. The cell may be, for example, a mammalian cell, an insect cell, a bacteria, etc. The cell may be able to express or expresses a polypeptide encoded by the polynucleotide described herein.
Methods of producing the polypeptides of the present invention encompassed herewith includes for example, culturing the cell in conditions allowing the transcription of a gene or expression of the polypeptide. The polypeptide may be recovered, for example, from cell lysate or from the cell supernatant.
5 The invention relates to the use of at least one polynucleotide comprising any one of SEQ. ID. NOs:1 to 33, SEQ ID NO.:85 or SEQ ID NO :86 their coding sequence.
substantially identical sequences, substantially complementary sequences or fragments thereof on an array. The array may be used in a method for diagnosing a bone remodeling disease or disorder by hybridizing the array with a patient sample
10 under conditions to allow complex formation, detecting complex formation, and comparing the amount of complex formation in the patient sample to that of standards for normal and diseased tissues wherein the complex formation in the patient sample indicates the presence of a bone remodeling disease or disorder. Of course, the use of a polynucleotide of the present invention in a diagnosis method is not dependent exclusively by way of a specific assay. The sequence or sequences may be used in conventionally used diagnosis methods known in the art.
The present invention also relates to a method of ameliorating bone remodeling disease or disorder symptoms. or for inhibiting or delaying bone disease or disorder.
the method may comprise: contacting a compound capable of specifically inhibiting activity or expression of a polynucleotide sequence described herein or a polypeptide described herein, in osteoclasts so that symptoms of the bone remodeling disease or disorder may be ameliorated, or the disease or disorder may be prevented, delayed or lowered.
The present invention further relates to a method for ameliorating bone remodeling disease or disorder symptoms, or for inhibiting or delaying bone disease or disorder, the method may comprise: contacting a compound capable of specifically promoting activity or expression of a polynucleotide sequence described herein or a polypeptide described herein, in osteoclasts so that symptoms of the bone remodeling disease or disorder may be ameliorated, or the disease or disorder may be prevented.
delayed or lowered.
The present invention also relates to a method of treating a condition in a mammal characterized by a deficiency in, or need for, bone growth or replacement and/or an undesirable level of bone resorption, which method may comprise
The present invention also relates to a method of ameliorating bone remodeling disease or disorder symptoms. or for inhibiting or delaying bone disease or disorder.
the method may comprise: contacting a compound capable of specifically inhibiting activity or expression of a polynucleotide sequence described herein or a polypeptide described herein, in osteoclasts so that symptoms of the bone remodeling disease or disorder may be ameliorated, or the disease or disorder may be prevented, delayed or lowered.
The present invention further relates to a method for ameliorating bone remodeling disease or disorder symptoms, or for inhibiting or delaying bone disease or disorder, the method may comprise: contacting a compound capable of specifically promoting activity or expression of a polynucleotide sequence described herein or a polypeptide described herein, in osteoclasts so that symptoms of the bone remodeling disease or disorder may be ameliorated, or the disease or disorder may be prevented.
delayed or lowered.
The present invention also relates to a method of treating a condition in a mammal characterized by a deficiency in, or need for, bone growth or replacement and/or an undesirable level of bone resorption, which method may comprise
11 administering to a mammalian subject in need of such treatment an effective amount of a suitable compound described herein.
The present invention further relates to a method of using a polynucleotide sequence described herein, a polypeptide described herein on an array and for the use of the array in a method for diagnosing a bone remodeling disease or disorder by hybridizing the array with a patient sample under conditions to allow complex formation, detecting complex formation, and comparing the amount of complex formation in the patient sample to that of standards for normal and diseased tissues wherein the complex formation in the patient sample may indicate the presence of a bone remodeling disease or disorder.
In accordance with the present invention, the polynucleotide sequence described herein may be used for somatic cell gene therapy or for stem cell gene therapy.
The invention also relates to a pharmaceutical composition comprising a polynucleotide described herein or a polypeptide encoded by the selected polynucleotide or portion thereof and a suitable pharmaceutical carrier.
Additionally, the invention relates to products, compositions, processes and methods that comprises a polynucleotide described herein, a polypeptide encoded by the polynucleotides a portion thereof. their variants or derivatives, for research.
biological, clinical and therapeutic purposes.
The NSEQs and PSEQs may be used in diagnosis, prognosis. treatment.
prevention, and selection and evaluation of therapies for diseases and disorders involving bone remodeling including, but not limited to, osteoporosis, osteopenia, osteomalacia, hyperparathyroidism, hyperthyroidism, hyperthyroidism, hypogonadism, thyrotoxicosis, systemic mastocytosis, adult hypophosphatasia, hyperadrenocorticism, osteogenesis imperfecta, Paget's disease, Cushing's disease/syndrome, Tumer syndrome, Gaucher disease, Ehlers-Danlos syndrome, Marfan's syndrome, Menkes' syndrome, Fanconi's syndrome, multiple myeloma, hypercalcemia, hypocalcemia, arthritides, periodontal disease. rickets (including vitamin D dependent, type I and It.
and x-linked hypophosphatemic rickets), fibrogenesis imperfecta ossium, osteosclerotic disorders such as pycnodysostosis and damage caused by macrophage-mediated inflammatory processes.
The present invention further relates to a method of using a polynucleotide sequence described herein, a polypeptide described herein on an array and for the use of the array in a method for diagnosing a bone remodeling disease or disorder by hybridizing the array with a patient sample under conditions to allow complex formation, detecting complex formation, and comparing the amount of complex formation in the patient sample to that of standards for normal and diseased tissues wherein the complex formation in the patient sample may indicate the presence of a bone remodeling disease or disorder.
In accordance with the present invention, the polynucleotide sequence described herein may be used for somatic cell gene therapy or for stem cell gene therapy.
The invention also relates to a pharmaceutical composition comprising a polynucleotide described herein or a polypeptide encoded by the selected polynucleotide or portion thereof and a suitable pharmaceutical carrier.
Additionally, the invention relates to products, compositions, processes and methods that comprises a polynucleotide described herein, a polypeptide encoded by the polynucleotides a portion thereof. their variants or derivatives, for research.
biological, clinical and therapeutic purposes.
The NSEQs and PSEQs may be used in diagnosis, prognosis. treatment.
prevention, and selection and evaluation of therapies for diseases and disorders involving bone remodeling including, but not limited to, osteoporosis, osteopenia, osteomalacia, hyperparathyroidism, hyperthyroidism, hyperthyroidism, hypogonadism, thyrotoxicosis, systemic mastocytosis, adult hypophosphatasia, hyperadrenocorticism, osteogenesis imperfecta, Paget's disease, Cushing's disease/syndrome, Tumer syndrome, Gaucher disease, Ehlers-Danlos syndrome, Marfan's syndrome, Menkes' syndrome, Fanconi's syndrome, multiple myeloma, hypercalcemia, hypocalcemia, arthritides, periodontal disease. rickets (including vitamin D dependent, type I and It.
and x-linked hypophosphatemic rickets), fibrogenesis imperfecta ossium, osteosclerotic disorders such as pycnodysostosis and damage caused by macrophage-mediated inflammatory processes.
12 Use of NSEQ as a Screening Tool The polynucleotides obtained by the present invention may be used to detect and isolate expression products, for example, mRNA, complementary DNAs (cDNAs) and proteins derived from or homologous to the NSEQs. In one embodiment the expression of mRNAs homologous to the NSEQs of the present invention may be detected. for example, by hybridization analysis. reverse transcription and in vitro nucleic acid amplification methods. Such procedures permit detection of mRNAs in a variety of tissue types or at different stages of development. The subject nucleic acids which are expressed in a tissue-specific or a developmental-stage-specific manner are useful as tissue-specific markers or for defining the developmental stage of a sample of cells or tissues that may define a particular disease state. One of skill in the art may readily adapt the NSEQs for these purposes.
Those skilled in the art will also recognize that the NSEQs, and its expression products such as cDNA nucleic acids and genomic DNA may be used to prepare short oligonucleotides sequences. For example, oligonucleotides having ten to twelve nucleotides or more may be prepared which hybridize specifically to the present NSEQs and cDNAs and allow detection. identification and isolation of unique nucleic sequences by hybridization. Sequences of for example, at least 15-20 nucleotides may be used and selected from regions that lack homology to other known sequences.
Sequences of 20 or more nucleotides that lack such homology show an increased specificity toward the target sequence. Useful hybridization conditions for probes and primers are readily determinable by those of skill in the art. Stringent hybridization conditions encompassed herewith are those that may allow hybridization of nucleic acids that are greater than 90% homologous but which may prevent hybridization of nucleic acids that are less than 70% homologous. The specificity of a probe may be determined by whether it is made from a unique region, a regulatory region, or from a conserved motif. Both probe specificity and the stringency of diagnostic hybridization or amplification (maximal, high, intermediate, or low) reactions may be determined whether the probe identifies exactly complementary sequences, allelic variants, or related sequences. Probes designed to detect related sequences may have at least 50% sequence identity to any of the selected polynucleotides.
It is to be understood herein that the NSEQs (substantially identical sequences
Those skilled in the art will also recognize that the NSEQs, and its expression products such as cDNA nucleic acids and genomic DNA may be used to prepare short oligonucleotides sequences. For example, oligonucleotides having ten to twelve nucleotides or more may be prepared which hybridize specifically to the present NSEQs and cDNAs and allow detection. identification and isolation of unique nucleic sequences by hybridization. Sequences of for example, at least 15-20 nucleotides may be used and selected from regions that lack homology to other known sequences.
Sequences of 20 or more nucleotides that lack such homology show an increased specificity toward the target sequence. Useful hybridization conditions for probes and primers are readily determinable by those of skill in the art. Stringent hybridization conditions encompassed herewith are those that may allow hybridization of nucleic acids that are greater than 90% homologous but which may prevent hybridization of nucleic acids that are less than 70% homologous. The specificity of a probe may be determined by whether it is made from a unique region, a regulatory region, or from a conserved motif. Both probe specificity and the stringency of diagnostic hybridization or amplification (maximal, high, intermediate, or low) reactions may be determined whether the probe identifies exactly complementary sequences, allelic variants, or related sequences. Probes designed to detect related sequences may have at least 50% sequence identity to any of the selected polynucleotides.
It is to be understood herein that the NSEQs (substantially identical sequences
13 and fragments thereof) may hybridize to a substantially complementary sequence found in a test sample. Additionally, a sequence substantially complementary to NSEQ
may bind a NSEQ found in a test sample.
Furthermore, a probe may be labelled by any procedure known in the art, for example by incorporation of nucleotides linked to a "reporter molecule". A
"reporter molecule", as used herein, may be a molecule that provides an analytically identifiable signal allowing detection of a hybridized probe. Detection may be either qualitative or quantitative. Commonly used reporter molecules include fluorophores, enzymes, biotin, chemiluminescent molecules, bioluminescent molecules, digoxigenin. avidin, streptavidin or radioisotopes. Commonly used enzymes include horseradish peroxidase. alkaline phosphatase. glucose oxidase and p-galactosidase. among others. Enzymes may be conjugated to avidin or streptavidin for use with a biotinylated probe. Similarly, probes may be conjugated to avidin or streptavidin for use with a biotinylated enzyme. Incorporation of a reporter molecule into a DNA probe may be by any method known to the skilled artisan, for example by nick translation, primer extension, random oligo priming, by 3' or 5 end labeling or by other means. In addition, hybridization probes include the cloning of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro. The labelled polynucleotide sequences may be used in Southern or northern analysis. dot blot, or other membrane-based technologies; in FOR technologies; and in micro arrays utilizing samples from subjects to detect altered expression. Oligonucleofides useful as probes for screening of samples by hybridization assays or as primers for amplification may be packaged into kits. Such kits may contain the probes or primers in a pre-measured or predetermined amount, as well as other suitably packaged reagents and materials needed for the particular hybridization or amplification protocol.ln another embodiment.
the invention entails a substantially purified polypeptide encoded by the polynucleotides of NSEQs, polypeptide analogs or polypeptide fragments thereof. The polypeptides whether in a premature, mature or fused form. may be isolated from lysed cells, or from the culture medium, and purified to the extent needed for the intended use. One of skill in the art may readily purify these proteins, polypeptides and peptides by any available procedure. For example, purification may be accomplished by salt fractionation, size exclusion chromatography, ion exchange chromatography, reverse phase chromatography, affinity chromatography and the like.
may bind a NSEQ found in a test sample.
Furthermore, a probe may be labelled by any procedure known in the art, for example by incorporation of nucleotides linked to a "reporter molecule". A
"reporter molecule", as used herein, may be a molecule that provides an analytically identifiable signal allowing detection of a hybridized probe. Detection may be either qualitative or quantitative. Commonly used reporter molecules include fluorophores, enzymes, biotin, chemiluminescent molecules, bioluminescent molecules, digoxigenin. avidin, streptavidin or radioisotopes. Commonly used enzymes include horseradish peroxidase. alkaline phosphatase. glucose oxidase and p-galactosidase. among others. Enzymes may be conjugated to avidin or streptavidin for use with a biotinylated probe. Similarly, probes may be conjugated to avidin or streptavidin for use with a biotinylated enzyme. Incorporation of a reporter molecule into a DNA probe may be by any method known to the skilled artisan, for example by nick translation, primer extension, random oligo priming, by 3' or 5 end labeling or by other means. In addition, hybridization probes include the cloning of nucleic acid sequences into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro. The labelled polynucleotide sequences may be used in Southern or northern analysis. dot blot, or other membrane-based technologies; in FOR technologies; and in micro arrays utilizing samples from subjects to detect altered expression. Oligonucleofides useful as probes for screening of samples by hybridization assays or as primers for amplification may be packaged into kits. Such kits may contain the probes or primers in a pre-measured or predetermined amount, as well as other suitably packaged reagents and materials needed for the particular hybridization or amplification protocol.ln another embodiment.
the invention entails a substantially purified polypeptide encoded by the polynucleotides of NSEQs, polypeptide analogs or polypeptide fragments thereof. The polypeptides whether in a premature, mature or fused form. may be isolated from lysed cells, or from the culture medium, and purified to the extent needed for the intended use. One of skill in the art may readily purify these proteins, polypeptides and peptides by any available procedure. For example, purification may be accomplished by salt fractionation, size exclusion chromatography, ion exchange chromatography, reverse phase chromatography, affinity chromatography and the like.
14 Use of NSEQ for Development of an Expression System In order to express a biologically active polypeptide, NSEQ. or derivatives thereof, may be inserted into an expression vector, i.e., a vector that contains the elements for transcriptional and translational control of the inserted coding sequence in a particular host. These elements may include regulatory sequences, such as enhancers. constitutive and inducible promoters, and 5 and 3' un-translated regions_ Methods that are well known to those skilled in the art may be used to construct such expression vectors. These methods include in vitro recombinant DNA techniques.
synthetic techniques, and in vivo genetic recombination_ A variety of expression vector/host cell systems known to those of skill in the art may be utilized to express NSEQ These include, but are not limited to.
microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with baculovirus vectors; plant cell systems transformed with viral or bacterial expression vectors; or animal cell systems. For long-term production of recombinant proteins in mammalian systems, stable expression in cell lines may be effected. For example, NSEQ may be transformed into cell lines using expression vectors that may contain viral origins of replication and/or endogenous expression elements and a selectable or visible marker gene on the same or on a separate vector. The invention is not to be limited by the vector or host cell employed.
In general, host cells that contain NSEQ and that express a polypeptide encoded by the NSEQ, or a portion thereof, may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to. DNA-DNA or DNA-RNA hybridizations. PCR amplification, and protein bioassay or immunoassay techniques that include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or amino acid sequences. Immunological methods for detecting and measuring the expression of polypeptides using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs). radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS), Those of skill in the art may readily adapt these methodologies to the present invention, The present invention additionally relates to a bioassay for evaluating compounds as potential antagonists of the polypeptide described herein, the bioassay may comprise:
a) culturing test cells in culture medium containing increasing concentrations of at least one compound whose ability to inhibit the action of a 5 polypeptide described herein is sought to be determined, wherein the test cells may contain a polynucleotide sequence described herein (for example, in a form having improved trans-activation transcription activity, relative to wild-type polynucleotide, and comprising a response element operatively linked to a reporter gene); and thereafter b) monitoring in the cells the level of expression of the product of 10 the reporter gene as a function of the concentration of the potential antagonist compound in the culture medium, thereby indicating the ability of the potential antagonist compound to inhibit activation of the polypeptide encoded by the polynucleotide sequence described herein.
The present invention further relates to a bioassay for evaluating compounds as
synthetic techniques, and in vivo genetic recombination_ A variety of expression vector/host cell systems known to those of skill in the art may be utilized to express NSEQ These include, but are not limited to.
microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with baculovirus vectors; plant cell systems transformed with viral or bacterial expression vectors; or animal cell systems. For long-term production of recombinant proteins in mammalian systems, stable expression in cell lines may be effected. For example, NSEQ may be transformed into cell lines using expression vectors that may contain viral origins of replication and/or endogenous expression elements and a selectable or visible marker gene on the same or on a separate vector. The invention is not to be limited by the vector or host cell employed.
In general, host cells that contain NSEQ and that express a polypeptide encoded by the NSEQ, or a portion thereof, may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to. DNA-DNA or DNA-RNA hybridizations. PCR amplification, and protein bioassay or immunoassay techniques that include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or amino acid sequences. Immunological methods for detecting and measuring the expression of polypeptides using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs). radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS), Those of skill in the art may readily adapt these methodologies to the present invention, The present invention additionally relates to a bioassay for evaluating compounds as potential antagonists of the polypeptide described herein, the bioassay may comprise:
a) culturing test cells in culture medium containing increasing concentrations of at least one compound whose ability to inhibit the action of a 5 polypeptide described herein is sought to be determined, wherein the test cells may contain a polynucleotide sequence described herein (for example, in a form having improved trans-activation transcription activity, relative to wild-type polynucleotide, and comprising a response element operatively linked to a reporter gene); and thereafter b) monitoring in the cells the level of expression of the product of 10 the reporter gene as a function of the concentration of the potential antagonist compound in the culture medium, thereby indicating the ability of the potential antagonist compound to inhibit activation of the polypeptide encoded by the polynucleotide sequence described herein.
The present invention further relates to a bioassay for evaluating compounds as
15 potential agonists for a polypeptide encoded by the polynucleotide sequence described herein, the bioassay may comprise:
a) culturing test cells in culture medium containing increasing concentrations of at least one compound whose ability to promote the action of the polypeptide encoded by the polynucleotide sequence described herein is sought to be determined, wherein the test cells may contain a polynucleotide sequence described herein (for example, in a form having improved trans-activation transcription activity, relative to wild-type polynucleotide, and comprising a response element operatively linked to a reporter gene); and thereafter b) monitoring in the cells the level of expression of the product of the reporter gene as a function of the concentration of the potential agonist compound in the culture medium, thereby indicating the ability of the potential agonist compound to promote activation of a polypeptide encoded by the polynucleotide sequence described herein.
Host cells transformed with NSEQ may be cultured under conditions for the expression and recovery of the polypeptide from cell culture. The polypeptide produced by a transgenic cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art.
expression vectors containing NSEQ may be designed to contain signal sequences
a) culturing test cells in culture medium containing increasing concentrations of at least one compound whose ability to promote the action of the polypeptide encoded by the polynucleotide sequence described herein is sought to be determined, wherein the test cells may contain a polynucleotide sequence described herein (for example, in a form having improved trans-activation transcription activity, relative to wild-type polynucleotide, and comprising a response element operatively linked to a reporter gene); and thereafter b) monitoring in the cells the level of expression of the product of the reporter gene as a function of the concentration of the potential agonist compound in the culture medium, thereby indicating the ability of the potential agonist compound to promote activation of a polypeptide encoded by the polynucleotide sequence described herein.
Host cells transformed with NSEQ may be cultured under conditions for the expression and recovery of the polypeptide from cell culture. The polypeptide produced by a transgenic cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art.
expression vectors containing NSEQ may be designed to contain signal sequences
16 that direct secretion of the polypeptide through a prokaryotic or eukaryotic cell membrane. Due to the inherent degeneracy of the genetic code, other DNA
sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express the polypeptide encoded by NSEQ. The nucleotide sequences of the present invention may be engineered using methods generally known in the art in order to alter the nucleotide sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and FOR
reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.
In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to.
acetylation, carboxylation. glycosylation. phosphorylation lipidation. and acylation.
Post-translational processing, which cleaves a -prepro" form of the polypeptide, may also be used to specify protein targeting, folding, and/or activity Different host cells that have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g.. CHO, HeLa, MDCK, HEK293, and W138) are available commercially and from the American Type Culture Collection (ATCC) and may be chosen to ensure the correct modification and processing of the expressed polypeptide.
Those of skill in the art will readily appreciate that natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence resulting in translation of a fusion polypeptide containing heterologous polypeptide moieties in any of the aforementioned host systems. Such heterologous polypeptide moieties may facilitate purification of fusion polypeptides using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein, thioredoxin, calmodulin binding peptide, 6-His (His), FLAG, c-myc. hemaglutinin (HA), and monoclonal antibody epitopes.
In yet a further aspect, the present invention relates to an isolated polynucleotide which may comprise a nucleotide sequence encoding a fusion protein, the fusion protein may comprise a fusion partner fused to a peptide fragment of a
sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express the polypeptide encoded by NSEQ. The nucleotide sequences of the present invention may be engineered using methods generally known in the art in order to alter the nucleotide sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and FOR
reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.
In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to.
acetylation, carboxylation. glycosylation. phosphorylation lipidation. and acylation.
Post-translational processing, which cleaves a -prepro" form of the polypeptide, may also be used to specify protein targeting, folding, and/or activity Different host cells that have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g.. CHO, HeLa, MDCK, HEK293, and W138) are available commercially and from the American Type Culture Collection (ATCC) and may be chosen to ensure the correct modification and processing of the expressed polypeptide.
Those of skill in the art will readily appreciate that natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence resulting in translation of a fusion polypeptide containing heterologous polypeptide moieties in any of the aforementioned host systems. Such heterologous polypeptide moieties may facilitate purification of fusion polypeptides using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein, thioredoxin, calmodulin binding peptide, 6-His (His), FLAG, c-myc. hemaglutinin (HA), and monoclonal antibody epitopes.
In yet a further aspect, the present invention relates to an isolated polynucleotide which may comprise a nucleotide sequence encoding a fusion protein, the fusion protein may comprise a fusion partner fused to a peptide fragment of a
17 protein encoded by, or a naturally occurring allelic variant polypeptide encoded by, the polynucleotide sequence described herein.
Those of skill in the art will also readily recognize that the nucleic acid and polypeptide sequences may be synthesized, in whole or in part. using chemical or enzymatic methods well known in the art. For example, peptide synthesis may be performed using various solid-phase techniques and machines such as the ABI
Peptide synthesizer (PE Biosystems) may be used to automate synthesis. If desired.
the amino acid sequence may be altered during synthesis and/or combined with sequences from other proteins to produce a variant protein.
Use of NSEQ as a Diagnostic Screening Tool The skilled artisan will readily recognize that NSEQ may be used for diagnostic purposes to determine the absence, presence, or altered expression (i.e.
increased or decreased compared to normal) of the gene. The polynucleotides may be at least nucleotides long or at least 12 nucleotides long, or at least 15 nucleotides long up to any desired length and may comprise complementary RNA and DNA molecules, branched nucleic acids. and/or peptide nucleic acids (PNAs). In one alternative, the polynucleotides may be used to detect and quantify gene expression in samples in which expression of NSEQ is correlated with disease. In another alternative, NSEQ
may be used to detect genetic polymorphisms associated with a disease. These polymorphisms may be detected in the transcript cDNA.
The invention provides for the use of at least one polynucleotide comprising NSEQ (e.g., an open reading frame of NSEQ, a substantially complementary sequence, a substantially identical sequence, and fragments thereof) on an array and for the use of that array in a method for diagnosing a bone remodeling disease or disorder by hybridizing the array with a patient sample under conditions to allow complex formation, detecting complex formation, and comparing the amount of complex formation in the patient sample to that of standards for normal and diseased tissues wherein the complex formation in the patient sample indicates the presence of a bone remodeling disease or disorder.
In another embodiment, the present invention provides one or more compartmentalized kits for detection of bone resorption disease states A first kit may have a receptacle containing at least one isolated probe Such a probe may be a
Those of skill in the art will also readily recognize that the nucleic acid and polypeptide sequences may be synthesized, in whole or in part. using chemical or enzymatic methods well known in the art. For example, peptide synthesis may be performed using various solid-phase techniques and machines such as the ABI
Peptide synthesizer (PE Biosystems) may be used to automate synthesis. If desired.
the amino acid sequence may be altered during synthesis and/or combined with sequences from other proteins to produce a variant protein.
Use of NSEQ as a Diagnostic Screening Tool The skilled artisan will readily recognize that NSEQ may be used for diagnostic purposes to determine the absence, presence, or altered expression (i.e.
increased or decreased compared to normal) of the gene. The polynucleotides may be at least nucleotides long or at least 12 nucleotides long, or at least 15 nucleotides long up to any desired length and may comprise complementary RNA and DNA molecules, branched nucleic acids. and/or peptide nucleic acids (PNAs). In one alternative, the polynucleotides may be used to detect and quantify gene expression in samples in which expression of NSEQ is correlated with disease. In another alternative, NSEQ
may be used to detect genetic polymorphisms associated with a disease. These polymorphisms may be detected in the transcript cDNA.
The invention provides for the use of at least one polynucleotide comprising NSEQ (e.g., an open reading frame of NSEQ, a substantially complementary sequence, a substantially identical sequence, and fragments thereof) on an array and for the use of that array in a method for diagnosing a bone remodeling disease or disorder by hybridizing the array with a patient sample under conditions to allow complex formation, detecting complex formation, and comparing the amount of complex formation in the patient sample to that of standards for normal and diseased tissues wherein the complex formation in the patient sample indicates the presence of a bone remodeling disease or disorder.
In another embodiment, the present invention provides one or more compartmentalized kits for detection of bone resorption disease states A first kit may have a receptacle containing at least one isolated probe Such a probe may be a
18 nucleic acid fragment which is present/absent in the genomic DNA of normal cells but which is absent/present in the genomic DNA of affected cells. Such a probe may be specific for a DNA site that is normally active/inactive but which may be inactive/active in certain cell types. Similarly, such a probe may be specific for a DNA site that may be abnormally expressed in certain cell types. Finally, such a probe may identify a specific DNA mutation. By specific for a DNA site is meant that the probe may be capable of hybridizing to the DNA sequence which is mutated, or may be capable of hybridizing to DNA sequences adjacent to the mutated DNA sequences. The probes provided in the present kits may have a covalently attached reporter molecule Probes and reporter molecules may be readily prepared as described above by those of skill in the art.
Use of NSEQ as a Therapeutic One of skill in the art will readily appreciate that the expression systems and assays discussed above may also be used to evaluate the efficacy of a particular therapeutic treatment regimen, in animal studies, in clinical trials, or to monitor the treatment of an individual subject. Once the presence of disease is established and a treatment protocol is initiated, hybridization or amplification assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate the level observed in a healthy subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to many years In yet another aspect of the invention, an NSEQ, a portion thereof, or its complement. may be used therapeutically for the purpose of expressing mRNA and polypeptide, or conversely to block transcription or translation of the mRNA.
Expression .. vectors may be constructed using elements from retroviruses, adenoviruses, herpes or vaccinia viruses, or bacterial plasmids, and the like. These vectors may be used for delivery of nucleotide sequences to a particular target organ, tissue, or cell population.
Methods well known to those skilled in the art may be used to construct vectors to express nucleic acid sequences or their complements.
Alternatively, NSEQ, a portion thereof, or its complement, may be used for somatic cell or stem cell gene therapy. Vectors may be introduced in vivo in vitro, and ex vivo. For ex vivo therapy, vectors are introduced into stem cells taken from the subject. and the resulting transgenic cells are clonally propagated for autologous
Use of NSEQ as a Therapeutic One of skill in the art will readily appreciate that the expression systems and assays discussed above may also be used to evaluate the efficacy of a particular therapeutic treatment regimen, in animal studies, in clinical trials, or to monitor the treatment of an individual subject. Once the presence of disease is established and a treatment protocol is initiated, hybridization or amplification assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate the level observed in a healthy subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to many years In yet another aspect of the invention, an NSEQ, a portion thereof, or its complement. may be used therapeutically for the purpose of expressing mRNA and polypeptide, or conversely to block transcription or translation of the mRNA.
Expression .. vectors may be constructed using elements from retroviruses, adenoviruses, herpes or vaccinia viruses, or bacterial plasmids, and the like. These vectors may be used for delivery of nucleotide sequences to a particular target organ, tissue, or cell population.
Methods well known to those skilled in the art may be used to construct vectors to express nucleic acid sequences or their complements.
Alternatively, NSEQ, a portion thereof, or its complement, may be used for somatic cell or stem cell gene therapy. Vectors may be introduced in vivo in vitro, and ex vivo. For ex vivo therapy, vectors are introduced into stem cells taken from the subject. and the resulting transgenic cells are clonally propagated for autologous
19 transplant back into that same subject. Delivery of NSEQ by transfection, liposome injections, or polycationic amino polymers may be achieved using methods that are well known in the art. Additionally, endogenous NSEQ expression may be inactivated using homologous recombination methods that insert an inactive gene sequence into the coding region or other targeted region of NSEQ.
Depending on the specific goal to be achieved, vectors containing NSEQ may be introduced into a cell or tissue to express a missing polypeptide or to replace a non-functional polypeptide. Of course, when one wishes to express PSEQ in a cell or tissue, one may use a NSEQ able to encode such PSEQ for that purpose or may directly administer PSEQ to that cell or tissue.
On the other hand, when one wishes to attenuate or inhibit the expression of PSEQ, one may use a NSEQ (e.g.. an inhibitory NSEQ) which is substantially complementary to at least a portion of a NSEQ able to encode such PSEQ.
The expression of an inhibitory NSEQ may be done by cloning the inhibitory NSEQ into a vector and introducing the vector into a cell to down-regulate the expression of a polypeptide encoded by the target NSEQ.
Vectors containing NSEQ (e.g., including inhibitory NSEQ) may be transformed into a cell or tissue to express a missing polypeptide or to replace a non-functional polypeptide. Similarly a vector constructed to express the complement of NSEQ
may be transformed into a cell to down-regulate the over-expression of a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof. Complementary or anti-sense sequences may consist of an oligonucleotide derived from the transcription initiation site nucleotides between about positions -10 and +10 from the ATG
are preferred. Similarly inhibition may be achieved using triple helix base pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee et al. 1994) Ribozymes, enzymatic RNA molecules, may also be used to catalyze the cleavage of mRNA and decrease the levels of particular mRNAs. such as those comprising the polynucleotide sequences of the invention. Ribozymes may cleave mRNA at specific cleavage sites. Alternatively, ribozymes may cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The construction and production of ribozymes is well known in the art.
RNA molecules may be modified to increase intracellular stability and half-life.
Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' 0-methyl 5 .. rather than phosphodiester linkages within the backbone of the molecule.
Alternatively, nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-. thio-, and similarly modified forms of adenine, cytidine, guanine, thymine. and uridine which are not as easily recognized by endogenous endonucleases, may be included.
10 In addition to the active ingredients, a pharmaceutical composition may contain pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations that may be used pharmaceutically.
For any compound, the therapeutically effective dose may be estimated initially 15 either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the concentration range and route of administration. Such information may then be used to determine useful doses and routes for administration in humans. These techniques are well known to one skilled in the art and a therapeutically effective dose refers to that amount of active
Depending on the specific goal to be achieved, vectors containing NSEQ may be introduced into a cell or tissue to express a missing polypeptide or to replace a non-functional polypeptide. Of course, when one wishes to express PSEQ in a cell or tissue, one may use a NSEQ able to encode such PSEQ for that purpose or may directly administer PSEQ to that cell or tissue.
On the other hand, when one wishes to attenuate or inhibit the expression of PSEQ, one may use a NSEQ (e.g.. an inhibitory NSEQ) which is substantially complementary to at least a portion of a NSEQ able to encode such PSEQ.
The expression of an inhibitory NSEQ may be done by cloning the inhibitory NSEQ into a vector and introducing the vector into a cell to down-regulate the expression of a polypeptide encoded by the target NSEQ.
Vectors containing NSEQ (e.g., including inhibitory NSEQ) may be transformed into a cell or tissue to express a missing polypeptide or to replace a non-functional polypeptide. Similarly a vector constructed to express the complement of NSEQ
may be transformed into a cell to down-regulate the over-expression of a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof. Complementary or anti-sense sequences may consist of an oligonucleotide derived from the transcription initiation site nucleotides between about positions -10 and +10 from the ATG
are preferred. Similarly inhibition may be achieved using triple helix base pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee et al. 1994) Ribozymes, enzymatic RNA molecules, may also be used to catalyze the cleavage of mRNA and decrease the levels of particular mRNAs. such as those comprising the polynucleotide sequences of the invention. Ribozymes may cleave mRNA at specific cleavage sites. Alternatively, ribozymes may cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The construction and production of ribozymes is well known in the art.
RNA molecules may be modified to increase intracellular stability and half-life.
Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' 0-methyl 5 .. rather than phosphodiester linkages within the backbone of the molecule.
Alternatively, nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-. thio-, and similarly modified forms of adenine, cytidine, guanine, thymine. and uridine which are not as easily recognized by endogenous endonucleases, may be included.
10 In addition to the active ingredients, a pharmaceutical composition may contain pharmaceutically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations that may be used pharmaceutically.
For any compound, the therapeutically effective dose may be estimated initially 15 either in cell culture assays or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the concentration range and route of administration. Such information may then be used to determine useful doses and routes for administration in humans. These techniques are well known to one skilled in the art and a therapeutically effective dose refers to that amount of active
20 ingredient that ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating and contrasting the ED50 (the dose therapeutically effective in 50% of the population) and L050 (the dose lethal to 50% of the population) statistics. Any of the therapeutic compositions described above may be applied to any subject in need of such therapy, including but not limited to mammals such as dogs, cats, cows, horses, rabbits, monkeys. and most preferably.
humans.
The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous.
intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
The term "Treatment" for purposes of this disclosure refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of
humans.
The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous.
intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.
The term "Treatment" for purposes of this disclosure refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of
21 treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
Use of NSEQ in General Research The invention finally provides products, compositions, processes and methods that utilize an NSEQ. their open reading frame, or a polypeptide encoded by the polynucleotides of NSEQ or their open reading frame, or a portion thereof, their variants, analogs, derivatives and fragments for research, biological, clinical and therapeutic purposes. For example, to identify splice variants, mutations, and polymorphisms NSEQ may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences such as promoters and other regulatory elements. Additionally, one may use an XL-PCR
kit (PE
Biosystems, Foster City Calif.). nested primers, and commercially available cDNA
libraries (Life Technologies, Rockville Md.) or genomic libraries (Clontech, Palo Alto Calif.) to extend the sequence.
The polynucleotides may also be used as targets in a micro-array. The micro-array may be used to monitor the expression patterns of large numbers of genes simultaneously and to identify splice variants, mutations, and polymorphisms.
.. Information derived from analyses of the expression patterns may be used to determine gene function, to understand the genetic basis of a disease, to diagnose a disease, and to develop and monitor the activities of therapeutic agents used to treat a disease. Microarrays may also be used to detect genetic diversity, single nucleotide polymorphisms which may characterize a particular population, at the genomic level.
In yet another embodiment. polynucleotides may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data.
The present invention more particularly relates in one aspect thereof to a method of representatively identifying an endogeneously differentially expressed sequence involved in osteoclast differentiation. The sequence may be, for example.
differentially expressed in a differentiated osteoclast cell compared to an
Use of NSEQ in General Research The invention finally provides products, compositions, processes and methods that utilize an NSEQ. their open reading frame, or a polypeptide encoded by the polynucleotides of NSEQ or their open reading frame, or a portion thereof, their variants, analogs, derivatives and fragments for research, biological, clinical and therapeutic purposes. For example, to identify splice variants, mutations, and polymorphisms NSEQ may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences such as promoters and other regulatory elements. Additionally, one may use an XL-PCR
kit (PE
Biosystems, Foster City Calif.). nested primers, and commercially available cDNA
libraries (Life Technologies, Rockville Md.) or genomic libraries (Clontech, Palo Alto Calif.) to extend the sequence.
The polynucleotides may also be used as targets in a micro-array. The micro-array may be used to monitor the expression patterns of large numbers of genes simultaneously and to identify splice variants, mutations, and polymorphisms.
.. Information derived from analyses of the expression patterns may be used to determine gene function, to understand the genetic basis of a disease, to diagnose a disease, and to develop and monitor the activities of therapeutic agents used to treat a disease. Microarrays may also be used to detect genetic diversity, single nucleotide polymorphisms which may characterize a particular population, at the genomic level.
In yet another embodiment. polynucleotides may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data.
The present invention more particularly relates in one aspect thereof to a method of representatively identifying an endogeneously differentially expressed sequence involved in osteoclast differentiation. The sequence may be, for example.
differentially expressed in a differentiated osteoclast cell compared to an
22 undifferentiated osteoclast precursor cell.
The method of the present invention may comprise:
a) separately providing total messenger RNA from (mature or intermediately) differentiated human osteoclast cell and undifferentiated human osteoclast precursor cell, the total messenger RNA may comprise, for example, at least one endogeneously differentially expressed sequence, b) generating single-stranded cDNA from each messenger RNA of differentiated human osteoclast cell and (e.g., randomly) tagging the 3'-end of the single-stranded cDNA with a RNA polymerase promoter sequence and a first sequence tag;
c) generating single-stranded cDNA from each messenger RNA of undifferentiated human osteoclast precursor cell and (e.g., randomly) tagging the 3'-end of the single-stranded cDNA with a RNA polymerase promoter sequence and a second sequence tag;
d) separately generating partially or completely double-stranded 5'-tagged-DNA from each of b) and c), the double-stranded 5'-tagged-DNA
may thus comprise in a 5' to 3' direction, a double-stranded RNA
polymerase promoter, a first or second sequence tag and an endogenously expressed sequence, e) separately linearly amplifying a first and second tagged sense RNA from each of d) with a RNA polymerase enzyme (which may be selected based on the promoter used for tagging), f) generating single-stranded complementary first or second tagged DNA
from one of e), g) hybridizing the single-stranded complementary first or second tagged DNA of f) with the other linearly amplified sense RNA of e).
h) recovering unhybridized RNA with the help of the first or second sequence tag (for example by PCR or hybridization), and' i) identifying (determining) the nucleotide sequence of unhybndized RNA.
Steps b) and/or c), may comprise generating a single copy of a single-stranded
The method of the present invention may comprise:
a) separately providing total messenger RNA from (mature or intermediately) differentiated human osteoclast cell and undifferentiated human osteoclast precursor cell, the total messenger RNA may comprise, for example, at least one endogeneously differentially expressed sequence, b) generating single-stranded cDNA from each messenger RNA of differentiated human osteoclast cell and (e.g., randomly) tagging the 3'-end of the single-stranded cDNA with a RNA polymerase promoter sequence and a first sequence tag;
c) generating single-stranded cDNA from each messenger RNA of undifferentiated human osteoclast precursor cell and (e.g., randomly) tagging the 3'-end of the single-stranded cDNA with a RNA polymerase promoter sequence and a second sequence tag;
d) separately generating partially or completely double-stranded 5'-tagged-DNA from each of b) and c), the double-stranded 5'-tagged-DNA
may thus comprise in a 5' to 3' direction, a double-stranded RNA
polymerase promoter, a first or second sequence tag and an endogenously expressed sequence, e) separately linearly amplifying a first and second tagged sense RNA from each of d) with a RNA polymerase enzyme (which may be selected based on the promoter used for tagging), f) generating single-stranded complementary first or second tagged DNA
from one of e), g) hybridizing the single-stranded complementary first or second tagged DNA of f) with the other linearly amplified sense RNA of e).
h) recovering unhybridized RNA with the help of the first or second sequence tag (for example by PCR or hybridization), and' i) identifying (determining) the nucleotide sequence of unhybndized RNA.
Steps b) and/or c), may comprise generating a single copy of a single-stranded
23 cDNA.
The method may further comprise the step of comparatively determining the presence of the identified endogeneously and differentially expressed sequence in a differentiated osteoclast cell relative to an undifferentiated osteoclast precursor cell.
A sequence which is substantially absent (e.g., totally absent or present in very low quantity) from one of differentiated osteoclast cell or an undifferentiated osteoclast precursor cell and present in the other of differentiated osteoclast cell or an undifferentiated osteoclast precursor cell may therefore be selected.
The sequence thus selected may be a positive regulator of osteoclast differentiation and therefore may represent an attractive target which may advantageously be used to promote bone resorption or alternatively such target may be inhibited to lower or prevent bone resorption.
Alternatively, the sequence selected using the above method may be a negative regulator of osteoclast differentiation and may therefore represent an attractive target which may advantageously be induced (e.g.. at the level of transcription, translation, activity etc.) or provided to a cell to lower or prevent bone resorption. Also such negative regulator may. upon its inhibition, serve as a target to promote bone resorption.
In accordance with the present invention, the sequence may be further selected based on a reduced or substantially absent expression in other normal tissue, therefore representing a candidate sequence specifically involved in osteoclast differentiation and bone remodeling.
The method may also further comprise a step of determining the complete sequence of the nucleotide sequence and may also comprise determining the coding sequence of the nucleotide sequence.
The present invention also relates in a further aspect, to the isolated endogeneously and differentially expressed sequence (polynucleotide and polypeptide) identified by the method of the present invention.
More particularly, the present invention encompasses a polynucleotide which may comprise the identified polynucleotide sequence a polynucleotide which may comprise the open reading frame of the identified polynucleotide sequence. a polynucleotide which may comprise a nucleotide sequence substantially identical to the
The method may further comprise the step of comparatively determining the presence of the identified endogeneously and differentially expressed sequence in a differentiated osteoclast cell relative to an undifferentiated osteoclast precursor cell.
A sequence which is substantially absent (e.g., totally absent or present in very low quantity) from one of differentiated osteoclast cell or an undifferentiated osteoclast precursor cell and present in the other of differentiated osteoclast cell or an undifferentiated osteoclast precursor cell may therefore be selected.
The sequence thus selected may be a positive regulator of osteoclast differentiation and therefore may represent an attractive target which may advantageously be used to promote bone resorption or alternatively such target may be inhibited to lower or prevent bone resorption.
Alternatively, the sequence selected using the above method may be a negative regulator of osteoclast differentiation and may therefore represent an attractive target which may advantageously be induced (e.g.. at the level of transcription, translation, activity etc.) or provided to a cell to lower or prevent bone resorption. Also such negative regulator may. upon its inhibition, serve as a target to promote bone resorption.
In accordance with the present invention, the sequence may be further selected based on a reduced or substantially absent expression in other normal tissue, therefore representing a candidate sequence specifically involved in osteoclast differentiation and bone remodeling.
The method may also further comprise a step of determining the complete sequence of the nucleotide sequence and may also comprise determining the coding sequence of the nucleotide sequence.
The present invention also relates in a further aspect, to the isolated endogeneously and differentially expressed sequence (polynucleotide and polypeptide) identified by the method of the present invention.
More particularly, the present invention encompasses a polynucleotide which may comprise the identified polynucleotide sequence a polynucleotide which may comprise the open reading frame of the identified polynucleotide sequence. a polynucleotide which may comprise a nucleotide sequence substantially identical to the
24 polynucleotide identified by the method of the present invention, a polynucleotide which may comprise a nucleotide sequence substantially complementary to the polynucleotide identified by the method of the present invention, fragments and splice variant thereof, provided that the sequence does not consist in or comprise SEQ ID
NO.:34.
In accordance with the present invention, the isolated endogeneously and differentially expressed sequence of the present invention may be a complete or partial RNA molecule.
Isolated DNA molecule able to be transcribed into the RNA molecule of the present invention are also encompassed herewith as well as vectors (including expression vectors) comprising the such DNA or RNA molecule.
The present invention also relates to libraries comprising at least one isolated endogeneously and differentially expressed sequence identified herein (e.g..
partial or complete RNA or DNA, substantially identical sequences or substantially complementary sequences (e.g. probes) and fragments thereof (e.g..
oligonucleotides)).
In accordance with the present invention, the isolated endogeneously and differentially expressed sequence may be selected, for example from the group consisting of a polynucleotide which may consist in or comprise.
a) any one of SEQ ID NO.:1 to 33. SEQ ID NO..85 or SEQ ID NO.-86.
5) the open reading frame of any one of SEQ ID NO.i1 to 33. SEQ ID
NO.:85 or SEQ ID NO.:86, c) a polynucleotide which may comprise a nucleotide sequence substantially identical to a) or b), and;
ci) a polynucleotide which may comprise a nucleotide sequence substantially comlpementary to any one of a) to c), c) fragments of any one of a) to d) In a further aspect the present invention relates to a polypeptide which may be encoded by the isolated endogeneously and differentially expressed sequence of the present invention.
In yet a further aspect the present invention relates to a polynucleotide able to encode a polypeptide of the present invention. Due to the degeneracy of the genetic code, it is to be understood herein that a multiplicity of polynucleotide sequence may encode the same polypeptide sequence and thus are encompassed by the present invention.
5 Exemplary polypeptides may comprise a sequence selected from the group consisting of any one of SEQ ID NO.: 48 to 80, a polypeptide encoded by SEQ ID
NO.:85 or SEQ ID NO. .86 The present invention also relates to an isolated non-human ortholog polynucleotide sequence (involved in bone remodeling), the open reading frame of the 10 non-human ortholog, substantially identical sequences, substantially complementary sequences, fragments and splice variants thereof.
The present invention as well relates to an isolated polypeptide encoded by the non-human ortholog polynucleotide as well as biologically active analogs and biologically active fragments thereof.
15 Exemplary embodiments of non-human (e.g., mouse) ortholog polynucleotides encompassed herewith include, for example, SEQ ID NO.35.
Exemplary embodiments of isolated polypeptide encoded by some non-human orthologs identified herein include for example, a polypeptide such as SEQ ID
NO '82 The present invention also more particularly relates, in an additional aspect 20 thereof, to an isolated polynucleotide which may be differentially expressed in differentiated osteoclast cell compared to undifferentiated human osteoclast precursor cell.
The isolated polynucleotide may comprise a member selected from the group consisting of:
NO.:34.
In accordance with the present invention, the isolated endogeneously and differentially expressed sequence of the present invention may be a complete or partial RNA molecule.
Isolated DNA molecule able to be transcribed into the RNA molecule of the present invention are also encompassed herewith as well as vectors (including expression vectors) comprising the such DNA or RNA molecule.
The present invention also relates to libraries comprising at least one isolated endogeneously and differentially expressed sequence identified herein (e.g..
partial or complete RNA or DNA, substantially identical sequences or substantially complementary sequences (e.g. probes) and fragments thereof (e.g..
oligonucleotides)).
In accordance with the present invention, the isolated endogeneously and differentially expressed sequence may be selected, for example from the group consisting of a polynucleotide which may consist in or comprise.
a) any one of SEQ ID NO.:1 to 33. SEQ ID NO..85 or SEQ ID NO.-86.
5) the open reading frame of any one of SEQ ID NO.i1 to 33. SEQ ID
NO.:85 or SEQ ID NO.:86, c) a polynucleotide which may comprise a nucleotide sequence substantially identical to a) or b), and;
ci) a polynucleotide which may comprise a nucleotide sequence substantially comlpementary to any one of a) to c), c) fragments of any one of a) to d) In a further aspect the present invention relates to a polypeptide which may be encoded by the isolated endogeneously and differentially expressed sequence of the present invention.
In yet a further aspect the present invention relates to a polynucleotide able to encode a polypeptide of the present invention. Due to the degeneracy of the genetic code, it is to be understood herein that a multiplicity of polynucleotide sequence may encode the same polypeptide sequence and thus are encompassed by the present invention.
5 Exemplary polypeptides may comprise a sequence selected from the group consisting of any one of SEQ ID NO.: 48 to 80, a polypeptide encoded by SEQ ID
NO.:85 or SEQ ID NO. .86 The present invention also relates to an isolated non-human ortholog polynucleotide sequence (involved in bone remodeling), the open reading frame of the 10 non-human ortholog, substantially identical sequences, substantially complementary sequences, fragments and splice variants thereof.
The present invention as well relates to an isolated polypeptide encoded by the non-human ortholog polynucleotide as well as biologically active analogs and biologically active fragments thereof.
15 Exemplary embodiments of non-human (e.g., mouse) ortholog polynucleotides encompassed herewith include, for example, SEQ ID NO.35.
Exemplary embodiments of isolated polypeptide encoded by some non-human orthologs identified herein include for example, a polypeptide such as SEQ ID
NO '82 The present invention also more particularly relates, in an additional aspect 20 thereof, to an isolated polynucleotide which may be differentially expressed in differentiated osteoclast cell compared to undifferentiated human osteoclast precursor cell.
The isolated polynucleotide may comprise a member selected from the group consisting of:
25 a) a polynucleotide which may comprise any one of SEQ ID NO. :1 to SEQ
ID NO.33, SEQ ID NO.:85 or SEQ ID NO.:86 b) a polynucleotide which may comprise the open reading frame of any one of SEQ ID NO.:1 to SEQ ID NO.33, SEQ ID NO.:85 or SEQ ID
NO.:86;
c) a polynucleotide which may comprise a transcribed or transcribable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO.33, SEQ ID NO. 85
ID NO.33, SEQ ID NO.:85 or SEQ ID NO.:86 b) a polynucleotide which may comprise the open reading frame of any one of SEQ ID NO.:1 to SEQ ID NO.33, SEQ ID NO.:85 or SEQ ID
NO.:86;
c) a polynucleotide which may comprise a transcribed or transcribable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO.33, SEQ ID NO. 85
26 or SEQ ID NO.86, which may be. for example, free of untranslated or untranslatable portion(s):
d) a polynucleotide which may comprise a translated or translatable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO.33, SEQ ID NO.:85 or SEQ
ID NO.:86 (e.g., coding portion), e) a polynucleotide which may comprise a sequence substantially identical (e.g., from about 50 to 100%, or about 60 to 100% or about 70 to 100%
or about 80 to 100% or about 85, 90, 95 to 100% identical over the entire sequence or portion of sequences) to a), b) c) or d).
f) a polynucleotide which may comprise a sequence substantially complementary (e.g.. from about 50 to 100% or about 60 to 1000/c or about 70 to 100% or about 80 to 100% or about 85. 90. 95 to 100%
complementarity over the entire sequence or portion of sequences) to a), 13). c) or d) and;
g) a fragment of any one of a) to f) h) including polynucleotides which consist in the above.
Exemplary polynucleotides fragments of those listed above comprises polynucleotides of at least 10 nucleic acids which may be substantially complementary to the nucleic acid sequence of any one of SEQ ID NO: 1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86, for example, fragments selected from the group consisting of any one of SEQ ID NO.: 42-45.
The present invention also relates to an isolated polynucleotide involved in osteoclast differentiation, the isolated polynucleotide may be selected. for example.
from the group consisting of;
a) a polynucleotide comprising any one of SEQ ID NO.: 1 to 33. SEQ ID
NO.:85 or SEQ ID NO.:86, b) a polynucleotide comprising the open reading frame of any one of SEQ
ID NO.: 1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86, c) a polynucleotide which may comprise a transcribed or transcribable portion of any one of SEQ. ID. NOsrl to SEQ ID NO.33, SEQ ID NO.:85 or SEQ ID NO.86, which may be, for example, free of untranslated or untranslatable portion(s);
d) a polynucleotide which may comprise a translated or translatable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO.33, SEQ ID NO.:85 or SEQ
ID NO.:86 (e.g., coding portion), e) a polynucleotide which may comprise a sequence substantially identical (e.g., from about 50 to 100%, or about 60 to 100% or about 70 to 100%
or about 80 to 100% or about 85, 90, 95 to 100% identical over the entire sequence or portion of sequences) to a), b) c) or d).
f) a polynucleotide which may comprise a sequence substantially complementary (e.g.. from about 50 to 100% or about 60 to 1000/c or about 70 to 100% or about 80 to 100% or about 85. 90. 95 to 100%
complementarity over the entire sequence or portion of sequences) to a), 13). c) or d) and;
g) a fragment of any one of a) to f) h) including polynucleotides which consist in the above.
Exemplary polynucleotides fragments of those listed above comprises polynucleotides of at least 10 nucleic acids which may be substantially complementary to the nucleic acid sequence of any one of SEQ ID NO: 1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86, for example, fragments selected from the group consisting of any one of SEQ ID NO.: 42-45.
The present invention also relates to an isolated polynucleotide involved in osteoclast differentiation, the isolated polynucleotide may be selected. for example.
from the group consisting of;
a) a polynucleotide comprising any one of SEQ ID NO.: 1 to 33. SEQ ID
NO.:85 or SEQ ID NO.:86, b) a polynucleotide comprising the open reading frame of any one of SEQ
ID NO.: 1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86, c) a polynucleotide which may comprise a transcribed or transcribable portion of any one of SEQ. ID. NOsrl to SEQ ID NO.33, SEQ ID NO.:85 or SEQ ID NO.86, which may be, for example, free of untranslated or untranslatable portion(s);
27 d) a polynucleotide which may comprise a translated or translatable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO 33, SEQ ID NO :85 or SEQ
ID NO.:86 (e.g., coding portion), e) a polynucleotide substantially identical to a). b), c) or d),; and:
f) a sequence of at least 10 nucleic acids which may be substantially complementary to the nucleic acid sequence of any one of SEQ ID
NO.:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86 or more particularly of a), b), c) or d).
In accordance with the present invention the isolated polynucleotide may be able to promote osteoclast differentiation (e.g., in a mammal or mammalian cell thereof), i.e, a positive regulator of osteoclast differenciation.
Further in accordance with the present invention, the isolated polynucleotide may be able to inhibit, prevent or lower osteoclast differentiation (e.g in a mammal or mammalian cell thereof), t. e, a negative regulator of osteoclast differenciation.
In yet a further aspect, the present invention relates to an isolated polynucleotide which may be able to inhibit osteoclast differentiation (e.g..
in a mammal or mammalian cell thereof). The polynucleotide may be selected, for example, from the group consisting of polynucleotides which may comprise a sequence of at least nucleic acids which is complementary to the nucleic acid sequence of any one of NSEQ described herein.
Suitable polynucleotides include, for example, a polynucleotide having or comprising those which are selected from the group consisting of SEQ ID NO. 42 to 45.
Suitable polynucleotides may be those which may be able to inhibit osteoclast differentiation which has been induced by an inducer of osteoclast differentiation such as those listed herein.
In accordance with the present invention, the polynucleotide may be for example, a RNA molecule, a DNA molecule, including those which are partial or complete, single-stranded or double-stranded, hybrids, etc.
The present invention also relates to a vector (e.g., an expression vector) comprising the polynucleotide of the present invention.
The present invention additionally relates in an aspect thereof to a library of polynucleotide sequences which may be differentially expressed in a differentiated
ID NO.:86 (e.g., coding portion), e) a polynucleotide substantially identical to a). b), c) or d),; and:
f) a sequence of at least 10 nucleic acids which may be substantially complementary to the nucleic acid sequence of any one of SEQ ID
NO.:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86 or more particularly of a), b), c) or d).
In accordance with the present invention the isolated polynucleotide may be able to promote osteoclast differentiation (e.g., in a mammal or mammalian cell thereof), i.e, a positive regulator of osteoclast differenciation.
Further in accordance with the present invention, the isolated polynucleotide may be able to inhibit, prevent or lower osteoclast differentiation (e.g in a mammal or mammalian cell thereof), t. e, a negative regulator of osteoclast differenciation.
In yet a further aspect, the present invention relates to an isolated polynucleotide which may be able to inhibit osteoclast differentiation (e.g..
in a mammal or mammalian cell thereof). The polynucleotide may be selected, for example, from the group consisting of polynucleotides which may comprise a sequence of at least nucleic acids which is complementary to the nucleic acid sequence of any one of NSEQ described herein.
Suitable polynucleotides include, for example, a polynucleotide having or comprising those which are selected from the group consisting of SEQ ID NO. 42 to 45.
Suitable polynucleotides may be those which may be able to inhibit osteoclast differentiation which has been induced by an inducer of osteoclast differentiation such as those listed herein.
In accordance with the present invention, the polynucleotide may be for example, a RNA molecule, a DNA molecule, including those which are partial or complete, single-stranded or double-stranded, hybrids, etc.
The present invention also relates to a vector (e.g., an expression vector) comprising the polynucleotide of the present invention.
The present invention additionally relates in an aspect thereof to a library of polynucleotide sequences which may be differentially expressed in a differentiated
28 osteoclast cell compared to an undifferentiated osteoclast precursor cell The library may comprise, for example. at least one member selected from the group consisting of a) a polynucleotide which may comprise any one of SEQ ID NO..1 to 33.
SEQ ID NO.:85 or SEQ ID NO.:86, b) a polynucleotide which may comprise the open reading frame of any one of SEQ ID NO.:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86, c) a polynucleotide which may comprise a transcribed or transcribable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO.33. SEQ ID NO.:85 or SEQ ID NO.86, which may be, for example, free of untranslated or untranslatable portion(s), d) a polynucleotide which may comprise a translated or translatable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO 33. SEQ ID NO.:85 or SEQ
ID NO 86 (e.g., coding portion), e) a polynucleotide which may comprise a sequence substantially identical (e.g., from about 50 to 100%, or about 60 to 100% or about 70 to 1000/0 or about 80 to 100% or about 85, 90. 95 to 100% identical over the entire sequence or portion of sequences) to a), b), c) or d):
f) a polynucleotide which may comprise a sequence substantially complementary (e.g., from about 50 to 100%, or about 60 to 100% or about 70 to 100% or about 80 to 100% or about 85, 90, 95 to 100%
complementarity over the entire sequence or portion of sequences) to a), b), c) old) and;
g) a fragment of any one of a) to d).
The present invention also relates to an expression library which may comprise a library of polynucleotides described herein. In accordance with the present invention, each of the polynucleotide may be contained within an expression vector.
Arrays and kits comprising a library of polynucleotide sequences (comprising at least one polynucleotide such as complementary sequences) of the present invention are also encompassed herewith The present invention also provides in an additional aspect, a pharmaceutical composition for inhibiting osteoclast differentiation (bone resorption and bone resorption related diseases or disorders), the pharmaceutical composition may
SEQ ID NO.:85 or SEQ ID NO.:86, b) a polynucleotide which may comprise the open reading frame of any one of SEQ ID NO.:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86, c) a polynucleotide which may comprise a transcribed or transcribable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO.33. SEQ ID NO.:85 or SEQ ID NO.86, which may be, for example, free of untranslated or untranslatable portion(s), d) a polynucleotide which may comprise a translated or translatable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO 33. SEQ ID NO.:85 or SEQ
ID NO 86 (e.g., coding portion), e) a polynucleotide which may comprise a sequence substantially identical (e.g., from about 50 to 100%, or about 60 to 100% or about 70 to 1000/0 or about 80 to 100% or about 85, 90. 95 to 100% identical over the entire sequence or portion of sequences) to a), b), c) or d):
f) a polynucleotide which may comprise a sequence substantially complementary (e.g., from about 50 to 100%, or about 60 to 100% or about 70 to 100% or about 80 to 100% or about 85, 90, 95 to 100%
complementarity over the entire sequence or portion of sequences) to a), b), c) old) and;
g) a fragment of any one of a) to d).
The present invention also relates to an expression library which may comprise a library of polynucleotides described herein. In accordance with the present invention, each of the polynucleotide may be contained within an expression vector.
Arrays and kits comprising a library of polynucleotide sequences (comprising at least one polynucleotide such as complementary sequences) of the present invention are also encompassed herewith The present invention also provides in an additional aspect, a pharmaceutical composition for inhibiting osteoclast differentiation (bone resorption and bone resorption related diseases or disorders), the pharmaceutical composition may
29 comprise, for example;
a) an isolated polynucleotide as defined herein (e.g., able to inhibit osteoclast differentiation) and:
b) a pharmaceutically acceptable carrier.
The present invention also provides in yet an additional aspect. a method for inhibiting osteoclast differentiation (e.g., for inhibiting bone resorption or for ameliorating bone resorption) in a mammal (individual) in need thereof (or in a mammalian cell), the method may comprise administering an isolated polynucleotide (e.g., able to inhibit osteoclast differentiation) or a suitable pharmaceutical composition comprising such suitable polynucleotide.
In accordance with the present invention, the mammal in need may suffer, for example and without limitation, from a condition selected from the group consisting of osteoporosis, osteopenia, osteomalacia, hyperparathyroidism, hyperthyroidism, hypogonadism, thyrotoxicosis, systemic mastocytosis, adult hypophosphatasia, hyperadrenocorticism, osteogenesis imperfecta. Paget's disease, Cushing's disease/syndrome, Turner syndrome, Gaucher disease, Ehlers-Danlos syndrome, Marfan's syndrome, Menkes' syndrome. Fanconi's syndrome. multiple myeloma.
hypercalcemia, hypocalcemia arthritides, periodontal disease. rickets (includIng vitamin D dependent, type I and II, and )(linked hypophosphatemic rickets) fibrogenesis imperfecta ossium, osteosclerotic disorders such as pycnodysostosis and damage caused by macrophage-mediated inflammatory processes, etc.
In a further aspect, the present invention relates to the use of an isolated polynucleotide (e.g., able to inhibit osteoclast differentiation) for the preparation of a medicament for the treatment of a bone resorption disease.
The present invention in another aspect thereof, provides a pharmaceutical composition for promoting osteoclast differentiation in a mammal in need thereof. The pharmaceutical composition may comprise for example;
a. an isolated polynucleotide (e.g.. able to promote osteoclast differentiation) and:
b. a pharmaceutically acceptable carrier.
The present invention also further provides a method for promoting osteoclast differentiation in a mammal in need thereof (or in a mammalian cell), the method may comprise, for example, administering an isolated polynucleotide (e.g., able to promote osteoclast differentiation) or a suitable pharmaceutical composition as described above.
The present invention additionally relates to the use of an isolated 5 polynucleotide (e.g.. able to promote osteoclast differentiation) for the preparation of a medicament for the treatment of a disease associated with insufficient bone resorption (e.g., hyperostosis) or excessive bone growth.
The present invention also relates to the use of at least one polynucleotide which may be selected from the group consisting of:
10 a) a polynucleotide comprising any one of SEQ ID NO.:1 to 33, SEQ ID
NO.:85 or SEQ ID NO .86.
b) a polynucleotide comprising the open reading frame of any one of SEQ
ID NO:1 to 33, SEQ ID NO.:85 or SEQ ID NO.86, c) a polynucleotide which may comprise a transcribed or transcribable 15 portion of any one of SEQ. ID. NOs:1 to SEQ ID NO.33, SEQ ID NO.:85 or SEQ ID NO.86, which may be, for example. free of untranslated or untranslatable portion(s);
d) a polynucleotide which may comprise a translated or translatable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO 33 SEQ ID NO :85 or SEQ
20 ID NO.:86 (e.g.. coding portion).
e) a polynucleotide comprising a sequence substantially identical (e.g., from about 50 to 100%, or about 60 to 100% or about 70 to 100% or about 80 to 100% or about 85. 90, 95 to 100% identical over the entire sequence or portion of sequences) to a), b), c) or d);
25 f) a polynucleotide comprising a sequence substantially complementary (e.g., from about 50 to 100`)/0, or about 60 to 100% or about 70 to 100%
or about 80 to 100% or about 85, 90, 95 to 100% complementarity over the entire sequence or portion of sequences) to a), b), c) or d), g) a fragment of any one of a) to f) and,
a) an isolated polynucleotide as defined herein (e.g., able to inhibit osteoclast differentiation) and:
b) a pharmaceutically acceptable carrier.
The present invention also provides in yet an additional aspect. a method for inhibiting osteoclast differentiation (e.g., for inhibiting bone resorption or for ameliorating bone resorption) in a mammal (individual) in need thereof (or in a mammalian cell), the method may comprise administering an isolated polynucleotide (e.g., able to inhibit osteoclast differentiation) or a suitable pharmaceutical composition comprising such suitable polynucleotide.
In accordance with the present invention, the mammal in need may suffer, for example and without limitation, from a condition selected from the group consisting of osteoporosis, osteopenia, osteomalacia, hyperparathyroidism, hyperthyroidism, hypogonadism, thyrotoxicosis, systemic mastocytosis, adult hypophosphatasia, hyperadrenocorticism, osteogenesis imperfecta. Paget's disease, Cushing's disease/syndrome, Turner syndrome, Gaucher disease, Ehlers-Danlos syndrome, Marfan's syndrome, Menkes' syndrome. Fanconi's syndrome. multiple myeloma.
hypercalcemia, hypocalcemia arthritides, periodontal disease. rickets (includIng vitamin D dependent, type I and II, and )(linked hypophosphatemic rickets) fibrogenesis imperfecta ossium, osteosclerotic disorders such as pycnodysostosis and damage caused by macrophage-mediated inflammatory processes, etc.
In a further aspect, the present invention relates to the use of an isolated polynucleotide (e.g., able to inhibit osteoclast differentiation) for the preparation of a medicament for the treatment of a bone resorption disease.
The present invention in another aspect thereof, provides a pharmaceutical composition for promoting osteoclast differentiation in a mammal in need thereof. The pharmaceutical composition may comprise for example;
a. an isolated polynucleotide (e.g.. able to promote osteoclast differentiation) and:
b. a pharmaceutically acceptable carrier.
The present invention also further provides a method for promoting osteoclast differentiation in a mammal in need thereof (or in a mammalian cell), the method may comprise, for example, administering an isolated polynucleotide (e.g., able to promote osteoclast differentiation) or a suitable pharmaceutical composition as described above.
The present invention additionally relates to the use of an isolated 5 polynucleotide (e.g.. able to promote osteoclast differentiation) for the preparation of a medicament for the treatment of a disease associated with insufficient bone resorption (e.g., hyperostosis) or excessive bone growth.
The present invention also relates to the use of at least one polynucleotide which may be selected from the group consisting of:
10 a) a polynucleotide comprising any one of SEQ ID NO.:1 to 33, SEQ ID
NO.:85 or SEQ ID NO .86.
b) a polynucleotide comprising the open reading frame of any one of SEQ
ID NO:1 to 33, SEQ ID NO.:85 or SEQ ID NO.86, c) a polynucleotide which may comprise a transcribed or transcribable 15 portion of any one of SEQ. ID. NOs:1 to SEQ ID NO.33, SEQ ID NO.:85 or SEQ ID NO.86, which may be, for example. free of untranslated or untranslatable portion(s);
d) a polynucleotide which may comprise a translated or translatable portion of any one of SEQ. ID. NOs:1 to SEQ ID NO 33 SEQ ID NO :85 or SEQ
20 ID NO.:86 (e.g.. coding portion).
e) a polynucleotide comprising a sequence substantially identical (e.g., from about 50 to 100%, or about 60 to 100% or about 70 to 100% or about 80 to 100% or about 85. 90, 95 to 100% identical over the entire sequence or portion of sequences) to a), b), c) or d);
25 f) a polynucleotide comprising a sequence substantially complementary (e.g., from about 50 to 100`)/0, or about 60 to 100% or about 70 to 100%
or about 80 to 100% or about 85, 90, 95 to 100% complementarity over the entire sequence or portion of sequences) to a), b), c) or d), g) a fragment of any one of a) to f) and,
30 h) a library comprising any one of a) to g) in the diagnosis of a condition related to bone remodeling (a bone disease).
31 Also encompassed by the present invention are kits for the diagnosis of a condition related to bone remodeling. The kit may comprise a polynucleotide as described herein.
The present invention also provides in an additional aspect, an isolated polypeptide (polypeptide sequence) involved in osteoclast differentiation (in a mammal or a mammalian cell thereof). The polypeptide may comprise (or consist in) a sequence selected from the group consisting of.
a) any one of SEQ ID NO . 48 to 80, b) a polypeptide able to be encoded and/or encoded by any one of SEQ ID NO.:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86 (their coding portion) c) a biologically active fragment of any one of a) or b), d) a biologically active analog of any one of a) or b).
In accordance with the present invention, the biologically active analog may comprise, for example, at least one amino acid substitution (conservative or non conservative) compared to the original sequence. In accordance with the present invention, the analog may comprise, for example, at least one amino acid substitution, deletion or insertion in its amino acid sequence.
The substitution may be conservative or non-conservative The polypeptide analog may be a biologically active analog or an immunogenic analog which may comprise. for example at least one amino acid substitution (conservative or non conservative), for example, 1 to 5 1 to 10 1 to 15, 1 to 20. 1 to 50 etc (including any number there between) compared to the original sequence. An immunogenic analog may comprise, for example, at least one amino acid substitution compared to the original sequence and may still be bound by an antibody specific for the original sequence.
In accordance with the present invention, a polypeptide fragment may comprise, for example, at least 6 consecutive amino acids, at least 8 consecutive amino acids or more of an amino acid sequence described herein.
In yet a further aspect, the present invention provides a pharmaceutical composition which may comprise, for example a polypeptide as described herein and a pharmaceutically acceptable carrier.
The present invention also provides in an additional aspect, an isolated polypeptide (polypeptide sequence) involved in osteoclast differentiation (in a mammal or a mammalian cell thereof). The polypeptide may comprise (or consist in) a sequence selected from the group consisting of.
a) any one of SEQ ID NO . 48 to 80, b) a polypeptide able to be encoded and/or encoded by any one of SEQ ID NO.:1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86 (their coding portion) c) a biologically active fragment of any one of a) or b), d) a biologically active analog of any one of a) or b).
In accordance with the present invention, the biologically active analog may comprise, for example, at least one amino acid substitution (conservative or non conservative) compared to the original sequence. In accordance with the present invention, the analog may comprise, for example, at least one amino acid substitution, deletion or insertion in its amino acid sequence.
The substitution may be conservative or non-conservative The polypeptide analog may be a biologically active analog or an immunogenic analog which may comprise. for example at least one amino acid substitution (conservative or non conservative), for example, 1 to 5 1 to 10 1 to 15, 1 to 20. 1 to 50 etc (including any number there between) compared to the original sequence. An immunogenic analog may comprise, for example, at least one amino acid substitution compared to the original sequence and may still be bound by an antibody specific for the original sequence.
In accordance with the present invention, a polypeptide fragment may comprise, for example, at least 6 consecutive amino acids, at least 8 consecutive amino acids or more of an amino acid sequence described herein.
In yet a further aspect, the present invention provides a pharmaceutical composition which may comprise, for example a polypeptide as described herein and a pharmaceutically acceptable carrier.
32 Methods for modulating osteoclast differentiation in a mammal in need thereof (or in a mammalian cell) are also provided by the present invention, which methods may comprise administering an isolated polypeptide (e.g., able to promote osteoclast differentiation) or suitable pharmaceutical composition described herein.
In additional aspects, the present invention relates to the use of an isolated polypeptide (e.g.. able to promote osteoclast differentiation) for the preparation of a medicament for the treatment of a disease associated with insufficient bone resorption.
Methods for ameliorating bone resorption in an individual in need thereof are also encompassed herewith, which method may comprise, for example administering an isolated polypeptide (e.g., able to inhibit osteoclast differentiation) or suitable pharmaceutical compositions which may comprise such polypeptide In accordance with the present invention, the mammal may suffer, for example, from a condition selected from the group consisting of osteoporosis, osteopenia, osteomalacia. hyperparathyroidism, hyperthyroidism, hypogonadism, thyrotoxicosis.
systemic mastocytosis, adult hypophosphatasia, hyperadrenocorticism, osteogenesis imperfecta, Paget's disease, Cushing's disease/syndrome, Turner syndrome, Gaucher disease, Ehlers-Danlos syndrome, Marfan's syndrome, Menkes' syndrome, Fanconi's syndrome, multiple myeloma, hypercalcemia, hypocalcemia, arthritides, periodontal disease. rickets (including vitamin D dependent, type I and II. and x-linked hypophosphatemic rickets), fibrogenesis imperfecta ossium, osteosclerotic disorders such as pycnodysostosis and damage caused by macrophage-mediated inflammatory processes, etc.
In yet a further aspect, the present invention relates to the use of a polypeptide able to inhibit osteoclast differentiation in the preparation of a medicament for the treatment of a bone resorption disease in an individual in need thereof The present invention also relates to a compound and the use of a compound able to inhibit (e.g., in an osteoclast precursor cell) the activity or expression of a polypeptide which may be selected, for example, from the group consisting of SEQ ID
NO.: 48 to 80 or a polypeptide encoded by SEQ ID NO :85 or SEQ ID NO.:86. in the preparation of a medicament for the treatment of a bone disease in an individual in need thereof.
In yet an additional aspect, the present invention relates to a method of diagnosing a condition related to a bone resorption disorder or disease in an individual
In additional aspects, the present invention relates to the use of an isolated polypeptide (e.g.. able to promote osteoclast differentiation) for the preparation of a medicament for the treatment of a disease associated with insufficient bone resorption.
Methods for ameliorating bone resorption in an individual in need thereof are also encompassed herewith, which method may comprise, for example administering an isolated polypeptide (e.g., able to inhibit osteoclast differentiation) or suitable pharmaceutical compositions which may comprise such polypeptide In accordance with the present invention, the mammal may suffer, for example, from a condition selected from the group consisting of osteoporosis, osteopenia, osteomalacia. hyperparathyroidism, hyperthyroidism, hypogonadism, thyrotoxicosis.
systemic mastocytosis, adult hypophosphatasia, hyperadrenocorticism, osteogenesis imperfecta, Paget's disease, Cushing's disease/syndrome, Turner syndrome, Gaucher disease, Ehlers-Danlos syndrome, Marfan's syndrome, Menkes' syndrome, Fanconi's syndrome, multiple myeloma, hypercalcemia, hypocalcemia, arthritides, periodontal disease. rickets (including vitamin D dependent, type I and II. and x-linked hypophosphatemic rickets), fibrogenesis imperfecta ossium, osteosclerotic disorders such as pycnodysostosis and damage caused by macrophage-mediated inflammatory processes, etc.
In yet a further aspect, the present invention relates to the use of a polypeptide able to inhibit osteoclast differentiation in the preparation of a medicament for the treatment of a bone resorption disease in an individual in need thereof The present invention also relates to a compound and the use of a compound able to inhibit (e.g., in an osteoclast precursor cell) the activity or expression of a polypeptide which may be selected, for example, from the group consisting of SEQ ID
NO.: 48 to 80 or a polypeptide encoded by SEQ ID NO :85 or SEQ ID NO.:86. in the preparation of a medicament for the treatment of a bone disease in an individual in need thereof.
In yet an additional aspect, the present invention relates to a method of diagnosing a condition related to a bone resorption disorder or disease in an individual
33 in need thereof. The method may comprise, for example, quantifying a polynucleotide described herein, such as, for example, polynucleotide selected from the group consisting of those comprising or consisting of (a) SEQ ID NO. :1 to 33, SEQ
ID NO.:85 or SEQ ID NO.86, (b) a polynucleotide which may comprise the open reading frame of SEQ ID NO.: 1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86, (c) a polynucleotide which may comprise a transcribed or transcribable portion of any one of SEQ. ID.
NOs:1 to SEQ ID NO.33, SEQ ID NO.:85 or SEQ ID NO.:86 (d) a polynucleotide which may comprise a translated or translatable portion of any one of SEQ. ID. NOs:1 to SEQ ID
NO.33, SEQ ID NO.:85 or SEQ ID NO.:86; (e) substantially identical sequences of any one of (a) to (d): (f) substantially complementary sequences of any one of (a) to (e), or a polypeptide sequence which may be selected, for example, from the group consisting of SEQ ID NO.: 48 to 80 or a polypeptide encoded by SEQ ID NO.:85 or SEQ ID
NO.:86, and analogs thereof in a sample from the individual compared to a standard or normal value The present invention also relates to an assay and method for identifying a gene and/or protein involved in bone remodeling. The assay and method may comprise silencing an endogenous gene of an osteoclast cell and providing the cell with a candidate gene (or protein). A candidate gene (or protein) positively involved in bone remodeling may be identified by its ability to complement the silenced endogenous gene. For example, a candidate gene involved in osteoclast differentiation provided to a cell for which an endogenous gene has been silenced. may enable the cell to differentiate in the presence of an inducer such as, for example, RANKL.
The present invention further relates to a cell expressing an exogenous form of any one of the polypeptide (including variants, analogs etc.) or polynucleotide of the present invention (including substantially identical sequences substantially complementary sequences, fragments, variants, orthologs etc).
In accordance with the present invention, the cell may be for example, a bone cell. Also in accordance with the present invention, the cell may be an osteoclast (at any level of differentiation).
As used herein the term "exogenous form" is to be understood herein as a form which is not naturally expressed by the cell in question.
In a further aspect, the present invention relates to an antibody (e.g..
isolated
ID NO.:85 or SEQ ID NO.86, (b) a polynucleotide which may comprise the open reading frame of SEQ ID NO.: 1 to 33, SEQ ID NO.:85 or SEQ ID NO.:86, (c) a polynucleotide which may comprise a transcribed or transcribable portion of any one of SEQ. ID.
NOs:1 to SEQ ID NO.33, SEQ ID NO.:85 or SEQ ID NO.:86 (d) a polynucleotide which may comprise a translated or translatable portion of any one of SEQ. ID. NOs:1 to SEQ ID
NO.33, SEQ ID NO.:85 or SEQ ID NO.:86; (e) substantially identical sequences of any one of (a) to (d): (f) substantially complementary sequences of any one of (a) to (e), or a polypeptide sequence which may be selected, for example, from the group consisting of SEQ ID NO.: 48 to 80 or a polypeptide encoded by SEQ ID NO.:85 or SEQ ID
NO.:86, and analogs thereof in a sample from the individual compared to a standard or normal value The present invention also relates to an assay and method for identifying a gene and/or protein involved in bone remodeling. The assay and method may comprise silencing an endogenous gene of an osteoclast cell and providing the cell with a candidate gene (or protein). A candidate gene (or protein) positively involved in bone remodeling may be identified by its ability to complement the silenced endogenous gene. For example, a candidate gene involved in osteoclast differentiation provided to a cell for which an endogenous gene has been silenced. may enable the cell to differentiate in the presence of an inducer such as, for example, RANKL.
The present invention further relates to a cell expressing an exogenous form of any one of the polypeptide (including variants, analogs etc.) or polynucleotide of the present invention (including substantially identical sequences substantially complementary sequences, fragments, variants, orthologs etc).
In accordance with the present invention, the cell may be for example, a bone cell. Also in accordance with the present invention, the cell may be an osteoclast (at any level of differentiation).
As used herein the term "exogenous form" is to be understood herein as a form which is not naturally expressed by the cell in question.
In a further aspect, the present invention relates to an antibody (e.g..
isolated
34 antibody), or antigen-binding fragment thereof, that may specifically bind to a protein or polypeptide described herein The antibody may be, for example a monoclonal antibody, a polyclonal antibody an antibody generated using recombinant DNA
technologies. The antibody may originate for example, from a mouse, rat or any other mammal.
The antibody may also be a human antibody which may be obtained, for example, from a transgenic non-human mammal capable of expressing human Ig genes. The antibody may also be a humanised antibody which may comprise, for example, one or more complementarity determining regions of non-human origin.
It may also comprise a surface residue of a human antibody and/or framework regions of a human antibody. The antibody may also be a chimeric antibody which may comprise, for example, variable domains of a non-human antibody and constant domains of a human antibody.
Suitable antibodies may also include, for example, an antigen-binding fragment.
an Fab fragment; an F(ab):, fragment, and Fv fragment, or a single-chain antibody comprising an antigen-binding fragment (e.g.. a single chain Fv) The antibody of the present invention may be mutated and selected based on an increased affinity and/or specificity for one of a polypeptide described herein and/or based on a reduced immunogenicity in a desired host.
The antibody may further comprise a detectable label attached thereto.
The present invention further relates to a method of producing antibodies able to bind to one of a polypeptide, polypeptide fragments, or polypeptide analogs described herein, the method may comprise:
a) immunizing a mammal (e.g., mouse, a transgenic mammal capable of producing human Ig, etc.) with a suitable amount of a PSEQ
described herein including, for example, a polypeptide fragment comprising at least 6 consecutive amino acids of a PSEQ:
b) collecting the serum from the mammal, and c) isolating the polypeptide-specific antibodies from the serum of the mammal The method may further comprise the step of administering a second dose to the animal.
The present invention also relates to a method of producing a hybridoma which secretes an antibody that binds to a polypeptide described herein, the method may comprise.
a) immunizing a mammal (e.g.. mouse. a transgenic mammal 5 capable of producing human lg. etc.) with a suitable amount of a PSEQ
thereof;
b) obtaining lymphoid cells from the immunized animal obtained from (a);
c) fusing the lymphoid cells with an immortalizing cell to produce 10 hybrid cells; and d) selecting hybrid cells which produce antibody that specifically binds to a PSEQ thereof.
The present invention further relates to a method of producing an antibody that binds to one of the polypeptide described herein, the method may comprise:
15 a) synthesizing a library of antibodies (antigen binding fragment) on phage or ribosomes.
b) panning the library against a sample by bringing the phage or ribosomes into contact with a composition comprising a polypeptide or polypeptide fragment described herein;
20 c) isolating phage which binds to the polypeptide or polypeptide fragment, and;
d) obtaining an antibody from the phage or ribosomes.
The antibody of the present invention may thus be obtained, for example, from a library (e.g., bacteriophage library) which may be prepared, for example, by 25 a) extracting cells which are responsible for production of antibodies from a host mammal:
b) isolating RNA from the cells of (a):
C) reverse transcribing mRNA to produce cDNA
d) amplifying the cDNA using a (antibody-specific) primer, and e) inserting the cDNA of (d) into a phage display vector or ribosome display cassette such that antibodies are expressed on the phage or ribosomes.
The host animal may be immunized with polypeptide and/or a polypeptide .. fragment and/or analog described herein to induce an immune response prior to extracting the cells which are responsible for production of antibodies The present invention also relates to a kit for specifically assaying a polypeptide described herein, the kit may comprise, for example, an antibody or antibody fragment capable of binding specifically to the polypeptide described herein.
The present invention further contemplates antibodies that may bind to PSEQ.
Suitable antibodies may bind to unique antigenic regions or epitopes in the polypeptides, or a portion thereof. Epitopes and antigenic regions useful for generating antibodies may be found within the proteins, polypeptides or peptides by procedures available to one of skill in the art. For example, short, unique peptide sequences may be identified in the proteins and polypeptides that have little or no homology to known amino acid sequences. Preferably the region of a protein selected to act as a peptide epitope or antigen is not entirely hydrophobic: hydrophilic regions are preferred because those regions likely constitute surface epitopes rather than internal regions of the proteins and polypeptides. These surface epitopes are more readily detected in samples tested for the presence of the proteins and polypeptides Such antibodies may include, but are not limited to; polyclonal, monoclonal. chimeric, and single chain antibodies, Fab fragments and fragments produced by a Fab expression library.
The production of antibodies is well known to one of skill in the art.
Peptides may be made by any procedure known to one of skill in the art, for example, by using in vitro translation or chemical synthesis procedures. Short peptides which provide an antigenic epitope but which by themselves are too small to induce an immune response may be conjugated to a suitable carrier. Suitable carriers and methods of linkage are well known in the art. Suitable carriers are typically large macromolecules such as proteins, polysaccharides and polymeric amino acids Examples include serum albumins. keyhole limpet hemocyanin, ovalbumin, polylysine and the like. One of skill in the art may use available procedures and coupling reagents to link the desired peptide epitope to such a carrier. For example. coupling reagents may be used to form disulfide linkages or thioether linkages from the carrier to the peptide of interest. If the peptide lacks a disulfide group, one may be provided by the addition of a cysteine residue. Alternatively, coupling may be accomplished by activation of carboxyl groups.
The minimum size of peptides useful for obtaining antigen specific antibodies may vary widely. The minimum size must be sufficient to provide an antigenic epitope that is specific to the protein or polypeptide The maximum size is not critical unless it is desired to obtain antibodies to one particular epitope. For example, a large polypeptide may comprise multiple epitopes. one epitope being particularly useful and a second epitope being immunodominant. Typically, antigenic peptides selected from the present proteins and polypeptides will range from 5 to about 100 amino acids in length. More typically, however, such an antigenic peptide will be a maximum of about 50 amino acids in length, and preferably a maximum of about 30 amino acids. It is usually desirable to select a sequence of about 6, 8, 10, 12 or 15 amino acids, up to about 20 or 25 amino acids.
Amino acid sequences comprising useful epitopes may be identified in a number of ways. For example, preparing a series of short peptides that taken together span the entire protein sequence may be used to screen the entire protein sequence.
One of skill in the art may routinely test a few large polypeptides for the presence of an epitope showing a desired reactivity and also test progressively smaller and overlapping fragments to identify a preferred epitope with the desired specificity and reactivity.
Antigenic polypeptides and peptides are useful for the production of monoclonal and polyclonal antibodies_ Antibodies to a polypeptide encoded by the polynucleotides of NSEQ, polypeptide analogs or portions thereof, may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, such as those that inhibit dimer formation, are especially preferred for therapeutic use.
Monoclonal antibodies may be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to. the hybridoma, the human B-cell hybridoma, and the EBV-hybridoma techniques. In addition, techniques developed for the production of chimeric antibodies may be used. Alternatively, techniques described for the production of single chain antibodies may be employed. Fabs that may contain specific binding sites for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof, may also be generated. Various immunoassays may be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art.
To obtain polyclonal antibodies, a selected animal may be immunized with a protein or polypeptide. Serum from the animal may be collected and treated according to known procedures. Polyclonal antibodies to the protein or polypeptide of interest may then be purified by affinity chromatography. Techniques for producing polyclonal antisera are well known in the art.
Monoclonal antibodies (MAbs) may be made by one of several procedures available to one of skill in the art, for example, by fusing antibody producing cells with immortalized cells and thereby making a hybridoma. The general methodology for fusion of antibody producing B cells to an immortal cell line is well within the province of one skilled in the art. Another example is the generation of MAbs from mRNA
extracted from bone marrow and spleen cells of immunized animals using combinatorial antibody library technology.
One drawback of MAbs derived from animals or from derived cell lines is that although they may be administered to a patient for diagnostic or therapeutic purposes, they are often recognized as foreign antigens by the immune system and are unsuitable for continued use. Antibodies that are not recognized as foreign antigens by the human immune system have greater potential for both diagnosis and treatment Methods for generating human and humanized antibodies are now well known in the art.
Chimeric antibodies may be constructed in which regions of a non-human MAb are replaced by their human counterparts. A preferred chimeric antibody is one that has amino acid sequences that comprise one or more complementanty determining regions (CDRs) of a non-human Mab that binds to a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof, grafted to human framework (FVV) regions. Methods for producing such antibodies are well known in the art.
Amino acid residues corresponding to CDRs and FVVs are known to one of average skill in the art A variety of methods have been developed to preserve or to enhance affinity for antigen of antibodies comprising grafted CDRs One way is to include in the chimeric antibody the foreign framework residues that influence the conformation of the CDR
regions. A second way is to graft the foreign CDRs onto human variable domains with the closest homology to the foreign variable region. Thus, grafting of one or more non-human CDRs onto a human antibody may also involve the substitution of amino acid residues which are adjacent to a particular CDR sequence or which are not contiguous with the CDR sequence but which are packed against the CDR in the overall antibody variable domain structure and which affect the conformation of the CDR
Humanized antibodies of the invention therefore include human antibodies which comprise one or more non-human CDRs as well as such antibodies in which additional substitutions or replacements have been made to preserve or enhance binding characteristics Chimeric antibodies of the invention also include antibodies that have been humanized by replacing surface-exposed residues to make the MAb appear human.
Because the internal packing of amino acid residues in the vicinity of the antigen-binding site remains unchanged, affinity is preserved. Substitution of surface-exposed residues of a polypeptide encoded by the polynucleotides of NSEQ (or a portion thereof)-antibody according to the invention for the purpose of humanization does not mean substitution of CDR residues or adjacent residues that influence affinity for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof.
Chimeric antibodies may also include antibodies where some or all non-human constant domains have been replaced with human counterparts. This approach has the advantage that the antigen-binding site remains unaffected. However, significant amounts of non-human sequences may be present where variable domains are derived entirely from non-human antibodies.
Antibodies of the invention include human antibodies (e.g . humanized) that are antibodies consisting essentially of human sequences. Human antibodies may be obtained from phage display libraries wherein combinations of human heavy and light chain variable domains are displayed on the surface of filamentous phage.
Combinations of variable domains are typically displayed on filamentous phage in the form of Fab's or scFvs. The library may be screened for phage bearing combinations of variable domains having desired antigen-binding characteristics. Preferred variable domain combinations are characterized by high affinity for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof. Preferred variable domain combinations may also be characterized by high specificity for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof. and little cross-reactivity to other related antigens. By screening from very large repertoires of antibody fragments, (2-10 x 1010) a good diversity of high affinity Mabs may be isolated, with many expected to 5 have sub-nanomolar affinities for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof.
Alternatively, human antibodies may be obtained from transgenic animals into which un-rearranged human Ig gene segments have been introduced and in which the endogenous mouse Ig genes have been inactivated. Preferred transgenic animals 10 contain very large contiguous Ig gene fragments that are over 1 Mb in size but human polypeptide-specific Mabs of moderate affinity may be raised from transgenic animals containing smaller gene loci. Transgenic animals capable of expressing only human Ig genes may also be used to raise polyclonal antiserum comprising antibodies solely of human origin.
15 Antibodies of the invention may include those for which binding characteristics have been improved by direct mutation or by methods of affinity maturation.
Affinity and specificity may be modified or improved by mutating CDRs and screening for antigen binding sites having the desired characteristics. CDRs may be mutated in a variety of ways. One way is to randomize individual residues or combinations of residues so that 20 in a population of otherwise identical antigen binding sites, all twenty amino acids may be found at particular positions. Alternatively, mutations may be induced over a range of CDR residues by error prone PCR methods. Phage display vectors containing heavy and light chain variable region gene may be propagated in mutator strains of E. coll.
These methods of mutagenesis are illustrative of the many methods known to one of 25 skill in the art.
Antibodies of the invention may include complete anti-polypeptide antibodies as well as antibody fragments and derivatives that comprise a binding site for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof Derivatives are macromolecules that comprise a binding site linked to a functional domain.
30 Functional domains may include, but are not limited to signalling domains, toxins.
enzymes and cytokines.
The antibodies obtained by the means described herein may be useful for detecting proteins, variant and derivative polypeptides in specific tissues or in body fluids. Moreover, detection of aberrantly expressed proteins or protein fragments is probative of a disease state. For example, expression of the present polypeptides encoded by the polynucleotides of NSEQ. or a portion thereof, may indicate that the protein is being expressed at an inappropriate rate or at an inappropriate developmental stage. Hence, the present antibodies may be useful for detecting diseases associated with protein expression from NSEQs disclosed herein.
A variety of protocols for measuring polypeptides, including ELISAs. RIAs, and FACS, are well known in the art and provide a basis for diagnosing altered or abnormal levels of expression. Standard values for polypeptide expression are established by combining samples taken from healthy subjects, preferably human, with antibody to the polypeptide under conditions for complex formation. The amount of complex formation may be quantified by various methods, such as photometric means. Quantities of polypeptide expressed in disease samples may be compared with standard values.
Deviation between standard and subject valuesmay establish the parameters for diagnosing or monitoring disease.
Design of immunoassays is subject to a great deal of variation and a variety of these are known in the art. Immunoassays may use a monoclonal or polyclonal antibody reagent that is directed against one epitope of the antigen being assayed Alternatively, a combination of monoclonal or polyclonal antibodies may be used which are directed against more than one epitope. Protocols may be based. for example, upon competition where one may use competitive drug screening assays in which neutralizing antibodies capable of binding a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof, specifically compete with a test compound for binding the polypeptide. Alternatively one may use, direct antigen-antibody reactions or sandwich type assays and protocols may. for example, make use of solid supports or immunoprecipitation. Furthermore, antibodies may be labelled with a reporter molecule for easy detection. Assays that amplify the signal from a bound reagent are also known. Examples include immunoassays that utilize avidin and biotin or which utilize enzyme-labelled antibody or antigen conjugates, such as ELISA
assays.
Kits suitable for immunodiagnosis and containing the appropriate labelled reagents include antibodies directed against the polypeptide protein epitopes or antigenic regions, packaged appropriately with the remaining reagents and materials required for the conduct of the assay. as well as a suitable set of assay instructions.
The present invention therefore provides a kit for specifically assaying a polypeptide described herein, the kit may comprise, for example, an antibody or antibody fragment capable of binding specifically to the polypeptide described herein.
In accordance with the present invention, the kit may be a diagnostic kit, which may comprise, a) one or more antibodies described herein; and b) a detection reagent which may comprise a reporter group In accordance with the present invention, the antibodies may be immobilized on a solid support. The detection reagent may comprise, for example, an anti-immunoglobulin, protein G. protein A or lectin etc. The reporter group may be selected, without limitation, from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.
In an additional aspect, the present invention provides a method for identifying an inhibitory compound (inhibitor, antagonist) which may be able to impair the function (activity) or expression of a polypeptide described herein, such as, for example. those which may be selected from the group consisting of SEQ ID NO ; 48 to 80 or a polypeptide encoded by SEQ ID NO 85 or SEQ ID NO '86. and analogs thereof. The method may comprise contacting the polypeptide or a cell expressing the polypeptide with a candidate compound and measuring the function (activity) or expression of the polypeptide. A reduction in the function or activity of the polypeptide (compared to the absence of the candidate compound) may positively identify a suitable inhibitory compound.
In accordance with the present invention; the impaired function or activity may be associated with a reduced ability of the polypeptide to promote osteoclast differentiation, such as osteoclast differentiation induced by an inducer described herein or known in the art.
In accordance with the present invention the cell may not naturally (endogenously) express (polypeptide may substantially be unexpressed in a cell) the polypeptide or analog or alternatively, the expression of a naturally expressed polypeptide analog may be repressed.
For example, suitable method of screening for an inhibitor of SEQ ID NO 1, may comprise repressing the expression of the mouse ortholog SEQ ID NO.:35 in a mouse osteoclast cell and evaluating differentiation of the osteoclast cell comprising SEQ ID NO. :1 in the presence or absence of a candidate inhibitor and for example, an inducer of osteoclast differentiation (e.g.. RANKLY
The present invention also provides a method for identifying an inhibitory compound (inhibitor, antagonist) able to impair the function (activity) or expression of a polypeptide such as, for example SEQ ID NO 1 or SEQ ID NO .2 The method may comprise, for example, contacting the (isolated) polypeptide or a cell expressing the polypeptide with a candidate compound and measuring the function (activity) or expression of the polypeptide. A reduction in the function or activity of the polypeptide (compared to the absence of the candidate compound) may thus positively identify a suitable inhibitory compound.
In accordance with the present invention, the impaired function or activity may be associated, for example, with a reduced ability of the polypeptide to inhibit or promote osteoclast differentiation.
The cell used to carry the screening test may not naturally (endogenously) express the polypeptide or analogs, or alternatively the expression of a naturally expressed polypeptide analog may be repressed.
The present invention also relates to a method of identifying a positive or a negative regulator of osteoclast differentiation_ The method may comprise for example. performing a knockdown effect as described herein. The method may more particularly comprise a) providing an osteoclast cell with a compound (e g siRNA) able to specifically inhibit a target sequence (e.g.. a polynucleotide or polypeptide as described herein), b) inducing differentiation (e.g., with an inducer such as.
for example, RANKL) and c) determining the level of differentiation of the osteoclast cell (e.g., measuring the number of differentiated cells, their rate of differentiation, specific marker of differentiation etc).
Upon inhibition of a positive regulator, the levels of osteoclast differentiation will appear lowered. Upon inhibition of a negative regulator, the level of osteoclast differentiation will apear increased.
Another method of identifying a positive or a negative regulator of osteoclast differentiation is to a) provide a cell with one of a target sequence described herein (polypeptide or polynucleotide able to express a polypeptide) b) to induce differentiation (e.g., with an inducer such as, for example, RANKL) and c) to determine the level of differentiation of the osteoclast cell (e.g., measuring the number of differentiated cells, their rate of differentiation, specific marker of differentiation etc).
A cell provided with a positive regulator of osteoclast differentiation may have an increased level of differentiation. A cell provided with a negative regulator of osteoclast differentiation may have a decreased level of differentiation.
The present invention aslo provides a method of identifying a compound capable of interfering with osteoclast differentiation, the method may comprise contacting a cell including therein a non-endogenous polynucleotide sequence comprising any one of SEQ ID NO.:1 to 33. 85 or 86 (a coding portion) and quantifying (e.g. the number of) differentiated osteoclasts. A reduction in osteoclast differentiation in the presence of the compound in comparison to the absence of the compound may be indicative of an antagonist of osteoclast differentiation, while an increase in osteoclast differentiation in the presence of the compound in comparison to the absence of the compound may be indicative of an agonist of osteoclast differentiation.
In accordance with the present invention, the cell may also comprise an endogenous form of a polynucleotide.
As used herein the term "endogenous" means a substance that naturally originates from within an organism, tissue or cell. The term "endogenous polynucleotide" refers to a chromosomal form of a polynucleotide or RNA
version (hnRNA. mRNA) produced by the chromosal form of the polynucleotide The term "endogenous polypeptide- refers to the form of the protein encoded by an -endogenous polynucleotide".
As used herein the term "non-endogenous" or -exogenous" is used in opposition to "endogenous" in that the substance is provided from an external source although it may be introduced within the cell. The term "non-endogenous polynucleotide" refers to a synthetic polynucleotide introduced within the cell and include for example and without limitation, a vector comprising a sequence of interest, a synthetic mRNA, an oligonucleotide comprising a NSEQ etc. The term "non-endogenous polypeptide" refers to the form of the protein encoded by an "non-endogenous polynucleotide", The present invention also relate to a method of identifying a compound capable of interfering with osteoclast differentiation, the method may comprise contacting a cell including therein a non-endogenous polypeptide sequence comprising any one of SEQ ID NO.: 48 to 80 and quantifying (e.g. the number of) differentiated osteoclasts. A reduction in osteoclast differentiation in the presence of the compound in comparison to the absence of the compound may be indicative of 5 an antagonist of osteoclast differentiation while an increase in osteoclast differentiation in the presence of the compound in comparison to the absence of the compound may be indicative of an agonist of osteoclast differentiation.
As used herein the term "sequence identity" relates to (consecutive) nucleotides of a nucleotide sequence which with reference to an original nucleotide 10 sequence. The identity may be compared over a region or over the total sequence of a nucleic acid sequence.
Thus, "identity" may be compared, for example, over a region of 3, 4, 5, 10, 19, 20 nucleotides or more (and any number there between). It is to be understood herein that gaps of non-identical nucleotides may be found between identical nucleic 15 acids. For example, a polynucleotide may have 100% identity with another polynucleotide over a portion thereof. However, when the entire sequence of both polynucleotides is compared, the two polynucleotides may have 50% of their overall (total) sequence identical to one another.
Polynucleotides of the present invention or portion thereof having from about 20 50 to about 100%, or about 60 to about 100% or about 70 to about 100% or about 80 to about 100% or about 85%, about 90%, about 95% to about 100% sequence identity with an original polynucleotide are encompassed herewith. It is known by those of skill in the art, that a polynucleotide having from about 50% to 100%
identity may function (e.g., anneal to a substantially complementary sequence) in a manner 25 similar to an original polynucleotide and therefore may be used in replacement of an original polynucleotide. For example a polynucleotide (a nucleic acid sequence) may comprise or have from about 50% to 100% identity with an original polynucleotide over a defined region and may still work as efficiently or sufficiently to achieve the present invention.
Percent identity may be determined, for example, with an algorithm GAP, BESTFIT', or FASTA in the Wisconsin Genetics Software Package Release 7.0, using default gap weights.
As used herein the terms " sequence complementarity" refers to (consecutive) nucleotides of a nucleotide sequence which are complementary to a reference PCT/CA2007/1)00210 (original) nucleotide sequence The complementarity may be compared over a region or over the total sequence of a nucleic acid sequence.
Polynucleotides of the present invention or portion thereof having from about to about 100%, or about 60 to about 100% or about 70 to about 100% or about 80 to about 100% or about 85%, about 90%, about 95% to about 100% sequence complementarity with an original polynucleotide are thus encompassed herewith.
It is known by those of skill in the art, that an polynucleotide having from about 50% to 100% complementarity with an original sequence may anneal to that sequence in a manner sufficient to carry out the present invention (e.g., inhibit expression of the original polynucleotide).
An "analogue" is to be understood herein as a molecule having a biological activity and chemical structure similar to that of a polypeptide described herein. An "analogue" may have sequence similarity with that of an original sequence or a portion of an original sequence and may also have a modification of its structure as discussed herein. For example, an "analogue" may have at least 90 A) sequence similarity with an original sequence or a portion of an original sequence. An "analogue" may also have, for example: at least 70 A) or even 50 A sequence similarity (or less, i.e.. at least 40%) with an original sequence or a portion of an original sequence Also, an "analogue" with reference to a polypeptide may have, for example, at least 50 % sequence similarity to an original sequence with a combination of one or more modification in a backbone or side-chain of an amino acid, or an addition of a group or another molecule, etc.
"Polynucleotide" generally refers to any polyribonucleotide or polydeoxyribo-nucleotide, which may be unmodified RNA or DNA, or modified RNA or DNA.
"Polynucleotides" include, without limitation single- and double-stranded DNA, DNA
that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions hybrid molecules comprising DNA and RNA that may be single-stranded or more typically double-stranded or a mixture of single- and double-stranded regions In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA
and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA.
thus "polynucleotide" embraces chemically. enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. 'Polynucleotide" includes but is not limited to linear and end-closed molecules. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.
"Polypeptides" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds (i.e., peptide isosteres). "Polypeptide" refers to both short chains, commonly referred as peptides, oligopeptides or oligomers, and to longer chains generally referred to as proteins. As described above, polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
As used herein the term "polypeptide analog" relates to mutants, variants, chimeras. fusions, deletions, additions and any other type of modifications made relative to a given polypeptide.
As used herein the term "biologically active" refers to a variant or fragment which retains some or all of the biological activity of the natural polypeptide, i.e., to be able to promote or inhibit osteoclast differentiation. Polypeptides or fragments of the present invention may also include "immunologically active" polypeptides or fragments.
"Immunologically active polypeptides or fragments may be useful for immunization purposes (e.g. in the generation of antibodies).
Thus. biologically active polypeptides in the form of the original polypeptides, fragments (modified or not), analogues (modified or not), derivatives (modified or not).
homologues, (modified or not) of the polypeptides described herein are encompassed by the present invention.
Therefore, any polypeptide having a modification compared to an original polypeptide which does not destroy significantly a desired biological activity is encompassed herein It is well known in the art, that a number of modifications may be made to the polypeptides of the present invention without deleteriously affecting their biological activity. These modifications may, on the other hand, keep or increase the biological activity of the original polypeptide or may optimize one or more of the particularity (e.g. stability, bioavailability, etc.) of the polypeptides of the present invention which, in some instance might be desirable. Polypeptides of the present invention may comprise for example, those containing amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are known in the art. Modifications may occur anywhere in a polypeptide including the polypeptide backbone the amino acid side-chains and the amino- or carboxy-terminus. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. It is to be understood herein that more than one modification to the polypeptides described herein are encompassed by the present invention to the extent that the biological .. activity is similar to the original (parent) polypeptide.
As discussed above, polypeptide modification may comprise, for example, amino acid insertion (i.e., addition), deletion and substitution (i.e., replacement), either conservative or non-conservative (e.g., D-amino acids, desamino acids) in the polypeptide sequence where such changes do not substantially alter the overall biological activity of the polypeptide.
Example of substitutions may be those, which are conservative (i.e., wherein a residue is replaced by another of the same general type or group) or when wanted non-conservative (i.e., wherein a residue is replaced by an amino acid of another type) In addition a non-naturally occurring amino acid may substitute for a naturally occurring amino acid (i.e., non-naturally occurring conservative amino acid substitution or a non-naturally occurring non-conservative amino acid substitution).
As is understood, naturally occurring amino acids may be sub-classified as acidic, basic, neutral and polar, or neutral and non-polar. Furthermore, three of the encoded amino acids are aromatic. It may be of use that encoded polypeptides differing from the determined polypeptide of the present invention contain substituted codons for amino acids, which are from the same type or group as that of the amino acid to be replaced. Thus, in some cases, the basic amino acids Lys, Arg and His may be interchangeable; the acidic amino acids Asp and Glu may be interchangeable, the neutral polar amino acids Ser, Thr, Cys, Gln. and Asn may be interchangeable:
the non-polar aliphatic amino acids Gly, Ala, Val. Ile, and Leu are interchangeable but because of size Gly and Ala are more closely related and Val, Ile and Leu are more closely related to each other. and the aromatic amino acids Phe. Trp and Tyr may be interchangeable_ It should be further noted that if the polypeptides are made synthetically, substitutions by amino acids, which are not naturally encoded by DNA (non-naturally occurring or unnatural amino acid) may also be made.
A non-naturally occurring amino acid is to be understood herein as an amino acid which is not naturally produced or found in a mammal A non-naturally occurring amino acid comprises a D-amino acid, an amino acid having an acetylaminomethyl group attached to a sulfur atom of a cysteine. a pegylated amino acid. etc.
The inclusion of a non-naturally occurring amino acid in a defined polypeptide sequence will therefore generate a derivative of the original polypeptide. Non-naturally occurring amino acids (residues) include also the omega amino acids of the formula NH2(CH2),COOH wherein n is 2-6, neutral nonpolar amino acids, such as sarcosine, t-butyl alanine, t-butyl glycine, N-methyl isoleucine, norleucine, etc.
Phenylglycine may substitute for Trp. Tyr or Phe; citrulline and methionine sulfoxide are neutral nonpolar.
cysteic acid is acidic, and ornithine is basic. Proline may be substituted with hydroxyproline and retain the conformation conferring properties.
It is known in the art that analogues may be generated by substitutional mutagenesis and retain the biological activity of the polypeptides of the present invention. These analogues have at least one amino acid residue in the protein molecule removed and a different residue inserted in its place. For example, one site of interest for substitutional mutagenesis may include but are not restricted to sites identified as the active site(s). or immunological site(s) Other sites of interest may be those, for example, in which particular residues obtained from various species are identical. These positions may be important for biological activity Examples of substitutions identified as "conservative substitutions" are shown in Table A.
If such substitutions result in a change not desired, then other type of substitutions.
denominated -exemplary substitutions" in Table A, or as further described herein in reference to amino acid classes, are introduced and the products screened.
In some cases it may be of interest to modify the biological activity of a polypeptide by amino acid substitution, insertion, or deletion. For example.
modification of a polypeptide may result in an increase in the polypeptide's biological activity, may modulate its toxicity, may result in changes in bioavailability or in stability.
or may modulate its immunological activity or immunological identity Substantial modifications in function or immunological identity are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation. (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based 5 on common side chain properties:
(1) hydrophobic: norleucine. methionine (Met), Alanine (Ala), Valine (Val), Leucine (Leu), lsoleucine (Ile) (2) neutral hydrophilic: Cysteine (Cys), Serine (Ser). Threonine (Thr) (3) acidic: Aspartic acid (Asp), Glutamic acid (Glu) 10 (4) basic: Asparagine (Asn), Glutamine (Gin), Histidine (His). Lysine (Lys) Arginine (Arg) (5) residues that influence chain orientation: Glycine (Gly), Proline (Pro);
and aromatic: Tryptophan (Trp), Tyrosine (Tyr), Phenylalanine (Phe) Non-conservative substitutions will entail exchanging a member of one of these 15 classes for another.
TABLE A. Examplary amino acid substitution Original residue Exemplary substitution = Conservative substitution Ala (A) Val. Leu, Ile Val Arg (R) Lys. Gin, Asn Lys Asn (N) Gin. His, Lys. Arg Gin Asp (D) Glu IGlu Cys (C) Ser Ser Gln (Q) Asn Asn Glu (E) Asp Asp Gly (G) Pro Pro His (H) Asn, Gin, Lys, Arg Arg !Original residue 'Exemplary substitution r Conservative substitution Ile (I) Leu, Val, Met. Ala, Phe, Leu norleucine Leu (L) Norleucine, Ile, Val, Met, Ile Ala, Phe Lys (K) Arg, Gin, Asn Arg Met (M) Leu, Phe. Ile Leu =
Phe (F) . Leu, Val. Ile, Ala Leu Pro (P) Gly Gly Ser (S) = Thr Thr Thr (T) Ser f Ser Tip (W) Tyr ; Tyr Tyr (Y) Trp, Phe, Thr, Ser Phe Val (V) Ile, Leu, Met, Phe, Ala, Leu norleucine It is to be understood herein; that if a "range" or "group" of substances (e.g.
amino acids). substituents" or the like is mentioned or if other types of a particular characteristic (e.g. temperature. pressure. chemical structure, time, etc) is mentioned, the present invention relates to and explicitly incorporates herein each and every specific member and combination of sub-ranges or sub-groups therein whatsoever Thus, any specified range or group is to be understood as a shorthand way of referring to each and every member of a range or group individually as well as each and every possible sub-ranges or sub-groups encompassed therein; and similarly with respect to any sub-ranges or sub-groups therein. Thus, for example, with respect to a percentage (c)/0) of identity of from about 80 to 100%, it is to be understood as specifically incorporating herein each and every individual %, as well as sub-range, such as for example 80%, 81%, 84.78%. 93%, 99% etc.; and similarly with respect to other parameters such as, concentrations, elements, etc.
It is in particular to be understood herein that the methods of the present invention each include each and every individual steps described thereby as well as those defined as positively including particular steps or excluding particular steps or a combination thereof; for example an exclusionary definition for a method of the present invention, may read as follows: "provided that said polynucleotide does not comprise or consist in SEQ ID NO.:34 or the open reading frame of SEQ ID
NO.:34"
or "provided that said polypeptide does not comprise or consist in SEQ ID
NO.:82" or "provided that said polynucleotide fragment or said polypeptide fragment is less than X unit (e.g., nucleotides or amino acids) long or more than X unit (e.g., nucleotides or amino acids) long".
Other objects, features, advantages, and aspects of the present invention will become apparent to those skilled in the art from the following description.
BRIEF DESCRIPTION OF THE DRAWINGS
In the appended drawings:
For each of Figures 1 to 34 and 38-39 macroarrays were prepared using RAMP
amplified RNA from human precursor cells (A-F 1), and differentiated intermediate (A-F
2 ¨ 3) and mature osteoclasts for four human donors (A-F 4), and 30 different normal human tissues (adrenal (A5), liver (B5), lung (C5), ovary (D5), skeletal muscle (E5), heart (F5), cervix (G5), thyroid (H5), breast (A6), placenta (B6), adrenal cortex (C6), kidney (D6), vena cava (E6), fallopian tube (F6), pancreas (G6), testicle (H6), jejunum (A7), aorta (B7), esophagus (C7), prostate (D7), stomach (E7), spleen (F7), ileum (G7), trachea (A8), brain (B8), colon (C8), thymus (D8), small intestine (E8), bladder (F8) and duodenum (G8)). The STAR dsDNA clone representing the respective SEQ ID NOs.
was labeled with 32P and hybridized to the macroarray. The probe labeling reaction was also spiked with a dsDNA sequence for Arabidopsis, which hybridizes to the same sequence spotted on the macroarray (M) in order to serve as a control for the labeling reaction. Quantitation of the hybridization signal at each spot was performed using a STORM 820 PhosphorimagerTM and the lmageQuantTM TL software (Amersham Biosciences, Piscataway, NJ). A log2 value representing the average of the signals for the precursors (A-F 1) was used as the baseline and was subtracted from the log2 value obtained for each of the remaining samples in order to determine their relative abundancies compared to the precursors and plotted as a bar graph (right panel).
Fig. 1 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 1. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 2 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 2. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 3 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 3. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 4 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 4. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 5 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 5. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 6 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected .. osteoclast-specific human SEQ ID NO. 6 The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 -Fig. 7 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 7. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 8 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO 8. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 9 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 9. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 10 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO, 10. The hybridization results obtained .. confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 -8).
Fig. 11 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 11. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
5 1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G 7 - 8):
Fig. 12 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 12. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher 10 expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8.:
Fig. 13 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 13. The hybridization results obtained 15 confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and AG
7 - 8).
Fig. 14 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected 20 osteoclast-specific human SEQ. ID, NO. 14. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 8):
Fig. 15 is a picture of the macroarray hybridization results and quantitation of 25 the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 15. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 -4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
30 Fig. 16 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 16 The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher, expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨8);
Fig. 17 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 17. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8..
Fig 18 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 18. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8):
Fig. 19 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 19. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8):
Fig. 20 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ ID, NO. 20. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8):
Fig. 21 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 21. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8):
Fig. 22 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 22. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G
7 - 8);
Fig. 23 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 23. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G
7 - 8):
Fig 24 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 24. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8);
Fig. 25 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 25. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8);
Fig. 26 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 26. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 -4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 -8):
Fig. 27 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID, NO. 27. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G
7 - 8);
Fig. 28 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 28. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8);
Fig. 29 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 29. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8).
Fig. 30 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 30. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G
7 - 8);
Fig. 31 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO, 31. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 32 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 32. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 -8).
Fig. 33 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 33. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 34 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 34. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8), Fig. 35 is a picture showing the knockdown effects on osteoclastogenesis by attenuating the endogenous expression of SEQ. ID. NO. 1 (A80326) and SEQ. ID.
NO.
2 (AB0369) using shRNA. A significant decrease in the number of multinucleated osteoclasts was observed from precursor cells infected with the AB0326 shRNA
(Figure 35A; bottom panel) and AB0369 shRNA (Figure 1B, bottom panel) compared to those with the lacZ shRNA (Figure 35A and B, top panels). These results clearly indicated that expression of the gene encoding SEQ. ID. NO. 1 (AB0326) and SEQ. ID, NO. 2 (AB0369) are required for osteoclast differentiation;
Fig. 36 is a picture showing the knockdown effects on osteoclastogenesis of the mouse orthologue for AB0326 (SEQ. ID. NO. 35) in the RAW 264.7 model using shRNA-0326.2 (SEQ. ID. NO. 45). The RAW-0326.2 cell line produced significantly less osteoclasts (Figure 36; bottom panel) compared to the cell line containing the scrambled shRNA (Figure 36; top panel). This result, coupled with that obtained in the human osteoclast precursor cells using the lentiviral shRNA delivery system demonstrate that in both human and mouse, AB0326 gene product is clearly required for osteoclastogenesis;
Fig. 37 is a picture showing the results of a functional complementation assay for SEQ. ID. NO. 1 (AB0326) in RAW-0326.2 cells to screen for inhibitors of osteoclastogenesis. The RAW-0326.2 cells transfected with the empty pd2 vector are unable to form osteoclasts in the presence of RANK ligand (center panel) indicating that the mouse AB0326 shRNA is still capable of silencing the AB0326 gene expression in these cells. Conversely, the cells transfected with the cDNA for the human AB0326 (pd2-hAB0326) are rescued and thus, differentiate more efficiently into osteoclasts in response to RANK ligand (right panel). Wild-type RAW 264.7 cells containing the empty vector (pd2) did not adversly affect the formation of osteoclasts in the presence of RANK ligand (left panel) ruling out an effect due to pd2 Thus, this 5 complementation assay can be used to screen for inhibitors of the human polypeptide;
Fig. 38 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential Expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 85. Macroarrays were prepared using RAMP
10 amplified RNA from human precursor cells (A-F 1), and differentiated intermediate and mature osteoclasts for four human donors (A-F 2 - 4), and 30 different normal human tissues (adrenal. liver, lung, ovary, skeletal muscle, heart, cervix, thyroid.
breast, placenta, adrenal cortex, kidney, vena cava, fallopian tube. pancreas, testicle, jejunum, aorta, esophagus, prostate. stomach, spleen, ileum, trachea, brain, colon, thymus.
15 small intestine, bladder and duodenum (A-H 5 - 6 and A-G 7 - 8)). The STAR clone representing SEQ. ID. NO. 85 was labeled with 32P and hybridized to the macroarray The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (Al - Fl) and little or no expression in all or most 20 normal tissues (A-H 5 - 6 and A-G 7 - 8), and, Fig. 39 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential Expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 86. Macroarrays were prepared using RAMP
amplified RNA from human precursor cells (A-F 1). and differentiated intermediate and 25 mature osteoclasts for four human donors (A-F 2 - 4), and 30 different normal human tissues (adrenal, liver, lung, ovary, skeletal muscle, heart, cervix, thyroid, breast, placenta, adrenal cortex, kidney, vena cava, fallopian tube, pancreas, testicle. jejunum, aorta, esophagus, prostate, stomach, spleen, ileum, trachea, brain, colon, thymus.
small intestine, bladder and duodenum (A-H 5 - 6 and A-G 7 - 8)). The STAR
clone 30 representing SEQ. ID NO. 86 was labeled with 32P and hybridized to the macroarray The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 -4) compared to the precursors (Al - Fl) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8).
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
The applicant employed a carefully planned strategy to identify and isolate genetic sequences involved in osteoclastogenesis and bone remodeling. The process involved the following steps: 1) preparation of highly representative cDNA
libraries using mRNA isolated from precursors and differentiated intermediate and mature osteoclasts of human origin; 2) isolation of sequences upregulated during osteoclastogenesis: 3) identification and characterization of upregulated sequences: 4) selection of upregulated sequences for tissue specificity; and 5) determination of knock-down effects on osteoclastogenesis. The results discussed in this disclosure demonstrate the advantage of targeting osteoclast genes that are specific to this differentiated cell type and provide a more efficient screening method when studying the genetic basis of diseases and disorders. Genes that are known to have a role in other areas of biology have been shown to play a critical role in osteoclastogenesis and osteoclast function. Genes that are known but have not had a role assigned to them until the present disclosure have also been isolated and shown to have a critical role in osteoclastogenesis and osteoclast function. Finally, novel genes have been identified and play a role, however, applicant reserves their disclosure until further study has been completed:
The present invention is illustrated in further details below in a non-limiting fashion.
A- Material and Methods Commercially available reagents referred to in the present disclosure were used according to supplier's instructions unless otherwise indicated. Throughout the present disclosure certain starting materials were prepared as follows:
B - Preparation of osteoclast differentiated cells The RAW 264.7 (RAW) osteoclast precursor cell line and human precursor cells (peripheral blood mononuclear cells or CD34+ progenitors) are well known in the art as murine and human models of osteoclastogenesis. These murine and human osteoclasts are therefore excellent sources of materials for isolating and characterizing genes specialized for osteoclast function.
Human primary osteoclasts were differentiated from G-CSF-mobilized peripheral blood mononuclear cells (Cambrex, East Rutherford, NJ) as described by the supplier in the presence of 35 ng/ml M-CSF and 100 ng/ml RANK ligand. Multinucleated TRAP-staining osteoclasts were visible by 11-14 days. Osteoclasts were also derived from human osteoclasts precursor cells (CD34+ progenitors) (Cambrex, East Rutherford, NJ) and cultured as described by the supplier. In the latter case, osteoclasts were obtained after 7 days.
RAW cells were purchased from American Type Culture Collection and maintained in high glucose DMEM containing 10% fetal bovine serum and antibiotics.
The cells were sub-cultured bi-weekly to a maximum of 10-12 passages. For osteoclast differentiation experiments, RAW cells were seeded in 96-well plates at a density of 4 x 103 cells/well and allowed to plate for 24h. Differentiation was induced in high glucose DMEM, 10% charcoal-treated foetal bovine serum (Hyclone, Logan, UT), 0.05%
BSA, antibiotics, 10 ng/ml macrophage colony stimulating factor (M-CSF), and 100 ng/ml receptor activator of NF-kB (RANK) ligand. The plates were re-fed on day 3 and osteoclasts were clearly visible by day 4. Typically, the cells were stained for tartrate-resistant acid phosphatase (TRAP) on day 4 or 5 unless otherwise indicated.
For TRAP
staining, the cells were washed with PBS and fixed in 10% formaldehyde for 1 h. After two PBS washes, the cells were rendered lightly permeable in 0.2% TritonTm X-100 in PBS for 5 min before washing in PBS. Staining was conducted at 37 C for 20-25 min in 0.01% Naphtol AS-MX phosphate, 0.06% Fast Red Violet, 50 mM sodium tartrate, mM sodium acetate, pH 5.2. Cells were visualized microscopically.
C- Method of Isolating Differentially Expressed mRNA
Key to the discovery of differentially expressed sequences unique to osteoclasts is the use of the applicant's patented STAR technology (Subtractive Transcription-based Amplification of mRNA; U.S. Patent No. 5,712,127 Malek et al., issued on January 27, 1998). In this procedure, mRNA isolated from intermediate and mature osteoclasts is used to prepare "tester RNA", which is hybridized to complementary single-stranded "driver DNA" prepared from osteoclast precursor mRNA and only the un-hybridized "tester RNA" is recovered, and used to create cloned cDNA libraries, termed "subtracted libraries". Thus, the "subtracted libraries" are enriched for differentially expressed sequences inclusive of rare and novel mRNAs often missed by micro-array hybridization analysis. These rare and novel mRNA are thought to be representative of important gene targets for the development of better diagnostic and therapeutic strategies.
The clones contained in the enriched "subtracted libraries' are identified by DNA sequence analysis and their potential function assessed by acquiring information available in public databases (NCB' and GeneCard). The non-redundant clones are then used to prepare DNA micro-arrays, which are used to quantify their relative differential expression patterns by hybridization to fluorescent cDNA probes.
Two classes of cDNA probes may be used those which are generated from either RNA
transcripts prepared from the same subtracted libraries (subtracted probes) or from mRNA isolated from different osteoclast samples (standard probes). The use of subtracted probes provides increased sensitivity for detecting the low abundance mRNA sequences that are preserved and enriched by STAR. Furthermore, the specificity of the differentially expressed sequences to osteoclast is measured by hybridizing radio-labeled probes prepared from each selected sequence to macroarrays containing RNA from different osteoclast samples and different normal human tissues. Additionally, Northern blot analysis is performed so as to confirm the presence of one or more specific mRNA species in the osteoclast samples.
Following this, the full-length cDNAs representative of the mRNA species and/or spliced variants are cloned in E. coli DH10B.
A major challenge in gene expression profiling is the limited quantities of RNA
available for molecular analysis The amount of RNA isolated from many osteoclast samples or human specimens (needle aspiration, laser capture micro-dissection (LCM) samples and transfected cultured cells) is often insufficient for preparing:
1) conventional tester and driver materials for STAR. 2) standard cDNA probes for DNA
micro-array analysis; 3) RNA macroarrays for testing the specificity of expression 4) Northern blots and; 5) full-length cDNA clones for further biological validation and characterization etc. Thus, the applicant has developed a proprietary technology called RAMP (RNA Amplification Procedure) (U.S. Patent Application No. 11/000,958 published under No. US 2005/0153333A1 on July 14. 2005 and entitled "Selective Terminal Tagging of Nucleic Acids"), which linearly amplifies the mRNA
contained in total RNA samples yielding microgram quantities of amplified RNA sufficient for the various analytical applications. The RAMP RNA produced is largely full-length mRNA-like sequences as a result of the proprietary method for adding a terminal sequence tag to the 3'-ends of single-stranded cDNA molecules, for use in linear transcription amplification. Greater than 99.5% of the sequences amplified in RAMP reactions show <2-fold variability and thus, RAMP provides unbiased RNA samples in quantities sufficient to enable the discovery of the unique mRNA sequences involved in osteoclastogenesis.
D- Preparation of Human Osteoclasts Subtracted Library Two human primary precursor cells from two different donors (Cambrex. East Rutherford, NJ), and the corresponding intermediate (day 3 and day 7) and mature (days 11-14) osteoclasts were prepared as described above Isolation of cellular RNA
followed by mRNA purification from each was performed using standard methods (Qiagen. Mississauga, ON). Following the teachings of Malek et al (U S Patent No 5,712.127), 2 pg of poly A+ mRNA from each sample were used to prepare highly representative (>2x106 CFU) cDNA libraries in specialized plasmid vectors necessary for preparing tester and driver materials. In each case, first-strand cDNA was synthesized using an oligo dT" primer with 3' locking nucleotides (e.g., A, G
or C) and containing a Not I recognition site. Next, second-strand cDNA synthesis was performed according to the manufacturer's procedure for double-stranded cDNA synthesis (Invitrogen, Burlington, ON) and the resulting double-stranded cDNA ligated to linkers containing an Asc I recognition site (New England Biolabs, Pickering, ON). The double-stranded cDNAs were then digested with Asc I and Not I restriction enzymes (New England Biolabs, Pickering, ON), purified from the excess linkers using the cDNA
fractionation column from Invitrogen (Burlington, ON) as specified by the manufacturer and each ligated into specialized plasmid vectors - p14 (SEQ. ID. NO 36) and p17+
(SEQ ID. NO:37) used for preparing tester and driver materials respectively Thereafter, the ligated cDNAs were transformed into E. coli DH10B resulting in the desired cDNA libraries (RAW 264.7-precursor-p14, RAW 264 7-precursor-p17+, RAW
264.7-osteoclasts-p14 and RAW 264.7-osteoclasts-p17+). The plasmid DNA pool for each cDNA library was purified and a 2-pg aliquot of each linearized with Not I
restriction enzyme. In vitro transcription of the Not I digested p14 and p17+
plasmid libraries was then performed with T7 RNA polymerase and sp6 RNA polymerase respectively (Ambion, Austin, TX).
Next, in order to prepare 3-represented tester and driver libraries, a 10-pg aliquot of each of the in vitro synthesized RNA was converted to double-stranded cDNA by performing first-strand cDNA synthesis as described above followed by primer-directed (primer OGS 77 for p14 (SEQ. ID. NO:40) and primer OGS 302 for 5 p17+ (SEQ. ID N0,41)) second-strand DNA synthesis using Advantage-2 Taq polymerase (BD Biosciences Clontech, Mississauga, ON). The sequences corresponding to OGS 77 and OGS 302 were introduced into the in vitro synthesized RNA by way of the specialized vectors used for preparing the cDNA libraries.
Thereafter, 6x 1-pg aliquots of each double-stranded cDNA was digested individually 10 with one of the following 4-base recognition restriction enzymes Rsa I.
Sau3A1, Mse I, Msp 1, MinP1 I and Bsh 12361 (MBI Fermentas, Burlington, ON), yielding up to six possible 3'-fragments for each RNA species contained in the cDNA library.
Following digestion, the restriction enzymes were inactivated with phenol and the set of six reactions pooled. The restriction enzymes sites were then blunted with T4 DNA
15 polymerase and ligated to linkers containing an Asc 1 recognition site.
Each linker-adapted pooled DNA sample was digested with Asc I and Not I restriction enzymes.
desalted and ligated to specialized plasmid vectors, p14 and p17 (p17 plasmid vector is similar to the p17+ plasmid vector except for the sequence corresponding to SEQ. ID.
N0,41), and transformed into E. coli DH10B. The plasmid DNA pool for each p14 and 20 p17 3'-represented library was purified (Qiagen, Mississauga, ON) and a 2-rig aliquot of each digested with Not 1 restriction enzyme. and transcribed in vitro with either T7 RNA polymerase or sp6 RNA polymerase (Ambion, Austin. TX). The resulting p14 3'-represented RNA was used directly as "tester RNA" whereas, the p17 3'-represented RNA was used to synthesize first-strand cDNA as described above, which then served 25 as "driver DNA". Each "driver DNA" reaction was treated with RNase A and RNase H to remove the RNA, phenol extracted and desalted before use.
The following 3'-represented libraries were prepared:
Tester 1 (donor 1 ¨ day 3) - human intermediate osteoclast-3' in p14 Tester 2 (donor 1 ¨ day 7 - human intermediate osteoclast)-3' in p14 30 Tester 3 (donor 1 ¨ day 11 - human mature osteoclast)-I in p14 Tester 4 (donor 2 ¨ day 3 - human intermediate osteoclast)-3 in p14 Tester 5 (donor 2 ¨ day 7 - human intermediate osteoclast)-3' in p14 Tester 6 (donor 2 ¨ day 13 - human mature osteoclast)-3' in p14 Driver 1 (donor 1 ¨ day 3) - human precursor-3' in p17 Driver 2 (donor 2¨ day 3) - human precursor-3' in p17 The tester RNA samples were subtracted following the teachings of U.S patent No. 5.712,127 with the corresponding driver DNA in a ratio of 1:100 for either 1-or 2-rounds following the teachings of Malek et at. (U.S. Patent No. 5,712,127).
Additionally, control reactions containing tester RNA and no driver DNA, and tester RNA plus driver DNA but no RNase H were prepared. The tester RNA remaining in each reaction after subtraction was converted to double-stranded DNA, and a volume of 5% removed and amplified in a standard PCR reaction for 30-cycles for analytical purposes.
The remaining 95% of only the driver plus RNase H subtracted samples were amplified for 4-cycles in PCR, digested with Asc I and Not I restriction enzymes, and one half ligated into the pCATRMAN (SEQ. ID. NO:38) plasmid vector and the other half, into the p20 (SEQ. ID. NO:39) plasmid vector. The ligated materials were transformed into E. coli DH1OB and individual clones contained in the pCATRMAN libraries were picked for further analysis (DNA sequencing and hybridization) whereas, clones contained in each p20 library were pooled for use as subtracted probes. Each 4-cycles amplified cloned subtracted library contained between 25.000 and 40.000 colonies The following cloned subtracted libraries were prepared:
SL90 - tester 1 (day 3 osteoclast) minus driver 1 (precursor) (1-round) in pCATRMAN, SL91 - tester 2 (day 7 osteoclast) minus driver 1 (precursor) (1-round) in pCATRMAN:
5L92-tester 3 (day 11 osteoclast) minus driver 1 (precursor) (1-round) in pCATRMAN:
SL108-tester 1 (day 3 osteoclast) minus driver 1 (precursor) (2-rounds) in pCATRMAN.
SL109-tester 2 (day 7 osteoclast) minus driver 1 (precursor) (2-rounds) in pCATRMAN:
SL110-tester3 (day 11 osteoclast) minus driver 1(precursor) (2-rounds) in pCATRMAN:
SL93 -tester 4 (day 3 osteoclast) minus driver 2 (precursor) (1-round) in pCATRMAN, SL94 - tester 5 (day 7 osteoclast) minus driver 2 (precursor) (1-round) in pCATRMAN, SL95-tester 6 (day 13 osteoclast) minus driver 2 (precursor) (1-round) in pCATRMAN, SL87 - tester 4 (day 3 osteoclast) minus driver 2 (precursor) (2-rounds) in pCATRMAN
SL88 - tester 5 (day 7 osteoclast) minus driver 2 (precursor) (2-rounds) in pCATRMAN:
SL89- tester 6 (day 11 osteoclast) minus driver 2 (precursor) (2-rounds) in pCATRMAN
A 5-pL aliquot of the 30-cycles PCR amplified subtracted materials described above were visualized on a 1.5% agarose gel containing ethidium bromide and then transferred to HybondTM N+ (Amersham Biosciences, Piscataway, NJ) nylon membrane for Southern blot analysis. Using radiolabeled probes specific to the CTSK
(cathepsin K;
NM_000396.2) gene, which is known to be upregulated in osteoclasts, and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase; M32599.1), which is a non-differentially expressed house-keeping gene, it was evident that there was subtraction of GAPDH but not CTSK. Based on these results, it was anticipated that the subtracted libraries would .. be enriched for differentially expressed upregulated sequences.
E - Sequence identification and annotation of clones contained in the subtracted libraries:
A total of 6,912 individual colonies contained in the pCATRMAN subtracted libraries (5L87-95 and SL108-110) described above were randomly picked using a Qbot (Genetix Inc., Boston, MA) into 60 pL of autoclaved water. Then, 42 pL of each was used in a 100-pL standard PCR reaction containing oligonucleotide primers, OGS
1 and OGS 142 and amplified for 40-cycles (94 C for 10 minutes, 40x (94 C for 40 seconds, 55 C for 30 seconds and 72 C for 2 minutes) followed by 72 C for 7 minutes) in 96-wells microtitre plates using HotStartTM Taq polymerase (Qiagen, Mississauga, ON).
The completed PCR reactions were desalted using the 96-well filter plates (Corning) and the amplicons recovered in 100 pL 10mM Tris (pH 8.0). A 5-pL aliquot of each PCR
reaction was visualized on a 1.5% agarose gel containing ethidium bromide and only those reactions containing a single amplified product were selected for DNA
sequence analysis using standard DNA sequencing performed on an ABI 3100 instrument (Applied Biosystems, Foster City, CA). Each DNA sequence obtained was given a Sequence Identification Number and entered into a database for subsequent tracking and annotation.
Each sequence was selected for BLAST analysis of public databases (e.g.
NCBI). Absent from these sequences were the standard housekeeping genes (GAPDH, actin, most ribosomal proteins etc.), which was a good indication that the subtracted library was depleted of at least the relatively abundant non-differentially expressed sequences.
Once sequencing and annotation of the selected clones were completed. the next step involved identifying those sequences that were actually upregulated in osteoclasts compared to precursors.
F - Hybridization analysis for identifying upregulated sequences The PCR amplicons representing the annotated sequences from the pCATRMAN libraries described above were used to prepare DNA microarrays The purified PCR amplicons contained in 70 pL of the PCR reactions prepared in the previous section was lyophilized and each reconstituted in 20 pL of spotting solution comprising 3xSSC and 0.1% sarkosyl. DNA micro-arrays of each amplicon in triplicate were then prepared using CMT-GAP2 slides (Corning, Corning, NY) and the GMS
spotter (Affymetrix, Santa Clara, CA).
The DNA micro-arrays were then hybridized with either standard or subtracted cy3 and cy5 labelled cDNA probes as recommended by the supplier (Amersham Biosciences, Piscataway, NJ). The standard cDNA probes were synthesized using RAMP amplified RNA prepared from the different human osteoclast samples and the corresponding precursors. It is well known to the skilled artisan that standard cDNA
probes only provide limited sensitivity of detection and consequently low abundance sequences contained in the cDNA probes are usually missed. Thus, the hybridization analysis was also performed using cy3 and cy5 labelled subtracted cDNA probes prepared from subtracted libraries representing the different tester and driver materials.
These subtracted libraries may be enriched for low abundance sequences as a result of following the teachings of Malek et al., and therefore. may provide increased detection sensitivity.
All hybridization reactions were performed using the dye-swap procedure as recommended by the supplier (Amersham Biosciences, Piscataway, NJ) and approximately 500 putatively differentially expressed upregulated (>2-fold) sequences were selected for further analysis.
G - Determining osteoclast specificity of the differentially expressed sequences identified:
The differentially expressed sequences identified in Section F for the different human osteoclast subtracted libraries were tested for osteoclast specificity by hybridization to nylon membrane-based macroarrays. The macroarrays were prepared using RAMP amplified RNA from human precursors and osteoclasts (intermediate and mature) of six independent experiments from 4 different donors (3 males and 1 female), and 30 normal human tissues (adrenal, liver, lung, ovary, skeletal muscle, heart, cervix, thyroid, breast, placenta, adrenal cortex, kidney, vena cava, fallopian tube, pancreas, testicle, jejunum, aorta, esophagus, prostate, stomach, spleen, ileum, trachea, brain, colon, thymus, small intestine, bladder and duodenum) purchased commercially (Ambion, Austin, TX). Because of the limited quantities of mRNA available for many of these samples, it was necessary to first amplify the mRNA using the RAMP
methodology. Each amplified RNA sample was reconstituted to a final concentration of 250 ng/pL in 3xSSC and 0.1% sarkosyl in a 96-well microtitre plate and 1 pL
spotted onto HybondTM N+ nylon membranes using the specialized MULTI-PRINTTm apparatus (VP Scientific, San Diego, CA), air dried and UV-cross linked. A total of 400 different sequences selected from 5L87-95 and SL108-110 were individually radiolabeled with a-32P-dCTP using the random priming procedure recommended by the supplier (Amersham, Piscataway, NJ) and used as probes on the macroarrays.
Hybridization and washing steps were performed following standard procedures well known to those skilled in the art.
Of the 500 sequences tested, approximately 85% were found to be upregulated in all of the osteoclast RNA samples that were used to prepare the macroarrays. However, many of these sequences were also readily detected in a majority of the different normal human tissues. Based on these results, those sequences that appeared to be associated with experimental variability and those that were detected in many of the other human tissues at significantly elevated levels were eliminated.
Consequently, only sequences, which appeared to be upregulated and highly osteoclast-specific, were selected for biological validation studies. Included in this set of 35 genes were 4 (SEQ.
ID. NOs. 30-33) where there was a significant upregulation in mature osteoclasts compared to most normal tissues but because the expression of these genes were 30 overall lower in the precursor cells, they appeared to be elevated in the normal tissues after quantitation Figure 30-33; bar graph). However, their expression in the normal tissues was still relatively lower than that of the mature osteoclasts. Thus, these genes may still be important regulators in osteoclastogenesis and bone resorption and were therefore selected for biological validation. This subset of 35 sequences does not included genes also identified such as, CTSK, TRAP, MMP9. CST3 and CKB amongst others since these were previously reported in the literature to be upregulated in osteoclasts. The macroarray data for CST3 (SEQ. ID.
NO. 34) is included to exemplify the hybridization pattern and specificity of a gene that 5 is already known to be a key regulator of the osteoclast resorption process. One gene (ANKH; SEQ. ID. NO. 17) was included in the subset of 35 genes although it was previously reported in the database (NCB! - Gene) to play a role in bone mineralization.
However, the observed bone phenotype resulting from mutations in the ANKH gene was not specifically linked to its upregulation in osteoclasts. Thus our data suggests the 10 important role for ANKH may be associated with osteoclast activity during bone remodeling.
Fig. 1-33, 38 and 39 show the macroarray patterns and quantitation of the hybridization signals of the osteoclasts and normal human tissues relative to precursor cells for the 35 sequences selected for biological validation. Amongst the 35 selected 15 sequences were 24 genes with functional annotation 9 genes with no functional annotation and 2 novel sequences (genomic hits). The identification of gene products involved in regulating osteoclast differentiation and function has thus led to the discovery of novel targets for the development of new and specific therapies of disease states characterized by abnormal bone remodeling. Representative sequences 20 summarized in Table 1 are presented below and corresponding sequences are illustrated in Table 5.
SEQ. ID. NO:1:
SEQ. ID. Na1 (Table 5) corresponds to a previously identified gene that 25 encodes a hypothetical protein. L00284266 with an unknown function (see Table 1).
We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 1), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
30 SEQ. ID. NO:2:
SEQ. ID. NO:2 (Table 5) corresponds to a previously identified gene that encodes a predicted open reading frame, C6orf82 with an unknown function (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 2), which have not been previously reported. At least 5 transcript variants of this gene coding for 3 protein isoforms has been identified so far (NCBI). Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:3:
SEQ. ID. NO:3 (Table 5) corresponds to a previously identified gene that encodes a hypothetical protein, L0C133308 with an unknown function (see Table 1) but may be involved in the process of pH regulation. We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 3), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:4:
SEQ. ID. NO:4 (Table 5) corresponds to a previously identified gene that encodes a hypothetical protein. L0C116211 with an unknown function (see Table 1) We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 4), which have not been previously reported. Thus, it is implified that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:5 SEQ. ID. NO:5 (Table 5) corresponds to a previously identified gene that encodes a predicted protein, L0C151194 (similar to hepatocellular carcinoma-associated antigen HCA557b). with unknown function (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 5), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:6:
SEQ. ID. NO:6 (Table 5) corresponds to a previously identified gene that encodes a protein, chemokine (C-X-C motif) ligand 5 (CXCL5), which is an inflammatory chemokine that belongs to the CXC chemokine family (see Table 1). We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 6), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling SEQ. ID. NO:7:
SEQ. ID. NO:7(Table 5) corresponds to a previously identified gene that encodes a protein, ATPase, H+ transporting. lysosomal accessory protein 2 (ATP6AP2), which is associated with adenosine triphosphatases (ATPases).
Proton-translocating ATPases have fundamental roles in energy conservation, secondary active transport, acidification of intracellular compartments, and cellular pH
homeostasis (see Table 1). We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 7), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:8 SEQ. ID. NO:8 (Table 5) corresponds to a previously identified gene that encodes a protein, ubiquitin-specific protease 12-like 1 (USP12). which is associated with ubiquitin-dependent protein catabolism (see Table 1) We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 8), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:9 SEQ. ID. NO:9 (Table 5) corresponds to a previously identified gene that encodes a protein, Ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog. yeast) (UBE2E1), which is associated with ubiquitin-dependent protein catabolism (see Table 1). So far, there are 2 transcript variants and protein isoforms reported for this gene We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 9). which have not been previously reported. Thus. it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling SEQ. ID. NO:10 SEQ. ID. NO.10 (Table 5) corresponds to a previously identified gene that encodes a protein, Emopamil binding protein-like (EBPL), which may have cholestenol delta-isomerase activity (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 10), which have not been previously reported Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:11 SEQ. ID. NO:11 (Table 5) corresponds to a previously identified gene that encodes a protein, development and differentiation enhancing factor 1 (DDEF1), which may be involved in cell motility and adhesion (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 11), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:12 SEQ. ID. NO 12 (Table 5) corresponds to a previously identified gene that encodes a protein. member 7 of the SLAM family (SLAM7), which may have receptor activity and involved in cell adhesion but still not fully characterized (see Table 1). We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 12), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:13 SEQ. ID. NO:13 (Table 5) corresponds to a previously identified gene that encodes a protein, Ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog. yeast) (UBE2E3), which is associated with ubiquitin-dependent protein catabolism (see Table 1). There are 2 transcript variants documented so far, which code for the same protein isofrom. We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 1), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:14 SEQ. ID. NO:14 (Table 5) corresponds to a previously identified gene that encodes a protein, Galanin (GAL), which is associated with neuropeptide hormone activity (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues except for colon (Figure 14) which have not been previously reported.
Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:15 SEQ. ID. NO:15 (Table 5) corresponds to a previously identified gene that encodes a protein, Cytokine-like nuclear factor n-pac (N-PAC), which may have oxireductase activity (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 15), which have not been previously reported.
However, some overexpression of this gene but still way below that of mature osteoclasts were seen in heart, fallopian tube, spleen and cervix. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:16 SEQ. ID. NO:16 (Table 5) corresponds to a previously identified gene that encodes a protein. Integrin alpha X (antigen CD11C (p150), alpha polypeptide) (ITGAX), which is involved in cell adhesion and ion binding (see Table 1) We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 16), which have not been previously reported. Minimal expression but much lower than mature osteoclasts is observed for this gene in adrenal, lung and spleen amongst the normal tissues. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:17 SEQ. ID. NO:17 (Table 5) corresponds to a previously identified gene that encodes a protein, Ankylosis. progressive homolog (mouse) (ANKH), which is involved in regulating pyrophosphate levels, suggested as a possible mechanism regulating tissue calcification (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 17), which have not been previously reported.
However, this gene has been reported to be involved in bone mineralization but without evidence of its upregulation in osteoclasts (Malkin et al., 2005). Thus, it is believed that 5 this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:18 SEQ. ID. NO:18 (Table 5) corresponds to a previously identified gene that encodes a protein, ATPase, H+ transporting. lysosomal 70kD. V1 subunit A.
which is involved in hydrogen-transporting ATPase activity, rotational mechanism (see Table 1).
10 We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 18). which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:19 15 SEQ. ID. NO:19 (Table 5) corresponds to a previously identified gene that encodes a predicted open reading frame coding for protein, FLJ10874 (chromosome 1 open reading frame 75), which has no known function (see Table 1). We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 19), which have not been 20 previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling SEQ. ID. NO:20 SEQ. ID. NO 20 (Table 5) corresponds to a previously identified gene that encodes a protein: Integrin beta 1 binding protein 1 (ITGB1BP1). which has an 25 important role during integrin-dependent cell adhesion (see Table 1).
Two transcript variants and protein isoforms for this gene has been isolated. We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 20), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis 30 and/or bone remodeling.
SEQ. ID. NO:21 SEQ. ID. NO:21 (Table 5) corresponds to a previously identified gene that encodes a protein, Thioredoxin-like 5 (TXNL5), which has no known function (see Table 1). We have demonstrated that this gene is significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues with the exception of esophagus (Figure 21), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:22 SEQ. ID. NO:22 (Table 5) corresponds to a previously identified gene that encodes a protein. C-type lectin domain family 4, member E (CLECSF9), which has no known specific function (see Table 1). Members of this family share a common protein fold and have diverse functions, such as cell adhesion, cell-cell signaling glycoprotein turnover and roles in inflammation and immune response. We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues with the exception of lung and spleen (Figure 22).
which have not been previously reported. At this point, we cannot rule out cross hybridization to family members in lung and spleen. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:23 SEQ. ID. NO 23 (Table 5) corresponds to a previously identified gene that encodes a protein, RAB33A, member RAS oncogene family (RAB33A). which has GTPase activity (see Table 1). We have demonstrated that this gene is significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues with the exception of brain (Figure 23), which have not been previously reported Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling SEQ. ID. NO:24 SEQ. ID. NO:24 (Table 5) corresponds to a previously identified gene that encodes a protein, Down syndrome critical region gene 1 (DSCR1), which interacts with calcineurin A and inhibits calcineurin-dependent signaling pathways, possibly affecting central nervous system development (see Table 1). There are 3 transcript variants and protein isofroms isolated so far. We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 24), which have not been previously reported, Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:25 SEQ. ID. NO:25 (Table 5) corresponds to a previously identified gene that encodes a protein, SNARE protein Ykt6 (YKT6), which is one of the SNARE
recognition molecules implicated in vesicular transport between secretory compartments (see Table 1). We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 25), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:26 SEQ ID. NO:26 (Table 5) corresponds to a previously identified gene that encodes a protein, Actinin, alpha 1 (ACTN1). which is cytoskeletal. and involved in actin binding and adhesion (see Table 1). We have demonstrated that this gene is significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 26), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:27 SEQ. ID. NO:27 (Table 5) corresponds to a previously identified gene that encodes a protein, CIpX caseinolytic peptidase X homolog (E. coli) (CLPX), which may be involved in protein turnover (see Table 1). We have demonstrated that this gene is significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 27), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:28 SEQ. ID. NO:28 (Table 5) corresponds to a previously identified gene that encodes a protein, Carbonic anhydrase II (CA2), which has carbonate dehydratase activity (see Table 1). Defects in this enzyme are associated with osteopetrosis and renal tubular acidosis (McMahon et al., 2001) and have been shown to be upregulated in mature osteoclasts under induced acidic pH conditions (Biskobing and Fan, 2000) We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells independent of induced acidic pH
conditions and other normal human tissues (Figure 28), which have not been previously reported. However, elevated expression of this gene was also observed in colon and stomach but still significantly below the levels of mature osteoclasts. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:29 SEQ. ID. NO:29 (Table 5) corresponds to a previously identified gene that encodes a protein, Sorting nexin 10 (SNX10), whose function has not been determined (see Table 1). We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and most normal human tissues (Figure 29).
which have not been previously reported However, elevated expression of this gene was also observed in liver, brain, lung, adrenal cortex, kidney and spleen but still significantly below the levels of mature osteoclasts. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:30 SEQ. ID. NO:30 (Table 5) corresponds to a previously identified gene that encodes a protein. Tudor domain containing 3 (TDRD3), whose function has not been determined but may be involved in nucleic acid binding (see Table 1). We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and most normal human tissues (Figure 30), which have not been previously reported. However, above baseline expression of this gene was observed in the normal human tissues because of a lower than normal precursor level but it was still significantly below the levels of mature osteoclasts, Thus, this gene was still selected. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:31 SEQ ID NO 31 (Table 5) corresponds to a previously identified gene that encodes a protein. Selenoprotein P. plasma. 1 (SEPP1), which has been implicated as an oxidant defense in the extracellular space and in the transport of selenium (see Table 1). This gene encodes a selenoprotein that contains multiple selenocysteines.
Selenocysteine is encoded by the usual stop codon UGA. The unususal amino acids are indicated as 'Li' in the amino acid sequence in SEQ. ID. NO:78 (Table 5) or by Xaa in the sequence listing. We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and most normal human tissues (Figure 31), which have not been previously reported However, above baseline expression of this gene was observed in the normal human tissues because of a lower than normal precursor level but it was still significantly below the levels of mature osteoclasts. Thus, this gene was still selected. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:32 SEQ. ID. NO:32 (Table 5) corresponds to a previously identified gene that encodes a hypothetical protein, KIAA0040. which has no known function (see Table 1).
We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and most normal human tissues (Figure 32). which have not been previously reported. However, above baseline expression of this gene was observed in the normal human tissues because of a lower than normal precursor level but it was still significantly below the levels of mature osteoclasts. Thus this gene was still selected. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:33 SEQ. ID. NO:33 (Table 5) corresponds to a previously identified gene that encodes a protein. Dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) (DPP4), which is an intrinsic membrane glycoprotein and a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides (see Table 1). We have demonstrated that this gene is markedly upregulated in , intermediate and mature osteoclast compared to precursor cells and most normal human tissues (Figure 33), which have not been previously reported. However, above baseline expression of this gene was observed in the normal human tissues except for placenta, lung, ovary, kidney, prostate and small intestine because of a lower than normal precursor level but it was still significantly below the levels of mature osteoclasts. Thus, this gene was still selected. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:34:
SEQ ID. NO:34 (Table 5) corresponds to a previously identified gene that encodes a protein, cystatin C precursor, with members of the cystatin family known to be inhibitor of cysteine proteases (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 34). which have not been previously 5 .. reported. However, it is well documented that cystatin C plays a critical role in inhibiting bone resorption due to osteoclasts (Brage et al . 2005) Thus, the hybridization profile for this gene is an excellent example of highly upregulated and specific sequences related to osteoclasts.
SEQ. ID. NO:85 10 SEQ. ID. NO:85 (Table 5) encodes an unknown protein found on chromosome 1 (clone RP11-344F13), which contains a novel gene (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 38), which have not been previously reported. Thus, it is implified that this gene may be 15 required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:86 SEQ. ID. NO 86 (Table 5) encodes no known protein. Unknown gene with matching Est sequence in the data base corresponding to BQ182670 isolated from an osteoarthritic cartilage sample (see Table 1). We have demonstrated that this gene is 20 significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 39). which have not been previously reported. Thus, it is implified that this gene may be required for osteoclastogenesis and/or bone remodeling.
25 .. H- Cloning of full-length cDNAs of selected sequences from osteoclast mRNA:
It was necessary to obtain full-length cDNA sequences in order to perform functional studies of the expressed proteins. Spliced variants are increasingly being implicated in tissue specific functions and as such, it is important to work with cDNA
clones from the system under study. Applicant also recognizes that spliced variants 30 may not always be involved. Thus. the applicant's approach has been to isolate the relevant full-length cDNA sequences directly from osteoclasts in order to identify variants and their potential role with respect to specificity Coding cDNA clones were isolated using both a 5'-RACE strategy (Invitrogen, Burlington, ON) and a standard two-primer gene specific approach in PCR. The 5'-RACE strategy used cDNA prepared from cap-selected osteoclast RNA and/or RAMP
amplified osteoclast RNA. For amplification using gene specific primers, either cDNA
prepared from RAMP RNA or total RNA was used. All cDNAs were synthesized following standard reverse transcription procedures (Invitrogen, Burlington.
ON) The cDNA sequences obtained were cloned in E.coli DH10B and the nucleotide sequences for multiple clones determined. Thereafter, the cDNA sequences for each set were aligned and the open reading frame(s) (ORF) identified using standard software (e.g.
ORF Finder-NCBI). Table 2 shows the concensus sequence of the cDNA clones for the coding region for SEQ. ID. NO.1 (SEQ. ID. NO. 83) and SEQ. ID. NO.2 (SEQ. ID.
NO
84) obtained from a human osteoclast sample, which were identical to that of the published sequences corresponding to Accession# NM_213602 and NM_001014433 (NCBI), respectively.
I- RNA Interference Studies RNA interference is a recently discovered gene regulation mechanism that involves the sequence-specific decrease in a gene's expression by targeting the mRNA
for degradation and although originally described in plants, it has been discovered across many animal kingdoms from protozoans and invertebrates to higher eukaryotes (reviewed in Agrawal et al., 2003). In physiological settings, the mechanism of RNA
interference is triggered by the presence of double-stranded RNA molecules that are cleaved by an RNAse III-like protein active in cells, called Dicer, which releases the 21-23 bp siRNAs. The siRNA, in a homology-driven manner, complexes into a RNA-protein amalgamation termed RISC (RNA-induced silencing complex) in the presence of mRNA to cause degradation resulting in attenuation of that mRNA's expression (Agrawal et al.. 2003).
Current approaches to studying the function of genes, such as gene knockout mice and dominant negatives, are often inefficient, and generally expensive, and time-consuming. RNA interference is proving to be a method of choice for the analysis of a large number of genes in a quick and relatively inexpensive manner. Although transfection of synthetic siRNAs is an efficient method, the effects are often transient at best (Hannon G J., 2002), Delivery of plasmids expressing short hairpin RNAs by stable transfection has been successful in allowing for the analysis of RNA
interference in longer-term studies (Brummelkamp et al., 2002; Elbashir et al., 2001). In addition, more recent advances have permitted the expression of siRNA molecules, in the form of short hairpin RNAs, in primary human cells using viral delivery methods such as lentivirus (Lee et al., 2004; Rubinson et at. 2003).
J- Determination of knockdown effects on osteoclastogenesis In order to develop a screening method for the human candidate genes. RNA
interference was adapted to deliver shRNAs into human osteoclast precursor cells so that the expression of the candidate genes could be attenuated This approach would then allow osteoclast differentiation to be carried out in cells containing decreased expression of these genes to determine their requirement, if any, in this process To this end, a commercial lentiviral shRNA delivery system (Invitrogen.
Burlington, ON) was utilized to introduce specific shRNAs into human osteoclast precursor cells. The techniques used were as described by the manufacturer unless otherwise stated. In this example, the results obtained for two of the candidate genes, SEQ. ID. NO. 1 (AB0326) and SEQ. ID. NO. 2 (AB0369) tested so far, are presented.
The proteins encoded by both of these two genes have no known function. The shRNA
sequences used to specifically target SEQ. ID. NO. 1 and SEQ. ID. NO. 2 were 5-CAGG000AGGAGTCCAATT-3' (SEQ. ID. NO. 42) and 5'-TCCCGTCTTTGGGTCAAAA-3' (SEQ. ID. NO. 43) respectively. Briefly, a template for the expression of the shRNA was cloned into the lentiviral expression vector and co-transfected in 293FT cells with expression vectors for the viral structural proteins After two days supernatants containing the lentivirus were collected and stored at ¨80 C
Human osteoclast precursors purchased from Cambrex (East Rutherford NJ) were seeded in 24-well plates and cultured in complete medium containing macrophage-colony stimulating factor and allowed to adhere for three days. After washing with PBS, the cells were infected with 20 MOls (multiplicity of infection) of either lentiviral particles containing a shRNA specific for the bacterial lacZ gene as a control (lacZ
shRNA) or SEQ. ID. NO. 1 (A80326 shRNA) or SEQ. ID. NO. 2 (AB0369 shRNA). After 24h, the infected cells were treated with same medium containing 100 ng/ml RANK ligand for 5 ¨ 8 days to allow for differentiation of osteoclast from precursor cells.
Mature osteoclasts were fixed with formaldehyde and stained for TRAP expression as follows the cells were washed with PBS and fixed in 10% formaldehyde for 1h. After two PBS
washes, the cells were lightly permeabilized in 0.2% Tritonna X-100 in PBS for 5 min before washing in PBS. Staining was conducted at 37 C for 20 ¨ 25 min in 0.01%
Naphtol AS-MX phosphate, 0.06% Fast Red Violet, 50 mM sodium tartrate, 100 mM
sodium acetate, pH 5.2. The stained cells were visualized by light microscopy and photographed (magnification: 40X). A significant decrease in the number of multinucleated osteoclasts was observed from precursor cells infected with the shRNA (Figure 35A; bottom panel) and AB0369 shRNA (Figure 35B; bottom panel) compared to those with the lacZ shRNA (Figure 35A and B; top panels).
Therefore, in both cases, the respective lentiviral shRNA (SEQ. ID. NOs. 42 and 43, respectively) (Table 4) perturbed osteoclastogenesis. These results clearly indicated that expression of the gene encoding SEQ. ID. NO. 1 (AB0326) and SEQ. ID. NO. 2 (AB0369) are required for osteoclast differentiation.
Similar experimentations to those described above are carried out for other sequences (SEQ ID NO.3 to SEQ ID NO.:33, SEQ ID NO.:85 or SEQ ID NO.:86).
K- Biological validation of the mouse orthologue for AB0326 (SEQ. ID. NO. 35) in osteoclastogenesis using the RAW 264.7 model As a means of developing a drug screening assay for the discovery of therapeutic molecules capable of attenuating human osteoclasts differentation and activity using the targets identified, it was necessary to turn to another osteoclast differentiation model. The RAW 264.7 (RAW) osteoclast precursor cell line is well known in the art as a murine model of osteoclastogenesis. However, due to the difficulty in transiently transfecting RAW cells, stable transfection was used as an approach where .. shRNA are expressed in the RAW cells constitutively. This permitted long term studies such as osteoclast differentiation to be carried out in the presence of specific shRNAs specific to the mouse orthologues of the human targets identified.
RAW cells were purchased from American Type Culture Collection (Manassass, VA) and maintained in high glucose DMEM containing 10% fetal bovine serum and antibiotics. The cells were sub-cultured bi-weekly to a maximum of 10-12 passages. For osteoclast differentiation experiments, RAW cells were seeded in 96-well plates at a density of 4 x 103 cells/well and allowed to plate for 24h. Differentiation was induced in high glucose DMEM, 10% charcoal-treated foetal bovine serum (obtained from Hyclone, Logan, UT), 0.05% BSA, antibiotics, 10 ng/ml macrophage colony stimulating factor (M-CSF), and 100 ng/ml RANK ligand. The plates were re-fed on day 3 and osteoclasts were clearly visible by day 4. Typically, the cells were stained for TRAP on day 4 or 5 unless otherwise indicated.
To incorporate the shRNA-expression cassettes into the RAW cell chromosomes, the pSilencer 2.0 plasmid (SEQ. ID. NO. 47) was purchased from Ambion (Austin, TX) and sequence-specific oligonucleotides were ligated as recommended by the manufacturer. Two shRNA expression plasmids were designed and the sequences used for attenuating the mouse ortholog of AB0326 (SEQ. ID. NO. 35) gene expression were 5'-GCGCCGCGGATCGTCAACA-3' (SEQ. ID. NO. 44) and 5'-ACACGTGCACGGCGGCCAA-3' (SEQ. ID. NO. 45). A plasmid supplied by Ambion containing a scrambled shRNA sequence with no known homology to any mammalian gene was also included as a negative control in these experiments. RAW cells were seeded in 6-well plates at a density of 5 x 105 cells/well and transfected with 1 pg of each plasmid using FugeneTM6 (Roche, Laval, QC) as described in the protocol.
After selection of stable transfectants in medium containing 2 pg/ml puromycin, the cell lines were expanded and tested in the presence of RANK ligand for osteoclastogenesis.
The stably transfected cell lines were designated RAW-0326.1, RAW-0326.2 and RAW-ctl. In 96-well plates in triplicate, 4 000 cells/well were seeded and treated with 100 ng/ml RANK ligand. After 4 days, osteoclasts were stained for TRAP expression and visualized by light microscopy (magnification was 40X and 100X as depicted in the left and right panels, respectively).
The representative results for the RAW-0326.2 line is shown in Figure 36. The RAW-0326.2 cell line produced significantly less osteoclasts (Figure 36; bottom panel) compared to the cell line containing the scrambled shRNA (Figure 36; top panel). The RAW-0326.1 cell line also showed attenuation of the mouse ortholog of AB0326 but not as pronounced (data not shown). Therefore, as observed for SEQ ID NO. :42 and 43, siRNAs to the mouse orthologue (SEQ. ID. NOs. 44 and 45) (Table 4) appear to phenotypically perturb osteoclast differentiation in the mouse model as well.
These results, coupled with that obtained in the human osteoclast precursor cells using the lentiviral shRNA delivery system (section J), demonstrate that in both human and mouse, AB0326 gene product is clearly required for osteoclastogenesis.
L- A functional complementation assay for SEQ. ID. NO. 1 (AB0326) in RAW 264.6 cells to screen for inhibitors of osteoclasto genesis To establish a screening assay based on SEQ. ID. NO. 1 (AB0326) to find small 5 molecules capable of attenuating osteoclast differentiation, the cDNA
encoding human A80326 was introduced into the RAW-0326.2 cell line. Thus, if the human AB0326 plays an identical functional role as the mouse orthologue in RAW 264.7 cells, it should restore the osteoclastogenesis capabilities of the RAW-0326.2 cell line.
To accomplish this task, the RAW-0326.2 cell line was transfected with an 10 eukaryotic expression vector encoding the full length cDNA for human AB0326, termed pd2-hAB0326. This expression vector (pd2, SEQ. ID. NO. 47) was modified from a commercial vector, pd2-EGFP-N1 (Clontech. Mountain View, CA) where the EGFP
gene was replaced by the full length coding sequence of the human AB0326 cDNA
The AB0326 gene expression was driven by a strong CMV promoter Stable 15 transfectants were selected using the antibiotic, G418. This resulted in a RAW-0326.2 cell line that expressed the human AB0326 gene product in which, the mouse orthologue of AB0326 was silenced. As a control. RAW-0326.2 cells were transfected with the pd2 empty vector, which should not complement the AB0326 shRNA
activity.
Also, the pd2 empty vector was transfected into RAW 264.7 cells to serve as a further 20 .. control. After selection of stable pools of cells, 4 000 cells/well were seeded in 96-well plates and treated for 4 days with 100 ng/ml RANK ligand. Following fixation with formaldehyde, the cells were stained for TRAP, an osteoclast-specific marker gene. As shown in Figure 37, the RAW-0326.2 cells transfected with the empty pd2 vector are still unable to form osteoclasts in the presence of RANK ligand (center panel) indicating 25 .. that the mouse AB0326 shRNA is still capable of silencing the AB0326 gene expression in these cells_ Conversely, the cells transfected with human AB0326 (pd2-hAB0326) are rescued and thus, differentiate into more osteoclasts in response to RANK ligand (right panel). RAW 264.7 cells containing the empty vector (pd2) did not adversly affect the formation of osteoclasts in the presence of RANK ligand (left panel) 30 .. These results confirm that the mouse and human orthologues of AB0326 are functionally conserved in osteoclast differentiation This particular type of cell-based assay can now serve as the basis for screening compounds capable of binding to and inhibiting the function of human AB0326. A compound library could be applied to this 'rescued' cell line in order to identify molecules (small molecule drugs, peptides, or antibodies) capable of inhibiting AB0326. Any reduction in osteoclast differentiation measured by a reduction in the expression of TRAP would be indicative of a decrease in human AB0326 activity.
This assay is applicable to any gene required for proper osteoclast differentiation in RAW
cells. A complementation assay can be developed for any human gene and used as the basis for drug screening.
Similar experimentation to those described above are carried out for other sequences (SEQ ID NO.3 to SEQ ID NO.:33 or SEQ ID NO.:85 or SEQ ID NO .86) This type of assay may be used to screen for molecules capable of increasing or decreasing (e.g., inhibiting) the activity or expression of NSEQ or PSEQ.
In the NSEQs of the present invention, their methods, compositions, uses, its, assays or else, the polynucleotide may either individually or in group (collectively) more particularly be (or may comprise or consist in) either;
a translatable portion of either SEQ ID NO.:1, of SEQ ID NO.:2, of SEQ ID
NO.:3, of SEQ ID NO.:4, of SEQ ID NO.:5, of SEQ ID NO.:6, of SEQ ID NO.:7, of SEQ
ID NO.:8, of SEQ ID NO.:9, of SEQ ID NO .10, of SEQ ID NO 11, of SEQ ID NO 12.
of SEQ ID NO.:13, of SEQ ID NO.:14, of SEQ ID NO :15, of SEQ ID NO.:16. of SEQ
ID NO 17 of SEQ ID NO 18, of SEQ ID NO :19, of SEQ ID NO 20. of SEQ ID
NO :21, of SEQ ID NO.:22, of SEQ ID NO .23. of SEQ ID NO ;24 of SEQ ID NO '25.
of SEQ ID NO :26. of SEQ ID NO. 27. of SEQ ID NO 28, of SEQ ID NO 29, of SEQ ID
NO.30, of SEQ ID NO. 31, of SEQ ID NO -32. of SEQ ID NO '33. of SEQ ID NO .85 or of SEQ ID NO. :86;
sequence substantially identical to a translatable portion of SEQ ID NO..1, of SEQ ID NO.:2, of SEQ ID NO :3, of SEQ ID NO.:4, of SEQ ID NO 5, of SEQ ID NO
6.
of SEQ ID NO.:7, of SEQ ID NO.:8, of SEQ ID NO.:9, of SEQ ID NO.:10, of SEQ ID
NO.:11, of SEQ ID NO.:12, of SEQ ID NO.13, of SEQ ID NO.:14, of SEQ ID NO. 15.
of SEQ ID NO.:16, of SEQ ID NO.:17, of SEQ ID NO.:18. of SEQ ID NO.:19, of SEQ
ID
NO :20, of SEQ ID NO.:21, of SEQ ID NO.:22, of SEQ ID NO. 23, of SEQ ID
NO.:24, of SEQ ID NO :25, of SEQ ID NO.:26, of SEQ ID NO :27, of SEQ ID NO -28, of SEQ ID
NO :29, of SEQ ID NO :30. of SEQ ID NO. 31, of SEQ ID NO 32, of SEQ ID NO 33.
of SEQ ID NO :85 or of SEQ ID NO '86:
a sequence substantially complementary to a translatable portion of SEQ ID
NO.:1, a fragment of a transcribable portion of SEQ ID NO. :1 of SEQ ID NO.
:2, of SEQ
ID NO.:3, of SEQ ID NO. 4, of SEQ ID NO.:5, of SEQ ID NO.:6, of SEQ ID NO 7, of SEQ ID NO.:8, of SEQ ID NO.:9, of SEQ ID NO.:10, of SEQ ID NO.:11, of SEQ ID
NO.:12, of SEQ ID NO.:13, of SEQ ID NO.:14, of SEQ ID NO.:15, of SEQ ID NO.
16.
of SEQ ID NO.17, of SEQ ID NO 18, of SEQ ID NO.:19, of SEQ ID NO.20. of SEQ ID
NO.21, of SEQ ID NO.:22, of SEQ ID NO. 23. of SEQ ID NO.:24, of SEQ ID NO 25, of SEQ ID NO 26, of SEQ ID NO.27, of SEQ ID NO.:28, of SEQ ID NO.:29, of SEQ ID
NO.:30, of SEQ ID NO 31, of SEQ ID NO..32, of SEQ ID Na.33, of SEQ ID NO .85 or of SEQ ID NO.:86:
a fragment of a sequence substantially identical to a translatable portion of SEQ
ID NO 1, of SEQ ID NO 2, of SEQ ID NO.:3, of SEQ ID NO 4, of SEQ ID NO. 5. of SEQ ID NO.:6. of SEQ ID NO :7, of SEQ ID NO 8, of SEQ ID NO 9. of SEQ ID
NO.:10. of SEQ ID NO.:11, of SEQ ID NO.:12. of SEQ ID NO.:13, of SEQ ID NO.
14, of SEQ ID NO.:15, of SEQ ID NO.:16, of SEQ ID NO.:17, of SEQ ID NO.:18, of SEQ
ID
NO.:19. of SEQ ID NO 20. of SEQ ID NO :21, of SEQ ID NO.:22, of SEQ ID NO 23, of SEQ ID NO.:24. of SEQ ID NO :25, of SEQ ID NO.:26, of SEQ ID NO.:27. of SEQ ID
NO.:28, of SEQ ID NO.:29, of SEQ ID NO.:30. of SEQ ID NO.:31. of SEQ ID NO
:32, of SEQ ID NO :33, of SEQ ID NO.:85 or of SEQ ID NO.:86;
a fragment of a sequence substantially complementary to a translatable portion of SEQ ID NO.:1, of SEQ ID NO. 2. of SEQ ID NO.:3, of SEQ ID NO .-4, of SEQ ID
NO 5, of SEQ ID NO.:6, of SEQ ID NO. 7, of SEQ ID NO .8. of SEQ ID NO .9. of SEQ
ID NO .10. of SEQ ID NO.:11. of SEQ ID NO.:12, of SEQ ID NO. 13. of SEQ ID
NO.14, of SEQ ID NO .15. of SEQ ID NO. 16 of SEQ ID NO 17. of SEQ ID NO -18.
of SEQ ID NO.:19, of SEQ ID NO :20. of SEQ ID NO :21, of SEQ ID NO .22 of SEQ ID
NO.:23. of SEQ ID NO.:24, of SEQ ID NO.:25, of SEQ ID NO.26. of SEQ ID NO .27.
of SEQ ID NO.:28, of SEQ ID NO.:29, of SEQ ID NO 30, of SEQ ID NO.:31. of SEQ ID
NO :32, of SEQ ID NO.:33, of SEQ ID NO.:85 or of SEQ ID NO :86;
or a library comprising any of the above_ In the PSEQs of the present invention, their methods, compositions, uses, kits assays, or else, the polypeptide may either individually or in group (collectively) more particularly be (or may comprise or consist in) either ;
SEQ ID NO.:48, SEQ ID NO.:49, SEQ ID NO.150, SEQ ID NO. 51, SEQ ID
NO.:52, SEQ ID NO :53, SEQ ID NO.:54, SEQ ID NO.:55, SEQ ID NO.:56. SEQ ID
NO. 57, SEQ ID NO :58, SEQ ID NO.:59, SEQ ID NO.:60, SEQ ID NO :61, SEQ ID
NO.:62, SEQ ID NO.:63, SEQ ID NO.:64, SEQ ID NO.:65, SEQ ID NO:66, SEQ ID
NO.:67, SEQ ID NO.:68, SEQ ID NO :69, SEQ ID NO.:70, SEQ ID NO.:71, SEQ ID
NO.:72, SEQ ID NO.:73, SEQ ID NO.74, SEQ ID NO.:75 SEQ ID NO.:76, SEQ ID
NO '77, SEQ ID NO.:78, SEQ ID NO.:79 or SEQ ID NO.:80;
a fragment of SEQ ID NO.:48, SEQ ID NO :49. SEQ ID NO .50, SEQ ID
NO.:51, SEQ ID NO.:52, SEQ ID NO.53, SEQ ID NO.:54, SEQ ID NO.:55, SEQ ID
NO.56, SEQ ID NO .57. SEQ ID NO :58, SEQ ID NO.:59, SEQ ID NO 60, SEQ ID
NO :61, SEQ ID NO.62, SEQ ID NO 63, SEQ ID NO.:64. SEQ ID NO 65, SEQ ID
NO..66. SEQ ID NO.:67, SEQ ID NO. 68, SEQ ID NO 69, SEQ ID NO.:70. SEQ ID
NO 71 SEQ ID NO.:72, SEQ ID NO .73. SEQ ID NO .74, SEQ ID NO.:75 SEQ ID
NO.:76, SEQ ID NO.77, SEQ ID NO.:78, SEQ ID NO.:79 or SEQ ID NO. 80;
or a biologically active analog, variant or a non-human hortologue of SEQ ID
NO.:48, SEQ ID NO.:49, SEQ ID NO.:50, SEQ ID NO .51, SEQ ID NO :52, SEQ ID
.. NO :53, SEQ ID NO.:54, SEQ ID NO.:55, SEQ ID NO.:56, SEQ ID NO. 57, SEQ ID
NO.:58, SEQ ID NO.:59, SEQ ID NO.:60, SEQ ID NO.:61, SEQ ID NO.:62, SEQ ID
NO.:63, SEQ ID NO.:64, SEQ ID NO.:65, SEQ ID NO.:66, SEQ ID NO.:67, SEQ ID
NO. 68, SEQ ID NO.:69, SEQ ID NO.70, SEQ ID NO.:71, SEQ ID NO.:72, SEQ ID
NO.:73, SEQ ID NO.:74, SEQ ID NO.:75 SEQ ID NO.76, SEQ ID NO.77. SEQ ID
NO.:78, SEQ ID NO.:79 or SEQ ID NO. 80.
One of skill in the art will readily recognize that orthologues for all mammals maybe identified and verified using well-established techniques in the art, and that this disclosure is in no way limited to one mammal The term ''mammal(s)" for purposes of this disclosure refers to any animal classified as a mammal, including humans, .. domestic and farm animals, and zoo, sports, or pet animals, such as dogs cats, cattle.
horses, sheep. pigs. goats, rabbits, etc. Preferably. the mammal is human.
The sequences in the experiments discussed above are representative of the NSEQ being claimed and in no way limit the scope of the invention. The disclosure of the roles of the NSEQs in osteoclastogenesis and osteoclast function satisfies a need in the art to better understand the bone remodeling process, providing new compositions that are useful for the diagnosis, prognosis, treatment, prevention and evaluation of therapies for bone remodeling and associated disorders.
The art of genetic manipulation, molecular biology and pharmaceutical target development have advanced considerably in the last two decades. It will be readily apparent to those skilled in the art that newly identified functions for genetic sequences and corresponding protein sequences allows those sequences, variants and derivatives to be used directly or indirectly in real world applications for the development of research tools, diagnostic tools, therapies and treatments for disorders or disease states in which the genetic sequences have been implicated.
TABLE 1 ¨ Differentially expressed sequences found in osteoclasts.
Nucleotide NCB! Accession ORF Function Sequence Unigene Number Nucleotide No. Positions/
#/Gene Symbol/Gen Polypeptide e ID sequence No.
SEQ ID NO. Hs.287692 NM 213602 150-1136 hypothetical protein 1 L0C284266;
/ CD33L3 encoding SEQ
membrane associated ID NO.:48 / 284266 function unknown SEQ ID NO. Hs.520070 NM 001014 104-700 chromosome 6 open 2 433¨ reading frame 82 / C6orf82 membrane associated with encoding SEQ unknown function ID NO.: 49 SEQ ID NO. Hs.546482 NM 178833 633-2246 hypothetical protein 3 L0C133308 possibly / L00133308 encoding SEQ
involved in regulation ID NO.: 50 /133308 of pH
SEQ ID NO. Hs.135997 NM_138461 112-741 transmembrane 4 L
4 six family member 19 / LOC116211 encoding SEQ
ID NO.: 51 ; function unknown SEQ ID NO. Hs.558655 NM_145280 172-82 hypothetical protein / LOC151194 encoding SEQ
ID NO.: 52 SEQ ID NO. Hs.89714 NM_002994 119-463 chemokine (C-X-C
6 motif) ligand / CXCL5 encoding SEQ
ID NO.: 53 precursor; chemokine Nucleotide NCB! Accession ORF Function Sequence Unigene Number Nucleotide No. Positions/
Gene Symbol/Gen Polypeptide e ID sequence No.
/ 6374 activity SEQ ID NO. Hs.495960 NM_005765 103-1155 ATPase, H+
7 transporting, / ATP6AP2 encoding SEQ
ID NO 54 lysosomal accessory .:
/10159 protein 2;receptor activity SEQ ID NO. Hs.42400 NM_182488 259-1371 ubiquitin-specific 8 protease 12-like 1;
cysteine-type / 219333 encoding SEQ endopeptidase activity ID NO.: 55 SEQ ID NO Hs 164853 NM 003341 175-756 ubiquitin-conjugating 9 enzyme E2E 1 isoform 1. ligase / 7324 encoding SEQ activity ID NO.: 56 SEQ ID NO. Hs.433278 NM_032565 53-673 emopamil binding 10 related protein.
/ EBPL
de1ta8-delta7 integral / 84650 encoding SEQ to membrane ID NO.: 57 SEQ ID NO. Hs.106015 NM_018482 29-3418 development and 11 differentiation enhancing factor 1.
/ 50807 encoding SEQ membrane ID NO.: 58 SEQ ID NO. Hs.517265 NM 021181 16-1023 SLAM family member 12 receptor activity / 57823 encoding SEQ
ID NO.. 59 SEQ ID NO Hs.470804 NM 006357 385-1008 ubiquitin-conjugating 13 enzyme E2E 3, ligase activity / 10477 encoding SEQ
ID NO.: 60 SEQ ID NO. Hs.278959 NM_015973 177-548 galanin preproprotein:
14 neuropeptide Nucleotide NCB! Accession ORF Function Sequence Unigene Number Nucleotide No. Positions/
#/Gene Symbol/Gen Polypeptide e ID sequence No.
/ GAL hormone activity /51083 encoding SEQ
ID NO.: 61 SEQ ID NO. NM_032569 NM_032569 19-1680 cytokine-like nuclear 15 factor n-pac: 3-/ N-PAC
hydroxyisobutyrate / 84656 encoding SEQ dehydrogenase-like ID NO.: 62 SEQ ID NO. Hs.248472 NM 000887 68-3559 integrin alpha X
16 precursor. cell-matrix / ITGAX
adhesion / 3687 encodingSEQ
SEQ ID NO. Hs.156727 NM_054027 321=1799 ankylosis. progressive 17 homolog. regulation of / ANKH
bone mineralization / 1827 encoding SEQ
ID NO.: 64 SEQ ID NO. Hs.477155 NM 001690 67-1920 ATPase. H+
18 transporting.
lysosomal 70kD, V1 / 523 encoding SEQ subunit A. isoform 1 ID NO.: 65 : proton transport.
hydrolase activity SEQ ID NO. Hs.445386 NM_018252 139-1191 hypothetical protein /55248 encoding SEQ
ID NO.: 66 SEQ ID NO. Hs 467662 NM 004763 170-772 integrin cytoplasmic 20 domain-associated / ITGB1BP1 encoding SEQ
ID NO.: 67 protein 1 : cell adhesion SEQ ID NO. Hs.408236 NM 032731 77-448 thioredoxin-like 5 / TXNL5 function unknown /84817 F encoding SEQ
ID NO: 68 L. ____________________________________________________________ _1 Nucleotide NCB! Accession ORF Function Sequence Number Nucleotide Unigene No. Positions/
#/Gene Symbol/Gen Polypeptide e ID sequence No.
SEQ ID NO. Hs.236516 NM 014358 152-811 C-type lectin.
22 superfamily member 9 / CLECSF9 encoding SEQ
ID NO.: 69 = ;integral to membrane SEQ ID NO I Hs.56294 NM 004794 265-978 ; Ras-related protein 23 ' Rab-33A; small GTPase mediated / 9363 encoding SEQ signal transduction ID NO: 70 SEQ ID NO. Hs.282326 NM 004414 73-831 calcipressin 1 isoform 24 a; interacts with calcineurin A and /1827 encoding SEQ inhibits calcineurin-ID NO.: 71 dependent signaling pathways SEQ ID NO. Hs.520794 NM 006555 158-754 SNARE protein Ykt6:
25 vesicular transport between secretory / 10652 encoding SEQ compartments ID NO.: 72 SEQ ID NO. Hs.509765 NM_001102 I 184-2862 alpha-actinin 1:
26 structural constituent / ACTN1 of cytoskeleton.
/ 87 encoding SEQ calcium ion binding ID NO: 73 SEQ ID NO. Hs.113823 NM 006660 73-1974 CIpX caseinolytic 27 protease X homolog;
/ CLPX
/ 10845 encoding SEQ energy-dependent ID NO.: 74 regulator of proteolysis SEQ ID NO. Hs.155097 NM_000067 66-848 carbonic anhydrase 28 carbonate / CA2 encoding SEQ
ID NO.: 75 dehydratase activity SEQ ID NO. Hs 520714 NM 013322 216-821 sorting nexin 10 / SNX10 encoding SEQ ; function unknown ID NO.: 76 SEQ ID NO. Hs.525061 I NM 030794 258-2213 tudor domain 30 I ¨
containing 3: nucleic / TDRD3 encoding SEQ
Nucleotide NCB! Accession ORF Function Sequence Unigene Number Nucleotide No. Positions/
#/Gene Symbol/Gen Polypeptide e ID sequence No.
/ 81550 ID NO.: 77 acid binding SEQ ID NO. Hs.275775 NM 005410 101-1246 selenoprotein P
/ SEPP1 encoding SEQ : extracellular space ' / 6414 ID NO 78 implicated in defense I
SEQ ID NO. Hs.518138 NM 014656 1 921-1382 1 KIAA0040 novel 32 protein / KIAA0040 encoding SEQ
/9674 ID NO.: 79 SEQ ID NO. Hs.368912 NM 001935 562-2862 dipeptidylpeptidase 33 IV:
/ DPP4 encoding SEQ activi aminopeptidase ty ID NO.: 80 SEQ ID NO. Hs.304682 NM 000099 76-516 cysteine protease 34 i /CST3 encoding SEQ inhibitor activity /1471 ID NO.: 81 SEQ ID NO. None AL357873 Novel novel /none /none SEQ ID NO. AL645465 novel J novel TABLE 2 ¨ Shows the concensus sequences for SEQ. ID. NO. 1 and SEQ. ID. NO. 2 cloned from a mature human osteoclast sample.
Sequence ORF Polypeptide Identification Nucleotide sequence No.
Positions SEQ ID NO. 83 1-987 SEQ ID NO. 48 SEQ ID NO. 84 I 1-471 SEQ ID NO. 49 TABLE 3 -List of mouse orthologue for AB0326 Sequence NCB! Accession ORF Nucleotide Polypeptide Identification Unigene Number Positions sequence Cluster No.
SEQ ID None XM_884636 122-1102/ SEQ ID 1 NO. 35 /L00620235 1 similar to neural cell NO .82 620235 adhesion molecule 1 /
= 2/unknown function TABLE 4 - list of additional sequences identification of plasmids and shRNA
oligonucleotides Sequence name Description Identification SEQ. ID. NO. 36 = p14 Vector for STAR
SEQ. ID. NO. 37 p17+ Vector for STAR
SEQ. ID. NO. 38 pCATRMAN Vector for STAR
SEQ. ID. NO. 39 p20 Vector for STAR
1 SEQ. ID. NO. 40 OGS 77 Primer used for STAR
p14 vector SEQ. ID. NO 41 OGS 302 Primer used for STAR
p17+ vector SEQ. ID. NO: 42 human 0326.1 siRNA sequence for SEQ. ID. NO. 1 SEQ. ID. NO: 43 Human 0369.1 shRNA sequence for SEQ. ID. NO. 2 SEQ. ID. NO: 44 mouse 0326.1 shRNA sequence for Sequence name Description Identification SEQ. ID. NO. 35 SEQ. ID. NO: 45 mouse 0326.2 shRNA sequence for SEQ ID NO. 35 SEQ. ID. NO: 46 pSilencer2.0 vector SEQ. ID. NO: 47 pd2 vector =
NucleotideSequence ORFs (5'-3') ^SEQIDNO.:1 SEQIDNO.:48 TCCGCCTCCCGCAGAGCCCACAGGGACCTGCAGATCTGAGTGCCCTGCCCACCCCCGCCCGCCTTCCTTCCCCCACCAC
GCCTGGGA MEKSIWLLACLAWVLPTGSFVRT
GGGCCCTCACTGGGGAGGTGGCCGAGAACGGGTCTGGCCTGGGGTGTTCAGATGCTCACAGCATGGAAAAGTCCATCTG
GCTGCTGG KIDTTENLLNTEVHSSPAQRWSM
CCTCCTTGCCGTGCGTTCTCCCGACAGGCTCATTTGTGAGAACTAAAATAGATACTACCGAGAACTTGCTCAACACAGA
GGTGCACA QVPPEVSAEAGDAAVLPCTFTHt, GCTCGCCAGCGCAGCGCTGGTCCATGCAGGTGCCACCCGAGGTGAGCGCGCAGGCAGGCGACGCGGCAGTGCTGCCCTC
CGCACCCGCACCGCCACTACGACGGGCCGCTGACGGCCATCTGGCGCGCGGGCGAGCCCTATGCGGGCCCGCAGGTGTT
CCGCTGCG FRCAAARGSELCQTALSLHGRFR
CTGCGCCGCGGGGCACCGAGCTCTGCCAGACGOCGCTGAGCCTGCACGGCCGCTTCCGCCTGCTGGGCAACCCGCGCCG
N.) CO TcTcGcTGcGcGTcGAGCGccTCGCCCTGGCTGAcGACCGcCGCTACTTcTGccGceTcGAGTTcc-CcGGceAcGTCCATGAceGcT RYFCRVEFAGDVHDRYESRHGVR
ACGAGAGCCGCCACGGCGTCCGCCTGCACGTGACAGCCGCGCCGCGGATCGTCAACATCTCCGTCCTGCCCAGTCCGGC
TCCGCGCGCTCTGCACTGCCGAAGGGGAGCCGCCGCCCGCCCTCCCCTGGTCCGGCCCGGCCCTGCGCAACAGCTTGGC
AGCCCTGC ALCTAEGEPPPALAWSGPALGNS
GGACCCCGCGTGAGGGTCACGGCCACCTAGTGACCGCCGAACTGCCCCCACTGACCCATGACGGCCGCTACACGTGTAC
GGCCGCCA LAAVRSPREGHGHLVTAELPALT
rn ACAGCCTGGGCCGCTCCGAGGCCAGCGTCTACCTCTTCCGCTTCCATGGCGCCAGCGCCGCCICGACGGTCGCCCTCCT
GCTCGGCG hDGRYTCTAANSLGRSEASVYLF N.) (1) CTCTCGGCTTCAAGGCGCTGCTGCTGCTCGGGGTCCTGGCCGCCCGCGCTGCCCGCCGCCGCCCAGAGCATCTGGACAC
CCCGGACA RFRGASGASTVALLLGALOFKAL
CCCCACCACGGTCCCAGGCCCAGGAGTCCAATTATGAAAATTTGAGCCAGATGAACCCCCGGAGCCCACCAGCCACCAT
GTGCTCAC LLLGVLAARAARRRPERLDTPDT N.) CGTGAGGAGTCC C TCAC C CAC CAA CAT C CATTTCACCACTGTAAAGAACAAA GGC CAGT GC GAGG
GGTTCTCCGGCACCTTGGCAGCCCC CAGCTGGGTGGCT C C TCC CCT GOT CAAGGT CAAGAC C CTGC T
CAAGGAGGCT CATCTGGC C T ATMCS P
N.) AGAGAGAGAGACAGAGAG TACAC GCA TTAGCT TGAGCGTGAAAC TTC CAGAAATG TT CC CTTGCC
CTTT CTTAC CTAGAACAC CTGC
TATAGTAAAGCAGACAGGAAACTGTT
a) "0 =
t.4 SEQIDNO . :2 SEQIDNO : 4 9 ACGGAAACGGGCGTGCCATTTCCGCGCACGTCTG CAGATGCGGTAGTCGATTGGT CAAGTCTCCCATGGCTCCTC
CTTCATCAGGAG MIGS GLAGSGGAGG PS S TVTWCA
GTGGGCAAACCGCGCCATGATAGGCTCGGGATTGGCTGGCTCTGGAGGCGCAGGTGGTCCTTCTTCTACTGTCACATGG
TGCGCGCT LFSNHVAATQASLLLS FVWMPAL
GTTTTCTAATCACGTGC-CTGCCACCCAGGCCTCTCTGCTCCTGTCTTTTGTTTGGATOCCGGCGCTGCTGCCTGTGGCCTCCCGCCT L
PVASRLLLL PRVLLTMASGS PP
TTTGTTGCTACCCC GP.GTCTTGCTGACCATGGCCTCTGGAAGCCCTCCGACC CAG CC CTCGCCGGCCTC GC-ATTCCGGCTCTGGCTA TQ PS PASDSG SGYVPGSVSAAFV
CGTTCCGGGCTCGGTCTCTGCAGCCTTTGTTACTTGCCCCAACGAGAAGGTCGCCAAGGAGATCGCcAGC-GCCGTGGTGGAGAAGCG TCPNEKVAKEIARAVVEICRLP_AC
CCTAGCAGCCTGCGTCAACCTCATCCCTcAGATTACATCCATCTATGAGTGGAAAGGGAAC-ATCGAGGAAGACAGTGAGGTGCTGAT VNL 'POI TS /YEWICGKIEEDS EV
GATGATTAAAACCCA.P.AGTTCCTTGGTCCCAGCTTTGACAGATTTTGTTCGTTCTGTGCACCCTTACGAAGTGGCCG
AGGTAP.TTGC LMM IKTQS S LvPALTD FVPsvHp ATTGC CTGTG
cAACP_GGGGAACTTTCCGTACCTGCAGTGGGTGCGCCAGGTCACAGAGTCAGTTTCTGACTCTATCACAGTC CTGC
C yEvAEVIALPVEQGNFPYLQWVE
ATGATGAGCCCTGTTCCTGCTCATCATGAAGATCCCCGCGATACTTCAACGCCTTCTGACTTCCAGGTGATGACTGGGC
CCCCAATA QvTESVSDS ITVLP
AATC CC GT CTTTGGGTCTCT CTG CCAAAAAAAAAAAAAAA
co co co rn n.) Cl) rn n.) rn co n.) N.) t.) SEQIDNO . :3 SEQIDNO . : 5 0 CGGTGTcTCGTCATCTCCGGGAAGACTCGGCGCCTGGGTCCG CG
CTCTcTGGGTAAGcTTICCGGGAAGCTTTCCCGGGAGCTCGCT MGDEDKRI TYED SEP S TGMNYTP
GGTCCTGGCCCCAGPAGCCTGCGGACCCGCCCAGGGAGGATAAGC.AGCTGAAAGACCGCGCGGTGcCGcTccGAGGCC
CCGGGACGT S MHQEAQEETIIMIGAGIDANE PT
GGGCCCATGGTCGGCCTGGCGCCAC CTTTCCGGGGGAAGCCACGCGCACGAGGCATCGCACG
CGGCTCTGCACCCGCGCCGCCGGAC EGS ILLKSSEKKLQETPTEANHV
CTGAAACCCGGCGGAGGGCACACGGGGCTGCCGCTecGGG C CC
CGGACCAACCCATGCTTACTCCGGAGCCTGTA.CCGGCGC CGACG QRLRQMLAC PPTIGLLDRVI TNVT
GGICGGACCTCCCTGCGCGGIGTCGCCCAGCGGG'ITCGTGCGAAAGGCOGGG CCGACTACACGCGG
TGCCGCGCCCTGAGAC:CGT TT I IVLLWAVMS ITGSECLPGGNL
ATCTGCAGTCAACGCAGCCTGCCGGCTCAGCCTGGGAAGATGCGCGAATCGGGAACCCCAGAGCGCGGTGGCTAGACCG
GGCTCCGC EGI I I LPYCAIIGGKLLGLIKLP
CGCCTCCCCCACAGCCCCITTCCTAATCGTTCAGACGGAGCCTGGICGAGTTCGCCGGAG-ACTGCCAGATCTCGTTCCTCTTCCCTG TL P PL PSLLGMLLAGFL/RNI PV
TGTCATCTTCTTAATTATAAATAATGGGGGATGAAGATAAAAGAATTACATATGAAGATTCAGAACCATCcACAGc-AATGAATTACA INDNVQIKHKWS S S LES IALS I I
CGCCCTCCATGCATCAAGAAGCACAGGAGGAGACAGTTATGAAGCTCAAAGGTATAC-ATGCAAATGAACCAACAGAAGGAAGTATTC LATRAGLGLDSICALKKLKGVCVRL
TTTTGAAAAGCAGTGP_AAAAP-kGCTACAAGAP_ACACCAACTGAAGCAAATCACGTACP.AAGACTGAGACAAATGCTGGCTTGCCCTC SMG PC
/VEACTSALLAHYLL GLP
CACATGGTTTACTGGACAGGGTCATAACAAATG T TACCATCATTGTTCTT
cn GTCTTCCTGGAGGAAACCTATTTC-GAATTATAATCCTATTCTATTGTGCCATCATTGGTGGTAAACTTTIGGGGCTTATTAAGTTAC
LLLQGGGYGVEKGVPTLLMAAGS
CTAcATTGCCTCCACTGCGTTCTCTTCTTGGCATGCTGCTTGCAGGGTTTCTaATCAGAAATATCCCAGTCATCAACGA
TAATGTGC FDDILAITGENTCLGIAESTGST
cn AGATCAAG CACAAGTGGTCTICCTCTITGAGAAGCATAGCCCTGTCTATCATTC TGGTTCGTC-CTGGCCTTC-GTCTC-GATTCAAAGG VENVLRGVLEVVIGVATGSVLGF
CO
CO
CC CTGAAGAAGTTAAAGGGCGTTTGTGTAAGACTGrccATGGGTCCCTGTATTGTC-GAGGCGTGCACATCTGCTCTTCTTGCCCATT F QYFP SRDQD KINCKRTFLVLG
171 CTGCTGGGTTTAC CATGGCAAIGGGGATTTATACTGGGTTTTGITTTAGGTGcT.GTATC T
CCAGCTGTTGTGc-TGCCTTcAATGc LSVLAvESSvHFGFPGSGGLCTL 0 --1 TCCTTTTGcAGGGAGGAGGCTATGGTGTTGAGAAGGGTG
TCCCAACCTTGCTCATSGCAGCTGGCAGCTTCGATGACATTCTGGCCA VMP.FLAGMGvirsEKAEVEKIIAV
fli TcAcToGcTTcAAcAcATGeTTGGGCATAGCCTTTTCCACAGGCTCTACTGICTTTAATGTCCTCAGAGGAGTTTIGGA
GGTGGTAA AwDI FULL FGL IGAEVS IAS LE n.) Cl) TTGGTGroccAAcTGGATemrrcTTGGATTTTTcATTcAGTAcTTTc CAAGCCGTGACC_AGGAcAAACTTGTGTGTAAGAGAAcAT PETVGLCVATVCIAVLIRILTTF co TCCTTGTGTTGGGGTTGTCTGTGCTAG CTGTGTTCAGCAGTGTGCATTTTGGTTTCC
CTGGATCAGGAGGACTGTGCACGTTGCTCA LMVCFAG PNLKEKI F S PAWLPK
Ill TGGCTTTC CTTGC_P_GGCATGGGATGGACCAGCGAAAAGGcAGAG G
TTGAAAAGATAATTGCAGTTGCCTGGGACATTITT CAGCC CC ATVQAAIGSVALDTP_RS HGEKQL 0 TTCTTITTSGACTAATTGGAGCAGAGGTATCTATTGCATCTCTCAGACCAGAAACIGTAGGCCTTIGTGTTGCCACCGT
AGGCATTG EDYGMDVLTVAELS IL ITAPIGS co CAGTATTGATACGAATTTTGACTACATTTCTGATGGTGTGTTTTGCTGGTITTAACTTAAAAGAAAAGATATTTATTTC
TTTTGcAT LLIGLLGpELLQKVERQNKDEEV 0 GGCTTCCAAAGGCCACAGTTCAGGCTGCAATAGGATCTGTGGCTTTGGACACAGCAAGGICACATGGAGAGAAACAATT
AGAGGACT QGETSvQV n.) rn ATGGAATGGATGTGTTGAcAGTGecATTTTTeTccATccTcATcAcAccccuakTTGGAAGTerccrTATTGGTTTAcT
GGGccccA.
GGCTTCTGCAGAAAGTTGAACATCAAAATAAAGATGAAGAAGTTCAAGGAGAGACTTcTGTGCAAGTTTAGAc-GTGAAAAGAGAGAG
cr) TGCTGAACATAATGITTAGAAAGCTGCTACTTTTTTCAAGATGCATATTGAAATP.TGTP.ATGITTAAGCTTAAAATG
TAATAGAACC
AP.P.AGTGTAGCTOTTTCTITAAACAGCATTTTTAGCCCTTGCTCTTTCCATGTGGGTGGTAATGATTCTATATCCCC
AAAAAAAAAA
AAAAAAAAAAA
'1.;w SEQIDNO.:4 SEQIDNO.:51 GACAACCTTCAGGTCCAGCCCTGGAGCMGAGGAGTGGAGCCCCACTCTGAAGACGCAGCCTITCTCCAGGTTCTGTCTC
TCCCATT MVSSPCTPASSRTCSRILGLSLG
CTGATTCTTGACACCAGATGCAGGATGGTGICCTCTCCCTGCACGCCGGDAAGCTCACGCACTTGCTCCCGTATCCTGW
ACTGAGC TAALFAAGANIZALLLPNWDVTYL
L.4 CTTGGGACTGCAGCCCTGTTTGCTGCTGGGGCaAACGTGGCACTCCTCCTTCCTAACTGGGATGTCACCTACCTGTTGA
GGGGCCTC LRGLLGRHAMLGTGLWGGGLMVL
CTTGCCAGGCATGCCATGCTGGGAACTGGGCTCTGGGGAGGAGGCCTCATGGTACTCACTGCAGCTATCCTCATCTCCT
TGATGGGC TAAILISLMGWRYGDFSKSGLCR
TGGAGATACGGCTGCTTCAGTAAGAGTGCGCTOTGTCGAAGCGTGCTTACTGCTCTOTTGTCAGGTGGCCTGGCTTTAC
TTGGAGCC SVLTALLSGGLALLGALICFVTS
CTGATTTGCTTTGTCACTTCTGGAGTTGCTCTGAAAGATCGTCCTTTTTGCATGTTTGATGTTTCATCCTTCAATCAGA
CACAAGCT GVALKDGPFCMFDVSSFNQTQAW
TGGAAATATGGTTACCCATTCAAAGACCTGCATAGTAGGAATTATCTGTATGACCGTTCGCTCTGGAACTCCGTCTSCC
TGGAGCCC KYGYPFKDLHSRNYLYDRSLWNS
TCTGCAGCTGTTGTCTGGCACGTGTCCCTCTTCTCCGCCCTTCTGTGCATCAGCCTGCTCCAGCTTCTCCTGGTGGTCG
TTCATGTC VCLEPSAAVVWHVSLFSALLCIS
ATCAACAGCCITCTGGGCCTTTTCTGCAGCCITTGCGAGAAGTGACAGGCAGAACCTTCACTTGCAAGCATGGGTGTTT
TCATCATC LLQLLLVVVHVINSLLGLFCSLC
GGCTGTCTTGAATCCTTTCTACAAGGAGTGGGTTCAGGCCDTCTGTGGTTAAAGACTGTATCCATGCTGTGCTCAAGGA
GGAACTGG EX
CAAATGCTGAATATTCTQCAGAAGAAATGCCTCAGCTTACAAAACATTTATCAGAAAACATTAAAGATAAATTAAAAGG
cn GTGAPIAAAAAASLAP.W...A.
n.) CCI
Cl) (13 (1) rn co n.) rn cr) H a H 0 n Z .-1 > +
a ,y1 E.HCP.IxIftii-i g>g NaJanqp xo.-lopcDogg a cz 4 0 8 Ee.
O 0 a. >1-INH,-H OH H (r) ui 14 u >
rsi It) E. H :.> ,..1 v..1 1-4 (01 III
- E.0( 05,,E.>.,1> 41 = CP1HcnCD4101--IFil-1 2 cnt n 11, H PC A
H Pk.....¶7:4 C.DZ CA
i'i),' cc',4 'A,'-. 8 g Cl) Z ,. > F. E. 1- i-1 pc 1....
HUH LA H El H [-J' (A r. r, ', 8 g 6, 6 0 g `E?. H El P. ti: I1 ) H 0 0 .E-.1: EC1 8 g 6 Pc E.0<a0UP0aH0E.E.E.Hu0000 0 0 U 0 0 / a U 0 0 a a 4 CD y CD CD y 0 a UUCDOr Hu E.0a0HuHouUu 0 cDa E.E.000HHHE.E.4 E. 0 u 0 a C. u u 0 E--, E. 0 0 u U 0 E. uu u 0 u Kt auchuF, a cD0E-+KCua H Hu00 a UUKI:E.E.Ucia a a UE.PagE.0 q0c9Hua 00 cDuug c..) Hu a cDUE.
LI 6 8 `,' U rEr Ec.) -.' t 6 E: , g g .,i. `,'c 8 HoHgour...,HHHHHu4H000 ,...) C., UuE.HHE.HuHu0HOuUHU a 0 0 u V U U H E., a E. 0 E. 4 E. a H u H U U
uUE.E.0UUuLD000U,H0a40Hu UOHHOH ,,: HUE.< KC 0, E-. E. E. U / CD t.
8 ug E6 [; 8 ,E=' E,-' 'E, E6' EY. 1 'E*4 El 6 ' C-D) El .
A .e.E.,,CPCOLDUE.C.)UE.,FICJE. CDOE.
UCDUE.E.E. E. E. a a U a a E. u U H 0 i E,-' 6 8 6 c,' 8 'e, i-_,) r;, ,,== E.-: E. .., '4 ',; F. SE5. 8 ri H 0 E. 0 a a U H a a H F. k.-, ,_, 0 E ,.) CD
ti:
E-. gr, 0 PC CD PC CD E-. CD A E-. U E. PC rt: U E. pl: U U
E-. 0 E. u 0 u 1. u cD, E. u a E. E. E. E-+
O E. E. u E. u E. a a a H 0 U F. t,=4 E. t). H S-2 8 g -,) -,"3 g ,`: ,E;.' g ill ,`-g) 6 8 g 6' r, g 8 g 0 gc98`gr,606'''''',.E.' (-) H PK [-I
E-1 Pf: CD 1-+ 0 E. Kg 0 6 ,r4 (x"C) 8 ,4 Ll r, g g 4 u E. CD CD, E. H A E. E. E. E. 0 a g 0 cD
Ii: CD a 0 CD 0 CD a CD a HUHU E. a u c..4 0 ,.
E-, 0 u 0 CD U r, E. E. E. a E-, PC F4 E. 0 E. A H 0 P. 'c'5 ,C-)p3EY+ -4' 8 r4 i,' ,:õ.5' ,.`3 `-' ,,.,:cH V-1.8 8 ri gouHo HuPc7F-. auat.1,,t..90 u0E.E.OuUE.E.HucDUE. g CD(D a U a E.00 H HuHE-4 a HUO 0 ci0 0 6 gl E( '2, Et , +Ea' r+ FY , Er'C P. U E. g 8 E.4 ., 00,,,,,,,,,,,E,,, H,/ g ,,,, ,6:
O g 0 CD H H F. 0.4 0 4 E. 0 c) U CD 6 !.. ts O 0 aULDE.0<0E.OHE.E. K4 r .
CDUOVE.CDCDC3U,rcrCr HE'F"1.(1EC, ECj (i EC. CD Li' LE-2. (Cni C:D 0 8 E1 8 `E?, EC,' [-_,' g 0 g0000g0g000ogggggiu..., 5 a CD ED H a < E. u H 4 E, 1-. F. PC CD E. A (9 A U
0 ,, 0 0 0 c..D H ,.- y y ,5 o y o E. F. .9 ,(i..., (0) 0 It H a 0 a H It 0 U a H U 0 H H H H
U 0 E. 0 E. H a a E-; a H E. H A U E. El El (8 a UHUIDE. aug a E.H auEE-:,,u b 4 r7Y)E.g.F-.) 8 6 2i, li:', d ' E,-' ..-), Eg N E--. 6 8 0 (C59 CD E. C.9 U C9 CD U U CD U E. HE. E.g O00 V E. pa ()i: Ha <Oa u 0 C) F,C U a U E. 0 E-+ E. / u < U E. 4 1 4 E-4 E.
OuggUE.c.DOuE. uuuE.HE.Huuu uHugUrg0Hu 4 0E+Huuqua y, HaU00a 0a HO,P4 gcr,,..,U,,E` ,,,L F. tc3 ',41, CD F. PI: A U r_.: ,(0.1 r!). id ,i: 6 t-; 6 E. A E. CD 1 8 r:, ,T4 8 (c)7 CD U U P4 It H U 0 Kg H 0 Kg a U H It 6r8b4EP.66.6,11 (1`6'El E, :: r, ,tc. r.)' 5 -,) 666`,Z6t-if-,' 6 n [-,'F-t)E,-,' ';'4U88 R
/
HUHOU004E.a, t._ E. F-. c cic.DE-+UOPC..) CI u 4 < 1-, CI 4 U Pt C.) E. E. CD E. U H PC CD C.), ,,,q E.
0 E-19 E-.) .)q 8 '6 8 8 `,-);; ,`,-) r. ,r;1; El El 8 ,` '6 fr4 O HU 0a H F-4 0 A 1.9 CD I. ID H U El C.) ,.., 8 6 In UUOU CD 1, a OU0a aHOHOA t.
- ii E. 0 C..) 0 E. E. a -a 0 E- , u a u WE-. E, c 0 , ,, rõ r. ,,. Ey, = E= E, E. H HO E. a Pc gg HOC) U E. U H
O 000 a Oa 00HuHOOF.C2S9,0p, y, = 0 ci. o 0 E. 0 E. g HE. E.C.TD E, 4 t-. ,-4. µc)., '7'6 fZI 0 a E.aUHE.H aHOE. 0 uu0 H OUUUCDOCDE.E, g q g ri r, 8 ,) ,-; ,,,t, 0 ,:4 0 0 0 A: H H E-1 U E-1 r.1, U f -I 4 E, 0 E,.., 0 E4 UCDUE-IC.DgUACDPCPCgE.
C) UCDO<OUPCE.C.JUE.UPgi-.H AHUULD
SUBSTITUTE SHEET (RULE 26) j. CI H
c.1) H 0 cri cl. m r=1 rt. < fir ci) H
o cn <
rn ?Ho. H
L2 (tt OEsEs E
t14 E. M
n cn a u oi ,a, H g g > a+ g 01 g g U 0 al al 0 g r14 H la, cn a a < m utno4E.W4E, E. 0 F. E. g4 of4E-,<HP<UHPE.0PU
UH,u4rouPPE,HoOppochouuouuE.,4 <OWEJ PCDHUDCJUA<E1 <o<opo4PE.PKE
pi.; E. H u CJHUE.E.E.UPHE.A0C)<CDOHUPE. 4 E.1 0 E. U E. A H u U KE < H g E. P 4 4 < E-, u o 4 < Kg E. P ,, Es Es E. H E A P 0 0 U E. E. A PA 4 A
U= POHUPHOPPHUAHE. UCDOCDE.K4CDOE.HP0 PUAOUIDUAOF. 4 E-I < F.0 UPOOPOHHAACDE.
E.00<E-..A,E.E.E.<4F.E.E.AUAUE-.00H L5UP 4 E.
U 0 F. u o 0 H 0 H H U 0 0 U Ui E. A p E. u UUFUHACJOOHE.E.00CDAOUU4 UU oHu OE. puoo 0 4 HOP OCJAPPOL)<U 0 HOLD E-4 E.E. , UPCDC)AAAE.C.?E.A AE.<uc.DAHUCA<AH 4H0 / AUPCDAUF.E.0,UHLDHE.,<UHAUC..5 HCDA E-.0E-, E-- UUCDOACD , HUCDE--.UE-.c1.<PCDC.) 4 Kg < 4 E.F.
UPE.A0A00E.0 UHAP CDHOOPAAE. E.F.E.
POUE-luAH<A 0,-4PU OPE. .4 OHAE. APE.
UCDOA E-.F.CDA.<0 E-.E.ULDE--.PCDOE-.F.E.A NH<
E.u0uHu4 044 UAHHUE. .< E.E.E.040E.
U U 0 CD U E. U 0 A 0 El 0 E. E. PA E. U < < CD CD 0 E. 0 0 E. U E.
0 U 0 U E. 0 0 E. u E-1 4,4 rc U a, E. F. A E. A E. El U o E. 4 4 u U H u E. E. A E. A U U A E. E. 0 4 E. U U < A U E. U < < E-, o E.
0 0 0 E . H U E. A. 0 A a. E.-, re, E-, U o H P E. 0 E. 0 c..) E. A < E. CD
H E. E. 0 E. () E. E. A n. 0 [-, < ril 0 r4., E. 0 Kg < 0 E-. E-, c..) A E. E.
<
u 0 U E-4 U r.) F. U 0 E--. < u E-, E. 0 H, E. E. U E, 0 E. q E-. E. E.
F.
H U U CD U E. F. 0 P E. A A U A: A A < < < CD U A U F. E. F. A
rUE.UPC-DA(DAE-.CJOHULDUC9HHHOU E.AOU
0 UPHUHE.AF.CDPAHCDCDPHE.PH AHCDP
00000 HHOAH E--.C9HU KE o 4 < H 10E.0=KqE;' U(DHIDA/HUACD E-, E-, U: Es E.P.A<OA< AAPAL) E-(C) U H gl.: A 0 H t. A A 0 A u u a, H 0 u H 0 A 4a. 0 00000 PA AAHE. P o o 4, u u < 4 0 POPE.E.HE-.
U U U E. A F. L3 P E. U E. A E. g E. U C) E. 0 A 0 0 gc ,:: 0 EA E--.
POO AuLIPHUHAAE.HE.00H<AACDHACDUHA
u u 4 4 CJO OPAUUAUPCJHOOPPOUHA F. HC) O U c.) E. E. P H E. 0 C.) F. E.
E. C.) 0 H 4 E. -A H E. U E. E. CD U E-.
UOUOAAHUF.HPHETUCDP-40E1OHE. F.0 H < 0 < 0 U H 0 H F. U E. CD A 1= U CD CD CD H H E. U A E.
HUUUE.CDOAAAPA.A 0,01ACDE. HUE. P0 U U H E. F. U E. a; A F. A H A
E. 4., E. U E. F. A 0 E. U El H 0 E.
E. E. 4 A U A E. E. U E. C) E. P A A C.) CD U 0 E. U .< 0 E. 0 ALDUCE.CJOHO E. APPC.5.ZE.r(000 AU 000E.
A E. U E. 00HU0 0 HHHHU40H.g0444 C.5 E. E. A
1 ci U U E. A E. 0 H 0 E. < CD C) A A Cl c.) 4 4; H E. U E. E-, E-, E-i U.U0 H00UH.c004,<0-444H 0 U CD P E. Hug() E. H o H E. P U E. .< .< 0 -. F. <
E. 0 r< H < .< 0 E. P Kg E. E. KE <
uu0 /E-,opuucn ,r, E-IHUOPPUUE-.U.APUHA, U u A. u E-. c-, o, U 4 H 4 E-, 4 U 0 .4 0 H 0 4 H 0 E. U E.
H 1.9 U U HPAE.E.C.DPg04a:
UAE.F.HPAACDE.
AACJUOCD < H 4 E. 5 ,,,.,õF, . 00H.40HU0E.E-.
000E.04.00CDP E.E.PH A Ag<CDOE.E1AF.
O E. A A a, 0 1-. E. A r< E. 4 E. U E. c.) U u A A
P E. 0 E.
0 A u U A A < E. E, 0 0 E. c) C. 0 < U < P A A F. H A U
U E. cn H cn 4 El A A CD F. A u E. 0 E. 0 Ci H 0 P E-' U , E' ,4 E. c) U E. 0 E. 0 U E. E. E. E. a, 0 A A A 0 E. 0 0 H U E. E. H E-, O<.<00HOUUE-,,<00H H<Kg aPKEEnHuo/pp ocio<ug< 1,..õ,,, A U F. U o 0 CJ E. E. r HUH0-40 A PHE-.UUAHHA < CJAOPPE. Es Es o 4 u o 4 H 0 A (-) E-, < P < re, o 4 < < 0 u H 0 0 E-, 0 gti < o o < 0 u 4 H < o PHAHAE.A AUCDOHUA cl u F. E. A, A A A 0 U 0 E. H F, C.) Ai A A 0 U A CD F. F. U 0 A
A E. c..) U A C.) 0 0 E. U C) E. CD A HUE-,0H0HU <40 UU000 < <HO HUE.0 HE.......:E.0E.C.7.<0 < A 1.E.
UE.E.UE. 0000 HEUHE.E. Ch ,cr H E. H 0 P r CJ CJ E.
O 0 CJ A U 0 A E. H < 8 E, 0 , Cl E. H E. E. g E. 0 0 4 P
,<HOUU0<00:E. H H t, 0 E., E-, 4 .I, E. E. E. A E. E-, E. E.
Pc tiE-,OUACDE.H0 4H04E.E.UE.U C.5 CDPAUH AU, (5 CD U A P a, 0 0 E-, E-1 P.< pc F. A E. 0 H < CD CD CD E. 4 4 El OULDOUCJOAD E. 4 En < E-, 0 < 4 0 < 0 F4 .'4 E-4 1. 0 0 4 Oes<UK:0H0.4E.KCE.E.C7HU HUUL7HHE-.U0.<
i 0",0U0 U,..,<-.< <0<HHE.H <HE.P0H0 < U F.
CJU(DAA UAHOUgHE--.UP A UCDUE.HE.HPU
F,C0E.HHouopppH4 E-.E.E.E.P PH<PHO HE-.E.
ti7 UU0H00,<HOHHH ACJHUHP UUL)PUE. H < H
=== OPOHOHAHHUHOOPAPH,OUAUF440E-10.< Of-'0 U E. 0 E. 0 0 E. CJ E-. t.9 C-. < <
..< E. E. U U 0 U E. 0 E. < H < 4 o < 0 E-I E. 0 0 E. C.) 0 0 E.
g E. E , E. 4 4 P C.J P 5 F. U A s4 H 0 Z A U 0 F. PA CI 0 A E. P <E.OH<E-. < E-, u < c) H 0 F. E. E.
IC) CDUHE.A<HUE-100A E4 E.U0E.OPU000 H E. 4 <
H < < U 0 0 0 U E. P A H A r 4 u c) E, 4 0 E. E-, F. 0 a. E. A H F.
0 000000HUAA10E.E.,<HHACJA E. 0 E-4 a El 4 Cs) 0 C.) EJ 0 E. E. 0 CJ F. A 0 CJ H H A E. 0 U Q 0 E. E--. 0 <
E. E.
Cs) POCDPOHOHoU OHAL5 ACJAULDOPOHOHA E.
V OUUPCDP4POE.00404000PHOPOHAE.APA:
SUBSTITUTE SHEET (RULE 26) SEQIDNO . : 7 SEQ IDNO . : 5 4 ),4 CTGGACGAGTCCGAGCGCGTCACCTCCTCACGCTCCGCCTGTCGCGGGTGTCccGcCGGCCCGTTCCGTGTCGCCCCGC
AGTGCTGC MAVFVVLLALVAGVLGNEFS ILK
GGCCGCCGCGGCACCATGGCTGTGTTTSTCGTGCTCCTGGCGTTGGIGGCGGGTGITTTGGGGAACGAGTTTAGTATAT
TAAAATCA SPGSVVFRNGNWPIPGERIPDVA
CCAGGGTCTGTTGTTTTCCGAAATC-GAAATTGGCCTATAC CAGGAGAGCGGATO CC.AGACGTGGC TC-CATTGTCCATGGGCTTCT DT ALSMGFSVKEDLSWPGLAVGNLF
GTGAAAGAAGACCTTTCTIGGCCAGGACICGCAGIGGGTAACCTGTTTCATCGTCGTCGGGCTACCC-GTGAACAAACTGGCTCTACC CC
CAGGCAGTGTCATTTCGTACCCTTTGGAGAATGCAGTTCCTTITAGTCTTGACAGTGTTSCAAAT VIS
YPLENAVPFSLDS VANS INS
TCCATTCACTCCTTATTTTCTGAGGAAACTCCTGTTSTTTTGCAGTTGGCTCCCAGTGAGGAP.AGAGTGTATATGGTA
GOGAAGGGA LES EETPVVL QLADS EERVYMVG
AACTCAGTGITTGAAGACCTTTCAGTCP_CCTTGCGCCAGCTCCGTAATCGCCTGTTTCAAGAAAACTCTGTTCTGAGT
TCACTCCCC KANSVFEDLSVTLRQLRNRLFQE
CTCAATTCTCTGAGTAGGAACAATGAAGTTGACCTGCTCTITCTTTCTGAACTGCAAGTGCTACATGP.TP.TTTCAAG
CTTGCTGTCT NSVLS S LPLNS LS RNNEVDLLFL
CGTCATAAGCATCTAGCCAAGGATCATTCTCCTGATTTATATTCACTGGAGCTGGCAGGTTTGGATGAAATTGGGAAGC
GTTATGGG SELQVLHDISSLLSRH.KHLAKDH
GAAGACTCTGAACAATTCAGAGATGCTTCTAAGATCCTTGTTGACGCTCTGCTLAAAGTTTGCAGATGACATGTAGAGT
CTTTATGGT SPDLYSLELAGLDEIGK-RYGEDS
cn GGGAATGCAGTGGTAGAGTTAGTCACTGTCAAGTCATTTGACACCTGCCTCATT.AGGAAGACAAGGACTATCCTTGAG
GCAAAACAA EQFRDASKILVDALQKFADDMYS
GCGAAGAACCCAGCAASTCCCTATAACCTTGCATATAAGTATAATITTGAATATTCCOTGGTTITCAACATGGTACTTT
GGATA.ATG LYGGNAVVELVTVKSFDTSLIP.K
CO
AT CGCCTTGGCGTTGGCTGTGATTATCACCTCTTACAATATTTC-GAACATG GATCCTSGATATC-ATAGCATCATTTATAGGATGACA TRTILEAKQAKN PAS PYNLAYKY
7=- 1 AAC CAGAAGATTCGAATGGATTGAATGTTACCIGTG CCAGAATTAGAAAAGGGGGTTGG2-'2=ATTGGCTGTTTTGTTAAA.ATATATCT NFEYSVVFNMVLWIMIALALAVI
T T T AG TGTGCTTT AAA G TAG AT A G T AT AC T TTA CAT T TA TAAAAAAAAAT CAP.A
TTTT GTT CTT TA TTTTG T GTG TGC CTGT GA T G T I TS YNIWNMD PGYDS I IYRMTNQ
TTTTCTAGAGTGAATTATAGTATTGACGTGAATCCCACTGTGGTATAGATTCCATAATATC.:CTTGAATATTATGATA
TAGGCATTTA KIRYLD ND
cn ATAACATTGATTTCATTCTGITTAATGAATTTGGAP.ATATGCACTGAAAGAP.ATGTAAPAC.ATTTAGAATAGCTCG
AAAGTGCACTGAATTTATTAGACAAACTTACGAATG CTTAACTTCTTTACACAGCATAGGTGAAAATCATAT
TTGGGCTATTGTATA
CTATGAACAATTTGTAAATGTCTTAATTTGATGTAAATAACTCTGAAACAAGAGAAAA' GGTTTTTAACTTAGAGTAGCCCTAAAATA
TGGATGTGCTTATATAATCGCTTAGTTTTGSAACTGTATCTGAGTAACAGAGGACAGCTOTTTTTTAACCCTCTTCTGC
AAGTTIGT co TGACCTACATGGGCTAATATGGATACTAAAAATACTACATTGATCTAAGAAGAAACTAGCCTTGTGGAGTATATAGATG
CTTTTCAT
TATACACACAAAAATcCcTGAGGGAcATTTTGAGGCATGRATATAAAAcATTTTTATTTCAGTAAcrrrrcceccTGTG
TAAGTTAc TATGGTTTGTGSTACAACTTCATTCTATAGAATATTAAGTGGAAGTGGGTGAATTCTACITTTTATGTTGGAGTGGACC
AATGTCTA
TCAAGAGTGACAAATAAAGTTP_ATGATGATTCCAAAAAAAAAA
;74 SEQIDNO : 8 SEQIDNO : 55 AGCGGGGCAGCGGCTGCGCCCTGCGCCGGGGCGGP.GCCGGGGGCGGGCCGGCGGCCC-GCAGGCGGGGGCTGGGGCCCGAGGCCGGGA ME ILMTvS KFAS I CTMGANASAL '76 GTGCCTGAGCGCCGGCGGCGACGACGGCAGCGGCGGCCCAGCGGGCTCGGTGGTTGGGTCCGCGGCGGCTCGGGGTCCG
CCCGCGGG EKE IGPEQFFVNEHYFGLVNEGN
CTGCGGTGCGAGCGGGCGGCCCGGCTCCCCTCCTCCCCCGCCCGCCGCCGCCGCTGTGATTGGGTGC-AAGATGGCGCTGGCCGGATG TCYCNSVLQALYECRPFREKVLA
GAAAT CC TAATGACAG T CTC CAAATTCGCCTC CA Tc TGTACcATGGG c G ccAATGCTTCC
GCATTAGAGAAAGAGATTGG TC CAGAA YKSQPRKKESI.LTCLADLEHs TA
CAGTTTCCGGTCAATGAGCACTATTTTGGATTAGTCAATTTTGGGAATACCTGCTACTGCAATTCAGTTCTTCAAGCAC
TTTATTTT TQKKKVGVIP PKKFITRLRKENE
TGTCGTCCATTTCGGGAAAAAGTTCTTGCGTATAAGAGTCAACCTAGGAAAAAGGAC-AGCCTTCTTACATGCTTAGCAGATCTCTTC LFDNYMQQDAHEFLNYLLNT IAD
C_ATAGCATAGCCACTCAGAAGAAAAAGGTTGGAGTAATACCCCCTAAGAAGTTCATCACAAGATTACGGAAAGAAAAT
GAGCTTTTT ILQEERKQEKQNGRDENGNIDNE
GACAACTACATGCAACAAGATGCCCATGAATTCTTAAATTACCTA.CTAAATACAATTGCTGATATTTTACAAGAAGAG
AGAAAGCAG !INNS TPDPTWVDEIFQGTLTNET
GAAAAACAAAATGGTCGTTTACCTAATGGTAATATTGATAATGAAAATAATP.ACAGCACACCAGACCCAACGTGGGTT
TTTCAGGGAACATTAACTAATGAAACCAGATGTCTTACTTGTGAAACTATAAGCAGCP_AAGATGAAGATTTTTTAGAC
CTTTCTGTT QNTS ITHCLRGF SNTETLC SEYK
co GACGTGGAACAAAATACATCAATTACTCACTGCTTAAGGGGTTTCAGCAACACAGAAACTCTGTGCAGTGAATACAAGT
ATTACTGT YYCEECRSKQEP_HKRMKvKKLPM
CO
GAAGAGTGTCGCAGCAAACAGGAAGcACACAA_ACGGATGAAAGTTAAAAAACTGCCCATGATTCTAGCTCTACACCTG
AAGAGATTT ILALHLK.RFKYMDQUIRYTKLSY n.) .4AATA.TATGGATCAACTTCATcGATATACAAAACTCTCTTACCGGGTAGTTTTTCCTTTAGP_ACTTCGTCTGTTTA
ACACTTCAGGT RVVEPLELRLENTSc-DATNEDRm co (xi GATGCCACCAATCCAGAcAGAATGTACGACCTTGTTGCTGTTGTGGTTCACTGTGGAAGTGGTCCcAATCGAGGCcATT
ATATTGCA YDLVAVVVECGSGENRGH.YIATV
ATAGTTAAGAGTCATGATTTTTGGTTGTTGTTTGATGACGACATTGTAGAAAAAATAGATGCACAAGCTATTGAAGAAT
TCTACGGG KSEDEVLLFDDDIVEKIDAQATE cD
TTGACATCAGATATCTCAAAGAACTCTGAGTCTGGTTACATCCTTTTCTATCAGTCTCGGGACTGAGAGGGAACCGTGA
TGAP_GAGA EFYGLTS D Is KNS Es G Y ILFYQS
n.) CACTTTCTGCCTCATTTCTTCTCTGGTTATTTTGGAAAGGATCAAGCACTGATTTTTCAAGAAAAGAGAAATGCAGGAA
co GGCAGTAGCACACTTTGCACACGATAP.AGCAAAGACGATGGATTGACAAGCCCTTCCGATCATGGTAGTTGATTTATT
TGCTCAGGT
n.) ATCATGCTGTCTC-TACAGTTCCATACAACAAGGAGGTGAAATCAGAGATACCAGCTCCTCTTTTAAAACAGCCTTCCAGTcATTGGC
ACGCATTTTCTCTTTATTAATTGCACCAATAATGCTTTGAATTCCTTGGGGGTGCAGTAGAAAGAATCGGAATCTGTGC
CGTATTGA
co TAAGGAGATGP.TGTTGAACACACTGCATAAATTTGCCTGGTTCAGTATGTATAGAAGCATATTCAGTGGTCTTTTCAA
GAGTAAACC
o AGAAATACTTTTGGGCCCAACACTTGCAGTTGCCTTCCTGATGTAAAAACTAACATGCTAGATAATCCAGTGTCGGGAA
GACAAAGA n.) TGITTTGCTTCTCTGAAGAAGCTTATAATAATATACAGTATATGTATATGTAGGGAGCAATTGGTCAAAAGTGGCTITT
TGTTTCCC
CAAGGGGAAAGACTC-GCTTTGTAATTATAATTTTTTCCTTATTTATTTTACTTAAAACTGGTAGAGTCTAAGTATTATATGAAGTGC
n.) CCATGATTCTGTCAGTAAATTTGAACATATTTTTATTAGTTAATGTCAGTTTP.AGTTGTCCTTTTGTTTGTTTCTATT
TTTAAGGTG
cr) AATTTTAATTTCTATCTGAAATCAGTTAAGATACCTTGAGP.AAAACTGCAGTGAGAGGAGATAAATATCCTTTTTCAG
GAGGAACTG
ATATCTCTGGCTAAATATTTGTCCTTTTATTATGGTTTCTAAATCAGTTA.TTTTcTTCAGCTTTAATTTCATAAAATT
AAAAAACTA
TTTTAAAAAAAAAAAP_AAAA.A.AAAAAAAAAAAAAAAAAAAA
rti 0) A E=1 cx= 2 04 A
2 In P. 0 p.. TH F. 0 cI) 2 õ-) .4 a=
cil P. c), fi, CI 0 Pc I U c4 0 0 F. 2 H
cnIccq.C9P..c.JIn :1 c 8 (utri Hx...,,_1 (1. H u uc H E. Pi 0 (c) 2 yoox&-,x 0 0 co 2 R cn P. 01 0 . U 0 VI 2 0 re, 2 2 0 2 a , 4 (X .0 .-.1 H 7. Pi P. 1 Ln E. Ey :3 1.4 2 E. in = P N >1 ,1-1 '', u, ,'-' == gc 0 P. < . X 0 P., 0 P Of I-1 (21 U H En S. 0 NI 1=4 ,..1 2 E. ?-. (.1 2 In 0. 1-4 2 0 PI E. 0 H CI 2 0 cc. I-I KC 0 E. (-c 41 f,,r cl cn p. 4 u u PI c() Ey cn a( C.) E-4 VI go , (.., 0 0 pr=C Lxt H . 54 0 (I) x E. 0 0 f2 3 PC P4 0 UHUU<OHOHO(..91c4E-.< 0 0 E. H 4 H < E. 0 1 c..) C.) C.) (.4 U 0 E. E. rl 0 U 0 0 u u U < E.
C9C9UOUUr4c4HuccU cl,E.0 E.UuE.C9yOUH
cg U U 0 H E. IJ F. cr C.) E. 0 .4 / 0 0 U E. U U 0 E. UE-; E. E . a; .0 U E. 4 E. 0 c4oduguE.1 E. A
0c9<HOCIE.c4E.E.U0E-.< 0 000c4FuU C.E.
0 0 (I, (11.9 4 c..) U E. u .4 C. H E. F. U 0 u (.4 E. (4 U u E. u g a ei Et E-, E.
UOU<HPUUE.HUUE.F. .4 0 0 1 0 U 0 0 E. cg u I
CDCD AP-A.440000 E. 0 4 U C.) CJ H 00E-(440HUE. E.
0 y clEIcEJU4(E.E. f-,U 00E+04 (.401H0 C) C) E.04(44Ou .41(.9E-(UE. C) c..9 (9 U U < E. 0 0 0 / 0 UE. E. 4 E. < u E. 4 U 0 U F.
A 0 A U U 0 E. U E. U U < 0 F. 4 U U 4. 1 0 E' U '. U c4 < HACDHAUE.CDA CD 0 0 H UUU
U 0 H < E. 4 CD E. g F. U E. g gcla E. uuout,oHouopog 00E.E. UCJE.HE.
U 0 0 < H U E. 4 0 A E. 0 A E. C.) 0 A CD U u F. u 0 U E. u E...
<C9C.).4.40EØ4U9c400E. ggE, u ED gE.E.CDHUE(..)000 , 1.--, V E.
UE.1 < .4 0 .4014,q8 1-(10E,40u4u 0uu04004 4 . 0 0 E.E-, pc g < 0 E. 0 E-, F4 F4 C,D C., &4 4F. P4OH<E.E.E.U<UCDPCOU 0 0 0 E. < 0 CJ E. C.) E.
O E. C.) cc. E-I E. 0 0 4, 0 <4 u E. < < 0 U
E. 0 F. c4 U .4 E. 0 E. 0 4 .400ua,U4(.94,004uHuH4 U E. E. U E. Kg F. E. /
C9 E. At E . ., ..0 U El a' Ei ral 0 u E-, u 0 a' 0 c.) H 4 0 U
(.7 (...) E-.
c4UUCDCDU HHHE. 4, C.) E--, C.!, V 44 C) U E. A, E. U
0 E. U 0 O0cJuE.F. CDCJA00E.E. E.H04 (9 0 u U < E. 0 E. (4 E. /
U 0 < 0 < 4 E. CJ 0 4'1 0 0 (-) 0 E. C.) F. E. E. F.
0 0 gr cr: E-' E-' F. U .4 0 U f-, 0 0 U E-== E. 0 0 0 a:
Kr. u UUUUHOH E. e. 0 4 E. C. F, 4, 0 = A 0 U E. U 0 E. EJE. A A C.) 0 CD A c9 Ci U 4; I---. C.) 0 E. 0 0 E.
O A H U C..) A U U 0 0 CD E . CD 0 E. f-, A
0 0 41. C.) E-4 t i 0 A E. E.
E.0,00AUACJACD,7=0E. 4 -,ugt, g.ou 0 u < 0 4 .0 0 C.) 4 E. E. A 0 0 0 E. PC U PC 0 0 1 u 0 U 0 cc C.) i H 4 0 U E. < H E. A A 0 E. E. E. F. (4 E-. 4 E.
U 4 U E. cl: U F. U 0 0 E. 4E. E. 4 E. U C. U V A ugo,E,E,E,Ur-c (..) (3 (1) u 0 0 E. < U
E.
r, UUCCE.OH04 a. r¶..7 UE.CDA a' oo o 0 E. E. E. F. 0 0 (..) O < E. U 0 E. E. < 4 U 0 U .4 U F. 4 <
(..) U H,4 0E. E. 0 4 4.
c-i' EE--: c.-h' cd t7i µ,'µIzi 0 8 P-, i-', 6' ti g 40E.c400F.C../HcJE.
0 E. E. E. 0 E. E. A E. U A
E. u F. < F4 HA CDE.AHE.0P0 =OUUACDUHUH 4 H
HCJU 0(....E.000HC..).4 F, < C.) E-, 00 <PC HOE--1q00 H
O 0 U ti U E. U A E. U E. (..9 0 E. 0 (J 0 U 0 E. A E. 0 re, 00C1HE.CD
CJ 0 (..) U E-4 E. E. < 0 cc < 0 U .4 c4 5 U, (..) (.... F. u < F. < r.
(.900 0.40u A 0E.64 ACDCDHA 000 HHUOHA E.
E. A E. 0 CD 0 g U E-40HU0E.E-, E. 00000001H<H
CJ Ou1 H E. E. cl<H0,404CJE HUF.C90H4 CJE.0 U H E. 0 E. F. F. E. < 0 c..) 0 E.+ 0 U E. 0 0 (-A _ E. E. E.
F. C.) U U A E. 0 / E. A A 4 E. 0I. CD E. 1 HAOUHE.HE-.C.JAH 000E.H
O C) U 0 0 E. CD H U 0 H 0 CD A E.
000H0000 i1 HO 0 A A A E. gc_10E-,E-104E-. 4 .4 000E.c..9C)(.9E-.00 UOUOUCJ U .4 0 4 E. E. c...1 E. E. Cd E.D E. A 0 E-= 0 0 A H
CD U CD E. 0 E. A U E. E. 4 u 0 (4 0 0 OUCDFAUHE.u4H
E. 0 A A E. E. A H rc E--, 0 0 E. E. F. E. E. HOUHOOHO .4 Lc U < U U E. 0 E. 0 H
O0004 r-, r-, u o o g E, ED 0 0 [-i U 0 E.E.
< 0 0 < c4 0 ct E. E. E. E. U u H 0 E. U
cJ E. (J U C.) CA
E. U 0 U E. H E. U U 0 0 A H CJ A CD A OU0HE.044 4 E. E-;
A C.) CD F. C-E CD A E--, A 0 0 E. H H U H A 0 CD (-= A 0 E. E. A CD E. 0 E. U 0 A A H H E. H 0 E. A A E--. Cll. A 0 H E. U E. E. A C.) C.D E.
ci E-. U E. cg U C.) < 0 F. E.
E.C_DH 4UCDHE.C.E040 E.04, 4 u0ouououe4ug oge-1 E. El =I' 4 E. H U E. E. E. OH HO
FI, on 0 U E. 0 0 .24 E. U 0 cl.) c..) 0 0 rt; U 0 U U 0 0 u E. A E. E. 0 < 0 0 C.) E. H u C.) < F. H
U .4 U 0 C.) E. E. U cg < E. E. U 4 U E. 0 E. E. H 4 H E. PC < < E.
O C.) cg 4.444E-,0000 4000 cp uu<E1 4 gal 0 U A El cr) E.0000HE.00A A A, 00E.E. H HOUU 004 E. A
== E-=4E.C.DAOCJUAUCJH CDE.H0 == UHE-=0 ACDE.E.0 = A U A A E. H Ei H 0 E.E. E. E. 0 U E. =
0 0 0 H 0 C.) A U LI E.
I
O u 4_ , 0 E.CDCDHOOU 0 ra,U0 2 U u 0 0 E. u cc 4 Li E. < u E. < .4 c..5 0 2 F. 0 C.) 5 E. E. U 0 ,....4 cJ
<
CI OU04000<<ciE.E.E.4U0E. n E.E.0 c9u<HE.E.<
H A r=D E. g A E. A a, a. E. [-,un; 4 4 4 ct H U E. 0 , E. 0 Li .4 U 0 (.9 01 a, guougg [-,uug E= A cc 0 U E. 0 0 c..9 0 U U E. 04 u F. 0 <
PI 0 U E. <, E. 0 0 u U H H E. cc U 0 E. U in E. 0 0 0 H E. A E. A E. 0 cn 0 0 4 A A 0 A E. A E. KC A H A E. < H cr) E. 0 u E. 0 F. U 0 E. H cl SUBSTITUTE SHEET (RULE 26) f:2)WE.Wc..20nXzE.Clg0Nr:4000(nr.i0Xrpfleipciult4f).
tnig,-100NIAMOH0+xc4Xx ',4 q ril r:4 .-IP.MOP
0 Ers 0 _10in,-j'.41-10,,-1+4(t)t.410h-10cocnci.ami.-100+(a., E. 34"A'vf1,-, El Z,.4u)8:',',"-teat-.4`jl`j1 2 ri c',.., ,9RE'T'IN2 ,q,-19,P,INN`08, R .6,, 22588 r, 0 'F-4 V2. E' Ef 11 (8, 2 rx, 22,E-3,8,gHo 8 0 6 R '61 'A }t: M Q r=1 ',I.
0 c'itEi',P2, >.n1-1,-',.-.2-1'4).
. 2 [-TO tc70('-+Ip141-1-iE.Or-134f..41.-1',31.541R mchOMA .. M
,f4 rnw_ wr-,g 4-4o141;YaCiat-IZE40u) 4ftrqln , xa - (44 M4-1aZ0zXOrrz4,4awor.404-404 fr, u) 4 .00Hca,c:
16 ,1 u '' 9 8' Er", 0 8 r7, 3 0' 0 8 8 8 g " " OZU z '-caE-4r4ZXE-4_,-104.1 carrl >1.9Hq0100qwwW1004E.Eactioqcnor4UP4 xo Q Ft to; 'EYx?c,-,Nwpatt,lt:Im uw441-44-14-404nui-4E-,ZmE.04:4 H cO>0 <>124f4r4pE.r=15114 E.-,PCHcnE-, E..10,0E.40 Ri gHE.z4c0X44MX0E.0(.9u0E-.c=?N0,0 E.PN'00,-44n cn ZOE, .111E-,0,-1P4001q>, 4y. x E-4 r.,1 x g r4C/),--14.71-uco0OH
,. ,0 , ,0 , ,µE. ,. _E-. H C. E". E-. < < L.7 0 E-. < 4 (.7 < < E-. E.-. Ed, U Ep 0 <
µ-.'s-',.',."0(-)<<E-,(900E-.E...C.DE-,<PCE-1L90Ktggiuu0u E-40HE-4000uE.E-Igu0E-.KtuKtuc(!),,i 8 te4 E., 8 v,,,,5,E,,,,,,,c;
4 U 0 E-, E. .1,' E. E. E. 4 < E. 4 E-4 0 0 A
Pc <F,E,U1.135UE.C9u44H0E.C90000(11.964UuU0UU
000FF(90t.00,00UUHF0 f...70E.0E-,<CJUE,<U,U0 g Ed,. VD 4H A 0 CJ U < 0 El CJ
0 444 0E-40E-4040 U y U
KG U 0 E. U E9 ill 8) 8) 8 Pc --,' 8 6 l 84 A 8 8) El EE-: 8 6 LI 0 05 8 .E-: 8 8, /
HE.V.) E.,:t 400,4;ugE-4KL41-.0H0 E--,440().(-)(puE.-.
u r-, < u u 0 4 4g0uE-.E-,ououuy UU0E.0 UUKGKG
010000E-, Pc t--,u00E--44CJHUE.<CE, OUOU 0E-4y0u 00E--40E-igg00g,,t0g ugH4E-4E-4U 4UggE-.0uugu H g c.h 0 0 0 u E-4 HOUgUKt cp gt g g OHO 4, t: 0 CJ C-c 0 p E. 4 /
F4'8vE=',E,-,:iP,u-,18g,Y, 8858800riEti,F4888El 8!
0E. HUO (J,PI,E, ,,,rt <00A
4000E0 E-400uuo0 KC0004 4.KtE-10uHugHu0F40E.E.
6uKtuuHE, a, 0 U g atO U U H 4 4 4 Kt u u u u E-, 4 E. E. 0 E. o<oFu4 6 6 8 e, 6 o 8 8 8 ti .4 0 il E', 0 8 il 8 r, 0 8 8 8 8 8 8 1..., 6 `, 1-2 6 i uuP,<()E-,4E-,<.,..Pue,E-:E-10E-,<E-,E,F, KGE.E-40g0KtU0 H4,400E-.0000400E/uuue,u0uuE-,000KtE--,Kta040 000H04000E,404<u(940E.<<UE.4E.OUHOUU<
LJUUHE.0444<gE.uuu0gE--,04u4.uogguoV)u,E, FC3c9u()(90UHE.4u4E.(9u0H44U0y4a401.0 ED4U
Eg 8 6 (94E-.F40uu4004u41.4Fr 0E-,p.-4040Sup 0E-4K4E-, a , g G U E. Kt .24 C. E. U U KG E 1 ,, 0 U t; , - , re -, 4, 0 Es : ,, EH.,q0cla;HHE.UF04004uE.000 4E.0 y ty-fl Hu<40 r=0E--,E,c9E-tU.QUE.KGE.,,GOOF,a,05s2u<s...p <0<4E-, F444(94H<F(94()UFFC3UF4U(6cE-JcEl ._-,.t.6 (.'6rõ 88808885 KV: 8 P.,(E_:88',C0 ricicrZgc'50Hu4EDF
U44UU44(9FuE.404/ 4UUUUE.44E.4U4UUU,64 EIE-400,4000400gE.0 0,tE-44E-4uuE-40',E-,uuuKtu u uuV-IE.,,44,tuE-4F,400E-.c.,00.E-40E-4000044uuu0,FE-1,, E-. 5 4E.040E.u4/E.E.04E.UUU4E-1H,14 tu:z8 (E,,, 8 ,3 6 c., y u E-. c..) (.1 o 9 u 4 E. 4 0 E-, 4 U 4 0 Li 4 u o, E. _ _ . _ a (9(9u0F4c5 ,a, f-_,, CJ El U H H E-I H'4 4; gC
E.H44UU_FLec2,c- j_.
,t-r'66 .(Cj5' 6 r . . 26 '7. L/ pE ' 0 4" 5 E-, E-, ',-), (-0. f -''.2 E--: .9, t [-i 16' 8 6 8 V: 6' E. L ' ', N i i uuKt E-4gt-.QC.),,rt./-.,.1 E-.t-,< t-,L",<t-.U(....CDC.90EJE-.4;<
CJUE-. UE.E--.<1=C<'Ut.)E. 6E-40E-400q000Ktc.68.6Er.-:, H<U0E.H<ACJAHKGcl.G.G0HUHU,HOUU
00 E. r. E., 0 < U 0 g U U E. 0 Ci 0 44U4UuHu4 OFE.40 U u 0 F-,. F F 4 H 4 U 0 E. E. C.) F 4 U U 4 4 4 0400E.P 0u0E-,04 A H C.7 H gt E. < 0 v H CI 8 8, V.: `;', (ei 8 -?e, 400E10E. 00F E.(90, 4 4yuuugE-.0 u ' t.-:,(6,0,-_,;
1L-Igl 6 ,(2,.(,' ,F,TEd rl(c-3'66'.=6c,-i 0 8 6 6 6 6 0 < E, õ 6 õ
EJ Ei) 0 8 E-, E.-4, 0 ,E-' ,4 E-, 0 '-' 0 F.,5 ,',),E`,6)8',,-E',1'6(E-2,6'u'UVii-2,6 c<'88`48888808g8,600q60 '6 P, i' tO , P., 'El '6 , V:686'8 O E-, E-, E-, E. H 1 0 E. KG E. <0.E,E.LJAUUHCAEc.; 8 8 [ -,- , i -2, 0 ,c _P4 * EL;
Kt 4 c..) 0 E. E. 0 CJ H A 0 Ci H 0 U E. 0 .
C9U0HOU OH UErE..0L,IHOKGE, .Cdtr,,,C(4 6 < 8 8 1 HHE.KGUUU U0 pc H CJ 4 F F F E. 4 0 u u 4E80004 4 0 0 0 0 HOUE.E.HOUst E. ,66re:2,, 6 U00E.UU0E.00<U<H4 F OF FOHUUU0 f.CD[49(,-)t 6 P-, 6 '6' V, 8 8 8 8 8 6 8 8 ,` 8 1 0 8 8 8 8 V46 6 8 8 8 8 't. ,<' ` 8, pci 8' 0 ri 8 8",µ": õ ',;!, E-: 8 8 Et: 0 1 8 8 E-., ,La.: El E-, E-, 0 0 4 E-, , 00E-.....0U0UUOC.70080E.U055U
UUUE.HOE.E.UE. 4 0 0 ''4 HO U E" V; , : 6 r, P. , 'El r j < 0 ! F(-0.1 8 (.) il OH
E.., 0 H E. KG U U 5G U E. .5q E. .,G 0 C..) Et , , , . , _ , , ,, ,,,, ,õ u , , . u 0040u0004g000-0$0t-,KtuguouucLjr,c, ,,,,, , d ,,, 0 t, 7 c' , 0, uE.c.,HUE.40E.E.OU,E--,c+E.,),<LJO<Hci, ,4E,,HH0,,1 ,t0,5E.,:,:c U 8 uu40.; ,RiK4OHHH51.0 rj,,cuu OFKt.EØ4, 0 0 nguKcuy,7.c. u<0uu0ogg u ,u,,,SE
HUOHUU04: <<E.0UUU<E,E.HKGE.00E-.00 a. -... , 0 E-. 0 ,..q U EG 0 U E. U P 4: C.7 ogguuE.4 H E. C...) E. U E. ,,q 0 q U CJ U
Ed :-, 2 0 8 El 0 ,".9 8 Eta, 0 R '.4) E' E4) .c) 6 --''') E. E..- g c'' 5) 6 :%) 6 6 6 'd H Pt (Ej.E ' ri , - , u u u < u k . -., c i E . uouH0yE-4E-4 0goc./ut.-4E3c)Fir 8 EE:,, - E. g 4 E-, g E, 00H<Uu<guyu,o4uu< , i, = E.y340E-, .eE.4E--,UE.D0004,04 uE-40uE-,u 4 2 i--,' 8 < 6 6 8 ,V: 6 r 8 `' ,,-Eil r.: EG' L., Et: il El 8 'd ',("C
Et: F,;c' 8 i-1 6 `,!) 6 6 al 0uu0u0000 E-40u0,<E.cp<E, y U0 8 8 8 ,E.4, EL,) ,, UAUE.OHU-5GOUUOU , 'a EY. P P. E1 ,,ri r 0 ,E.-. ',=._4, .i.
. ,, ,, ODE. ....' 1.D E. 0 E. 0 U E. 0 0 0 r hi) 868 08E,:-'c 8E-.4'c,`,.?.0(''S,`:488ElEltli--.D 8ev, 6UE18888 SUBSTITUTE SHEET (RULE 26) (9Z 37112:1)133HS ainiasans .3n nignn,3 4,. 2 0 r3 .3 n . non.3n5.63oHnnoonHon Hn " Ho 5 0 n 0 25 '.--1 .1 ?-1 ?'-3' 'An n n OH H 3 4F3' 2,'23 8 'n-3 r.31 loon.3.3.343HOHH, c).3,3 r3S,5.a.3 Hann 9,00 ,o, n .--3 Hnnrn).o,-3,-.3-30 - a5.1-3 no..3oo4.r 13p2.-3 nH 9 >> r flgnoaann.30).(1,3 ononn.3.3 Pg.), 1 >9-) !:-.1 Peen'5"),151-)g:,!'3r,-.3)229,53-19:,,,c)51., 0 .-3 H )... >.. 0 ,-3 r) r) .-3 p 0 'n, 0 H H 0 .-3 H H H n .3 .3 .3 a .3 n n 0 0 0 O.3.3 9,0.3PcHS..300.3HH>000.--3(39,X, nnnononnnn,Ron, S,4-3.30n0H GI .-3 I n S,HrI0H
O n n ona..-30.3nnons,9 n.3:1.00. P 4 H H . / ''... 3 3. 3, H n o.3 3. ,i, 0 H a ,3>
= 3= br nG) 2o.'"
9' 9-' 'An 8rc) Pr, On 9,-6) R nn ',-1 9 c) C) ,o.-306.1ann..3o>+-3 .3c,-).3.-3a.g.3nnor Han H.3n.3 :,µ05..00rn.-30,-n5.nna.3.3.3aannong a 0 P H P 0 3, annr r3npr,.30,nnotor,.35Ø0 .3 S.. .3 n 9. CI 0 4-)I1 .-.3 ,-)RnnooRn4-1),pon,Rnn E
;-3 H H 05.0 0-3 OH) .3.30Hr r r . - .-- . i .3 00nROR:,, ,:,,-, p o.... > 0 >c, H .3 .--3 .-.3 0 H P H 0 0 0 3, 0 0 H . 0 P 3... 0 > 50. 0 O G) ... 0 0 n H n ).. o r .3 0 .3 H H
0 n n r 5- .-3 .3 .3 ..-A :0 n > p > >
'c)5' rIn'vC. H,3 '(1)9"',931')?-'3*H1:-V'V-)','-',92,99`)88)`'') 5 9 C1)9.1.8 ,(23 1--3 'p .-3 ; H 1123 H .3 n n ' , (C) a P o .3 P, .3 rri 1 1 / (IR (-)RhH.-3no ..on .3 Ø,p,o,-3h)o.pr,,,I 0.30,0>a O n H:nanng.35.
.3H.30n:, HH.-3.-30000.-3.30nnn = nHnonr .3n,3 a.) (30.-3000.-300.3nno.3;>0:P H n .-3 on H H H 3, =-= 0 1.. H 3, RR,-3 .00o00,AR 4-,,,,,,- o,-3(-)0 , Rni-an,-,, Ho.3s , - 3 n > r3r3 :3, P '.-1:3=.0? .3p,,annon .3 H nan.3.3nnpHH c.(-,,t-3a.onn Ho.30 ,0n .3 r .3 .-3 .ona,-3,,,- H P H H 3., ?.., 3, H 1-3 g n 0 n r n o n ).., 0 H
.L.oHn a or :vr. a naHH a n > .-3 .-3 H H n :-3 .3npna,30naa aran,-3nneln,,,,- H H P ,,o.3,-;)..L..,ornnHan0s=,,grn Hp .3.3a or '),r o or HnHHnHgor .3 4-)na., :,.pan nn H .3 0 n n n g a. n r rn Haa5. 0 a> r ,-.3 , a o nnon .-3 9. .3r n.3?.noHngr r)Hn',-, r nr H n no o,-30.3,0nn '. 33 an H. -3 Hc- ) 51 aC") 5.'D. Ha Ha 2 Pp cl 2 Ha Hn Hn r .' . ' P '0 P. i -, o'-3 H na ) .(; ) Hn an .' 'a nn na '.( ) (-) >0 I
C) , , .,. .4 1-3,3 Ho p, ,1 . , ,, ., - , or ) p, , -34 .) no > ,. 3 2 2 r, r. ) i 2 c). 3 2 kJ . p : 1 .0 ou 1 r, n: i , , ,,.v rn 5 2 n 5 .0 2 $.. .3 .3,Rn04-14-)onRono> :,,,-304,4-)noonqiinop0,-.2nn4-) ;J. a a n n 0 o > n H H .+ A3 o . n H o H a o n n .-3 r-=-) 3Q,-D6)),,, H .-3 .3 H ,-3n1=,pp, r,n.,1 .36.),-3 ,(-3.-3,-3-,n,-3.3nnant0:1:,0000 ir4 >0 n H 1 ?in ,3)::. ,,3 >.:_3 6-1 2 4)$ 61.3,.3a 8 cl .'l. ;,,..3 1,-13 Ho n,-3 HP 2 kr) 2 6):i. ._3=P 2,,.,>4-),.., rn o.aa.-3.3 4,01-3, .3 H H H r. ,A n a .3 .3 n .3 nonnon ono nR>R,R00(,,,,,,-36),-31,r,,),,a.-3n9oRn nPn,-3):,..-32 p , , ,-, ,,-, a ,-, .3 H H H H ra ,r, o . 0 n .3 r ;1, ,, N-, n > H n n 5. n a a na 9 .-3.10PP5,PP Hon G-,,nnon.3 HPHOIPHOH00 Ha HH Ha 0 P= , c-)' Pn ' - 'n 1 9 RH '$3 Q nn ).3) n'''' '-'0 H Ho '''a >. -3 '30 2 a >6 ) P Qn >r ) 2 8 2 2 1-3 a H P ,1 0 n 3' H a n n n n o 1-3 r n > ,A n .3 IA a .3 n > o H n n .3 n tv Hong3'c)5.3' .3 S, .3 S.' .3n>n.3.grnanHo o on> ri-I
HaHHHHono.iagoa.nnHHo ' p p .3 I-3 H t--3 G :,>.. ,.,-, a, n R .3 H n a H .4 H o o n H H r H r R ?., o R 0 o 0 n n R n H
b . 3 0 O.30.3 R p.:,,' 0 R ,?,,,, 1 .1 ,,-_33 ,..,6 p, ;-.i ,,-,3 (?)...0)00.-3 0 > 0 .3 0 0 ,, PA 08 '0, 9,. , >1 0,93 1-3 .03 1 H nn na 0.3 ,_.3,, HH,Ao ,A:P ,..-3 Ho :1-3 CE1 ??-3:,,, 4( -1, , . ,'4.- )' r).-'3 P3n (;),93 >2 n)r) C) n,-3 ,-3 0 y, .3 n H S.. H 0 H 9, .3 n () H n .3 , H 0 0 P. > n.in 3, H PnE.3.3.-3,-3Hnao.,-3,-3,3 n a r 04-)Pn,--3,-34.),non Ivna,3 00a.-1,-3> ,ronHon.3 nSln, pnprInn annpv-.3a, R,-)43' n,-3,,,- ,,,nn(i) nn5nR,R,.-30 Rc-1 0 0 4-) 0 P. .-3 n n .3 ,, .3 .3 0 p, pr. Ho H 0 .-3 0 H 3, 0 H I 3 3. nr 3,H.3(--)00n ,-3:i,0401-30,-3,P,3,..30 .3pFinano 3'3,nr-1 a n .3 ,--3 0 0 0 0 0 0 0 r- .3 ,--3> . 3 H H 0 n o H ,r, > 0 ,-3 .-3 n a .3 o n n ,--3 0,-3,-3,3,--30.-3.3a3'.3aHHog0:va,0n3'a.oaa3'0.ona '-a3 G3S . .- 3.-3 1 Hn Ha ra 1 . 'c- ) ' -/ G - ) an Hn . 1 H, 3 n> Q. - 3 2 ' - 30 n P., r3S . .. D ' ' 30 1 H9 ,- 9 P. 5-' ' ' . G )9 , 8 C'n 3. 0 H .-3 33' H H 0 n n n ,-3 :1, ..3 3. 3')' 0 H 0 0 0 P. C))' H
0 P 3, n HHHn.3.30.3nr H5.0Hagp.3 0.3,--1nRn,R4-)04-)on -3().-3() H H 3, ..3.3n.3 nran.loani,1-3 .0,:vnn.--onn, .3 n cn Z hi HK) .ti 0 H
...I hi 0 X .11 t. k. HO
U H 01 730.-c..i.t.tx300t.0,ou3r3uu3 0 (C) 73733rI73O1:-.73cr33,ho .-3 En N
73H0t+-3,o07,,Ln<0.zit.-. kilo() H 0 Z P, C 0 0 0 (r) >, ,o ,31 a 41 '-33, W
trl H H cn H .11 H 0 L---. ( H 73 L--. r3 t-. En 0 '1 0 r=) t. 0 RI ft, Cn 0 N tr, C.) Cl) En OHNUNUNO 9=1 .3 Z .3 ),1 .-C En tt1 DJ z 0 En t. hi H H Lo icp y 0 id 4-) ki 73 oxZt-ipoot-itimat-,.311-10 HD-Jo*cit_-.Utri-I=.0 Cf. U-3 r. 73 30 X C x t", Lw. 730 (-'0 rii-V kl 0 Erl,r( .10 ED H W H C:1 ci It 71 En H En ,u 0 In Z ti ('3) C)'!) ,1:1 0, P.-. CA hi ti) 03) 73 H030I H'-!) ti0 r.f), t.tazH
0H ,t1 Z ti 'A (7) apttiNtIroc cn M 0 VI C ,cr t.-1 tzr H .3 Id rn x to it, og,cr3, ' ',, TiN 'R, .t. ,:i ,C-Z,,, -,1,,, , , , ? , ,, 2, i : , 73 -21,_3 ',1õ3 Fr , H tr.1 P.. NJ ICI 3, V, X X W N ..1 ,ci qi ati .3 L-. ti../ L-. 9. 0 0 'CI ,d H L-", t.i Z rd .t7 En 43 zi-ocooitooz thix 01z000IL00ZV3/13d AGTTCTTTTTCCCCCAGAGGGGAAAGTTATGTTcTGCAAATAGTGTGTGTCTTATTTTACTGTTGAACAGCAATTGCTA
TTTATTTT
TTTATTGCCTAGAACTTCAACATGTTGTATAGGAATCCTGTAGTGCCACTAGTTAAATGCcC-AATTCTCATCTGGATGTTACCATeA
AACATCAGTACACTTGTCATTTCACATGTGTTTAATGTGACAGTTTTTCAGTACTGTATGTGTTAATTTCTACTTTTTT
TAATATTT
AAAATTGCTTTTAAATAAACATATTCTCAGTTGATCCC
c.4 n.) CO
co cp n.) rn cnni n.) co n.) rn 0) SEQIDNO.:22 SEQIDNO.:59 CITCCAGAGAGCAATATGGCTGGITCCCCAACATGCCTCACCCTCATCTATATCCTTTGGCAGCTCACAGGOTCAGCAG
CCCGTGAAAGAGCTGGICGGITCCGTIGGTGGGGCCGTGACTTICCCCCTGAAGICCAAAGTAAAGCAAGITCACTCTA
TTGTCTGG GPVKELVGSVGGAVTFPLKSKVK
w ACCTTCAACACAACCCCTCTTGTCACCATACAGCCAGAAGGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGA
GAGTAGAC QVDSIVWTENTTPLVTIQPEGGT
TICCCAGAIGGAGGCTACTCCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCAGGGATCTACTATGTGGGOATATACA
GCTCATCA IIVTQNRNRERVDFPDGGYSLKL
CTCCAGCAGCCCTCCACCCAGGAGTACGTGCTGCATGTCTACGAGCACCTGTCAAAGCCTAAAGICACCATGGGTCTGC
AGAGCAAT SKLKENDSGIYYVGIYSSSLQQP
AAGAATGGCACCTGTGTGACCAATCTGACATGCTGCATGGAACATGGGGAAGAGGATGTGATTIATACCTOGAAGGCCC
IGGGGCAA SIQEYVTEVY7HL&KPKVTMGLQ
OCAGCCAATGAGTCCOATAATOGGTCCATCCTCCCCATCTCCTGGAGATGGGGAGAAAGTGATATGACCTTCATCTGCG
TTGCCAGG SNKNGTCVTNLTCCMEHGEEDVI
AACCCTGTCAGCAGAAACTTCTCAAGCCCCATCCTTGCCAGGAAGCTCTGTOAAGGTGCTGCTGATGACCCAGATTCCT
CCATGGTC YTWKALGOAANESHNOSILPISW
CTCCTGIGTCTCCTGTIGGIGCCCCTCCTGCTCACTCTCTTIGTACTGGGGCTATTTCTTIGGITICTGAAGAGAGAGA
GACAAGAA RWGESDMTFICVARNPVSRNSS
GAGTACATTGAAGAGAAGAAGAGAGIGGACATTIGICGGGAAACTCCTAACATATGCCCCCATTCTGGAGAGAACACAG
AGTACCAC PILARKLCEGAADDPDSSMVLLC
ACAATCCCTCACACTAATAGAACAATCCTAAAGGAAGATCCAGCAAATACGGTTTACTCCACTGIGGAAATACCGAAAA
AATCCCCACTCACTGCTCACGATGCCAGACACACCAAGGCTATTTGCCTATGAGAATOTTATCTAGACAGCAGTOCACT
CCCCTAAG RQBEYIEEKERVDICREIPNICP
TCTCTGCTCAAAAAARAAACAATICTCGCCCCAAAGAAAACAATCAGAAGAATTCACTGAITTGACTAGAAACATCAAG
CO
cn AAGAAcGTTGAcTTTTTTccAGGATAAATTATcTcTGATGcTTcTTTAGATTTAAGAGTTcATAATTccATccAcTGcT
GAGAAATc ANTIryszwEiplacmENplisLLTm TCCTCAAACCCAGAAOGTTTAATCACTICATCCCAAAAATGGGATTGTGAATGTCAGCAAACCATAAAAAAAGTGCTTA
GAAGTATT PDTPRLFAYENVI
CCTATAGAAATGTAAATGCAACOTCACACATATTAATGACAGCCTGTTGTATTAATGATGGCTCCAGGTCAGTGTCTGG
AGTTTCAT CD
CO
TCCATCCCAGGGCTTGGAIGTAAGGATTATACCAAGAGTCTIGCTACCAGGAGGGCAAGAAGACCAAAACAGACAGACA
AGTCCAGC
fli AGAAGCAGATGCACCTGACAAAANIGGAIGTATTAATTGGCTCTATAAACTATGTGCCCAGCACTATGCTGAGCTTACA
CTAATTGG
Cn TCAGACGTGCTGTCTGCCCICATGAAATTGGCTCCAAATGAATGAACTACTTTCATGAGCAGTTGTAGCAGGCCTGACC
ACAGATIC
CCAGAGGGCCAGGIGTOGATCCACAGGACTTGAAGGICAAAGTTCACAAAGATGAAGAATCAGGGTAGCTCACCATGTT
TGGCAGAT
rn ACTATAATGGAGACACAGAAGTGTGCATGGCCCAAGGACAAGGACCTCCAGCCAGGCTTCATTTAIGCACTTGTCCTGC
AAAAGAAA
AGTCTAGGTTTTAAGGCTGTGCCAGAACCCATCCCAATAAAGAGACCGAGTCTGAAGTCACATTGTAAATCTAGTGTP.
GGAGACTTG CO
GAGTcAGGcAGTGAGAcTGGTGGGGCACGGGGGGCAGTGGGTACTTGTAAACCTTTAARGATGGTTAATTCATTcAATA
GATATTTA
n.) TTAAGAACCTATGCGGCCCGGCATGGIGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGTGGGTCATC
TGAGGICA
rn GGAGTTCAAGACCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAGATACAAAAATTTGCTGAGCGTGGTOGTG
TOCACCTO
TAATCCCAGCTACTCGAGAGGCCAAGGCATGAGAATCGCTTGAACCTGGGAGGTGGAGGTTGCAGTGAGCTGAGATGGC
ACCACTGC
ACTCC'GCCTAGGCAACGAGAGCAAAACTCCAATACAAACAAACAAACAAACACCTGTGCTAGGTCAGTCTGGCACGTA
AGATGAAC
ATCCC
ACCAACACAGAGCTCACOATCTCTTATACTTAAGTGAAAAACATGGGGAAGGGGAAAGGGGAATGGCTGCTTITGATAT
GT
TCCCTOACACATATCTTGAATOGAGACCTCCCTACCAAGTGATOAAAGTOTTGAAAAACTTAATAACAAATGCTTOTTG
GGCAAGAA
TGGGATTGAGGATTATCTTCTCTCAGAAAGGCATTGTGAAGGAATTGAGCCAGATCTCTCTCCCTACTGCAAAACCCTA
TIGTAGTA
AAAAAGTCTTCTTTACTATCTTAATAAAACAGATATTGTGAGATTCAAAAAAAAAAAAAAAA
< Or X H Z En ,-, A 00HACJHcn ccl 0 Z H
CONHZ.IZE.ON
0 camea4H.car, a , cog z n fa E1E < W, W. Ei, o. KrOxH,.-1 ri) r4 En Kt: PI fr, 2 ril 2 .1 44 qD
.= a a, E. a, a. fl, Q .1 = .1NMAC=1 = (El Co M c). la, M .1 .4 = a x a, c4 a4 u) 0 w a, to n 0 a, u fa 0 Z
n H A a, w H E. n o ci) a H OZZXP.Q
0 z q E. DI u) cn C. .1 H 0 rc..DZMC.1 41 0 Z Z =< Z 0 cc) .1 0( 41 3 A .4 0 ul O000H0H<UN<DHU<0E. u < < < E-, 4 E.
CJUUCDuU0E.
0 0 C) 0 UE-10,04E-EU0E.
U 0 00E-.4 0000/U/E-./ ..eUN Er4U 0<u<4U4F-.
U<E..)00(!),,E.E.L) UOU E. E. uUU0Kc0E.F.
00000,-CE-1000(..)<0 C.)0004.0/0,<E-,40E-.P FEE, A, i= C-.) U 0 < C.) 0 E.
0C)H<V9aE.
NUCJOCDC)<U0NE.,<HE.0 4 0 <00U ()KEE.
0 0 0 4 4 KCD0CJKCE..<00UH0 U<CDE. c.JHrg 0 0 0 0 U U N a CJ < 0UHNOUH0, 0 0 U a E-( C.) U
(JOU u(.9 0 C.) E. U N < U 0 E. 0 0 E. C.) <
ULDUE.UUE.
00000C.JHUCJE.<0E.C.DCD<H 0 0 0 D < E. E.
000 CD H CD E. H E. E. 0-1 < u 0 < 4oug4 UU0000E.0 U 0 E. uogouoo-04 E. U 4 E. E. C.) 0U0<0E-.0E.
UUOciu<<EDU 4 E. c) Pg 0 U <
U U E. H a 0 E. E. a C.) KC E-.000,<E-, U Cr E. E. 0 U E-, 0 CDCDU<CDHOH
U U CJ H 0 a, OUUOUUUNKt CJUE.U0aU a; u 4. ,--C E.CDUE.CDua a. E, U CD 5 o u f-, gl, O 0 0 .4 u 4 E--+ 4 04 0 u 4 E, 0 CJ CD E. 0 C.9 u CD 0 C.) CJ 1 el 0000c.JaNUCJOC.5<<<<<e) E. HOHHHU E.
0 U U < E.-, 0 UE.U00(.9,<<WV/<<04c_) E. C., 0 < E. 0 E. 0 0 E.
our,uogoor401, Q U E. E. 0 0 E. E. 00H00UE-EP
(.9,i i CD U H U 0 F U D
O U U CJ a a, CD E. U E. U E. E. 4 F CJ 0 HUUCU0Ha U H<H CD E.UKC<KC E. 4UU H E-, U<EJ
UUu/< U00/
< / U ci 04V4o4U.CFu u 4 L h (..) F .5 U 4C1Uu4u4,u E-4 E. cD a E. E. < 000aa E.
0 F.
000000Hu OUOUCIOUU
O C.) < U < < 0 < < E. U u < 0 E. U U E.
U 0 CJ U U E. 0 O E. 0 H 0 0 < H H U 0 < o < < o < <
0000 E.) 0 F.
ED E. U U U E. pr, 0 KC CD 0 0 H E.
OUU000E.E.
E 0 u4DourcuouE,d, f,u i 000E, O E, u E-1 u 4 U 4 0 4 U / / E. E. cl OUU0cHU
O 0 C.) E. 0 0 E.) E. E. / uuUC.)01 UHE.
0 U U CJ E. C.) 0 0 E.
O U U E. < U E-1 0 E. U U < F. 0 E. 4 F.
E. 0 F, 0 E. 8 , õ E-. 0 E - - , c _1 F 4 H E. c.,), 0 E. E. 0 E , U ()C./UE.(700U
CD U C) C.9 a U a, D E.E. .a. E. U E., U U .5 E. E-, u u0r400,-4040E,E, 040 100,0-4 0U00,<<UH0 9 ,c u 0 u u E-, .i. 4 EJ E.) U 4 E. 0 CJ 4 L. in 0 V U E. KC
0UU<00UKO0N00DE4 4 0 yoE-.4,400444P,440 of-,,,S 000E-.0o4 U E. 0 u < E. E. ti 0 0 0 E. 0 U E. E. E. 0 u CD 0 C.) H 1) U <
U u 0 < E. < c..9 0 H0000U000 z-,0E,00E-4441 Ci 0 Ci 0 E-4 < < 0 E-, E. CD U KC C.) 0 0 <EJE-.0U
/ 00H-4E-.000E.
UOU<UE.E. a c..) U E. E. < H U 5.
CJ = < U E. 4 0 U U < u H E. E. 0 U U U U CD 0 E. u Ou<N0a0DE.C.DHCJUNE. ,a, 0 o 0-,4u00E,00u 04 0 0 4 <u<a1H,4000U0U0a4 0 0000 E.0 E-. 0 OurJuKeuE-.0E-.0U<H<HE.E.0 000,<0E.u40 0000000HE.
uU00 8 4 4 H 0 ONUCJNOUNOUNC)H00_. 4 6 Uc..)<E. OOP
Ci <
DuUNUNaHH0000E.HH KC 0 U C) E. C., CD 8 0 U U 0 E. 0 C.) a, 0 U) 0 E. D U 0 CD E. 000 H H E. ,1 E. E. U E. U U E. C) 0 4: 0 0 .g 0 0 A: F, ,1 000 00F4 ,E, u (3 4 El 4 < UE-40 0 0 00 < 0 <0< U 004; < 00 (JO< E.< H U000UH<0E-, U U U C.) 0 0 CD .<
= 0= UC.)0CJUUUC700KCU<<EHE.CD =
0 OHOOUH<U0E.HyHOUHE.F. 0 000 E.U-KHE.
2 uu 0E--,(JE-00¶Jogt, E.00E.E.H Z U(1)0 U,40E-,4 q 0 0 0 U 0 0 U < < E. < 0 E--, H .< 4 E. n of:Jo 04)0p, H F<HUU< UOUCJOHE.HUHU H UUE, 00UE.E-, 0 UOUUOU HE.H044HUOUU 01 4U<O0UE, < 0 C.1 404000 444H0004E-t-,0 w 0rf:00E,0u40 En 00u000 0 H E. E. 0 CD U H 0 < < cr) U 0 < KC < E. CI E. E.
SUBSTITUTE SHEET (RULE 26) SEQIDNO.:15 SEQIDNO.:62 CGGTGGTTGGGTGGTAAGATGGCGGCTGTGAGTCTGCGGCTCGGCGACTTGGTGT.GOGGGAAACTCGGCCGATATCCT
CCTTGGCCA MAAVSLRLGDLVWGKLGRYPPWP
GGAAAGATTGTTAATCCACCAAAGGACTTGAAGAAACCTCGCGGAAAGAAATGCTTCTTTGTGAAATTTTTTGGAACAG
AAGATCAT GKIVNPPKDLKKPRGKKCFFVKF
GCCTGGATCAAAGTGGAACAGCTGAAGCCATATCATGCTCATAAAGAGGAAATGATAAAAATTAACAAGGGTAAACGAT
TCCAGCAA FGTEDHAWIKVEQLKETHAHKEE
GCGGTAGATGCTGTCGAAGAGTTCCTCAGGAGAGCCAAAGGGAAAGACCAGACGTCATCCCACAATTCTTCTGATGACA
AGAATCGA MIKINKGKRFQQAVDAVEEFLRR
CGTAATTCCAGTGAGGAGAGAAGTAGGCCAAACTCAGGTGATGAGAAGCGCAAACTTAGCCTGTCTGAAGGGAAGGTGA
AGAAGAAC AKGKDQTSSHNSSDDRNRRNSSE
ATGGGAGAAGGAAAGAAGAGGGTGTCTTCAGGCTCTTCAGAGAGAGGCTCCAAATCCCCTCTGAAAAGAGCCCAAGAGC
AAAGTCCC ER'SRPNSGDEKRKLSLSEGKVKK
CGGAAGCGGGGTCGOCCCCCAPAGGATGAGAAGGATCTCACCATCCCGGAGTCTAGTACCGTGAAGGGGATGATGGCCG
GACCGATG NMGEGKKRVSSGSSERGSKSPLK
GCCGCGTTTAAATGGCAGCCAACCGCAAGCGAGCCTGTTAAAGATGCAGATCCTCATTTCCATCATTTCCTGCTAAGCC
AAACAGAG RAQEQSPRKRGRPPKDEKDLTIP
AAGCCAGCTGTCTGTTACCAGGCAATCACGAAGAAGTTGAAAATATGTGAAGAGGAAACTGGCTCCACCTCCATCCAGG
CAGCTGAC ESSTVKGMMAGPMAAFKWQPTAS
AGCACAGCCGTGAATGGCAGCATCACACCCACAGAMAAAAGATAGGATTTTTGGGCCTTGGTCTCATGGGAAGTGGAAT
CGTCTCC EPVXDADPHEHRFLLSQTEKPAV
AACTTGCTAAAAATGGGTCACACAGTGACTGTCTGGAACCGCACTGCAGAGAAATGTGATTTGTTCATCCAGGAGGGGG
cn GGAAGAACCCCCGCTGAAGTCGTCTCAACCTGCGACATCACTTTCGCCTGCGIGTCGGATCCCAAGGCGGCCAAGGACC
TGGTGCTG ADSTAVNGSTTPTDKKIGFLGLG
GGCCCCAGTGGTGTGCTGCAAGGGATCCGCCCTGGGAAGTGCTACGTGGACATGTCAACAGTGGACGCTGACACCGTCA
CTGAGCTG LMGSGIVSNLLKMGHTVTVWURT
n.) CO
GCCCAGGTGATTGTGTCCAGGGGGGGGCGCTTTCTGGAAGCCCCCGTCTCAGGGAATCAGCAGCTGTCTAATGACGGGA
TGTTGGTG AEKCDLFIQEGARLGRTPAEVVS
cn co ATCTTAGCGGCTGGAGACAGGGGCTTATATGAGGACTGCAGCAGCTGCTTCCAGGCGATGGGGAAGACCTCCTTCTTCC
TAGGTGAA TCDITFACVSDPKAAKDLVLGPS
GTGGGCAATGCAGCCAAGATGATGCTGATCGTGAACATGGTCCAAGGGAGCTTCATGGCCACTATTGCCGAGGGGCTGA
CCCTGGCC GVLQGIRPGKCYVDMSTVDADTV
CAGGTGACAGGCCAGTCCCAGCAGACACTCTTGGACATCCTCAATCAGGGACAGTTGGCCAGCATCTTCCTGGACCAGA
AGTGCCAA TELAQVIVSRGGRFLEAPVSGNQ
AATATCCTGCAAGGAAACTTTAAGCCTGATTTCTACCTGAAATACATTCAGAAGGATCTCCGCTTAGCCATTGCGCTGG
GTGATGCG QLSNDGMLVILAAGDRGLYEDCS n.) Cl) GTCAACCATCCGACTCCCATGGCAGCTGCAGCAAATGAGGTGTACRAAAGAGCCAAGGCGCTGGACCAGTCCGACAACG
ATATGTCC SCFQAMGKTSPFLGEVGNAAKMM
GCCGTGTACCGAGCCTACATACACTAAGCTGTCCACACCCCGCCCTCACCCCTCCAATCCCCCCTCTGACCCCCTCTTC
CTCACATG LIVNMVQGSFMATIAEGLTLAQV n.) GGGTCGGGGGCCTGGGAGTTCATTCTGGACCAGCCCACCTATCTCCATTTCCTTTTATACAGACTTTGAGACTTGCCAT
CAGCACAG TGQSQQTLLDILNQGQLASIFLD
CACACAGCAGCACCCTTCCCCTGAGGCCGGTGGGGAGGGGACAAGTGTCAGCAGGATTGGCGTGTGGGAAAGCTCTTGA
GCTGGGCA QKCONILQGNEKPDPYLKYIQKD
CTGGCCCCCCGGACGAGGTGGCTGTGTGTTCACACACACACACACACACACACACACACACACACACAGGCTCTCGcCC
CAGGATAG LRLAIALGDAVNHPTPMAAAANE
n.) AAGCTGCCCAGAAACTGOTGCCTGGCTTTTTTTCTTCCGAGCTTGTCTTATCTCAAAcCCCTTCCAGTCAAGGAACTAG
AATCAGCA VYKRAKALDQSDNDMSAVYRAYI
r¨
ACGAGAGTTGGAAGCCTTCCCACAGCTTCCCCCAGAGCGAAGAGGcTGTAGTCATGTCCCCATCCCCCACTGGATTCCC
TACAAGGA H
=
GAGGCCTTGGGCCCAGATGAGCCAGTACAGACTCCAGACAGAGGGGCCCTTGGGGCCCTCCAACCTCAGGTGATGAGCT
GAGAAAGA
cn TGTTCACGTCTAAGCGTCCAGTGTGCACCCAGCGCTCCATAGACGCCTTTGTGAACTGAAil_AGAGACTGGCAGAGTC
CCGAGAAGAT
GGGGCCCTGGCTTTCCAGGGAGTGCAGCAAGCAGCCGGCCTGCAGGTGAGOATGGAGGCCCGGCCCTCACCGCCTCGAA
GCCATGCC
CCAGATGCCACTGCCACAGCGGGCGCTCGCTCCTCCCTAGGCTOTTTTAGTATTTGGATTTGCATTCCATCCCTTGGGA
GGGAGTCC
TCAGGGCCACTAGTGATGAGCCAAGAGGAGTGGGGGTTGGGGGCGCTCCTTTCTGTTTCCGTTAGGCCACAGACTCTTC
ACCTGGCT
CTGAAGAGCCACTCTTACCTCGGTCCCCTCCCAGTGGTCCCACCTTCTCCACCCTGCCCTGCCAAGTCCCCTOCATGCC
CACCGCTC
"''r'ATCCTCPCTCrTrTCrCTCTTCCTCCCGTGGAGACAGTATTTCTTTCTGTCTGTCCCTTTGGCCCAGACCCAGC
CTGACCAACG
ATGAGCATTTCTTAGGCTCAGCTCTTGATACGGAAACGAGTGTCTTCACTCCAGCCAGCATCATGGTCTTCGGTGCTTC
CCGGGCCC
GGGGTCTGTCGGGAGGGAAGAGAACTGGGCCTGACCTACCTGAACTGACTGGCCCTCCGAGGTGGGTCTGGGACATCCT
AGAC-GCCC
TACATTTGTCCTTGGATAGGGGACCGGGGGGGGCTTGGAATGTTGCAAAAAAAAAGTTACCCAAGGGATGTCAGTTTTT
TATCCCTC
TGCATGGGTTGGATTTTCCAAAATCATAATTTGCAGAAGGAAGGCCAGCATTTACGATGCAATP_TGTAATTATATATA
GGGTGC-CCA c.4 CACTAGGGCGGGGTCCTTCCCCC CTACACAGCTTTG GC CCCTTTCAGAGATTAGAAACTGGGTTAGAGGATTG
CAGAAGACGAG TGG
GGGGAGGGCAGGCAAGATGCCTGTCGGGTTTTTAGCACAGTTCATTTCACTGGGATTTTGAAGCATTTCTGTCTGAACA
CAAGCCTG
TTCTP_GTCCTGGCGGPACP_CACTGGGGGTGGGGGCGGGGCAAC-ATGCGGTAATGAAACCGGTTAGTCAATTTTGTCTTAATATTGTT
GACAATTGTGTAAAGTTCCTTTTTATGAATATTTCTGTTTP.AGCTATTTCACCTTTCTTTTGAAATCCTTCCCTTTTA
AGGAGAAAA
TGTGACACTTGTGAAAPAGCTTC-TP.AGAAAGCCCCTCCCTTTTTTTCTTTAAACCTTTAAATGACAAATCTAGGTAATTAAGGTTGT
GAATTTTTATTTTTGCTTTGTTTTTAATGAACATTTGTCTTTCAGAATAGGATTGTGTGATAATGTTTAAATGGCAAAA
ACAMACA
TGATTTTGTGCAATTAACAAAGCTACTGCAAGAAAAATAAAACACTTCTTGGTAACACAAAAAAAP-AAAAAAAAAAA.k 0 cn n.) CO
co cn n.) r r n.) rn co n.) rn ct) 1,4 C) 0 4E44 cna a FAH 4 4 ca OH
E.FFC>..U(Drtu)0 H>Og CYcnW.lOrr.-.4E3 a In t-1 r4 ft, 0 L-10,Cr:1>.-41X
>. -4 4. ot ri) 04 al E....4a cn A w a EH .. H r...
ti, x > pa. 4 01 1-1 0, a PI
0,4 > E.C.Da al -t AHHaHaa HS,,,CaE,ZHE, W
En 0a0 CD
Hanar.µ,EHE1>p4nE.Ocnr44cnop%arx.-fataa.-1 0 a. 4E1,01-10r., A =1AXE-,x0,--,vraomp c4 4ucn o c.r1 E-4 41 0 E-, aHr=.0 tae,0 HP-.20)01-,00 ..
r..10)0lHata0 E.C1011.CJaaa01,4.,S.a H ChHa S.H0>a,00a0 a aHN
2 '' 1 S ,, '8, 'C4 P-, PI l'F'4 r3"' '.' 2 cl ECD' 'al .2.1 f;4' 2 g 1 . PI ''' 0 0(aqn L, >4 >4 Fifil00(/)1:4>=' E, KC H 4 0 a CY a gq>Nr.,r.arr,cnr:d ci¶..H1-1 ara r.,-) Hvj )-1 o Cl) U W I HO) C.DC.DOHC,,,4 4 0,510H a ?00,01-101:) VD 0 PI4 W I-I PI 0 01 CP g rZ4 r,u)MOOmar EnZa$1,00NI--1,4 14 01 a 01 0 a a 4 .-1 4 a a Cl) CD X CD ci> H
CD fLi a a 4 2 H
= a a Ed E. E. a E. 0 4 a S-t x 0 ul .. po 0 E. S. A
actli...
0 C., KC U 4 Z 01 r a vl 0 Kt CDPF.1.-1 OH 00) Z P4040) r44,,ia QHF4ox F. .4 pc.DcDMCD4aWaEn A
H Hi:i' EY,1 P44EU.3. 2 rti (I V, `,_.1 r,'n4 F61, CO 'I? EC
5. 8 F c) 1 2 O. 21 _ 0, g 4.1 ci, ci, 0, u, 0, ,-4 H D., 0 . . ,..., cy z 0 cn p En a n 44 E.r.1 >,,10> CP t-I 01HHaF-1,0,fr,aZ0Howaa?Haa awn;
Ca Ca F. cti 0 0 U a H 0) a 4 .- n w x En a Z t4 0 ua >, 1=1 ci ..> 0. 4 0 u) Cl) _ 00 CD HUHHU H4U4CDUE.,4 000CDUOUUHHHE.PCD
00004a: E. E. HOHUOUCJu 0000 CDKCH HOE,E, F. 4 E.
4HHULJUOU<CDP,HOUUOU0OUCDUUCJHUUCJUKt 000 CDE,Pt 40 OHaHauu0a0 E.,4 HUHOCDU 4 (Duo 000000o4UUaa0u0a0<uuua0augtE.044 outpououu uu4E.oucDUUU0E.000,11UH 4 4U0 000E.F4 400 4004 4 4F.c.JOUHE.C9cDE.40 0-' C) UCJE, 0E,UeU0.40:0C.JHUE-t4000.040u4.44u4u uu u0(.94r..1(9Uu.440o0u040Huociouougu u4_. CJ g E, CD E, 4 A A U F. a:
F. 4 E, u H E. F. a: E, H U 4 E, 0 4 gOuE.404 4 00 Fl,c7CJO0C.DE-.401,UcJuUcJU HOC) 00 CJOUOCDU UU OCDUCJOgCJOUE.CDOUE.UHUU0 0 F. 1, 4 a: E. E. EH 0 EH
H E., u, < EH U H. a. 4 E. 4:g0U00I:t.
0Ha00E-100Uu<H a uOuuH,EHUHHaa0,<Hu H. 0 H a EH a EH g E-iHOUCJUUE-.E.UOCJOE.W0E.UuC, 0 0 0 H Q 0 CJ 4 .4 4 H U 4 U U C., 4 0 U E. KC F. 0 0 0 E. H E, U C., 4U044 A 00 .40,E,000H 40 HOE.DUCJUUU0 0 E.E.H
OCJE,004,40a,AE,E.T_DHC)u000F.CDC.DHUUHUUUE, HHUHOU0.4 PC HE' OH HE.E.CJUE-tHOOVJU
.4E-.0000,4CD UAL CDOHCDF.F.000000H4 HO HOC) CJU KFCUUCJOU C.,04 H4 4HuuE.0E.00000uuu.40 F. U U U CD C_D E. E. E. 4 E. H a, CD 0 E. U U C.D CD U 4 g o g5 uEH<E, 0 0 a 0 H EH 0 E a a EH E-, 0 0 0 a EH H. 0 0 a 000 C,,0 HOC) g 4 PC 0 0 0 u EHUDaUUHOUUE_IHoUUEHEH 00000 HUH< F4 AHU U0O<HUHEHOEHHOUCDE,HU 4F. 004 u44000HHOOCDOE,HUOHOPUHOHUg 0 CJ (DOC?
EHOqouou0 CJE-.E.OUCDUE,UOUUCJCD 0 OA 0 0 uuy E'e(JP:.:4;EHUaEHre.uHauF,a0.4()EDUE.a, PH Ftgu 00 .10C-Jua,E, 400CDE.F.F.0 UUU<HUOU00.4 U00 CJ cD a U U 0 0 U U 1.-. 0 0 U U E. OUuH, 0 CJ U E. (...! CD U E. I, E.-.
4: g dU4CDE,4 CJUCDPOUU4 U00 Kt E,00,1,4 0 U
00 CJut-44.---,0,4004F4HANCDOCDUOFPCUE,CJ g U
HO CJOLDu0,40u E. E-,UUCDUC.Dc.70000CDUU 0 04 0K4UE,HUHLJUHE. 0E-.40U0CDa:41.204F.CDCD
5 (9 5 F. CD U CD 0 E. 4 a' 4 4 -4 H a: E. 0 CD 0 cD H 0 U 0 a a H a U E.,.. Hgg g:g 6 UOUCDCA UUFFC E.U00004 CJOUOuHU 0 0000 El U u Ft, U Ft u 4 E. U E. 0 0 0 ,...) U
CD CJ g 0 E, U U Ci U E. a E.-, g: g0ug06 E-.00E.4400Uu0E.ouE.4uUu0u u 4 0 u 0 0 4 E. E, a: 0 0 U U C., g U E. U H
U C-, E., C... CD u ug cDHUUUHUE--tet HUOH 4 HUHOC.DUHOUE. H CDE-.0 HO OUVUOE, KCKCE...a 40HUE.HUCDOOKCUOU H 0.40 [JO E.UUUHE,UCJUCJOUOU C.DUK4 0004E-, 0 U00 O H CD E. 0 E. E. .. F. E. CD a, U
H KC a; 4 6oci0E,H.,HE,06,H0 E-, 8000E, Huuya0CDUH ouc..900auuaa0 0 u CJUOUUCDHU5 0 H, H U u C9 0 u u U u u u 0 c_, E-,E;
6 6' ',;` 8) ,') 8 E-' t,"0 6 8 Ec; '4 8 6 6 (,-p) ,tt' 6 8 6 8 t-i it, 6 ., 8 HO 0UCJE.DUUg U000HyuUCDUOCDNE.H. c..),p(õJ 5 p OH H U U Kt CD CJ 4 H 4 U 0 4 c, 0 4 4 0 CD
N 0 E, V. ,I. 1 Y 71.3 ,,...; L-6, OHOyOuCJHU Kg Ug 0 rz.,00 E.CDOUOUgg ,4, V
4 E.CDCJOUU CJOUUCJ E-I 0 0 U C.) U 0 U 0 0,<U0uHuuu O00,<EHuuEHEHu0U0HaL)Ha0H4EHE-<:HHHV 1 5 O 0 Hoc) 5 E.E-,c)0 c. HouougH04uU4HUHu004 E-1 A:guE.0Uu0OugUoHuu0E.uuuguHuuu 40'u OH u0E.Horc guuugt.gu .4E.00E,H1D1HOE-.0 u CJF.E.UUHUU0 CDUOLDUCDCJUHo_40E.uu uouu 0H0 C., 0 0 V 0 U F. 4 CD 1, u F. 0 E. U u u UE-,C9IJU C.,HOU
0U4044HE.444u4,E,CJUOUCJHE-,ggg00 0 0 g 4 OE.a000440004 guE,04000000H000HOE.
C-; E. U HUU00 E, 0 E, 0 C./ CJ 0 0 0 V E, U U 0 OUEHHOUHL) aUUOUUHEHEHO<UU0HEHOuE, r' OH H HO 0 rc ,I HO
gg0CE,gergU0g0H0CD5U0000HUgggUE-.5, Fa, U E--, UK,HHHUCJUE,E.HgEHEHEJUEDHHauurJUUUuOUC9 0 u 4 U U U. 0 u 0 0 U U E. 4 4 E, U 0 U u U U CD 4 4 a 0 a a EH
E-,oHauUH E-1 E, U 0 E.!) E-, 0 g CD g 0 0 g CJ gg g a c.9 o cp g Pc u UgOUUUg E-, HUHEHUHUEDUUEHOUu0uUgC70Hrg U E, Kg 0 0 0 C.1 E, U 0 Ft E. E. U E. H F, E-, 4 H 0 F. E. CJ E. 0 H. g 0 E, E-, 0 g .-4 0 E. E-, 0 0 g g g U 54 U 0 4 0 u 4 u E..) E-, 0 0 0 0 4 0 Huouuou000uu0guuguH00000c-,00E-'06 u 0 F. g U E. 0 4 E. 0 CJ a: 4 U E, 0 A F. 0 -4 H 4 0 4 u K4 EHEH0 E, 0 (I) E-, a U 0 u E, 0 U 0 a a EH a 0 U H -a a 0 0 u o a ci E-, 0 0 Uri:0 00 u k c.) 0 E-, u E. 0 u ci 0 u ULDUC104000Uou 00HS,UHaCJE-HaEH/aEHUaUE-,040 HE.E.E.UUE.0 440o4ciouE.F4 0E,gUt..70H0g 00CJUgUOU
UCJUHE,CJUCJUgU 00E,OC.700000-10000UHOU
U H 0 CD c..) H E. 0 0 U E. F. 4 E-, U E. 4 E. 0 0 C., 0 CD H KC 0 E. E. E.
to E. E. 4E. E. E. KC Ks: 4 1, 0 E, A 0 U 0 KG C., H CD U 0 E. U CD CD H
U U U
H 0 0 CJO 0 Ut..10 000,gC9E,E.J00 CJOE-, 40 QUO UCJUOC.) O H 4 4 u 0 E. u E. U 4 4 F. U 0 0 E. 4 0 5 0 (9 E. u E. E-I 5 U E. U
= H0000HUUUCDCDCDUOHCDKCO4PCOCDCJg0-IUF.CHUH
0 HUgucpuu 5 UE,C1g4UC.9r E, UKCCõDOULDOUCJOEJOU
O UHOgHHHUgg ...COE, OUOHOE,gUE,E,CJUE, C) V VOE'VUE,g00-g u 5 5 ,t 5 5 c. E.,40U4OUCDHE.
H g VE--.UUg0C9UUHOUUE,00U0HUOHOU gE, 000 CO HE,E,HUOPH H E-.KCC1E-10000gE,E,UgE.(7OUgU
PI 0 0 0, U H 0 0 U E. F. H 1-. E. E. ..< E. 0 0 CJ U 0 0 U 0 g g g Ii) g gC-DUOUHU, 0E,f, E.) . 0 gu 00gg 4 E-, E,0000u SUBSTITUTE SHEET (RULE 26) 41 4, P) C!) H c,i H HE-'> cr) fl, in < ri, 0 ora, ozoit_1õ1õ,,,120.-g.a,41a> H >, pk: cr) g .' ', 4 9 ti F4 1:4 c`-=1 tia cr;' 6 gi '8 0 0 H E-, R. H 0 H Op cr) rg 0 u) H H CD
.-1E-, Urr.1,--1)-1C10140zHENEAHM.-1Z
CDH,1E1 caxpc9r.,,,g1 cl.,irni=11<
0 C. ZZ 44 .4 tg .1E-.1., a, ,--1 0 4. c=1 .-D.L.-.P4,0g EnE.c/22>HE-. <<UZE, ,-)P1 õ-,--'1,4a,C7HD4H<grx-, WHOOF-(H.-1%
=tr),-1(1HH.-Ice,x(00100H<MNE-.,-IZL4 H 1 c.) .-1 H 0 U fa, H, Cl >.,n õ,,,E, 0 0) 1,) 1-1.H Ho)?-,OHHa, Cl) Cl 0)0 4c. 0) g I-4 >-, P.
VI U 'Kg CI 4.4) X r-41 p to > U A cal > frG ul 0 P,, 0. :. 4. .f.go.,ixoa> c,r)cd7 µ24,-.1a. Ch rtiCDH E-, ',-.1 > Cl Cl) z.9 x 1:1, 5,1134,111,0F,401,4r4E. H H (1)Ilt[1.1> H H C.1E-.
1 E-1,3,4u)4 gC 0.-Ivn?-.uir., a; ,cy H G4D
01,404 u) U)E.4 u) ..> C.) > OH LD E-, 02 E,E,., >-,CDE..,4X1-t00u)00 a >0 Ptr.,44..u) p4HH H .altno+Hr=4,-10.,E-4 E,H.E-,-,H a-.0-,0 HHHH:1)cni-11-.10,a-,01 CiL)C)<<CDHUE-,<HuquHrrHEJOUOC),<
4 4 4 0 4 E-,UH<<C)<<UNg .4 UE. E. H K:0 0000 OUUUCIUHUgg UH E-.."4,4:ETIU 0 0 E. E-.C5g a a E.,<UUUUE-,C7CDUUCJOg0 < E-, < U 0 < E-. C) E. U g U C) E. 4, E-, E-, E. 0 0 0.1; E.
C9 40 UOUOULDUCJE,<E,<U0CDOCICJH
g < a: g U E-, CD E-t U e, u 0 H E--, E-, C.) E-, pG E-, H 0 0 () uguUUCJOCDCJUE-,HCD<HE-,E,<CD0H,0E-, U 0 ,4 r- USD(.9 Cl C.) E. r.4 U, 0 d E. E-. 0 0 < 0 0 E. ci C.) < g 0 < H < 0 U 0 chd KC UH 0 < 4 E-, H 0 H cD
000uUcho,CH<CJE,u<a:E-,QUCDHgc..) U
C)HULDUCJOgUITgc E-. JUCDHOgHguC) u 00 < H UUH c.) 0 ...4 0 H,C.) E-, c9 PK 00 /:
O u 0 E-, U U < 0 ,g= < 0 N (--, U a' U
u F-, C.) 4, E.
U U U U U E. uUque0Hduut_!,F. of.) 0. U
O 0 0 ,,. E-, < U < a, E-, < 0 E, c.) E-, E, u 0 0 0 0 H
O < a: < 0 < < 0 g H 0 < IJ < H C.) E-, af, 0 Ei H <
f-, 0 C.) E-+ C9 CD 0 U U 0 E-, 0 E-, H H U H E, 0 E-, a, c..) u CDE-1(1,<<H,E-,<E,CDOC.9rchuOU<c)0(7 uchg CD<H,HuH<C7E, C.JCJHOE-,CD<<H
C.) H. E. 0 0 E-, 0 U C.) C) C9 H H. U E-, tg H
g 0 E-, <
E-,<E-,E.E.<<CJE.CD00HOE-,E,HuE-,000CD
E4b000UCD<O0U<U<HUU0CDE-10<g O 00 E-,HOHOE.000E.HUHE.U0 4E.
E. ti E. 4 a H E. E. gi E. U H 0 UPg 4 CIE.,404 '400 U 0 .1 CJ g 4 0 U U 0 C.) E-, .< 0 E-, U 0 0 H gli U < EP U, 0 r... 0 a, U a. U U U < E. u U U C) Ci 0 ry a.
HOU< E-, a q .4 .4 000HP0udUc9KC,Q.0 O<OH K4u.c2 0H d0dUHE.u<KCHE.0<
U0 4 00uH0 004dE.P00CDUH0E.0 4 E. gg 0 0 0 g4 u 4 4 U U 0 HE-..= 0 E.. E. gC E-. < 0 00E-,<E-.000<HUE,OHH000<<UHE, O E-, CJ CJ 0 0 0 0 0 0 0 0 0 g H. F. U E, 0 0 U U grt , , .4 H, E-, 4 E-if,d H < H. U E-, H < E. C.) Q CD U H U 0 Li A. CJOU00000CJ<UHuHOCDE-,U000 u0H0E-.00H0<c9000000<CJOUg E. H 0 E-. C.) E-, H 0 HP .4; ..4 0 H E-, U E+ a; 0 c7 CD 0 =
K4 u ri ,=4 CDHCD<CJOUCJEAHHE-,C)Uc9g 4 H
00gUat<CDHE.uuUu<0HHOOLIC9HH
dUE.000d000<uH0u<U0Hu gCH
000 0 0 E-, u U 0 < 0 0 0 H. E-, 0 C) < U HOF
O 4dH gCuE.HuUc9 Kt uHE-,HOUHHOHai E-1 0 a; 0 0 E-1 Ei 0 rr g L9 E-, 4 U E. OUHUE.C.5<HKI, ugC0E.Ug4u 0 g4Uu H dd V< 00a: H> .4 t9 r." E-4 g -,,4 CJ U C) C.) E-4 / U g CD H 0 U U (,.7 0 R , U R. ;
,d0Ougc c9E-tH4 4 <, .9Hc9,<C),<UCDHE, t..) 0 0 0 0 d U 0 0 U E. 0 E. E. () a4 0 U CD E. E.
UHU 0 HUU HUE. Hr-C H U ....¶9E.H E. H U 0 HOC) ruuci H0000E.4.:0E-10 E. UHE.0 UU ti OUUC90..t Ø...400410<gF-, 0 0 U 0 E-, 0 E7, E. < u E-, ,.., < () C.) C..) c...1 c...) C.9 0 C...) U < Pq 0 u E. 0 4uu0 (900 gcuOUUHUHE.K4UUuE.Kr HE-, 0HC9 004U U) Ho uuHud c9E.u0E.DdHu cDug H I--Ø<<c)E-.C.)CJE--,E,<<UU<UOUOE, HOC!) HC0004CDUOHUHOO<HuHE-,uHF, O(000 E--,UE-, 0 .1: C9 H E. H C9 U 0 0 U rt., U E. C./ 4, 0 CI8E.KUE.0 HU HE, HOE. HE-000U 0 H ,:l .4 u 6 U000,4E-4C)<U<HH000CD<OLDUCD<0 CD 0 C.7 < U 0 0 CD a, CD c) E-, 0 0 H U 0 0 < ,,C H .4 O U < rcg E. d 0 H H 1-, < < U C.) 0 0 U g 0 c7 g 0 E--, <
OUU00,<UH,<5-.00E,c9<010g0E-,C),<E, O00E-, 0 1.00 < E.0<(..E.E. OCIa, U 0 0 OH u HUE-' 0 0 0: E-, E-, E, E. 0 0 U U E. U E. E. a u (.9 u a E-, E-. E.E.0E. d E.u0 00 u dc1C9 HUH 04:E.
U uu (.9 U H 0 0 H E.HuHu uold (JP <Hu0E-.
O E. U gC E. u 0 < u 0 / U U E--, CJ 0 0 E-, H u H, ch u <
<CD<C9HHOL)00 UULDUHE.OUHOCDO.
CDUC)<C100C)00 000HOUHOPUE0 C,94UUrE,CD<OCJ E-.00(.1HC..)0CDC)00 0 OH El Hu 0000 U 0 g E-, U E-. C) 0 C.9 L. g 1 E-, E-, 0 0 C.) 0 0 0 E. 0 E. E. c) E. E--, u .4 E-, 0 Uci H
E-.F<HHCDOE-.<P6Hg<UOUUOLDOU U
O E, g H. < E. E.-, c7 u a' ' U 0 0 U 0 CD U CD g H, U E-, E-, r<C)0(1c)000<cichHouutiguOUUUHO
ucJC)V9cJ C9C9CDOU<H,C7<HHIUU 4 HUOHO
,< g U<OHOH O CJ UHHUUE-,HOOH F.
E . 1 U U UH,HU,OC)0<c)E--,E.F.C)<<000H
O00 E. E. E. U 0 U 0 H 0 0 U 0 Ca E. U U 4 E, U E-, (9 (9 F:4 Li C9 0 0 0 0 < g 0 0 U < g wHuu c..1 U E. u u 0 o ci F,UHE-,E,C)C7H<UCJOHUUE-.0,4,<H, 0 E-, (.7 < U u b E-, E.0 E. E. 0 V. 0 U 0 E. 4 d u H 0 L'.'oc . H E. C.J E-.<HUClUg UC)C9H<c)c)E.E-.E, uuc..)<0<000.< 0(0C)<HUU.C7gUg<
<H04E1 004E. 0F:400000U gCuc90E.
0HUrr UUNKC000E.0004E.E.Hu0KCE.<
E. u E. ciuuuuu U 0 E. u H d 0 E. < E. E. H 0 KC gc __ ......
SUBSTITUTE SHEET (RULE 26) H> g a z g a a E. 0 H> a 4 E. a a ria g g cl a g X u >-, cx)Xr4E4HE.E.HzryHI-1.-Jgri 0 04HZI.,[4Hu)0E.
E.-, P, H 4 u H U) cnurg 1-10 a P. E. or., = 4 r.=.X0 4 X 4 01:4 r E. a E.-, re a g P, E 14 H EZ H Z 4:) cD C.) til HP 1,--10X
H 0 x g =?-t re, a a>. p, 0 S.. .-1 E--, a n ri,z a g H (..9>ull-tEnz 0HP, Ul 4 r=-=
.-1 CI1 ,-Icil 400 q gX a Hat:404 43 -,KCY,enE.C.9X.44H cPCIEE).0P,<L1) X04.4ZX>.E.H41.Hul >fr.,C..1-ir.. HON
Z
0 E-1D3.-. > HZ .4E.E.P. 04E4 Z ,-100rK?aloax 5 ., ,r.,,_,,., ,,..õ..., 0 El, 0 a -4 a rig>. gclgi-IX?1,E,E-tg E. g H. UN pirnr=101-,HE-, 1.4 CI) .94X040.4X
C, N z.DEri fl ti';'-, g, , 41 E'-.1 'El gi U) O 4 U E. 0 Eh 0 g U 0 E. E-, 0 E. E. 0 Ei 0 0 0 0 4 E. 4 D 0 0 U 4 C.) HOUU.HHUO U 00H0UUE.004400 H044H4 HOP
0 0 0 4 E. 0 E. 0 4 a: 0 U P L.) E. 4 E. E. 0 CD E-1 E. E. 0 44 0 44 4 ES
E. HO < < U 0 Ogg 0.4 C.) E. 0 U CD 4 Ft4 E.0E-t0U0U0 HUUHE.EJUOU0004 E-,q444 (Duo C90 u U 0 HUHHO OPOUPH OC.9E-.E.CDE. 00000 4 u 4 HUU 4 0 0 E. 4 0 Ft 4 0 Fl 0. E9 4 4.4E-10 O04f.0 UHU
E-,0u0OUD0UU0UuHO0 ED ouU00i-,400E, "-,0 E. UUHOUCDUH<H0004 KCEDULtugE.K4u044 OPH
EJ 0 0 U 0 U 0 E. 0 U C.) 44 CD kJ ,...0 0 <4 0 44 0 0 E. 4 H E. U 0 0 E. U
HUU0 0, E. 4 0 E. E. U L!) E-, EJO<OCJUHOPOUCJ U 4 HUH
< E.) 1. U CD (_) 4 E. E-, 0 E. 0 E-I ,4 E. E. E. 0 U 0 E. E.
U CJ C., C., 0 D0004 000guEtu044404E.E-,00000)E.K4 000 0= 00UHUE. <OH HPH<HHUE.<44HPUUEJLI0UU
0 CD C.) 0 E. 4 0 0 0 E. 0 < U 0 KC, E. a; U0OuHu0 HOE. < HO
0 UcJUU UOCDHE.0CDUOUU UU,44CJE.C.)<CEIHO OU
CJ C.) CD C. UE-, E. E. 0 E. U 4 u 4 E. E. E-, 0 g, 0 0 4 u (9 E. <
EJOGE.0E.0004441: 044U 0 0000E-.0 44U PE, 00 UUHIOCJOHHUU 000 44 0004E.DuE,<0 OF
E. 00 <HP440000E01 U E.E.00HD<U0E. OE.
E.Ou UH4UULD4,4UHO U4000E.EnOUE--,< <E.<
E.,...40(Doc9E-.00,4 U404_940E. UHOLDHC/CDHC) UgU
E.< 0H444040E-t0E-,u00 4 E.PH440E-.0 0E.0 01)E.
1-' '":0000000E-.0gE.U0L-, 4 0000E. e, g 01) g C.) r r, E.
E.00E,11,E-.E. C. C II E-. OUE-,Ouuu 0000000HE. < .1: E ' E.
E. 0 E. < 0 a', U 0 E. E. kJ < 0 04 HU U04 0 UE-,U<EA Cf.. C.) 4 1 OC)(..)H000 444H CD<HOULDU 000 4400C)OUC) (JO
E. E-. 0 E.J E. E. E. 44 U E. E , 0 E. al E. H E. E. U Cl 44 E. < 4 U 0 E. r"
H
O 00 g H oo,,,,c9c9 0 0 E-t Et 0 0 E. y 0 0 E-, Et U 4 0 (.7 E, 0 4 E.
O0000CJOHOF,E.H04g000004044.,E.00 E. pc E.
EtuU0KCUUKCHE.E.4E-tUUr H H U KC El EJ440E. 4 00P
CJ 000 0E.044r)(J,CDUC)4 HOCJHOE.E.OHUOHHE.
UCJ0000 U c..1, 44Kcoc_Do 0 E.00E.FitiUU/0 OFF, uuuuE,KC Et 4 u04 E-tguuuE.K4 .,,=
E. 0 0 0 < F. a: 0 U 0 0 < rr .1G U, E. E-, U 0 < < E. 0 4 4: < C.' 0 0 4U000 HUHUOUUCJ5,C) OUHOE.44E.C..4 0 OP a;
0000.000E-.0Cuq(DE-,0400H00ggcDE-,00Hugga, 0 CD C-) 4 0 CD 4 a: 0 0 0 0 0 U < < H g E. g 0 U(DUE-,H0 OUE.
O <OU at 00004 o0E-,E.ODUUU00E.0000U OrCU
O 0 0 U H E. 0 4 E. E. E. E. E. 0 CJ 0 E. U0444 0 E. 4 CD EJ C.) 0 0 L) 4 (-, C) g 0 4 E. 44 <U40 4E-, 4 00E200(.00g E-,<F, 4 0E.E.0000(J00 UCE.E.OUPOC..)00 4CUUCJ CD CIE. gy CD
CJUCD at at 0KCKCF,E.4K4uE.0HOUPPOU40 44, ciC) CD cit E-.
KJ CD E-. u c9 cr9 P H C9 E. (.9 0 (9 E4 E. C.) 0 0 < < E. E. U ,4 4 U 0 <
0 HUHU04C<E.H CD00E.000E-ty00u4KCK? (-tug cIt u OUE.0u400u4E-,youE-tHE.H <PEAUE.tJH E.CDEJ gl.
Ur.)004E-1.4000 HUUCJO<HU <VJO4C.)44 E. HOP
O 0000004E-14UUE.U0 0HU 0 EJ4C)4< E. U4g 0 0 0 0 EH 0 E. E-c (,) C, C7 0 < E. E. u E. E. 4, CJ E. E. 4 0 a; kJ E.
0 E. 0 E. < 4 E.E.E.E.04E.U00(70<0 E-, o E-. o 4 U 0 4 19<0000 HouciE.04UE.E.Jc/OHE.UCD< 4r0H
000 F' 0C-)040 H HqE-lu tE.E.Pu HoO4HHE-.Oo 0 uou0(90.400.4u4.5044HOE-,4 0E.HOE.E-, E-, E.cD E.
OCJUE-.0 Out...cid, 04 dur....HHUEDOVEJP:HOUCJE-.00 O CD 0 0 Et E. ,4 c9 u u E-, c_9 (D CI g 0 E. c., u g E. E-, U E. E. E. CD U U
UE-.(9 E. UU.-4 <OH <4 <044, HOA,40 V< KC a V J 0 0 0 0 0 0 I-Ø40cDO Ho o (Doc.9 gouH5E.ouu uociutial '(-)t-,0c-,E,E-,a:E-,EJ U440(9(.0 ,0<<F,HUHU00UU
000 at ugUE.U000q4 guE,40 <04LTE-,000 u C-- , < F,E L,F UU00,,UE.,..0uOuQ)up g UE. 1-,4 HHHU
E-, 0 U 0 E. 4 E. U 4 0 E-, u u E. U U. E. -4 4 u u 0 0 4 u o 0 c...) OE.U400E-.CDE.E. 4U<HC.)40 44004000 <E. 0 4C at U
C.) E. U U CD U 19 a: C.) rt U CI V E. V CJ 4 0 0 u 0 CJ E. u u E. C) 0 <
< (..., c..9 o E. E. E. E. E. 0 E. E. U f. .4 E. < E. E. 4 H E. E. a; LI U
<<CDOE.CDCD,CUOU<CD<<U0UOPOHE. at OUCJUE.E.
O0 4U Ci40 0000000Pgd<00000 OCJCJUHU, 5,0CD OPUE.E.E. HE.E.E. ci4UUCJOH44CDUE-10 OVE.E.
i U Et uu &4 0uUH O c., U40 4 4 4.9 HO 00o4 CJEJ 4 E.
O 4U HOE-.0 40 0 UUE.000HOOPO < F.c CJE. 0400 <000CD<CD0UPUdE-.E. , E.E.EHE-14,40,4 c.-30 OUP 4 U000000 40000 40 OE, 4uHOE.E. uE.E.(DPU
HOUQuO0U0 ut...Dug 4 HUOU,e-,<<E. Hu4HE.E-, O40UE.,4 E. <0E-144E.UgUQE-,<Ou DE,HUU 0000 HUUE-,400U4 E.OUUEDOCOUHE44040UH '4(70 H
N CJOU 000 E.E.,4 HOE.HEDUOE-,000040PHUOU<U
,-, 0,4 04E-,4 <HO 00E-,U<PHHOUUUUH 4tJE. at <,,'I, 0 000004 :.E.,,t,40400E.4E.1-,u0UHE.E.UU U4 <
= 000 4UU UtDuU004HuU04E.HOuUE.4 DE9g, O 000 OUE-,E.U,<0.4HUocDgcc.9E-.8o0o(Deo uc94 o Z 4cDC)ouc.9 c94E-1H4E-.4oHocpu c., QE.E.44H0c9 O Uat000>000ciL c!..Ho E. C. 0 C. C.) C. C9 E-, 0 H. CD Li E-, 0 cl .4 H 0 0 U CD C.) HU El< .:, , 04 C.) U C., E. E. U E.
H E. 0 ,,4 0 E.4 0000 o? Ho U UE-10E-,04 <0,,,,' UOU 0 0,404 4 4 0E.E.0 ("DUE, E4 <0 0 UUE.uHu u ot.30<pu 4U ouciugu0u 0000 en 4 F,0 E, 4 0400 4 H4 Ou 4CHOE.HUg44 4U0 00E-,E-, SUBSTITUTE SHEET (RULE 26) __________________________________________________ -UHU<4E.4044HE.E. E-, E, U
H. PUL)04:4HOE/UHE.000 U 0 H H E. E.
OHE.E.UUE. 0 E. 0 H U 0 H U
CDUU4E-, OH 00E-.4UUHE.
440UOLDOE. 4HOHOU 0 4' U ci 0 4 CD U U 4 U
0 E. E. 4 F. 0 vc.94 .5 E-.ouq.c 000E-, /
55E-.00.4uc.5 E. 4 0 U
uF.0t/HE-,40 0 UHOOU4 0 E. OH 4 H 4 pc 0 OH 40404, I
E-. 0 0 0 4 0 U, 4 KC
L)E.U0E.E4.4HU 04 46<4.0 C.) U 4 U u o E., y o 0 0 0 4 U 4 U 0 4' 0 0 0 E-4 0 0 0 KC
4 E.F.F.H0E-.04H000044 E.U4V.I.E.E.00)0H<UHOO
E-.04 000E-, F., .4E-,E-,Huu05 500 0E-,E,40000E-,00,50 UHUu 4E.E.0001.4 0(30WH E, H 0 g, F. Ul 4, 0 u u .5 E.F.UPUE.U4E. H 4, 4 4: CD EJ
U ,,,,. 0 0 A: 0 OUL)E.E.E.000<0 H4E-.0,-C
E.040E-14HUKCHHO HOHUU
U 4L)04E.OUE.40F,H E, E. U U
HUH0 E-,L(q4;HugE, 4 g4U
ypcc..,E-.E-,01,00,.1:
H2404 H 0000H<OHU
HIUU
UFO() HgE,U0H00UUHU
WUHHOH
OHU u E-. E, U 0 0 4 Ci 4 0 U 4 E. H F. 0 E. H 0 0 .4 U
U 4 u 0 U 0 gc E. 0 L.) F. F4 4 ..= E. U
C/E. OH HE.L)40 E.00 E.E.H4E. UQu4E-.0EUHHE.40 HO00 E. L) u U
E--.H00 UgH4UK40E, HUH 4 H E. P KC
H ,..c ,,c t-, ,,c E-, E-, c9 0= ,,,cfCgtogc F. 0 4 H U E. U 0 4 0 4 E. 0 H 0 0 E. 4 0 pc E. H E. E, 0 0 0 0 HHHU,4,4r1tH00E-,4 H0E-IU
CJUU4U 4 rd E-1 CD C.) Fl: U, E, E-1 C5 U
,ouc.., py00 HE-,04(7E-, 0004 40g4g E-.E-,E-,E,Ur0c,)0 4.E-IHE,a, Kr UOUE-,0 04c.7E, COUHO CSUKCE,C9E, H0H0 EA 40HOUE.44 00E. 0c1)04 E. HE-.0E, H40E-.
U 4 U 4 H, 4., H 0 C C < E. E . E . I< CC!
E, H E-, U E, < E-1 H 0 H U U E.-, UUHH
H 0 E-+ 0 0 4 0 0 H E, CD
r..7 U ,r4 0 H H 4 4 0 4 0 E. u 4 0 ,c L) E. 4 H. U U 4 0 F. 0 1 CD
C '4 U 0 U 0 g HHH 4 E. 4 E. -,40UHUH40 0 4 F . u L9 UF,<E,H0E.C3F.00uH0E,44 E, E--, q E. u 4 E. C.) 4 C!)u 0 4 0 4 E.) 0 4 E. U E. 0 0 4 0 0 0 E. U H 4 P E-.
E. H C.) E. 0 0 E. 4 HO
U E. 4 4 0 E. g H 4 E. E-. 0 5 u u u C.) U E. u .4 0 Ci44000,4uUKCE, 4*O.U.UU4E.01E.U04C)E..4 E. u 0 , 401/H4HE.
UuC)40444.40E.E.H.E. 4 u 1-, 1 SUBSTITUTE SHEET (RULE 26) SEQIDNO :18 SEQIDNO . : GS 1,0 GACAGCCTCTGGGICCTCGGTCGGTACAGTCTCTGCACCTCGCGCCCCAGCAGGTAAACTAACATTATGGATTTTTCCA
AGCTACCC MDFS KLPKILDEDKESTEGYVEG
AAAATACTCG.ATGAAGATAAAGAAAGCACATTIGGTTATGTGCATGGGGTCTCAGGACCTGTGGTTACA.GCCTGTGA
CATGGCGGGT VSGPVVTACDMAGAAMYELVRVG
1,4 GCAGCCATGTATGAGCTGGTGAGA.GTGGGCCACAGCGAATTGGTTGGAGAGATTATTCGATTGGAGGGTGACATGC-CTACTATTCAG HS ELVGE I IRLEGDMATIQVYEE
GTGTATCAAGAAACTICTGGIGIGTCTGTIGGAGATCCTG'TACTTCC-CACTGGTAPACCCCICTCTGTAGAGCTIGGICCTGGCATT TS GVSVGD PVLRTGKPLSVELGP
ATGGGAG CCATT TTTGATGGTATT CAAAGAC C TTTG TC GGATATCAGCAGT CAGAC C CAAAG
CATCTA CATCC CCAGAGGAGTAP.AC G TMGAIFDGIQRPLSD IS SQT QS
GTGICTGCTCTTAGCAGAGATATCAAATGGGACTITACACCTIGCAAAAACCTACGGGTTGGTAGTCATATCACTGGCG
GAGACATT IYIPRGVNVSALS RD IKWD FTPC
TATGGAATTGICAGTGAGAACTCGCTTATCAAACACP_A_AATCATGTTACCCCCACGAAACAGAGGAACTGTAACTTA
CAn'TGCTCCA KNLRVGSH I TGGD IYGIVS ENS L
CCTGGGAATTATGATP_CCTCTGATGTTGTCTTGGAGCTIGAATTTGAAGGIGT.A_A_A_GGAGAAGTTCACCATGGT
GCAAGTATGGCCT IKHKIML PPRNRGPVTYTAPPGN
GTACGTCAAGTTCGAC CTGTCACTGAGAAGCTGC CAGCCP_ATCATCCTCTGTTGACTGG
CCAGAGAGTCCTTGATG CCCTTTTTCCG YDTSDVVLELEFEGVKEKFTMVQ
TGTGICCAGGGAGGAACTP_CTGCTATCCCTGGAGCCITTGGCTGIGGAAAGACAGTGATATCACAGTCTCTATCCAAG
TATTCTAAC VWPVRQVRPVTE.KLPANHPLLTG
cn =
AGTGATGTAATCATCTATGTAC-GATGTGGTGAAAGAGGAAATGAGATGICTGAAGTCCTCCGGGACTICCCAGAGCTCACAAT.GGAG
QRVLDALFPCVQGGTTAI PGAFG n.) CO
GTTGATGGTAAGGTAGAGTCAP.TTATGAAGAGGACAGCTTTGGTAGCCAATACCTCCAATATGCCTGTTGCTGCTAGA
GAAGCCTCT CGKTVIS QS LS KYSNSDVT IYVG
co (I) ATTTATACTGGAATCACACTGICAGAGTACTICCGTGACATGGGCTATCATGTCAGTATGATGGCTGACTCTACCTCTA
GAGGCCCTTAGAGAAATCTCTG GTCGTTTAGCTGAAATGCC TGCAGATAGTGGAT ATCCAG
CCIATCTIGGTGCCCGTCTGGCCT CG GKVES IMKRIALvANTSNmPVAA
TITTATGP_ACGAGCAGGCAGGGTGAAATGTCTIGGAAATCCTGAAAGAGAAGGGAGTGTCAGCATTGTP.C-GAGCAGTTICTCCACCT HEASIYTGI TLSEYFRDMGYHVS
-GGIGGTGATT'ITTCTGATCCAGTTACATCTGCCACTCTIGGTATCGTTCAGGTGITCTGOGC3CTTAGATAAGAAACT
AGCTCAACGT MMADSTSRWAEALREISGRLAEM n.) AAGCATTTC CCCTCTGT CAATTGGC TCATCAG CTACAG CAAG TATATGCG TGCC TTGGATG
P_ATACTATGACAAA CACTTCACAGAG PADS GYPAYLGARLAS FYERAGR
cn =
TTCG TTC C TCTGAGGA
CGAAAGCTAAGGAAATTCTG CAGGAAGAAGAAGAC CTGGCAGAAA TTGTACAGCT TGTGGGAAAGG CTTCT
VKCLGNPEREGSvS IVGAvS PPG n.) TIGGCAGAAACAGATAAAATCACTCTGGAGGTAGCAAAACTTATCAAAGATGATTTCCTACAACAAAATGC-ATATACTCCTTATGAC GDFSD PVTSATLGIVQVFWGLDK
co ¨1 AGGTTCTGCCCATTCTACAAGACAGTAGGGATGCTGICC_AACATGATTGCATTTTATGATATGGCTCGTP.GAGCTGT
TGAAACCACT KLAQRKTIFPSVNWLISYSKYMRA
GCCCAGAGTGACAATAAAAT CACATGGTCCATTATTCGTGAGCACATGGGAC-ACATC
CTCTATAAACTTTCCTCCATGAAATTCAAG LDEYYDKHFTEFVPLRTKAICEIL
n.) GATCCACTGAAAGATGGTGAGGCAAAGATCAAAAGCGACTATGCACAACTTCTTGAAGACATGCAGAATG
CATTCCGTAG CCTTGAA QE EEDLAE VQLVGKAS LAETDK
r"
GATTP_GAAGCCITGAAGATTACP.ACTGTGATTTCCTITTCCTCAGCAAGCTCCIATGTGTATATTTTCCTGAATTTC
TCATCTCAAA ITLEVAKL I KDDFLQQNGYT PYD
CCCITTGCTICITTATTGTGCAGCTTTGAGACTAGTGCCTATGTGTGTTATTTGITTCCcTOTTTTITTGGTAGGICTT
ATATAAAA RFC P FYKTVGMLSNMIAFYDMAR
cr) CAAACATTC CTT TGTTCTAGTGTTGTGAAG GGC CT CCCICTT CCTT
TATCTGAAGT GG TGAATATAGTAAATATACATTCTGGT TAC RAVETTAQSDNKITWS I IRE HMG
ACTACTGTAAACTIGTATGTAGGGTGATGACCCTCTTIGTCCTAGGTGTACCCITTCCICATCTCTATTXL.ATTGTAA
A.CAGGACTA DILYKLSSMKFKD PLKDGEAKIK
CTGCATGTACTCTCTTTGCAGTGAATTIGGAAIGGAAGGCCAGGTTTCTATP.ACTTTTGAACAGGTACTITGTGAAAT
GACTCAATT SDYAQLLEDmQNAFRs LED
TCTATTGTGGTAAGCTCATTGGCAGCTTAGCATTTTGCAP.AGGAATTGCTTTGCAGGAAATATTTAATTITCAAAAAC
ATAATGATT
PATGTTCCAATTATGCATCACTTC
CCCCAGTATAAATCAGGAATGTTTGTGAGAAACCATTGGGAACTATACTCTTTTTATTTTTAT
TTITTATTTITTTTATTATTTITTITTIGGGGA_CGGAGTGICCCTCTTGTTGCCCAGGCTGGAGTGCAATGGCGTGAT
CTTGGCTCA
.75 t7.-J
, EJ 0 0 4, u E. H Er.
8 [5 8 41 0 g il 8 [5 u 8 8 8 6' il 8' 0 8 El ri [5 '.; f5 1 1 0 8 6 r r 5 P, f-J1.1 E. E::
0 Eg-44 OH
CJEDg4Pgra: CD E.HC9Lio.E.0 C.74000H
El ii [5 P El [5 UHEH5 0 F.' 0 0 1 El CJ 0 E. L9 F. C9 E. Eq E. E.4 H C7 g4 CJ
KJ H
8 8 0 f5 8 L7 g g .c) [; I?: Et4 F13 g 8 f5 P. il r i HUHry E4 El, U 8 tl 0 CJ C., ,4 o c!.! u, u o o c-, -' ..
',;., El 8 0 2 6' 8 2 E= 6 g 0 0 0 E. Eg' g E: [5 H El HUH
HHKDKJHULDg4C7 g/LJCDOC9 g ,gc o E. E--.
8 8 8 0 ,t fl 2 6' 6 ' 8,-, [5 0 82 `.0 EY, 8 El [5 [5 il N 8 E. F.' EH F7' El El El P. El 0 8 U 8 U
`-' ' " E' C.) 2. El E-4 El Eg EL1 C?) 5 r.,. r, (9tr...
(ii,..! (6. (,,i v_..
V El u c) E. F E4 rg 0 U
UH
U (.7 E.
UH 0 E. E. EA CD Pc E, CJ 611 g 0 0 F. F, F.
IJ gE.E.E.UHC9gL7 gc .0 p o . 5 b ii 8u r; V' g c[i r4' ri E ([ 3E, r5 P, '[:.5 3-, !'-' 1 000 ,0000.4 i -,¶.E--.E-.-0¶-,u,cHuL) U g `d 6'. ,E 0 0 HHH0 !i 8 0 El _ Ei Eluur E-'1uf81.ur,E'E(2, oci -,7 ' CJ 0 u (7 K../ H E. E. 0 F.
C-) V, 0 cA i E r fl ,'-Z E, 0 'i 1 El fl 8 E( 0 0 H u C.) CJ (9U U F, E. 0 E. 0 CD 0 H U E. H E.
E. H H E. 0 EA g g g EA C7 cn rc H O. ., ,H,. P EL1 E.-, El g E. H 04 gli i. li Pi g..., gS2C1 EHgC7HHHH,Uoiti Hti gHg4HP_P
,E1, ii E-.' P 8 P. E E.'; t', 8 r r, v, 8, ' ;!,c' kJ V, ri 0 E.
8 8 2 il t5 g/ E. E.
E' " '' t-' 8 5 'r. F4 V., E-2 P. r ..4 6' 8 1 8" " " E'. 1 cõ 0 8 8 0 E5 2 El 0 1 E5 E5 g ';-4' ;5. El E.
., 0 8., .2 õ Eõ E.
HEC), Et.., ,F"-, __ , tj,.! CH, " r,4. [5 1 [5 i4 EE3 r ',c. g g U 'El r, r 4 g ,, , ,-, r, ti 0 0 CD KC E4 rg Ch rg 0 F. Cp 0 Ch E" F.
ii KJ E.
F?-:, ,t...;
b`'E----:Eirs,n_i8,`,-4-'E--:.nr-90E100E-.01-50 $) R 8, [5 t; EJEc.3.
/
4) ,e, u g g !-. Ch CJ gi CJ CJ tJ C) C..) u E. 19 H
C7 E4 CD 0 H E, E. 0 CD U E. E. 0 g F. U E6. 1 ,(.1,1 .4 El 8 2 EI [5 .' 1 8 . EE--,' fl 8 8 ',;.!. `E-4 u 4 ' SUBSTITUTE SHEET (RULE 26) SEQIDNO . :19 SEQIDNO . 166 0 1,0 CTGCGTCCG MIRQERS TS YQELS EELVQVVES
TGCGCCGCGGGCTGGGGCGGTCTCAGGTGTGCCGPAGCTCTGGTCAGTGCCATGATCCGGCAGGAGCGCTCCP_CATCC
TACCAGGAG SELADEQDKETVRVQGPGILPGL
C TGAGTGAGGAGTTGGTC CAGGTGGTTGAGAGCTCAGAG CTGGCAGACGAG
CAGGACAAGGAGACGGTCAGAGTCCAAGG TCCGGGT DSESASSS IRF S KACLICNVESVL
ATCTTACCAGGCCTGGACAGCGAGTCCGCCTCCAGCAGCATCGGCTICAGCAAGGCCTGCCTGAAGAACGTCTTCTCGG
TCCTACTC LIFTYLLLMAVAVELVYRTITDF
AT.CTTCATCTACCTGCTGCTCATGGCTGTGGCCGTCTTCCTGGTCTACCGGACCATCAC.AGACTTTCGTGAGAAACT
CAAGCACC CT . REKLKHPVMSVSYICEVDRYDAPG
GTCATGTCTGTGTCTTACAAGGAAGTGGATCC-CTATGA.TGCCCCAGGTATTGCCTTGTACC
CCGGTCAGGCCCAGTTGCTCAGCTGT IALYPGQAQLLSCKHHYEVTPPL
AAGCACCATTACGAGGTCATTCCTCCTCTGACAAGCCCTGGCCAC-CCGGGTGACATGAATTGCACCACCCAGAGGATCAACTACACG TS PGQPGDMNCTTQRINYTDPFS
GACCCCTTCTCCAATCAGACTGTGAAATCTGCCCTGATTGTCCAGGGGCCCCGGGAAGTGAAAAAGCGGGAGCTGG'TC
TTCCTCCAG NQTVKSALIVQGPREVKKRFLVF
TTCCGCCTGAACAAGAGTAGTGAGGACTTCAGCGCCATTGATTAGCTCCTCTTCTCTTCTTTCCAGGAGTTCCTGCAAA
GCCCAAAC LQFRLNKS SED FSAIDYLLFS S F
AGGGTAGGCTTCATGCAGGCCTGTGAGAGTGCCTGTTCCAGCTGGAAGTTCTCTGGGGGCTTCCGCACCTGGGTCAAGA
TGTCACTG QEFLQS PNRVGFMQACESACSSW
GTAAAGACCAAGGAGGAGGATGGGCGGGAAGCAGTGGAGTTCCGGCAGGAGACAAGTGTGGTTAACTACATTGACCAGA
GCCAAAA.AAAGTGCTCA_ATTGTTTTTTGTGGTCTTTGAATGGAAAGATCCTTTCATCCAGAAAGTCCAAGATATAGT
CACTGCC_AAT EAVEFRQETSVVNYIDQRPAAKK
cn CC TTGGAACACAAT TGCTGTT CTCTGTGG CG C CTTCTTGG CAT TATTTAAAG CAGCAGAGTTTG C
CO
ATCAAAATTAGAAAGAGATACCTTAPAAGAAG.AGGTCAGGCAACGP.GCCACATAAGCTGAAGTCACCTCGCGTTGTT
TAGAGAACTC- TANPWNTIALLCGAFLALFKAAE n.) cn co TCCACATCAATGGGAGCTGTCATCACTTCCACTTTGTAP-ACGGAGCTATCAACAATCCTGTACTCACTTGAAGAAATGGGGCCTTGC MIMS I KWMI KIRKRYLKRRGQA
tri 7:1 TGGGAGGAACAGCATGTAAAACTGGAACTTCTAACCCCGTCCCAPAAGAGGCGGTGTAGAGCCTAATAGAAGAGACTAA
TGGATAAA TSHIS op CCTACAAGTTATTTAAATATTTAAATTATTAATAAACTTTTTAAAGAGCTGGCCAATGACTTTTGAATAGGGTTTGTAG
AAGATG CC
TTTCTTCCTGTTTGGTTCATTGTATTGTATTAGGTTAAGCTCTACTAGGGTAATC-PAGGCTCTACTTTTCACTTTTTAAAAGTGGAC n.) cn AAAAGAGTGTGATITTc7rmccAAAAATTccrGAGTATcAAGAcGTGcAGGTcATGcrrTGGAGccTATccAcTGTAcA
cAATGG
CAAAACCGTATGACTTTGGCATCATCTG CCATTGATG
TCCAGCCTCTGACATGCTCTTTGATTTGTTAAATGTTAAATGAGACTTTA
n.) AGGCTACTAGAAACTAGTAATTAAGTTTCTTAATGGACTGAGTAGCCACCTACTTGTCCGGCTAGAATGTTTGTTGATG
TATGAGTT
TAGATTAACACTCAAAAGCACTAGGACAGATGTACATAGAAGGTGCCTACTCATTGTATTTTGATGATTTCATTAACAG
GTAAATAA co AAGTTAATACAAAAGGAACGAGTGTGACAATATGAATATCTGCTCAATCATCGGGCACAATTACTTTCATTTGGTGACT
TCCAAGGA
CAAAAAGGTAGTATGAGTCTGGACTCCCAAGATGGATCTAACTCTCAAGGTATGTTCTAACTGCTTCCAGGGAAGGGTT
TGTTAGGC
ATGGCAACTGATGGCAGGTGTCCAGAAAGAGTGACCTGGTGTCCCCGAGGAAGCTGGGTTPACTCTTTACTGTGTCCAC
AAAACTAC
CCATCATATGAGGAAGGGGTATACGCAGTGTGACCCTCAAAAAG
CTTTTAGCCTAGCCTTTGACAGAAATGAGTATGCATTAAAAAA
=
cr) AAGTCTATTTTTCACATTAAGGTTCTAAAAATTGTTTCCAGAGTTTTAAATTATTTATGTGCCTGTTGCTTCAAAGAGG
ACTTGGTA
GCATTTCCTAAATTTTGTAATCTGGCTTCCGATAATCCAAAGGGP.ATAACTCAAATGTATGAATAGGCATTTTAAATG
GGAAGPAAC
TGTTTTTTGGATGAATGATTAAAAGTGAACTGTATAAAG
SEOIDNO : 2 0 SEQIDNO . 67 GCGGACGTGGGCAGGAGGGCTGGAAAAGCCGGCGCTGGAGCGGGAACGGGAGTAGCTGCCTGGGCGCCAAAGGCCGCGG
CACTCCCA MFRKGKKRHSSSSSQSSEISTKS
CGCGGACCCCGAAGTC
CGCAACCCGGGGATGGGCCCGCGGCTGCGAGGGGATCTTCTCTGGATCAAGCAATGGTGGTGAAAAATG TT
KSVDSSLGGLSRSSTVASLDTDS
TCGCAAGGGCAAAAAACGACACAGTAGTAGCAGTTCCCAAAGTAGCGAAATCAGTACTAAGAGCAAGTCTGTGGATTCT
AGCCTTGG TKS S GQSNNNSDTCAS FRI KYVG
GGGTCTTTCACGATCCAGCACTGTGGCCAGCCICGACACAGATTCCACCAAAAGCTCAGGACAAAGCAACAATAATTCA
GALACCTG AIEKLKLSGKGLEGPLDLINYI
TGCAGAATTTCGAATAAAATATGTTGGTGCCATTGAGAAACTGAAACTCTCCGAGGGAAAP.GGCCTTGAAGGGCCATT
AGACCTGAT DvAQQDGKLPFVPPEEEFIMGVS
AAATTATATAGACGTTGCCCAGCP_AGATSGMAGTTGCCTITTGTTCCTCCGGAGGAAGA_a_TTTATTATGGGAGTTT
CCA.2-.' GTATGG KYGIKVSTSDQYDVLERIGILLYLI
CATAAAAGTATCAACATCAGATCAATATGAIGTTTTGCACAGGC.ATGCTCTCTACTTAATAATCCGGATGGTGTGTTA
CGP.TGACGG IPMVCYDDGLGAGKSLLALKTTD
TCTGGGGGCGGGAAAAAGCTTACTGGCTCTGAAGACCACAGATGCAP_CCAATGAGGAATAC.11_GCCTGTGGGTTTA
TCP_GTCCAACAG ASNEEYSLIWY. QCNSLEQAQAIC
CCTGGAACA.AGCACAAGCCATTTGCAAGGTTTTATCCACCGCTTTTGACTCTGTATTAACATCTGAGAAACCCTGAAT
CCTGCAATC KVLSTAFDSVLTSEKP
AAGTAGAAGTCAACTTCATCTGAAAGTTCAGCTGTTTTCAAACTGCAATGCTGAAATGTTATGCAAATAATGAAGTTAT
CCCTTGCT
CTAGATITTCTGAAGAAAATGGATTGTOTAAAATGCTGATCATTTGTTTATTAAAATGTGTCCTATTACACAGTGAGTT
ATGAAGTCATCTATITTCTGGGCTACTTCATTTC-TCITTTTCAACTTCTAATAAGCTTAACCTAAGTGTCP_CGAAGACGAGA
cn TGTCACAGAGGTCCACTCAGTGACAAACACACACTGAP.GGCCTGAGGGAAGACTGAGGACATGGGCTCAGTGGTGGCT
TCCCAGTCA
N.) CO TGGTATCACTGGCATGGACCTCTGTCCGGCAGAGGTC-TGGACTGGP_GACCAGGATTCATGCTGGTCTGGAACAATGACATTGCCAAC
cn co TTAAGACACACAAAGCAGATTTTCAGAAGTGTCTGGTCAP.GATAP_CATGCIGGCCAACCACAATTCCTAGAGTTAII
GAGAACCTTAA tri AAGATTACCGCTCATGCTAAAAGTATGTAAAGATCCCATGTACAGTATGATAGTGTACTTTTITTAAAGGACTC-TC.AATATACAAAA
CT T TAAAGATTAPAAACATTAAAAATAA.AARAA
rrl N.) cn SEQIDNO.:21 SEQIDNO.:68 N.) CCTCGCCCCGCCTACGCGGGAAC CC.AACCGCGGCGACCGGACGTGCACTCCTCCAGTAGCGOCTGCACGT
CCTGCAATGGC CCGCTA MARYEEVSVSGFEEFHRAVEQIIN
co TGAGGAGGTGAGCGTGTCCGGCTTCGAGGAGTTCCACCGGGCCGTGGAACAGCACAATGGCAAGACCATTTTCGCCTAC
TITAcGGG GKTIFAYFTGSKDAGGKSWCPDC
=
TTCTAAGGACGCCG-GGGCGAAA_AGCTCGTSCCCCGACTGCGTC-CAGGCTGP.ACCAGTCGTACGAGAGGGGCTGRAGCACATTP-GTGA
VQAEPVVREGLKIIISEGCVFIYC N.) AGGATGTGTGTTCATCTACTCCCAAGTAGGAGAAAAGCCTTATTGGAAAGATCCAAATAATGACTTCAGAAAAAACTTG
AAAGTAAC QVGEKPYWKDPNNDFRKNLKVTA
rn AGCAGTGCCTACACTACTTAAGTATGGAACACCTCAAAAACTGGTAGAATCTGAGTGTCTTCAGGCCAACCTOGTGGAA
ATGTTGTT VPTLLKYGTPQIGIATESECLQ.ANL
cr) CTCTGAAGATTAAGATTTTAGGATGGCAATCATgTCTTGATSTCCTGATTTGTTCTAGTATCAATAP_ACTGTATACTT
GCTTTGAAT VEMLFS ED
TCATGTTAGCAATAAATCATGTTAAP_AP_P_ACTGGCATGTGTCTAAACAATAGAGTGCTATTAAMTGCCCATGP.AC
CTTTAGTTTGC
CTGTAATACATGGATATTTTTAAGATATAP
kGAAGTCTTCAGAAATAGCAGTAAAGGCTCAAAGGAACGTGATTCTTGAAGGTGACG
GTAATACCTA.A.AAACTCCTAAAGGTGCAGAGC
r) ___________________________________ _ ______________________________________________________ a E., >4 >4 4 tee en pao z 14' 2 6 [:4, ,t1 EF, Fi 'tin' ,Z' [I 8" CE!: 6 f=1 ' ix, E-0 tx4 P-I Cil Eir o 0 UHIZC.1U fe.1M
0 or 4 u F Cil 0 P4 Cf) 4 F F 4 al (.1/-14./0/-14e0tZ cc) P ,, .` ' c3 CO rar 0 H 41 0 ... ..., Z
H
or co>crrucni-raNzH
E.) 440E-.04E.E.rPCJ004U4U0H4E. 4 U
00E-ruEruo4 UHHOHUCJOHE.0440H
4E-.00H000 UE.E.C.DHHOC.DE.40E.U<C) CD C..) u 4 H /4 0 U E. U E. 4 /4 C./ E. E-. Ei E. U E. 4 4 E. H
OPCDCDP0H4 4 404 rt. C-, (..) 4 4UHUE.C.DHE-e 4 0 Er Kg U o 4 u 4 u 4 o o o Er u U F K4 F E.
8 E-, 2: /,Yt r g g 8 8 6 8 0... * 00 8 2 r 04 8 4E); 4444 E
04 u u u c.9 o E-r 4 u 4 ,r, 4 E--.00U0 u U, 4 4 --r) -..r, g cE?, p, t 8 4 '6 8 ( 9=5 r, 'd 6 i:: 8 EU (0) (,- )4 8 [Ell UP EreE.C./ 4CDUCDE-1 .e,CD O Ce 44,HUCDUH u E.
4 U El 0 C., 4 4 H 4 H E. 0 4 C9 E. H 4 H C, C.) el. 4 C/E.H HE.CJC540 E.C..1.0 4 r, E. C.) CDUUU
ti El r.i 8482 ,1 4, v6P r, EY. b" 'E5. .1 8Ø184V-.1-1 1 E. u 0 4 , 0 0 0 u Er , 4 ci 4 Er E. Er 4 or Er 0 0 .,0, U.OgFUUF 4 E. (9 -4 4 4 E.HPHUHH/4/4E-14 Ig6c,..),4H/E,c9CJE.U. UU. C) 4 E.H4E.HU0 4H
C1E.CJE.1E.V. 8 Et, 2 f,-:: 8 6 c,,-49r-18ggreE/:: 8 8 8 ,'¶ 8 8 8 8 2 0. '6 5 c,' Ft: 8' 0 6 8 8 8 Et: 8 El '' ',.-4 Et: * E,"El '6 r-: 8 8 8 8 '6 cE.--.9 8 8 [--: 8' 2 .), " 2 8 V. , c jr- :
Ec : .1 8 ii: E;;; ._,;) ,v ,,E.. [11 0 _,,., U 0 E-, 0 0 E-. E- , H E-/
E. i...,,1 t-j, ,4 0 0 E. E. U U 4 E. 0 r.E.--/) 1 Eli (C-.).1 (5 E-.) Er-/) E. 0. * 2 ..=; E.
.er, 4 H CD -4 Ce KJ U. E. CD, A. 0 0 E. C., C.) U E. E. ,-,q CD C..1 H 0 0 0 (-) 4 4 4 KI, Kg E4 0 0 U F F. 0 4 04 E. U U E.
H40 CDUC.D. Pr F H44E.UUHHHE-.4E.E.Ch .4) Ell 8 Pi 6 .,L3 , ,&' LI 2 t; - L ) , 5 gu pu f=-,.F3: 9.() r Et: g: .), EE:: r_: i:i ,e,' ,,:,), O00 H0E-e4 .44.')FUOF t-'0,-,P 40H0E.UH
E. 4 E. CD U 0 0 0 0 H E. E. CD (9 E. 4 U 4 Er E. 0 . 0 E. 0 4 f'- .) /L) '6 :4, 8 8, 8 8 8 0, 4';
.,,,,(1 n''. 8 44) fl 8 8 :2 8 ,Ejii E,="g` L'D t i H00E/U040040E. ll , C.J E.U00,,H g4CIE.0 4 C.1 0 4 E-/ E. 0 4 E. el, 4 E. 4 CD E. U 0 4 0 o Er E. 4 0 4 Ej, el..! F.) E.:C' il 8 8 V. 6 4 8 8 El 8 b? 8 8 8 8 6 8 8 8 6 E -. E. 0 U C ./ E . CD 0 H 4 4 e5 0 E . E . 0 , r_ ." 1 [7 : !,. , [_q, ,E7gi r, 8, 8 rE--.) 2 'E-4, $ 8' u. i-4 r6 8' 4 8, 8 o E. E. u R ED u .
I
* u 111 8 8. 'C.' 8 u 8 8 8 8 V-.4 -,' 8 8 (c)D E;t' id CEi E4' ELIE ECDPSFE4'E 6680,868E,A;.8i--1288E.
1--,' 0 8 'E--: 8, 8' .-', 8 8 ''. r-: 8 ',-3 '' 8 8 8 t.-: ,c.-Z f.. Ec-,' E,;'4 ,1 6 8 'El u t".' * 6 8 6 * -.' r. u Eg C,4) ,Ei 8 8 2 8 8 8 ,,c ., 0 E., 0 0 /4 U E. CD U 4 CD 4 U E. U 0 E. U E. KC 0 H H
r E -.) E4 ,?4 E- .- : t5 E: : . .7 i [ 7 '6 8 8 8 2 Et 6 8 8 flt' -.91 01 E-' CDHU,-, 000.cCJE-.4E.E.U0E.E.E.CDULeHE.
I
CD 4 0 0 H E. El La (.1 A -4 0 Er p. sd. o 4 ce.-15 u 6 6, c-.-! ,,,,, ,,E,9 E=;-c`
HCDH00ETE-..De44H Liu 44 õ.c-.1. . _ ' 0 4 C./ E. 4 E. CD E. 0 4 E. E. E. E. U 6 t, r..., 6 re, ,t--,,. t., ,._.,., / it'u EE -,/ t' H E. F EE-4 1(Ch ECY') E )/ 8 [1 EC ', tin H) (E 2, CE '8 E' 4 F.9 /L,-11 8 tl: 8 8 u 8 8 8 6 EE---'. 6 '0' 8 il E-. 2 V-.' 4 r, 8 O440 4. CD CD CD E. H E. E. , c[....), EE.3 E. E,o.-, E., ,c..-4, 0 Ec-,, Ec-jr Ec:., cc!, o 0 E. 0 0 4 0 0 H 0 4 C. V, Fi ,f:) 8 6 E. 0 (.7) H rõ
ci: El 0 0 ., 4 ' 0 , 6' ' 2 8H 81 ' - '8 . 4 .1 . 8 .-.4 ! -, 3 1E - ' r.
7 EC- :( 9 r ,E ) 8H UC 9 ' -. . I .0 6H X * - ' I : 1H SH H8 .*E I
u 0 u E. E. Ci C.) 0 El 4 E. H 0 4 E. I ET, C..1 0 C.1 4 0 E-e E.
EJ 0 4 0 4 u 4 Er 4 0 ,E,. E.' CJE1HHE.Et,.(2 f -I 2 ,F,- Et: V-: 8 -,' 1 w &: 8 4 8 u El u r: 6 8 8) 2 E-1 E. n C4 5 y,, ku k" E,:4' -). B E 8 E;r:., ii 8 Ec-_,"E-4 Eg 8 E,--: b' 8 V ', 6' `E-_,) CV ,-, c-4, ...= %, CJ U E. 4 E. 4 4 CD 41040E-ruE-1 E. F 4 (5 0 004UE.004CJE.E.40 0040U 4H4E.
. E-14H4HOU4E-144 4H00_4440HUE.00 c)C.)Q00E.E.CDHpUL)C.)4E-, 4pOrEc, Z
O P4 '6 c; 8 6 P-, 8 6 i--: 8 8' 8 r. 8 ',J. ',=-'t `,4 8, 8 8 8 r: 1-_.= .A
H
a 8 0 6 8 8 8 * `,,) 6 b' 8 E' Vc V: Et: 8 8 Cf.) [7 r7 'E4.: 6 Et: '6 2 E4 `E--,) 1 Pi 8 4 8 8 6 8 8 ,,.. ,E.t 6 8 `..": 2 8 8 8 8 8 r, 2 O _ SUBSTITUTE SHEET (RULE 26) SEQIDNO : 7 0 1,4 CCTCCTCTCCCTGG CTTTTGTGTTGGTGCCTCCGAGCTGCAAGGAGGGTGCGCTGGAGGAGGAGGAGGGG
GGCCCGGAGTGAGAGGC MAQP ILGHGS LQPASAAGLAS LE
ACCCCCTTCACGCGCGCGCGCGCACAcGGTGCCGGCGCACGCACACACGGGCGGACACACACACACGCGCGCACACACA
CACGCACA LDS S LDQvVQTRIFKI I VIGDSN
GAGCTCGCTCGCCTCGAGCGCACGAACGTGGACGTTCTCTTTGTGTGGAGCCCTCAAGGGC-GGTTGGGGCCCCGGTTCGGTCCGGGG VGKTCLTFRFCGGTFPD KTEAT I 1,4 GAGATGGCGCAGCCCATCCTGGGccATGGGAGcCTGcAcCcCGCCTCGGccGCTGGCCTGGCGTCCCTGGAGCTcGAcT
CGTCGcTG GVDFREKTvEIEGERTKvQviNDT
GACCAGTACGTGCAGATTCGCATCTTCAAAATAATCGTGATTGGGGACTCCAACGTGGGCA.AGACCTGCCTC-ACCTTCCGCTTCTGC AC-QERFRKSMvERyyRNvRAvvF
GGGGGTACCTTCCCAGACAAGACTGAAGCCACCATCGGCGTGGACTTCAGGGAGAAGACCGTGGAAATCGAGGGCGAGA
AGATCAAG VYDVTKMTS FTNLKMWTQECNGH
GTTCAGGTGTGGGACACAGCAGGTCAGGAACGTTTCCGCAAAAGCATGDTCGAC-CATTACTACCGCAACGTACATGCCGTGGTCTTC AVPPLVPKVLVGNKCDLREQIQV
GTCTATGACGTCACCAAGATGACATCTTTCACCAACCTCAAAATGTGGATCCAAGAATGCAATGGGCATGCTGTGCCCC
CACTAGTC PSNLALKFADAHNMLLFETSAKD
CCCAAAGTGCTTGTGGGCAACAAGTGTGACTTGAGGGAACAGATCCAGGTGCCCTCCAACTTAGCCCTGAAATTTGCTG
ATGCCCAC PKESQNVESIFMCLAcRLKAQKS 0 AACATGCTCTTGTTTGAGACATCGGCCAAGGACCCCAAAGAGAGCCAGAACGTGGAGTCC-ATTTTCATGTGCTTC-GCTTGCCGATTG LLYRDAERQQGKVQKLEFPQRAN
cn AAGGCCCAGAAATCCCTGCTGTATCGTGATGCTGAGAGGCAGCAGGGGAAGGTGCAGAPACTGGAGTTCCCACAGGAAG
CTAACAGT S KTS C PC
n.) AAAACTTCCTGTCCTTGTTGAAACCAAACGAT.ATAAATACAAGATAAATTATCACTGGAGTTTTTTCTTTCCCTTTTT
TCTGTGcCT
CO GCATAATGCTGACACCTGCTTGTTTCCATAC_P.AATTGATATCAAAATAAAATTTGTATAGATT
.AAAAAAA co cn ¨4 rn Cl) rn rn co n.) r¨
k.4 SEQIDNO . : 2 4 SEQIDNO . :71 GGAGCGCGTGAGGCTCCGGCGCGCAAGCCCGGAGCAGCCCGCTGGGGCGcAcAGGGTCGCGcGGGCGCGGGGATC-GAGGACGGCGTG NEDGVAGPQLGAAAEAARAP...EAR
GCCGGTCCCCAGCT.
CGGGGCCGCGGCGGAGGCGGCGGAGGCGGCCGAGGCGCGAGCGCGGCCCGGGGTGACGCTGcGGCC CTTCGCG
ARPGVTLAP FA PLSGAAEADEGG
CC
CCTCTCGGGGGCGGCCGAGGCGGACGAGGGCGGCGGCGACTGGAGCTTCATTGACIGCGAGATGGAGGAGGTGGACCTG
CRGGAC GEMS FIDCENEEVDLQDLPSATI
CTGCCCAGCGCCACCATCGCCTGTCACCIGGACCCGCGCGTGITCGTGGACGGCCTGTGCCGGGCCAAATTTGAGTCCC
TCTITAGG ACHTZPRVFVDGLCRAKFESI,FR
ACGTATGACAP.GGACATCACCTITCAGTATITTAAGAGCTTCAA.ACGAGTCACAATAAACTICAGCAACCCCITCTC
CGCAGCAGAT TYDKDITFQYFKS FKRVRINFSN
GCCAGGCTCCAGCTOCATAAGACTGAGITTCTGGGAAAGGAAATCAAGTTATATTITGCTCAGACCTTACACATAGGAA
GCTCACAC PFSAADARLQL.HKTEFT,GICEMICI, CIGGCTCCGCCAAATCCAGACAAGCAGITTCTGATCTOCCCTCCCGCCTCTCCC-CCAGTGGGATGGAAACA_kC-TGGAAGATGCGACC YFAQTLH GS S HLAP PNPD KQFL
CCAGTCATAAACTATGATCTCTTATATGCCATCTCCAAGCTGGGGCCAGGGGAAAAGTATGAATTGCACGCAGCGACTG
ACACCACT IS PPAS PPVGWKQVEDATPVINY
CCCAGCGTGC-TGGTCCATGTAIGTGAGAGTGATCAAGAGAAGGAGGAAGAAGAGGAAATGGAAAGANTGAGGAGACCTAAGCCAAAA
ATTATCCAGACCAGGAGGCCGGAGTACACGCCGATCCACCTCAGCTGAA.CTGGCACGCGACGAGGACGCATTCCAAAT
CATACTCAC TPSVVW11.7CESDQEKEEEEEMER
GGGAGGAATCTT
TTACTGTGGAGGIGCCIGGTCACGACTTCTICGGAGGIGGCAGCCGAGATCGGGGIGGCAGRAATQCCAGTICAT
MRRPKPKI/QTRRPF,YT.PIIILS
GTTGCTCAGAAGAGAATCAAGGCCGTGICCCCTTGTTCTAATGCTGCACACCAGTTACTGITCATGGCACCCGGGAATG
ACTTGGGC
CAATCACTGAGTTIGTGGTGATCGCACAAGGACATTTGGGACTGICTTGAGA.AAACAGATP.ATGATAGTGITTTGTA
CTIGTTCTIT
TCTGGIAGGTTCTGICTGIGCCAACGGCAGGITGATCAGTGAGCTCAGGAGAGAGCTTCCTGITTCTAAGTGGCCTGCA
GGGGCCAC n.) CO
TCICTACTGGTAGGAAGAGGTACCACAGGAAGCCGCCTAGTGCAGAGAGGTTGTGAA.P.ACAGCAGCAATGCAATGIG
GAAATTGTAG El) CO
=ITC CTI'T
CTICCCTCATGITCTCATGITTGTGCATGTATATTACTGATTTACAAGP_CTAACCITIGTTCGTATATAAAGTTACA
tri CCGTTGTTGTT'ITACATCTITTGGGAAGCCAGGAAAGCGTTIGGAAAACGTATCACCTTICCCAGATTCTCGGATTCT
CGACTCTTT
GCAACAGCACTTGCTTGCGGAACTCTTCCTGGA.ATGCATTCACTCAGC.ATCCCCAACCGTGCAACGTGTAACTTGTG
CTITTGCAAA
M
AGAAGTIGATCTGAPIATTCCTCTSTAGAATTTAGCTTATACAATTCAGAGAATAGCAGTTTCACTGCCAACTTTTAGT
GGGTGAGA.A n.) ATITTAGTTTAGGTGTTTC-GGATCGGACCTCAGTTTCTGTTGTTTCTTTTATGIGGTGGTTTCTATACATGAATCATAGCCAAAAAC
TTITTIGGAAACTGTTGGTTGAGATAGTTGGTTCTTTTACCCCACGAAGACATCAAGATACACTTGTAAATAAAGCTGA
TAGCATAT n.) ATTCATACC7GTTGTACACTTGGGTGAAAAGTATGGCAGTGGGAGACT.AAGATGTATTAACCTACCTC-TGAATCATATGTTCTAGGA
AA.A.GCTGTTCCCATGTCTAACAGGACTTGAATTCAAAGCATGTCAAGIGGATAGTAGATCTGTGGCGATATGAGAGG
GATGCAGTGC .. co CTITCCCCATTCATICCIGATGGAATTGTTATACTAGGTTAACATTTGTAATTTITTTCTAGTTGTAATGTGTATGICT
GGTAAATA .. n.) C GGTATTATATTTTGGCCTTACAATACCGTAAC_.kATTITTC-TCATTITGAAATACTTAATGCCAAGTAACAATGCATGCTTIGGAAAT
r-m TTGGAAGATGOTTTTATTCTTTGAGPAGCAAATATGTTTGCATTARATGCTTTGATTGTTCATATCAAGAAATTGATTG
AACGTTCT
CAAACCCTGTTTACGGTACTTGGTAAGAGGGAGCCGGTTIGGGAGAGACCATTGCATCGCTGICCAAGTGTTTCTTGTT
AAGTGCTT
*-7-;
TTAAACTGGAGAGGCTAACCTCAAAATATITTIITTP_A-CTGCATTCTATAATAAATOGGCACAGTATGCTCCTTACAGAAAAAAAAA
A A AW IA ARA AAAAAAP..21_ AAA
;==
SEQIDNO . :25 SE Q IDNO . :72 14 ..., GATTGCGAGCCAGGAGGAGGAAGCC GGCGGTGGC CCCGTCAGCAGCCGGCTGCTGAGAGGCCGGTAGGCGGCC-GCGGTCCCGAGGGG
--, CGGCGGCCGCGCTOCTCCCTGAGAACGC-GTCC CGCAGCTGGGCAGGCGGGCGOCCTGAGC-GCGCGGAGCCATGAAGCTGTACAG CC T MKS, YS LSVIZYKGEAKVIILLKAAY 'a CAGCGTCCTCTACAAAGGCGAGGCCAAGGTGGTGCTGCTCAAAGCCGCATACGATGTGTCTTCCTICAGCTITTTC
DVS S FS FFQRSSVQEFMTFTSQLCAGAGATCCAG Co4 IVERSSKGTRASVKEQDYLCHVY
COTTCAGGAATTCATGACCTTCACGAGTCAACIGP_TTOTGGAGCGCTCATCGAAAGGCACTAGAGCTTCTGTCAAAGA
ACA.AGACTA 4=
TCTGTGcc P.CGTCTACGICCGGAATGATAGTCTIGCAGGTOTGGICATTGCTGACAATGAATACCCATCCCGGGIGGCCTITACCT
T VRNDSLAGVVIADNEYPSRVAFT
GCTGGAGAAGGTACTAGATGANITCTCCAAGCAAGICGACAGGATAGACTGGCCAGTAGGATCCCCIGCTACAATCCAT
TACCcAGC LLEKVLD E FS KQVDRIDWPVGSP
CCTGGATGGTCACCTCAGTAGATACCAGAACCCACGAGAAGCTGATCCCATGACTAAAGTGCAGGCCGA_ACTAGATC-AGP_CCAAAAT ATIHYPALDGELSRYQNPREADP
MTKVQAELDETKIILHNTMESLL
CATTCTGCACAACACCATGGAC-TCTCTGTTAGAGCGAGGTGAGAAGCTAGATGACTTGGTOTCCAAATCCGAGGTGCTGGGAACACA
GTCTAAAGCCTICTATAA.b_ACTGCCCGSAAACAAAACTCATGCTGTGCCATCATOTGATGC2-,' GCCTGCCAGAGGCCCAATGCTGGAA ERCEKLDDLVSKSEVLGTQSKAF
TCGCAC CAT CATTCACATCAGAACTGCAGCCCCTGGA.AAAGAAGAGACAGCCATAC-ACGAGGAGCr=AGAGTGGGGGCAGACTCGC CA YKTARXQNS CCAIM
TTTITATITTGAAGTTCCTOCGAGAAATGGATGGTGGAAGGGTGGCC-AATTTGAGGTCCCCAAAGGIGTATTITTOGGCAAATGAAACCATAAACTCCGACTGGCTTCTGTAGATGCCAAAGGCCT
CTITTTCA
Cl) GCTAACCCTOGGAAGGCTCTGIGGGAGGGAGGTCGGAGCCAGCTGTTICTCCATCITTGGTATATCTITGGATCTTATT
TGTACATT o C
tv CO
AATGATATTAACACTCCAGTGGGGGGTC-GGGAGTCCCTGATGCTAGGGCTGGGGIGOGTGGAGTTTGAAGACTCTTGGGAAAGCCTC ...1 Cl) TCC
TGGGGCCACTGTTGGGGGIGGGAGTGAGCCCACCACAGAGGCCACAGGCAGGCCCCCACTTCAGGCCCAAGGC
CTGGGGCGGGG .. _ co GOAACAGTCACTGOGTCTCAGATTCTGAGACTGTTOTTTAGCTTACCTTICTGCTAGGATIGC-CTICCCGCAGAGGGCAGGGCCCAT (V
.) G
o.
C
CCTAAGCAGCTTCCAAGTCCCACAAAGGTGGCTTGTGGGAGGATITGGRAGGAGCTGCATTGIGGGCGC-GGAGTGIGTGGGTTGGGT cn ¨I
TCGTACCAGCAAGTAGACTAGGAACTGAGCCCAGGAA.AGGGGGATGTITTCCTGGTGTTTGGATGGTCAGCTOGGAGT
GICCATCAT
M
n.) CAGGGGAAGATCAAACACAGGTGCACTCAGCTGCCCAGGGCCTCTOGGACACTTGCCTTGACTTGCAACTTGCCTTGAA
Cl) 1-, TCARAGCAGCAGGIGCTGIGGTCTCTCAUATTGATITTTATTTGACTCTGTGGCTCTAAGACTGCCITGA.A.CCGCCT
GAGGCCTAT tv M
GCATcTGAACAAGTGGGTCTCTCCCTTGAGC_ACCAGGAGTGGOTGCCAGCCGGCCCCGAGGATTCCCAGCACCCCACC
TATGGTCIT I
o M
GCCAGCATAGGCTTGCTAGTTCCTTCTTGOTCAGAGGTAGCTGCAGAOGGGGGAGGCCAAGGOTTTGGTCTAAGCTGTG
CCCTGCCA co I
CCTGGCAGGAGGCCCACTCACTGCCCAAGTCATGGCAACAGGCTGGAGCAGCCCAGGAGATGGGCCTP_AAATGTTCTC
GATCCCTTG o X c GGTCCTAGTGTTATGTTCCAGTCTGCCCACCTGTGCTCAGGATGCAGCCCTGGGATCCAGCACCCATGGAAGCTTCTGC
TGGGATGG tv r TGICACCTATGGGITTTGAACC_AGTGIGGTATGGICCTTGGGAGCTCTGCTCTGAGCTTGCCACACTGCTGAGAGCAC
CCACTOTCC
rn TGACCAGAGICTCAGTGGTCCTGACCCCCAATGTGGGCAGGGGCTGGGCAGGAGGGTGGGGICTGCTGTGGGTTCAGAG
GACTCCAC
ry cn CTCCTGGCTGGTTTACCTGCTGCTGCCCATTTT CTCTGGGTACTCCEGGCCAGAGGAC
TTTAGCCTACCCCTGAAGAG CCTGTCCAT
.....
GTCATTTTCCTACTGCCATAGATACCCTAAGCCCAGGOCCCCTTG.AGGCCCAGACTCAOCCTGCCCACTGGTOCCGGA
GACGGAGTO
GAGTGGGCCTGGATCCGAGGGATGCTACCTCTCCCTTTC
CCACTTGAGGACCCTGGOGAGAGATGGGGGCGGGGAAAATGGAGGTAT
GAATTTGOGGTAAGAGGAAGTGAGATCTCCGCTTGCAGGTCAGCCCCTGCCTTGCAGGGCC-GC-CTGGCTTGACTCAGGCCCTGTGAG *10 n ATAGAGGGCCCAGCCCAGCCCCACCCACAGATCCCCTGCTCCIGTTGIGTTCTGTTGTAAAICATTTGGCGAGACTCTA
TTTTAG TA
-i ACTGCTGCCTAACTTCCCTr2TGTTCTATTTGAGAGGCGCCTGTCTGGATAAAGTTGICTTGAAATTTCAAAAAAAPAA
-AAAAAP.A n - -_______________________________________________________________________________ __________ k=J
--A
kJ
...6 =
(9z 9-mH) 133HS 3iniusens anan9n0o4392,nn9n.30nnon9n9009,annnn in 2,99,0n0 9.- CI H 0n09-9.3n9,009nnn02,9,02,no9,0 oi na0onn02.002,n0.30(30annn.3>nopaponan o . (.70oP ,.c)onaa.35,A.an,b,n6-)a)...- anaPP:'06)apna H
0 .--3n0.39(30.3n.--399.-309.3909-n0an.3n9innna o an0nnnhnonnroonann=00nno.--3n9,annn.--3 9.30.30nnnnnn nn9-na9-02,nn2,9,-36)o6).3 ,,c.) o paanr).,,,>a,,o, aap>6)6) a 0 0 0 a.. na a> a.3o6) =
nnnnnoci)oonanoonnnnon, narann =
a .- a anan2,02,9029,- 0 H 9.-nny,n "D, 0 0 0 n H 0 P= n n NJ
al OH annanonanoo.3nonn00,3nHpn00.3n -,06).,->c.,a,-3n.-36).-.3nacinnnaanolopn.-6,n H b, x..po. 0 0 4) a. .4 Is Is a ,-, 4, n Is a 0 0 0 Is H 0 Is 0 Is 0 ),,, --3nn 0 r) a n a a n o a .p.. a a 0 o o n n n a a n a a a a a n a a 2,.--3nn2.nnann.-390.00.30009,909,-n09-onnn0 n.-3n2,009,009.3.3n996)9,n0n 99,099 02,92,n9 nonnonnnfrInna.-3.30a0.309.00.3n90n0o0no 9, 2, OH 9. 9 n 9 n a 9 a n o n 2. .3 0 n ). 0 =., 6) oaaonaan a ona ananon000nnaonnnob.nnnonno0nn O0/000.3no2,906)6).-3000.39,n0ao0n9:0n2,0nn 9n02,90000>ono2,n0 ,.--3tapnann.-3 a> :0,- a4),.,nn C) 0 y, o 0 o 0 0 0 .3 n 0 0 y, n n 6) n 6) o o n .3 n 6) 6) n a Is a Is a onenonnn09,9,annnon9n.30)-30n509, H 0 H
D. 0 D. 0 H D. :D., 0 > .3nn6)e32,0.3 H n a n a a a a .-3 a ,r, 0 4) n nr-32.0JJnonnannnonnanoonn .3 .3 n o n o a a n a naoc)6),a0non2,92,99=0nnn09.- nan9pns.nno .3 =,n)=,,,PP6-ipn,-3.-3no6)10'bnnaaa>nan;0.-anca a6).-3 anao .- anon.3.-05,A0n6)n6)n0onnn9a09 C) 2. n n - '0 0 9 0 a n n o a 0 0 o .3 2. 0 y, J, 0 0 0 n 'p 9 0 n 0 a oo,_3000y,,n9-*ppn.3aoap.-3ar)n n :r. n n o anan .3 o a n n a a .3 a as n .3 o a a a a o n n .p.
naaann>nna6-19-nopon9n-309,-loon9 90 a nan:p.p .,.2,0n 91-30.32,09.9.9(3.300n0nno 0 nnanonaaanan, 0410000000).-3000ann0 06-)00:,.>a=,4.> anra).,nonnooann>nno>xi-n 1, .:naanonn2,0,--3 nn0002,09,- ,-3)=. .-3.-3.3..- an annnnnnnanno naaannaa oonoononna n=,(-)5.D=,anannnon,..6.1a>,..a,n):,,an.-iann Onan09,-399.19.9.36)nano>apnPaoa:roao6)6) C) - 0 Is 0 n r) 0 4-) 0 0 0 0 a n c) o a 0 a n a a Isb 00063.3.3a no9n9002,00 -9na.--3onn2,9no9,anb, F-1.-34-).-3,-3,An C) Is a .3 n H .3 Is > S). ),, > 0 P 0 1-3 ,-3 a , , , r ) ) 0 Is 15p a a 13 a Is 6) 0 =,.-3nonnvonapannoomnonnnoonoanna n>2,0 n9 ar06.).too.onnoaaanann.bbabb.-ib 1 nn.ana r) > Jr,(33-nn 99 ..-36-)p> a aonnagb 0 I-) n:0(,).-3annoa ,=,-6)nn 000nnoonno>n nna ,n ant0(30:0.30oD,,na>o 6) nanbnaanna):,.3non )nonp,..-3 .,nn6),--3.3 ,. .oc) b.a:l..-,on.-3no-3()15,A6) C) Is n n H 0 0 a 0 0 n n a n n 0 D. 0 0 0 .3 n 0 0 0 n n n n 0 0 0 no2,00a9-9n9n909nonan99,09,0n99.3nn90 99,32,(39,906).-3.3.3-3a)%.-1.-3na.-3>n,--3annon anaanoannaannananonannaannbnpba C)06)6) o n .0(300n2,00n0o0o2,a2,a3ann.-305,:'000y.0 *1 .v 0 0 4") rt 1,. nonnna,--30.3nno.332,10 up.3n9-on ann.-302, Jr,nn9nn000(-3(30.3 9 nannn.30 =,ap,--3 6-1.3 aHnf-3,,-=,,,a,,PPaP) .3 a a a .+- 6,6)6) annpnn 0 ra 6) annonnan n n H n 0 C) .4 0 n 2, o n c-3 0 -39n 2-,n:02,nnn>onn9np63.-3.---39,0 00(3'002.9 :00n -,.-30-3.-3:0;0.-in>'.0pnap,0n;pna,.0,-3,-3ob'paa nonp 0 .3 .3 nnoonnoonaannn00000n o anon aaaacia),,a.-3)=onaa.36-)anaaaroa96-3 009 n 0 09,n92. a 0 .-3 a annn .-.3 .3 >, a a > a n H 0 0 P= ,,, 1 C) 9 n nn00n.30n.lon.3n2,nr3002,0nnn o (73'30 9.0n0n0n9o2,9ann02,009n2,0aa9-2,no G/n On06-32,02.09.3-3 :09nn2.0J,,209,02,09- 0 a n x, n nnnnan 0H0r00000000D.00H00000 0 0 oannaano> naapon ,- oPnnno - no2,9n0o noaaPaa>41 >>5,,pnaa0 6-)c-Y.3PnP a> apnana C) n a n a 0 0 0 r.,) 9no99nn a n a 0 0 0 0 0 0 (2, G) 0 :?=, 0 r) n npa>c)06).nap->ana:,.-3.31-3nbab,annnynnr) a)..aa:r9>'pt-3.-36)Pan.-3.-3n a 6).36,n)d .,.,a o, ,nn>>can aaononao>nanpanannoa 0 (739- annn9on9n 2,909,2,nonnrn.06)aannnn:woon'ivbb 6-) > nno .-3.3.36) a x, c) ;w 4-) > H' ..- on:00.3Paana b.-3.3),a ann on>noonan 0000:voaoaoaanannnononn onatapnnov.-loano0naG)044.3,-Ionana),, 0 H )-3 a -,a>6--..,6) .3 0 0 0 :v H (-,, P' tap ana6....3>a 06) a a a a 0 0 6) 0 0 H 0 0 0 0 0 0 0 0 H 0 n GI 0 0 >pr 0 0 0 r) O cl, a (-,) n n > n a a n ono>. 2,n2,0n9onnaaay,nnn 00no9.--3:0nHnana:t. - P ,,,:l.,,--3n.-3P>oantn,..--3p n na=pannnnanna a:Nana/Dana =,..3.-)nonnnanP
aoa,aa:onnanb)Japo.na oona.3 ono ,,a6". , 0 0 0 > 0 .-3 Han'pa.3>nrinannal-3.3.--3n02.02,99.32.nn nOn0nn00.3non90nnno6)na9J.9 ,-3 =,Øi-annan - ________________________________________________________ Al 1.1 r z x pi CA 10 tn H 0 0 0 r a '4 tol p r<<
V 0 0 a on a < p 0630 r tri 21 r tyi z ,t, pi pi H ti < ,-ti tn V' Y...) Cn .3 .ti .. H
tn H Pi 0 0 ..3 to to o ).. o zt x z x 'to, toi :b' Pi H PI t. a to > a b to to o x ..., r ar rltitoiko<arNNtxtro.-3 tpit-tzto z 0 En 1-C t=i z to ..zt 41 Pi a . 0 Col En 70 XP P.HZ
tr1 õrt,, 0 0 C b toi tri Pi 0 H tC 70 )-4 hri N ,,i Pi i, ,-.3Hxf--iN < azx .1,,v] tri'xi 63.-4z63 .<xpqr ,-1 H 0 0 0) ED, M A htl H )0 1-4 trs n r n a to a H Pi co to Pi to -4 H.41-1PdPotong .,--3, W CO toPNni orator ..1-ico6)xxl-Eit.18 ,,, 61 <H H t-' to .--. 2, pi H li apoiroirtotri H <ro 63<663HatoitoN-4 ri n) H X
).) ).< H 0 +el H tn ,ro 0 D. < En H 0 Pi H 0 H =
0 ,r.-.3 ow..1 10 H . :.,q c=16-), Hi 0 tn En 64 6') 0 X 4 tn PI .< 0 0 0 H tg. H hi '4 ;-3 ,o 9 ad hi i--. ,o rd n o I-I C,J < 'n 0 Pri I.<
0 0, 0 H < PD D:, t=1 Pi :4 x ,o a .- tr, a H )0 H P. tu En X ..n .3 to ),,,- ql G) 10 t, tn t-f t=i <.4Hor a or, tIN =Z H b .3 7d1-101 1=1 t-I,vP;) Ai HcNn ti V) .3 t7 ,-3 > HHH )--4). H7J1-10C).ti tianx.oior zz z z o r r H Ea toi r n H r lo xt z to .- z rol o H z p .3 N X Cfl tl 0 1.i riPit-taa= .,=at-.ti-.Norz .3 7elt,00ct. r .1-tt.i.-ir x r-Ixtqtiapitri x?.,colotaNxt4 o,xPz1 En 0 D=, 0 H ND 0 moor 0 0H0011:100<trIXH z Pi t.i w Z1-060/LOOZ OA%
01Z000/L00ZVJ/Icl [1,1 P `), 0 .4 H 01 a a, g 1.71 H Q E'1, 2 HP4>-.00:rEo HEXION01-10M,-4>a) ;110 1.,..UEnE.H.a,a1 U/9.E.1.4...x0r1.,rot-I r:14 Q N
rCli col Evl 6' 'Eli Z' 2 N
Walt...WED.-4H '-N 0 ;.. `j)" N '3 1 5 2 q Di 2J`-', ,n)g; .: ,(:), c,4 ,1 iu r' ., c' p 8 6 8 P. 2' ill 8" nF.. .7._ Cil E 2 3 P r.... 6 8 ai I E. HUUUHUU
U E..) E. < el 8 6 El 8 8 8 El 8 8 ..e 6 8 6 6 8 6 8 b' '6 8 6 8 8 L') 6' U E. t", E-, E-. U 0 g H u 0 F Er H F. i6 U(.UU ' 8 ,V, '6 6 8 b' .e) t.", t.; E,-e' 6 U(.90,0 0 E.) E. 0 H u E.
U U04:0 (<; rl. E. 1-' E.E' 2 4E-ic.2u C., .1: () C.) . 0 0 CJE.U0E.cieUt. H0000 0 HI V F i) (E 2, t - .7 , uE.0E.NUU0<E-.HbrdHOS,C?E-j'!'j U U..Ale.,..1;"E-.'3; 8 .`' 0 0 6" E-.00E.HH
V. EC.) EET 1 rY' H 8 ' 8 8 E... 8." ..,- 8 6 E. E. 0 < < 0:
< H E-, < HO
U 0 < 0 < 0 < ,t.4 80,`,-e'',-,i'ElaltLe) 6,t10.68,1Te:,,1 E--).
E.... 0 E. < E. E. 0 0 E. < E. 0 u 0 E. 0 0 (-. 8 8 6 8 '1 l E 4 .()=
;..0 5 = g," '6 8 8 8 0 8 0 0 < 0 0 U.) . Rp -..) 6. 6 -; rõ , , ,. ,,, ,., 1 F. E. 0 0 E. U 0 < < U <
.-4) 8 8 8,te'888 El086168818 '.',-,'8.'6""..;
0HUUUHE.
U E. " " EE-_.,..,=6..E6.NE1E6-3,8,- , .9t-f_i . = C.> E. E. U H E.-, UU= HU= O ., E. ' , , , u E- .
0 U < U 0 0 0 0 <
U 0 E. 0 0 < a' 0 < (11 E. < 0 gi, UUHHUUHHHHA
8 b. 8 8 . `,1i 8 ,, p4 u, [-_! u 0 E. A r; t-,¶0"6 0 i'-', b ;11 . 0 E
El.) 6 EE.. 8 ECD. (S. F.:0Ha,UU00,4,0 rt, U 1 E-7 EiC1 P. Er , E. -. -4' ) 000 8 8 f,-"q '' 8 8 r-, 8 8' '' L?
E. < E. 1,4 E-, U (..) = 8 866E86 EU' E. U H. 8El0888-itiu8 u u CI E-, < H p (.9 (D U E. E-. q u F. CD E-, 0 E. 0 E. 0 g C.) F4 p k_,,, 8 8 8 8 8 u 0 E.-. u 0 E.- L=e u,:c ,H El _=), F,' ,c? EP., `- =Z E.
888,08 t_') EY180.i.708.0E.00000E-,<OUUE.90,<
U u U U E. E. E. y g ei E-4 E,r-t. E,'5, Cp t1,4 0.
4' 8 8 Pe 8 n (V '1.
U r..) 0 0 [.. E. C.:.
U . 8 r-% 8 ,t,l, 'd 6 P4 ', * (E?, 8 P A F, ,$) (E2, r(-4) U c... g ., E.
E. 0 0 E. 0 E. u 886V-D,rl.`-'8H6,6",te' 68$'6",e88 u U E. < < E. 0 E.U0H0E--,< 86:80186808,e8i-,8 Elt;86886 E.E.UHU<E. 0H000,0u0U00UU0OHL.90 cp g (.../
u cl C.) r, C 7 = U CI
O 0 H E. E. H (9 (9 "E'ElE16%-lEt;ii8 66[1 6 ",,C, t;il `1 :t 8 8, 8 8 ,'el 8 R i.i-) !4._: Eq'4 s'-.J.) 0 < < 0 L.)L.... U Pa; L-, t. 0 E.. <PH .o.q c E.E.E.000 = 0, E. E. E. H E. H
i-j (.;rj, 6 8 2 8 6 8 8 WV ))0U 8 .18U 6 '0" 0 ',', u E-, u E,E.E.F.
<UU<HU0 E:). Hb' El 8 r4 0 6 6V661868`8E,,[483, E. u E. U 0 0 E.
00<<E.E.0 8 6 1E-4 8 8 8 8 ,Ee" ("- 8 `,= 6 6 u 8 8 ''c 8 E. : r 4 < u E.E. u E. g H 0H E. <PUUK.) E.C..) HHO00E. 0 HU
OCJOUL)E.0 0 0 0 0 0 r.-) E. u F=C 0 F. u c.D o o .1. g u u E. Kr q 8 8 8 t -,' 6 8 i s..). c? EC-; t P :<( 5 , .5E- ' 0 EP, 59 ((i 'k' 'd b' i"-: gi 8 8 8 8 q 8 ',i u 0 C.1 E. U E.
UE. 0e. FA:U L--,-. 8 El ,E,-" 8 'Et O 0 0 0 E.
H0000HH 00<< HARI. E,:,-. (i.) tE....% E, .6. ,E,-if, E--,, cc.-= 8 (,-_,., '.g.
00UUUU Ft: E.' ti CD el r2) (t=. CD E, c.) E. g 0 (.3 cD 0 E. E-, H EA
O u y < U E. U ''' u . ,I= p= c ' 0000<00 0 cDUE.,<U0 6 HD 8 g t 6 "i-9 6 t.>" 8p 0 u E. E. 0 H U E. u ,i, E--. < E.
< E. H < E.., 0 0 A
8 8 8 8 8 8 ocu<000[900000000UOU g u 0, OU 8 8 8 1 8 El r. h9 ri E,E, 8 0E.E.
O= 0U 8 8 0 8' (,: E;e" ,e 6 `,'e 8' 8 8 `,e) 8 ?-.. 8 E;e1 V: 6 c., E--. g (9 g E-.
CJOCUHE.
E,E,,e0E.-,, 8' 8 8 6, 8 6 8 8 6 8 ., 6 r," ri 8 0 8 8" 6) ) tj 8 r." 8 8 " < 1 " < ,9 " 6 5 tl 8 1 8 6 . 8 8 8 O000HHH s '4" uPu H K.
...)z) <U00000 8 8 8 re ' 8 EC', I `'. b' 8 8 8 8 8 8 8 ' U u u L) H H 6 (Du 8 6_, '6 QPI: 0 r 8 6" 6 `c-,) 8 CE.-.7 6 8 6 6 8 El u 8 8E, .)CE_, .
000 PPE. H OHHOOUE.0< 8 E.- p., i. (F_D 0 H U U E. 0 U 0 E. (W.' 04i:0 0 (C) 880PeEl88 rii SUBSTITUTE SHEET (RULE 26) H X a H >.;> z z H g a o w ul w p4 ;=4 (:)1 rK al z a a x 0 cn g ,-1 n....õNp gt=21E--,owz a, a al 1:14 T4 H p ral Z A z ,-1 X rc. E. E. a Z
E. a r4 f4 En n, z 1-1 0 En 0 in pi ,--1 fri z ,-.4 z a Cn C/3 0 E. Z 0 0 Si 0 fi= cn Er] p HOO N Ln ri-4X01X>Ent.DEn>
01 rri > x 1.-a OHH R - pHarlac_9>Ø-1 ,-1 X C9 q 0, q = 0 a 4 4 ,-.1 W X E, }-1 C4 E. P E. En ..4 A 0 C.1 En f4 a, H 1:4 n 01 >-, 0 4 a H pi X E4 cn CI Ex. 14 a >4 fat H XrdcncnzMar.n..1.-10g a q r4 0 En ac q P-, 0 01 :4 E4 a al Ea a g A 0 > La z t4 cn 0 09 PE4 la 0 H
4: 0 Z E4 GI crE
U E. E. E. E. CD4HE,<<OU40004H440 U 4 c9UONHHHUgUHFH
H u ED U E. 0 u CD u 0 u u E. 0 E.
E. 4 E. H g OHHHUUN H4E.HEDHHOE-, H Ft CD 0 E.
H u 0 0 g E-.0000(90H0c.DE. CDE.OHE.<
u H H a; g OUP NOHuOugOEHUE.gH0 E-I= ggUE. E. u o 0 U 0 u 0 A U F. .6 EH 0 CD 4 UOHHH
CDOE,E.H u 0 a, H u U E. g U E.
U U H U H U U U u 0 E. 0 0 c...1 E. u 0 0 0 0 g 404 E-1 E.
4 U 4 H HOUF4UH4E.CDOE.OHEAU 0E.
E. E. 0 5 C9HUUgH uguE.HE-ogy E. at coq 4 4 t g (-1 g F. 0 t..9 C.) 0 F00 0 U 0 H 0 H 0 g u g g 0 E. 0 E. g UUOUUNgE-.0 UHHHEHHOU
E. g U E. A g E. g 4 g: ED g (.1) C.) CD E. u 0 g g E.
0 0 0 ci E. tH E, u U A d H Eg E-, E-, E.9 E. u ri, E-, E, 0 0 OuucDCDCDOcJa,a,004 ,,;0 U 0 U E. E. A E.E.UULDH40H
0 0 U fa: Kr: HOUE.E.E.E.E.00 E--.
u U H A H g U H ., 1= ": U 0= 0 UU4E.OUOUUpt0E-, UPC 00uUUE-,HH44 V. E. E. U
E.../ U g UQUAUOUE.U00A H4HE.
gc9C9UF1,000:000gH ,AE-,ci UHUU 00A gq0c...90,,,,IgHHAa.OH E.
E.HgEHU U A U 0 U g g A U 4 0 E. g 4 u g u H Ft OUE. 6,ANg ONUCJO,AE. E. H
U U g 0 g 0 Cy E. 4 c.910U/gE-.AgUONON
4 U E. H 0 E.HHOOE. Augu0E.OggH 4 E. UE-,4p,4E-,4 UHAEHEHAHNE.C.../0 u 4E.400 HE-,u40<0 N E. 4 UgHg A 0000 E, E.H0gc..90E-.00 Ougul. 0 0 U E. u u E. 0 E. E. EH H
HUH0U1Uc1HHH
UUHOUUH
U Ci g o c.) c..) E. E. 0 < HNO0UuHUHAC9E.ga,C9 0 H
CDU4,HE-, HUHO
u E. E. E. E.
UOCDE,E. c90E-,0C9UOE.OAHHc_9gHHOH
uHEHHE, cic_90AgOc9000uUE-.0HE-4r4 0 A u E-, 0 0 A u al 0 o E. 0 g u H U H H 0 g E.
gg0u0 000 0000E-100HgE.E.0 gE-, c.9 u g g H C./000AEHLYUc9u0E-, g E. g OHuHU
g g E. 0 a; a.,E.Auu 0HguuNgUE-.00H
000 H. A 0 E. H u E.U05HgEDUE.00d0g00 = g 0 A g 000H(9000,ACDHHgE.A,Agg 000 U E. EH E. 0 u A C.7 E-, N U E-, E-, U pc q E. A A u OguggE.E.HH0HUogUE-,gH
AH0H0 U0E-.019HOU0U0,110U0gHg 0 E. E. E. 1 U U u 0 E. E. (.9 g E-. H U
CD E.', CD ED H OUU,AE.g U01..90Hgg0 4 4 E-, E. E. 1.9 g A UUUOU0 HgUOUNOE, E. 4 4 HHOH u g u E. La; 0 0 g u 0 E. H E. E. E. H 0 E. 1 0 g H u 0 E. g A 0 H U E. Pt 0E-, < I
.=-1 E-, E-4 ED Ci C., E. H (.7 U 0 a; H c) E. 0 0 E. H E. I
co OHUHU ru OOHUUUHOHOH ac I
E. U U 0 0 = = g g E-, 0 0 E. U U U g A E. H 0 A g U
U
U u 0 H EH
0 044E-104CDHa,<H004<0UU
Z. UUAL9E-.4.0000.guHH.a;HE.g g H 0 U c_i 0 u.__,UUUUU0c9acCJEDOUH U
H
H 0 0 c.., g 0 g 0 g g g g r4 OuguHuguU0 7gE.c-)0C.91-.0 cn SUBSTITUTE SHEET (RULE 26) Cr4 S4 i,..1 E al E. I4 CD
PC CI 0 CI (11 H = re) D/ 0 4 cn RI '04 U CJ Op U) D4 a .4 4 cil C11 Z 0 Z C4 DI CD E./
E, n4 2 0 E. Z ch a X !-I LE. .1 CI X cn C4 > H DI .4 U) C) , ID
r...
ts1 , F4 6 0, tc A E
= c,1 c) . cl, C) cn H H C.;
C> HK,..1[401.4C10 Z 0 >. iZ rs) 4 4 rs1 2 A 0 DI Kr) H
a ca.U01.1:4tagcn rsi rs, Fs, tr) ',>
U) _ ___________________________________________________ Uuu5C) 40EDUU E. E.E.HUE.E.H05E,E.H.45HE.0 f .4 L) E. I. .g cb c) kDi.-. 5HOHHOUHE.H05H1.55E.E.E.E.H
u u e.) E. 5 0 1-, 4 L) C..7 (.7 50000E.4,0Upcur.)0.4000HHOH5H5E.5 r.J U E.E.)044 rJ CJ H C.) / a' H H
6 0 CI E. U g .4 E. CD U
C.) EH E. E. E. t) 4 , 4 0 .4 E. / E. U 4 E-, EA EA
E. E. 0 C9 .4 E. 4 U
0 HOH0000,4505E.E.OH<H050.4H5.4E-1555 1, UUE-.0045HUE.54.E.5H0H5,400-5555HH, u a U)0 0 H E, 5 5 u .4 E. 4, 4 E. C) CD E. 0 a 0 4 E. L) CD E. CD E. a 4F-.
E. C) .4 .4 C) 0 CD C.) cD c) C) E. C) a A E.4 U E. CD .4 c) .4 E. E. C) 0 0 4 U 0 0 5 LI E. H (J 0 a: E. E. E. u E. U 5 0 CJ 5 0 E. E. E. H
4. 0 I. 0 E. E. CJ H 5 E. 5 1. E. E. H U 4 E, t.) (.7 f4 E. u H 5 0 E. 5 0 U 0 rt E. 0 E. E. 0 u u E. E. EA F, 5 (9 0 u H 5 0 E. H U rai L.7 E. E.
H'-)a, 00 H 5. 0 0 .4 0 5 E. / 0 0 0 5 F4 g 0 E, H H (.3 5 E. 5 H U ei E.
O 0 5 H E. 0 CD<Ha H0r<cDUE.HaV.,<H4a 4 u H 4 4 UUAU 5 .4 4. ED0 4 0 u u E.C.> 5. r.) 0 u C.) < u 0 H < E. a CD CD 0 C) 4 U 0 Pk C.) E. 4 E. 0 E. U FQ E. 4 0 E. C) 5 E, CJ
= 0.1 O C) 4,, E. ,4 0 0 E. CD
C.) 0 / a 0 E, A E. E. U 0 CC 4 U A 0, E. U 0, 9 O (i l'1,4 6t U U H 0 E. 5. ,4 4 .5 g Fl. 0 E./ CI 9 Ply A ec 5. U 5 CD 0 0 4 KC CD 1, 0 E. ,4 i-, E-, (7 CD C) 4 0 0 t9 U E. E. CD CD A U E. () .4 F. E. E. E. E. A 0 E. E. E.
E.
0 (.) ,4 t-i E. E. U E. E. C.) E. C9 E. E. E. CJ E. CD KC E-, 4 E, 4 E.
0 cD to 0 0 cD E.1 E4 E. 4 .4 E. E. E. u gq CJ 0 44 0 E. E. C) EJ C..) Ch. E. CI cc O Ch 0 E. CD U U ED c) PC CJ 0 E. F. E. 4 E. C9 0 4 () E. CD 4 4 V. 4 CD .e C) 0 4 E. 5 0 E. . E. 0 0 U E. (.4 54 E. a C) .4 H H 5 E. 5, U 0 0 E, 4U C) 4 EH C) C) Lh 4 0 C) H U u 0 5 (I E, t) 0 0 E. 4 CD E.
CD U E. C) 0 0 u U .4 H E. E. 0 E. CD E, .4 E, E. E. t) E. g4 U E. E. (9 a g U E. g F, g g Kt 0 E. U
cJ H E. E. H E. 1 a / E. H .4 F. CD 5 E. 5 U) E. E. ED U () c) U E. 4 51 E. / 4 u 4 E. E4 E.) 4 E. 1 EH 4 9 0 0 0 E, CD () F. E. E. g V H C/ KC E. F. E. ,4 C9 0 E. .5 CD FL
CD 04 E. E4 0 CD E. E. t9 E. E. C.) 0 CD 0 1, E. E. E. C9 tJ
,..c E. 0 CD 4 .4 4: E. t) L) .4 .4 .4 U Cl) 0 4 .4 E-, L.) t) Kc E4 .4 1 4 C.) C..) 4 E.
0 gl, 0 IJ 0 E, U 44.4 Ch Pt El 0 C.) .4 C) 0C C9 E. ch 0 E. (9 (D
0 (D
CD L) a 4: E. g 0 0 <
, t, 0 a E. ch 4 Cl) 0 I, 4 F. .0 E. I, .4 E. a E. E. t) E. t. 4 0 E. A
i (9 .µ4 (9 E. 0 U 0,4 .4 a. 0 0 FC CD CI E. E. A
E'l H 0 0 E. E. t) E. E. A
KC 0 H U E, KC Cl) A U Cl) E. 0 U 0 .4 04 4-4 E--, Ei 4 0 ,4 (.1 F. E, .4 E. E. 4 CI E. 0 E. E. rC 4 0 E, E+ U .4 E, eC 0 CD P4 E. .4 C) E. E. E., 0 ,, E. C) E. E.
CD LD CD F. gC CD H ft El U U E. (.3 PC Cl) .4 (J E., E, E4 4 Ch 0 e---, A pc () 4-, 4, c) 04 E. K: 5 E. g rg. g4 u 4 E. U c) E-4 f. E-, E' E. H E. H CD a H E. .4 U 5 CD 0 0 u CD 4 0 d Cl) H L. E. U E. CD E. E. H g4 E. a < E. t) u E. E. E. E. 0 0, 0 F. U 0 ED a u E. .4 4 C., .4 E. a U E4 E, E.-, F. Ft El Ft 9 E. CJ F. U
..4 E.
O E. 0 E, ,4 ll.0 E4 0 E.
0 E. E. E. .4 .4 0 .4 4 E. CD .4 Ch f,.9 ,.-oq E. E. E. E. 1-4 ED 0 E. u E. CJ E, E, E. CD i, E. (..) .4 .4 0 u U .4 C.9 E4 E. a E. 4 U Ft El HU0H5E,H um:4 5.UHE.E.05.40 -5E.ciE. E-I U E. E, Cl U E.
CD CD F. E. E. E. 0 E, CD c) u F. a t, 0 E. 0 E. E., PC .4 t) 0 .4 .4 .4 E. H
E. E.
U Ci CD C) '' E". C,. U .4 CD .4 C 0 E., .0 I, .4 gr, .4 CD gl 4.) H.4 H 0 44 E.) 4 ,4 CD 04 Cl) F., E-. ,4 E. 0 E. H, 4 4 CD E4 CD FN PC CD 44 H-4 E. E. HO 0 HO
E.. ci E. c9 4, F. E. E. .4 C) o,' C. a () a E. .4 a E. 4 0 Cl) () V E. < E.
Cl El E.
() (9 4 CD .4 C9 E. CD E. E. 5 CD CI C9 gC U E. Ch E. CD g4 E. U U U 40044 CD C./ 0 4 (7, f. E. 5 4 C./ E. H. a 4 C) 0 4 .4 CD g4 u (9 E. 0 E. L9 C) .4 .4 0 c) U E. eD Pi, CJ U 4 0 0 ,-. ,,,t: a 1-, E., E. 44 () (.9 0 E. 4 g g th PIC
E. 0 u 4 C.) 0 E. CD .4 0 .0 E, E+ .0 PC E, .4 (.7, g4 .4 0 F. .4 C. E. E. C) 0 cC 6c .4 pc c3 Ch Ch (di g ...q u) < 0 C.) 1 C) E. E. E. a E. E. H E. U A E. E. E. C) FL E. Ch cC .0 c) 0 CS K., g T., L9 g g Kt E.-, 0 PC CI U PC
Pt E. a .4 E. F. c) a 4 .4 E--, t) g (D () C'D '4 , (' 0 E. Ci E. 0 E. U .4 E. U 44, .4 E. E. .4 g .4 E. E. U c.) Ch E., C).4 E. 9 4, 04 E. E. E. C/ C) () E.
.4 a E-1 E-, 1,-, CD H.4 0 E. E. CD F.
c) 0 0 u cn A4 u U)'1 F. .4 E. c1 .4 .4 u E. E-1 E. u E. g 1-, E. ,.4 0 .4 E.
CI
Ch U) C) Ea E-4 E. (9 0 a CJ E. < FL A E. 4 4 CJ Ch E, 0 E. E.
E. U < E.
CJ U 0 E. 0 C) a 0 E. c) 0 E. E. 5 4 E. E. 4 E. E. E. a E.
CD 0 E. 4;
Cl) t) CD 4 E. F. 0 0 th / 0 H c9 LA E. 4 (9 E. F. E. U E. E. E.
E. L) 0 a 01 0 C .4 C-9 CJ 4C C El E. a 0 E. () 0 F. E. E.
0 U CJ E. HC9 cC +C gC
N CD 0 0 CD 0 U EA LI C) U 4 Ch c9 E. 4 E. .4 ft E4 r4 c) 4 E. CJ E. E.
C) 0 CD .4 E, U U E. 0 r4 .4 E. E. CD / 5 .4 E. CD CD E. 0 E. 04 u < LD
= CD (h .4 E. .4 E. c) I. E. .4 E. C5 .4 E, E.
E. u E. C.) E. E. E. C.) E. rg E. rJ E.
6 C) 0 0 0 CJ H E. E. 0 U).4 El 5 0 CD u CD E. u E. gf E. E.
E. H.4 .4.4 Z CD U 0 C) 1 0 C9 0 CD E. 0 .4 U E. .4 0 F. .4 .4 0 .4 0 E.
E. CJ 0 E.
Cl ,, 0 C.) E. 01 ii E. pc a .4 E. 0 .4 0 0 C.) E4 E. E. E, E. 4 E. CJ 1 CD
H C) 0 0 .4 c) 5 0 4 E. E4 Ch C.) , E. C) 0 E. 0 C5 CD .4 .0 al 0 01 E. a E.
ril 0 0 E, 0 E, cf 0 u p< 5 v4 E. 5 E. eD c) 5 g4 E. f. 4 U 0 04 rC 4 E.
L., FL c) _ SUBSTITUTE SHEET (RULE 26) , g N al > 01 hi t-q 0 a, __ p4 44 0 44 (0) al 01 tn R EA Z 1,4 ti3 74 4 fii U.) 0 Er, (-4 4 z 51 CD CD, 0 fl, g 0) E, r4 CY 0 014 Z pg, 4 74 0) I-. rl .4 2 r,4 H H 4 HO 2 6 c,2 .r: w P 4 P N ,.1 ',-?, f4 P
04.p.4c5r)0.0y04,-i uenci.-107E-.44y3 eip ,g0:441[01(30 ff, gi m m gl g 1 g (n P, FA e4 c, c7 O4 0 1 4,2 '1 E. 4.1 C)0 P1 CD 4 .3 C4 g ph4 w pl c.) .4 0 V4 i-, a. i-4 74 7. 4 04 ',1 1,:,1 '2 2 P R 6. ,Y, ','e: ..'," '4 g r, t=,,1 F:,,: '("l ,?,' 8:
.. (, E. E. K HZ OH g3 ,. ,-1 i9 5 oa u in pt C7 P. E.
al en 0) 0 > z a, 0 c4 01 G-I c. C.! La P. ta Pi Z P4 C) (:YE--vrgp1;,4, xa. P ':', VI Co CA CI CO olxAzxgg 1-4 til (4 E. .4 ;4 0) 0 z 44 P.; (9 r' 2 01 ?4 ka e4 Ch Pi CD Pi C7 era En VA p4 X .t ,1 y, _ CC i 11 t cn X Vi 0 .4 cy 0 4c Z A LU Fl 1-4 ,4 0 Z ?A 0 0 Ei a. pl fil E. 01 __________________________________________________ _ 0 (5 CT t9 c9 c) gS g 4 CD CT, ci g4 CD El g 0 E. E4 U 0 U E. ,. .4 0 E. u (4 (5 4 gt c) U .4 44 P4 kJ c) 0 t5 44 E4 c--) Ke, L, CD CI C/ 0 (.., 0 .1, 0 C-4 0 0, 0 0 A CD c.) 0 E. ti K4 0 U g g 0 t; g 3 59 r, 8 t; ,i): ,'-s' g 6 ES N E4 ';(1, `4 V, 8 8 4 ES
( i94 p4 0 D il ri 8 il 0, H =,,c H 0 0 0 9 c) ci u C) 4 E.
E4 (9 u g u (9 H .4 (9 PC U CD, U fa: E4 Al, Ali 0 AC) , [1 '6 t"), E7,e' q [:', ',q1 ','cli F, EE i?, 1 El N [--: 8 t-j ,1 8 8) E ,11 (3 (7 0 A Ch C9 (D Cõ) CI Ch Ch. C.) (D gl 0 rC ,C,.?, Ci p, () E4 C) 4 ..-, [5 ,T. E1 8 '6 U , () 8 ,V 'A N' ', ';;4! ES ES El El fl'. V, El i4 H q 6 E' 6 8 ES 8 0 ES E3 ". 8 E4 6 El El N 8 1-4 8 El 3 t4 C? f-J' 9 P, cry t51 ,, ,,_3. 1 tl t-D. * .1 6 8 8 8 8 õ N '4 f5 6 '4,)!.
,, ,.-- ,- ,-.. ,,, ,--. ,-, ,c, E. (9 E. E. E. 4 .t E4 4 4 E.
44 44 44 E. A, (J E--+ El C5 CD u E, 04 E, 0 FF (.7 u E. 12 1 pg., U r( 0 r( 4 ,. 0 L.) p g p (9, E., 0 0, E" 8 0 ;l E4 8 8 ' 4 'C I'S 0 il 8 E?, E4 0 6 '' 8 ES 8 ES Ea 'A g 1 t-r-i' * 0 8 1 8 t.:: cfl (VII 0. P.0 L55 (,-4. cl 8 6 ',..:-ii i--: E
, E, E. 0, C) 0: 0 E. E-, Ch 0: LJ 4. 0 rr 0: 0 0 E, rc 0 (4 E. ,4 E, (2) ,,, E.
,,, ot 8 0 8 i-9' 8 r.;i " gi 8 8 ',:' (C.)) Eg--,C g: ,-,c' g:9 8 :-T) E:1 2 fC' 1--:
g .,1, !-.4' 'icli 4'-' 'g E4 8 g t,'. Li 8 ti; E.)4 t--_,µ g, 8 L9 E; g !;
[:: t; 0 (1, ,E,t' ,.
u E. E. E. 0 E-, .4 &I E-, k-, 4 (D (9 F4 () re 0 E, ES ,4 A '.1/, 0 (h E, E.
0 -.... Al 'E.1 .( g r. El ,V1 8 8 I'D' E: 8 8 g g trj 1 g 8 8 )- ',,',.
t; 8 2, El 14 21 i(9 E.) 0 I-, Li CJ U Ch E. 0 u CD Pk E. iii t,) Cu. .4 E-,--4. ,6 ,õõ:
:õ9, 0 Eg 8 l 8 `4": El E5 E,'t 4 r) ,`µ,, 1 5 1, H 0 E. U t9 Z1,9 0 ti p cn 8 E u V,' P. ',', 8 8 8 El ,,, 0 '6' ,., 1-4 N ES 4 8 [l 8 El * Up (4, -'4 [4 8 'E1 E:' d E: 8 E, il t2, 0 8 8 0, ES
8 0 El CD E. u g E. U E. py (9 (D o< E. ci E-, C) 44 H g g g 0 44 E, E--, H 0 co E, E. 0 ... g .4 0 Ch r.) H El H c5 E. E. .t AI; 0 E. V E. ri 0 F6 r-, (1 gi H Eg- 0 E9, 8 E,-,' 8 u ',,- '2,. 8 -_1 s 1 v, il õ õ õ õ ,, õ õ ,, 4 õ E. 44 c) E. t.) Ch 0 0 CT
04 E--. Ei (9 0, g (9.(D " EC71 g"1 " ACH 8 '4" 6 :). ",,i1 6 t; ,":- 6 U t;
6 [5 tD r, i g'; L9 8 6 6 0 0 gC f-f 4 0 g E. (9 C) g 0 U E. 0 c5 EA 19 g gc Ef gC 0, F, E-, H E. 0 E. E4 4 0 E. g E. E, c, g (9 H CJ cD gs (9 (9 E.
2 8 (,-:4 5 El Eg ,'-' 8 6 -!, ?) E4 E4 N E,, g El 0, t; 'A ES 'i g ES 11 8 8 Eõ ',,'-'4 El 0 E: 6 El 6 (., El 8 El E, 0 El 6 El ',,-.4 i4 0 6 6 il E4 tri 0 ',,- E;-, F, I?, [?, g N N 0 El N P, ',.-NI 8 8 il; g E4 El H HLDHHHHU<UHH Ca H 0 Huu.Ku4p.[-,tciusrt..-2,b6 , 1.-.:4 kJ (9 PE, F, E. A CD 4 0 xl, 4 0 U, ,4 ..' 4c 0 Oc E-, E.? c7 0 E. 1 c) f, c) gs ,t- 0 / cl 8 8 6 0, 8 8 V 6 '4 F.: E., 8 El 4 1 N 8 8 i f5 E_,E, 4..E.r.,,,,g(90_0004000, g 0 g d, g 0 H 0,, il 8 E4 V. El 4 g 8 8 8 E4 V, 8 4 8 El u g 0 8 E, El 8 8 ',,i 0 f" 6 8 ES 1 8 g E4 8 8 6 () 6 6 CD E6 6 t; c=-ii i.) U
[..)) 8 E. n C) Eci'i ,1 'a 8 6 E, ES (4i ES ES g, ES 8 ES I:: 8 E. 0 E, 0 CD g4 0 E. 0 gt u c) u g 0 E. ps ch. 8 c7 g, cõD, c..3 c_.õ) (y, t5 8 E. E. 0 E. (J E, E. F. F, r g y t: El g t.,. E, 6. u 40 4 ..-..3 c, E. CJ E. C.) F. E. E, V CD U N., A 4 U E. E. 4 04 E. U 0 0 0 E., KC a, E. 4 4 .,µ ,E1 0 t,i tl tt..-; cl Ec, tr:!õ i...1 '4! ri 8. 6 8 8 6 El 8 66 ES 8 ES 2(i ', (i g E.
E.
ts r. C., ,4 a LI l..! H 04 4 U U u Kt g4 .4 44 0 41, 0 A pc gs (9 E. E. 4 E.
2 8 Ig." t'D t--1 ,'=.4 8 H EE:" tej 6 5 8 R ",-4 -*)' El E-,' 0 0, 4 8 8 Et: 8 0 -2.
.. E.-. CD E. (J CI CJ CD 0 E., I-4 f4 ,4 g4 c, 0 () E-, cl () ,4 0 k-, E. pt c? E. c) cD E.
1 H g(6 _ õ ,. õ. , õ,_ 91 E, U.C) El (9 E-f CJ 4 E, 0 C.) ,S4 E. E. 44 . y.D
t:,., t::: .02 ci-õ, , _ .s.? r.-õ, C) kJ E. E. 44 E. cD E4 CD 0 CS ki 5s 5s 5s s9 il t7., ,a ri, Lc...), D ;..f;. ,,_._ 7,1!
1-4 L) g W (2) LI (--1 () E-' 4004 Pi 8' 8 8 d E. 'A 0 1 E. 0 CJ= 0 H
O
1 V. g E.'.!).!
SUBSTITUTE SHEET (RULE 26) SEQIDNO . : 3 1 S
EQIDNO . : 7 8 ATAAATATCAGAGTGTGCTGCTGTGGCTTTGTGGAGCTGCC.AGAGTAAAGCAAAGAGAAAGGAAGCAGGCCCGTTGGA
AGTGGTTGT NWRSLGLALALCLLPSGGTESQD
GACAAOCCCAGCAATGTGGAGAAGCCIGGGGCTTGCCCTGGCTCTCTGTCTCCTCCCATCGGGAGGAACAGAGAGCCAG
GACCAAAG QS S LCKQEPAWS I RDQD PlvILNSN =.c CTCCTTATGTAAGCAACCCCCAGCCTGGAGCATAAGAGATCAAGATTCPATGCTAAACTCCAATGGTTCAGTGACTGTG
GTTGCTCT GSVTVVALLQASITYLCILQASKI, TCTTCAAGCCAGCTGATACCTGTGCATACTGCAGGCATCTAAATTAGAAGACCTGCGAGTAA.A.ACTGAAGAAAGP.A
GGATATTCIAA EDLRVKLICKEGYSNISYIVVNHQ
TATTTCT TATAT TO TTG TTAAT CATCAAGGAATCTC TTCT CGAT TAAAATA CA CACATC
TT1tAGAATAAGGTTTCAGAGCATATT CC GT S SELKYTELENICVSEHIPVYQ
TGTTTATCP.ACAAGAAGAAAACCAAPICAGATGTCTGGACTCTITTARATC-GAP..GCAAAGATGACTTCOTCATATATGATAGATGTGG QEENQTDVWTLLNGSKDDFLIYD
CCGTOTTGTATATCATCTTGGTTTC-CCTTITTCCTTCCTAACTTICCCATATGTAGAAGP.AGCCATTAAGATTGCTTACTGTGAP.AA
RCGRLVYHLGLPFSFLTFPYVEE
GAAAIGTGGP.AACTGCTCTCTCACGACTCTCAAAGATGP.AGACTITTGTAAACG
TGTATCTTTGGCTACTGTGGATAAAACAGTTGA AIKIAYCF,KKCGNCSLTTLKDED
AACTCCATCGCCTCATTACCATCATGAGCATCATCACAATCATG'GACATCAGCACCTTGGCAGCAGTGAGCTTICAGA
GAATC.AGCA PCKRVSLATVDKTVETPSEHY1111 ACCAGGAGCACCAAATGCTCCTACTCATCCTGCTCCTCCAGGCCITCATCACCACCATAAGCACAAGGGTCAGCATAGG
CAGGGICA EHBHNHGFIQHLGSSELSENQQPG C) CCCAGAGAACCGAGATATGOCAGCAAGTGAAGATTTACAAGATTTACAAAAGAAGCTCTGTCGAAAGAGATGTATA_kA
TCAATTACT APNAPTH PAP PGLEHHHEEKGQH
cn CTGIA.AATTGCCCAOP_GATTCAGAGTTGGCTCCTAGGAGCTGATGCTGCCATTc.;TCGP.CATCTGATATTTGAAA
AAACAGGGTCTGC RQGHPENRDMPASEDLQDLQICKL
AATCACTTGACAGTGTAAAGAA.A.A.ocTOcCATCTTTATGTAGCTGACAGGGACTTCGGGCAGAGGAGAACATARCT
GAATCTTGTCA CRKRCINQLLCKLPTDSELAPRS N.) GTGACGTTTGCCTCCAGCTGCCTGACAAATAAGTCAGCAGCTTATACCCACAGAAGCCAGIGCCAGTTGACGCTGAAAG
AATCAGGC UCCHCRHLIFEKTGSAITUQCKE co cn A.kkAAP.GTGAGAATGACCTTCAAACTAAATATTTAAi% ATAGGACATP_CTCCCCAATTTAC-T
CTAGACACAATTICATTTCCAGCATT NLPSLCS UQG LRAEENITE S CQU
TTTATAAACTACCAAATTAGTGAACCAWATAGAAATTAGATTTGTGCAAACATGGAGAAATCTACTGAATTGGCTTCCA
GATTTT EL PPAALIQI S QQL IPTEASAS tiR CO
Az...kTITTATGTCATAGAAATATTGACTCAAACCATATTTTTTATGAIGGAGCF_ACTGAAAGGTGATTGCAGCTIT
TGGTTAATATGT ITKNQAKKUELTPSN
Ill N.) CITTTITTTTCTTTITCCAGTGTTCTATTTGCTTTAATGAGAATAGAPACGTAPACTATGACCTAGGGGITTCTGTTGG
ATAATTAG
Cl) CAGTTTAGAATGGAGGAAGAACAACAAAGACATGOTTTCCATTITTTICTTTAOTTATCTCTCAAAACAATATTACTTT
GTOTTTTc N.) PATCTTCTACITITAACTAATAAAATAAGTGGATTTTGTATTTTAAGATCCAGAAATAoTTAACACGTGAATATTTTGC
TAAAAAAG
CATATATAACTATTTTAAATATCCATTTATCTTTIGTATATCTAAGACTCATCCTGATTITTACTATCACACATGAATA
AAGCCTIT co GTATCTTTCTTTCTCTAATGTTGTATCATACTCTTCTAAAACTTGAGTGGCTGTCTTAAAAGATATAAGGGGAAAGATA
ATATTGTC
TGTCTCTATATTGCTTAGTAAGTATTTCCATAGTCP_ATGATGGITTAATAGGTP.P.P_CCAAACCCTATAAACCTGA
CCTCCTTTATGG N.) TTAATACTATTAAGCAAGAATGCAGTACAGAATTGGATACAGTACGGATTTGICCAAATAla_ATTCAATAAPAACCTT
AAAGCTGAAA
AAA.PAP
4A.A.A.AAAAAAAAAAAPLAWAAAAAAAAAMAAAAAAAAAAWMAP.P_AAAPAP_a_ARARAAAAAPAAAA
C) -17!
U M: CO
EC; CI, mii, P H Li H ED 11 11 µ81 R FL-). c4''. j C)) 1 0 E. fr. ii, P. ,H g r=
.--.
r4c4C.7200 c; 1 14 P., .1 f... 8, z n En H . En H P.
i, ccs , _ia ,i ,.1 , .), ) g 2r ,, 2:
u U 4 C.) ci U 0 U, a 4), 0 0 (.9 U ,4 u4 0 0 AT, A 0 0 a E. CD
CD CD 0 a 0 E. A ED H 0 H 4, 0 H 0 a EDE..) F. a a U 0E. a H
E.DaEDE.DE.ArCED ciaNgaE.HuUEDED aNaaE.AE-1 (90ag UUCDON 000euu0NrCEDgEDF.¾(900HHU
0004 r E-.00UH4e,0,E.0HauguHE-,aHqqag EiNaUUEDgE.HHE.JurcaCiUHOONOaraCiaaau U E. 0 CI, U 0 U U EJ I. a ED a E. F. a U a E. 0 F. U a E. E.-. E-. 0.1. E.
H
U F. 0 a Ei E. 0 CD E. C. E. 0 u ED CD u U a 0 0 0 E. a 0 a a ED E. 0 8o 01. 1---, 0., 3,q tici ,4ch 8E. ,c,r):Ci (E2,0 Ei, E6,E-. cti r6(.7 3. .
c Ei .,,,, . - , 8E7, 8 ,,_,,,,, Et E,5:E. E.b, ctiDN ELIE. au ,,,;.a EC:
ci 0 U a U 0 a a a 0 a E.1 E. a AUHHUHUUAH
[...E-.E.,400Uu0E-.0uUcDciUUgOtEDE.rCHE--.H.H.E.NU
u H g U E. 0 U U a 0 r1: g 0 0 a C.> E. CD E. E. 0 c..) 0 u u .=:q ,. U
H
ci U F. H. a V H E. ...4 0 0 a a a 0 E. U a E. 0 F.
UH0CDUOU,HEDaa g 4 0 NH AA 0 A EDUrc AgONE.Ha H. F. a E. 0 A A F. E. CD C.; cD U, E.... CD A U U g q g E. E. H ED F.., H 0 F. F.
UgUU00-achagUEDaE.gHaciclug00E-'00 a U 0 E. 0 E. U a E. CDUE.E.0<0000,< <UCD<CD E. a E.
rCaUOUE.iy0CDONUagE.c.DE-10 HIE-IgUaa0 , g U 0 U g 0 0 e-.. g g E. V U a F. g E-, CD E. U E. * ED 6 0 U ci CD
6 E, E-. U
o o ,.: u 6 6 6 6 6 r, ,P4 `.,-- 8 8 E,-; r, c.i CC; (..,0 8 6 q 6 8 0,0, El g 0 U U 5 U, ci U a; E. 0 E. E. A a, E-. AgAHuHr4U4,0E--,[y, ce, EE2, ,.,., EC-% t., E(.3 ,.., 0) u":" go tC).E. EC) EY< ECU r4a, - '54 ''. - A 80 t - -15 ' Ed Ef 5A
6E - µ Ec:j C9E - , 0) 8 0, 05 Hu uE, DO S. EY. 6 5 q u E . q o (5 0 u c5 r4 E... 0 N g a E.) Ci C./ ,, A E-1 * 0 E8 E-. Ea, r, Ey, < E4 C) - - 5 .0 c' '- )0 Pi rd At ' cD, N P. , ' ' - - 4, P. , 6" ) E i j- d ' 0_ , ' - " )), c (6 0, u?' 8, " "(3 0Ã ' '6' 8 8 u4 F-; gE' E.CDHOgau*.gOON ''' , YV9C-"--"-)t'5,-c) 6 '4 cr_,' i-.)., b' ri '6' Er_; r, 8 S 6 u 1:: ,E,7,1 u E9 `,J,2, 8 8 0 ri CE'l E.' El. 0 < U U a;
E E. F.
UU.,40:Na CDFE-, Er-,_,Vi.r.. cD<CDEUE.CDCDUytEicC--.CD,Api,El:
re..1) (.;- ccj7 E9 ..j.) t-; 6 u P. o ,V: '0' -)' ';5 E6 E i--.' 'E,' 8 `-',.,=c 8 `,-t' 0 A 1 '6; 0 (.6 u .. u, gr, o u E-4, i--. gc U 0 C.J C..! 0 CD gt CD o, u E--, ,.., E-, C.) < CD g, .-5 0 ,4 O ,.,. a t-j 0 ,l, '. Q Ki. fr. 0 rt. E. ri E. ET. a 0 u q E-, H GC u y * .E4;
' .4 8 `,- c' c, c. ) . i ; EY, ,V, cc:9 Ec?, b) i-- ..) ,..-.)D 8 8 1-.' 8 5 8 6 f_-.; ..',' 5 o 8 8 ..4 C!) ,4 CD 0 C. F-, E-, 0 A U U U U E. E-, a E. U El a 0 Ei 0 -a E. H c; a o F.
g U CD a U E. u ED 0 r4; u F. C.; <4 E. a; CJ H A < 0 E. U a 0 U u 0 < C., U CD < U 0 E. 0 E. a U 0 0 CD U U E. g E. CD 4. f. F A CD E. CD U < < E.
CDHACJEE<HAEC.,<E-,a:p4ue. HuciE.ciE.E.F.E.JauH
E. ci 0 H E... U 0 0 ED g g Ey a u H U 0 a CD A 0 0 E. U * (El a Ed FD 8C . D E,8 --)j,,4 114 '-''F'4 c.). rA 8 84 g 80 L"5:_) F.7 tE:'90; EE 1H .
H E 1 ---- j ' 6E - , 8E - , ', V- , Q '' E - ', r. i r (4 r. ;- .
CDONOutiE-.0gOgagE.F.agu-a0000E.PF!ED,HHC),1 O C. c.) r-, u u E-, u .< A 0 0 CJ CD 0 < U < a FI: < U E.E.00ua L,-,' '11 i E 0 (...) 0 CD E. CJ 0 0 0 C. 0 U E 0 u g 0 F, c" u ,rq ,a E-, u E. 0 E. au OCJAUCDHCJE.01EgFU,CD,CD<F<CCD.CIFEC,D,,E.10, GC E0 N Al 8 `,' , 8, 5: 84 `E. 3 8 8 o o 4, '4 6 5: , E--: Egl [7.1. .?C E. F4 8 F4 E., ,,, : o o ,s1 5, 0 E. 0 0 0 4 0, 0 g a U U < ,..., < E. U C9 0 4. < E . F. E. f. E. a: < a,, a.
ug,4E-,u5,ouo,cuuu,..,4,,,q aHUHaE.E.E.Hociuci H 0 CD E. H u U 0 A ED ED Ei ED Ei E. E. a 0 E. 0 F. E. ED H 0 A H H F. CD
U A E. CDUNE.HC/F<FEE.C.9<H<EUEUCD A E. A Cc/CD ,a.
0 CD U U 0 0 a UUAU CD u E--. 0 LI UNHU AU a E. E. u, 1.... UN
O 0 0 a a r...D Pc 0 I.) E..D < H. < 0 H g.. H g U 0 U H a H 0 0 ri. :,;,, t. EL:
Ha .: E, ,O, E. 0 E.gauCDE-..0ci,HEDHuNuE-.HHEiu ,ug, CJ v 0 U U CD < U U U a a; C--, E. a E. F. y 0 C.) E. a y A
A H ET. E-, El O00<cJVD0000,E440.< 0<ECJ<< gyE,E0,80(E-1_, l(D)t-_,,, 46 _ .> , ,I. C-. F-' H8 aU 8 '' t". ; L5 E -,Ed L') ( ), = El E5 v", . ; " 1E
. UU (E . 40 EC la . " jd 6.0 5E - , 1 Hc 9 *H 0, : E - ', 4 u' 4 ' r UOUOUNE-400E. 400UUHHE-100044 4 UNEDa U A E. E. cD H. a CD ED U
CD a E. E. H a N ED E. H. 0 _ I-4, c-2 u F. p. El CDUUF0<0000EC.1<UUCHEE 0E-..E-IA!,JEFSJI.
C., CD FC 44 :viE-,04uE,-grE-.0400,4 0(.7,.k 0 t'. a, N t' u gc9000 piaaHUcigHUEDHEJOgaH (ED. 8 p. Ev8 ,F,.
Ci CD a CJ CD E-, C., 0 Cl E. 0 0 tJ c..., 0 F C-1 E. E 0 A U , EN a 0 C.D 0 ,4 -...4 o o ., u u ,,, a: H 0 g U E-. 0 a E. q -.¶.. 0 E. H. E. E-_, H. H
,-,1 HuHga -agE-rauci HEE.C.0U FFC-JU .50_. ,-, ;, 0A0,000A001r-, A AAF. u u u E....uHaH 0 gli =
a 00 F-1 P, `,.-.Z 8 E' 8 u 8 c.) 6 ',-_), (-'4 `,-)) ,E -. 6 8 6 V, : 8 Vc E. EE-2.
2 CDU 00cDOUrCHO UN. t--, 0000E. <U<E0C-,y Ec OHOHUg., ,4uoyqc).1-,,tugug-,a,.._ C-cl < c...?, L'.. ra ,C,D, ..-), y. y o9 0 0 .. .9 A E-,,..0-..:Q1 CDHA,5. UV
1-2 ,..2 ,:...; L., -.., =3 õy4 ,E.,:, E, r,,,,, c, ,E1,. ,,,,,.
0 E--, A 0 A cJC/Cia:FE-. E-,, N ,, '41-"i'''''''' .<F E-;
PI U Ei 0 ED E. 0 H a U U 0 . u E. u H 0 u 0 H E. CD E. 1-. U 0 0 U ED E---. 0 ED H ,= A C.) N 0 U H g (9 0 E-. a E. g U g 0 0 CD 0 a a E-. 0 SUBSTITUTE SHEET (RULE 26) ()(..qggc-,u(..,E--.rigHF-toHggr-,gp.¶Jg H <U0HUHOE.E,u&-gHaHugHR.0E-E. H g U F. E. < E. CD 4 U 0 E.
C.9 1 < 4 4 u u .4 u Q.)t, E..) 4 a 0 E. EE. OUUCDOU<C9CDHUU U
E.C9H. <UU
0040E-..4U<dULDC9 L.)/auL9a 6 4 <OUHUrc 4 ciE.a:4E-,0E.0 UE.04, 0 U E. H c) C.) H C..) au,uouaHa H CD 4 CD CJ E.
U40E.C900(JaUU4C9H4f.0 0 000 4 H H g H 4 (7 U 04 H LI 0 U U U H'( ,4 a: 0 4 E.
U a, HC) < < < E. E-4 44 U < E. U UHU 1.
CD E. U 0 0 0 U H 0 E. CD L9 U F. H a.E.a:U CD L9 U
HOUC-904UUCJ<< aLpuHHa L.) ouga HuugH E. E. 4 U U u 0 E-. E. u E. 4 E. U
U 000 c,CJ44000U E. <HU4 OU 4u U < E. 0 .< 0 E. E. E. E. 4 < U E. U 4 0 4 Ui E. 0 CJO<CJOU40000044 4044400 U4 < E. E. < K4E. dup.40uouud HOHH
ChUU HQUCJE.HU < C9UU a E.I.C9C90 a 00C) UOUUE.U<HCJ0404 C.),c4 1C) 0 CJ E. 0 ci C., E. C.) U C., C.) CJ E. c..) 04 U E. u a HoHauuoHluuouaHoaugaH a ou 0 U U E. 0 u < 0 E. g C.`J E. 0 4 0 U U E. ....., F.
a, 42 u 0 a; u E. -04 0 UHU < 0 HHE.E-10C.DdCJUJOE-.0 ()C./ CDC/HOLD
H F. U 0 4 (.1 0 E. < E. 0 C9 U 0 g 4 4 U U E. E. E.
H 4 E. U 0 0 ac...),ouHE,uu U)-' E. U U 4 4 .4 CJ 0 (.9 E. 0 CD E. U V a: E. < g 4 E. E. H 0 ED E.
Ud4HUUE. U0HUE.0 U<UU00 g ouuuHaa uat-AuvougE.ogHoa C9E.CIPUUUCDULDUUL944U0C90<40 0 0 4 4 0 E. U < U 0 E. .4 0 0 0 U < 4, 0 H
E. 4 < 0 44 44 0 0 E. 4 U 44 44 4 0 4 C.) U U 0 E.
O (I 0 UUOHUU<UU0u0 E. 4UE.<0 OUrCJOHu 4 a,(JC7aLTH,ua 4 0 CD D, E. E. U 4 < 0 0 E. 0 a, 0 E. < E. C) U E.
4 a HUCDUCJ<E.HE.4)a; E.cil.ry<ci(D4., OE.OcJE.OHre.4Ur 0/4 00H0E.
0444000 <004 04 <E.000<
E.H00H4E. UCDHU 00 HUH E. <
CDE.4E.Uc9E.C9E.HUUHUD HUH4E-,.0 E.HUgU(90E-.40E.L9U<UHUUUD k.) E.
U I-. U < H < 4 4 U C.5. U H U 0 r4 0 E. E. V E. E. F.
0 4 4 0 E. E. C) 0 Ci a, E. C) H 0 0 E. U U C.!) 4 E. 0 0 H CD 4 U U H 0 U U E. 4 H. U CD U E. C) 0 < E. E. U
O d I, CJUE.C.) OU 404 <ULDHUUHC,CDUE.
4E.E.AU<<gt-.<000E-.4E-140<HE.<c) E,dr,40(.9uuE,4[-.F.Hu0E.E-,-.4 C.? a, 0 U C.) HUCJE.E.E.CDUE. E-4 44 U C901-.1.04,04 4 4 E4 0 U 4 u 4 4 rd E--, E. U qa E. 0 U U EJ U H E.
UHUUCDHUL10 HCJ aCDE-10U<HUOCJ
'CU U < 4 4 4 4 E. _ , E. E. u CD H E. E.
HO 'CU 04 0 chuUt.H0 r,,t,t / 0 E.
E. UF<U<UULDHU aoua aua u E.
C.) HU ONE.HEJ E.4 E. E--, CD < 0 CD ,...0 E-. E. 0 0 E. .-r_ , u 0 c) El u C!) E. c..) U 4 E-. E , U E. a; H 0 E. LD 0 gE4uU4HaLDOE.UUCDE.PHOUH40.<
U E-. E. 0 U 0 a E. CD E. I. 0 0 U U C9 < 4 U U < < , U4UHU406.00U<CDOPHHU040H<
E. 4 < 0 F,C 1. E. 0 E. UHU C) 'C HE. CD 4 F. E. E. 0 H
u H U E. U 0 E. gga E. U 0 U 1. E. E. CD E. E. t, E. H
CJ g U u H u E. 0 FL Pc E. E. u 0 H 4 4 F. u (.1 E. 0 UUUOU4U00,a.E.E.44HH 00U 4UE.
0E.E.000UE.<E,HUL)'0U0H HU ciU c.) E. au', E. 4 E. .4 u u u C.) E. E. E. 04 E. U 4 g 4 E.
c_) 0.4 uu00004u OH HHU E. E. u H U g 0 0 H
U0C7H<HOUUCJWUCDE. E-i g E-4 PHUO E.
<HOLJUUE.Urd 4 <1. 0 HO HiJC7E.0 0004UU0E.E. 0E.U4UHO V.)H0 '04 E.
E.E. U 0 0 4 U 4 4 u E. F. d 4 H E. 0 E-. a 4 0 UUE.C.)E.U04 E.E.E.00uU uHHOE.E.
40UOUKE.E.C.)4E.E.0000 4.4U C.)< 004 E.C.J040400000UHOHE.gouuuaH04 O4UH<H4U04 0U440E.4 HUOHO (1)U
O U U < E. 0 4 E. U 0 U < u < 0 E. H 0 E, 0 F.E.r<U4OULAUHUOLDOCJ .,.. aucauE-.
E.g<HUOUH c9CJE.00C7H E. E. < HE.
Ci c.D E. 0 0 4 0 0 E. < U CD 4 E. 0 C.9 1 a E. U 6 O < 0 E. U 0 E. H 4: CD U E. F. E. rd 0 ' E. a CD 0 pq E. u U E. 0040U <UUUU4L9E.<0 E. U PIS E.
U a' C.7 E. H E. U CD E. U E. CJ E. U U 1 H. 4 0 C.) 5 E.
C9 d E. 0 U 0U PUL)E.E.gur, HU< 4 OE.U4H(JE.u4UHE.UUU UHOE-4<.
SUBSTITUTE SHEET (RULE 26) E-, 0Z0HOC4H,p,IXO>.>.:OH>-,tncoZzi-10>aZcoE. tn H,.1>,c)11-1).4>a.riz>0000 egclizaHoolmuHw 2CD
H H H0 C.+ pr4EntAlrE.NHel0, 0 H CI) 0 (f) E. 0 0 Q4 H VI , a-, En a 4.1 0 E. 0 H rAC E. 0 E, H a, D. >. 0 0 Z 0 cn H
E.Fin >OHIZ}A 4a.rif4>44[4,--Ig .,-4x3,41.1H
,E40 t:2to, >gu2tnn pH 4 74 14 ,..1 0 a. < . CA a 44 EA, E4 M
1 a 0 X 4 U a 0 41 4 U x 0 3 z w co 3 RI z '41 a 0 3 z r4 H H z ix CD AEG E. e4 < 2 En En DJ, 5,a>. cn E4 E. H E. rAl a, 4 Cgt+ HOP-10Z 5,--1XCY cr-1 OH (11C,.->-' 00a),,CCnC.Dr4 >0.Zcon a c-1 coo q 4 >4 e, La -., ZHHHHHHO [4 a 4 u rAl H a .,4, 0 0 > 0 C
,0 00Srilr-,H .04H HCak-,Z0141440NE-40U1-1 r.,-,g >.w>4.4w ..-1E.,-.1>co3g I-1 En>H0p>Z0E400.ale4 OHEn> PI
= t9pg ,-4t0tAl Az ,,ACEnf.a. z tnala..-la-.40Ene4000,4E.
0 4 P, H CD X c4 12 41 0 E. g4 e4 (5 E. E.
FA.1 U a, (7 4 [,, 0 C4 CD Ei e4 Z
H ,.azz,41?-+H (.9010V,ZHHHENci) R
till>, E.0>HUO
H P-O F E q ril ,A4 =,=4 0 Ha,a4Ht).74E.En.-A,P,EnU PlEntina,HEacn0a EnE.N>r4 cn X cl, c4 >, En 4 a. al E. E.E., E. > 1.0 ...I CI) H x,-1C211...cr)>001gc.9 4r-Dr=1 E4 U 0 U U 0 0 < E. E. EA H r) U U g g E. 0 E. 0 E, Ch 0 F, a: < 0 U
O UUUUUUN. g A5 0 <EDUON g g ti i ,5 H
<NOLO<
HE-EL/0000U HO 0,40000000,C 4.0,400E.
uulAcDOHNE, <0 CD OUCDHE. g HUOUUUHO
H
UHOUCDUC)C) HUHOUHE.C.90g HH g E.KCUggE.E.KC
U 0 u CD .C..9 U 0 f=C CD g E. 0 0 U U U E. g 0 0 g C.) U N E. 4, 41 CD
C.) Ch 0 CD U U CD H U g E. El g 0 f-, (9 E. < U t. E. 0 El 0 Er C.) a; U
U
HOHKCHHOgg(JUUUUHUUCJUggHUHguE.L.DC)g U KC U U U u o H. Li E. CSOHHUHHHUHH U CI 0 a; a; .4 000 UUHCJgE.E.E.0,,HHHCDC.9gUOKCHE.E.C.90HE.Ua H .-1: E.
U 0 U 0 g H 0 C) KC U C.) 0 0 U g H g g g CD g E. g U Cj HHH
C.)<,CU HUCD g U gE.E.E.E.CDC)00(9g0 C.) 000 g U
l'OUC)E-',40,1A0,400,400,4F.E. E.H.NOHOE.c....CU
0 0 CD U H CD H g4 0 gt 0 C.) 0 4 C.) g g C., E-4 E.0 B 6 E. 0 rC
CDC)u0PCJ , F CDE.HgE.C.Dgc.11c9 Hga; E. PHU H CD
HUQE.C.DC9uUHUKCUCDE.E.E.HHgUE.HCDE-4u0 U E-,u .E.Duc.)40E-,HE4E-,c)c)E.E..1 0 4 U a. a4 E4 4 04;
u g< C) 0 gc u c.) U U E. E. g g U CD E. H U C.) E.-, 4 U U 0 ,..c 4 (E-,0 upc(DE.H.0,4E.H(.9E,U<NH.CDUTDUE.. UH0E.CDU00 4, 0 F-.00 UU0 0 < ,A4 < E. 0 C.) U H E. g 0 E-, < E. 0 E. U E, E. E.
H 0 CD A4 a: U 0 a: E, (D u 0 < 0 E. 0 E. 0 At E. E. 0 0 U t) 4 (9 4 0 HIDUUCJUQUg4H0 OuHUHUH E.H.400 HgCLDFu.,C
E.K4 UU E.O K4Pc .4 H0040 .4 H .4 0 E. H g C9 U U g H U
0 E.
CDHE.C9 CJUU0 00 gHHHHOHHE.HUE.H UggE.E.0 HHUH CD U> E. E. E. CD CD E. U u F. UE.HU H r,4 F E. CD U> 4 0 0 0 E, U r4 C) 0 F. (..) AC E. 0 a: Ch a: E. H < N 0 0 ,E4 U 0 4: E, F F4 0 E. 0 PHE.CDCDUC)C9C)HE. Ug4HE.HUgac F, E4 < 0 QJ E-, E-) 0 0 0 < , O E. U CD 0 C., E. A4 E. .45.4KCUUUHHAHHOgCDUC),<CDU g H KCOCD UPPUgUa,UUCJUE.4 g OH 4E--,0E.HE.C.9E.c.9 C) CD 00C-)E.U0 gOgUgt.)0E. E. E.5 0 0 < 00.4E.5005C9U
E. H U U U E. 0 E. <4 E. 0 C) g4 E. CJ 0 0 CD E, 0 E-, 0 t, (.7 E.55 E. CJ
Lir - D ,q: Q CD C9 g Ci C.) 0 g a; E. 0 g õ, F Eg4 E.. 0 u E.C.) g a, 0 E.
/
OUC)0C9tig0Hggn.HgE. CDHOUg UOggUga 0 OH UUOCDO E.E.V OUPCJI ,gUlDgQ C9g0C)C),g F4 E-O CD C) t..) C.) U 0 a; E.
g H g F, a, E. E. E. 0 0 C) UHUH < ,E4 0 CD 0 H00000E-.0g4PC0d F00r40E.r4 550E400E. E.00D
C9OUUr4UCDF 000d clE.E.CDOCIUgE.E.E.E4.4E-,E.cD 0 O CD H C.) u ,4 0 e< 0 <
KC Ci E. E. C.) E. U CD g H g g4 .--4 g4 U 0 E. U E.
U CJ C) U U Ch 0 0 E. 0 E.
C.) U 0 4 E. E. ED E. U H E. g E. 0 0 E. E. <
OgCJE.CJO a g gOUE. 4 ( ( 4 H H CDPE.HHUHUO<HaC,A4U
o PC ti (i < < (3 Q 0 E--, 5 E-, ,4 g 0 U E. AC U ED C) < < g4 0 <C CD .4 0 ,4 u0u0EØ45.5 E.a..400u0.4H,4000NON5uLDE-, UHNO,C(900,AcUULDE.c.),414E.UP,A4,4 E-4 q r4, E-= H ,14 g 0 H
CDCJE.CDE.Ha;CDE. E. AA: 0 E. AC U .A.c u < 0 a. a. 0 a, pc H 0 0 E. 0 HOHUN0,1.0HE4H .4 0 u .c. E. 5 5 0 0 d, <0E.C.)0gUU
E.HULDE. (9cD-UH,040 H -,A4UOHON,E4a4E,CDEDH<Uclac O 0 U U U E.,. E. t., E. ac, A4 PqE-,E-104,0Pc E, H QH CDOUE.a;
500E-004 E.000 ,00000.404u0u 5.4000 u5CDUO<CDUUKCH<HH g HE.E.c9H CD g C_9 U H E---, U 4: 0 4:
0 0 U U U C., L., 4G ==C C_J HHHAH U C.) E--. E-1 1...) /..0 < E. u 0 0 UHU
E. OLD (-) 0 C9 '4 4 F,F,Hor.DE.000514 OU00,4E.00 E4E4U00g00g5U0g. E.H a; E - -, 0 0 0 (-) < 4 A E U H CD CD CD u tl', 0 E. 0 0 E4 E-, gr. . U CD U (.9 0 E. H Ell 14. U H
H U Kr.
KCO00000Q E.-. HO 4 H. 0 < (9, 0 ,A4 0 ,C < HH HO 0 0 ED
9 c., E. F.
U CD U U C!) 0 0 Q E. E. H (.9 U a, E-4 CO
H U c..) E., 0 H U E. H U 0 E. < 0 c..) U C) U E. g E. E. H 0 Kt: u U 0 H H E. 0 E . < 0 E. E. c.) E.
E4 CD CD <4 U El 4 ci 4 4 4 < H c9 0 < 6 g < (9 AU 4 C7 E. 0 E. E4 ,4 U 0 0 cD E. 0 0 0 C) 0 U 0 U U C.) g E. U 0 CD HUH HA
CD CD CD C, H 0 ." E..., E. CD E. H 4 4 ,,, H E. a; H 4 g E. CD E.
C.) 0 6, CJ
O U U U U U C.9 ch U cD E.
U (5(5 a, a' C) U g CD :. E. 0 E. C7 4 U CD E, CD 4 U UU 4 CD CD 4 E. 00 E. E. F. 0, CD O. CD i. <4 4 E-' E' El E-' C.JU
E. 0 E. U 0 0 g H CD < A A g U E-4 U 0 4, c5 -. U 4 E. 4 C.) '4 4 4 U U f4 0 4 U CD CD <4 H U u .4 C. u () E. 4 E. C.) E. a, .:4 E. c9 0 E. 0 0 E-4 kJ U U F. C) CJ E. 4 C7 CD al g H a; (9 0 () U> (9 H> (9 4 4 (9 E.
E. (7 0 U c.9 u C) U g 4 0 0 G.4 P 5 < E. 4 0 .4 c) 5 E. g E. E. E. a. C5 a:
(D E. U ,24 E. < E. U E. CD 0 ( CD U r4 .4 u E4 4 0 c; E. 5 4 CD c9 4 0 cD c9 0 F.
Hc) 0 c.) (..) f.9 E. 0 E. F. E.. 0 ,c c) g U 0 .=C U 0 CD
E, E, 4..) E. <4 E, <
O (-, E' gUHUE. U U A 0 OUUcl HuF, 0 Co C, 4 E--, g4 H E. CD 5 O CD 0 E. CD g CD g 0 CD E. C.) CD U E. E-, 0 E.
.,.4 H 0.0 E. CD C5 D ET' 1 U CA F. U 0 <C 0 C.: E. H
E, F E. E. E. H E., E-, 0 CJ Pi, E. 0 U g H P,.. E. U.
.4 E-, 0 (,) H 0 E4 0 A5 U E. Z <4 F. CI U E. CD
C'J <4 H 5 E--. E. ,5 5 0 cJ U 0 U CJ 0 < 4 () (7 E-, 0 A E. 0 KC u E. 0 C) E. <C U E. CJ
KCC.100C..)00u OH E.E--gCaa,H, 4 E, g4()U0(40E,419 OC)A000UE, E-,c)E-.4.4c)cDuE,H5u0 5 0 E. E. t.c.)0 45.0)00055 E.E.HHHOUtDgH g HOE.,.¶,c) H F.E.E.
ocE.c),,CUchgcuAg4HtQg4,4g4H-pcUE.Fr.gr_Du H K4 H .-Cc7 cD
ni UCDQUChg 0E.E.E.HguE.E.E.K400CDEAu,c40 H F H U00 ol 000c)Uul.gE.C7a,004 E. 0 pc < E. 0 < U U < (el ED 04 Fs U
O CJ 0 U 0 U t.) 0 C.) 0 PC E. CD a, E. E. U a, CJ E. El 0 E. U E. < a4 0 0 E. E. U 0 U 0 E. U g4 E. U g E. H E, 0 C.) Pc 5 5 E-4 H 0 4 a, u Q c.) 0 u 0. UUUUUHUgHHE.HHrCH ggo<0 Hg HUg Ug 0 0 E.
Z < E. (9 () 0 E. E. C., E. U E. E. 1 E. E. HUH OH .4 4 OH U E. U U
LD ,4 0 uoucDpc,E-, E-4,c:E.,CE. HA OH E.-1-gc..95.00CDE.C.) gOE.0 E.
H HO HE.CAUCDC-9.4E-,.4 (94 00E-,u.40 uf.E.50E40 0) EICDOU0 EJE.E.PHUHa/U g4r44Cic.) E.004 Kt; ,C E. P
HEH gOE. E.E.Ug ga; pC <CDOUC)C9C) 9 CiUgUCDE.C) CS U U 0 0 U CD U U < g 0 0 0 0 C.9 CJ N .=4 g4 N 0 gg U 4, t.D
g C) SUBSTITUTE SHEET (RULE 26) AGAAATTCAACAGTCATGAGCAGAGCTGAAAATTTTAAACAAGTTGAGTACCTCCTTATTCATGGAACAGCAGATGATA
ACGTTCAC RAENFKQVEYLLIHGTADDNVHF
TTTCAGCAGTCAGCTCAGATCTCCAAAGCCCTGGTCGATGTTGGAGTGGATTTCCAGGCAATGTGGTATACTGATGAAG
ACCATGGA QQSAQISKALVDVGVDFQAMWYT
ATAGCTAGCAGCACAGCACACCAACATATATATACCCACATGAGCCACTTCATAAAACAATGTTTCTCTTTACCTTAGC
ACCTCAAA DEDHGIASSTAHQHIYTHMSHFI
ATACCATGCCATTTAAAGCTTATTAAAACTCATTTTTGTTTTCATTATCTCAAAACTGCACTGTCAAGATGATGATGAT
CTTTAAAA KQCFSLP
TACACACTCAAATCAAGAAACTTAAGGTTACCTTTGTTCCCAAATTTCATACCTATCATCTTAAGTAGGGACTTCTGTC
TTCACAAC
AGATTATTACCTTACAGAAGTTTGAATTATCCGGTCGGGTTTTATTGTTTAAAATCATTTCTGCATCAGCTGCTGAAAC
AACAAATA
GGAATTGTTTTTATGGAGGCTTTGCATAGATTCCCTGAGCAGGATTTTAATCTTTTTCTAArTGGAcTGGTTGAAATGT
TGTTCTC'r TCTTTAAAGGGATGGCAAGATGTGGGCAGTGATGTCACTAGGGCAGGGACAGGATAAGAGGGATTAGGGAGAGAAGATA
GCAGGGCA
TGGCTGGGAACCCAAGICCAAGCATACCAACACGAGCAGGCTACTGTCAGCTCCCCTCGGAGAAGAGCTGTTCACAGCC
AGACTGGC
ACAGTTTTCTGAGAAAGACTATTCAAACAGTCTCAGGAAATCAAATATGCAAAGCACTGACTTCTAAGTAAAACCACAG
AAGACTCCAAAGAAATGTAAGGGAAACTGCCAGCAACGCAGGCCCCCAGGTGCCAGTTATGGCTATAGGTGCTACAAAA
ACACAGCA P
cn AGGGTGATGGGAAAGCATTGTAAATGTGCTTTTAAAAAAAAATACTGATGTTCCTAGTGAAAGAGGCAGCTTGAAACTG
rs, CO
ACACATCAGCTTGCCCTGTTAAAAGATGAAAATATTTGTATCACAAATCTTAACTTGAAGGAGTCCTTGCATCAATTTT
TCTTATTT
cATTrcTTTGAGTGTcTTAATTAAAAGAATATTTTAAcTTccTTGGAcTcATTTTAAAAAATGGAAcATAApATAcAAT
eTTATGTA
TTATTATTcccATTcTAcATAcTATGGAATTTcTcccAGTcATTTRATAApaGTGccTTcATTTTTavAGALAAAAAAA
rs, cn SEQIDNO.:34 SEQIDNO.:81Ill CGCAGCGGGTCCTCTCTATCTAGCTCCAGCCTCTCGCCTGCGCCCCACTCCCCGCGTCCCGCGTCCTAGCCGACCATGG
CCGGGCCC MAGPLRAPLLLLAILAVALAVSP
CTGCGCGCCCCGCTGCTCCTGCTGGCCATCCTGGCCGTGGCCCTGOCCGTGAGCCCCGCGGCCGGCTCCAGTCCCGGCA
rs, CGCCTGGTGGGAGGCCCCATGGACGCCAGCGTGGAGGAGGAGGGTGTGCGGCGTGCACTGGACTTTGCCGTCGGCGAGT
ACAACAAA EGVRRALDFAVGEYNKASNDMYH
GCCAGCAACGACATGTACCACAGCCGCGCGCTGCAGGTGGTGCGCGCCCGCAAGCAGATCGTAGCTGGGGTGAACTACT
TCTTGGAC SRALQVVRARKQIVAGVNYFLDV
GTGGAGCTGGGCCGAACCACGTGTACCAAGACCCAGCCCAACTTGGACAACTGCCCCTTCCATGACCAGCCACATCTGA
AAAGGAAA ELGRTTCTKTQPNLDNCPFHDQP
cs) GCATTCTGCTCTTTCCAGATCTACGCTGTGCCTTGGCAGGGCACAATGACCTTGTCGAAATCCACCTGTCAGGACGCCT
AGGGGTCT HLKRKAFCSFQIYAVPWQGTNTL
GTACCGGGCTGGCCTGTGCCTATCACCTCTTATGCACACCTCCCACCCCCTGTATTCCCACCCCTGGACTGGTGGCCCC
TGCCTTGG SKSTCQDA
GGAAGGTCTCCCCATGTGCCTGCACCAGGAGACAGACAGAGAAGGCAGCAGGCGGCCTTTGTTGCTCAGCAAGGGGCTC
TGCCCTCC
CTCCTTCCTTCTTGCTTCTCATAGCCCCGGTGTGCGGTGCATACACCCCCACCTCCTGCAATAAAATAGTAGCATCGGC
AAAAAAAA
pokkAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
17.1 SEQIDNO.:35 SEQIDNO.:82 CCCAGCGGCCCTGCAGACTTGGCACAGAGCACACCCACCTGCCTTTGTCACAGCACACTAAGAAGGTTCTCTGTGGTGA
CCAGGCTG MEGSLQLLACLACVLQMGSLVKT (.=
GGTAGAGGGCTGCTGGGTCTGCAGGCGTCAGAGCATGGAGGGGTCCCTCCAACTCCTGGCCTGCTTGGCCTGTGTGCTC
CAGATGGG RRDASGDLLNTEAHSAPAQRWSM
ATCCCTTGTGAAAACTAGAAGAGACGCTTCGGGGGATCTGCTCAACACAGAGGCGCACAGTGCCCCGGCGCAGCGCTGG
TCCATGCA QVPAEVNAEAGDAAVLPCTFTHP
GGTGCCCGCGGAGGTGAACGCGGAGGCTGGCGACGCGGCGGTGCTGCCCTGCACCTTCACGCACCCGCACCGCCACTAC
GACGGGCC HRHYDGPLTAIWRSGEPYAGPQV
GCTGACGGCCATCTGGCGCTCGGGCGAGCCGTACGCOGGCCCGCAGGTGTTCCGCTGCACCGCGGCGCCGGGCAGCGAG
CTGTGCCA FRCTAAPGSELCQTALSLHGRFR
GACGGCGCTGAGCCTGCACGGCCGCTTCCGCCTGCTGGGCAACCCGCGCCGCAACGACCTGTCCCTGCGCGTCGAGCGC
CTCGCCCT LLGNPRRNDLSLRVERLALADSG
GGCGGACAGCGGCCGCTACTTCTGCCGCGTGGAGTTCACCGGCGACGCCCACGATCGCTATGAGAGTCGCCATGGGGTC
CGTCMCG RYFCRVEFTGDAHDRYESRHGVR.
CGTGACTGCTGCGCCGCGGATCGTCAACATCTCGGTGCTGCCGGGCCCCGCGCACGCCTTCCGCGCGCTCTGCACCGCC
GAGGGGGA LRVTAAPRIVNISVLPGPAHAFR
GCCCCCGCCCGCCCTCGCCTGGTCGGGTCCCGCCCCAGGCAACAGCTCCGCTGCCCTGCAGGGCCAGGGTCACGGCTAC
CGCCGAGTTGCCCGCGCTGACCCGCGACGGCCGCTACACGTGCACGGCGGCCAATAGCCTGGGCCGCGCCGAGGCCAGC
GTCTACCT SAALQGQGHGYQVTAELPALTRD
GTTCCGCTTCCACGGCGCCCCCGGAACCTCGACCCTAGCGCTCCTGCTGGGCGCGCTGGGCCTCAAGGCCTTGCTGCTG
CTTGGCAT GRYTCTAANSLGRAEASVYLERE
TCTGGGAGCGCGTGCCACCCGACGCCGACTAGATCACCTGGTCCCCCAGGACACCCCTCCACGTGCGGACCAGGACACT
TCACCTAT RGAPGTSTLALLLGAILLKALLL N.) CO CTGGGGCTGAGCTGAAGAAATAGAAGATCTGAAAGACCTGCATAAACTCCAACGCTAG
LGILGARATRRRLDHLVPOTPP
cn RADQDTSPIWGSAEEIEDLIOLH
KLQR
N.) co n.) .00 t.) ___________________________________________________ , ___________________________________________________ , 8 8 ,E,' El El 8 ,' 8 8 8 (5C) 2 6 El 8 24 El El 4 4 El 8 Et: 6 4 6 L
E. 0 c9 .4 E. A4 C) E. gg (7 CI L9 0 H c) c) c) g (9 E, E.
(5 0 y E, E. 4 E. E. .4 () (7 E., 0 (7 .., r4 0 p (7 4 (5.4 CD r4 U U .0 C) (50 g4 y a C) CD a .8 P. Et. r) E4 8 8 ,',,', 6 8 8 El 8 8 8 ;1 8 Ll Et.' 6 8 tl 8 8 8 4 ,'-4' 8 ti, E.4 0 4 0 (7 0 E-, .4 H 0 0 E. 0 E4 E., CY 0 .4 E. 0 E. CY H E, gg H.4 0 E,'- El 8 '6''' 8 8 8 El El 8 E3 El 2 6 8 El 8 " 6 El El 6 2 8 2 8 0 E. Cy E. E. 0 0 U c.) Cc 0 .4 0 LD .4 .4 ,1 0 E. t) 6. (9 4) E. Ed= Ei t-I gq CD E.
0 .4 .4 EA (5 g C.) (7 C) K1: E, L3 E. CY H E. C9 E. C) .4 0 (7 E. (7 E.
El E. a 0 u E. C.) E. E. E. L7 0 CD 0 0 EA E. .4 (9 E. E., c9 ,r, u u t4 (7 (9 (9 E, E. c) c..?
8 El 5 8 8 E4 2 8 8 8 El 2 2 6 ," 8 El 8 8 0 8 S () 2 "..1 F-,' E-ii 8 8' g E. 4 E, EA 0 < .4 E. Cy AII S4 E. E.
(9 E. E. c9 E. r. AcJgL9U E. 0 c) ED c, (9 E. E. ,4 y : .1; Ei E. .4 L7 y c) E-4 .4 (9 u 4 fg E. ci .4 E4 E, 4 EJ CY
,i34 (5' 6 1 6 8 g 8 Cj U 8 61 .4( u,5 (g9c I; Eci; r.
6 U i% 0 t; o [1 o 8, tl 0 (D E, E. CD E. C) (7 I. < L9 E. ., L3 0 o.C, ,,t I) E. CD I. (9 E. c9 E, CY CD .0 C.3 E.
6 El 8 E, 8 El E1 0 " 8 8 8 8 8 2 6 E4 ,`,4) 8 6 EI [5 2 El 6 [5 El g) F. 8 El il 1 E4' 8 El 8 El f4 El ',- 6 LS 6 El '8 ',-'4 8 4 6 8 ': 6 El 6 E.- g [5 f 2 4 8 E--,,' E P. 6 6' ';',1 Z5 6 8 El f4 El 8 1 '-i 8, 8 i4 8 8 6 '<' 8 '4. '.' 68 0 E. U CD U 0 (9 U CD U U ,,,: t. E. .1, E7 (9 .4 E.
u H f', 0 b; 0 .-4 n.: E4 8 8 F' E f. 8 .-_' E4 6 El 8 f4 2: S 8 6 g 8 8 El E':-8 El 8 El u H t-.4' P. t;
'6 EC-1 P. U ': 8 'il' 8 8 8 8 8 F:.' il t.
(-:, 8 '6'i?, i P4 6 El 6 8 8 8 < 6 u E. c9 C) U 4 = 0 E. E. F. .4 EA EA .1, E. < r4 (7 E. .4 EA 0 0 ,q CD ge si, (7 [1 t7 8 F.% E-61 8 P. g; Ed 8 8 E, ,HUH 8 EE.--1 4 8 6 E--,' 6 -?. Z5 6 Z'3 8 '.'4 8 .4 U C9 CD E. E. E, C) c9 C) 04 Ci (J c,C FC E. E. E. C) .e L7 C9 Al C) E, i1 U CD gg (9 .., C9 E-2. i-l; Cl E4 8 8 6 8 6 u '2 8 r3 8 2 6' 6' 6 6 [2, [1 6 gll Eil c' P .',4! 6 E., _ k4 4 4 El! CD E.
B 8 6 El P-: 8 2 8 El El 8 '4 El El El 6 8 t1 El 6 g fl 8' 8 EY. r, 8 0 (2 E. 0 0 .4 E.) (7 Cy 0 L3 L) .., E, 0 0 E.
.4 (5 0 _ , u I. .4 .4 U Ot .() 0 0 L9 F. (-4 u .4 u u U E. E. U CJ 0 LI H .4 c) L) gq ID E. E. (J (9 CD a < < < --_, (...! C), 0 i'!.'5 r, p."r, p.r,õ ,<L) ti 6 El 8 8 0 8 8 2 6 j 8 2 'i 8 El 8 2 4 8 8 6 '6 8 .õ ., u c7 (9 E. 0 E4 E. p; E. E. ,4 .4 u L9 4 u U C7 L3 E.
(-4 (.4 (5 E. (J c9 0 0 L9 0 E. (9 L9 E, E. E-, 0 0 0 U oe C3 C.) 0 E. C3 U .4 (7 E. 0 4 C.) .4 ,4 U L9 o Cy C.) 0 0 Li CD .4 E. 0 C7 4. ,' 0 EA E. H 0 .4 E. E. t7 EA .4 .4 0 H
0 0 () HUH U E. U CD C9 .4 El E.7 0 cl CI L9 E. T.? E. y U y E. < p (q Ei 8 E, 8 ..g.
?.-2 !I, E., 4 8 CY cc?, C) Ei.J, CJUnUOUy CD y y 5 1;-. QD U c,,. 0 ko. i..; .3 r_.
0 ,....; c(-:11 Lc..., E4 < u 2 CD il CY -.3 up fr"... up _-.4 2 f--! E.% S E.
0 E. ,- E. 0 c9 C. c) CD 0 ,C u H Pc C9 u u CD ci u E, Ll 0 Pt; tC4 . E. (9 U C9 !dc H
E. Li E. 0 0 C7 (7 C) C) E4 ' E. CJ 0 U 0 4 4 Ft E, U E, 0 ,C CI E. 0 0 6 s_,,. ,õ, g il 2. 6 6 g g El 0 t--: ,' 8 ri!
6 8 8 8, El 6 6 8 El 8 (;.i El 8 () 8 ',' 3 6 ,, 0 , E. C3 0 ,,C E. c9 4 E. H E. 0 0 ,4 .4 ,E-A S.? S2 p S2 g ,H ,, ,S.%
..,' rci! ,J 8 Fcd:
(,, FC f= E. E-. C3 E, (3 U 0 a: E. 4 0 U 5 E. u C2 .1; V ,,, c. H " " ..., a t_: 6, (J 0 P. El 6 8 S 8, 8 8 ' 8 6 El 4 (3 Vi E4-4' g EE1 8 8 El 2 (9 ..' 0 0 =....
U Cy Cy .4 El cy u E, .4 c9 CD L9 .4 L) .4 c) c9 E. C.) 0 U E.
F. L7 ,rC () C) C.) 0 rt 0 0 CD H ,,t L3 L3 E., E. E. E. 0 CD e E. xl: 0 C9 0 Ei U 0 c../ gg E. y CD UP. c9 f3 El 8 8 8 8' 6 8 Et-2 8 8 8 0 6 El 0 8 E3 il L 6 II,' g 8 8 8 6 1 8 8 F. 8 El 8 8 El EL El 8 8 4 8 El 2: 6 8 2 i- El r g t; 8 El 8 8 E, 6 4 " El t5 8 4 8 6 8 8 4 8 8 EY E. 8 0 t7 E. 8 8 8 ,, 6 i:: 8 6' 8 P. E.' 8 8 8 0 8 2 8 8 8 E., '..- 8 il El 2 8 1 8 2 2 2 11 6 t; P.
' E"' 8 ,'C E3 2 8 8 2 8 E-3 6 8 8 6 ,'' 8 E-4' '6 E5 g E.-4' ,11 El 8 4 8 8 6 E--. (2 C9 O C) _ g (.1 () CD EA (7 (7 (7 C, q CJ C5 P Kg (.9 g4 cp u Kc E. (9 A C./ 0 4 0 c9 C..9 0 CD 0 ,4 (9 E. E. c9 cy g4 u E-, gt, Ft (50 ,4 (7 6g CY 04 c7 Cy U HUH , cp Kg p p. ,.,..1 0 .Ei'-c' !c.-.!! " ,-4, (;. Pu --.F! '' " -.)..), '',6. Li Y." 8 0 8 V, 8 6' g P. g g (4 ,, ,_, ....,,,,,_,,_. E- ,,,, (il ,,. ,..., ,v li V., g Pd, e,C U E. U E. L.) C) C.) C9 CJ E, CJ a ,,, [5 8 El El 12. 8 El E. a E.-4' t.-). El 4. E-, El 4 8 ',,' 8 ,g:. El El 8 t5 El ,.., E., 0 < E4 '41 4 E. 0 0 (9 0 C9 0 E. gg 0 I) I) C9 El I) __ CD .r...p p c__, p --._. J. s.p E ! I.--!
.: 8 8 8 El 0 8 El 8 8 8 8 8 6 8, ';-4' 6 6 2 E 8 8 8 8 8 8 (.,. ;!.' -!, 0 CY 0 E. 0 CD E-4 0 t4 K4 CD CY E. CY E. E. CP E. 64 4 C.) [-", E. E.
L7 E. 0 E. E. 0 C9 CY E.
E g g il ill i,-4' ,D4 V. 6. 8 il 8 8 t; (35 !- F. ("6 Eg-4' (el Z;
ti 6 Eg t5 El CD E' " E. 0 CD E' '.' CI 09 u (9 c9 t. E. 4, F. CD ., 0 c) E. E. c9 U 0 E. C) 4 U F. 0 L.?
g Er.. t5. Eg cj '6 [7'9 t5 t5 8 8 0 8 ; 8 8 f:: ill [-p: 8 P. 8 f5 2 ?- 4 2 ,,õ ", 060E-.6uu<ugug ..õ.E.,(2.1E-. 4 CDUCDC.100E.E. .0 vi SUBSTITUTE SHEET (RULE 26) C.) CD 04 H g H 0 HE. A
U, E-.UUCD<U000U0 00CJE.E.OUHU U
< 0 g0E-'0E--'0UciatUactU< ,E.C9H<OUOU0C7E.
U U at E. U C7 E. 0 U U E. H 0 < A H 0 0 EA El at rz4 H
U H
0 cl C.JHUHOV.hat0H0C7(7< <UE.CJ<E.UHHE.E, U CJ<<HE. UE. (9HE.dUCIC7E.UUU<C7HE.0 u U 0 aCUPHOHL70 <C)(70<04 ogq. uu,,cgc...qu<
u H 8 8 (Ei 1 .2 ('-.; 8 8 8 3 8 8 fl El P, 8 E9 :2 E LI: 3 8 r, 8 8 --:
i E. C., 0 U 0 f-, 0 gq K: 0 0 0 H E-I E-+ U 0 H 0 at 0 E. 0 F.5 E. d E. I.
U UE.<0,E.CØ0d0U000L)UHdCh 0,<C7 UUHUU
C7 0 UU<NOUUUUU<U0 4 A .4 0 H
E...) H 0 A' ..., 0 E. H
0 A 00H<Chat CJOU<NUHUE.H0HU<C10a4 E-, g g u <HUal,F,(30000E.E.FtC7HHC7dLJUd E-, ...1 A 0 0 U
0 0 E. 0 0 E. U E. 0 U 0 C) 0 C) E. 0 0 at 0 E. 0 E. U 0 < U U U, C7 (Fl!) A .4 HHE.A.4 E.HA U.4..GEØ4.4E.E.OHNOHE. U
E-, E. rtE.UU<Upt 0d HOE.E.00E.E.<<UUChatH E.
0 H OH0000000 U0L7do. 6i9oPuotn E.U000 (... A; 4 0 0 0 E. 0 E. 0 0 E-. 4 0 H a, 1 < U E. (7 H 0 H (9 E.
(.9 H (70HHOE.<H<UUE.0000.< CJUUrd0d0E.<
E. U E.E.<U0ChacH(9<(.7000E.<0 UatUUE.Uat E.4 CD
0: ei CDUat.E.HOE.OHCJUE.Hat Oat E.HE.(70<<C9H<E, 0 0 0 0 u H < 0 I. U 0 E. C7 U d 0 0 C) CJ Cl rt at U H U (.7 < 0 U
d E. at HUUUU < E, E. < E-,0HuE.o<ECJC7UucJH A, Et t.
U H E-, 0 0 < E. N U 0 < U 0 U E. 0 U E. E. U E. 0 U < 0 < <
O H E.0,00<U0000U<U< NEI
FC7f4HUE,<UU
E-4 a, E. E. < U H U < g E. U U 0 CJ E, C..1 U E. N U E. 0 E. U
1.9 U .4 n. 0 U E. 0 U E, <00 HO<C7(90E.UUE.< E. C_7 E. U U
U U OUNE-,010U0UUUUUU E.01HAEØ40U0 A
U 0 UUC)<U <0.-I<U00W0E.< H H u U 0 E. E. E. U
at 0 <C70CJED UU<OE-,<H<HHat E.< -gq c.9 E-, e, E.,qc5 E. c.) HOE.00HUCha,H(J<LJHUHLDH g4 ID pc H e4 cõ, ri: 41 H
Ecu UU
?, H 0 H 0 0 E. (9 U C.9 < 0 H E. E. 0 E. H E. U E. 4... E-. 0 0 0 E. E. HO 0 UrcUU < <E-.E.E-, U < 0 0< U E. U
g4c)of--,ugot., dUdE.U(DE.E.C9HE.at H E.Hgq_. E.
0 0 CI E.E.E.CIUUUCJOUat000<00UUNHUHU
E, 0 HUOU.< HH0U0HU<OZDUP4 HOULDCDH; H a.
(2., U U(7000 OUUUE.HULJE.E.HatUE.E.U< A. E. U
E-, H. cp 0 E. 0 0 E. E., ,4 Fr CD (...1 N 4 < E--+ L7 U 0 E. 0 Ch < c9 H
0 d AF40UCJAUCh.4 UUCJUeHOWN A 00,ACJE-.4 U
O 0 0 C.)00 0UUHHUU0OH <UU ONHU 00,...
00 UE.<<OD<U<HUU<ON(.9 U0000NuCA
(FU 1-i H < < UUUUUUCFUU
HO E. U 0 0 0 d g U CD CD H CD H E-+ 4 E. E. A 0 A 0 4.qAHAZDOH00E-,E.HUEJ00 CiEJOHE.J.....<0E.
E. 4 0 A 4 U < U 0 0 U 0 < E-, 0 0 4 4 U H E-. E-. U < E-. H 0 E. < <
0 0 E. U 0 u 0 W ,r H C.7 U U C.) oc E-, CD F. L) CJ C.) H gq Ci 0 H 0 U 0 0 H 0:qt,UUL)1.)UKC U 00 U OUC1 Ea 000 0 U 0. g u r_i Ch .t (70H<U0E. E. E-, U 0 < U 0 gqou ,-quu,4 U 0 0 U H
,t 0 U d E-1000<0U<U0.<0<4,00 HH0E.<0H<E.
OH' U UUU<OO<U<E.<0000UUHUU< Kg AHOU0 0 E. 0 0000000HOHLJOL10.4.4E-40H0FAOHOUA
0 E. ,i= 0 < U 0 C9 E. L. U 0 E.
a( U < U U U U E. CJ CJ U E. U < U U CJ
A U ,= U000.4 at E. 0 < N E. E.
C7 (7 d HUOU00E-, < < 0 E.
O -..,q H 4!0oE-,ouHUU0 6tHCJOU HUOatOrt HHOUat F4 Pc 0 D 0 e. g: F-4 pg C) u CS C.) 0 U 4 t. < E. E. < H 0 u cp 0. E.
0 U 0 U 0: ,..., E. NAOHE-.0 AUCJC/HUE..40E-,..,00.110A A
E-, 0 0 4 0 0 E-, U U 0 E. .4 0 < U 0 < Q 4 0 0 HU,G0 U a. H, E. 0 U 0 H 0 0 U E.
< 0 E. (E-.) EC-7' 8 3 8 Ec2 '6 'il4 ti t-D' 8' 8 2 N it', ',." 8 8 -'. E. A H. . H
H E. 0 4 0 0 04!C7U0C74!HE.C7UUOUU0UHUUHE.0 Ch U a' E-I U < C_7 U E. 0 0 H H H 0 U
< 0 E. kJ H < U 0 0 E. H d H
H 0 d (7 0 EJ 0 u CJ U CJ H CJ H E.
E. E. 0 H at ac 0 0 < at 0 H 0 U
E. 0 H E. H HO 0-F-' ,ri:ogyugovHOK4,o,--¶--, HOU [J
g4 K4 E. EA < CJ U 0 E. 8 E. U 0 U 0 H < C.) U E. E. 0 U (9 H E-, 0 0 U
0 Ci a=C OUU0a, 2.< E. U < u 0 u H 4 Ei u r..) 4 0 A 4 0 Ft g gC
U HO ,C Ci U U ' U 0 E-. E. C.) u C./ E. g u 0 ,: E-4 0 H 4 E. U E. 0 E. E.
0 A 0 0 0 < E-, A 0 A 0 0 A E., U 0 U E-. 0 4 I. A U 0 H A A A E.
.FU C) 0 0 U U U C7H00 00000E. ..4 CD
< 0 0 d E. 0 at < U
CD Clg g 0 E.-, U H E-, 0 U g UN g g LD 0 g CD g 1 E.pc g CD 0, N U CD H C..) uHue,i,uu,-5. ouHH ust: 4000 000 r", E.U<NR00001UUUKOU UH E0E-100cy E. E. 0 == 00.4E-, UUE--..1,4.40000 < U E. CJ
E. U u c..) q A E. E. = A 0 q E-, 0 CD E. a, a, E. E. < H d E. < < 0 at 0 E. 0 <
0 +, U 0 U U fat H E. E. E. H d d U 4. 0 E. E.
I. < PC .4 E.H 4 (7 <
8 u '' z 0 ,..c EØ4 L--, 000000E-..40uU0E.L.A00U0u EJ E.-. C:1 0 0 A U 0 E. -4 0 E. U U 0 U 0 A 0 E. H A A 0 0 0 0 4..) 0 E.
H4!UNNE.4!UUUOUH00H4!p4u04!uoutpc..)u O U E. 0 E-. 01 0 0. 5--, 0 H
0 ,< 0 U H. U E.. E. 0 H < .4 0 0 H H. H 0 E, E. 0 .4 r4 [--. E. o 0 c4 E--, E-, 0 U
E. A 0 U E. 0 0 H 0 E. H C., E. E-, < H U
< 0 0 cri E. E-, E. <
U f-, .4 .4 C. 0 0 HUUE.J.:G4,4HurcuchuuE.<
, __ -SUBSTITUTE SHEET (RULE 26) E. 4 0 U U 0 0 040E.U0H00400000440E.C.)04u U U, 4 0 0 U E. U u 0 al E. E. 4 Er. C.7 E. U E. 0 4 E. U CD U U U Ff ,..0 E.
< C9 4 4 F.S.u04000E.00E.4E.0HOU 4 0 4 H 1 c.) 4 0 0 0 4 U 0 (Cl U 0 c.) 4 U 4 H H 4 H 0 4 E. 0- H. A
C.) 0 4 Ci E. U 1A HOC) 0 0 E. U 0 0 E. E. 0 H 0 E.
Cif. uUCJO H E. C.7 U H a. 0 C.) C-, CD 44 0 (Cl 0 E. U U H A E. o Er, U
El %E-41 8 i u040u0Uuuc)OuPUE.4E.E.)4000 4 0 Pi, g r , C 9 Pc r4 C ) C 2 (Cl CD OH4 E.H.C.300E.HE.
4 E. 0 E. U 3 U 0 4 U U 4 0 H E. E. 4 H. H 4 H 4 F.7 E. 4 E. 0 E., 4 U . E. 0 ( E. 0 E. U 0 4 H C.) 4 U H
0 E. 0 E. A E.7 F. 4 U (41 0, E. 4 U u F.-,00E.Ou0,40HE.E.OE.HE. Hut. U
4000000 E. E. E. U 0 C.) 4 U U 4 4 E-, E. E. U .4 0 0 4 U E.
0 4 U < c!) < U r..) 0 0 CD ft U A H U C.9 E-t E-1 0 E. E 4 H E. H 4 0 4 E. H P.< 0 E. E. 0 E. E. 4 0 U 4 0 .:Dq ill) E74 ti9 8 8 (i-_,) '65 (.1,, 8 8 '(5 EY. 8 8 t; 6' i--', t--,' 4 0 U C.) EJ E. H u ,..i E. H E. 0 Er. E-.,. C.) 4 g E, E. 4 E. El 0 4 U 4 E.) E. E. 4 rc 0 U E. u 4 E. 0 U 0 E. U y ro 0 E, 0 Li 1E1(400Ft 0 0 gt U 0 4 C i 0 U E.) 4 E. 0 0 E. 4 0 c.) 4 E.) I. 0 OUE.004 rt:HOUE.E.U000H4UU OHHU00 EA 4 u u A C.} 0 0 : C . - l',',q E.) 4 H. U (..) 4 (Cl El 0 4 A U00019HUO
0 4 0 0 E. C.7 u OU414C;Uu0u(7040 1.5 A A u A q E. A
w g E, A CD C9 C.? E.044000Ht..9E-.1.4E.E. 40404 a,C..)0 C..) 0 F', 0 E. r4 U ,,4 0 0 0 E.--.00E-,PE-,0000 UU0E.0040 r.q E-, U 0 0 -KC 4 0 ,,t 0 0 0 c.) .r E. 0 0 4 4 0 E. E. E. u 4 E. E. 0 E.
C) H H H 0 H E. 4UV004H0uuuLD HOHUCJUE.4U0H
4 E. 4 .4 0 0 E. 0 0 CJ U ci 0 4 t..) 0, u U Q.) U 0 4 Er. 0 c...D 0 0 U 4, 4:
0 .4 E. 0 U U a: Q.) E. 0 E. E. H U 0 4 CJOgc0(.744,<CDU<U000 U E. E. 4 0 0 E-, 0 0 4 0 (-) r- LI C.D rc U 4: < C.) C.9 4 H E. 0 E. 4 0 F. 4 O4400HU 40CD4U4E.60UUOUUE.uc..)44H0u O C.) E. 4 E. 4 0 HEDUUE.C9H C9U044 4HUE40 uHuu O 4 E. 0 E. 0 u 4 E. 4 0 E. 4 E. u 0 4' 4 E. U E. E. 4 4 u E. u 0 E. 0 AHAHOAH E. H E. u E.) E. 4 u g u U U 0 E. U C.) U E. U a, 0 U
4 4 U C) E. U E. 0 4 E, 0 4 E. E. E. 0 CD < / f--, u 0 u 0 0 H 4 4 0 E. 0 Ci E. cD 4 CJ 40UHuu04E.UOu E.00404E.H0U
..¶7/00C1E. U I. < U U U u c...q u 4 E. 4 H E. 4 H 0 U 0 0 E. u ga; U U 0 CD U E.<<CDNE-, 9, U UUE-UP<C9 E. < U 0 4, 0 4 0 0 r...) C.) C..)0U0E.4U C.)040400E.0 .40 00,HE, 0 40 000 4 0 CJ ' <UHE.E.NUC E-,<CDC...DCDUUOU<
0 CD < < 4: CD 0 U U 0 F E. 0 F. U CD r..) 0 4 4 E. 4 0 0 E. E, 4 E. 4 /E. 4 a. u E. CD CJ 0 a: 0 C.) 0 0 4 E. E. 0 C l 0 CD 0 C.) 0 C.) E. U C.) E. E.
e. E-, 0 E. 4 U 4 4 C., E. 0 0 E. E. E. 0 U a: 0 E. U E. 4 U 0 0 E. E.4 UCJE-.040 E. a, U U U C.) E. 0 E. H E. E-, (9 E. 4 4 0 0 4 4 0 E. 0 E.E.0U<F, E. E. 4 9, ,4 0 < C.) U < U U E. U gE CD < E. U E. CJ 0 4, U 0 0 0 CD CD ,4 E. U u E-, U CD U CD E. < U 0 F E. CD U 0 E. E. CD 0 <FUUUF 0 H 4 4 E. 0 4 0 0 C9 0 E. 4 E. U H E. 0 U 4 E. C.9 E. U
C) 0 4 4 0 0 0 V . 4 0 E. 4 U 4 0 0 0 E. 4 H 0 U 4 t7 4 4 U 4 4 o E, u u u El E. E. 4 C.) 0 E-, H Ei UUHAUCD<HCIE.,<FUE.EDE.
U E. E-, F. 0 ED 4 E. 0 4 U 4 C.9 0 4 E. U 0 U E. 0 4 E. 4 L., 0 H 4 4 4 0 4 0 A A o 0 .4 HUUE.00000U0H4,040U4H044 CD E. U 0 U U 0 40E.HuuluH440t....404010or...)Hu H F < H F 0 0 0 .4 U C--, c-, r..7 C.) Li Ft, u H H C.), 0 4 4 0 0 0 E.
10C)00H0 E.C.90000, UU040C) 4 C.) E. E. 0 C. C.) 0 CDUCDU<C9 OUU01-, ,:4 400004 4UHEJHUUU
00UUH40 4 E. U 0 H 4; E. E. 1,4 E. 4 0 E. AgoguE, 9 :=,.n t-, E. u ,,c ,,, o U U E. E-, EA E. , a: U < CD E-, E. E. <
< E. H 4 U
U u 0 E. 0 u 0 0 Ci 0 4H0 0000H4Ouu OH 400uu 8 ',-'t 6' x): 8 tj i 0 ,x, E. , u Er, (..J U 0 U 0 4, 0 E. E-. 4 .4 0 0 0 0 U U
0E,E.4UUUOUE.UCDE.44004:0E-,UOu 4 E. C.) 0 U H U C.)00E.04 4 0 U H U E. F 0 E. < < U CD E. H E. (5 44 F 0 < 0 E. CD < 0HHOU4H400H00E.C9E.E-,C) E. H 4 I.
0 H 0 C.) 0 E. 0 C., 0 U E. 4 4 E. 0 0 E. 0 U U 4 Ft E. 0 4 0 0 L.) 0 E.
0 6q u o g (9 E-, 4 UUUOU0C9HE.4E-40 OUE.E.OUUHU
< U CJ U ti r4 U 4 4 0 4404 < U 0 4 E. < < E. 0 E-. E. E.
E. 0 E.
CJOUE.0CD<E, < 0 U < < < CO 8 o (E-4 8 ,r5 8 8 `-, 8 '.,? Et?, 8 EY, ,E' E(1, 8 (C-P0' SI
rDE-.00E-400 E. E. 0 4 uguE,c9c..9(.94 upugE.-,uE.C-, f-, E. E. U 0 U U E. 0 < E.. 44 U H r E. F 4 r..) 0 0 E. Li 0 U 4 0 H E. 0 E. gC E. u 4 0 E. F. 4 c.. E. 0 0 4uo(94c.924clouguE)0A
u 4 u H EJ E. E. 0 E--µ E. E. U U 0 a; CI CO E. E. ii u 0 U H E. 4 0 E. 0 0H4HOCIU 0 et O 0 0 U 0 U U E. 0 E. 0 E. E. u E. C.) U 0 U
4HOEJE.E.0 oru,SUOUE-.4E-.00E-.'0E-.E.u04E.OE-,u 0 4 0 u .4 H 0 E. 4 4 E-.04000E.F.E.00E.040E.0 E-.4 H H U CI 0 4 4 E. OHE.E. A 0400000UUE,4000H A 40 0 8000004 U E.E.0 UUOU40C94.440HuE.0 4u 0 U 0 C./ e= E-, 0 4 Ft r.., 4 0 CD U 4 E.
U Fi 0 E. E. 0 H CJ 4 0 0 E. 0 0 CJ.40UHU co CJUE-4000C90E.E.40E.HUAU(..)4H A 4 0 El E. E. 0 4o4(9 rn H U U El CD CI C.9 CJ CD U E. 0 0 4 0 E. 0 E. [..) 0 u u U E-4 E - . U 4 4 0 0 = = 0004,004'E.FE.U.:4:0<<FUCJ u u c_q o HEØ4H0t1 = 4C.)44E.E.14U44E.U44HHOE.H0E.E.
E.H00040 0 u K.7 E-, E, 0.4 u 4 u E. 4C.,CJUE.40U4 < Hurl;
E.E.E9EHE.Uu Z UU4u40 r0E.E.00E.E.44UU04H
O004C.)E.H0 A 00u0000 U(9044,400HCIU0E.00 U U 4 E. E. 4 E. E. H E. 0 E. 0 E. 0 0 E. 4 0 E. 4 EJ U 4 0 E. 0 E, 0 E.
0 E. E. 0 0 CJ ,4 u a F. E. 0 E-. 4 E. A V U E. U 0 Ct) 0 4. U C.) C.) g 0 < 0 4E-. 40E000 ta k4000a.E.040000E-.=40 0400E+04 u 0 4 0 E. 0 U E. 0 H u E. 0 E. 0 E. U U E. E. 4 L) ,4 E. E. E. 0 0 4 4 0 F.
SUBSTITUTE SHEET (RULE 26) .. __________________________________________________ r..) 0 4 H U C.) Ci a, b) E. U a CD E. tD 0 u a a E. CD
H a 0 0 A U E. E. a 0 0 F. (--)aE. E-,q0E.00t.)E.E-i0 A .5 aE.00HE-.
ac-DaaCJOE,u CD a E. 0 a 0 a 0 a a, U E.-, (JAE, U
u CD C.) E. a E. a 0 0 CJ E. I U 0 0 E. C.) U U a 0 Ci 0 A E. 0 E. CD tJ a , F. 0 H CD CD a, U 0 0 a 0 a 0 / U U a U
E. U u 0 a 0 0 E. F. LI 0 0 C-3 F. E.
a, a a gl. U U E. CJ H H C)0000LJ U0CJHUE.CDF. E-.C.)HC) 0 H. 0 0 E. 0 A U CD0E.E.0a0CDUE.aE-.001.0E.E.U0aE, 0 a cA CJ 0 CI E---. H 0 a H E. 0 a ft 0 V ID E. E. T. ti 0 E. 0 ,a 0 E. 0 HaCJ Cit5C.D0 _____________________________ 0 0 CD a E--. E. a 0 Ft CD CJ 0 0 0 0 U E-. a 0 u t j E , 00CD C..1 /you 1. 0 U u u 0 0 4 u 0 4 Ug,A0 OU0 1 E-, 0 H 0 A u 0 u g z. C.) E.-, o I-, E. 9 H. U a 0 0 E. u 0 a A a: 0 E. E. E. E. 0 0 0 CD 0 H. F. A 0 H E. C) a 0U a E.
0 E. a 0 F. ch E.0HCJHOU000LJE-.0040E-,0E-.0cD
I
U < A 1-, 0 < U 0 < E. E. P C.) ft a ch a, a E. U C.) U
U 0 u E. 0 CD 000 a a a E. E. U 4.4 E-, U 4 < E-, E-, 0 H. E.
U E. E. cD U H. I--.HUE.E.H AcJ
UH<OU0 HachUaa (1,_ , u q 0 Ht_DHHOChE.Hrt auu a E. CJ Ci C.) E. 0 Chc-JE.HuCJuUL) 00(Daaa0CDE.000 aU0a4C2CDU PHaaE.C9HUCh A H 40E-,Kcul 4 uE., 0 E. 0 E. 0 0 0 t. E-. E-.0-aa0HaEla 0HCJ000a uCiCift 0 U E. E. E. 0 0 a CJE.aa0chaE.C.Da0000Ha0 Ugtue HuaCJAaCh C7 <000H0HOHL/CJE,H<CJAHHHOO<
.40HUOUCJC) CDE.a0a0E.C.)0E.0UKC00UuCia 4 u E-, 0 F.E.4 H E. 0 0 a 0C-A 0,< 0H E, aPIDEACJE.CD p 0 .000 UaOuth0H0 00E. E.HUclaCJOUHEDUE. a E-, (..) E-i 0 E. a 0 u 0 C.) a CD, (!) E. V a 0 0 0 U CD U Kt: ti a E. E---. a E. 0 .4 E.
H a, 0 0 0 U E-. a 0 000HaUHluaaH00C9UE. A 001) F-' F-' 0 a a E-. E. U a a 0 E.(DE-.00E-.a,CDUHCha000E.c.JCJHa' a000E-.0000 ,E.E.
Cha000CJCJ0000E.0aHal.C3 E.
0 0 El H 1=4 a 0 0 a a <UP U<Alr4U0000E-4<.4 H H U r.) 0 0 A 0/6C 0 U H H UyO<UU H, 0 a a E. E. a a E. a a CD
E. Kg E. C.) 0 0 E. CI U H U 0 0 H CJ 0 E.
C) a, 0 E. C.) E. 0 E. a 0 ...4 H
a a. E. 0 Ft CD E. 0 .4000E-, 0 0 H 0 0 CD a 0 E. E. E. 0 E. E. H
CJ E.
0 0 E. 0 U 0 E. 0 cJ U 0 E. E. E. E. E. U 0 0 a u c) rt 4 E. E. E. U a 0 0 arDaCJ0,40,Ha E. E. a 0 0 0 0 0 a 0 at E. 0 0 E. E. 0 E. E. a H E.
0 a 0 U 0 0 a, U a U C) a E-, 0 < u ci U U 0 0 A 0 0 0 < 0 0 U U H
HCJOUH0C9,AH CI C9 V E. .4 a, H E. 0 0 ID L. 0 Ft 0 0 U a E. 0 0 CD
E. ,..q.Nuugq,c0 U E, U U 0 < 0 0 CJ u H E-, U 0 E, E-, H a C.) P E. 0 0 a a E. H 0 0 U CD a; 0 0 a; U H E, < a CD C) E. C.) a E. 0 CI 0 E. C.) 0 a F-. '1. a C) CD .0 0 uucDocuuuu AE,00E-.4 00 A
U H.E.0cDCJUE. E.aE.E.chuuE.E.u00C9 E-,4uu 0 E-' Hu 0 E. a E. 0 a 0 E. E-.<0001CJ r4E-4(JuK40E,0g4 u 00,0 C.; aUHUE.E.O auE.E.U.a achCJU)0000a0 ChEt aU
U 0 E. a E. 0 0 c.) Kc ath0a0a, CJOC,DE.CDE.Hat-.E.
aC)ach a a E. 0 U Er E. CD a 00CDCJaCh0E-.0cDE.HH uucDua u 0 0E, E. 0 a 0 0 a E. C9 E. H0E-4000000aE.00a-4,0E.F.E.CiaH
E. E. E. 0 0 0 a a E. Ei E. 0 a U U c3 0 a H. 0 U U 0 a E. 0 H ci C.) CJ E.
C.)0a00000a a,00000000a0000000 E.CD0C.D
E.C9a0000,E.Ch PCU0E.00E.H.E.00a00,400 aChua 4V)uachuE.c.) 0 E. H E. ch a 0 0 a u 0 a 0 rt < 0 0 H H CD H
!.2 H E. 0 p50.-40 H U 0 U E. 0 4 CJ A H < 0 U U 0 0 0 f.-4 Li 0 a a CD CJ E. EA CJ A A U 0 CD 0 (.70554uuE-,(DHOOUC544A<HUE-, 49 54 ,,.,4 E-, 0 C..) < ,,,C T.!) H L.) < ,r4 U H a: H U 0 a a H 0 E. E. a A CJ
E-, a E. EA 0 U CD a 0 a uach(JrcHE-,00HaUatJur.JUE.ci(JyH
U E. E. ch E. H 0 0 u 0 u 0 0 E. a E. CD A E. E. E. 0 0 a A E. C.) 0 U SJ
CD
F. CD tJ 0 a U E. E. 0 1DE..100HuUcDaH000 HUChacha U Cr) U a E. F. a; H H 0 H ,,4c.),¶,v()U0c.)K4E.A
H E. a H. C;; u F. 0 H F. 0 0 (..) .4 U UEJ '0g4A(.7E,HclUUUHUH<OH<U
U < H U E, 0 CJ 0 444E-tuutiC--, 4 0 u0 AU UcDE-.0-ach ,r0U 0E-.0C)E. 0 a u a E--, a U U F. 1--. , E. E. 0 0 H < 0 0 0 u U E-, Ci C.) u 0 o U 0 H U 0 U u H L-, U H U 0 U 0 < H A (.9 0 E-, .4 U U ,=4 (D 4!) U f--, A ,:4 A Er E. a 0 0 0 0 a E. H. CD C.) U 0 U 0 CD
U E.
r. ' 6 P. 8 6 0 F. C9 U E, 0 CD E.
E., E-. CD 0 C 0 H. ci E. a U 0 HUUacJtJUUHUE.E.E.E.c7F.aaChcha 0 E. a a F. a 0 aucJaE.E.a0achauciaUUH0acD.CF.
0 E-+UE-, UUUch F. U 0 0 a E. C) 0 H C, CD U 0 E. a u C.) E. E. 0 0 O 0 E. / E. a E. 0 0 H H 0 H g H 0 at 0 0 0 0 El PCH0F.E.01-)44 0 AU 0 a a 0 E-t a u 0 0 CJ H. a, CJ <000Fla H EJ U < 0 al O HA E-, 0 H U gq E.000E. CDHE-.0C.)0F.a0C-DaHIDHaE.
Cl E, Ei ft U H 0 a; 000F E.ft U 4 00< E.-.uuu H04E-, 4(...0 H E, a E. ft 0 U a u U a a 0 U 0 E. 0 CD 0 0 CD 0 0 H a CD g 0 0, a H E. a ch U 0 0 U 0 art0HE.E.E.00 ur-140y0c0 04 0 CJ C., 0 < 0 a 0 F` C., 0 (5 C H (-) U P U 0 C,C.) 0E.E.0a am, 4 E. E. E. E. 40 E-. [-, 0 0 C.) E-, 0 r.. . .9 ( 7 CD u u 4 0 u K4 Ki (J E-, K. E.
E. a E. H a CD t) 0 FtHO C.)0lJE, 4u0c.90 .< Kcc..)E , u O 0 0 E. E. U E. cn U Ch 0 u C.) ch E. E, E.
0, E -. ..: u I -. 4 9 0 CD E. 4 E- . U C...) m E. CJ Fg 8 H. H. E-,-. E. a CJ a 0 H E. H <
E. a U a 0 - 0 0 U
EEc,,,t-i,c3., 6 6 6 ';'4 t-A 8 0 Et (i (-i 8, t8J P . 0õ' op' E t ;- , ' ' , ,H1 6' N 1 E9 (.., 8 8' rl 8 '(', -,) (E.% -'. t.," 8 6 i-', r.j4 [ ; 8 El 14 8 ti: 6 'El E. u I
o= puo,,,,,,,E,., u H HUUU E. < 4 E . 0 p E. -, c / i -_,4 ,6 t . ; g f_c, )., Ha rg E,....00 K. 4 0. E. E-E r4: E-1 v400000E-4E.
E. 0 u E. E. E. 0 E. E. v-a H 0 U U Pe, a a CD a a 0 0 E. a H 0 H E.
a E. a H a 0: 0 0 H cri E. U E. 0 a u ch a u0 00uu 40 0 to E-. E-, SUBSTITUTE SHEET (RULE 26) GTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAA
GCGGTTAG
CTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAAT
TCTCTTAC
TGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGA
CCGAGTTG
CTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCT
TCGGGGCG
AAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCT
TTTACTTT
CACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGA
ATACTCAT
ACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAA
ACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACC
TATAAAAA
TAGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAG
ACGGTCAC
AGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGG
CTTAACTA
TGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATOCGTAAGGAGAAAATAC
CGCATCAG
GCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCG
AAAGGGGG
ATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGG
CSEQIDNO.:40 CO
Cl) AATTCTAATACGACTCACTATAGGGAGACGAGAGCACCTGGATAGGTT
SEQIDNO.:41 CAD IA
CD
GCCTGCACCAACAGTMACA
Cl) SEQIDNO.:42 rn SEQIDNO.:43 TCCCGTCTTTGGGTCANAA
r¨
SEQIDNO.:44 17.! GCGCCGCGGATCGTCAACA
SEQIDNO.:45 ACACGTGCACGGCGGC CAA
ra SEQIDNO : 4 6 TCGCGCGTTTCGGIGATGAtGGTGAAAACCTCTGACACATGCAGCTCCCC-GAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGA
GCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGICGGGGCTGGCTTAACTATGCGGCATCAGAGCAGAT
TGTACTGA
GP.GIGCACCATATGCGGIGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCCCATCAGGCGCCATTCGCCATTCA
GGCTGCGCA
ACTGTTGGGAAGGGCGATCGGTGCGGGCCICTTCGCTATTACGCCAGCTGGCGAPAGGGGGATGTGCTGCAAGGCGATT
AAGTTGGG
TAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGCCAAGCTTITCCAAAP.AACTACCGTTGTTA
TAGGTGTCT
CTTGAACACCTATA.n.CAMCGTAGTGGATCCCGCGTCCITTCCACAAGATATATILAACCLA_AGAAATCGAAATACT
TTCAAGTTACG
GTAAGCATATGATAGTCCATTITAAAACATAATTTTP_AAACTGCAPACTACCCAAGAAATTATTACTTTCTACGTCP-CGTATTTTGT
ACTA.ATATCITTGIGTTTACAGTCAR_ATTAATTCTAAITATCTCTCTAACAGCCTTGTATCGTATATGCAAATATGA
AGGAATCATG
GGAAATAGGCCCTCTICCTGCCCGACCTTGGCGCGCGCTCGGCGCGCGGTCACGCTCCGTCACGTGGTGCGTTTTGCCT
GCGCGTCT
TTCCACTGGGGAATTCATGCTTCTCCTCCCTTTAGTGAGGGTAATTCTCTCTCTCTCCCTATAGTGAGTCGTATTAATT
CCTTCTCT
TCTATAGIGTCACCTAAATCGTTGCAATTCGTAATCATGTCATACCIGTTTCCTGTGTGAAATIGTTATCCGCTCACAA
TTCCACAC
cn .RAcATAccheccGep.Accth,AAGTGTAAAeccTeGeGTGccTAATGAGTGAccTAAcTcAcATTAATTGcGTTecG
crcAcmccc GCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTG
C1:1 TCCGCTTCCTCGCTCACICACTCGCTGCGCTCGGTCGTICGGCTGCGGCGAGCGGTATCAGCTCACTCP_AAGGCGGI-zkATACGGTTA n.) cn co TC CACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGC
C.AGCAAAAGGCCAGGP.ACCGTAAAP.AGGCCGCGTTGCTG
GCGTTTITCCATAGGCTCCGCCCCCCTGACGP.GCATCACARAAATCGACGCTCAAGICAGAGOTGGCGAAACCCGACA
GGACTATAA
AGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCG
CCTTTCTC
CCTTCGGGAP,GCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTG
GGCTGTOTG n.) cn CACGAACCCCCCGTTCAGCCCGACCGCMCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGP-CTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTP
_ACTACGGC n.) TACACTAGRAGAP.CAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTICGGAWAGAGTTGGTAGCTCTTGATC
CGGCAAA .. 0 AAAACCACCGCTGGTAGCGGIGGTTTTITTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGA.AGAT
CCITTGATC co TTTICTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATITTGGTCATGAGATTATCAAAAAGGATCT
TCACCTAG
n.) C ATCCTTITAAATT
'AAAAgTGAAGTTTTAAATCAATCTAAAGTATATATGAGTAARCTTGGICTGACAGTTACCAATGCTTPLATCAGT
r-GAGGCACCTATCTCAGCGATCTGTCTATTTCGTICATCCATAGTTGCCTGACTCCCCGTCGTGTAGATPACTACGATAC
GGGAGGGC
TTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCT CAC CGGCTC
CAGATTTATCAGCAATAAACCAGCCAGCCGGA
2) AGTAGTTCG
CCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCAT
TCAGCTCC
GGTTCCCAAcGATcAAGGCGAGTTAcATGATcCCCcATGTTGTCcAAAA;U,GCGGTTAC-CTCCTTCGGTCCTCCGATCGTTGTCAGA
AGTAAGTTGGCCGCAGTGTTATCACTcATeeTTATGGCAGCACTGCATAATTcTcTTAcT=ATGccATccGTAAGATGc TTTTCT
GraAcTcGTGAGTACTrP
ACCGCGCCACATAGCAGAACTTMAA.AGTGCTCATCATTGGAAAACGTTCTTCGC-GGCGA;a-A.ACTCTCAAGGATCTTP.CCGCTGTTG
-_________________________________________________ i gur...)...quouout,opociur.
u 0 U 0; U 0 CI T.9 U U U 0 U U U EJ E. 0 E.
E?, tCjD 8 g EY, il b' ill 8 8 8 '6 8 8 ti 8 0 E. .4 0 < H UUUUUUUUUO
E.E.urJuU04.0H<E.HUQU0,0 FI E-..4UDEDE.OchouUou5440 5400 UE...4E-louour.7(.70uu0E-.
UUHUUUUU g 5 <4 E- , Ci E-, (DE.uUtD0c.DuchUuu00, -, 0 UU0000UUHrc<
HHU < H, 0 U 0 CJ U E.
u u-, 0000 0 u u u c2<UUUH 4:0c.D0c9UUFC< H
O u U E. U E. CD U ci U E. U < 0 0 <
HE--,HUrCE-, <04:0U0E-,HU UE-, UHHHHUUUUUUUUUU
E. E. UUHUUUHUHUOHU
HE-.0u0HE-,<EDUr_DU<POU Hrg PHOO<HP<UOuyCJUHUE.00;
0 CJ 0 E. CJ CJ CJ EJ 0 U 0 U E. 0 E.
U 0 E. < 0 H 0 0 0 C) 0 u E. H H
UUUUUUUUUUUOU
U= EUUUUHUUUHU
H= E, CDUUugu0,000cJEJOHuc., HUE.,<U0CDHUE3UUraciUCJ E. 4 4 (JE-, i E--.E.E-.4u540oViuvuE.uE, .4u 0, ,,,C0uE.HU .0ciu<00 E.
0 u E. U u 0 cJ 00000g E-, t-, E. < CD 0 E. U CD 0 < U U (9 t. 4.
U 0 g U U0E-14:0u0cDCJUu<HFU
E.E.E.00UHUOU(Dua, V (.7 C.!) C9 H U
g E. E-i C.9 g U E-, U U a, E. 0 u E. E. CJ E. 0 a U0E-.<<HuUUUuuLEULDUE.E.
O H < 0 4, U CD rC U E., E, U F,C CJ 0 FE.
4 E. 0 0 E. 0 CD C.J 0 0 0 0 4 E. CD 4 CI 0 U 040E.4E.uourf uouuu44 E-, H 0 E. < OUNOUHU a, U cd 04 4. 4.
E.C<UrCUOUEDuouU0,-CFUE-,E.
uchrc UHU<UU0000(DUUEJHEJ
E. = C.) 0 U 0 UOUH ED U E. C) U) OUHU<UO<UUCDUUCJOE.4HA
E. g E. 0 c-D C-) g U .: C- , U CJ E--, E. C., F, Q 0 C.>
kJ 0 F4 0 < E. H U 0 < 0 E. CD El C.) U U E. 0 0,14 UHUUUUHUUUUHH
4 0 < 0 0 0 4 U 0 ,_< CJ V CD U 0 U 4 0 0 UCDCJUO< f"UUC-1 CDC 7 0 ouout.54 u u 54 u 4 u (.7 u u u u u u u a; 4 E, H CJ
CJ 4 H CJ U CJ < LI U 0 CDOE.04044E, 44 <FOLUU<UCD<CDUOUrc pc H
UE.004000000CDUCDU4HUH
O ,uq o u u f. E-, u 4 4 E. UHUU<.CDE.
E. 4 U U U E. 0 CD CD 0 E.54E.7uouE., E.
O 0 0 U HUU CD U 0 U 0 0 U E. 4 H
UCD<QUUHUHU<<CJOH044E, E. 0 CD 0 E. gl, U C., 0 u 0 0 cD 0 0 < 0 0 ,4C
U4H Hup,c0<UULDEJCDUcDcD0E.c., < < 4(70E-.4E.704uuElugE744.7, urpCDUC90000CDUCJO <0 .5 U HO rCuHre,c_DUcicDcauurr<
u U0UuuciPE-, E. E. H 0 E. g E. 4 ,7(,1 E-,E.OU E.U000< HUCDOUEIE.0 0 0 E. U 0 U 0 CD Ca C_D 0 CD 0 U U E. < 1 E.
E.E.7E-.54 0 CJ 0 U U 0 0 0 0 < < 0 U U. CD
CDCIHHE.UOU<24HUE.00,4 al u E . CJ V 0 V C,7 0 CJ ,... 0 0 0 C..) U 0 0 u E-, 4 0 E.C1E.UOU
O E. H 4 4 H V kJ CJ0u000uucDUH
O 0 U u U E.C.DUOUCJUOU< E-, E-, u E. ouuuuu4 c940uuuUouE. C.) H C) C) 000 Oa UPCOUCD,CCJUUHU
O KCHHOU<UCDUUCDOUCDU<4 0 µCUULDCDUUU<UCDE, 4,<HOCD04 4 CD
U0E. F,000E.404000 004 4 U 49 <4 OHOHOUVIDOOUth< E. U 0 E-, < E. CD 0 < CJ < U E., g E. UUOU 4 0 .-4E-., g .K4 0 U 0 01=4 O OgUUUUg 0 0 E, 0 UN.. UOUUUU- gUOUU E-, U
1=4 0 .4 0 U E-, CJE,00,<UUCDE.4UCJ4 E.
SUBSTITUTE SHEET (RULE 26) SEQIDNO , :47 TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTA
AATGGCCC
GCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTC.AATAATGACGTATGTTCCCATAGTAACGCCAATAGGGAC
TITCCATTG
ACGTCAATGGGIGGAGTATTTACGGTMACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTA
TTGACGT
CAATGACGGTAAATGGCCCGCCTGGCATTATGcCCAGTACATGAcCTTATGGGAcTTTccTACTTGGCAGTACATCTAC
GTATTAGT
CATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCA
AGTCTCCA
CCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCA
TTGACGCA
AATGCGCGGTAGGCGTGTACGC-TGGGAGGTCTATATAAGCAGAGCTC-GTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCA
GATCTCGAGCTCAAGCTTCGAATTCTGCAGTCGACGGTACcGcc-GGCCCGGGATCcACCGGGGCCGCGACTCTAGATCATAATCAGC
CATACCACATTTGTAGAGGTTTTAcTTGCTTTAAAMACCTCCCAcACCTCCCCCTGAACCTGAAACATAAAATGAATGC
AATTGTT
GTTGT TAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCAT CACAAATT
TCACAAATAAAGCATTT TTTTCACTG
cn CATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGTAAATTGTAAGCGTTLATATTTTGTTAAAATTC
GCGTTAAA
ITTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAP.AATCCCTTATAAATCAAAAGAATAGACCGA
GATAGGGTT
(/) GAGTGTTGTTCCAGTTTGGAACAAGAGTC
cACTATTAAAGAAcGTGGACTccAACGTCAAAGGGcGAAAAACCGTCTATCAGGGcGA
:71 TGGCCCACTACGTGAACCATCACCCTAATCAAGTTTITTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAA
GGGAGcCC
co CCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGG
GCGCTGGC
AAGTGTAGCGGTCACGCTGCGCGTAAcCACCAcACCcGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACT
Cr) APATGTGCGCGGAACCCCTATTTGTTTATTTTTCTI4AATAcATTCAAATATGTATCCGCTCATGAGACAATAACCCTG
ATAAATGCT
TCAATAATATTGAAAAAGGAAGAGTCCTGAGGCC-GPAAC-APiccAGCTGTGGARTGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGC
n.) rn TCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAIATTAGTCAGCRACCAGGTGTGGAAAGTCcCcAGGcTCCCCA
AGTATGcAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCcCGCCCCTAACTCCGC
CCAGTTCC n.) GCCCATT CT C CGCCCCATGGCTGACTAATTT TT TTTATTTATG CAGAGGCCGAGGCCGCCT CGGCCT
CTGAGCTATTCCAGAAGTAG
TGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAA
CAAGATGG co r-ATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACP.P_CAGACAATCGGCTGCT
CTGATGCCGC
CGTGTTCCGGCTGTCAGCGCAGGGC- CGCCCGGTTCTT TT TGTC AAGACCGA CCTGTCCGGTGC
CCTGAATGAACTGCAAGACGAGGC n.) cr) AGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGP-AGGGACTGGCTGCT
A T TGGGCGAAGTG C CGGGGCAGGATCT CCTGT CATCT CA CCTTGC TCCT
GCCGAGAAAGTATCCATCATGGCTGAT G CAATGCGGCG
GCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGARACATCGCATCGAGCGAGCACGTACTCGGATG
GAAGCCGG
TC TTGTCGATCAGGATGATC TGGACGAAGAGC AT CAGGGGC TCGCGCCAGC C GP.AC TGTTCGC
CAGGCTCAAGGCGAGCATGCCCGA
CGGCGAGGATCTCGTCGTGACCCATGGC GATGCCTGCTT G CCGAATATCATGGTGGAAAATGGCCGCTTT
TCTGGAT T CAT CGACTG
TGGCCGGCTGGGTGTGGCC-GACCGCTATCAGGACATAGCGTTGCcTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGA
ccecrrcorccrccrrrAce-GTATcGccGcTcccGATTcGcAGcccArrcGccTTcTATceccrrctrGAccAorrcrTcreAcceGG
ACT CTGGGGTTCap 4ATOAC_'CGACCAAGCC.',ACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCIATGAAAGGTTG
k=.) .11.,õc, flc 0 0)0E--.4a a pc 00 0 0 a.
(34; U 0 rn a. P4 ri 4 0 0 .Z
O fa4 tal a+ U) 1-1 PI U) CD 4 F.I 4 O ui 0 o=C [..1 p4 ,-1 p4 ,-4 a+En FS al ic) U .-1 H 0 cn al co a. U a, F.
H = = pt 0 51 E. En CI KS H a. [4 PC crl ri) rd = ,-1 ,-1 < ,-.1 0 2 a I:4 C.,.1 P4 E. < 41 U0 ,-IZCIlfaci 1..¶,) P. 0 a. 0 0 0 HZ VI > 0 pc a > -4 al cn F. cn 0 4 a.
4) f:) H 0 a 0 En OH EnE-. P.,>.<ZUr.(4000U
O0 V,P0..XU0F., Ug0 0 aZ
'c) Crl c4 H ri4 E-I
H ul 0 E. U u 0 0 g 0 0 0 F. 0 U H 0 0 0 U U U U 0 OUgU00 (.7 0 0 (.9 0 0 U 'H < (J c. 0 00 00000000000 OHUE-.0<<OHOE.E-.<0 0 U C.) 0 0 0 0 F. 0 cJ 0 000000u 4 (.9 0 u 0 u 0 U 0 E. 0 0 a: <0000<UUOUU
E.0:0UUUOUUUU
U<PCOPUFE <0000 HU C)U<HOKCOUOOPC
00000000HE-.<000 al 00HUPC 0 PC g 0 PC
E-c 0 0 CJ U 0 U 0 U C I 0 KCUOUE.U.PCOU04E-.00 g<00000E-.Cic.)0 0 < 0 0 < E-. C) 0 E. 4 0 0 0 < 0 0 0 C.) 0 0 H. 0 0 0 KC
U U 0 El 0 P <000000PCUPO
00000000000:
0 <000400 0 0 PC rOOP<PCDC_DO0 OHE.0100E-.00 HUH U 0 U U 0 U 0 E. 0 0 H<<OH C.,,<<0;d0<0 , 0 0 < g 0 U U < 0 0 -E. pc u 0 0 U H 0 0 u PC KC00E-.0 Ouci0r4 C.) 0 U u 0 U 0 0 0 < < 0 u U 00 0 (,) 0 0 U 0 CJ 0 0 EJ U 0 0 0 < 0 < uH01-.0000000 Fo0r3FigHU 0 <PS 0 .= a Fl 0 H EJ C) CJ c) u E. 0 E-.
0ggc0u0E-Tr_DE,0(.9E-40r-+ a. 0 U 0 0 c.7 C.) 4 LI U f-, 0 < 0 0 0 E. C.) a: 0 < H 0 0 C) El pc 0 0 1 O <KC PC g HE-.4:Hour.Dc.) goggurDc9clur.9 =
0g000 E-, OUO<E-.00 0 U U 0 u u u 0 U 0 FigUU0 HH,OU0.:< g4 E. H000400000 i 00000000E-100 H010000:0000E.
E.E.C.10 E.E.1.0000U H u U U KC 000E-.001 4,100 0000C)C.) 0 0 HU FE 0 0 KCC)guut, C./ < CJ (.1 E-c U 00000000 <000000000E, E--.U00UHC)(3000 a: UPPCJUE-cUP<CDPE
CJ 0 < U P U 0 0 0 0 0 0 P 0 P OUKCOOCJOHO Pr H0H0<0<0000 0 g E, 01.7 0 0 0 0 0 4 0 06 4 U 4 0 4 4 U E-cPCJUPU 0 KCO<H<KCE-10 HU
OKS0000000<< Uu chuucJC)UOUO=uF.
00UKCE.<FSE-.<<c) uu <0(700000000 CJ P U P C.J U t.7 Ci 0 0 U 0t-.0000040E-.<
0 P 0 u 0 u al 0 0 U F. E-4 c.) E. 0 0 El guur.90g 0 0 U 0 U 0 < U U 0 0 O (..) (..) C.7 g U C.) 0 0 0 E-. 0 u a; E--. i--.
(.., g 00 HFS
0000000 -pc El00H UE-.00c.)000c,nou (J 0UU < H<FS 400 <00 0000000000 FS 0 FS Pc HOUUHUrOU E. C') d g 0 E. 0 0: < E. U
U0U00H0U0F. 0000 00000000000 CJUOP gug FEUOPEPOP Huu000E-.00C90 F. y00 0 0 H 0 0 HOPC04000004 000FE00<0P00 C., Pc Ci 0 CJ 0 FE 0 g 0 pc: Fc 0 0 u ci cJ u u 0 u 0 U
HOOUHP c FCE--c< H <0 E. 0 < 0 0 HP40 PC 0 u FSOOHHE, UU0U0HE. 00000000C) H
O < 0 E. E-.0 0000000 0000U0UH0 0 E-c pc rc r_l g EJOUHUKC (DUE-. UU<O000 0000 <00 g 0 . P 1 0 U 0 0 PC P E-c 0 0 U U U CJ CJ 0 0 H V
CDOUPCE,E, <P0E-cOCJO 0 PC 0 00U 0000 FE
0 r., (..) U E. E. ,.= 0 c.J < 0 U C9 H E.000H000E.00 H U E. U < H U KC 0 < 0 4 E-. PC E-. 0 0 0 U FS C7 CJ 0 0 U
ugou w ch CD 0 C) E--. 0 U g U 0000000U0UPE PC
0 0 < rS H 0 H < < 0 0 g 0Ug00<000E-100 0 P 0 0 < < 0 0 E-.
U= PEPUPE-cCJUUO<OOP UCIOPCJUUOUE.CJO
U C.) P 0 0 < 0 P < H U 0000E-.,<H0gUUU
Og C_h CJ U 0 E-c E-= E-c C.) 0 0 Pc 0 0 g 4000E.C)<0.t 0 O 00c)<<C)C)<KC r-1 PE P H 0 CJ U C) 0 CJ 0 0 0 C.) U PC
FEFEOCJE-c<OOLIPFEOPP PpCHOFEOUP00PC 0 0 0 CD V FE P Pc 0 < E. E-c 0 E-c P CJOHH00000C)0E-c 0 0 CJ FE E-c Pc 0 E-c P 0 < < KC H. 000000000000 0 4 0 0 < 0 0 0 0 4 0 o 0 u F.E.00<< 0:00HUO
U g 0 0 E. U < < U P < PC 0 0 0 0 4 EJ 0:0000CJUH
c_.) 0 < U < U < g c...q gopc HU 0000000<000 0 00 pc 00E.E. E-. C..) 0 E-1 0 0 0 0 g C.) P 0 g 0 0 U E--. 0 P
H I U 0, E. E. 00011CJOUH 00E+0 000 CDFSL)FS <
HKCE-.E-.C) uchgg goo() ug UOUU00E-.000 HuuH0HUH0E.< U
0 E. E. ugogr.90c9E-, F=4 <00000HE-.00<
C.) PUE--cc.JOOFE <OOP H 0000000.00000 H PUO0P0PUCJOE.P rn 0<PPC000000E-1 0 c'500POFEUEJOPPCPEUP co H<0000 g0C/0 <E.PPrE0E-cPPU0C-IgU == 000000 L ..) 0 u U P <
i 00 H00E-.00U< <000 = E. H U < 0 0 < g E. < U
C...7 H E. E. < F. E. E. 0 E. 0 E 0 0 (J 0 U < 0 U FE E-c 0 0 Li 0<0P0UPPC/0UC)00 Z OgUUU0UU004 E-c E. 0 F4 0 P 00 0-4 E-.0(9E-1E-. .zi 0000 0E-100UKS u 00000000.4E.<< [Jo H 0P000000CJFE00 O000< F.H.E.000< ou 0 00000 000004 C) O000E--.<00,40c)HFSH al H<0CJE-+E-.E-.E.000 0 cf) g 0, CD 0 U E. 0 U 0 E. 0 <
SUBSTITUTE SHEET (RULE 26) =
Co4 SEQIDNO :84 Identical to ATGCCGGCGCTGCTGCC TGTGGCC TCCCGCC TTTTGTTGC TACCCCGAGT CT TGCTGAC
CATGGCCTCTGGAAGCC C TCCGACC CAG SEQIDNO . : 4 9 CCCTCGCCGGCCTCGGATT CCGGCTC TGGC TACGTTCCGGGCTCGGTC TC TGCAGCCTTTGTTAC
TTGCCCCAACGAGAAG GT CGCC MIGSGLAGSGGAGGPSSTVTWCA
AAGGAGATCGCCAGGG C CGTGGT GGAGAAGCGCCTAGCAG CCTGCGTCAAC C TCATC C
CTCAGATTACATC CATC TAT GAGTGGAAA LFSNHVAATQAS LLLS FVWMPAL
GGGAAGATCGAGGAAGACAGTGAGGTGCTGATGATGATTAAAAC CCAAAGTTC C TTGGT CCCAGC
TTTGACAGAT TTT GT T CGTTC T L PVASRLLLLPRVLLTMASGSPP
GTGCACCCTTACGAAGTGGC CGAGGTAATTGCATTGCCTGTGGAACAGGGGAACTTTC CG TACC TGCAGTGGG
T GC GCCAGGTCACA TOPS PASDS GS GYVPGSVSAAFV
co GAGTCAGTTTCTGACT C TAT CACAGTCCTG C CATGA
VNL I PQ I TS IYEWKGK TEED S EV
CO
cr) YEVAEVIALPVE Q GNI" P YLQWVR
QVTESVS DS I TVL P
SEQ ID NO. 85:
.A
rn CATGTGCCAACATGCAGGTTTG CTCATATNTATAC TT T TGCCATGTTGG T GTGC T GCACCCATTAACT
CGTCATTTAGCAT TAGGTA
TAT T T CTTAATGCTAT C C CTCC CCCCTCCCTC CAC C CCACAACAGTCCC CGC TGGTGTGTGAT G
TT CCCAAAT T TTTT TT T TC TCAT
rTl rrl CANCATTATCNCTAAACAACATTGAATGAAACAACATTGAGGAT
CTGCTATATTTGAAAATAAAAATATAACTAAAAATAATACAAA
TTTTAAAAATACAGTG TAACAA CTATTTACATAGAATTTACATTGTATTAGGTATTGNANGTAAT CTAGAG TT
GAT TTAAAGGAGGG
GNGT C CAAACTTTTGGC TT CCCTGGGCCACAC TGGAANAANAATTGTC TTGGGCTACCCATAAAATACAC
TAACAATAGC TGATAAC
GA
SEQ ID NO. 86 GC TGATT TACAGAGTTT CCT CCTTATAATAT TCAAATG T
CCATTTTCAATAACAGCAACAAACTACAAAGAAACAGGAAAG TAT GG T
CTACTCACAGA
"t1 =
=
REFERENCES:
PATENTS:
U.S. Patent No. 5,712,127 Malek et al.. January 27, 1998 U.S. Patent No. 6,498,024, Malek et al.. December 24, 2002 U.S. Patent Application No. 11/000,958 field on December 2, 2003 published under No. US 2005/0153333A1 on July 14, 2005 and entitled 'Selective Terminal Tagging of Nucleic Acids' US Patent 6.617 434 Duffy, September 9, 2003 US Patent 6,451,555 Duffy. September 17, 2002 OTHER REFERENCES:
1. Frost H.M., 1964 Dymanics of Bone Remodeling. In: Bone Biodynamics. Little and Brown, Boston, MA, USA pp 315:
2. Baron, R., Anatomy and Biology of Bone Matrix and Cellular Elements, In:
Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Fifth Edition 2003. American Society for Bone and Mineral Research, Washington DC.
pp 1-8, 3. Jilka, R. L. et at,, "Increased Osteoclast Development After Esgtrogen Loss:
Mediation by Interleukin-6", Science 257: 88-91 (1992) 4. Poli. V et al., "Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion", EMBO J 13 1189-1196 (1994).
5. Srivastava, S et al.. "Estrogen Blocks M-CSF Gene Expression and Osteoclast Formation by Regulating Phosphorylation of Egr-1 and Its Interaction with Sp-1", J
Olin Invest 102: 1850-1859 (1998).
6. de Vernejoul, M. C., "Dynamics of Bone Remodeling: Biochemical and Pathophysiological Basis", Eur J Olin Chem Olin Biochem 34: 729-734 (1996).
7. Netzel-Arnett. S., J. D. Hooper, et al. (2003). "Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer." Cancer Metastasis Rev 22(2-3): 237-58.
8. Shan, J.
L. Yuan, et al. (2002). "TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells."CancerRes 62(1): 290-4.
9. Yuan, L.. J. Shan, et al. (1999). "Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer." Cancer Res 59(13):
3215-21.
Nishi, T. and M. Forgac (2002). "The vacuolar (H+)-ATPases--nature's most versatile proton pumps." Nat Rev Mol Cell Biol 3(2): 94-103.
10 11. Nishi, T . S. Kawasaki-Nishi, et al (2003) "Expression and function of the mouse V-ATPase d subunit isoforms." J Biol Chem 278(47) 46396-402 12. Morello, R., L. Tonachini, et al. (1999). "cDNA cloning, characterization and chromosome mapping of Crtap encoding the mouse cartilage associated protein."
Matrix Biol 18(3): 319-24.
13. Tonachini, L., R. Morello, et al. (1999). "cDNA cloning, characterization and chromosome mapping of the gene encoding human cartilage associated protein (CRTAP)." Cytogenet Cell Genet 87(3-4): 191-4.
14. Kawai, J., A. Shinagawa, et al. (2001). "Functional annotation of a full-length mouse cDNA collection." Nature 409(6821): 685-90.
15. Strausberg, R. L.. E. A. Feingold. et al. (2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences." Proc Natl Acad Sci U S A 99(26): 16899-903.
16. Janssen.
E.. M. Zhu, et al (2003). "LAB- a new membrane-associated adaptor molecule in B cell activation." Nat lmmunol 4(2): 117-23 17. Kawaida, R.. T. Ohtsuka, et al. (2003). "Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL." J Exp Med 197(8): 1029-35.
18. Agrawal, N., P. V. Dasaradhi, et al. (2003). "RNA interference: biology, mechanism, and applications." Microbiol Mol Biol Rev 67(4): 657-85.
19. Hannon, G. J. (2002). "RNA interference." Nature 418(6894)= 244-51 20. Brummelkamp, T. R. R Bernards. et al. (2002). "A system for stable expression of short interfering RNAs in mammalian cells." Science 296(5567): 550-3 21. Elbashir, et al. (2001). "Duplexes of 21-nucleotide RNAs mediate RNA
interference in cultured mammalian cells." Nature 411(6836): 494-8.
22. Lee, J. S. Z. Hmama, et al. (2004). "Stable gene silencing in human monocytic cell lines using lentiviral-delivered small interference RNA. Silencing of the p110alpha isoform of phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1alpha,25-dihydroxycholecalciferol and bacterial lipopolysaccharide." J Biol Chem 279(10): 9379-88.
23. Rubinson, D. A. C. P. Dillon, et al. (2003). "A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference." Nat Genet 33(3)= 401-6.
24. Boyle. W J W S. Simonet, et al (2003). "Osteoclast differentiation and activation " Nature 423(6937). 337-42 25. Gee et al. In: Huber and Carr (1994) Molecular and Immunologic Approaches.
Futura Publishing Co., Mt. Kisco N.Y., pp. 163-177.
26. Smith, A. N. F. Jouret, et al. (2005). "Vacuolar H+-ATPase d2 subunit:
molecular characterization, developmental regulation. and localization to specialized proton pumps in kidney and bone." J Am Soc Nephrol 16(5): 1245-56 27. Smith, A. N.. J. Skaug, et al. (2000). "Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing." Nat Genet 26(1): 71-5.
28. Stehberger, P. A., N. Schulz, et al. (2003). "Localization and regulation of the ATP6V0A4 (a4) vacuolar H+-ATPase subunit defective in an inherited form of distal renal tubular acidosis." J Am Soc Nephrol 14(12)- 3027-38.
29. Malkin I, Dahm S. Suk A Kobyliansky E. Toliat M. Ruf N. Livshits C.
Nurnberg P
Association of ANKH gene polymorphisms with radiographic hand bone size and geometry in a Chuvasha population. Bone. 2005 Feb;36(2).365-73 30 McMahon C, VVill A, Hu P, Shah GN, Sly WS, Smith OR Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome. Blood. 2001 Apr 1:97(7).1947-50.
31. Biskobing DM, Fan D. Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature osteoclasts. Calcif Tissue Int 2000 Aug:67(2).178-83.
32. Brage M, Abrahamson M. Lindstrom V, Grubb A, Lerner UH. Different cysteine proteinases involved in bone resorption and osteoclast formation. Calcif Tissue Int. 2005 Jun;76(6):439-47. Epub 2005 May 19.
technologies. The antibody may originate for example, from a mouse, rat or any other mammal.
The antibody may also be a human antibody which may be obtained, for example, from a transgenic non-human mammal capable of expressing human Ig genes. The antibody may also be a humanised antibody which may comprise, for example, one or more complementarity determining regions of non-human origin.
It may also comprise a surface residue of a human antibody and/or framework regions of a human antibody. The antibody may also be a chimeric antibody which may comprise, for example, variable domains of a non-human antibody and constant domains of a human antibody.
Suitable antibodies may also include, for example, an antigen-binding fragment.
an Fab fragment; an F(ab):, fragment, and Fv fragment, or a single-chain antibody comprising an antigen-binding fragment (e.g.. a single chain Fv) The antibody of the present invention may be mutated and selected based on an increased affinity and/or specificity for one of a polypeptide described herein and/or based on a reduced immunogenicity in a desired host.
The antibody may further comprise a detectable label attached thereto.
The present invention further relates to a method of producing antibodies able to bind to one of a polypeptide, polypeptide fragments, or polypeptide analogs described herein, the method may comprise:
a) immunizing a mammal (e.g., mouse, a transgenic mammal capable of producing human Ig, etc.) with a suitable amount of a PSEQ
described herein including, for example, a polypeptide fragment comprising at least 6 consecutive amino acids of a PSEQ:
b) collecting the serum from the mammal, and c) isolating the polypeptide-specific antibodies from the serum of the mammal The method may further comprise the step of administering a second dose to the animal.
The present invention also relates to a method of producing a hybridoma which secretes an antibody that binds to a polypeptide described herein, the method may comprise.
a) immunizing a mammal (e.g.. mouse. a transgenic mammal 5 capable of producing human lg. etc.) with a suitable amount of a PSEQ
thereof;
b) obtaining lymphoid cells from the immunized animal obtained from (a);
c) fusing the lymphoid cells with an immortalizing cell to produce 10 hybrid cells; and d) selecting hybrid cells which produce antibody that specifically binds to a PSEQ thereof.
The present invention further relates to a method of producing an antibody that binds to one of the polypeptide described herein, the method may comprise:
15 a) synthesizing a library of antibodies (antigen binding fragment) on phage or ribosomes.
b) panning the library against a sample by bringing the phage or ribosomes into contact with a composition comprising a polypeptide or polypeptide fragment described herein;
20 c) isolating phage which binds to the polypeptide or polypeptide fragment, and;
d) obtaining an antibody from the phage or ribosomes.
The antibody of the present invention may thus be obtained, for example, from a library (e.g., bacteriophage library) which may be prepared, for example, by 25 a) extracting cells which are responsible for production of antibodies from a host mammal:
b) isolating RNA from the cells of (a):
C) reverse transcribing mRNA to produce cDNA
d) amplifying the cDNA using a (antibody-specific) primer, and e) inserting the cDNA of (d) into a phage display vector or ribosome display cassette such that antibodies are expressed on the phage or ribosomes.
The host animal may be immunized with polypeptide and/or a polypeptide .. fragment and/or analog described herein to induce an immune response prior to extracting the cells which are responsible for production of antibodies The present invention also relates to a kit for specifically assaying a polypeptide described herein, the kit may comprise, for example, an antibody or antibody fragment capable of binding specifically to the polypeptide described herein.
The present invention further contemplates antibodies that may bind to PSEQ.
Suitable antibodies may bind to unique antigenic regions or epitopes in the polypeptides, or a portion thereof. Epitopes and antigenic regions useful for generating antibodies may be found within the proteins, polypeptides or peptides by procedures available to one of skill in the art. For example, short, unique peptide sequences may be identified in the proteins and polypeptides that have little or no homology to known amino acid sequences. Preferably the region of a protein selected to act as a peptide epitope or antigen is not entirely hydrophobic: hydrophilic regions are preferred because those regions likely constitute surface epitopes rather than internal regions of the proteins and polypeptides. These surface epitopes are more readily detected in samples tested for the presence of the proteins and polypeptides Such antibodies may include, but are not limited to; polyclonal, monoclonal. chimeric, and single chain antibodies, Fab fragments and fragments produced by a Fab expression library.
The production of antibodies is well known to one of skill in the art.
Peptides may be made by any procedure known to one of skill in the art, for example, by using in vitro translation or chemical synthesis procedures. Short peptides which provide an antigenic epitope but which by themselves are too small to induce an immune response may be conjugated to a suitable carrier. Suitable carriers and methods of linkage are well known in the art. Suitable carriers are typically large macromolecules such as proteins, polysaccharides and polymeric amino acids Examples include serum albumins. keyhole limpet hemocyanin, ovalbumin, polylysine and the like. One of skill in the art may use available procedures and coupling reagents to link the desired peptide epitope to such a carrier. For example. coupling reagents may be used to form disulfide linkages or thioether linkages from the carrier to the peptide of interest. If the peptide lacks a disulfide group, one may be provided by the addition of a cysteine residue. Alternatively, coupling may be accomplished by activation of carboxyl groups.
The minimum size of peptides useful for obtaining antigen specific antibodies may vary widely. The minimum size must be sufficient to provide an antigenic epitope that is specific to the protein or polypeptide The maximum size is not critical unless it is desired to obtain antibodies to one particular epitope. For example, a large polypeptide may comprise multiple epitopes. one epitope being particularly useful and a second epitope being immunodominant. Typically, antigenic peptides selected from the present proteins and polypeptides will range from 5 to about 100 amino acids in length. More typically, however, such an antigenic peptide will be a maximum of about 50 amino acids in length, and preferably a maximum of about 30 amino acids. It is usually desirable to select a sequence of about 6, 8, 10, 12 or 15 amino acids, up to about 20 or 25 amino acids.
Amino acid sequences comprising useful epitopes may be identified in a number of ways. For example, preparing a series of short peptides that taken together span the entire protein sequence may be used to screen the entire protein sequence.
One of skill in the art may routinely test a few large polypeptides for the presence of an epitope showing a desired reactivity and also test progressively smaller and overlapping fragments to identify a preferred epitope with the desired specificity and reactivity.
Antigenic polypeptides and peptides are useful for the production of monoclonal and polyclonal antibodies_ Antibodies to a polypeptide encoded by the polynucleotides of NSEQ, polypeptide analogs or portions thereof, may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, such as those that inhibit dimer formation, are especially preferred for therapeutic use.
Monoclonal antibodies may be prepared using any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to. the hybridoma, the human B-cell hybridoma, and the EBV-hybridoma techniques. In addition, techniques developed for the production of chimeric antibodies may be used. Alternatively, techniques described for the production of single chain antibodies may be employed. Fabs that may contain specific binding sites for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof, may also be generated. Various immunoassays may be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art.
To obtain polyclonal antibodies, a selected animal may be immunized with a protein or polypeptide. Serum from the animal may be collected and treated according to known procedures. Polyclonal antibodies to the protein or polypeptide of interest may then be purified by affinity chromatography. Techniques for producing polyclonal antisera are well known in the art.
Monoclonal antibodies (MAbs) may be made by one of several procedures available to one of skill in the art, for example, by fusing antibody producing cells with immortalized cells and thereby making a hybridoma. The general methodology for fusion of antibody producing B cells to an immortal cell line is well within the province of one skilled in the art. Another example is the generation of MAbs from mRNA
extracted from bone marrow and spleen cells of immunized animals using combinatorial antibody library technology.
One drawback of MAbs derived from animals or from derived cell lines is that although they may be administered to a patient for diagnostic or therapeutic purposes, they are often recognized as foreign antigens by the immune system and are unsuitable for continued use. Antibodies that are not recognized as foreign antigens by the human immune system have greater potential for both diagnosis and treatment Methods for generating human and humanized antibodies are now well known in the art.
Chimeric antibodies may be constructed in which regions of a non-human MAb are replaced by their human counterparts. A preferred chimeric antibody is one that has amino acid sequences that comprise one or more complementanty determining regions (CDRs) of a non-human Mab that binds to a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof, grafted to human framework (FVV) regions. Methods for producing such antibodies are well known in the art.
Amino acid residues corresponding to CDRs and FVVs are known to one of average skill in the art A variety of methods have been developed to preserve or to enhance affinity for antigen of antibodies comprising grafted CDRs One way is to include in the chimeric antibody the foreign framework residues that influence the conformation of the CDR
regions. A second way is to graft the foreign CDRs onto human variable domains with the closest homology to the foreign variable region. Thus, grafting of one or more non-human CDRs onto a human antibody may also involve the substitution of amino acid residues which are adjacent to a particular CDR sequence or which are not contiguous with the CDR sequence but which are packed against the CDR in the overall antibody variable domain structure and which affect the conformation of the CDR
Humanized antibodies of the invention therefore include human antibodies which comprise one or more non-human CDRs as well as such antibodies in which additional substitutions or replacements have been made to preserve or enhance binding characteristics Chimeric antibodies of the invention also include antibodies that have been humanized by replacing surface-exposed residues to make the MAb appear human.
Because the internal packing of amino acid residues in the vicinity of the antigen-binding site remains unchanged, affinity is preserved. Substitution of surface-exposed residues of a polypeptide encoded by the polynucleotides of NSEQ (or a portion thereof)-antibody according to the invention for the purpose of humanization does not mean substitution of CDR residues or adjacent residues that influence affinity for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof.
Chimeric antibodies may also include antibodies where some or all non-human constant domains have been replaced with human counterparts. This approach has the advantage that the antigen-binding site remains unaffected. However, significant amounts of non-human sequences may be present where variable domains are derived entirely from non-human antibodies.
Antibodies of the invention include human antibodies (e.g . humanized) that are antibodies consisting essentially of human sequences. Human antibodies may be obtained from phage display libraries wherein combinations of human heavy and light chain variable domains are displayed on the surface of filamentous phage.
Combinations of variable domains are typically displayed on filamentous phage in the form of Fab's or scFvs. The library may be screened for phage bearing combinations of variable domains having desired antigen-binding characteristics. Preferred variable domain combinations are characterized by high affinity for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof. Preferred variable domain combinations may also be characterized by high specificity for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof. and little cross-reactivity to other related antigens. By screening from very large repertoires of antibody fragments, (2-10 x 1010) a good diversity of high affinity Mabs may be isolated, with many expected to 5 have sub-nanomolar affinities for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof.
Alternatively, human antibodies may be obtained from transgenic animals into which un-rearranged human Ig gene segments have been introduced and in which the endogenous mouse Ig genes have been inactivated. Preferred transgenic animals 10 contain very large contiguous Ig gene fragments that are over 1 Mb in size but human polypeptide-specific Mabs of moderate affinity may be raised from transgenic animals containing smaller gene loci. Transgenic animals capable of expressing only human Ig genes may also be used to raise polyclonal antiserum comprising antibodies solely of human origin.
15 Antibodies of the invention may include those for which binding characteristics have been improved by direct mutation or by methods of affinity maturation.
Affinity and specificity may be modified or improved by mutating CDRs and screening for antigen binding sites having the desired characteristics. CDRs may be mutated in a variety of ways. One way is to randomize individual residues or combinations of residues so that 20 in a population of otherwise identical antigen binding sites, all twenty amino acids may be found at particular positions. Alternatively, mutations may be induced over a range of CDR residues by error prone PCR methods. Phage display vectors containing heavy and light chain variable region gene may be propagated in mutator strains of E. coll.
These methods of mutagenesis are illustrative of the many methods known to one of 25 skill in the art.
Antibodies of the invention may include complete anti-polypeptide antibodies as well as antibody fragments and derivatives that comprise a binding site for a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof Derivatives are macromolecules that comprise a binding site linked to a functional domain.
30 Functional domains may include, but are not limited to signalling domains, toxins.
enzymes and cytokines.
The antibodies obtained by the means described herein may be useful for detecting proteins, variant and derivative polypeptides in specific tissues or in body fluids. Moreover, detection of aberrantly expressed proteins or protein fragments is probative of a disease state. For example, expression of the present polypeptides encoded by the polynucleotides of NSEQ. or a portion thereof, may indicate that the protein is being expressed at an inappropriate rate or at an inappropriate developmental stage. Hence, the present antibodies may be useful for detecting diseases associated with protein expression from NSEQs disclosed herein.
A variety of protocols for measuring polypeptides, including ELISAs. RIAs, and FACS, are well known in the art and provide a basis for diagnosing altered or abnormal levels of expression. Standard values for polypeptide expression are established by combining samples taken from healthy subjects, preferably human, with antibody to the polypeptide under conditions for complex formation. The amount of complex formation may be quantified by various methods, such as photometric means. Quantities of polypeptide expressed in disease samples may be compared with standard values.
Deviation between standard and subject valuesmay establish the parameters for diagnosing or monitoring disease.
Design of immunoassays is subject to a great deal of variation and a variety of these are known in the art. Immunoassays may use a monoclonal or polyclonal antibody reagent that is directed against one epitope of the antigen being assayed Alternatively, a combination of monoclonal or polyclonal antibodies may be used which are directed against more than one epitope. Protocols may be based. for example, upon competition where one may use competitive drug screening assays in which neutralizing antibodies capable of binding a polypeptide encoded by the polynucleotides of NSEQ, or a portion thereof, specifically compete with a test compound for binding the polypeptide. Alternatively one may use, direct antigen-antibody reactions or sandwich type assays and protocols may. for example, make use of solid supports or immunoprecipitation. Furthermore, antibodies may be labelled with a reporter molecule for easy detection. Assays that amplify the signal from a bound reagent are also known. Examples include immunoassays that utilize avidin and biotin or which utilize enzyme-labelled antibody or antigen conjugates, such as ELISA
assays.
Kits suitable for immunodiagnosis and containing the appropriate labelled reagents include antibodies directed against the polypeptide protein epitopes or antigenic regions, packaged appropriately with the remaining reagents and materials required for the conduct of the assay. as well as a suitable set of assay instructions.
The present invention therefore provides a kit for specifically assaying a polypeptide described herein, the kit may comprise, for example, an antibody or antibody fragment capable of binding specifically to the polypeptide described herein.
In accordance with the present invention, the kit may be a diagnostic kit, which may comprise, a) one or more antibodies described herein; and b) a detection reagent which may comprise a reporter group In accordance with the present invention, the antibodies may be immobilized on a solid support. The detection reagent may comprise, for example, an anti-immunoglobulin, protein G. protein A or lectin etc. The reporter group may be selected, without limitation, from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.
In an additional aspect, the present invention provides a method for identifying an inhibitory compound (inhibitor, antagonist) which may be able to impair the function (activity) or expression of a polypeptide described herein, such as, for example. those which may be selected from the group consisting of SEQ ID NO ; 48 to 80 or a polypeptide encoded by SEQ ID NO 85 or SEQ ID NO '86. and analogs thereof. The method may comprise contacting the polypeptide or a cell expressing the polypeptide with a candidate compound and measuring the function (activity) or expression of the polypeptide. A reduction in the function or activity of the polypeptide (compared to the absence of the candidate compound) may positively identify a suitable inhibitory compound.
In accordance with the present invention; the impaired function or activity may be associated with a reduced ability of the polypeptide to promote osteoclast differentiation, such as osteoclast differentiation induced by an inducer described herein or known in the art.
In accordance with the present invention the cell may not naturally (endogenously) express (polypeptide may substantially be unexpressed in a cell) the polypeptide or analog or alternatively, the expression of a naturally expressed polypeptide analog may be repressed.
For example, suitable method of screening for an inhibitor of SEQ ID NO 1, may comprise repressing the expression of the mouse ortholog SEQ ID NO.:35 in a mouse osteoclast cell and evaluating differentiation of the osteoclast cell comprising SEQ ID NO. :1 in the presence or absence of a candidate inhibitor and for example, an inducer of osteoclast differentiation (e.g.. RANKLY
The present invention also provides a method for identifying an inhibitory compound (inhibitor, antagonist) able to impair the function (activity) or expression of a polypeptide such as, for example SEQ ID NO 1 or SEQ ID NO .2 The method may comprise, for example, contacting the (isolated) polypeptide or a cell expressing the polypeptide with a candidate compound and measuring the function (activity) or expression of the polypeptide. A reduction in the function or activity of the polypeptide (compared to the absence of the candidate compound) may thus positively identify a suitable inhibitory compound.
In accordance with the present invention, the impaired function or activity may be associated, for example, with a reduced ability of the polypeptide to inhibit or promote osteoclast differentiation.
The cell used to carry the screening test may not naturally (endogenously) express the polypeptide or analogs, or alternatively the expression of a naturally expressed polypeptide analog may be repressed.
The present invention also relates to a method of identifying a positive or a negative regulator of osteoclast differentiation_ The method may comprise for example. performing a knockdown effect as described herein. The method may more particularly comprise a) providing an osteoclast cell with a compound (e g siRNA) able to specifically inhibit a target sequence (e.g.. a polynucleotide or polypeptide as described herein), b) inducing differentiation (e.g., with an inducer such as.
for example, RANKL) and c) determining the level of differentiation of the osteoclast cell (e.g., measuring the number of differentiated cells, their rate of differentiation, specific marker of differentiation etc).
Upon inhibition of a positive regulator, the levels of osteoclast differentiation will appear lowered. Upon inhibition of a negative regulator, the level of osteoclast differentiation will apear increased.
Another method of identifying a positive or a negative regulator of osteoclast differentiation is to a) provide a cell with one of a target sequence described herein (polypeptide or polynucleotide able to express a polypeptide) b) to induce differentiation (e.g., with an inducer such as, for example, RANKL) and c) to determine the level of differentiation of the osteoclast cell (e.g., measuring the number of differentiated cells, their rate of differentiation, specific marker of differentiation etc).
A cell provided with a positive regulator of osteoclast differentiation may have an increased level of differentiation. A cell provided with a negative regulator of osteoclast differentiation may have a decreased level of differentiation.
The present invention aslo provides a method of identifying a compound capable of interfering with osteoclast differentiation, the method may comprise contacting a cell including therein a non-endogenous polynucleotide sequence comprising any one of SEQ ID NO.:1 to 33. 85 or 86 (a coding portion) and quantifying (e.g. the number of) differentiated osteoclasts. A reduction in osteoclast differentiation in the presence of the compound in comparison to the absence of the compound may be indicative of an antagonist of osteoclast differentiation, while an increase in osteoclast differentiation in the presence of the compound in comparison to the absence of the compound may be indicative of an agonist of osteoclast differentiation.
In accordance with the present invention, the cell may also comprise an endogenous form of a polynucleotide.
As used herein the term "endogenous" means a substance that naturally originates from within an organism, tissue or cell. The term "endogenous polynucleotide" refers to a chromosomal form of a polynucleotide or RNA
version (hnRNA. mRNA) produced by the chromosal form of the polynucleotide The term "endogenous polypeptide- refers to the form of the protein encoded by an -endogenous polynucleotide".
As used herein the term "non-endogenous" or -exogenous" is used in opposition to "endogenous" in that the substance is provided from an external source although it may be introduced within the cell. The term "non-endogenous polynucleotide" refers to a synthetic polynucleotide introduced within the cell and include for example and without limitation, a vector comprising a sequence of interest, a synthetic mRNA, an oligonucleotide comprising a NSEQ etc. The term "non-endogenous polypeptide" refers to the form of the protein encoded by an "non-endogenous polynucleotide", The present invention also relate to a method of identifying a compound capable of interfering with osteoclast differentiation, the method may comprise contacting a cell including therein a non-endogenous polypeptide sequence comprising any one of SEQ ID NO.: 48 to 80 and quantifying (e.g. the number of) differentiated osteoclasts. A reduction in osteoclast differentiation in the presence of the compound in comparison to the absence of the compound may be indicative of 5 an antagonist of osteoclast differentiation while an increase in osteoclast differentiation in the presence of the compound in comparison to the absence of the compound may be indicative of an agonist of osteoclast differentiation.
As used herein the term "sequence identity" relates to (consecutive) nucleotides of a nucleotide sequence which with reference to an original nucleotide 10 sequence. The identity may be compared over a region or over the total sequence of a nucleic acid sequence.
Thus, "identity" may be compared, for example, over a region of 3, 4, 5, 10, 19, 20 nucleotides or more (and any number there between). It is to be understood herein that gaps of non-identical nucleotides may be found between identical nucleic 15 acids. For example, a polynucleotide may have 100% identity with another polynucleotide over a portion thereof. However, when the entire sequence of both polynucleotides is compared, the two polynucleotides may have 50% of their overall (total) sequence identical to one another.
Polynucleotides of the present invention or portion thereof having from about 20 50 to about 100%, or about 60 to about 100% or about 70 to about 100% or about 80 to about 100% or about 85%, about 90%, about 95% to about 100% sequence identity with an original polynucleotide are encompassed herewith. It is known by those of skill in the art, that a polynucleotide having from about 50% to 100%
identity may function (e.g., anneal to a substantially complementary sequence) in a manner 25 similar to an original polynucleotide and therefore may be used in replacement of an original polynucleotide. For example a polynucleotide (a nucleic acid sequence) may comprise or have from about 50% to 100% identity with an original polynucleotide over a defined region and may still work as efficiently or sufficiently to achieve the present invention.
Percent identity may be determined, for example, with an algorithm GAP, BESTFIT', or FASTA in the Wisconsin Genetics Software Package Release 7.0, using default gap weights.
As used herein the terms " sequence complementarity" refers to (consecutive) nucleotides of a nucleotide sequence which are complementary to a reference PCT/CA2007/1)00210 (original) nucleotide sequence The complementarity may be compared over a region or over the total sequence of a nucleic acid sequence.
Polynucleotides of the present invention or portion thereof having from about to about 100%, or about 60 to about 100% or about 70 to about 100% or about 80 to about 100% or about 85%, about 90%, about 95% to about 100% sequence complementarity with an original polynucleotide are thus encompassed herewith.
It is known by those of skill in the art, that an polynucleotide having from about 50% to 100% complementarity with an original sequence may anneal to that sequence in a manner sufficient to carry out the present invention (e.g., inhibit expression of the original polynucleotide).
An "analogue" is to be understood herein as a molecule having a biological activity and chemical structure similar to that of a polypeptide described herein. An "analogue" may have sequence similarity with that of an original sequence or a portion of an original sequence and may also have a modification of its structure as discussed herein. For example, an "analogue" may have at least 90 A) sequence similarity with an original sequence or a portion of an original sequence. An "analogue" may also have, for example: at least 70 A) or even 50 A sequence similarity (or less, i.e.. at least 40%) with an original sequence or a portion of an original sequence Also, an "analogue" with reference to a polypeptide may have, for example, at least 50 % sequence similarity to an original sequence with a combination of one or more modification in a backbone or side-chain of an amino acid, or an addition of a group or another molecule, etc.
"Polynucleotide" generally refers to any polyribonucleotide or polydeoxyribo-nucleotide, which may be unmodified RNA or DNA, or modified RNA or DNA.
"Polynucleotides" include, without limitation single- and double-stranded DNA, DNA
that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions hybrid molecules comprising DNA and RNA that may be single-stranded or more typically double-stranded or a mixture of single- and double-stranded regions In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA
and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA.
thus "polynucleotide" embraces chemically. enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. 'Polynucleotide" includes but is not limited to linear and end-closed molecules. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.
"Polypeptides" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds (i.e., peptide isosteres). "Polypeptide" refers to both short chains, commonly referred as peptides, oligopeptides or oligomers, and to longer chains generally referred to as proteins. As described above, polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
As used herein the term "polypeptide analog" relates to mutants, variants, chimeras. fusions, deletions, additions and any other type of modifications made relative to a given polypeptide.
As used herein the term "biologically active" refers to a variant or fragment which retains some or all of the biological activity of the natural polypeptide, i.e., to be able to promote or inhibit osteoclast differentiation. Polypeptides or fragments of the present invention may also include "immunologically active" polypeptides or fragments.
"Immunologically active polypeptides or fragments may be useful for immunization purposes (e.g. in the generation of antibodies).
Thus. biologically active polypeptides in the form of the original polypeptides, fragments (modified or not), analogues (modified or not), derivatives (modified or not).
homologues, (modified or not) of the polypeptides described herein are encompassed by the present invention.
Therefore, any polypeptide having a modification compared to an original polypeptide which does not destroy significantly a desired biological activity is encompassed herein It is well known in the art, that a number of modifications may be made to the polypeptides of the present invention without deleteriously affecting their biological activity. These modifications may, on the other hand, keep or increase the biological activity of the original polypeptide or may optimize one or more of the particularity (e.g. stability, bioavailability, etc.) of the polypeptides of the present invention which, in some instance might be desirable. Polypeptides of the present invention may comprise for example, those containing amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are known in the art. Modifications may occur anywhere in a polypeptide including the polypeptide backbone the amino acid side-chains and the amino- or carboxy-terminus. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. It is to be understood herein that more than one modification to the polypeptides described herein are encompassed by the present invention to the extent that the biological .. activity is similar to the original (parent) polypeptide.
As discussed above, polypeptide modification may comprise, for example, amino acid insertion (i.e., addition), deletion and substitution (i.e., replacement), either conservative or non-conservative (e.g., D-amino acids, desamino acids) in the polypeptide sequence where such changes do not substantially alter the overall biological activity of the polypeptide.
Example of substitutions may be those, which are conservative (i.e., wherein a residue is replaced by another of the same general type or group) or when wanted non-conservative (i.e., wherein a residue is replaced by an amino acid of another type) In addition a non-naturally occurring amino acid may substitute for a naturally occurring amino acid (i.e., non-naturally occurring conservative amino acid substitution or a non-naturally occurring non-conservative amino acid substitution).
As is understood, naturally occurring amino acids may be sub-classified as acidic, basic, neutral and polar, or neutral and non-polar. Furthermore, three of the encoded amino acids are aromatic. It may be of use that encoded polypeptides differing from the determined polypeptide of the present invention contain substituted codons for amino acids, which are from the same type or group as that of the amino acid to be replaced. Thus, in some cases, the basic amino acids Lys, Arg and His may be interchangeable; the acidic amino acids Asp and Glu may be interchangeable, the neutral polar amino acids Ser, Thr, Cys, Gln. and Asn may be interchangeable:
the non-polar aliphatic amino acids Gly, Ala, Val. Ile, and Leu are interchangeable but because of size Gly and Ala are more closely related and Val, Ile and Leu are more closely related to each other. and the aromatic amino acids Phe. Trp and Tyr may be interchangeable_ It should be further noted that if the polypeptides are made synthetically, substitutions by amino acids, which are not naturally encoded by DNA (non-naturally occurring or unnatural amino acid) may also be made.
A non-naturally occurring amino acid is to be understood herein as an amino acid which is not naturally produced or found in a mammal A non-naturally occurring amino acid comprises a D-amino acid, an amino acid having an acetylaminomethyl group attached to a sulfur atom of a cysteine. a pegylated amino acid. etc.
The inclusion of a non-naturally occurring amino acid in a defined polypeptide sequence will therefore generate a derivative of the original polypeptide. Non-naturally occurring amino acids (residues) include also the omega amino acids of the formula NH2(CH2),COOH wherein n is 2-6, neutral nonpolar amino acids, such as sarcosine, t-butyl alanine, t-butyl glycine, N-methyl isoleucine, norleucine, etc.
Phenylglycine may substitute for Trp. Tyr or Phe; citrulline and methionine sulfoxide are neutral nonpolar.
cysteic acid is acidic, and ornithine is basic. Proline may be substituted with hydroxyproline and retain the conformation conferring properties.
It is known in the art that analogues may be generated by substitutional mutagenesis and retain the biological activity of the polypeptides of the present invention. These analogues have at least one amino acid residue in the protein molecule removed and a different residue inserted in its place. For example, one site of interest for substitutional mutagenesis may include but are not restricted to sites identified as the active site(s). or immunological site(s) Other sites of interest may be those, for example, in which particular residues obtained from various species are identical. These positions may be important for biological activity Examples of substitutions identified as "conservative substitutions" are shown in Table A.
If such substitutions result in a change not desired, then other type of substitutions.
denominated -exemplary substitutions" in Table A, or as further described herein in reference to amino acid classes, are introduced and the products screened.
In some cases it may be of interest to modify the biological activity of a polypeptide by amino acid substitution, insertion, or deletion. For example.
modification of a polypeptide may result in an increase in the polypeptide's biological activity, may modulate its toxicity, may result in changes in bioavailability or in stability.
or may modulate its immunological activity or immunological identity Substantial modifications in function or immunological identity are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation. (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based 5 on common side chain properties:
(1) hydrophobic: norleucine. methionine (Met), Alanine (Ala), Valine (Val), Leucine (Leu), lsoleucine (Ile) (2) neutral hydrophilic: Cysteine (Cys), Serine (Ser). Threonine (Thr) (3) acidic: Aspartic acid (Asp), Glutamic acid (Glu) 10 (4) basic: Asparagine (Asn), Glutamine (Gin), Histidine (His). Lysine (Lys) Arginine (Arg) (5) residues that influence chain orientation: Glycine (Gly), Proline (Pro);
and aromatic: Tryptophan (Trp), Tyrosine (Tyr), Phenylalanine (Phe) Non-conservative substitutions will entail exchanging a member of one of these 15 classes for another.
TABLE A. Examplary amino acid substitution Original residue Exemplary substitution = Conservative substitution Ala (A) Val. Leu, Ile Val Arg (R) Lys. Gin, Asn Lys Asn (N) Gin. His, Lys. Arg Gin Asp (D) Glu IGlu Cys (C) Ser Ser Gln (Q) Asn Asn Glu (E) Asp Asp Gly (G) Pro Pro His (H) Asn, Gin, Lys, Arg Arg !Original residue 'Exemplary substitution r Conservative substitution Ile (I) Leu, Val, Met. Ala, Phe, Leu norleucine Leu (L) Norleucine, Ile, Val, Met, Ile Ala, Phe Lys (K) Arg, Gin, Asn Arg Met (M) Leu, Phe. Ile Leu =
Phe (F) . Leu, Val. Ile, Ala Leu Pro (P) Gly Gly Ser (S) = Thr Thr Thr (T) Ser f Ser Tip (W) Tyr ; Tyr Tyr (Y) Trp, Phe, Thr, Ser Phe Val (V) Ile, Leu, Met, Phe, Ala, Leu norleucine It is to be understood herein; that if a "range" or "group" of substances (e.g.
amino acids). substituents" or the like is mentioned or if other types of a particular characteristic (e.g. temperature. pressure. chemical structure, time, etc) is mentioned, the present invention relates to and explicitly incorporates herein each and every specific member and combination of sub-ranges or sub-groups therein whatsoever Thus, any specified range or group is to be understood as a shorthand way of referring to each and every member of a range or group individually as well as each and every possible sub-ranges or sub-groups encompassed therein; and similarly with respect to any sub-ranges or sub-groups therein. Thus, for example, with respect to a percentage (c)/0) of identity of from about 80 to 100%, it is to be understood as specifically incorporating herein each and every individual %, as well as sub-range, such as for example 80%, 81%, 84.78%. 93%, 99% etc.; and similarly with respect to other parameters such as, concentrations, elements, etc.
It is in particular to be understood herein that the methods of the present invention each include each and every individual steps described thereby as well as those defined as positively including particular steps or excluding particular steps or a combination thereof; for example an exclusionary definition for a method of the present invention, may read as follows: "provided that said polynucleotide does not comprise or consist in SEQ ID NO.:34 or the open reading frame of SEQ ID
NO.:34"
or "provided that said polypeptide does not comprise or consist in SEQ ID
NO.:82" or "provided that said polynucleotide fragment or said polypeptide fragment is less than X unit (e.g., nucleotides or amino acids) long or more than X unit (e.g., nucleotides or amino acids) long".
Other objects, features, advantages, and aspects of the present invention will become apparent to those skilled in the art from the following description.
BRIEF DESCRIPTION OF THE DRAWINGS
In the appended drawings:
For each of Figures 1 to 34 and 38-39 macroarrays were prepared using RAMP
amplified RNA from human precursor cells (A-F 1), and differentiated intermediate (A-F
2 ¨ 3) and mature osteoclasts for four human donors (A-F 4), and 30 different normal human tissues (adrenal (A5), liver (B5), lung (C5), ovary (D5), skeletal muscle (E5), heart (F5), cervix (G5), thyroid (H5), breast (A6), placenta (B6), adrenal cortex (C6), kidney (D6), vena cava (E6), fallopian tube (F6), pancreas (G6), testicle (H6), jejunum (A7), aorta (B7), esophagus (C7), prostate (D7), stomach (E7), spleen (F7), ileum (G7), trachea (A8), brain (B8), colon (C8), thymus (D8), small intestine (E8), bladder (F8) and duodenum (G8)). The STAR dsDNA clone representing the respective SEQ ID NOs.
was labeled with 32P and hybridized to the macroarray. The probe labeling reaction was also spiked with a dsDNA sequence for Arabidopsis, which hybridizes to the same sequence spotted on the macroarray (M) in order to serve as a control for the labeling reaction. Quantitation of the hybridization signal at each spot was performed using a STORM 820 PhosphorimagerTM and the lmageQuantTM TL software (Amersham Biosciences, Piscataway, NJ). A log2 value representing the average of the signals for the precursors (A-F 1) was used as the baseline and was subtracted from the log2 value obtained for each of the remaining samples in order to determine their relative abundancies compared to the precursors and plotted as a bar graph (right panel).
Fig. 1 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 1. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 2 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 2. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 3 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 3. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 4 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 4. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 5 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 5. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 6 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected .. osteoclast-specific human SEQ ID NO. 6 The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 -Fig. 7 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 7. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 8 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO 8. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 9 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR selected osteoclast-specific human SEQ. ID. NO. 9. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F 1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 10 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO, 10. The hybridization results obtained .. confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 -8).
Fig. 11 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 11. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
5 1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G 7 - 8):
Fig. 12 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 12. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher 10 expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8.:
Fig. 13 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 13. The hybridization results obtained 15 confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and AG
7 - 8).
Fig. 14 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected 20 osteoclast-specific human SEQ. ID, NO. 14. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 8):
Fig. 15 is a picture of the macroarray hybridization results and quantitation of 25 the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 15. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 -4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
30 Fig. 16 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 16 The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher, expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨8);
Fig. 17 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 17. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8..
Fig 18 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 18. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8):
Fig. 19 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 19. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8):
Fig. 20 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ ID, NO. 20. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8):
Fig. 21 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 21. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8):
Fig. 22 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 22. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G
7 - 8);
Fig. 23 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 23. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G
7 - 8):
Fig 24 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 24. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8);
Fig. 25 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 25. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8);
Fig. 26 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 26. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 -4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 -8):
Fig. 27 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID, NO. 27. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G
7 - 8);
Fig. 28 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 28. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8);
Fig. 29 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 29. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8).
Fig. 30 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 30. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 -6 and A-G
7 - 8);
Fig. 31 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO, 31. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8):
Fig. 32 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 32. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 -8).
Fig. 33 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 33. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8);
Fig. 34 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 34. The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 ¨ 4) compared to the precursors (A-F
1) and little or no expression in all or most normal tissues (A-H 5 ¨ 6 and A-G 7 ¨ 8), Fig. 35 is a picture showing the knockdown effects on osteoclastogenesis by attenuating the endogenous expression of SEQ. ID. NO. 1 (A80326) and SEQ. ID.
NO.
2 (AB0369) using shRNA. A significant decrease in the number of multinucleated osteoclasts was observed from precursor cells infected with the AB0326 shRNA
(Figure 35A; bottom panel) and AB0369 shRNA (Figure 1B, bottom panel) compared to those with the lacZ shRNA (Figure 35A and B, top panels). These results clearly indicated that expression of the gene encoding SEQ. ID. NO. 1 (AB0326) and SEQ. ID, NO. 2 (AB0369) are required for osteoclast differentiation;
Fig. 36 is a picture showing the knockdown effects on osteoclastogenesis of the mouse orthologue for AB0326 (SEQ. ID. NO. 35) in the RAW 264.7 model using shRNA-0326.2 (SEQ. ID. NO. 45). The RAW-0326.2 cell line produced significantly less osteoclasts (Figure 36; bottom panel) compared to the cell line containing the scrambled shRNA (Figure 36; top panel). This result, coupled with that obtained in the human osteoclast precursor cells using the lentiviral shRNA delivery system demonstrate that in both human and mouse, AB0326 gene product is clearly required for osteoclastogenesis;
Fig. 37 is a picture showing the results of a functional complementation assay for SEQ. ID. NO. 1 (AB0326) in RAW-0326.2 cells to screen for inhibitors of osteoclastogenesis. The RAW-0326.2 cells transfected with the empty pd2 vector are unable to form osteoclasts in the presence of RANK ligand (center panel) indicating that the mouse AB0326 shRNA is still capable of silencing the AB0326 gene expression in these cells. Conversely, the cells transfected with the cDNA for the human AB0326 (pd2-hAB0326) are rescued and thus, differentiate more efficiently into osteoclasts in response to RANK ligand (right panel). Wild-type RAW 264.7 cells containing the empty vector (pd2) did not adversly affect the formation of osteoclasts in the presence of RANK ligand (left panel) ruling out an effect due to pd2 Thus, this 5 complementation assay can be used to screen for inhibitors of the human polypeptide;
Fig. 38 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential Expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 85. Macroarrays were prepared using RAMP
10 amplified RNA from human precursor cells (A-F 1), and differentiated intermediate and mature osteoclasts for four human donors (A-F 2 - 4), and 30 different normal human tissues (adrenal. liver, lung, ovary, skeletal muscle, heart, cervix, thyroid.
breast, placenta, adrenal cortex, kidney, vena cava, fallopian tube. pancreas, testicle, jejunum, aorta, esophagus, prostate. stomach, spleen, ileum, trachea, brain, colon, thymus.
15 small intestine, bladder and duodenum (A-H 5 - 6 and A-G 7 - 8)). The STAR clone representing SEQ. ID. NO. 85 was labeled with 32P and hybridized to the macroarray The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 - 4) compared to the precursors (Al - Fl) and little or no expression in all or most 20 normal tissues (A-H 5 - 6 and A-G 7 - 8), and, Fig. 39 is a picture of the macroarray hybridization results and quantitation of the signal intensities showing the differential Expression data for STAR
selected osteoclast-specific human SEQ. ID. NO. 86. Macroarrays were prepared using RAMP
amplified RNA from human precursor cells (A-F 1). and differentiated intermediate and 25 mature osteoclasts for four human donors (A-F 2 - 4), and 30 different normal human tissues (adrenal, liver, lung, ovary, skeletal muscle, heart, cervix, thyroid, breast, placenta, adrenal cortex, kidney, vena cava, fallopian tube, pancreas, testicle. jejunum, aorta, esophagus, prostate, stomach, spleen, ileum, trachea, brain, colon, thymus.
small intestine, bladder and duodenum (A-H 5 - 6 and A-G 7 - 8)). The STAR
clone 30 representing SEQ. ID NO. 86 was labeled with 32P and hybridized to the macroarray The hybridization results obtained confirms its upregulation in all of the human osteoclast samples with generally higher expression in the more mature osteoclasts (A-F 2 -4) compared to the precursors (Al - Fl) and little or no expression in all or most normal tissues (A-H 5 - 6 and A-G 7 - 8).
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
The applicant employed a carefully planned strategy to identify and isolate genetic sequences involved in osteoclastogenesis and bone remodeling. The process involved the following steps: 1) preparation of highly representative cDNA
libraries using mRNA isolated from precursors and differentiated intermediate and mature osteoclasts of human origin; 2) isolation of sequences upregulated during osteoclastogenesis: 3) identification and characterization of upregulated sequences: 4) selection of upregulated sequences for tissue specificity; and 5) determination of knock-down effects on osteoclastogenesis. The results discussed in this disclosure demonstrate the advantage of targeting osteoclast genes that are specific to this differentiated cell type and provide a more efficient screening method when studying the genetic basis of diseases and disorders. Genes that are known to have a role in other areas of biology have been shown to play a critical role in osteoclastogenesis and osteoclast function. Genes that are known but have not had a role assigned to them until the present disclosure have also been isolated and shown to have a critical role in osteoclastogenesis and osteoclast function. Finally, novel genes have been identified and play a role, however, applicant reserves their disclosure until further study has been completed:
The present invention is illustrated in further details below in a non-limiting fashion.
A- Material and Methods Commercially available reagents referred to in the present disclosure were used according to supplier's instructions unless otherwise indicated. Throughout the present disclosure certain starting materials were prepared as follows:
B - Preparation of osteoclast differentiated cells The RAW 264.7 (RAW) osteoclast precursor cell line and human precursor cells (peripheral blood mononuclear cells or CD34+ progenitors) are well known in the art as murine and human models of osteoclastogenesis. These murine and human osteoclasts are therefore excellent sources of materials for isolating and characterizing genes specialized for osteoclast function.
Human primary osteoclasts were differentiated from G-CSF-mobilized peripheral blood mononuclear cells (Cambrex, East Rutherford, NJ) as described by the supplier in the presence of 35 ng/ml M-CSF and 100 ng/ml RANK ligand. Multinucleated TRAP-staining osteoclasts were visible by 11-14 days. Osteoclasts were also derived from human osteoclasts precursor cells (CD34+ progenitors) (Cambrex, East Rutherford, NJ) and cultured as described by the supplier. In the latter case, osteoclasts were obtained after 7 days.
RAW cells were purchased from American Type Culture Collection and maintained in high glucose DMEM containing 10% fetal bovine serum and antibiotics.
The cells were sub-cultured bi-weekly to a maximum of 10-12 passages. For osteoclast differentiation experiments, RAW cells were seeded in 96-well plates at a density of 4 x 103 cells/well and allowed to plate for 24h. Differentiation was induced in high glucose DMEM, 10% charcoal-treated foetal bovine serum (Hyclone, Logan, UT), 0.05%
BSA, antibiotics, 10 ng/ml macrophage colony stimulating factor (M-CSF), and 100 ng/ml receptor activator of NF-kB (RANK) ligand. The plates were re-fed on day 3 and osteoclasts were clearly visible by day 4. Typically, the cells were stained for tartrate-resistant acid phosphatase (TRAP) on day 4 or 5 unless otherwise indicated.
For TRAP
staining, the cells were washed with PBS and fixed in 10% formaldehyde for 1 h. After two PBS washes, the cells were rendered lightly permeable in 0.2% TritonTm X-100 in PBS for 5 min before washing in PBS. Staining was conducted at 37 C for 20-25 min in 0.01% Naphtol AS-MX phosphate, 0.06% Fast Red Violet, 50 mM sodium tartrate, mM sodium acetate, pH 5.2. Cells were visualized microscopically.
C- Method of Isolating Differentially Expressed mRNA
Key to the discovery of differentially expressed sequences unique to osteoclasts is the use of the applicant's patented STAR technology (Subtractive Transcription-based Amplification of mRNA; U.S. Patent No. 5,712,127 Malek et al., issued on January 27, 1998). In this procedure, mRNA isolated from intermediate and mature osteoclasts is used to prepare "tester RNA", which is hybridized to complementary single-stranded "driver DNA" prepared from osteoclast precursor mRNA and only the un-hybridized "tester RNA" is recovered, and used to create cloned cDNA libraries, termed "subtracted libraries". Thus, the "subtracted libraries" are enriched for differentially expressed sequences inclusive of rare and novel mRNAs often missed by micro-array hybridization analysis. These rare and novel mRNA are thought to be representative of important gene targets for the development of better diagnostic and therapeutic strategies.
The clones contained in the enriched "subtracted libraries' are identified by DNA sequence analysis and their potential function assessed by acquiring information available in public databases (NCB' and GeneCard). The non-redundant clones are then used to prepare DNA micro-arrays, which are used to quantify their relative differential expression patterns by hybridization to fluorescent cDNA probes.
Two classes of cDNA probes may be used those which are generated from either RNA
transcripts prepared from the same subtracted libraries (subtracted probes) or from mRNA isolated from different osteoclast samples (standard probes). The use of subtracted probes provides increased sensitivity for detecting the low abundance mRNA sequences that are preserved and enriched by STAR. Furthermore, the specificity of the differentially expressed sequences to osteoclast is measured by hybridizing radio-labeled probes prepared from each selected sequence to macroarrays containing RNA from different osteoclast samples and different normal human tissues. Additionally, Northern blot analysis is performed so as to confirm the presence of one or more specific mRNA species in the osteoclast samples.
Following this, the full-length cDNAs representative of the mRNA species and/or spliced variants are cloned in E. coli DH10B.
A major challenge in gene expression profiling is the limited quantities of RNA
available for molecular analysis The amount of RNA isolated from many osteoclast samples or human specimens (needle aspiration, laser capture micro-dissection (LCM) samples and transfected cultured cells) is often insufficient for preparing:
1) conventional tester and driver materials for STAR. 2) standard cDNA probes for DNA
micro-array analysis; 3) RNA macroarrays for testing the specificity of expression 4) Northern blots and; 5) full-length cDNA clones for further biological validation and characterization etc. Thus, the applicant has developed a proprietary technology called RAMP (RNA Amplification Procedure) (U.S. Patent Application No. 11/000,958 published under No. US 2005/0153333A1 on July 14. 2005 and entitled "Selective Terminal Tagging of Nucleic Acids"), which linearly amplifies the mRNA
contained in total RNA samples yielding microgram quantities of amplified RNA sufficient for the various analytical applications. The RAMP RNA produced is largely full-length mRNA-like sequences as a result of the proprietary method for adding a terminal sequence tag to the 3'-ends of single-stranded cDNA molecules, for use in linear transcription amplification. Greater than 99.5% of the sequences amplified in RAMP reactions show <2-fold variability and thus, RAMP provides unbiased RNA samples in quantities sufficient to enable the discovery of the unique mRNA sequences involved in osteoclastogenesis.
D- Preparation of Human Osteoclasts Subtracted Library Two human primary precursor cells from two different donors (Cambrex. East Rutherford, NJ), and the corresponding intermediate (day 3 and day 7) and mature (days 11-14) osteoclasts were prepared as described above Isolation of cellular RNA
followed by mRNA purification from each was performed using standard methods (Qiagen. Mississauga, ON). Following the teachings of Malek et al (U S Patent No 5,712.127), 2 pg of poly A+ mRNA from each sample were used to prepare highly representative (>2x106 CFU) cDNA libraries in specialized plasmid vectors necessary for preparing tester and driver materials. In each case, first-strand cDNA was synthesized using an oligo dT" primer with 3' locking nucleotides (e.g., A, G
or C) and containing a Not I recognition site. Next, second-strand cDNA synthesis was performed according to the manufacturer's procedure for double-stranded cDNA synthesis (Invitrogen, Burlington, ON) and the resulting double-stranded cDNA ligated to linkers containing an Asc I recognition site (New England Biolabs, Pickering, ON). The double-stranded cDNAs were then digested with Asc I and Not I restriction enzymes (New England Biolabs, Pickering, ON), purified from the excess linkers using the cDNA
fractionation column from Invitrogen (Burlington, ON) as specified by the manufacturer and each ligated into specialized plasmid vectors - p14 (SEQ. ID. NO 36) and p17+
(SEQ ID. NO:37) used for preparing tester and driver materials respectively Thereafter, the ligated cDNAs were transformed into E. coli DH10B resulting in the desired cDNA libraries (RAW 264.7-precursor-p14, RAW 264 7-precursor-p17+, RAW
264.7-osteoclasts-p14 and RAW 264.7-osteoclasts-p17+). The plasmid DNA pool for each cDNA library was purified and a 2-pg aliquot of each linearized with Not I
restriction enzyme. In vitro transcription of the Not I digested p14 and p17+
plasmid libraries was then performed with T7 RNA polymerase and sp6 RNA polymerase respectively (Ambion, Austin, TX).
Next, in order to prepare 3-represented tester and driver libraries, a 10-pg aliquot of each of the in vitro synthesized RNA was converted to double-stranded cDNA by performing first-strand cDNA synthesis as described above followed by primer-directed (primer OGS 77 for p14 (SEQ. ID. NO:40) and primer OGS 302 for 5 p17+ (SEQ. ID N0,41)) second-strand DNA synthesis using Advantage-2 Taq polymerase (BD Biosciences Clontech, Mississauga, ON). The sequences corresponding to OGS 77 and OGS 302 were introduced into the in vitro synthesized RNA by way of the specialized vectors used for preparing the cDNA libraries.
Thereafter, 6x 1-pg aliquots of each double-stranded cDNA was digested individually 10 with one of the following 4-base recognition restriction enzymes Rsa I.
Sau3A1, Mse I, Msp 1, MinP1 I and Bsh 12361 (MBI Fermentas, Burlington, ON), yielding up to six possible 3'-fragments for each RNA species contained in the cDNA library.
Following digestion, the restriction enzymes were inactivated with phenol and the set of six reactions pooled. The restriction enzymes sites were then blunted with T4 DNA
15 polymerase and ligated to linkers containing an Asc 1 recognition site.
Each linker-adapted pooled DNA sample was digested with Asc I and Not I restriction enzymes.
desalted and ligated to specialized plasmid vectors, p14 and p17 (p17 plasmid vector is similar to the p17+ plasmid vector except for the sequence corresponding to SEQ. ID.
N0,41), and transformed into E. coli DH10B. The plasmid DNA pool for each p14 and 20 p17 3'-represented library was purified (Qiagen, Mississauga, ON) and a 2-rig aliquot of each digested with Not 1 restriction enzyme. and transcribed in vitro with either T7 RNA polymerase or sp6 RNA polymerase (Ambion, Austin. TX). The resulting p14 3'-represented RNA was used directly as "tester RNA" whereas, the p17 3'-represented RNA was used to synthesize first-strand cDNA as described above, which then served 25 as "driver DNA". Each "driver DNA" reaction was treated with RNase A and RNase H to remove the RNA, phenol extracted and desalted before use.
The following 3'-represented libraries were prepared:
Tester 1 (donor 1 ¨ day 3) - human intermediate osteoclast-3' in p14 Tester 2 (donor 1 ¨ day 7 - human intermediate osteoclast)-3' in p14 30 Tester 3 (donor 1 ¨ day 11 - human mature osteoclast)-I in p14 Tester 4 (donor 2 ¨ day 3 - human intermediate osteoclast)-3 in p14 Tester 5 (donor 2 ¨ day 7 - human intermediate osteoclast)-3' in p14 Tester 6 (donor 2 ¨ day 13 - human mature osteoclast)-3' in p14 Driver 1 (donor 1 ¨ day 3) - human precursor-3' in p17 Driver 2 (donor 2¨ day 3) - human precursor-3' in p17 The tester RNA samples were subtracted following the teachings of U.S patent No. 5.712,127 with the corresponding driver DNA in a ratio of 1:100 for either 1-or 2-rounds following the teachings of Malek et at. (U.S. Patent No. 5,712,127).
Additionally, control reactions containing tester RNA and no driver DNA, and tester RNA plus driver DNA but no RNase H were prepared. The tester RNA remaining in each reaction after subtraction was converted to double-stranded DNA, and a volume of 5% removed and amplified in a standard PCR reaction for 30-cycles for analytical purposes.
The remaining 95% of only the driver plus RNase H subtracted samples were amplified for 4-cycles in PCR, digested with Asc I and Not I restriction enzymes, and one half ligated into the pCATRMAN (SEQ. ID. NO:38) plasmid vector and the other half, into the p20 (SEQ. ID. NO:39) plasmid vector. The ligated materials were transformed into E. coli DH1OB and individual clones contained in the pCATRMAN libraries were picked for further analysis (DNA sequencing and hybridization) whereas, clones contained in each p20 library were pooled for use as subtracted probes. Each 4-cycles amplified cloned subtracted library contained between 25.000 and 40.000 colonies The following cloned subtracted libraries were prepared:
SL90 - tester 1 (day 3 osteoclast) minus driver 1 (precursor) (1-round) in pCATRMAN, SL91 - tester 2 (day 7 osteoclast) minus driver 1 (precursor) (1-round) in pCATRMAN:
5L92-tester 3 (day 11 osteoclast) minus driver 1 (precursor) (1-round) in pCATRMAN:
SL108-tester 1 (day 3 osteoclast) minus driver 1 (precursor) (2-rounds) in pCATRMAN.
SL109-tester 2 (day 7 osteoclast) minus driver 1 (precursor) (2-rounds) in pCATRMAN:
SL110-tester3 (day 11 osteoclast) minus driver 1(precursor) (2-rounds) in pCATRMAN:
SL93 -tester 4 (day 3 osteoclast) minus driver 2 (precursor) (1-round) in pCATRMAN, SL94 - tester 5 (day 7 osteoclast) minus driver 2 (precursor) (1-round) in pCATRMAN, SL95-tester 6 (day 13 osteoclast) minus driver 2 (precursor) (1-round) in pCATRMAN, SL87 - tester 4 (day 3 osteoclast) minus driver 2 (precursor) (2-rounds) in pCATRMAN
SL88 - tester 5 (day 7 osteoclast) minus driver 2 (precursor) (2-rounds) in pCATRMAN:
SL89- tester 6 (day 11 osteoclast) minus driver 2 (precursor) (2-rounds) in pCATRMAN
A 5-pL aliquot of the 30-cycles PCR amplified subtracted materials described above were visualized on a 1.5% agarose gel containing ethidium bromide and then transferred to HybondTM N+ (Amersham Biosciences, Piscataway, NJ) nylon membrane for Southern blot analysis. Using radiolabeled probes specific to the CTSK
(cathepsin K;
NM_000396.2) gene, which is known to be upregulated in osteoclasts, and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase; M32599.1), which is a non-differentially expressed house-keeping gene, it was evident that there was subtraction of GAPDH but not CTSK. Based on these results, it was anticipated that the subtracted libraries would .. be enriched for differentially expressed upregulated sequences.
E - Sequence identification and annotation of clones contained in the subtracted libraries:
A total of 6,912 individual colonies contained in the pCATRMAN subtracted libraries (5L87-95 and SL108-110) described above were randomly picked using a Qbot (Genetix Inc., Boston, MA) into 60 pL of autoclaved water. Then, 42 pL of each was used in a 100-pL standard PCR reaction containing oligonucleotide primers, OGS
1 and OGS 142 and amplified for 40-cycles (94 C for 10 minutes, 40x (94 C for 40 seconds, 55 C for 30 seconds and 72 C for 2 minutes) followed by 72 C for 7 minutes) in 96-wells microtitre plates using HotStartTM Taq polymerase (Qiagen, Mississauga, ON).
The completed PCR reactions were desalted using the 96-well filter plates (Corning) and the amplicons recovered in 100 pL 10mM Tris (pH 8.0). A 5-pL aliquot of each PCR
reaction was visualized on a 1.5% agarose gel containing ethidium bromide and only those reactions containing a single amplified product were selected for DNA
sequence analysis using standard DNA sequencing performed on an ABI 3100 instrument (Applied Biosystems, Foster City, CA). Each DNA sequence obtained was given a Sequence Identification Number and entered into a database for subsequent tracking and annotation.
Each sequence was selected for BLAST analysis of public databases (e.g.
NCBI). Absent from these sequences were the standard housekeeping genes (GAPDH, actin, most ribosomal proteins etc.), which was a good indication that the subtracted library was depleted of at least the relatively abundant non-differentially expressed sequences.
Once sequencing and annotation of the selected clones were completed. the next step involved identifying those sequences that were actually upregulated in osteoclasts compared to precursors.
F - Hybridization analysis for identifying upregulated sequences The PCR amplicons representing the annotated sequences from the pCATRMAN libraries described above were used to prepare DNA microarrays The purified PCR amplicons contained in 70 pL of the PCR reactions prepared in the previous section was lyophilized and each reconstituted in 20 pL of spotting solution comprising 3xSSC and 0.1% sarkosyl. DNA micro-arrays of each amplicon in triplicate were then prepared using CMT-GAP2 slides (Corning, Corning, NY) and the GMS
spotter (Affymetrix, Santa Clara, CA).
The DNA micro-arrays were then hybridized with either standard or subtracted cy3 and cy5 labelled cDNA probes as recommended by the supplier (Amersham Biosciences, Piscataway, NJ). The standard cDNA probes were synthesized using RAMP amplified RNA prepared from the different human osteoclast samples and the corresponding precursors. It is well known to the skilled artisan that standard cDNA
probes only provide limited sensitivity of detection and consequently low abundance sequences contained in the cDNA probes are usually missed. Thus, the hybridization analysis was also performed using cy3 and cy5 labelled subtracted cDNA probes prepared from subtracted libraries representing the different tester and driver materials.
These subtracted libraries may be enriched for low abundance sequences as a result of following the teachings of Malek et al., and therefore. may provide increased detection sensitivity.
All hybridization reactions were performed using the dye-swap procedure as recommended by the supplier (Amersham Biosciences, Piscataway, NJ) and approximately 500 putatively differentially expressed upregulated (>2-fold) sequences were selected for further analysis.
G - Determining osteoclast specificity of the differentially expressed sequences identified:
The differentially expressed sequences identified in Section F for the different human osteoclast subtracted libraries were tested for osteoclast specificity by hybridization to nylon membrane-based macroarrays. The macroarrays were prepared using RAMP amplified RNA from human precursors and osteoclasts (intermediate and mature) of six independent experiments from 4 different donors (3 males and 1 female), and 30 normal human tissues (adrenal, liver, lung, ovary, skeletal muscle, heart, cervix, thyroid, breast, placenta, adrenal cortex, kidney, vena cava, fallopian tube, pancreas, testicle, jejunum, aorta, esophagus, prostate, stomach, spleen, ileum, trachea, brain, colon, thymus, small intestine, bladder and duodenum) purchased commercially (Ambion, Austin, TX). Because of the limited quantities of mRNA available for many of these samples, it was necessary to first amplify the mRNA using the RAMP
methodology. Each amplified RNA sample was reconstituted to a final concentration of 250 ng/pL in 3xSSC and 0.1% sarkosyl in a 96-well microtitre plate and 1 pL
spotted onto HybondTM N+ nylon membranes using the specialized MULTI-PRINTTm apparatus (VP Scientific, San Diego, CA), air dried and UV-cross linked. A total of 400 different sequences selected from 5L87-95 and SL108-110 were individually radiolabeled with a-32P-dCTP using the random priming procedure recommended by the supplier (Amersham, Piscataway, NJ) and used as probes on the macroarrays.
Hybridization and washing steps were performed following standard procedures well known to those skilled in the art.
Of the 500 sequences tested, approximately 85% were found to be upregulated in all of the osteoclast RNA samples that were used to prepare the macroarrays. However, many of these sequences were also readily detected in a majority of the different normal human tissues. Based on these results, those sequences that appeared to be associated with experimental variability and those that were detected in many of the other human tissues at significantly elevated levels were eliminated.
Consequently, only sequences, which appeared to be upregulated and highly osteoclast-specific, were selected for biological validation studies. Included in this set of 35 genes were 4 (SEQ.
ID. NOs. 30-33) where there was a significant upregulation in mature osteoclasts compared to most normal tissues but because the expression of these genes were 30 overall lower in the precursor cells, they appeared to be elevated in the normal tissues after quantitation Figure 30-33; bar graph). However, their expression in the normal tissues was still relatively lower than that of the mature osteoclasts. Thus, these genes may still be important regulators in osteoclastogenesis and bone resorption and were therefore selected for biological validation. This subset of 35 sequences does not included genes also identified such as, CTSK, TRAP, MMP9. CST3 and CKB amongst others since these were previously reported in the literature to be upregulated in osteoclasts. The macroarray data for CST3 (SEQ. ID.
NO. 34) is included to exemplify the hybridization pattern and specificity of a gene that 5 is already known to be a key regulator of the osteoclast resorption process. One gene (ANKH; SEQ. ID. NO. 17) was included in the subset of 35 genes although it was previously reported in the database (NCB! - Gene) to play a role in bone mineralization.
However, the observed bone phenotype resulting from mutations in the ANKH gene was not specifically linked to its upregulation in osteoclasts. Thus our data suggests the 10 important role for ANKH may be associated with osteoclast activity during bone remodeling.
Fig. 1-33, 38 and 39 show the macroarray patterns and quantitation of the hybridization signals of the osteoclasts and normal human tissues relative to precursor cells for the 35 sequences selected for biological validation. Amongst the 35 selected 15 sequences were 24 genes with functional annotation 9 genes with no functional annotation and 2 novel sequences (genomic hits). The identification of gene products involved in regulating osteoclast differentiation and function has thus led to the discovery of novel targets for the development of new and specific therapies of disease states characterized by abnormal bone remodeling. Representative sequences 20 summarized in Table 1 are presented below and corresponding sequences are illustrated in Table 5.
SEQ. ID. NO:1:
SEQ. ID. Na1 (Table 5) corresponds to a previously identified gene that 25 encodes a hypothetical protein. L00284266 with an unknown function (see Table 1).
We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 1), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
30 SEQ. ID. NO:2:
SEQ. ID. NO:2 (Table 5) corresponds to a previously identified gene that encodes a predicted open reading frame, C6orf82 with an unknown function (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 2), which have not been previously reported. At least 5 transcript variants of this gene coding for 3 protein isoforms has been identified so far (NCBI). Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:3:
SEQ. ID. NO:3 (Table 5) corresponds to a previously identified gene that encodes a hypothetical protein, L0C133308 with an unknown function (see Table 1) but may be involved in the process of pH regulation. We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 3), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:4:
SEQ. ID. NO:4 (Table 5) corresponds to a previously identified gene that encodes a hypothetical protein. L0C116211 with an unknown function (see Table 1) We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 4), which have not been previously reported. Thus, it is implified that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:5 SEQ. ID. NO:5 (Table 5) corresponds to a previously identified gene that encodes a predicted protein, L0C151194 (similar to hepatocellular carcinoma-associated antigen HCA557b). with unknown function (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 5), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:6:
SEQ. ID. NO:6 (Table 5) corresponds to a previously identified gene that encodes a protein, chemokine (C-X-C motif) ligand 5 (CXCL5), which is an inflammatory chemokine that belongs to the CXC chemokine family (see Table 1). We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 6), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling SEQ. ID. NO:7:
SEQ. ID. NO:7(Table 5) corresponds to a previously identified gene that encodes a protein, ATPase, H+ transporting. lysosomal accessory protein 2 (ATP6AP2), which is associated with adenosine triphosphatases (ATPases).
Proton-translocating ATPases have fundamental roles in energy conservation, secondary active transport, acidification of intracellular compartments, and cellular pH
homeostasis (see Table 1). We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 7), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:8 SEQ. ID. NO:8 (Table 5) corresponds to a previously identified gene that encodes a protein, ubiquitin-specific protease 12-like 1 (USP12). which is associated with ubiquitin-dependent protein catabolism (see Table 1) We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 8), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:9 SEQ. ID. NO:9 (Table 5) corresponds to a previously identified gene that encodes a protein, Ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog. yeast) (UBE2E1), which is associated with ubiquitin-dependent protein catabolism (see Table 1). So far, there are 2 transcript variants and protein isoforms reported for this gene We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 9). which have not been previously reported. Thus. it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling SEQ. ID. NO:10 SEQ. ID. NO.10 (Table 5) corresponds to a previously identified gene that encodes a protein, Emopamil binding protein-like (EBPL), which may have cholestenol delta-isomerase activity (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 10), which have not been previously reported Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:11 SEQ. ID. NO:11 (Table 5) corresponds to a previously identified gene that encodes a protein, development and differentiation enhancing factor 1 (DDEF1), which may be involved in cell motility and adhesion (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 11), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:12 SEQ. ID. NO 12 (Table 5) corresponds to a previously identified gene that encodes a protein. member 7 of the SLAM family (SLAM7), which may have receptor activity and involved in cell adhesion but still not fully characterized (see Table 1). We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 12), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:13 SEQ. ID. NO:13 (Table 5) corresponds to a previously identified gene that encodes a protein, Ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog. yeast) (UBE2E3), which is associated with ubiquitin-dependent protein catabolism (see Table 1). There are 2 transcript variants documented so far, which code for the same protein isofrom. We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 1), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:14 SEQ. ID. NO:14 (Table 5) corresponds to a previously identified gene that encodes a protein, Galanin (GAL), which is associated with neuropeptide hormone activity (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues except for colon (Figure 14) which have not been previously reported.
Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:15 SEQ. ID. NO:15 (Table 5) corresponds to a previously identified gene that encodes a protein, Cytokine-like nuclear factor n-pac (N-PAC), which may have oxireductase activity (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 15), which have not been previously reported.
However, some overexpression of this gene but still way below that of mature osteoclasts were seen in heart, fallopian tube, spleen and cervix. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:16 SEQ. ID. NO:16 (Table 5) corresponds to a previously identified gene that encodes a protein. Integrin alpha X (antigen CD11C (p150), alpha polypeptide) (ITGAX), which is involved in cell adhesion and ion binding (see Table 1) We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 16), which have not been previously reported. Minimal expression but much lower than mature osteoclasts is observed for this gene in adrenal, lung and spleen amongst the normal tissues. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:17 SEQ. ID. NO:17 (Table 5) corresponds to a previously identified gene that encodes a protein, Ankylosis. progressive homolog (mouse) (ANKH), which is involved in regulating pyrophosphate levels, suggested as a possible mechanism regulating tissue calcification (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 17), which have not been previously reported.
However, this gene has been reported to be involved in bone mineralization but without evidence of its upregulation in osteoclasts (Malkin et al., 2005). Thus, it is believed that 5 this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:18 SEQ. ID. NO:18 (Table 5) corresponds to a previously identified gene that encodes a protein, ATPase, H+ transporting. lysosomal 70kD. V1 subunit A.
which is involved in hydrogen-transporting ATPase activity, rotational mechanism (see Table 1).
10 We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 18). which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:19 15 SEQ. ID. NO:19 (Table 5) corresponds to a previously identified gene that encodes a predicted open reading frame coding for protein, FLJ10874 (chromosome 1 open reading frame 75), which has no known function (see Table 1). We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 19), which have not been 20 previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling SEQ. ID. NO:20 SEQ. ID. NO 20 (Table 5) corresponds to a previously identified gene that encodes a protein: Integrin beta 1 binding protein 1 (ITGB1BP1). which has an 25 important role during integrin-dependent cell adhesion (see Table 1).
Two transcript variants and protein isoforms for this gene has been isolated. We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 20), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis 30 and/or bone remodeling.
SEQ. ID. NO:21 SEQ. ID. NO:21 (Table 5) corresponds to a previously identified gene that encodes a protein, Thioredoxin-like 5 (TXNL5), which has no known function (see Table 1). We have demonstrated that this gene is significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues with the exception of esophagus (Figure 21), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:22 SEQ. ID. NO:22 (Table 5) corresponds to a previously identified gene that encodes a protein. C-type lectin domain family 4, member E (CLECSF9), which has no known specific function (see Table 1). Members of this family share a common protein fold and have diverse functions, such as cell adhesion, cell-cell signaling glycoprotein turnover and roles in inflammation and immune response. We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues with the exception of lung and spleen (Figure 22).
which have not been previously reported. At this point, we cannot rule out cross hybridization to family members in lung and spleen. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:23 SEQ. ID. NO 23 (Table 5) corresponds to a previously identified gene that encodes a protein, RAB33A, member RAS oncogene family (RAB33A). which has GTPase activity (see Table 1). We have demonstrated that this gene is significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues with the exception of brain (Figure 23), which have not been previously reported Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling SEQ. ID. NO:24 SEQ. ID. NO:24 (Table 5) corresponds to a previously identified gene that encodes a protein, Down syndrome critical region gene 1 (DSCR1), which interacts with calcineurin A and inhibits calcineurin-dependent signaling pathways, possibly affecting central nervous system development (see Table 1). There are 3 transcript variants and protein isofroms isolated so far. We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 24), which have not been previously reported, Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:25 SEQ. ID. NO:25 (Table 5) corresponds to a previously identified gene that encodes a protein, SNARE protein Ykt6 (YKT6), which is one of the SNARE
recognition molecules implicated in vesicular transport between secretory compartments (see Table 1). We have demonstrated that this gene is significantly upregulated in mature osteoclast compared to precursor cells and other normal human tissues (Figure 25), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:26 SEQ ID. NO:26 (Table 5) corresponds to a previously identified gene that encodes a protein, Actinin, alpha 1 (ACTN1). which is cytoskeletal. and involved in actin binding and adhesion (see Table 1). We have demonstrated that this gene is significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 26), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:27 SEQ. ID. NO:27 (Table 5) corresponds to a previously identified gene that encodes a protein, CIpX caseinolytic peptidase X homolog (E. coli) (CLPX), which may be involved in protein turnover (see Table 1). We have demonstrated that this gene is significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 27), which have not been previously reported. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:28 SEQ. ID. NO:28 (Table 5) corresponds to a previously identified gene that encodes a protein, Carbonic anhydrase II (CA2), which has carbonate dehydratase activity (see Table 1). Defects in this enzyme are associated with osteopetrosis and renal tubular acidosis (McMahon et al., 2001) and have been shown to be upregulated in mature osteoclasts under induced acidic pH conditions (Biskobing and Fan, 2000) We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells independent of induced acidic pH
conditions and other normal human tissues (Figure 28), which have not been previously reported. However, elevated expression of this gene was also observed in colon and stomach but still significantly below the levels of mature osteoclasts. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:29 SEQ. ID. NO:29 (Table 5) corresponds to a previously identified gene that encodes a protein, Sorting nexin 10 (SNX10), whose function has not been determined (see Table 1). We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and most normal human tissues (Figure 29).
which have not been previously reported However, elevated expression of this gene was also observed in liver, brain, lung, adrenal cortex, kidney and spleen but still significantly below the levels of mature osteoclasts. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:30 SEQ. ID. NO:30 (Table 5) corresponds to a previously identified gene that encodes a protein. Tudor domain containing 3 (TDRD3), whose function has not been determined but may be involved in nucleic acid binding (see Table 1). We have demonstrated that this gene is markedly upregulated in mature osteoclast compared to precursor cells and most normal human tissues (Figure 30), which have not been previously reported. However, above baseline expression of this gene was observed in the normal human tissues because of a lower than normal precursor level but it was still significantly below the levels of mature osteoclasts, Thus, this gene was still selected. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:31 SEQ ID NO 31 (Table 5) corresponds to a previously identified gene that encodes a protein. Selenoprotein P. plasma. 1 (SEPP1), which has been implicated as an oxidant defense in the extracellular space and in the transport of selenium (see Table 1). This gene encodes a selenoprotein that contains multiple selenocysteines.
Selenocysteine is encoded by the usual stop codon UGA. The unususal amino acids are indicated as 'Li' in the amino acid sequence in SEQ. ID. NO:78 (Table 5) or by Xaa in the sequence listing. We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and most normal human tissues (Figure 31), which have not been previously reported However, above baseline expression of this gene was observed in the normal human tissues because of a lower than normal precursor level but it was still significantly below the levels of mature osteoclasts. Thus, this gene was still selected. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:32 SEQ. ID. NO:32 (Table 5) corresponds to a previously identified gene that encodes a hypothetical protein, KIAA0040. which has no known function (see Table 1).
We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and most normal human tissues (Figure 32). which have not been previously reported. However, above baseline expression of this gene was observed in the normal human tissues because of a lower than normal precursor level but it was still significantly below the levels of mature osteoclasts. Thus this gene was still selected. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:33 SEQ. ID. NO:33 (Table 5) corresponds to a previously identified gene that encodes a protein. Dipeptidylpeptidase 4 (CD26, adenosine deaminase complexing protein 2) (DPP4), which is an intrinsic membrane glycoprotein and a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides (see Table 1). We have demonstrated that this gene is markedly upregulated in , intermediate and mature osteoclast compared to precursor cells and most normal human tissues (Figure 33), which have not been previously reported. However, above baseline expression of this gene was observed in the normal human tissues except for placenta, lung, ovary, kidney, prostate and small intestine because of a lower than normal precursor level but it was still significantly below the levels of mature osteoclasts. Thus, this gene was still selected. Thus, it is believed that this gene may be required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:34:
SEQ ID. NO:34 (Table 5) corresponds to a previously identified gene that encodes a protein, cystatin C precursor, with members of the cystatin family known to be inhibitor of cysteine proteases (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 34). which have not been previously 5 .. reported. However, it is well documented that cystatin C plays a critical role in inhibiting bone resorption due to osteoclasts (Brage et al . 2005) Thus, the hybridization profile for this gene is an excellent example of highly upregulated and specific sequences related to osteoclasts.
SEQ. ID. NO:85 10 SEQ. ID. NO:85 (Table 5) encodes an unknown protein found on chromosome 1 (clone RP11-344F13), which contains a novel gene (see Table 1). We have demonstrated that this gene is markedly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 38), which have not been previously reported. Thus, it is implified that this gene may be 15 required for osteoclastogenesis and/or bone remodeling.
SEQ. ID. NO:86 SEQ. ID. NO 86 (Table 5) encodes no known protein. Unknown gene with matching Est sequence in the data base corresponding to BQ182670 isolated from an osteoarthritic cartilage sample (see Table 1). We have demonstrated that this gene is 20 significantly upregulated in intermediate and mature osteoclast compared to precursor cells and other normal human tissues (Figure 39). which have not been previously reported. Thus, it is implified that this gene may be required for osteoclastogenesis and/or bone remodeling.
25 .. H- Cloning of full-length cDNAs of selected sequences from osteoclast mRNA:
It was necessary to obtain full-length cDNA sequences in order to perform functional studies of the expressed proteins. Spliced variants are increasingly being implicated in tissue specific functions and as such, it is important to work with cDNA
clones from the system under study. Applicant also recognizes that spliced variants 30 may not always be involved. Thus. the applicant's approach has been to isolate the relevant full-length cDNA sequences directly from osteoclasts in order to identify variants and their potential role with respect to specificity Coding cDNA clones were isolated using both a 5'-RACE strategy (Invitrogen, Burlington, ON) and a standard two-primer gene specific approach in PCR. The 5'-RACE strategy used cDNA prepared from cap-selected osteoclast RNA and/or RAMP
amplified osteoclast RNA. For amplification using gene specific primers, either cDNA
prepared from RAMP RNA or total RNA was used. All cDNAs were synthesized following standard reverse transcription procedures (Invitrogen, Burlington.
ON) The cDNA sequences obtained were cloned in E.coli DH10B and the nucleotide sequences for multiple clones determined. Thereafter, the cDNA sequences for each set were aligned and the open reading frame(s) (ORF) identified using standard software (e.g.
ORF Finder-NCBI). Table 2 shows the concensus sequence of the cDNA clones for the coding region for SEQ. ID. NO.1 (SEQ. ID. NO. 83) and SEQ. ID. NO.2 (SEQ. ID.
NO
84) obtained from a human osteoclast sample, which were identical to that of the published sequences corresponding to Accession# NM_213602 and NM_001014433 (NCBI), respectively.
I- RNA Interference Studies RNA interference is a recently discovered gene regulation mechanism that involves the sequence-specific decrease in a gene's expression by targeting the mRNA
for degradation and although originally described in plants, it has been discovered across many animal kingdoms from protozoans and invertebrates to higher eukaryotes (reviewed in Agrawal et al., 2003). In physiological settings, the mechanism of RNA
interference is triggered by the presence of double-stranded RNA molecules that are cleaved by an RNAse III-like protein active in cells, called Dicer, which releases the 21-23 bp siRNAs. The siRNA, in a homology-driven manner, complexes into a RNA-protein amalgamation termed RISC (RNA-induced silencing complex) in the presence of mRNA to cause degradation resulting in attenuation of that mRNA's expression (Agrawal et al.. 2003).
Current approaches to studying the function of genes, such as gene knockout mice and dominant negatives, are often inefficient, and generally expensive, and time-consuming. RNA interference is proving to be a method of choice for the analysis of a large number of genes in a quick and relatively inexpensive manner. Although transfection of synthetic siRNAs is an efficient method, the effects are often transient at best (Hannon G J., 2002), Delivery of plasmids expressing short hairpin RNAs by stable transfection has been successful in allowing for the analysis of RNA
interference in longer-term studies (Brummelkamp et al., 2002; Elbashir et al., 2001). In addition, more recent advances have permitted the expression of siRNA molecules, in the form of short hairpin RNAs, in primary human cells using viral delivery methods such as lentivirus (Lee et al., 2004; Rubinson et at. 2003).
J- Determination of knockdown effects on osteoclastogenesis In order to develop a screening method for the human candidate genes. RNA
interference was adapted to deliver shRNAs into human osteoclast precursor cells so that the expression of the candidate genes could be attenuated This approach would then allow osteoclast differentiation to be carried out in cells containing decreased expression of these genes to determine their requirement, if any, in this process To this end, a commercial lentiviral shRNA delivery system (Invitrogen.
Burlington, ON) was utilized to introduce specific shRNAs into human osteoclast precursor cells. The techniques used were as described by the manufacturer unless otherwise stated. In this example, the results obtained for two of the candidate genes, SEQ. ID. NO. 1 (AB0326) and SEQ. ID. NO. 2 (AB0369) tested so far, are presented.
The proteins encoded by both of these two genes have no known function. The shRNA
sequences used to specifically target SEQ. ID. NO. 1 and SEQ. ID. NO. 2 were 5-CAGG000AGGAGTCCAATT-3' (SEQ. ID. NO. 42) and 5'-TCCCGTCTTTGGGTCAAAA-3' (SEQ. ID. NO. 43) respectively. Briefly, a template for the expression of the shRNA was cloned into the lentiviral expression vector and co-transfected in 293FT cells with expression vectors for the viral structural proteins After two days supernatants containing the lentivirus were collected and stored at ¨80 C
Human osteoclast precursors purchased from Cambrex (East Rutherford NJ) were seeded in 24-well plates and cultured in complete medium containing macrophage-colony stimulating factor and allowed to adhere for three days. After washing with PBS, the cells were infected with 20 MOls (multiplicity of infection) of either lentiviral particles containing a shRNA specific for the bacterial lacZ gene as a control (lacZ
shRNA) or SEQ. ID. NO. 1 (A80326 shRNA) or SEQ. ID. NO. 2 (AB0369 shRNA). After 24h, the infected cells were treated with same medium containing 100 ng/ml RANK ligand for 5 ¨ 8 days to allow for differentiation of osteoclast from precursor cells.
Mature osteoclasts were fixed with formaldehyde and stained for TRAP expression as follows the cells were washed with PBS and fixed in 10% formaldehyde for 1h. After two PBS
washes, the cells were lightly permeabilized in 0.2% Tritonna X-100 in PBS for 5 min before washing in PBS. Staining was conducted at 37 C for 20 ¨ 25 min in 0.01%
Naphtol AS-MX phosphate, 0.06% Fast Red Violet, 50 mM sodium tartrate, 100 mM
sodium acetate, pH 5.2. The stained cells were visualized by light microscopy and photographed (magnification: 40X). A significant decrease in the number of multinucleated osteoclasts was observed from precursor cells infected with the shRNA (Figure 35A; bottom panel) and AB0369 shRNA (Figure 35B; bottom panel) compared to those with the lacZ shRNA (Figure 35A and B; top panels).
Therefore, in both cases, the respective lentiviral shRNA (SEQ. ID. NOs. 42 and 43, respectively) (Table 4) perturbed osteoclastogenesis. These results clearly indicated that expression of the gene encoding SEQ. ID. NO. 1 (AB0326) and SEQ. ID. NO. 2 (AB0369) are required for osteoclast differentiation.
Similar experimentations to those described above are carried out for other sequences (SEQ ID NO.3 to SEQ ID NO.:33, SEQ ID NO.:85 or SEQ ID NO.:86).
K- Biological validation of the mouse orthologue for AB0326 (SEQ. ID. NO. 35) in osteoclastogenesis using the RAW 264.7 model As a means of developing a drug screening assay for the discovery of therapeutic molecules capable of attenuating human osteoclasts differentation and activity using the targets identified, it was necessary to turn to another osteoclast differentiation model. The RAW 264.7 (RAW) osteoclast precursor cell line is well known in the art as a murine model of osteoclastogenesis. However, due to the difficulty in transiently transfecting RAW cells, stable transfection was used as an approach where .. shRNA are expressed in the RAW cells constitutively. This permitted long term studies such as osteoclast differentiation to be carried out in the presence of specific shRNAs specific to the mouse orthologues of the human targets identified.
RAW cells were purchased from American Type Culture Collection (Manassass, VA) and maintained in high glucose DMEM containing 10% fetal bovine serum and antibiotics. The cells were sub-cultured bi-weekly to a maximum of 10-12 passages. For osteoclast differentiation experiments, RAW cells were seeded in 96-well plates at a density of 4 x 103 cells/well and allowed to plate for 24h. Differentiation was induced in high glucose DMEM, 10% charcoal-treated foetal bovine serum (obtained from Hyclone, Logan, UT), 0.05% BSA, antibiotics, 10 ng/ml macrophage colony stimulating factor (M-CSF), and 100 ng/ml RANK ligand. The plates were re-fed on day 3 and osteoclasts were clearly visible by day 4. Typically, the cells were stained for TRAP on day 4 or 5 unless otherwise indicated.
To incorporate the shRNA-expression cassettes into the RAW cell chromosomes, the pSilencer 2.0 plasmid (SEQ. ID. NO. 47) was purchased from Ambion (Austin, TX) and sequence-specific oligonucleotides were ligated as recommended by the manufacturer. Two shRNA expression plasmids were designed and the sequences used for attenuating the mouse ortholog of AB0326 (SEQ. ID. NO. 35) gene expression were 5'-GCGCCGCGGATCGTCAACA-3' (SEQ. ID. NO. 44) and 5'-ACACGTGCACGGCGGCCAA-3' (SEQ. ID. NO. 45). A plasmid supplied by Ambion containing a scrambled shRNA sequence with no known homology to any mammalian gene was also included as a negative control in these experiments. RAW cells were seeded in 6-well plates at a density of 5 x 105 cells/well and transfected with 1 pg of each plasmid using FugeneTM6 (Roche, Laval, QC) as described in the protocol.
After selection of stable transfectants in medium containing 2 pg/ml puromycin, the cell lines were expanded and tested in the presence of RANK ligand for osteoclastogenesis.
The stably transfected cell lines were designated RAW-0326.1, RAW-0326.2 and RAW-ctl. In 96-well plates in triplicate, 4 000 cells/well were seeded and treated with 100 ng/ml RANK ligand. After 4 days, osteoclasts were stained for TRAP expression and visualized by light microscopy (magnification was 40X and 100X as depicted in the left and right panels, respectively).
The representative results for the RAW-0326.2 line is shown in Figure 36. The RAW-0326.2 cell line produced significantly less osteoclasts (Figure 36; bottom panel) compared to the cell line containing the scrambled shRNA (Figure 36; top panel). The RAW-0326.1 cell line also showed attenuation of the mouse ortholog of AB0326 but not as pronounced (data not shown). Therefore, as observed for SEQ ID NO. :42 and 43, siRNAs to the mouse orthologue (SEQ. ID. NOs. 44 and 45) (Table 4) appear to phenotypically perturb osteoclast differentiation in the mouse model as well.
These results, coupled with that obtained in the human osteoclast precursor cells using the lentiviral shRNA delivery system (section J), demonstrate that in both human and mouse, AB0326 gene product is clearly required for osteoclastogenesis.
L- A functional complementation assay for SEQ. ID. NO. 1 (AB0326) in RAW 264.6 cells to screen for inhibitors of osteoclasto genesis To establish a screening assay based on SEQ. ID. NO. 1 (AB0326) to find small 5 molecules capable of attenuating osteoclast differentiation, the cDNA
encoding human A80326 was introduced into the RAW-0326.2 cell line. Thus, if the human AB0326 plays an identical functional role as the mouse orthologue in RAW 264.7 cells, it should restore the osteoclastogenesis capabilities of the RAW-0326.2 cell line.
To accomplish this task, the RAW-0326.2 cell line was transfected with an 10 eukaryotic expression vector encoding the full length cDNA for human AB0326, termed pd2-hAB0326. This expression vector (pd2, SEQ. ID. NO. 47) was modified from a commercial vector, pd2-EGFP-N1 (Clontech. Mountain View, CA) where the EGFP
gene was replaced by the full length coding sequence of the human AB0326 cDNA
The AB0326 gene expression was driven by a strong CMV promoter Stable 15 transfectants were selected using the antibiotic, G418. This resulted in a RAW-0326.2 cell line that expressed the human AB0326 gene product in which, the mouse orthologue of AB0326 was silenced. As a control. RAW-0326.2 cells were transfected with the pd2 empty vector, which should not complement the AB0326 shRNA
activity.
Also, the pd2 empty vector was transfected into RAW 264.7 cells to serve as a further 20 .. control. After selection of stable pools of cells, 4 000 cells/well were seeded in 96-well plates and treated for 4 days with 100 ng/ml RANK ligand. Following fixation with formaldehyde, the cells were stained for TRAP, an osteoclast-specific marker gene. As shown in Figure 37, the RAW-0326.2 cells transfected with the empty pd2 vector are still unable to form osteoclasts in the presence of RANK ligand (center panel) indicating 25 .. that the mouse AB0326 shRNA is still capable of silencing the AB0326 gene expression in these cells_ Conversely, the cells transfected with human AB0326 (pd2-hAB0326) are rescued and thus, differentiate into more osteoclasts in response to RANK ligand (right panel). RAW 264.7 cells containing the empty vector (pd2) did not adversly affect the formation of osteoclasts in the presence of RANK ligand (left panel) 30 .. These results confirm that the mouse and human orthologues of AB0326 are functionally conserved in osteoclast differentiation This particular type of cell-based assay can now serve as the basis for screening compounds capable of binding to and inhibiting the function of human AB0326. A compound library could be applied to this 'rescued' cell line in order to identify molecules (small molecule drugs, peptides, or antibodies) capable of inhibiting AB0326. Any reduction in osteoclast differentiation measured by a reduction in the expression of TRAP would be indicative of a decrease in human AB0326 activity.
This assay is applicable to any gene required for proper osteoclast differentiation in RAW
cells. A complementation assay can be developed for any human gene and used as the basis for drug screening.
Similar experimentation to those described above are carried out for other sequences (SEQ ID NO.3 to SEQ ID NO.:33 or SEQ ID NO.:85 or SEQ ID NO .86) This type of assay may be used to screen for molecules capable of increasing or decreasing (e.g., inhibiting) the activity or expression of NSEQ or PSEQ.
In the NSEQs of the present invention, their methods, compositions, uses, its, assays or else, the polynucleotide may either individually or in group (collectively) more particularly be (or may comprise or consist in) either;
a translatable portion of either SEQ ID NO.:1, of SEQ ID NO.:2, of SEQ ID
NO.:3, of SEQ ID NO.:4, of SEQ ID NO.:5, of SEQ ID NO.:6, of SEQ ID NO.:7, of SEQ
ID NO.:8, of SEQ ID NO.:9, of SEQ ID NO .10, of SEQ ID NO 11, of SEQ ID NO 12.
of SEQ ID NO.:13, of SEQ ID NO.:14, of SEQ ID NO :15, of SEQ ID NO.:16. of SEQ
ID NO 17 of SEQ ID NO 18, of SEQ ID NO :19, of SEQ ID NO 20. of SEQ ID
NO :21, of SEQ ID NO.:22, of SEQ ID NO .23. of SEQ ID NO ;24 of SEQ ID NO '25.
of SEQ ID NO :26. of SEQ ID NO. 27. of SEQ ID NO 28, of SEQ ID NO 29, of SEQ ID
NO.30, of SEQ ID NO. 31, of SEQ ID NO -32. of SEQ ID NO '33. of SEQ ID NO .85 or of SEQ ID NO. :86;
sequence substantially identical to a translatable portion of SEQ ID NO..1, of SEQ ID NO.:2, of SEQ ID NO :3, of SEQ ID NO.:4, of SEQ ID NO 5, of SEQ ID NO
6.
of SEQ ID NO.:7, of SEQ ID NO.:8, of SEQ ID NO.:9, of SEQ ID NO.:10, of SEQ ID
NO.:11, of SEQ ID NO.:12, of SEQ ID NO.13, of SEQ ID NO.:14, of SEQ ID NO. 15.
of SEQ ID NO.:16, of SEQ ID NO.:17, of SEQ ID NO.:18. of SEQ ID NO.:19, of SEQ
ID
NO :20, of SEQ ID NO.:21, of SEQ ID NO.:22, of SEQ ID NO. 23, of SEQ ID
NO.:24, of SEQ ID NO :25, of SEQ ID NO.:26, of SEQ ID NO :27, of SEQ ID NO -28, of SEQ ID
NO :29, of SEQ ID NO :30. of SEQ ID NO. 31, of SEQ ID NO 32, of SEQ ID NO 33.
of SEQ ID NO :85 or of SEQ ID NO '86:
a sequence substantially complementary to a translatable portion of SEQ ID
NO.:1, a fragment of a transcribable portion of SEQ ID NO. :1 of SEQ ID NO.
:2, of SEQ
ID NO.:3, of SEQ ID NO. 4, of SEQ ID NO.:5, of SEQ ID NO.:6, of SEQ ID NO 7, of SEQ ID NO.:8, of SEQ ID NO.:9, of SEQ ID NO.:10, of SEQ ID NO.:11, of SEQ ID
NO.:12, of SEQ ID NO.:13, of SEQ ID NO.:14, of SEQ ID NO.:15, of SEQ ID NO.
16.
of SEQ ID NO.17, of SEQ ID NO 18, of SEQ ID NO.:19, of SEQ ID NO.20. of SEQ ID
NO.21, of SEQ ID NO.:22, of SEQ ID NO. 23. of SEQ ID NO.:24, of SEQ ID NO 25, of SEQ ID NO 26, of SEQ ID NO.27, of SEQ ID NO.:28, of SEQ ID NO.:29, of SEQ ID
NO.:30, of SEQ ID NO 31, of SEQ ID NO..32, of SEQ ID Na.33, of SEQ ID NO .85 or of SEQ ID NO.:86:
a fragment of a sequence substantially identical to a translatable portion of SEQ
ID NO 1, of SEQ ID NO 2, of SEQ ID NO.:3, of SEQ ID NO 4, of SEQ ID NO. 5. of SEQ ID NO.:6. of SEQ ID NO :7, of SEQ ID NO 8, of SEQ ID NO 9. of SEQ ID
NO.:10. of SEQ ID NO.:11, of SEQ ID NO.:12. of SEQ ID NO.:13, of SEQ ID NO.
14, of SEQ ID NO.:15, of SEQ ID NO.:16, of SEQ ID NO.:17, of SEQ ID NO.:18, of SEQ
ID
NO.:19. of SEQ ID NO 20. of SEQ ID NO :21, of SEQ ID NO.:22, of SEQ ID NO 23, of SEQ ID NO.:24. of SEQ ID NO :25, of SEQ ID NO.:26, of SEQ ID NO.:27. of SEQ ID
NO.:28, of SEQ ID NO.:29, of SEQ ID NO.:30. of SEQ ID NO.:31. of SEQ ID NO
:32, of SEQ ID NO :33, of SEQ ID NO.:85 or of SEQ ID NO.:86;
a fragment of a sequence substantially complementary to a translatable portion of SEQ ID NO.:1, of SEQ ID NO. 2. of SEQ ID NO.:3, of SEQ ID NO .-4, of SEQ ID
NO 5, of SEQ ID NO.:6, of SEQ ID NO. 7, of SEQ ID NO .8. of SEQ ID NO .9. of SEQ
ID NO .10. of SEQ ID NO.:11. of SEQ ID NO.:12, of SEQ ID NO. 13. of SEQ ID
NO.14, of SEQ ID NO .15. of SEQ ID NO. 16 of SEQ ID NO 17. of SEQ ID NO -18.
of SEQ ID NO.:19, of SEQ ID NO :20. of SEQ ID NO :21, of SEQ ID NO .22 of SEQ ID
NO.:23. of SEQ ID NO.:24, of SEQ ID NO.:25, of SEQ ID NO.26. of SEQ ID NO .27.
of SEQ ID NO.:28, of SEQ ID NO.:29, of SEQ ID NO 30, of SEQ ID NO.:31. of SEQ ID
NO :32, of SEQ ID NO.:33, of SEQ ID NO.:85 or of SEQ ID NO :86;
or a library comprising any of the above_ In the PSEQs of the present invention, their methods, compositions, uses, kits assays, or else, the polypeptide may either individually or in group (collectively) more particularly be (or may comprise or consist in) either ;
SEQ ID NO.:48, SEQ ID NO.:49, SEQ ID NO.150, SEQ ID NO. 51, SEQ ID
NO.:52, SEQ ID NO :53, SEQ ID NO.:54, SEQ ID NO.:55, SEQ ID NO.:56. SEQ ID
NO. 57, SEQ ID NO :58, SEQ ID NO.:59, SEQ ID NO.:60, SEQ ID NO :61, SEQ ID
NO.:62, SEQ ID NO.:63, SEQ ID NO.:64, SEQ ID NO.:65, SEQ ID NO:66, SEQ ID
NO.:67, SEQ ID NO.:68, SEQ ID NO :69, SEQ ID NO.:70, SEQ ID NO.:71, SEQ ID
NO.:72, SEQ ID NO.:73, SEQ ID NO.74, SEQ ID NO.:75 SEQ ID NO.:76, SEQ ID
NO '77, SEQ ID NO.:78, SEQ ID NO.:79 or SEQ ID NO.:80;
a fragment of SEQ ID NO.:48, SEQ ID NO :49. SEQ ID NO .50, SEQ ID
NO.:51, SEQ ID NO.:52, SEQ ID NO.53, SEQ ID NO.:54, SEQ ID NO.:55, SEQ ID
NO.56, SEQ ID NO .57. SEQ ID NO :58, SEQ ID NO.:59, SEQ ID NO 60, SEQ ID
NO :61, SEQ ID NO.62, SEQ ID NO 63, SEQ ID NO.:64. SEQ ID NO 65, SEQ ID
NO..66. SEQ ID NO.:67, SEQ ID NO. 68, SEQ ID NO 69, SEQ ID NO.:70. SEQ ID
NO 71 SEQ ID NO.:72, SEQ ID NO .73. SEQ ID NO .74, SEQ ID NO.:75 SEQ ID
NO.:76, SEQ ID NO.77, SEQ ID NO.:78, SEQ ID NO.:79 or SEQ ID NO. 80;
or a biologically active analog, variant or a non-human hortologue of SEQ ID
NO.:48, SEQ ID NO.:49, SEQ ID NO.:50, SEQ ID NO .51, SEQ ID NO :52, SEQ ID
.. NO :53, SEQ ID NO.:54, SEQ ID NO.:55, SEQ ID NO.:56, SEQ ID NO. 57, SEQ ID
NO.:58, SEQ ID NO.:59, SEQ ID NO.:60, SEQ ID NO.:61, SEQ ID NO.:62, SEQ ID
NO.:63, SEQ ID NO.:64, SEQ ID NO.:65, SEQ ID NO.:66, SEQ ID NO.:67, SEQ ID
NO. 68, SEQ ID NO.:69, SEQ ID NO.70, SEQ ID NO.:71, SEQ ID NO.:72, SEQ ID
NO.:73, SEQ ID NO.:74, SEQ ID NO.:75 SEQ ID NO.76, SEQ ID NO.77. SEQ ID
NO.:78, SEQ ID NO.:79 or SEQ ID NO. 80.
One of skill in the art will readily recognize that orthologues for all mammals maybe identified and verified using well-established techniques in the art, and that this disclosure is in no way limited to one mammal The term ''mammal(s)" for purposes of this disclosure refers to any animal classified as a mammal, including humans, .. domestic and farm animals, and zoo, sports, or pet animals, such as dogs cats, cattle.
horses, sheep. pigs. goats, rabbits, etc. Preferably. the mammal is human.
The sequences in the experiments discussed above are representative of the NSEQ being claimed and in no way limit the scope of the invention. The disclosure of the roles of the NSEQs in osteoclastogenesis and osteoclast function satisfies a need in the art to better understand the bone remodeling process, providing new compositions that are useful for the diagnosis, prognosis, treatment, prevention and evaluation of therapies for bone remodeling and associated disorders.
The art of genetic manipulation, molecular biology and pharmaceutical target development have advanced considerably in the last two decades. It will be readily apparent to those skilled in the art that newly identified functions for genetic sequences and corresponding protein sequences allows those sequences, variants and derivatives to be used directly or indirectly in real world applications for the development of research tools, diagnostic tools, therapies and treatments for disorders or disease states in which the genetic sequences have been implicated.
TABLE 1 ¨ Differentially expressed sequences found in osteoclasts.
Nucleotide NCB! Accession ORF Function Sequence Unigene Number Nucleotide No. Positions/
#/Gene Symbol/Gen Polypeptide e ID sequence No.
SEQ ID NO. Hs.287692 NM 213602 150-1136 hypothetical protein 1 L0C284266;
/ CD33L3 encoding SEQ
membrane associated ID NO.:48 / 284266 function unknown SEQ ID NO. Hs.520070 NM 001014 104-700 chromosome 6 open 2 433¨ reading frame 82 / C6orf82 membrane associated with encoding SEQ unknown function ID NO.: 49 SEQ ID NO. Hs.546482 NM 178833 633-2246 hypothetical protein 3 L0C133308 possibly / L00133308 encoding SEQ
involved in regulation ID NO.: 50 /133308 of pH
SEQ ID NO. Hs.135997 NM_138461 112-741 transmembrane 4 L
4 six family member 19 / LOC116211 encoding SEQ
ID NO.: 51 ; function unknown SEQ ID NO. Hs.558655 NM_145280 172-82 hypothetical protein / LOC151194 encoding SEQ
ID NO.: 52 SEQ ID NO. Hs.89714 NM_002994 119-463 chemokine (C-X-C
6 motif) ligand / CXCL5 encoding SEQ
ID NO.: 53 precursor; chemokine Nucleotide NCB! Accession ORF Function Sequence Unigene Number Nucleotide No. Positions/
Gene Symbol/Gen Polypeptide e ID sequence No.
/ 6374 activity SEQ ID NO. Hs.495960 NM_005765 103-1155 ATPase, H+
7 transporting, / ATP6AP2 encoding SEQ
ID NO 54 lysosomal accessory .:
/10159 protein 2;receptor activity SEQ ID NO. Hs.42400 NM_182488 259-1371 ubiquitin-specific 8 protease 12-like 1;
cysteine-type / 219333 encoding SEQ endopeptidase activity ID NO.: 55 SEQ ID NO Hs 164853 NM 003341 175-756 ubiquitin-conjugating 9 enzyme E2E 1 isoform 1. ligase / 7324 encoding SEQ activity ID NO.: 56 SEQ ID NO. Hs.433278 NM_032565 53-673 emopamil binding 10 related protein.
/ EBPL
de1ta8-delta7 integral / 84650 encoding SEQ to membrane ID NO.: 57 SEQ ID NO. Hs.106015 NM_018482 29-3418 development and 11 differentiation enhancing factor 1.
/ 50807 encoding SEQ membrane ID NO.: 58 SEQ ID NO. Hs.517265 NM 021181 16-1023 SLAM family member 12 receptor activity / 57823 encoding SEQ
ID NO.. 59 SEQ ID NO Hs.470804 NM 006357 385-1008 ubiquitin-conjugating 13 enzyme E2E 3, ligase activity / 10477 encoding SEQ
ID NO.: 60 SEQ ID NO. Hs.278959 NM_015973 177-548 galanin preproprotein:
14 neuropeptide Nucleotide NCB! Accession ORF Function Sequence Unigene Number Nucleotide No. Positions/
#/Gene Symbol/Gen Polypeptide e ID sequence No.
/ GAL hormone activity /51083 encoding SEQ
ID NO.: 61 SEQ ID NO. NM_032569 NM_032569 19-1680 cytokine-like nuclear 15 factor n-pac: 3-/ N-PAC
hydroxyisobutyrate / 84656 encoding SEQ dehydrogenase-like ID NO.: 62 SEQ ID NO. Hs.248472 NM 000887 68-3559 integrin alpha X
16 precursor. cell-matrix / ITGAX
adhesion / 3687 encodingSEQ
SEQ ID NO. Hs.156727 NM_054027 321=1799 ankylosis. progressive 17 homolog. regulation of / ANKH
bone mineralization / 1827 encoding SEQ
ID NO.: 64 SEQ ID NO. Hs.477155 NM 001690 67-1920 ATPase. H+
18 transporting.
lysosomal 70kD, V1 / 523 encoding SEQ subunit A. isoform 1 ID NO.: 65 : proton transport.
hydrolase activity SEQ ID NO. Hs.445386 NM_018252 139-1191 hypothetical protein /55248 encoding SEQ
ID NO.: 66 SEQ ID NO. Hs 467662 NM 004763 170-772 integrin cytoplasmic 20 domain-associated / ITGB1BP1 encoding SEQ
ID NO.: 67 protein 1 : cell adhesion SEQ ID NO. Hs.408236 NM 032731 77-448 thioredoxin-like 5 / TXNL5 function unknown /84817 F encoding SEQ
ID NO: 68 L. ____________________________________________________________ _1 Nucleotide NCB! Accession ORF Function Sequence Number Nucleotide Unigene No. Positions/
#/Gene Symbol/Gen Polypeptide e ID sequence No.
SEQ ID NO. Hs.236516 NM 014358 152-811 C-type lectin.
22 superfamily member 9 / CLECSF9 encoding SEQ
ID NO.: 69 = ;integral to membrane SEQ ID NO I Hs.56294 NM 004794 265-978 ; Ras-related protein 23 ' Rab-33A; small GTPase mediated / 9363 encoding SEQ signal transduction ID NO: 70 SEQ ID NO. Hs.282326 NM 004414 73-831 calcipressin 1 isoform 24 a; interacts with calcineurin A and /1827 encoding SEQ inhibits calcineurin-ID NO.: 71 dependent signaling pathways SEQ ID NO. Hs.520794 NM 006555 158-754 SNARE protein Ykt6:
25 vesicular transport between secretory / 10652 encoding SEQ compartments ID NO.: 72 SEQ ID NO. Hs.509765 NM_001102 I 184-2862 alpha-actinin 1:
26 structural constituent / ACTN1 of cytoskeleton.
/ 87 encoding SEQ calcium ion binding ID NO: 73 SEQ ID NO. Hs.113823 NM 006660 73-1974 CIpX caseinolytic 27 protease X homolog;
/ CLPX
/ 10845 encoding SEQ energy-dependent ID NO.: 74 regulator of proteolysis SEQ ID NO. Hs.155097 NM_000067 66-848 carbonic anhydrase 28 carbonate / CA2 encoding SEQ
ID NO.: 75 dehydratase activity SEQ ID NO. Hs 520714 NM 013322 216-821 sorting nexin 10 / SNX10 encoding SEQ ; function unknown ID NO.: 76 SEQ ID NO. Hs.525061 I NM 030794 258-2213 tudor domain 30 I ¨
containing 3: nucleic / TDRD3 encoding SEQ
Nucleotide NCB! Accession ORF Function Sequence Unigene Number Nucleotide No. Positions/
#/Gene Symbol/Gen Polypeptide e ID sequence No.
/ 81550 ID NO.: 77 acid binding SEQ ID NO. Hs.275775 NM 005410 101-1246 selenoprotein P
/ SEPP1 encoding SEQ : extracellular space ' / 6414 ID NO 78 implicated in defense I
SEQ ID NO. Hs.518138 NM 014656 1 921-1382 1 KIAA0040 novel 32 protein / KIAA0040 encoding SEQ
/9674 ID NO.: 79 SEQ ID NO. Hs.368912 NM 001935 562-2862 dipeptidylpeptidase 33 IV:
/ DPP4 encoding SEQ activi aminopeptidase ty ID NO.: 80 SEQ ID NO. Hs.304682 NM 000099 76-516 cysteine protease 34 i /CST3 encoding SEQ inhibitor activity /1471 ID NO.: 81 SEQ ID NO. None AL357873 Novel novel /none /none SEQ ID NO. AL645465 novel J novel TABLE 2 ¨ Shows the concensus sequences for SEQ. ID. NO. 1 and SEQ. ID. NO. 2 cloned from a mature human osteoclast sample.
Sequence ORF Polypeptide Identification Nucleotide sequence No.
Positions SEQ ID NO. 83 1-987 SEQ ID NO. 48 SEQ ID NO. 84 I 1-471 SEQ ID NO. 49 TABLE 3 -List of mouse orthologue for AB0326 Sequence NCB! Accession ORF Nucleotide Polypeptide Identification Unigene Number Positions sequence Cluster No.
SEQ ID None XM_884636 122-1102/ SEQ ID 1 NO. 35 /L00620235 1 similar to neural cell NO .82 620235 adhesion molecule 1 /
= 2/unknown function TABLE 4 - list of additional sequences identification of plasmids and shRNA
oligonucleotides Sequence name Description Identification SEQ. ID. NO. 36 = p14 Vector for STAR
SEQ. ID. NO. 37 p17+ Vector for STAR
SEQ. ID. NO. 38 pCATRMAN Vector for STAR
SEQ. ID. NO. 39 p20 Vector for STAR
1 SEQ. ID. NO. 40 OGS 77 Primer used for STAR
p14 vector SEQ. ID. NO 41 OGS 302 Primer used for STAR
p17+ vector SEQ. ID. NO: 42 human 0326.1 siRNA sequence for SEQ. ID. NO. 1 SEQ. ID. NO: 43 Human 0369.1 shRNA sequence for SEQ. ID. NO. 2 SEQ. ID. NO: 44 mouse 0326.1 shRNA sequence for Sequence name Description Identification SEQ. ID. NO. 35 SEQ. ID. NO: 45 mouse 0326.2 shRNA sequence for SEQ ID NO. 35 SEQ. ID. NO: 46 pSilencer2.0 vector SEQ. ID. NO: 47 pd2 vector =
NucleotideSequence ORFs (5'-3') ^SEQIDNO.:1 SEQIDNO.:48 TCCGCCTCCCGCAGAGCCCACAGGGACCTGCAGATCTGAGTGCCCTGCCCACCCCCGCCCGCCTTCCTTCCCCCACCAC
GCCTGGGA MEKSIWLLACLAWVLPTGSFVRT
GGGCCCTCACTGGGGAGGTGGCCGAGAACGGGTCTGGCCTGGGGTGTTCAGATGCTCACAGCATGGAAAAGTCCATCTG
GCTGCTGG KIDTTENLLNTEVHSSPAQRWSM
CCTCCTTGCCGTGCGTTCTCCCGACAGGCTCATTTGTGAGAACTAAAATAGATACTACCGAGAACTTGCTCAACACAGA
GGTGCACA QVPPEVSAEAGDAAVLPCTFTHt, GCTCGCCAGCGCAGCGCTGGTCCATGCAGGTGCCACCCGAGGTGAGCGCGCAGGCAGGCGACGCGGCAGTGCTGCCCTC
CGCACCCGCACCGCCACTACGACGGGCCGCTGACGGCCATCTGGCGCGCGGGCGAGCCCTATGCGGGCCCGCAGGTGTT
CCGCTGCG FRCAAARGSELCQTALSLHGRFR
CTGCGCCGCGGGGCACCGAGCTCTGCCAGACGOCGCTGAGCCTGCACGGCCGCTTCCGCCTGCTGGGCAACCCGCGCCG
N.) CO TcTcGcTGcGcGTcGAGCGccTCGCCCTGGCTGAcGACCGcCGCTACTTcTGccGceTcGAGTTcc-CcGGceAcGTCCATGAceGcT RYFCRVEFAGDVHDRYESRHGVR
ACGAGAGCCGCCACGGCGTCCGCCTGCACGTGACAGCCGCGCCGCGGATCGTCAACATCTCCGTCCTGCCCAGTCCGGC
TCCGCGCGCTCTGCACTGCCGAAGGGGAGCCGCCGCCCGCCCTCCCCTGGTCCGGCCCGGCCCTGCGCAACAGCTTGGC
AGCCCTGC ALCTAEGEPPPALAWSGPALGNS
GGACCCCGCGTGAGGGTCACGGCCACCTAGTGACCGCCGAACTGCCCCCACTGACCCATGACGGCCGCTACACGTGTAC
GGCCGCCA LAAVRSPREGHGHLVTAELPALT
rn ACAGCCTGGGCCGCTCCGAGGCCAGCGTCTACCTCTTCCGCTTCCATGGCGCCAGCGCCGCCICGACGGTCGCCCTCCT
GCTCGGCG hDGRYTCTAANSLGRSEASVYLF N.) (1) CTCTCGGCTTCAAGGCGCTGCTGCTGCTCGGGGTCCTGGCCGCCCGCGCTGCCCGCCGCCGCCCAGAGCATCTGGACAC
CCCGGACA RFRGASGASTVALLLGALOFKAL
CCCCACCACGGTCCCAGGCCCAGGAGTCCAATTATGAAAATTTGAGCCAGATGAACCCCCGGAGCCCACCAGCCACCAT
GTGCTCAC LLLGVLAARAARRRPERLDTPDT N.) CGTGAGGAGTCC C TCAC C CAC CAA CAT C CATTTCACCACTGTAAAGAACAAA GGC CAGT GC GAGG
GGTTCTCCGGCACCTTGGCAGCCCC CAGCTGGGTGGCT C C TCC CCT GOT CAAGGT CAAGAC C CTGC T
CAAGGAGGCT CATCTGGC C T ATMCS P
N.) AGAGAGAGAGACAGAGAG TACAC GCA TTAGCT TGAGCGTGAAAC TTC CAGAAATG TT CC CTTGCC
CTTT CTTAC CTAGAACAC CTGC
TATAGTAAAGCAGACAGGAAACTGTT
a) "0 =
t.4 SEQIDNO . :2 SEQIDNO : 4 9 ACGGAAACGGGCGTGCCATTTCCGCGCACGTCTG CAGATGCGGTAGTCGATTGGT CAAGTCTCCCATGGCTCCTC
CTTCATCAGGAG MIGS GLAGSGGAGG PS S TVTWCA
GTGGGCAAACCGCGCCATGATAGGCTCGGGATTGGCTGGCTCTGGAGGCGCAGGTGGTCCTTCTTCTACTGTCACATGG
TGCGCGCT LFSNHVAATQASLLLS FVWMPAL
GTTTTCTAATCACGTGC-CTGCCACCCAGGCCTCTCTGCTCCTGTCTTTTGTTTGGATOCCGGCGCTGCTGCCTGTGGCCTCCCGCCT L
PVASRLLLL PRVLLTMASGS PP
TTTGTTGCTACCCC GP.GTCTTGCTGACCATGGCCTCTGGAAGCCCTCCGACC CAG CC CTCGCCGGCCTC GC-ATTCCGGCTCTGGCTA TQ PS PASDSG SGYVPGSVSAAFV
CGTTCCGGGCTCGGTCTCTGCAGCCTTTGTTACTTGCCCCAACGAGAAGGTCGCCAAGGAGATCGCcAGC-GCCGTGGTGGAGAAGCG TCPNEKVAKEIARAVVEICRLP_AC
CCTAGCAGCCTGCGTCAACCTCATCCCTcAGATTACATCCATCTATGAGTGGAAAGGGAAC-ATCGAGGAAGACAGTGAGGTGCTGAT VNL 'POI TS /YEWICGKIEEDS EV
GATGATTAAAACCCA.P.AGTTCCTTGGTCCCAGCTTTGACAGATTTTGTTCGTTCTGTGCACCCTTACGAAGTGGCCG
AGGTAP.TTGC LMM IKTQS S LvPALTD FVPsvHp ATTGC CTGTG
cAACP_GGGGAACTTTCCGTACCTGCAGTGGGTGCGCCAGGTCACAGAGTCAGTTTCTGACTCTATCACAGTC CTGC
C yEvAEVIALPVEQGNFPYLQWVE
ATGATGAGCCCTGTTCCTGCTCATCATGAAGATCCCCGCGATACTTCAACGCCTTCTGACTTCCAGGTGATGACTGGGC
CCCCAATA QvTESVSDS ITVLP
AATC CC GT CTTTGGGTCTCT CTG CCAAAAAAAAAAAAAAA
co co co rn n.) Cl) rn n.) rn co n.) N.) t.) SEQIDNO . :3 SEQIDNO . : 5 0 CGGTGTcTCGTCATCTCCGGGAAGACTCGGCGCCTGGGTCCG CG
CTCTcTGGGTAAGcTTICCGGGAAGCTTTCCCGGGAGCTCGCT MGDEDKRI TYED SEP S TGMNYTP
GGTCCTGGCCCCAGPAGCCTGCGGACCCGCCCAGGGAGGATAAGC.AGCTGAAAGACCGCGCGGTGcCGcTccGAGGCC
CCGGGACGT S MHQEAQEETIIMIGAGIDANE PT
GGGCCCATGGTCGGCCTGGCGCCAC CTTTCCGGGGGAAGCCACGCGCACGAGGCATCGCACG
CGGCTCTGCACCCGCGCCGCCGGAC EGS ILLKSSEKKLQETPTEANHV
CTGAAACCCGGCGGAGGGCACACGGGGCTGCCGCTecGGG C CC
CGGACCAACCCATGCTTACTCCGGAGCCTGTA.CCGGCGC CGACG QRLRQMLAC PPTIGLLDRVI TNVT
GGICGGACCTCCCTGCGCGGIGTCGCCCAGCGGG'ITCGTGCGAAAGGCOGGG CCGACTACACGCGG
TGCCGCGCCCTGAGAC:CGT TT I IVLLWAVMS ITGSECLPGGNL
ATCTGCAGTCAACGCAGCCTGCCGGCTCAGCCTGGGAAGATGCGCGAATCGGGAACCCCAGAGCGCGGTGGCTAGACCG
GGCTCCGC EGI I I LPYCAIIGGKLLGLIKLP
CGCCTCCCCCACAGCCCCITTCCTAATCGTTCAGACGGAGCCTGGICGAGTTCGCCGGAG-ACTGCCAGATCTCGTTCCTCTTCCCTG TL P PL PSLLGMLLAGFL/RNI PV
TGTCATCTTCTTAATTATAAATAATGGGGGATGAAGATAAAAGAATTACATATGAAGATTCAGAACCATCcACAGc-AATGAATTACA INDNVQIKHKWS S S LES IALS I I
CGCCCTCCATGCATCAAGAAGCACAGGAGGAGACAGTTATGAAGCTCAAAGGTATAC-ATGCAAATGAACCAACAGAAGGAAGTATTC LATRAGLGLDSICALKKLKGVCVRL
TTTTGAAAAGCAGTGP_AAAAP-kGCTACAAGAP_ACACCAACTGAAGCAAATCACGTACP.AAGACTGAGACAAATGCTGGCTTGCCCTC SMG PC
/VEACTSALLAHYLL GLP
CACATGGTTTACTGGACAGGGTCATAACAAATG T TACCATCATTGTTCTT
cn GTCTTCCTGGAGGAAACCTATTTC-GAATTATAATCCTATTCTATTGTGCCATCATTGGTGGTAAACTTTIGGGGCTTATTAAGTTAC
LLLQGGGYGVEKGVPTLLMAAGS
CTAcATTGCCTCCACTGCGTTCTCTTCTTGGCATGCTGCTTGCAGGGTTTCTaATCAGAAATATCCCAGTCATCAACGA
TAATGTGC FDDILAITGENTCLGIAESTGST
cn AGATCAAG CACAAGTGGTCTICCTCTITGAGAAGCATAGCCCTGTCTATCATTC TGGTTCGTC-CTGGCCTTC-GTCTC-GATTCAAAGG VENVLRGVLEVVIGVATGSVLGF
CO
CO
CC CTGAAGAAGTTAAAGGGCGTTTGTGTAAGACTGrccATGGGTCCCTGTATTGTC-GAGGCGTGCACATCTGCTCTTCTTGCCCATT F QYFP SRDQD KINCKRTFLVLG
171 CTGCTGGGTTTAC CATGGCAAIGGGGATTTATACTGGGTTTTGITTTAGGTGcT.GTATC T
CCAGCTGTTGTGc-TGCCTTcAATGc LSVLAvESSvHFGFPGSGGLCTL 0 --1 TCCTTTTGcAGGGAGGAGGCTATGGTGTTGAGAAGGGTG
TCCCAACCTTGCTCATSGCAGCTGGCAGCTTCGATGACATTCTGGCCA VMP.FLAGMGvirsEKAEVEKIIAV
fli TcAcToGcTTcAAcAcATGeTTGGGCATAGCCTTTTCCACAGGCTCTACTGICTTTAATGTCCTCAGAGGAGTTTIGGA
GGTGGTAA AwDI FULL FGL IGAEVS IAS LE n.) Cl) TTGGTGroccAAcTGGATemrrcTTGGATTTTTcATTcAGTAcTTTc CAAGCCGTGACC_AGGAcAAACTTGTGTGTAAGAGAAcAT PETVGLCVATVCIAVLIRILTTF co TCCTTGTGTTGGGGTTGTCTGTGCTAG CTGTGTTCAGCAGTGTGCATTTTGGTTTCC
CTGGATCAGGAGGACTGTGCACGTTGCTCA LMVCFAG PNLKEKI F S PAWLPK
Ill TGGCTTTC CTTGC_P_GGCATGGGATGGACCAGCGAAAAGGcAGAG G
TTGAAAAGATAATTGCAGTTGCCTGGGACATTITT CAGCC CC ATVQAAIGSVALDTP_RS HGEKQL 0 TTCTTITTSGACTAATTGGAGCAGAGGTATCTATTGCATCTCTCAGACCAGAAACIGTAGGCCTTIGTGTTGCCACCGT
AGGCATTG EDYGMDVLTVAELS IL ITAPIGS co CAGTATTGATACGAATTTTGACTACATTTCTGATGGTGTGTTTTGCTGGTITTAACTTAAAAGAAAAGATATTTATTTC
TTTTGcAT LLIGLLGpELLQKVERQNKDEEV 0 GGCTTCCAAAGGCCACAGTTCAGGCTGCAATAGGATCTGTGGCTTTGGACACAGCAAGGICACATGGAGAGAAACAATT
AGAGGACT QGETSvQV n.) rn ATGGAATGGATGTGTTGAcAGTGecATTTTTeTccATccTcATcAcAccccuakTTGGAAGTerccrTATTGGTTTAcT
GGGccccA.
GGCTTCTGCAGAAAGTTGAACATCAAAATAAAGATGAAGAAGTTCAAGGAGAGACTTcTGTGCAAGTTTAGAc-GTGAAAAGAGAGAG
cr) TGCTGAACATAATGITTAGAAAGCTGCTACTTTTTTCAAGATGCATATTGAAATP.TGTP.ATGITTAAGCTTAAAATG
TAATAGAACC
AP.P.AGTGTAGCTOTTTCTITAAACAGCATTTTTAGCCCTTGCTCTTTCCATGTGGGTGGTAATGATTCTATATCCCC
AAAAAAAAAA
AAAAAAAAAAA
'1.;w SEQIDNO.:4 SEQIDNO.:51 GACAACCTTCAGGTCCAGCCCTGGAGCMGAGGAGTGGAGCCCCACTCTGAAGACGCAGCCTITCTCCAGGTTCTGTCTC
TCCCATT MVSSPCTPASSRTCSRILGLSLG
CTGATTCTTGACACCAGATGCAGGATGGTGICCTCTCCCTGCACGCCGGDAAGCTCACGCACTTGCTCCCGTATCCTGW
ACTGAGC TAALFAAGANIZALLLPNWDVTYL
L.4 CTTGGGACTGCAGCCCTGTTTGCTGCTGGGGCaAACGTGGCACTCCTCCTTCCTAACTGGGATGTCACCTACCTGTTGA
GGGGCCTC LRGLLGRHAMLGTGLWGGGLMVL
CTTGCCAGGCATGCCATGCTGGGAACTGGGCTCTGGGGAGGAGGCCTCATGGTACTCACTGCAGCTATCCTCATCTCCT
TGATGGGC TAAILISLMGWRYGDFSKSGLCR
TGGAGATACGGCTGCTTCAGTAAGAGTGCGCTOTGTCGAAGCGTGCTTACTGCTCTOTTGTCAGGTGGCCTGGCTTTAC
TTGGAGCC SVLTALLSGGLALLGALICFVTS
CTGATTTGCTTTGTCACTTCTGGAGTTGCTCTGAAAGATCGTCCTTTTTGCATGTTTGATGTTTCATCCTTCAATCAGA
CACAAGCT GVALKDGPFCMFDVSSFNQTQAW
TGGAAATATGGTTACCCATTCAAAGACCTGCATAGTAGGAATTATCTGTATGACCGTTCGCTCTGGAACTCCGTCTSCC
TGGAGCCC KYGYPFKDLHSRNYLYDRSLWNS
TCTGCAGCTGTTGTCTGGCACGTGTCCCTCTTCTCCGCCCTTCTGTGCATCAGCCTGCTCCAGCTTCTCCTGGTGGTCG
TTCATGTC VCLEPSAAVVWHVSLFSALLCIS
ATCAACAGCCITCTGGGCCTTTTCTGCAGCCITTGCGAGAAGTGACAGGCAGAACCTTCACTTGCAAGCATGGGTGTTT
TCATCATC LLQLLLVVVHVINSLLGLFCSLC
GGCTGTCTTGAATCCTTTCTACAAGGAGTGGGTTCAGGCCDTCTGTGGTTAAAGACTGTATCCATGCTGTGCTCAAGGA
GGAACTGG EX
CAAATGCTGAATATTCTQCAGAAGAAATGCCTCAGCTTACAAAACATTTATCAGAAAACATTAAAGATAAATTAAAAGG
cn GTGAPIAAAAAASLAP.W...A.
n.) CCI
Cl) (13 (1) rn co n.) rn cr) H a H 0 n Z .-1 > +
a ,y1 E.HCP.IxIftii-i g>g NaJanqp xo.-lopcDogg a cz 4 0 8 Ee.
O 0 a. >1-INH,-H OH H (r) ui 14 u >
rsi It) E. H :.> ,..1 v..1 1-4 (01 III
- E.0( 05,,E.>.,1> 41 = CP1HcnCD4101--IFil-1 2 cnt n 11, H PC A
H Pk.....¶7:4 C.DZ CA
i'i),' cc',4 'A,'-. 8 g Cl) Z ,. > F. E. 1- i-1 pc 1....
HUH LA H El H [-J' (A r. r, ', 8 g 6, 6 0 g `E?. H El P. ti: I1 ) H 0 0 .E-.1: EC1 8 g 6 Pc E.0<a0UP0aH0E.E.E.Hu0000 0 0 U 0 0 / a U 0 0 a a 4 CD y CD CD y 0 a UUCDOr Hu E.0a0HuHouUu 0 cDa E.E.000HHHE.E.4 E. 0 u 0 a C. u u 0 E--, E. 0 0 u U 0 E. uu u 0 u Kt auchuF, a cD0E-+KCua H Hu00 a UUKI:E.E.Ucia a a UE.PagE.0 q0c9Hua 00 cDuug c..) Hu a cDUE.
LI 6 8 `,' U rEr Ec.) -.' t 6 E: , g g .,i. `,'c 8 HoHgour...,HHHHHu4H000 ,...) C., UuE.HHE.HuHu0HOuUHU a 0 0 u V U U H E., a E. 0 E. 4 E. a H u H U U
uUE.E.0UUuLD000U,H0a40Hu UOHHOH ,,: HUE.< KC 0, E-. E. E. U / CD t.
8 ug E6 [; 8 ,E=' E,-' 'E, E6' EY. 1 'E*4 El 6 ' C-D) El .
A .e.E.,,CPCOLDUE.C.)UE.,FICJE. CDOE.
UCDUE.E.E. E. E. a a U a a E. u U H 0 i E,-' 6 8 6 c,' 8 'e, i-_,) r;, ,,== E.-: E. .., '4 ',; F. SE5. 8 ri H 0 E. 0 a a U H a a H F. k.-, ,_, 0 E ,.) CD
ti:
E-. gr, 0 PC CD PC CD E-. CD A E-. U E. PC rt: U E. pl: U U
E-. 0 E. u 0 u 1. u cD, E. u a E. E. E. E-+
O E. E. u E. u E. a a a H 0 U F. t,=4 E. t). H S-2 8 g -,) -,"3 g ,`: ,E;.' g ill ,`-g) 6 8 g 6' r, g 8 g 0 gc98`gr,606'''''',.E.' (-) H PK [-I
E-1 Pf: CD 1-+ 0 E. Kg 0 6 ,r4 (x"C) 8 ,4 Ll r, g g 4 u E. CD CD, E. H A E. E. E. E. 0 a g 0 cD
Ii: CD a 0 CD 0 CD a CD a HUHU E. a u c..4 0 ,.
E-, 0 u 0 CD U r, E. E. E. a E-, PC F4 E. 0 E. A H 0 P. 'c'5 ,C-)p3EY+ -4' 8 r4 i,' ,:õ.5' ,.`3 `-' ,,.,:cH V-1.8 8 ri gouHo HuPc7F-. auat.1,,t..90 u0E.E.OuUE.E.HucDUE. g CD(D a U a E.00 H HuHE-4 a HUO 0 ci0 0 6 gl E( '2, Et , +Ea' r+ FY , Er'C P. U E. g 8 E.4 ., 00,,,,,,,,,,,E,,, H,/ g ,,,, ,6:
O g 0 CD H H F. 0.4 0 4 E. 0 c) U CD 6 !.. ts O 0 aULDE.0<0E.OHE.E. K4 r .
CDUOVE.CDCDC3U,rcrCr HE'F"1.(1EC, ECj (i EC. CD Li' LE-2. (Cni C:D 0 8 E1 8 `E?, EC,' [-_,' g 0 g0000g0g000ogggggiu..., 5 a CD ED H a < E. u H 4 E, 1-. F. PC CD E. A (9 A U
0 ,, 0 0 0 c..D H ,.- y y ,5 o y o E. F. .9 ,(i..., (0) 0 It H a 0 a H It 0 U a H U 0 H H H H
U 0 E. 0 E. H a a E-; a H E. H A U E. El El (8 a UHUIDE. aug a E.H auEE-:,,u b 4 r7Y)E.g.F-.) 8 6 2i, li:', d ' E,-' ..-), Eg N E--. 6 8 0 (C59 CD E. C.9 U C9 CD U U CD U E. HE. E.g O00 V E. pa ()i: Ha <Oa u 0 C) F,C U a U E. 0 E-+ E. / u < U E. 4 1 4 E-4 E.
OuggUE.c.DOuE. uuuE.HE.Huuu uHugUrg0Hu 4 0E+Huuqua y, HaU00a 0a HO,P4 gcr,,..,U,,E` ,,,L F. tc3 ',41, CD F. PI: A U r_.: ,(0.1 r!). id ,i: 6 t-; 6 E. A E. CD 1 8 r:, ,T4 8 (c)7 CD U U P4 It H U 0 Kg H 0 Kg a U H It 6r8b4EP.66.6,11 (1`6'El E, :: r, ,tc. r.)' 5 -,) 666`,Z6t-if-,' 6 n [-,'F-t)E,-,' ';'4U88 R
/
HUHOU004E.a, t._ E. F-. c cic.DE-+UOPC..) CI u 4 < 1-, CI 4 U Pt C.) E. E. CD E. U H PC CD C.), ,,,q E.
0 E-19 E-.) .)q 8 '6 8 8 `,-);; ,`,-) r. ,r;1; El El 8 ,` '6 fr4 O HU 0a H F-4 0 A 1.9 CD I. ID H U El C.) ,.., 8 6 In UUOU CD 1, a OU0a aHOHOA t.
- ii E. 0 C..) 0 E. E. a -a 0 E- , u a u WE-. E, c 0 , ,, rõ r. ,,. Ey, = E= E, E. H HO E. a Pc gg HOC) U E. U H
O 000 a Oa 00HuHOOF.C2S9,0p, y, = 0 ci. o 0 E. 0 E. g HE. E.C.TD E, 4 t-. ,-4. µc)., '7'6 fZI 0 a E.aUHE.H aHOE. 0 uu0 H OUUUCDOCDE.E, g q g ri r, 8 ,) ,-; ,,,t, 0 ,:4 0 0 0 A: H H E-1 U E-1 r.1, U f -I 4 E, 0 E,.., 0 E4 UCDUE-IC.DgUACDPCPCgE.
C) UCDO<OUPCE.C.JUE.UPgi-.H AHUULD
SUBSTITUTE SHEET (RULE 26) j. CI H
c.1) H 0 cri cl. m r=1 rt. < fir ci) H
o cn <
rn ?Ho. H
L2 (tt OEsEs E
t14 E. M
n cn a u oi ,a, H g g > a+ g 01 g g U 0 al al 0 g r14 H la, cn a a < m utno4E.W4E, E. 0 F. E. g4 of4E-,<HP<UHPE.0PU
UH,u4rouPPE,HoOppochouuouuE.,4 <OWEJ PCDHUDCJUA<E1 <o<opo4PE.PKE
pi.; E. H u CJHUE.E.E.UPHE.A0C)<CDOHUPE. 4 E.1 0 E. U E. A H u U KE < H g E. P 4 4 < E-, u o 4 < Kg E. P ,, Es Es E. H E A P 0 0 U E. E. A PA 4 A
U= POHUPHOPPHUAHE. UCDOCDE.K4CDOE.HP0 PUAOUIDUAOF. 4 E-I < F.0 UPOOPOHHAACDE.
E.00<E-..A,E.E.E.<4F.E.E.AUAUE-.00H L5UP 4 E.
U 0 F. u o 0 H 0 H H U 0 0 U Ui E. A p E. u UUFUHACJOOHE.E.00CDAOUU4 UU oHu OE. puoo 0 4 HOP OCJAPPOL)<U 0 HOLD E-4 E.E. , UPCDC)AAAE.C.?E.A AE.<uc.DAHUCA<AH 4H0 / AUPCDAUF.E.0,UHLDHE.,<UHAUC..5 HCDA E-.0E-, E-- UUCDOACD , HUCDE--.UE-.c1.<PCDC.) 4 Kg < 4 E.F.
UPE.A0A00E.0 UHAP CDHOOPAAE. E.F.E.
POUE-luAH<A 0,-4PU OPE. .4 OHAE. APE.
UCDOA E-.F.CDA.<0 E-.E.ULDE--.PCDOE-.F.E.A NH<
E.u0uHu4 044 UAHHUE. .< E.E.E.040E.
U U 0 CD U E. U 0 A 0 El 0 E. E. PA E. U < < CD CD 0 E. 0 0 E. U E.
0 U 0 U E. 0 0 E. u E-1 4,4 rc U a, E. F. A E. A E. El U o E. 4 4 u U H u E. E. A E. A U U A E. E. 0 4 E. U U < A U E. U < < E-, o E.
0 0 0 E . H U E. A. 0 A a. E.-, re, E-, U o H P E. 0 E. 0 c..) E. A < E. CD
H E. E. 0 E. () E. E. A n. 0 [-, < ril 0 r4., E. 0 Kg < 0 E-. E-, c..) A E. E.
<
u 0 U E-4 U r.) F. U 0 E--. < u E-, E. 0 H, E. E. U E, 0 E. q E-. E. E.
F.
H U U CD U E. F. 0 P E. A A U A: A A < < < CD U A U F. E. F. A
rUE.UPC-DA(DAE-.CJOHULDUC9HHHOU E.AOU
0 UPHUHE.AF.CDPAHCDCDPHE.PH AHCDP
00000 HHOAH E--.C9HU KE o 4 < H 10E.0=KqE;' U(DHIDA/HUACD E-, E-, U: Es E.P.A<OA< AAPAL) E-(C) U H gl.: A 0 H t. A A 0 A u u a, H 0 u H 0 A 4a. 0 00000 PA AAHE. P o o 4, u u < 4 0 POPE.E.HE-.
U U U E. A F. L3 P E. U E. A E. g E. U C) E. 0 A 0 0 gc ,:: 0 EA E--.
POO AuLIPHUHAAE.HE.00H<AACDHACDUHA
u u 4 4 CJO OPAUUAUPCJHOOPPOUHA F. HC) O U c.) E. E. P H E. 0 C.) F. E.
E. C.) 0 H 4 E. -A H E. U E. E. CD U E-.
UOUOAAHUF.HPHETUCDP-40E1OHE. F.0 H < 0 < 0 U H 0 H F. U E. CD A 1= U CD CD CD H H E. U A E.
HUUUE.CDOAAAPA.A 0,01ACDE. HUE. P0 U U H E. F. U E. a; A F. A H A
E. 4., E. U E. F. A 0 E. U El H 0 E.
E. E. 4 A U A E. E. U E. C) E. P A A C.) CD U 0 E. U .< 0 E. 0 ALDUCE.CJOHO E. APPC.5.ZE.r(000 AU 000E.
A E. U E. 00HU0 0 HHHHU40H.g0444 C.5 E. E. A
1 ci U U E. A E. 0 H 0 E. < CD C) A A Cl c.) 4 4; H E. U E. E-, E-, E-i U.U0 H00UH.c004,<0-444H 0 U CD P E. Hug() E. H o H E. P U E. .< .< 0 -. F. <
E. 0 r< H < .< 0 E. P Kg E. E. KE <
uu0 /E-,opuucn ,r, E-IHUOPPUUE-.U.APUHA, U u A. u E-. c-, o, U 4 H 4 E-, 4 U 0 .4 0 H 0 4 H 0 E. U E.
H 1.9 U U HPAE.E.C.DPg04a:
UAE.F.HPAACDE.
AACJUOCD < H 4 E. 5 ,,,.,õF, . 00H.40HU0E.E-.
000E.04.00CDP E.E.PH A Ag<CDOE.E1AF.
O E. A A a, 0 1-. E. A r< E. 4 E. U E. c.) U u A A
P E. 0 E.
0 A u U A A < E. E, 0 0 E. c) C. 0 < U < P A A F. H A U
U E. cn H cn 4 El A A CD F. A u E. 0 E. 0 Ci H 0 P E-' U , E' ,4 E. c) U E. 0 E. 0 U E. E. E. E. a, 0 A A A 0 E. 0 0 H U E. E. H E-, O<.<00HOUUE-,,<00H H<Kg aPKEEnHuo/pp ocio<ug< 1,..õ,,, A U F. U o 0 CJ E. E. r HUH0-40 A PHE-.UUAHHA < CJAOPPE. Es Es o 4 u o 4 H 0 A (-) E-, < P < re, o 4 < < 0 u H 0 0 E-, 0 gti < o o < 0 u 4 H < o PHAHAE.A AUCDOHUA cl u F. E. A, A A A 0 U 0 E. H F, C.) Ai A A 0 U A CD F. F. U 0 A
A E. c..) U A C.) 0 0 E. U C) E. CD A HUE-,0H0HU <40 UU000 < <HO HUE.0 HE.......:E.0E.C.7.<0 < A 1.E.
UE.E.UE. 0000 HEUHE.E. Ch ,cr H E. H 0 P r CJ CJ E.
O 0 CJ A U 0 A E. H < 8 E, 0 , Cl E. H E. E. g E. 0 0 4 P
,<HOUU0<00:E. H H t, 0 E., E-, 4 .I, E. E. E. A E. E-, E. E.
Pc tiE-,OUACDE.H0 4H04E.E.UE.U C.5 CDPAUH AU, (5 CD U A P a, 0 0 E-, E-1 P.< pc F. A E. 0 H < CD CD CD E. 4 4 El OULDOUCJOAD E. 4 En < E-, 0 < 4 0 < 0 F4 .'4 E-4 1. 0 0 4 Oes<UK:0H0.4E.KCE.E.C7HU HUUL7HHE-.U0.<
i 0",0U0 U,..,<-.< <0<HHE.H <HE.P0H0 < U F.
CJU(DAA UAHOUgHE--.UP A UCDUE.HE.HPU
F,C0E.HHouopppH4 E-.E.E.E.P PH<PHO HE-.E.
ti7 UU0H00,<HOHHH ACJHUHP UUL)PUE. H < H
=== OPOHOHAHHUHOOPAPH,OUAUF440E-10.< Of-'0 U E. 0 E. 0 0 E. CJ E-. t.9 C-. < <
..< E. E. U U 0 U E. 0 E. < H < 4 o < 0 E-I E. 0 0 E. C.) 0 0 E.
g E. E , E. 4 4 P C.J P 5 F. U A s4 H 0 Z A U 0 F. PA CI 0 A E. P <E.OH<E-. < E-, u < c) H 0 F. E. E.
IC) CDUHE.A<HUE-100A E4 E.U0E.OPU000 H E. 4 <
H < < U 0 0 0 U E. P A H A r 4 u c) E, 4 0 E. E-, F. 0 a. E. A H F.
0 000000HUAA10E.E.,<HHACJA E. 0 E-4 a El 4 Cs) 0 C.) EJ 0 E. E. 0 CJ F. A 0 CJ H H A E. 0 U Q 0 E. E--. 0 <
E. E.
Cs) POCDPOHOHoU OHAL5 ACJAULDOPOHOHA E.
V OUUPCDP4POE.00404000PHOPOHAE.APA:
SUBSTITUTE SHEET (RULE 26) SEQIDNO . : 7 SEQ IDNO . : 5 4 ),4 CTGGACGAGTCCGAGCGCGTCACCTCCTCACGCTCCGCCTGTCGCGGGTGTCccGcCGGCCCGTTCCGTGTCGCCCCGC
AGTGCTGC MAVFVVLLALVAGVLGNEFS ILK
GGCCGCCGCGGCACCATGGCTGTGTTTSTCGTGCTCCTGGCGTTGGIGGCGGGTGITTTGGGGAACGAGTTTAGTATAT
TAAAATCA SPGSVVFRNGNWPIPGERIPDVA
CCAGGGTCTGTTGTTTTCCGAAATC-GAAATTGGCCTATAC CAGGAGAGCGGATO CC.AGACGTGGC TC-CATTGTCCATGGGCTTCT DT ALSMGFSVKEDLSWPGLAVGNLF
GTGAAAGAAGACCTTTCTIGGCCAGGACICGCAGIGGGTAACCTGTTTCATCGTCGTCGGGCTACCC-GTGAACAAACTGGCTCTACC CC
CAGGCAGTGTCATTTCGTACCCTTTGGAGAATGCAGTTCCTTITAGTCTTGACAGTGTTSCAAAT VIS
YPLENAVPFSLDS VANS INS
TCCATTCACTCCTTATTTTCTGAGGAAACTCCTGTTSTTTTGCAGTTGGCTCCCAGTGAGGAP.AGAGTGTATATGGTA
GOGAAGGGA LES EETPVVL QLADS EERVYMVG
AACTCAGTGITTGAAGACCTTTCAGTCP_CCTTGCGCCAGCTCCGTAATCGCCTGTTTCAAGAAAACTCTGTTCTGAGT
TCACTCCCC KANSVFEDLSVTLRQLRNRLFQE
CTCAATTCTCTGAGTAGGAACAATGAAGTTGACCTGCTCTITCTTTCTGAACTGCAAGTGCTACATGP.TP.TTTCAAG
CTTGCTGTCT NSVLS S LPLNS LS RNNEVDLLFL
CGTCATAAGCATCTAGCCAAGGATCATTCTCCTGATTTATATTCACTGGAGCTGGCAGGTTTGGATGAAATTGGGAAGC
GTTATGGG SELQVLHDISSLLSRH.KHLAKDH
GAAGACTCTGAACAATTCAGAGATGCTTCTAAGATCCTTGTTGACGCTCTGCTLAAAGTTTGCAGATGACATGTAGAGT
CTTTATGGT SPDLYSLELAGLDEIGK-RYGEDS
cn GGGAATGCAGTGGTAGAGTTAGTCACTGTCAAGTCATTTGACACCTGCCTCATT.AGGAAGACAAGGACTATCCTTGAG
GCAAAACAA EQFRDASKILVDALQKFADDMYS
GCGAAGAACCCAGCAASTCCCTATAACCTTGCATATAAGTATAATITTGAATATTCCOTGGTTITCAACATGGTACTTT
GGATA.ATG LYGGNAVVELVTVKSFDTSLIP.K
CO
AT CGCCTTGGCGTTGGCTGTGATTATCACCTCTTACAATATTTC-GAACATG GATCCTSGATATC-ATAGCATCATTTATAGGATGACA TRTILEAKQAKN PAS PYNLAYKY
7=- 1 AAC CAGAAGATTCGAATGGATTGAATGTTACCIGTG CCAGAATTAGAAAAGGGGGTTGG2-'2=ATTGGCTGTTTTGTTAAA.ATATATCT NFEYSVVFNMVLWIMIALALAVI
T T T AG TGTGCTTT AAA G TAG AT A G T AT AC T TTA CAT T TA TAAAAAAAAAT CAP.A
TTTT GTT CTT TA TTTTG T GTG TGC CTGT GA T G T I TS YNIWNMD PGYDS I IYRMTNQ
TTTTCTAGAGTGAATTATAGTATTGACGTGAATCCCACTGTGGTATAGATTCCATAATATC.:CTTGAATATTATGATA
TAGGCATTTA KIRYLD ND
cn ATAACATTGATTTCATTCTGITTAATGAATTTGGAP.ATATGCACTGAAAGAP.ATGTAAPAC.ATTTAGAATAGCTCG
AAAGTGCACTGAATTTATTAGACAAACTTACGAATG CTTAACTTCTTTACACAGCATAGGTGAAAATCATAT
TTGGGCTATTGTATA
CTATGAACAATTTGTAAATGTCTTAATTTGATGTAAATAACTCTGAAACAAGAGAAAA' GGTTTTTAACTTAGAGTAGCCCTAAAATA
TGGATGTGCTTATATAATCGCTTAGTTTTGSAACTGTATCTGAGTAACAGAGGACAGCTOTTTTTTAACCCTCTTCTGC
AAGTTIGT co TGACCTACATGGGCTAATATGGATACTAAAAATACTACATTGATCTAAGAAGAAACTAGCCTTGTGGAGTATATAGATG
CTTTTCAT
TATACACACAAAAATcCcTGAGGGAcATTTTGAGGCATGRATATAAAAcATTTTTATTTCAGTAAcrrrrcceccTGTG
TAAGTTAc TATGGTTTGTGSTACAACTTCATTCTATAGAATATTAAGTGGAAGTGGGTGAATTCTACITTTTATGTTGGAGTGGACC
AATGTCTA
TCAAGAGTGACAAATAAAGTTP_ATGATGATTCCAAAAAAAAAA
;74 SEQIDNO : 8 SEQIDNO : 55 AGCGGGGCAGCGGCTGCGCCCTGCGCCGGGGCGGP.GCCGGGGGCGGGCCGGCGGCCC-GCAGGCGGGGGCTGGGGCCCGAGGCCGGGA ME ILMTvS KFAS I CTMGANASAL '76 GTGCCTGAGCGCCGGCGGCGACGACGGCAGCGGCGGCCCAGCGGGCTCGGTGGTTGGGTCCGCGGCGGCTCGGGGTCCG
CCCGCGGG EKE IGPEQFFVNEHYFGLVNEGN
CTGCGGTGCGAGCGGGCGGCCCGGCTCCCCTCCTCCCCCGCCCGCCGCCGCCGCTGTGATTGGGTGC-AAGATGGCGCTGGCCGGATG TCYCNSVLQALYECRPFREKVLA
GAAAT CC TAATGACAG T CTC CAAATTCGCCTC CA Tc TGTACcATGGG c G ccAATGCTTCC
GCATTAGAGAAAGAGATTGG TC CAGAA YKSQPRKKESI.LTCLADLEHs TA
CAGTTTCCGGTCAATGAGCACTATTTTGGATTAGTCAATTTTGGGAATACCTGCTACTGCAATTCAGTTCTTCAAGCAC
TTTATTTT TQKKKVGVIP PKKFITRLRKENE
TGTCGTCCATTTCGGGAAAAAGTTCTTGCGTATAAGAGTCAACCTAGGAAAAAGGAC-AGCCTTCTTACATGCTTAGCAGATCTCTTC LFDNYMQQDAHEFLNYLLNT IAD
C_ATAGCATAGCCACTCAGAAGAAAAAGGTTGGAGTAATACCCCCTAAGAAGTTCATCACAAGATTACGGAAAGAAAAT
GAGCTTTTT ILQEERKQEKQNGRDENGNIDNE
GACAACTACATGCAACAAGATGCCCATGAATTCTTAAATTACCTA.CTAAATACAATTGCTGATATTTTACAAGAAGAG
AGAAAGCAG !INNS TPDPTWVDEIFQGTLTNET
GAAAAACAAAATGGTCGTTTACCTAATGGTAATATTGATAATGAAAATAATP.ACAGCACACCAGACCCAACGTGGGTT
TTTCAGGGAACATTAACTAATGAAACCAGATGTCTTACTTGTGAAACTATAAGCAGCP_AAGATGAAGATTTTTTAGAC
CTTTCTGTT QNTS ITHCLRGF SNTETLC SEYK
co GACGTGGAACAAAATACATCAATTACTCACTGCTTAAGGGGTTTCAGCAACACAGAAACTCTGTGCAGTGAATACAAGT
ATTACTGT YYCEECRSKQEP_HKRMKvKKLPM
CO
GAAGAGTGTCGCAGCAAACAGGAAGcACACAA_ACGGATGAAAGTTAAAAAACTGCCCATGATTCTAGCTCTACACCTG
AAGAGATTT ILALHLK.RFKYMDQUIRYTKLSY n.) .4AATA.TATGGATCAACTTCATcGATATACAAAACTCTCTTACCGGGTAGTTTTTCCTTTAGP_ACTTCGTCTGTTTA
ACACTTCAGGT RVVEPLELRLENTSc-DATNEDRm co (xi GATGCCACCAATCCAGAcAGAATGTACGACCTTGTTGCTGTTGTGGTTCACTGTGGAAGTGGTCCcAATCGAGGCcATT
ATATTGCA YDLVAVVVECGSGENRGH.YIATV
ATAGTTAAGAGTCATGATTTTTGGTTGTTGTTTGATGACGACATTGTAGAAAAAATAGATGCACAAGCTATTGAAGAAT
TCTACGGG KSEDEVLLFDDDIVEKIDAQATE cD
TTGACATCAGATATCTCAAAGAACTCTGAGTCTGGTTACATCCTTTTCTATCAGTCTCGGGACTGAGAGGGAACCGTGA
TGAP_GAGA EFYGLTS D Is KNS Es G Y ILFYQS
n.) CACTTTCTGCCTCATTTCTTCTCTGGTTATTTTGGAAAGGATCAAGCACTGATTTTTCAAGAAAAGAGAAATGCAGGAA
co GGCAGTAGCACACTTTGCACACGATAP.AGCAAAGACGATGGATTGACAAGCCCTTCCGATCATGGTAGTTGATTTATT
TGCTCAGGT
n.) ATCATGCTGTCTC-TACAGTTCCATACAACAAGGAGGTGAAATCAGAGATACCAGCTCCTCTTTTAAAACAGCCTTCCAGTcATTGGC
ACGCATTTTCTCTTTATTAATTGCACCAATAATGCTTTGAATTCCTTGGGGGTGCAGTAGAAAGAATCGGAATCTGTGC
CGTATTGA
co TAAGGAGATGP.TGTTGAACACACTGCATAAATTTGCCTGGTTCAGTATGTATAGAAGCATATTCAGTGGTCTTTTCAA
GAGTAAACC
o AGAAATACTTTTGGGCCCAACACTTGCAGTTGCCTTCCTGATGTAAAAACTAACATGCTAGATAATCCAGTGTCGGGAA
GACAAAGA n.) TGITTTGCTTCTCTGAAGAAGCTTATAATAATATACAGTATATGTATATGTAGGGAGCAATTGGTCAAAAGTGGCTITT
TGTTTCCC
CAAGGGGAAAGACTC-GCTTTGTAATTATAATTTTTTCCTTATTTATTTTACTTAAAACTGGTAGAGTCTAAGTATTATATGAAGTGC
n.) CCATGATTCTGTCAGTAAATTTGAACATATTTTTATTAGTTAATGTCAGTTTP.AGTTGTCCTTTTGTTTGTTTCTATT
TTTAAGGTG
cr) AATTTTAATTTCTATCTGAAATCAGTTAAGATACCTTGAGP.AAAACTGCAGTGAGAGGAGATAAATATCCTTTTTCAG
GAGGAACTG
ATATCTCTGGCTAAATATTTGTCCTTTTATTATGGTTTCTAAATCAGTTA.TTTTcTTCAGCTTTAATTTCATAAAATT
AAAAAACTA
TTTTAAAAAAAAAAAP_AAAA.A.AAAAAAAAAAAAAAAAAAAA
rti 0) A E=1 cx= 2 04 A
2 In P. 0 p.. TH F. 0 cI) 2 õ-) .4 a=
cil P. c), fi, CI 0 Pc I U c4 0 0 F. 2 H
cnIccq.C9P..c.JIn :1 c 8 (utri Hx...,,_1 (1. H u uc H E. Pi 0 (c) 2 yoox&-,x 0 0 co 2 R cn P. 01 0 . U 0 VI 2 0 re, 2 2 0 2 a , 4 (X .0 .-.1 H 7. Pi P. 1 Ln E. Ey :3 1.4 2 E. in = P N >1 ,1-1 '', u, ,'-' == gc 0 P. < . X 0 P., 0 P Of I-1 (21 U H En S. 0 NI 1=4 ,..1 2 E. ?-. (.1 2 In 0. 1-4 2 0 PI E. 0 H CI 2 0 cc. I-I KC 0 E. (-c 41 f,,r cl cn p. 4 u u PI c() Ey cn a( C.) E-4 VI go , (.., 0 0 pr=C Lxt H . 54 0 (I) x E. 0 0 f2 3 PC P4 0 UHUU<OHOHO(..91c4E-.< 0 0 E. H 4 H < E. 0 1 c..) C.) C.) (.4 U 0 E. E. rl 0 U 0 0 u u U < E.
C9C9UOUUr4c4HuccU cl,E.0 E.UuE.C9yOUH
cg U U 0 H E. IJ F. cr C.) E. 0 .4 / 0 0 U E. U U 0 E. UE-; E. E . a; .0 U E. 4 E. 0 c4oduguE.1 E. A
0c9<HOCIE.c4E.E.U0E-.< 0 000c4FuU C.E.
0 0 (I, (11.9 4 c..) U E. u .4 C. H E. F. U 0 u (.4 E. (4 U u E. u g a ei Et E-, E.
UOU<HPUUE.HUUE.F. .4 0 0 1 0 U 0 0 E. cg u I
CDCD AP-A.440000 E. 0 4 U C.) CJ H 00E-(440HUE. E.
0 y clEIcEJU4(E.E. f-,U 00E+04 (.401H0 C) C) E.04(44Ou .41(.9E-(UE. C) c..9 (9 U U < E. 0 0 0 / 0 UE. E. 4 E. < u E. 4 U 0 U F.
A 0 A U U 0 E. U E. U U < 0 F. 4 U U 4. 1 0 E' U '. U c4 < HACDHAUE.CDA CD 0 0 H UUU
U 0 H < E. 4 CD E. g F. U E. g gcla E. uuout,oHouopog 00E.E. UCJE.HE.
U 0 0 < H U E. 4 0 A E. 0 A E. C.) 0 A CD U u F. u 0 U E. u E...
<C9C.).4.40EØ4U9c400E. ggE, u ED gE.E.CDHUE(..)000 , 1.--, V E.
UE.1 < .4 0 .4014,q8 1-(10E,40u4u 0uu04004 4 . 0 0 E.E-, pc g < 0 E. 0 E-, F4 F4 C,D C., &4 4F. P4OH<E.E.E.U<UCDPCOU 0 0 0 E. < 0 CJ E. C.) E.
O E. C.) cc. E-I E. 0 0 4, 0 <4 u E. < < 0 U
E. 0 F. c4 U .4 E. 0 E. 0 4 .400ua,U4(.94,004uHuH4 U E. E. U E. Kg F. E. /
C9 E. At E . ., ..0 U El a' Ei ral 0 u E-, u 0 a' 0 c.) H 4 0 U
(.7 (...) E-.
c4UUCDCDU HHHE. 4, C.) E--, C.!, V 44 C) U E. A, E. U
0 E. U 0 O0cJuE.F. CDCJA00E.E. E.H04 (9 0 u U < E. 0 E. (4 E. /
U 0 < 0 < 4 E. CJ 0 4'1 0 0 (-) 0 E. C.) F. E. E. F.
0 0 gr cr: E-' E-' F. U .4 0 U f-, 0 0 U E-== E. 0 0 0 a:
Kr. u UUUUHOH E. e. 0 4 E. C. F, 4, 0 = A 0 U E. U 0 E. EJE. A A C.) 0 CD A c9 Ci U 4; I---. C.) 0 E. 0 0 E.
O A H U C..) A U U 0 0 CD E . CD 0 E. f-, A
0 0 41. C.) E-4 t i 0 A E. E.
E.0,00AUACJACD,7=0E. 4 -,ugt, g.ou 0 u < 0 4 .0 0 C.) 4 E. E. A 0 0 0 E. PC U PC 0 0 1 u 0 U 0 cc C.) i H 4 0 U E. < H E. A A 0 E. E. E. F. (4 E-. 4 E.
U 4 U E. cl: U F. U 0 0 E. 4E. E. 4 E. U C. U V A ugo,E,E,E,Ur-c (..) (3 (1) u 0 0 E. < U
E.
r, UUCCE.OH04 a. r¶..7 UE.CDA a' oo o 0 E. E. E. F. 0 0 (..) O < E. U 0 E. E. < 4 U 0 U .4 U F. 4 <
(..) U H,4 0E. E. 0 4 4.
c-i' EE--: c.-h' cd t7i µ,'µIzi 0 8 P-, i-', 6' ti g 40E.c400F.C../HcJE.
0 E. E. E. 0 E. E. A E. U A
E. u F. < F4 HA CDE.AHE.0P0 =OUUACDUHUH 4 H
HCJU 0(....E.000HC..).4 F, < C.) E-, 00 <PC HOE--1q00 H
O 0 U ti U E. U A E. U E. (..9 0 E. 0 (J 0 U 0 E. A E. 0 re, 00C1HE.CD
CJ 0 (..) U E-4 E. E. < 0 cc < 0 U .4 c4 5 U, (..) (.... F. u < F. < r.
(.900 0.40u A 0E.64 ACDCDHA 000 HHUOHA E.
E. A E. 0 CD 0 g U E-40HU0E.E-, E. 00000001H<H
CJ Ou1 H E. E. cl<H0,404CJE HUF.C90H4 CJE.0 U H E. 0 E. F. F. E. < 0 c..) 0 E.+ 0 U E. 0 0 (-A _ E. E. E.
F. C.) U U A E. 0 / E. A A 4 E. 0I. CD E. 1 HAOUHE.HE-.C.JAH 000E.H
O C) U 0 0 E. CD H U 0 H 0 CD A E.
000H0000 i1 HO 0 A A A E. gc_10E-,E-104E-. 4 .4 000E.c..9C)(.9E-.00 UOUOUCJ U .4 0 4 E. E. c...1 E. E. Cd E.D E. A 0 E-= 0 0 A H
CD U CD E. 0 E. A U E. E. 4 u 0 (4 0 0 OUCDFAUHE.u4H
E. 0 A A E. E. A H rc E--, 0 0 E. E. F. E. E. HOUHOOHO .4 Lc U < U U E. 0 E. 0 H
O0004 r-, r-, u o o g E, ED 0 0 [-i U 0 E.E.
< 0 0 < c4 0 ct E. E. E. E. U u H 0 E. U
cJ E. (J U C.) CA
E. U 0 U E. H E. U U 0 0 A H CJ A CD A OU0HE.044 4 E. E-;
A C.) CD F. C-E CD A E--, A 0 0 E. H H U H A 0 CD (-= A 0 E. E. A CD E. 0 E. U 0 A A H H E. H 0 E. A A E--. Cll. A 0 H E. U E. E. A C.) C.D E.
ci E-. U E. cg U C.) < 0 F. E.
E.C_DH 4UCDHE.C.E040 E.04, 4 u0ouououe4ug oge-1 E. El =I' 4 E. H U E. E. E. OH HO
FI, on 0 U E. 0 0 .24 E. U 0 cl.) c..) 0 0 rt; U 0 U U 0 0 u E. A E. E. 0 < 0 0 C.) E. H u C.) < F. H
U .4 U 0 C.) E. E. U cg < E. E. U 4 U E. 0 E. E. H 4 H E. PC < < E.
O C.) cg 4.444E-,0000 4000 cp uu<E1 4 gal 0 U A El cr) E.0000HE.00A A A, 00E.E. H HOUU 004 E. A
== E-=4E.C.DAOCJUAUCJH CDE.H0 == UHE-=0 ACDE.E.0 = A U A A E. H Ei H 0 E.E. E. E. 0 U E. =
0 0 0 H 0 C.) A U LI E.
I
O u 4_ , 0 E.CDCDHOOU 0 ra,U0 2 U u 0 0 E. u cc 4 Li E. < u E. < .4 c..5 0 2 F. 0 C.) 5 E. E. U 0 ,....4 cJ
<
CI OU04000<<ciE.E.E.4U0E. n E.E.0 c9u<HE.E.<
H A r=D E. g A E. A a, a. E. [-,un; 4 4 4 ct H U E. 0 , E. 0 Li .4 U 0 (.9 01 a, guougg [-,uug E= A cc 0 U E. 0 0 c..9 0 U U E. 04 u F. 0 <
PI 0 U E. <, E. 0 0 u U H H E. cc U 0 E. U in E. 0 0 0 H E. A E. A E. 0 cn 0 0 4 A A 0 A E. A E. KC A H A E. < H cr) E. 0 u E. 0 F. U 0 E. H cl SUBSTITUTE SHEET (RULE 26) f:2)WE.Wc..20nXzE.Clg0Nr:4000(nr.i0Xrpfleipciult4f).
tnig,-100NIAMOH0+xc4Xx ',4 q ril r:4 .-IP.MOP
0 Ers 0 _10in,-j'.41-10,,-1+4(t)t.410h-10cocnci.ami.-100+(a., E. 34"A'vf1,-, El Z,.4u)8:',',"-teat-.4`jl`j1 2 ri c',.., ,9RE'T'IN2 ,q,-19,P,INN`08, R .6,, 22588 r, 0 'F-4 V2. E' Ef 11 (8, 2 rx, 22,E-3,8,gHo 8 0 6 R '61 'A }t: M Q r=1 ',I.
0 c'itEi',P2, >.n1-1,-',.-.2-1'4).
. 2 [-TO tc70('-+Ip141-1-iE.Or-134f..41.-1',31.541R mchOMA .. M
,f4 rnw_ wr-,g 4-4o141;YaCiat-IZE40u) 4ftrqln , xa - (44 M4-1aZ0zXOrrz4,4awor.404-404 fr, u) 4 .00Hca,c:
16 ,1 u '' 9 8' Er", 0 8 r7, 3 0' 0 8 8 8 g " " OZU z '-caE-4r4ZXE-4_,-104.1 carrl >1.9Hq0100qwwW1004E.Eactioqcnor4UP4 xo Q Ft to; 'EYx?c,-,Nwpatt,lt:Im uw441-44-14-404nui-4E-,ZmE.04:4 H cO>0 <>124f4r4pE.r=15114 E.-,PCHcnE-, E..10,0E.40 Ri gHE.z4c0X44MX0E.0(.9u0E-.c=?N0,0 E.PN'00,-44n cn ZOE, .111E-,0,-1P4001q>, 4y. x E-4 r.,1 x g r4C/),--14.71-uco0OH
,. ,0 , ,0 , ,µE. ,. _E-. H C. E". E-. < < L.7 0 E-. < 4 (.7 < < E-. E.-. Ed, U Ep 0 <
µ-.'s-',.',."0(-)<<E-,(900E-.E...C.DE-,<PCE-1L90Ktggiuu0u E-40HE-4000uE.E-Igu0E-.KtuKtuc(!),,i 8 te4 E., 8 v,,,,5,E,,,,,,,c;
4 U 0 E-, E. .1,' E. E. E. 4 < E. 4 E-4 0 0 A
Pc <F,E,U1.135UE.C9u44H0E.C90000(11.964UuU0UU
000FF(90t.00,00UUHF0 f...70E.0E-,<CJUE,<U,U0 g Ed,. VD 4H A 0 CJ U < 0 El CJ
0 444 0E-40E-4040 U y U
KG U 0 E. U E9 ill 8) 8) 8 Pc --,' 8 6 l 84 A 8 8) El EE-: 8 6 LI 0 05 8 .E-: 8 8, /
HE.V.) E.,:t 400,4;ugE-4KL41-.0H0 E--,440().(-)(puE.-.
u r-, < u u 0 4 4g0uE-.E-,ououuy UU0E.0 UUKGKG
010000E-, Pc t--,u00E--44CJHUE.<CE, OUOU 0E-4y0u 00E--40E-igg00g,,t0g ugH4E-4E-4U 4UggE-.0uugu H g c.h 0 0 0 u E-4 HOUgUKt cp gt g g OHO 4, t: 0 CJ C-c 0 p E. 4 /
F4'8vE=',E,-,:iP,u-,18g,Y, 8858800riEti,F4888El 8!
0E. HUO (J,PI,E, ,,,rt <00A
4000E0 E-400uuo0 KC0004 4.KtE-10uHugHu0F40E.E.
6uKtuuHE, a, 0 U g atO U U H 4 4 4 Kt u u u u E-, 4 E. E. 0 E. o<oFu4 6 6 8 e, 6 o 8 8 8 ti .4 0 il E', 0 8 il 8 r, 0 8 8 8 8 8 8 1..., 6 `, 1-2 6 i uuP,<()E-,4E-,<.,..Pue,E-:E-10E-,<E-,E,F, KGE.E-40g0KtU0 H4,400E-.0000400E/uuue,u0uuE-,000KtE--,Kta040 000H04000E,404<u(940E.<<UE.4E.OUHOUU<
LJUUHE.0444<gE.uuu0gE--,04u4.uogguoV)u,E, FC3c9u()(90UHE.4u4E.(9u0H44U0y4a401.0 ED4U
Eg 8 6 (94E-.F40uu4004u41.4Fr 0E-,p.-4040Sup 0E-4K4E-, a , g G U E. Kt .24 C. E. U U KG E 1 ,, 0 U t; , - , re -, 4, 0 Es : ,, EH.,q0cla;HHE.UF04004uE.000 4E.0 y ty-fl Hu<40 r=0E--,E,c9E-tU.QUE.KGE.,,GOOF,a,05s2u<s...p <0<4E-, F444(94H<F(94()UFFC3UF4U(6cE-JcEl ._-,.t.6 (.'6rõ 88808885 KV: 8 P.,(E_:88',C0 ricicrZgc'50Hu4EDF
U44UU44(9FuE.404/ 4UUUUE.44E.4U4UUU,64 EIE-400,4000400gE.0 0,tE-44E-4uuE-40',E-,uuuKtu u uuV-IE.,,44,tuE-4F,400E-.c.,00.E-40E-4000044uuu0,FE-1,, E-. 5 4E.040E.u4/E.E.04E.UUU4E-1H,14 tu:z8 (E,,, 8 ,3 6 c., y u E-. c..) (.1 o 9 u 4 E. 4 0 E-, 4 U 4 0 Li 4 u o, E. _ _ . _ a (9(9u0F4c5 ,a, f-_,, CJ El U H H E-I H'4 4; gC
E.H44UU_FLec2,c- j_.
,t-r'66 .(Cj5' 6 r . . 26 '7. L/ pE ' 0 4" 5 E-, E-, ',-), (-0. f -''.2 E--: .9, t [-i 16' 8 6 8 V: 6' E. L ' ', N i i uuKt E-4gt-.QC.),,rt./-.,.1 E-.t-,< t-,L",<t-.U(....CDC.90EJE-.4;<
CJUE-. UE.E--.<1=C<'Ut.)E. 6E-40E-400q000Ktc.68.6Er.-:, H<U0E.H<ACJAHKGcl.G.G0HUHU,HOUU
00 E. r. E., 0 < U 0 g U U E. 0 Ci 0 44U4UuHu4 OFE.40 U u 0 F-,. F F 4 H 4 U 0 E. E. C.) F 4 U U 4 4 4 0400E.P 0u0E-,04 A H C.7 H gt E. < 0 v H CI 8 8, V.: `;', (ei 8 -?e, 400E10E. 00F E.(90, 4 4yuuugE-.0 u ' t.-:,(6,0,-_,;
1L-Igl 6 ,(2,.(,' ,F,TEd rl(c-3'66'.=6c,-i 0 8 6 6 6 6 0 < E, õ 6 õ
EJ Ei) 0 8 E-, E.-4, 0 ,E-' ,4 E-, 0 '-' 0 F.,5 ,',),E`,6)8',,-E',1'6(E-2,6'u'UVii-2,6 c<'88`48888808g8,600q60 '6 P, i' tO , P., 'El '6 , V:686'8 O E-, E-, E-, E. H 1 0 E. KG E. <0.E,E.LJAUUHCAEc.; 8 8 [ -,- , i -2, 0 ,c _P4 * EL;
Kt 4 c..) 0 E. E. 0 CJ H A 0 Ci H 0 U E. 0 .
C9U0HOU OH UErE..0L,IHOKGE, .Cdtr,,,C(4 6 < 8 8 1 HHE.KGUUU U0 pc H CJ 4 F F F E. 4 0 u u 4E80004 4 0 0 0 0 HOUE.E.HOUst E. ,66re:2,, 6 U00E.UU0E.00<U<H4 F OF FOHUUU0 f.CD[49(,-)t 6 P-, 6 '6' V, 8 8 8 8 8 6 8 8 ,` 8 1 0 8 8 8 8 V46 6 8 8 8 8 't. ,<' ` 8, pci 8' 0 ri 8 8",µ": õ ',;!, E-: 8 8 Et: 0 1 8 8 E-., ,La.: El E-, E-, 0 0 4 E-, , 00E-.....0U0UUOC.70080E.U055U
UUUE.HOE.E.UE. 4 0 0 ''4 HO U E" V; , : 6 r, P. , 'El r j < 0 ! F(-0.1 8 (.) il OH
E.., 0 H E. KG U U 5G U E. .5q E. .,G 0 C..) Et , , , . , _ , , ,, ,,,, ,õ u , , . u 0040u0004g000-0$0t-,KtuguouucLjr,c, ,,,,, , d ,,, 0 t, 7 c' , 0, uE.c.,HUE.40E.E.OU,E--,c+E.,),<LJO<Hci, ,4E,,HH0,,1 ,t0,5E.,:,:c U 8 uu40.; ,RiK4OHHH51.0 rj,,cuu OFKt.EØ4, 0 0 nguKcuy,7.c. u<0uu0ogg u ,u,,,SE
HUOHUU04: <<E.0UUU<E,E.HKGE.00E-.00 a. -... , 0 E-. 0 ,..q U EG 0 U E. U P 4: C.7 ogguuE.4 H E. C...) E. U E. ,,q 0 q U CJ U
Ed :-, 2 0 8 El 0 ,".9 8 Eta, 0 R '.4) E' E4) .c) 6 --''') E. E..- g c'' 5) 6 :%) 6 6 6 'd H Pt (Ej.E ' ri , - , u u u < u k . -., c i E . uouH0yE-4E-4 0goc./ut.-4E3c)Fir 8 EE:,, - E. g 4 E-, g E, 00H<Uu<guyu,o4uu< , i, = E.y340E-, .eE.4E--,UE.D0004,04 uE-40uE-,u 4 2 i--,' 8 < 6 6 8 ,V: 6 r 8 `' ,,-Eil r.: EG' L., Et: il El 8 'd ',("C
Et: F,;c' 8 i-1 6 `,!) 6 6 al 0uu0u0000 E-40u0,<E.cp<E, y U0 8 8 8 ,E.4, EL,) ,, UAUE.OHU-5GOUUOU , 'a EY. P P. E1 ,,ri r 0 ,E.-. ',=._4, .i.
. ,, ,, ODE. ....' 1.D E. 0 E. 0 U E. 0 0 0 r hi) 868 08E,:-'c 8E-.4'c,`,.?.0(''S,`:488ElEltli--.D 8ev, 6UE18888 SUBSTITUTE SHEET (RULE 26) (9Z 37112:1)133HS ainiasans .3n nignn,3 4,. 2 0 r3 .3 n . non.3n5.63oHnnoonHon Hn " Ho 5 0 n 0 25 '.--1 .1 ?-1 ?'-3' 'An n n OH H 3 4F3' 2,'23 8 'n-3 r.31 loon.3.3.343HOHH, c).3,3 r3S,5.a.3 Hann 9,00 ,o, n .--3 Hnnrn).o,-3,-.3-30 - a5.1-3 no..3oo4.r 13p2.-3 nH 9 >> r flgnoaann.30).(1,3 ononn.3.3 Pg.), 1 >9-) !:-.1 Peen'5"),151-)g:,!'3r,-.3)229,53-19:,,,c)51., 0 .-3 H )... >.. 0 ,-3 r) r) .-3 p 0 'n, 0 H H 0 .-3 H H H n .3 .3 .3 a .3 n n 0 0 0 O.3.3 9,0.3PcHS..300.3HH>000.--3(39,X, nnnononnnn,Ron, S,4-3.30n0H GI .-3 I n S,HrI0H
O n n ona..-30.3nnons,9 n.3:1.00. P 4 H H . / ''... 3 3. 3, H n o.3 3. ,i, 0 H a ,3>
= 3= br nG) 2o.'"
9' 9-' 'An 8rc) Pr, On 9,-6) R nn ',-1 9 c) C) ,o.-306.1ann..3o>+-3 .3c,-).3.-3a.g.3nnor Han H.3n.3 :,µ05..00rn.-30,-n5.nna.3.3.3aannong a 0 P H P 0 3, annr r3npr,.30,nnotor,.35Ø0 .3 S.. .3 n 9. CI 0 4-)I1 .-.3 ,-)RnnooRn4-1),pon,Rnn E
;-3 H H 05.0 0-3 OH) .3.30Hr r r . - .-- . i .3 00nROR:,, ,:,,-, p o.... > 0 >c, H .3 .--3 .-.3 0 H P H 0 0 0 3, 0 0 H . 0 P 3... 0 > 50. 0 O G) ... 0 0 n H n ).. o r .3 0 .3 H H
0 n n r 5- .-3 .3 .3 ..-A :0 n > p > >
'c)5' rIn'vC. H,3 '(1)9"',931')?-'3*H1:-V'V-)','-',92,99`)88)`'') 5 9 C1)9.1.8 ,(23 1--3 'p .-3 ; H 1123 H .3 n n ' , (C) a P o .3 P, .3 rri 1 1 / (IR (-)RhH.-3no ..on .3 Ø,p,o,-3h)o.pr,,,I 0.30,0>a O n H:nanng.35.
.3H.30n:, HH.-3.-30000.-3.30nnn = nHnonr .3n,3 a.) (30.-3000.-300.3nno.3;>0:P H n .-3 on H H H 3, =-= 0 1.. H 3, RR,-3 .00o00,AR 4-,,,,,,- o,-3(-)0 , Rni-an,-,, Ho.3s , - 3 n > r3r3 :3, P '.-1:3=.0? .3p,,annon .3 H nan.3.3nnpHH c.(-,,t-3a.onn Ho.30 ,0n .3 r .3 .-3 .ona,-3,,,- H P H H 3., ?.., 3, H 1-3 g n 0 n r n o n ).., 0 H
.L.oHn a or :vr. a naHH a n > .-3 .-3 H H n :-3 .3npna,30naa aran,-3nneln,,,,- H H P ,,o.3,-;)..L..,ornnHan0s=,,grn Hp .3.3a or '),r o or HnHHnHgor .3 4-)na., :,.pan nn H .3 0 n n n g a. n r rn Haa5. 0 a> r ,-.3 , a o nnon .-3 9. .3r n.3?.noHngr r)Hn',-, r nr H n no o,-30.3,0nn '. 33 an H. -3 Hc- ) 51 aC") 5.'D. Ha Ha 2 Pp cl 2 Ha Hn Hn r .' . ' P '0 P. i -, o'-3 H na ) .(; ) Hn an .' 'a nn na '.( ) (-) >0 I
C) , , .,. .4 1-3,3 Ho p, ,1 . , ,, ., - , or ) p, , -34 .) no > ,. 3 2 2 r, r. ) i 2 c). 3 2 kJ . p : 1 .0 ou 1 r, n: i , , ,,.v rn 5 2 n 5 .0 2 $.. .3 .3,Rn04-14-)onRono> :,,,-304,4-)noonqiinop0,-.2nn4-) ;J. a a n n 0 o > n H H .+ A3 o . n H o H a o n n .-3 r-=-) 3Q,-D6)),,, H .-3 .3 H ,-3n1=,pp, r,n.,1 .36.),-3 ,(-3.-3,-3-,n,-3.3nnant0:1:,0000 ir4 >0 n H 1 ?in ,3)::. ,,3 >.:_3 6-1 2 4)$ 61.3,.3a 8 cl .'l. ;,,..3 1,-13 Ho n,-3 HP 2 kr) 2 6):i. ._3=P 2,,.,>4-),.., rn o.aa.-3.3 4,01-3, .3 H H H r. ,A n a .3 .3 n .3 nonnon ono nR>R,R00(,,,,,,-36),-31,r,,),,a.-3n9oRn nPn,-3):,..-32 p , , ,-, ,,-, a ,-, .3 H H H H ra ,r, o . 0 n .3 r ;1, ,, N-, n > H n n 5. n a a na 9 .-3.10PP5,PP Hon G-,,nnon.3 HPHOIPHOH00 Ha HH Ha 0 P= , c-)' Pn ' - 'n 1 9 RH '$3 Q nn ).3) n'''' '-'0 H Ho '''a >. -3 '30 2 a >6 ) P Qn >r ) 2 8 2 2 1-3 a H P ,1 0 n 3' H a n n n n o 1-3 r n > ,A n .3 IA a .3 n > o H n n .3 n tv Hong3'c)5.3' .3 S, .3 S.' .3n>n.3.grnanHo o on> ri-I
HaHHHHono.iagoa.nnHHo ' p p .3 I-3 H t--3 G :,>.. ,.,-, a, n R .3 H n a H .4 H o o n H H r H r R ?., o R 0 o 0 n n R n H
b . 3 0 O.30.3 R p.:,,' 0 R ,?,,,, 1 .1 ,,-_33 ,..,6 p, ;-.i ,,-,3 (?)...0)00.-3 0 > 0 .3 0 0 ,, PA 08 '0, 9,. , >1 0,93 1-3 .03 1 H nn na 0.3 ,_.3,, HH,Ao ,A:P ,..-3 Ho :1-3 CE1 ??-3:,,, 4( -1, , . ,'4.- )' r).-'3 P3n (;),93 >2 n)r) C) n,-3 ,-3 0 y, .3 n H S.. H 0 H 9, .3 n () H n .3 , H 0 0 P. > n.in 3, H PnE.3.3.-3,-3Hnao.,-3,-3,3 n a r 04-)Pn,--3,-34.),non Ivna,3 00a.-1,-3> ,ronHon.3 nSln, pnprInn annpv-.3a, R,-)43' n,-3,,,- ,,,nn(i) nn5nR,R,.-30 Rc-1 0 0 4-) 0 P. .-3 n n .3 ,, .3 .3 0 p, pr. Ho H 0 .-3 0 H 3, 0 H I 3 3. nr 3,H.3(--)00n ,-3:i,0401-30,-3,P,3,..30 .3pFinano 3'3,nr-1 a n .3 ,--3 0 0 0 0 0 0 0 r- .3 ,--3> . 3 H H 0 n o H ,r, > 0 ,-3 .-3 n a .3 o n n ,--3 0,-3,-3,3,--30.-3.3a3'.3aHHog0:va,0n3'a.oaa3'0.ona '-a3 G3S . .- 3.-3 1 Hn Ha ra 1 . 'c- ) ' -/ G - ) an Hn . 1 H, 3 n> Q. - 3 2 ' - 30 n P., r3S . .. D ' ' 30 1 H9 ,- 9 P. 5-' ' ' . G )9 , 8 C'n 3. 0 H .-3 33' H H 0 n n n ,-3 :1, ..3 3. 3')' 0 H 0 0 0 P. C))' H
0 P 3, n HHHn.3.30.3nr H5.0Hagp.3 0.3,--1nRn,R4-)04-)on -3().-3() H H 3, ..3.3n.3 nran.loani,1-3 .0,:vnn.--onn, .3 n cn Z hi HK) .ti 0 H
...I hi 0 X .11 t. k. HO
U H 01 730.-c..i.t.tx300t.0,ou3r3uu3 0 (C) 73733rI73O1:-.73cr33,ho .-3 En N
73H0t+-3,o07,,Ln<0.zit.-. kilo() H 0 Z P, C 0 0 0 (r) >, ,o ,31 a 41 '-33, W
trl H H cn H .11 H 0 L---. ( H 73 L--. r3 t-. En 0 '1 0 r=) t. 0 RI ft, Cn 0 N tr, C.) Cl) En OHNUNUNO 9=1 .3 Z .3 ),1 .-C En tt1 DJ z 0 En t. hi H H Lo icp y 0 id 4-) ki 73 oxZt-ipoot-itimat-,.311-10 HD-Jo*cit_-.Utri-I=.0 Cf. U-3 r. 73 30 X C x t", Lw. 730 (-'0 rii-V kl 0 Erl,r( .10 ED H W H C:1 ci It 71 En H En ,u 0 In Z ti ('3) C)'!) ,1:1 0, P.-. CA hi ti) 03) 73 H030I H'-!) ti0 r.f), t.tazH
0H ,t1 Z ti 'A (7) apttiNtIroc cn M 0 VI C ,cr t.-1 tzr H .3 Id rn x to it, og,cr3, ' ',, TiN 'R, .t. ,:i ,C-Z,,, -,1,,, , , , ? , ,, 2, i : , 73 -21,_3 ',1õ3 Fr , H tr.1 P.. NJ ICI 3, V, X X W N ..1 ,ci qi ati .3 L-. ti../ L-. 9. 0 0 'CI ,d H L-", t.i Z rd .t7 En 43 zi-ocooitooz thix 01z000IL00ZV3/13d AGTTCTTTTTCCCCCAGAGGGGAAAGTTATGTTcTGCAAATAGTGTGTGTCTTATTTTACTGTTGAACAGCAATTGCTA
TTTATTTT
TTTATTGCCTAGAACTTCAACATGTTGTATAGGAATCCTGTAGTGCCACTAGTTAAATGCcC-AATTCTCATCTGGATGTTACCATeA
AACATCAGTACACTTGTCATTTCACATGTGTTTAATGTGACAGTTTTTCAGTACTGTATGTGTTAATTTCTACTTTTTT
TAATATTT
AAAATTGCTTTTAAATAAACATATTCTCAGTTGATCCC
c.4 n.) CO
co cp n.) rn cnni n.) co n.) rn 0) SEQIDNO.:22 SEQIDNO.:59 CITCCAGAGAGCAATATGGCTGGITCCCCAACATGCCTCACCCTCATCTATATCCTTTGGCAGCTCACAGGOTCAGCAG
CCCGTGAAAGAGCTGGICGGITCCGTIGGTGGGGCCGTGACTTICCCCCTGAAGICCAAAGTAAAGCAAGITCACTCTA
TTGTCTGG GPVKELVGSVGGAVTFPLKSKVK
w ACCTTCAACACAACCCCTCTTGTCACCATACAGCCAGAAGGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGA
GAGTAGAC QVDSIVWTENTTPLVTIQPEGGT
TICCCAGAIGGAGGCTACTCCCTGAAGCTCAGCAAACTGAAGAAGAATGACTCAGGGATCTACTATGTGGGOATATACA
GCTCATCA IIVTQNRNRERVDFPDGGYSLKL
CTCCAGCAGCCCTCCACCCAGGAGTACGTGCTGCATGTCTACGAGCACCTGTCAAAGCCTAAAGICACCATGGGTCTGC
AGAGCAAT SKLKENDSGIYYVGIYSSSLQQP
AAGAATGGCACCTGTGTGACCAATCTGACATGCTGCATGGAACATGGGGAAGAGGATGTGATTIATACCTOGAAGGCCC
IGGGGCAA SIQEYVTEVY7HL&KPKVTMGLQ
OCAGCCAATGAGTCCOATAATOGGTCCATCCTCCCCATCTCCTGGAGATGGGGAGAAAGTGATATGACCTTCATCTGCG
TTGCCAGG SNKNGTCVTNLTCCMEHGEEDVI
AACCCTGTCAGCAGAAACTTCTCAAGCCCCATCCTTGCCAGGAAGCTCTGTOAAGGTGCTGCTGATGACCCAGATTCCT
CCATGGTC YTWKALGOAANESHNOSILPISW
CTCCTGIGTCTCCTGTIGGIGCCCCTCCTGCTCACTCTCTTIGTACTGGGGCTATTTCTTIGGITICTGAAGAGAGAGA
GACAAGAA RWGESDMTFICVARNPVSRNSS
GAGTACATTGAAGAGAAGAAGAGAGIGGACATTIGICGGGAAACTCCTAACATATGCCCCCATTCTGGAGAGAACACAG
AGTACCAC PILARKLCEGAADDPDSSMVLLC
ACAATCCCTCACACTAATAGAACAATCCTAAAGGAAGATCCAGCAAATACGGTTTACTCCACTGIGGAAATACCGAAAA
AATCCCCACTCACTGCTCACGATGCCAGACACACCAAGGCTATTTGCCTATGAGAATOTTATCTAGACAGCAGTOCACT
CCCCTAAG RQBEYIEEKERVDICREIPNICP
TCTCTGCTCAAAAAARAAACAATICTCGCCCCAAAGAAAACAATCAGAAGAATTCACTGAITTGACTAGAAACATCAAG
CO
cn AAGAAcGTTGAcTTTTTTccAGGATAAATTATcTcTGATGcTTcTTTAGATTTAAGAGTTcATAATTccATccAcTGcT
GAGAAATc ANTIryszwEiplacmENplisLLTm TCCTCAAACCCAGAAOGTTTAATCACTICATCCCAAAAATGGGATTGTGAATGTCAGCAAACCATAAAAAAAGTGCTTA
GAAGTATT PDTPRLFAYENVI
CCTATAGAAATGTAAATGCAACOTCACACATATTAATGACAGCCTGTTGTATTAATGATGGCTCCAGGTCAGTGTCTGG
AGTTTCAT CD
CO
TCCATCCCAGGGCTTGGAIGTAAGGATTATACCAAGAGTCTIGCTACCAGGAGGGCAAGAAGACCAAAACAGACAGACA
AGTCCAGC
fli AGAAGCAGATGCACCTGACAAAANIGGAIGTATTAATTGGCTCTATAAACTATGTGCCCAGCACTATGCTGAGCTTACA
CTAATTGG
Cn TCAGACGTGCTGTCTGCCCICATGAAATTGGCTCCAAATGAATGAACTACTTTCATGAGCAGTTGTAGCAGGCCTGACC
ACAGATIC
CCAGAGGGCCAGGIGTOGATCCACAGGACTTGAAGGICAAAGTTCACAAAGATGAAGAATCAGGGTAGCTCACCATGTT
TGGCAGAT
rn ACTATAATGGAGACACAGAAGTGTGCATGGCCCAAGGACAAGGACCTCCAGCCAGGCTTCATTTAIGCACTTGTCCTGC
AAAAGAAA
AGTCTAGGTTTTAAGGCTGTGCCAGAACCCATCCCAATAAAGAGACCGAGTCTGAAGTCACATTGTAAATCTAGTGTP.
GGAGACTTG CO
GAGTcAGGcAGTGAGAcTGGTGGGGCACGGGGGGCAGTGGGTACTTGTAAACCTTTAARGATGGTTAATTCATTcAATA
GATATTTA
n.) TTAAGAACCTATGCGGCCCGGCATGGIGGCTCACACCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGTGGGTCATC
TGAGGICA
rn GGAGTTCAAGACCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAGATACAAAAATTTGCTGAGCGTGGTOGTG
TOCACCTO
TAATCCCAGCTACTCGAGAGGCCAAGGCATGAGAATCGCTTGAACCTGGGAGGTGGAGGTTGCAGTGAGCTGAGATGGC
ACCACTGC
ACTCC'GCCTAGGCAACGAGAGCAAAACTCCAATACAAACAAACAAACAAACACCTGTGCTAGGTCAGTCTGGCACGTA
AGATGAAC
ATCCC
ACCAACACAGAGCTCACOATCTCTTATACTTAAGTGAAAAACATGGGGAAGGGGAAAGGGGAATGGCTGCTTITGATAT
GT
TCCCTOACACATATCTTGAATOGAGACCTCCCTACCAAGTGATOAAAGTOTTGAAAAACTTAATAACAAATGCTTOTTG
GGCAAGAA
TGGGATTGAGGATTATCTTCTCTCAGAAAGGCATTGTGAAGGAATTGAGCCAGATCTCTCTCCCTACTGCAAAACCCTA
TIGTAGTA
AAAAAGTCTTCTTTACTATCTTAATAAAACAGATATTGTGAGATTCAAAAAAAAAAAAAAAA
< Or X H Z En ,-, A 00HACJHcn ccl 0 Z H
CONHZ.IZE.ON
0 camea4H.car, a , cog z n fa E1E < W, W. Ei, o. KrOxH,.-1 ri) r4 En Kt: PI fr, 2 ril 2 .1 44 qD
.= a a, E. a, a. fl, Q .1 = .1NMAC=1 = (El Co M c). la, M .1 .4 = a x a, c4 a4 u) 0 w a, to n 0 a, u fa 0 Z
n H A a, w H E. n o ci) a H OZZXP.Q
0 z q E. DI u) cn C. .1 H 0 rc..DZMC.1 41 0 Z Z =< Z 0 cc) .1 0( 41 3 A .4 0 ul O000H0H<UN<DHU<0E. u < < < E-, 4 E.
CJUUCDuU0E.
0 0 C) 0 UE-10,04E-EU0E.
U 0 00E-.4 0000/U/E-./ ..eUN Er4U 0<u<4U4F-.
U<E..)00(!),,E.E.L) UOU E. E. uUU0Kc0E.F.
00000,-CE-1000(..)<0 C.)0004.0/0,<E-,40E-.P FEE, A, i= C-.) U 0 < C.) 0 E.
0C)H<V9aE.
NUCJOCDC)<U0NE.,<HE.0 4 0 <00U ()KEE.
0 0 0 4 4 KCD0CJKCE..<00UH0 U<CDE. c.JHrg 0 0 0 0 U U N a CJ < 0UHNOUH0, 0 0 U a E-( C.) U
(JOU u(.9 0 C.) E. U N < U 0 E. 0 0 E. C.) <
ULDUE.UUE.
00000C.JHUCJE.<0E.C.DCD<H 0 0 0 D < E. E.
000 CD H CD E. H E. E. 0-1 < u 0 < 4oug4 UU0000E.0 U 0 E. uogouoo-04 E. U 4 E. E. C.) 0U0<0E-.0E.
UUOciu<<EDU 4 E. c) Pg 0 U <
U U E. H a 0 E. E. a C.) KC E-.000,<E-, U Cr E. E. 0 U E-, 0 CDCDU<CDHOH
U U CJ H 0 a, OUUOUUUNKt CJUE.U0aU a; u 4. ,--C E.CDUE.CDua a. E, U CD 5 o u f-, gl, O 0 0 .4 u 4 E--+ 4 04 0 u 4 E, 0 CJ CD E. 0 C.9 u CD 0 C.) CJ 1 el 0000c.JaNUCJOC.5<<<<<e) E. HOHHHU E.
0 U U < E.-, 0 UE.U00(.9,<<WV/<<04c_) E. C., 0 < E. 0 E. 0 0 E.
our,uogoor401, Q U E. E. 0 0 E. E. 00H00UE-EP
(.9,i i CD U H U 0 F U D
O U U CJ a a, CD E. U E. U E. E. 4 F CJ 0 HUUCU0Ha U H<H CD E.UKC<KC E. 4UU H E-, U<EJ
UUu/< U00/
< / U ci 04V4o4U.CFu u 4 L h (..) F .5 U 4C1Uu4u4,u E-4 E. cD a E. E. < 000aa E.
0 F.
000000Hu OUOUCIOUU
O C.) < U < < 0 < < E. U u < 0 E. U U E.
U 0 CJ U U E. 0 O E. 0 H 0 0 < H H U 0 < o < < o < <
0000 E.) 0 F.
ED E. U U U E. pr, 0 KC CD 0 0 H E.
OUU000E.E.
E 0 u4DourcuouE,d, f,u i 000E, O E, u E-1 u 4 U 4 0 4 U / / E. E. cl OUU0cHU
O 0 C.) E. 0 0 E.) E. E. / uuUC.)01 UHE.
0 U U CJ E. C.) 0 0 E.
O U U E. < U E-1 0 E. U U < F. 0 E. 4 F.
E. 0 F, 0 E. 8 , õ E-. 0 E - - , c _1 F 4 H E. c.,), 0 E. E. 0 E , U ()C./UE.(700U
CD U C) C.9 a U a, D E.E. .a. E. U E., U U .5 E. E-, u u0r400,-4040E,E, 040 100,0-4 0U00,<<UH0 9 ,c u 0 u u E-, .i. 4 EJ E.) U 4 E. 0 CJ 4 L. in 0 V U E. KC
0UU<00UKO0N00DE4 4 0 yoE-.4,400444P,440 of-,,,S 000E-.0o4 U E. 0 u < E. E. ti 0 0 0 E. 0 U E. E. E. 0 u CD 0 C.) H 1) U <
U u 0 < E. < c..9 0 H0000U000 z-,0E,00E-4441 Ci 0 Ci 0 E-4 < < 0 E-, E. CD U KC C.) 0 0 <EJE-.0U
/ 00H-4E-.000E.
UOU<UE.E. a c..) U E. E. < H U 5.
CJ = < U E. 4 0 U U < u H E. E. 0 U U U U CD 0 E. u Ou<N0a0DE.C.DHCJUNE. ,a, 0 o 0-,4u00E,00u 04 0 0 4 <u<a1H,4000U0U0a4 0 0000 E.0 E-. 0 OurJuKeuE-.0E-.0U<H<HE.E.0 000,<0E.u40 0000000HE.
uU00 8 4 4 H 0 ONUCJNOUNOUNC)H00_. 4 6 Uc..)<E. OOP
Ci <
DuUNUNaHH0000E.HH KC 0 U C) E. C., CD 8 0 U U 0 E. 0 C.) a, 0 U) 0 E. D U 0 CD E. 000 H H E. ,1 E. E. U E. U U E. C) 0 4: 0 0 .g 0 0 A: F, ,1 000 00F4 ,E, u (3 4 El 4 < UE-40 0 0 00 < 0 <0< U 004; < 00 (JO< E.< H U000UH<0E-, U U U C.) 0 0 CD .<
= 0= UC.)0CJUUUC700KCU<<EHE.CD =
0 OHOOUH<U0E.HyHOUHE.F. 0 000 E.U-KHE.
2 uu 0E--,(JE-00¶Jogt, E.00E.E.H Z U(1)0 U,40E-,4 q 0 0 0 U 0 0 U < < E. < 0 E--, H .< 4 E. n of:Jo 04)0p, H F<HUU< UOUCJOHE.HUHU H UUE, 00UE.E-, 0 UOUUOU HE.H044HUOUU 01 4U<O0UE, < 0 C.1 404000 444H0004E-t-,0 w 0rf:00E,0u40 En 00u000 0 H E. E. 0 CD U H 0 < < cr) U 0 < KC < E. CI E. E.
SUBSTITUTE SHEET (RULE 26) SEQIDNO.:15 SEQIDNO.:62 CGGTGGTTGGGTGGTAAGATGGCGGCTGTGAGTCTGCGGCTCGGCGACTTGGTGT.GOGGGAAACTCGGCCGATATCCT
CCTTGGCCA MAAVSLRLGDLVWGKLGRYPPWP
GGAAAGATTGTTAATCCACCAAAGGACTTGAAGAAACCTCGCGGAAAGAAATGCTTCTTTGTGAAATTTTTTGGAACAG
AAGATCAT GKIVNPPKDLKKPRGKKCFFVKF
GCCTGGATCAAAGTGGAACAGCTGAAGCCATATCATGCTCATAAAGAGGAAATGATAAAAATTAACAAGGGTAAACGAT
TCCAGCAA FGTEDHAWIKVEQLKETHAHKEE
GCGGTAGATGCTGTCGAAGAGTTCCTCAGGAGAGCCAAAGGGAAAGACCAGACGTCATCCCACAATTCTTCTGATGACA
AGAATCGA MIKINKGKRFQQAVDAVEEFLRR
CGTAATTCCAGTGAGGAGAGAAGTAGGCCAAACTCAGGTGATGAGAAGCGCAAACTTAGCCTGTCTGAAGGGAAGGTGA
AGAAGAAC AKGKDQTSSHNSSDDRNRRNSSE
ATGGGAGAAGGAAAGAAGAGGGTGTCTTCAGGCTCTTCAGAGAGAGGCTCCAAATCCCCTCTGAAAAGAGCCCAAGAGC
AAAGTCCC ER'SRPNSGDEKRKLSLSEGKVKK
CGGAAGCGGGGTCGOCCCCCAPAGGATGAGAAGGATCTCACCATCCCGGAGTCTAGTACCGTGAAGGGGATGATGGCCG
GACCGATG NMGEGKKRVSSGSSERGSKSPLK
GCCGCGTTTAAATGGCAGCCAACCGCAAGCGAGCCTGTTAAAGATGCAGATCCTCATTTCCATCATTTCCTGCTAAGCC
AAACAGAG RAQEQSPRKRGRPPKDEKDLTIP
AAGCCAGCTGTCTGTTACCAGGCAATCACGAAGAAGTTGAAAATATGTGAAGAGGAAACTGGCTCCACCTCCATCCAGG
CAGCTGAC ESSTVKGMMAGPMAAFKWQPTAS
AGCACAGCCGTGAATGGCAGCATCACACCCACAGAMAAAAGATAGGATTTTTGGGCCTTGGTCTCATGGGAAGTGGAAT
CGTCTCC EPVXDADPHEHRFLLSQTEKPAV
AACTTGCTAAAAATGGGTCACACAGTGACTGTCTGGAACCGCACTGCAGAGAAATGTGATTTGTTCATCCAGGAGGGGG
cn GGAAGAACCCCCGCTGAAGTCGTCTCAACCTGCGACATCACTTTCGCCTGCGIGTCGGATCCCAAGGCGGCCAAGGACC
TGGTGCTG ADSTAVNGSTTPTDKKIGFLGLG
GGCCCCAGTGGTGTGCTGCAAGGGATCCGCCCTGGGAAGTGCTACGTGGACATGTCAACAGTGGACGCTGACACCGTCA
CTGAGCTG LMGSGIVSNLLKMGHTVTVWURT
n.) CO
GCCCAGGTGATTGTGTCCAGGGGGGGGCGCTTTCTGGAAGCCCCCGTCTCAGGGAATCAGCAGCTGTCTAATGACGGGA
TGTTGGTG AEKCDLFIQEGARLGRTPAEVVS
cn co ATCTTAGCGGCTGGAGACAGGGGCTTATATGAGGACTGCAGCAGCTGCTTCCAGGCGATGGGGAAGACCTCCTTCTTCC
TAGGTGAA TCDITFACVSDPKAAKDLVLGPS
GTGGGCAATGCAGCCAAGATGATGCTGATCGTGAACATGGTCCAAGGGAGCTTCATGGCCACTATTGCCGAGGGGCTGA
CCCTGGCC GVLQGIRPGKCYVDMSTVDADTV
CAGGTGACAGGCCAGTCCCAGCAGACACTCTTGGACATCCTCAATCAGGGACAGTTGGCCAGCATCTTCCTGGACCAGA
AGTGCCAA TELAQVIVSRGGRFLEAPVSGNQ
AATATCCTGCAAGGAAACTTTAAGCCTGATTTCTACCTGAAATACATTCAGAAGGATCTCCGCTTAGCCATTGCGCTGG
GTGATGCG QLSNDGMLVILAAGDRGLYEDCS n.) Cl) GTCAACCATCCGACTCCCATGGCAGCTGCAGCAAATGAGGTGTACRAAAGAGCCAAGGCGCTGGACCAGTCCGACAACG
ATATGTCC SCFQAMGKTSPFLGEVGNAAKMM
GCCGTGTACCGAGCCTACATACACTAAGCTGTCCACACCCCGCCCTCACCCCTCCAATCCCCCCTCTGACCCCCTCTTC
CTCACATG LIVNMVQGSFMATIAEGLTLAQV n.) GGGTCGGGGGCCTGGGAGTTCATTCTGGACCAGCCCACCTATCTCCATTTCCTTTTATACAGACTTTGAGACTTGCCAT
CAGCACAG TGQSQQTLLDILNQGQLASIFLD
CACACAGCAGCACCCTTCCCCTGAGGCCGGTGGGGAGGGGACAAGTGTCAGCAGGATTGGCGTGTGGGAAAGCTCTTGA
GCTGGGCA QKCONILQGNEKPDPYLKYIQKD
CTGGCCCCCCGGACGAGGTGGCTGTGTGTTCACACACACACACACACACACACACACACACACACACAGGCTCTCGcCC
CAGGATAG LRLAIALGDAVNHPTPMAAAANE
n.) AAGCTGCCCAGAAACTGOTGCCTGGCTTTTTTTCTTCCGAGCTTGTCTTATCTCAAAcCCCTTCCAGTCAAGGAACTAG
AATCAGCA VYKRAKALDQSDNDMSAVYRAYI
r¨
ACGAGAGTTGGAAGCCTTCCCACAGCTTCCCCCAGAGCGAAGAGGcTGTAGTCATGTCCCCATCCCCCACTGGATTCCC
TACAAGGA H
=
GAGGCCTTGGGCCCAGATGAGCCAGTACAGACTCCAGACAGAGGGGCCCTTGGGGCCCTCCAACCTCAGGTGATGAGCT
GAGAAAGA
cn TGTTCACGTCTAAGCGTCCAGTGTGCACCCAGCGCTCCATAGACGCCTTTGTGAACTGAAil_AGAGACTGGCAGAGTC
CCGAGAAGAT
GGGGCCCTGGCTTTCCAGGGAGTGCAGCAAGCAGCCGGCCTGCAGGTGAGOATGGAGGCCCGGCCCTCACCGCCTCGAA
GCCATGCC
CCAGATGCCACTGCCACAGCGGGCGCTCGCTCCTCCCTAGGCTOTTTTAGTATTTGGATTTGCATTCCATCCCTTGGGA
GGGAGTCC
TCAGGGCCACTAGTGATGAGCCAAGAGGAGTGGGGGTTGGGGGCGCTCCTTTCTGTTTCCGTTAGGCCACAGACTCTTC
ACCTGGCT
CTGAAGAGCCACTCTTACCTCGGTCCCCTCCCAGTGGTCCCACCTTCTCCACCCTGCCCTGCCAAGTCCCCTOCATGCC
CACCGCTC
"''r'ATCCTCPCTCrTrTCrCTCTTCCTCCCGTGGAGACAGTATTTCTTTCTGTCTGTCCCTTTGGCCCAGACCCAGC
CTGACCAACG
ATGAGCATTTCTTAGGCTCAGCTCTTGATACGGAAACGAGTGTCTTCACTCCAGCCAGCATCATGGTCTTCGGTGCTTC
CCGGGCCC
GGGGTCTGTCGGGAGGGAAGAGAACTGGGCCTGACCTACCTGAACTGACTGGCCCTCCGAGGTGGGTCTGGGACATCCT
AGAC-GCCC
TACATTTGTCCTTGGATAGGGGACCGGGGGGGGCTTGGAATGTTGCAAAAAAAAAGTTACCCAAGGGATGTCAGTTTTT
TATCCCTC
TGCATGGGTTGGATTTTCCAAAATCATAATTTGCAGAAGGAAGGCCAGCATTTACGATGCAATP_TGTAATTATATATA
GGGTGC-CCA c.4 CACTAGGGCGGGGTCCTTCCCCC CTACACAGCTTTG GC CCCTTTCAGAGATTAGAAACTGGGTTAGAGGATTG
CAGAAGACGAG TGG
GGGGAGGGCAGGCAAGATGCCTGTCGGGTTTTTAGCACAGTTCATTTCACTGGGATTTTGAAGCATTTCTGTCTGAACA
CAAGCCTG
TTCTP_GTCCTGGCGGPACP_CACTGGGGGTGGGGGCGGGGCAAC-ATGCGGTAATGAAACCGGTTAGTCAATTTTGTCTTAATATTGTT
GACAATTGTGTAAAGTTCCTTTTTATGAATATTTCTGTTTP.AGCTATTTCACCTTTCTTTTGAAATCCTTCCCTTTTA
AGGAGAAAA
TGTGACACTTGTGAAAPAGCTTC-TP.AGAAAGCCCCTCCCTTTTTTTCTTTAAACCTTTAAATGACAAATCTAGGTAATTAAGGTTGT
GAATTTTTATTTTTGCTTTGTTTTTAATGAACATTTGTCTTTCAGAATAGGATTGTGTGATAATGTTTAAATGGCAAAA
ACAMACA
TGATTTTGTGCAATTAACAAAGCTACTGCAAGAAAAATAAAACACTTCTTGGTAACACAAAAAAAP-AAAAAAAAAAA.k 0 cn n.) CO
co cn n.) r r n.) rn co n.) rn ct) 1,4 C) 0 4E44 cna a FAH 4 4 ca OH
E.FFC>..U(Drtu)0 H>Og CYcnW.lOrr.-.4E3 a In t-1 r4 ft, 0 L-10,Cr:1>.-41X
>. -4 4. ot ri) 04 al E....4a cn A w a EH .. H r...
ti, x > pa. 4 01 1-1 0, a PI
0,4 > E.C.Da al -t AHHaHaa HS,,,CaE,ZHE, W
En 0a0 CD
Hanar.µ,EHE1>p4nE.Ocnr44cnop%arx.-fataa.-1 0 a. 4E1,01-10r., A =1AXE-,x0,--,vraomp c4 4ucn o c.r1 E-4 41 0 E-, aHr=.0 tae,0 HP-.20)01-,00 ..
r..10)0lHata0 E.C1011.CJaaa01,4.,S.a H ChHa S.H0>a,00a0 a aHN
2 '' 1 S ,, '8, 'C4 P-, PI l'F'4 r3"' '.' 2 cl ECD' 'al .2.1 f;4' 2 g 1 . PI ''' 0 0(aqn L, >4 >4 Fifil00(/)1:4>=' E, KC H 4 0 a CY a gq>Nr.,r.arr,cnr:d ci¶..H1-1 ara r.,-) Hvj )-1 o Cl) U W I HO) C.DC.DOHC,,,4 4 0,510H a ?00,01-101:) VD 0 PI4 W I-I PI 0 01 CP g rZ4 r,u)MOOmar EnZa$1,00NI--1,4 14 01 a 01 0 a a 4 .-1 4 a a Cl) CD X CD ci> H
CD fLi a a 4 2 H
= a a Ed E. E. a E. 0 4 a S-t x 0 ul .. po 0 E. S. A
actli...
0 C., KC U 4 Z 01 r a vl 0 Kt CDPF.1.-1 OH 00) Z P4040) r44,,ia QHF4ox F. .4 pc.DcDMCD4aWaEn A
H Hi:i' EY,1 P44EU.3. 2 rti (I V, `,_.1 r,'n4 F61, CO 'I? EC
5. 8 F c) 1 2 O. 21 _ 0, g 4.1 ci, ci, 0, u, 0, ,-4 H D., 0 . . ,..., cy z 0 cn p En a n 44 E.r.1 >,,10> CP t-I 01HHaF-1,0,fr,aZ0Howaa?Haa awn;
Ca Ca F. cti 0 0 U a H 0) a 4 .- n w x En a Z t4 0 ua >, 1=1 ci ..> 0. 4 0 u) Cl) _ 00 CD HUHHU H4U4CDUE.,4 000CDUOUUHHHE.PCD
00004a: E. E. HOHUOUCJu 0000 CDKCH HOE,E, F. 4 E.
4HHULJUOU<CDP,HOUUOU0OUCDUUCJHUUCJUKt 000 CDE,Pt 40 OHaHauu0a0 E.,4 HUHOCDU 4 (Duo 000000o4UUaa0u0a0<uuua0augtE.044 outpououu uu4E.oucDUUU0E.000,11UH 4 4U0 000E.F4 400 4004 4 4F.c.JOUHE.C9cDE.40 0-' C) UCJE, 0E,UeU0.40:0C.JHUE-t4000.040u4.44u4u uu u0(.94r..1(9Uu.440o0u040Huociouougu u4_. CJ g E, CD E, 4 A A U F. a:
F. 4 E, u H E. F. a: E, H U 4 E, 0 4 gOuE.404 4 00 Fl,c7CJO0C.DE-.401,UcJuUcJU HOC) 00 CJOUOCDU UU OCDUCJOgCJOUE.CDOUE.UHUU0 0 F. 1, 4 a: E. E. EH 0 EH
H E., u, < EH U H. a. 4 E. 4:g0U00I:t.
0Ha00E-100Uu<H a uOuuH,EHUHHaa0,<Hu H. 0 H a EH a EH g E-iHOUCJUUE-.E.UOCJOE.W0E.UuC, 0 0 0 H Q 0 CJ 4 .4 4 H U 4 U U C., 4 0 U E. KC F. 0 0 0 E. H E, U C., 4U044 A 00 .40,E,000H 40 HOE.DUCJUUU0 0 E.E.H
OCJE,004,40a,AE,E.T_DHC)u000F.CDC.DHUUHUUUE, HHUHOU0.4 PC HE' OH HE.E.CJUE-tHOOVJU
.4E-.0000,4CD UAL CDOHCDF.F.000000H4 HO HOC) CJU KFCUUCJOU C.,04 H4 4HuuE.0E.00000uuu.40 F. U U U CD C_D E. E. E. 4 E. H a, CD 0 E. U U C.D CD U 4 g o g5 uEH<E, 0 0 a 0 H EH 0 E a a EH E-, 0 0 0 a EH H. 0 0 a 000 C,,0 HOC) g 4 PC 0 0 0 u EHUDaUUHOUUE_IHoUUEHEH 00000 HUH< F4 AHU U0O<HUHEHOEHHOUCDE,HU 4F. 004 u44000HHOOCDOE,HUOHOPUHOHUg 0 CJ (DOC?
EHOqouou0 CJE-.E.OUCDUE,UOUUCJCD 0 OA 0 0 uuy E'e(JP:.:4;EHUaEHre.uHauF,a0.4()EDUE.a, PH Ftgu 00 .10C-Jua,E, 400CDE.F.F.0 UUU<HUOU00.4 U00 CJ cD a U U 0 0 U U 1.-. 0 0 U U E. OUuH, 0 CJ U E. (...! CD U E. I, E.-.
4: g dU4CDE,4 CJUCDPOUU4 U00 Kt E,00,1,4 0 U
00 CJut-44.---,0,4004F4HANCDOCDUOFPCUE,CJ g U
HO CJOLDu0,40u E. E-,UUCDUC.Dc.70000CDUU 0 04 0K4UE,HUHLJUHE. 0E-.40U0CDa:41.204F.CDCD
5 (9 5 F. CD U CD 0 E. 4 a' 4 4 -4 H a: E. 0 CD 0 cD H 0 U 0 a a H a U E.,.. Hgg g:g 6 UOUCDCA UUFFC E.U00004 CJOUOuHU 0 0000 El U u Ft, U Ft u 4 E. U E. 0 0 0 ,...) U
CD CJ g 0 E, U U Ci U E. a E.-, g: g0ug06 E-.00E.4400Uu0E.ouE.4uUu0u u 4 0 u 0 0 4 E. E, a: 0 0 U U C., g U E. U H
U C-, E., C... CD u ug cDHUUUHUE--tet HUOH 4 HUHOC.DUHOUE. H CDE-.0 HO OUVUOE, KCKCE...a 40HUE.HUCDOOKCUOU H 0.40 [JO E.UUUHE,UCJUCJOUOU C.DUK4 0004E-, 0 U00 O H CD E. 0 E. E. .. F. E. CD a, U
H KC a; 4 6oci0E,H.,HE,06,H0 E-, 8000E, Huuya0CDUH ouc..900auuaa0 0 u CJUOUUCDHU5 0 H, H U u C9 0 u u U u u u 0 c_, E-,E;
6 6' ',;` 8) ,') 8 E-' t,"0 6 8 Ec; '4 8 6 6 (,-p) ,tt' 6 8 6 8 t-i it, 6 ., 8 HO 0UCJE.DUUg U000HyuUCDUOCDNE.H. c..),p(õJ 5 p OH H U U Kt CD CJ 4 H 4 U 0 4 c, 0 4 4 0 CD
N 0 E, V. ,I. 1 Y 71.3 ,,...; L-6, OHOyOuCJHU Kg Ug 0 rz.,00 E.CDOUOUgg ,4, V
4 E.CDCJOUU CJOUUCJ E-I 0 0 U C.) U 0 U 0 0,<U0uHuuu O00,<EHuuEHEHu0U0HaL)Ha0H4EHE-<:HHHV 1 5 O 0 Hoc) 5 E.E-,c)0 c. HouougH04uU4HUHu004 E-1 A:guE.0Uu0OugUoHuu0E.uuuguHuuu 40'u OH u0E.Horc guuugt.gu .4E.00E,H1D1HOE-.0 u CJF.E.UUHUU0 CDUOLDUCDCJUHo_40E.uu uouu 0H0 C., 0 0 V 0 U F. 4 CD 1, u F. 0 E. U u u UE-,C9IJU C.,HOU
0U4044HE.444u4,E,CJUOUCJHE-,ggg00 0 0 g 4 OE.a000440004 guE,04000000H000HOE.
C-; E. U HUU00 E, 0 E, 0 C./ CJ 0 0 0 V E, U U 0 OUEHHOUHL) aUUOUUHEHEHO<UU0HEHOuE, r' OH H HO 0 rc ,I HO
gg0CE,gergU0g0H0CD5U0000HUgggUE-.5, Fa, U E--, UK,HHHUCJUE,E.HgEHEHEJUEDHHauurJUUUuOUC9 0 u 4 U U U. 0 u 0 0 U U E. 4 4 E, U 0 U u U U CD 4 4 a 0 a a EH
E-,oHauUH E-1 E, U 0 E.!) E-, 0 g CD g 0 0 g CJ gg g a c.9 o cp g Pc u UgOUUUg E-, HUHEHUHUEDUUEHOUu0uUgC70Hrg U E, Kg 0 0 0 C.1 E, U 0 Ft E. E. U E. H F, E-, 4 H 0 F. E. CJ E. 0 H. g 0 E, E-, 0 g .-4 0 E. E-, 0 0 g g g U 54 U 0 4 0 u 4 u E..) E-, 0 0 0 0 4 0 Huouuou000uu0guuguH00000c-,00E-'06 u 0 F. g U E. 0 4 E. 0 CJ a: 4 U E, 0 A F. 0 -4 H 4 0 4 u K4 EHEH0 E, 0 (I) E-, a U 0 u E, 0 U 0 a a EH a 0 U H -a a 0 0 u o a ci E-, 0 0 Uri:0 00 u k c.) 0 E-, u E. 0 u ci 0 u ULDUC104000Uou 00HS,UHaCJE-HaEH/aEHUaUE-,040 HE.E.E.UUE.0 440o4ciouE.F4 0E,gUt..70H0g 00CJUgUOU
UCJUHE,CJUCJUgU 00E,OC.700000-10000UHOU
U H 0 CD c..) H E. 0 0 U E. F. 4 E-, U E. 4 E. 0 0 C., 0 CD H KC 0 E. E. E.
to E. E. 4E. E. E. KC Ks: 4 1, 0 E, A 0 U 0 KG C., H CD U 0 E. U CD CD H
U U U
H 0 0 CJO 0 Ut..10 000,gC9E,E.J00 CJOE-, 40 QUO UCJUOC.) O H 4 4 u 0 E. u E. U 4 4 F. U 0 0 E. 4 0 5 0 (9 E. u E. E-I 5 U E. U
= H0000HUUUCDCDCDUOHCDKCO4PCOCDCJg0-IUF.CHUH
0 HUgucpuu 5 UE,C1g4UC.9r E, UKCCõDOULDOUCJOEJOU
O UHOgHHHUgg ...COE, OUOHOE,gUE,E,CJUE, C) V VOE'VUE,g00-g u 5 5 ,t 5 5 c. E.,40U4OUCDHE.
H g VE--.UUg0C9UUHOUUE,00U0HUOHOU gE, 000 CO HE,E,HUOPH H E-.KCC1E-10000gE,E,UgE.(7OUgU
PI 0 0 0, U H 0 0 U E. F. H 1-. E. E. ..< E. 0 0 CJ U 0 0 U 0 g g g Ii) g gC-DUOUHU, 0E,f, E.) . 0 gu 00gg 4 E-, E,0000u SUBSTITUTE SHEET (RULE 26) 41 4, P) C!) H c,i H HE-'> cr) fl, in < ri, 0 ora, ozoit_1õ1õ,,,120.-g.a,41a> H >, pk: cr) g .' ', 4 9 ti F4 1:4 c`-=1 tia cr;' 6 gi '8 0 0 H E-, R. H 0 H Op cr) rg 0 u) H H CD
.-1E-, Urr.1,--1)-1C10140zHENEAHM.-1Z
CDH,1E1 caxpc9r.,,,g1 cl.,irni=11<
0 C. ZZ 44 .4 tg .1E-.1., a, ,--1 0 4. c=1 .-D.L.-.P4,0g EnE.c/22>HE-. <<UZE, ,-)P1 õ-,--'1,4a,C7HD4H<grx-, WHOOF-(H.-1%
=tr),-1(1HH.-Ice,x(00100H<MNE-.,-IZL4 H 1 c.) .-1 H 0 U fa, H, Cl >.,n õ,,,E, 0 0) 1,) 1-1.H Ho)?-,OHHa, Cl) Cl 0)0 4c. 0) g I-4 >-, P.
VI U 'Kg CI 4.4) X r-41 p to > U A cal > frG ul 0 P,, 0. :. 4. .f.go.,ixoa> c,r)cd7 µ24,-.1a. Ch rtiCDH E-, ',-.1 > Cl Cl) z.9 x 1:1, 5,1134,111,0F,401,4r4E. H H (1)Ilt[1.1> H H C.1E-.
1 E-1,3,4u)4 gC 0.-Ivn?-.uir., a; ,cy H G4D
01,404 u) U)E.4 u) ..> C.) > OH LD E-, 02 E,E,., >-,CDE..,4X1-t00u)00 a >0 Ptr.,44..u) p4HH H .altno+Hr=4,-10.,E-4 E,H.E-,-,H a-.0-,0 HHHH:1)cni-11-.10,a-,01 CiL)C)<<CDHUE-,<HuquHrrHEJOUOC),<
4 4 4 0 4 E-,UH<<C)<<UNg .4 UE. E. H K:0 0000 OUUUCIUHUgg UH E-.."4,4:ETIU 0 0 E. E-.C5g a a E.,<UUUUE-,C7CDUUCJOg0 < E-, < U 0 < E-. C) E. U g U C) E. 4, E-, E-, E. 0 0 0.1; E.
C9 40 UOUOULDUCJE,<E,<U0CDOCICJH
g < a: g U E-, CD E-t U e, u 0 H E--, E-, C.) E-, pG E-, H 0 0 () uguUUCJOCDCJUE-,HCD<HE-,E,<CD0H,0E-, U 0 ,4 r- USD(.9 Cl C.) E. r.4 U, 0 d E. E-. 0 0 < 0 0 E. ci C.) < g 0 < H < 0 U 0 chd KC UH 0 < 4 E-, H 0 H cD
000uUcho,CH<CJE,u<a:E-,QUCDHgc..) U
C)HULDUCJOgUITgc E-. JUCDHOgHguC) u 00 < H UUH c.) 0 ...4 0 H,C.) E-, c9 PK 00 /:
O u 0 E-, U U < 0 ,g= < 0 N (--, U a' U
u F-, C.) 4, E.
U U U U U E. uUque0Hduut_!,F. of.) 0. U
O 0 0 ,,. E-, < U < a, E-, < 0 E, c.) E-, E, u 0 0 0 0 H
O < a: < 0 < < 0 g H 0 < IJ < H C.) E-, af, 0 Ei H <
f-, 0 C.) E-+ C9 CD 0 U U 0 E-, 0 E-, H H U H E, 0 E-, a, c..) u CDE-1(1,<<H,E-,<E,CDOC.9rchuOU<c)0(7 uchg CD<H,HuH<C7E, C.JCJHOE-,CD<<H
C.) H. E. 0 0 E-, 0 U C.) C) C9 H H. U E-, tg H
g 0 E-, <
E-,<E-,E.E.<<CJE.CD00HOE-,E,HuE-,000CD
E4b000UCD<O0U<U<HUU0CDE-10<g O 00 E-,HOHOE.000E.HUHE.U0 4E.
E. ti E. 4 a H E. E. gi E. U H 0 UPg 4 CIE.,404 '400 U 0 .1 CJ g 4 0 U U 0 C.) E-, .< 0 E-, U 0 0 H gli U < EP U, 0 r... 0 a, U a. U U U < E. u U U C) Ci 0 ry a.
HOU< E-, a q .4 .4 000HP0udUc9KC,Q.0 O<OH K4u.c2 0H d0dUHE.u<KCHE.0<
U0 4 00uH0 004dE.P00CDUH0E.0 4 E. gg 0 0 0 g4 u 4 4 U U 0 HE-..= 0 E.. E. gC E-. < 0 00E-,<E-.000<HUE,OHH000<<UHE, O E-, CJ CJ 0 0 0 0 0 0 0 0 0 g H. F. U E, 0 0 U U grt , , .4 H, E-, 4 E-if,d H < H. U E-, H < E. C.) Q CD U H U 0 Li A. CJOU00000CJ<UHuHOCDE-,U000 u0H0E-.00H0<c9000000<CJOUg E. H 0 E-. C.) E-, H 0 HP .4; ..4 0 H E-, U E+ a; 0 c7 CD 0 =
K4 u ri ,=4 CDHCD<CJOUCJEAHHE-,C)Uc9g 4 H
00gUat<CDHE.uuUu<0HHOOLIC9HH
dUE.000d000<uH0u<U0Hu gCH
000 0 0 E-, u U 0 < 0 0 0 H. E-, 0 C) < U HOF
O 4dH gCuE.HuUc9 Kt uHE-,HOUHHOHai E-1 0 a; 0 0 E-1 Ei 0 rr g L9 E-, 4 U E. OUHUE.C.5<HKI, ugC0E.Ug4u 0 g4Uu H dd V< 00a: H> .4 t9 r." E-4 g -,,4 CJ U C) C.) E-4 / U g CD H 0 U U (,.7 0 R , U R. ;
,d0Ougc c9E-tH4 4 <, .9Hc9,<C),<UCDHE, t..) 0 0 0 0 d U 0 0 U E. 0 E. E. () a4 0 U CD E. E.
UHU 0 HUU HUE. Hr-C H U ....¶9E.H E. H U 0 HOC) ruuci H0000E.4.:0E-10 E. UHE.0 UU ti OUUC90..t Ø...400410<gF-, 0 0 U 0 E-, 0 E7, E. < u E-, ,.., < () C.) C..) c...1 c...) C.9 0 C...) U < Pq 0 u E. 0 4uu0 (900 gcuOUUHUHE.K4UUuE.Kr HE-, 0HC9 004U U) Ho uuHud c9E.u0E.DdHu cDug H I--Ø<<c)E-.C.)CJE--,E,<<UU<UOUOE, HOC!) HC0004CDUOHUHOO<HuHE-,uHF, O(000 E--,UE-, 0 .1: C9 H E. H C9 U 0 0 U rt., U E. C./ 4, 0 CI8E.KUE.0 HU HE, HOE. HE-000U 0 H ,:l .4 u 6 U000,4E-4C)<U<HH000CD<OLDUCD<0 CD 0 C.7 < U 0 0 CD a, CD c) E-, 0 0 H U 0 0 < ,,C H .4 O U < rcg E. d 0 H H 1-, < < U C.) 0 0 U g 0 c7 g 0 E--, <
OUU00,<UH,<5-.00E,c9<010g0E-,C),<E, O00E-, 0 1.00 < E.0<(..E.E. OCIa, U 0 0 OH u HUE-' 0 0 0: E-, E-, E, E. 0 0 U U E. U E. E. a u (.9 u a E-, E-. E.E.0E. d E.u0 00 u dc1C9 HUH 04:E.
U uu (.9 U H 0 0 H E.HuHu uold (JP <Hu0E-.
O E. U gC E. u 0 < u 0 / U U E--, CJ 0 0 E-, H u H, ch u <
<CD<C9HHOL)00 UULDUHE.OUHOCDO.
CDUC)<C100C)00 000HOUHOPUE0 C,94UUrE,CD<OCJ E-.00(.1HC..)0CDC)00 0 OH El Hu 0000 U 0 g E-, U E-. C) 0 C.9 L. g 1 E-, E-, 0 0 C.) 0 0 0 E. 0 E. E. c) E. E--, u .4 E-, 0 Uci H
E-.F<HHCDOE-.<P6Hg<UOUUOLDOU U
O E, g H. < E. E.-, c7 u a' ' U 0 0 U 0 CD U CD g H, U E-, E-, r<C)0(1c)000<cichHouutiguOUUUHO
ucJC)V9cJ C9C9CDOU<H,C7<HHIUU 4 HUOHO
,< g U<OHOH O CJ UHHUUE-,HOOH F.
E . 1 U U UH,HU,OC)0<c)E--,E.F.C)<<000H
O00 E. E. E. U 0 U 0 H 0 0 U 0 Ca E. U U 4 E, U E-, (9 (9 F:4 Li C9 0 0 0 0 < g 0 0 U < g wHuu c..1 U E. u u 0 o ci F,UHE-,E,C)C7H<UCJOHUUE-.0,4,<H, 0 E-, (.7 < U u b E-, E.0 E. E. 0 V. 0 U 0 E. 4 d u H 0 L'.'oc . H E. C.J E-.<HUClUg UC)C9H<c)c)E.E-.E, uuc..)<0<000.< 0(0C)<HUU.C7gUg<
<H04E1 004E. 0F:400000U gCuc90E.
0HUrr UUNKC000E.0004E.E.Hu0KCE.<
E. u E. ciuuuuu U 0 E. u H d 0 E. < E. E. H 0 KC gc __ ......
SUBSTITUTE SHEET (RULE 26) H> g a z g a a E. 0 H> a 4 E. a a ria g g cl a g X u >-, cx)Xr4E4HE.E.HzryHI-1.-Jgri 0 04HZI.,[4Hu)0E.
E.-, P, H 4 u H U) cnurg 1-10 a P. E. or., = 4 r.=.X0 4 X 4 01:4 r E. a E.-, re a g P, E 14 H EZ H Z 4:) cD C.) til HP 1,--10X
H 0 x g =?-t re, a a>. p, 0 S.. .-1 E--, a n ri,z a g H (..9>ull-tEnz 0HP, Ul 4 r=-=
.-1 CI1 ,-Icil 400 q gX a Hat:404 43 -,KCY,enE.C.9X.44H cPCIEE).0P,<L1) X04.4ZX>.E.H41.Hul >fr.,C..1-ir.. HON
Z
0 E-1D3.-. > HZ .4E.E.P. 04E4 Z ,-100rK?aloax 5 ., ,r.,,_,,., ,,..õ..., 0 El, 0 a -4 a rig>. gclgi-IX?1,E,E-tg E. g H. UN pirnr=101-,HE-, 1.4 CI) .94X040.4X
C, N z.DEri fl ti';'-, g, , 41 E'-.1 'El gi U) O 4 U E. 0 Eh 0 g U 0 E. E-, 0 E. E. 0 Ei 0 0 0 0 4 E. 4 D 0 0 U 4 C.) HOUU.HHUO U 00H0UUE.004400 H044H4 HOP
0 0 0 4 E. 0 E. 0 4 a: 0 U P L.) E. 4 E. E. 0 CD E-1 E. E. 0 44 0 44 4 ES
E. HO < < U 0 Ogg 0.4 C.) E. 0 U CD 4 Ft4 E.0E-t0U0U0 HUUHE.EJUOU0004 E-,q444 (Duo C90 u U 0 HUHHO OPOUPH OC.9E-.E.CDE. 00000 4 u 4 HUU 4 0 0 E. 4 0 Ft 4 0 Fl 0. E9 4 4.4E-10 O04f.0 UHU
E-,0u0OUD0UU0UuHO0 ED ouU00i-,400E, "-,0 E. UUHOUCDUH<H0004 KCEDULtugE.K4u044 OPH
EJ 0 0 U 0 U 0 E. 0 U C.) 44 CD kJ ,...0 0 <4 0 44 0 0 E. 4 H E. U 0 0 E. U
HUU0 0, E. 4 0 E. E. U L!) E-, EJO<OCJUHOPOUCJ U 4 HUH
< E.) 1. U CD (_) 4 E. E-, 0 E. 0 E-I ,4 E. E. E. 0 U 0 E. E.
U CJ C., C., 0 D0004 000guEtu044404E.E-,00000)E.K4 000 0= 00UHUE. <OH HPH<HHUE.<44HPUUEJLI0UU
0 CD C.) 0 E. 4 0 0 0 E. 0 < U 0 KC, E. a; U0OuHu0 HOE. < HO
0 UcJUU UOCDHE.0CDUOUU UU,44CJE.C.)<CEIHO OU
CJ C.) CD C. UE-, E. E. 0 E. U 4 u 4 E. E. E-, 0 g, 0 0 4 u (9 E. <
EJOGE.0E.0004441: 044U 0 0000E-.0 44U PE, 00 UUHIOCJOHHUU 000 44 0004E.DuE,<0 OF
E. 00 <HP440000E01 U E.E.00HD<U0E. OE.
E.Ou UH4UULD4,4UHO U4000E.EnOUE--,< <E.<
E.,...40(Doc9E-.00,4 U404_940E. UHOLDHC/CDHC) UgU
E.< 0H444040E-t0E-,u00 4 E.PH440E-.0 0E.0 01)E.
1-' '":0000000E-.0gE.U0L-, 4 0000E. e, g 01) g C.) r r, E.
E.00E,11,E-.E. C. C II E-. OUE-,Ouuu 0000000HE. < .1: E ' E.
E. 0 E. < 0 a', U 0 E. E. kJ < 0 04 HU U04 0 UE-,U<EA Cf.. C.) 4 1 OC)(..)H000 444H CD<HOULDU 000 4400C)OUC) (JO
E. E-. 0 E.J E. E. E. 44 U E. E , 0 E. al E. H E. E. U Cl 44 E. < 4 U 0 E. r"
H
O 00 g H oo,,,,c9c9 0 0 E-t Et 0 0 E. y 0 0 E-, Et U 4 0 (.7 E, 0 4 E.
O0000CJOHOF,E.H04g000004044.,E.00 E. pc E.
EtuU0KCUUKCHE.E.4E-tUUr H H U KC El EJ440E. 4 00P
CJ 000 0E.044r)(J,CDUC)4 HOCJHOE.E.OHUOHHE.
UCJ0000 U c..1, 44Kcoc_Do 0 E.00E.FitiUU/0 OFF, uuuuE,KC Et 4 u04 E-tguuuE.K4 .,,=
E. 0 0 0 < F. a: 0 U 0 0 < rr .1G U, E. E-, U 0 < < E. 0 4 4: < C.' 0 0 4U000 HUHUOUUCJ5,C) OUHOE.44E.C..4 0 OP a;
0000.000E-.0Cuq(DE-,0400H00ggcDE-,00Hugga, 0 CD C-) 4 0 CD 4 a: 0 0 0 0 0 U < < H g E. g 0 U(DUE-,H0 OUE.
O <OU at 00004 o0E-,E.ODUUU00E.0000U OrCU
O 0 0 U H E. 0 4 E. E. E. E. E. 0 CJ 0 E. U0444 0 E. 4 CD EJ C.) 0 0 L) 4 (-, C) g 0 4 E. 44 <U40 4E-, 4 00E200(.00g E-,<F, 4 0E.E.0000(J00 UCE.E.OUPOC..)00 4CUUCJ CD CIE. gy CD
CJUCD at at 0KCKCF,E.4K4uE.0HOUPPOU40 44, ciC) CD cit E-.
KJ CD E-. u c9 cr9 P H C9 E. (.9 0 (9 E4 E. C.) 0 0 < < E. E. U ,4 4 U 0 <
0 HUHU04C<E.H CD00E.000E-ty00u4KCK? (-tug cIt u OUE.0u400u4E-,youE-tHE.H <PEAUE.tJH E.CDEJ gl.
Ur.)004E-1.4000 HUUCJO<HU <VJO4C.)44 E. HOP
O 0000004E-14UUE.U0 0HU 0 EJ4C)4< E. U4g 0 0 0 0 EH 0 E. E-c (,) C, C7 0 < E. E. u E. E. 4, CJ E. E. 4 0 a; kJ E.
0 E. 0 E. < 4 E.E.E.E.04E.U00(70<0 E-, o E-. o 4 U 0 4 19<0000 HouciE.04UE.E.Jc/OHE.UCD< 4r0H
000 F' 0C-)040 H HqE-lu tE.E.Pu HoO4HHE-.Oo 0 uou0(90.400.4u4.5044HOE-,4 0E.HOE.E-, E-, E.cD E.
OCJUE-.0 Out...cid, 04 dur....HHUEDOVEJP:HOUCJE-.00 O CD 0 0 Et E. ,4 c9 u u E-, c_9 (D CI g 0 E. c., u g E. E-, U E. E. E. CD U U
UE-.(9 E. UU.-4 <OH <4 <044, HOA,40 V< KC a V J 0 0 0 0 0 0 I-Ø40cDO Ho o (Doc.9 gouH5E.ouu uociutial '(-)t-,0c-,E,E-,a:E-,EJ U440(9(.0 ,0<<F,HUHU00UU
000 at ugUE.U000q4 guE,40 <04LTE-,000 u C-- , < F,E L,F UU00,,UE.,..0uOuQ)up g UE. 1-,4 HHHU
E-, 0 U 0 E. 4 E. U 4 0 E-, u u E. U U. E. -4 4 u u 0 0 4 u o 0 c...) OE.U400E-.CDE.E. 4U<HC.)40 44004000 <E. 0 4C at U
C.) E. U U CD U 19 a: C.) rt U CI V E. V CJ 4 0 0 u 0 CJ E. u u E. C) 0 <
< (..., c..9 o E. E. E. E. E. 0 E. E. U f. .4 E. < E. E. 4 H E. E. a; LI U
<<CDOE.CDCD,CUOU<CD<<U0UOPOHE. at OUCJUE.E.
O0 4U Ci40 0000000Pgd<00000 OCJCJUHU, 5,0CD OPUE.E.E. HE.E.E. ci4UUCJOH44CDUE-10 OVE.E.
i U Et uu &4 0uUH O c., U40 4 4 4.9 HO 00o4 CJEJ 4 E.
O 4U HOE-.0 40 0 UUE.000HOOPO < F.c CJE. 0400 <000CD<CD0UPUdE-.E. , E.E.EHE-14,40,4 c.-30 OUP 4 U000000 40000 40 OE, 4uHOE.E. uE.E.(DPU
HOUQuO0U0 ut...Dug 4 HUOU,e-,<<E. Hu4HE.E-, O40UE.,4 E. <0E-144E.UgUQE-,<Ou DE,HUU 0000 HUUE-,400U4 E.OUUEDOCOUHE44040UH '4(70 H
N CJOU 000 E.E.,4 HOE.HEDUOE-,000040PHUOU<U
,-, 0,4 04E-,4 <HO 00E-,U<PHHOUUUUH 4tJE. at <,,'I, 0 000004 :.E.,,t,40400E.4E.1-,u0UHE.E.UU U4 <
= 000 4UU UtDuU004HuU04E.HOuUE.4 DE9g, O 000 OUE-,E.U,<0.4HUocDgcc.9E-.8o0o(Deo uc94 o Z 4cDC)ouc.9 c94E-1H4E-.4oHocpu c., QE.E.44H0c9 O Uat000>000ciL c!..Ho E. C. 0 C. C.) C. C9 E-, 0 H. CD Li E-, 0 cl .4 H 0 0 U CD C.) HU El< .:, , 04 C.) U C., E. E. U E.
H E. 0 ,,4 0 E.4 0000 o? Ho U UE-10E-,04 <0,,,,' UOU 0 0,404 4 4 0E.E.0 ("DUE, E4 <0 0 UUE.uHu u ot.30<pu 4U ouciugu0u 0000 en 4 F,0 E, 4 0400 4 H4 Ou 4CHOE.HUg44 4U0 00E-,E-, SUBSTITUTE SHEET (RULE 26) __________________________________________________ -UHU<4E.4044HE.E. E-, E, U
H. PUL)04:4HOE/UHE.000 U 0 H H E. E.
OHE.E.UUE. 0 E. 0 H U 0 H U
CDUU4E-, OH 00E-.4UUHE.
440UOLDOE. 4HOHOU 0 4' U ci 0 4 CD U U 4 U
0 E. E. 4 F. 0 vc.94 .5 E-.ouq.c 000E-, /
55E-.00.4uc.5 E. 4 0 U
uF.0t/HE-,40 0 UHOOU4 0 E. OH 4 H 4 pc 0 OH 40404, I
E-. 0 0 0 4 0 U, 4 KC
L)E.U0E.E4.4HU 04 46<4.0 C.) U 4 U u o E., y o 0 0 0 4 U 4 U 0 4' 0 0 0 E-4 0 0 0 KC
4 E.F.F.H0E-.04H000044 E.U4V.I.E.E.00)0H<UHOO
E-.04 000E-, F., .4E-,E-,Huu05 500 0E-,E,40000E-,00,50 UHUu 4E.E.0001.4 0(30WH E, H 0 g, F. Ul 4, 0 u u .5 E.F.UPUE.U4E. H 4, 4 4: CD EJ
U ,,,,. 0 0 A: 0 OUL)E.E.E.000<0 H4E-.0,-C
E.040E-14HUKCHHO HOHUU
U 4L)04E.OUE.40F,H E, E. U U
HUH0 E-,L(q4;HugE, 4 g4U
ypcc..,E-.E-,01,00,.1:
H2404 H 0000H<OHU
HIUU
UFO() HgE,U0H00UUHU
WUHHOH
OHU u E-. E, U 0 0 4 Ci 4 0 U 4 E. H F. 0 E. H 0 0 .4 U
U 4 u 0 U 0 gc E. 0 L.) F. F4 4 ..= E. U
C/E. OH HE.L)40 E.00 E.E.H4E. UQu4E-.0EUHHE.40 HO00 E. L) u U
E--.H00 UgH4UK40E, HUH 4 H E. P KC
H ,..c ,,c t-, ,,c E-, E-, c9 0= ,,,cfCgtogc F. 0 4 H U E. U 0 4 0 4 E. 0 H 0 0 E. 4 0 pc E. H E. E, 0 0 0 0 HHHU,4,4r1tH00E-,4 H0E-IU
CJUU4U 4 rd E-1 CD C.) Fl: U, E, E-1 C5 U
,ouc.., py00 HE-,04(7E-, 0004 40g4g E-.E-,E-,E,Ur0c,)0 4.E-IHE,a, Kr UOUE-,0 04c.7E, COUHO CSUKCE,C9E, H0H0 EA 40HOUE.44 00E. 0c1)04 E. HE-.0E, H40E-.
U 4 U 4 H, 4., H 0 C C < E. E . E . I< CC!
E, H E-, U E, < E-1 H 0 H U U E.-, UUHH
H 0 E-+ 0 0 4 0 0 H E, CD
r..7 U ,r4 0 H H 4 4 0 4 0 E. u 4 0 ,c L) E. 4 H. U U 4 0 F. 0 1 CD
C '4 U 0 U 0 g HHH 4 E. 4 E. -,40UHUH40 0 4 F . u L9 UF,<E,H0E.C3F.00uH0E,44 E, E--, q E. u 4 E. C.) 4 C!)u 0 4 0 4 E.) 0 4 E. U E. 0 0 4 0 0 0 E. U H 4 P E-.
E. H C.) E. 0 0 E. 4 HO
U E. 4 4 0 E. g H 4 E. E-. 0 5 u u u C.) U E. u .4 0 Ci44000,4uUKCE, 4*O.U.UU4E.01E.U04C)E..4 E. u 0 , 401/H4HE.
UuC)40444.40E.E.H.E. 4 u 1-, 1 SUBSTITUTE SHEET (RULE 26) SEQIDNO :18 SEQIDNO . : GS 1,0 GACAGCCTCTGGGICCTCGGTCGGTACAGTCTCTGCACCTCGCGCCCCAGCAGGTAAACTAACATTATGGATTTTTCCA
AGCTACCC MDFS KLPKILDEDKESTEGYVEG
AAAATACTCG.ATGAAGATAAAGAAAGCACATTIGGTTATGTGCATGGGGTCTCAGGACCTGTGGTTACA.GCCTGTGA
CATGGCGGGT VSGPVVTACDMAGAAMYELVRVG
1,4 GCAGCCATGTATGAGCTGGTGAGA.GTGGGCCACAGCGAATTGGTTGGAGAGATTATTCGATTGGAGGGTGACATGC-CTACTATTCAG HS ELVGE I IRLEGDMATIQVYEE
GTGTATCAAGAAACTICTGGIGIGTCTGTIGGAGATCCTG'TACTTCC-CACTGGTAPACCCCICTCTGTAGAGCTIGGICCTGGCATT TS GVSVGD PVLRTGKPLSVELGP
ATGGGAG CCATT TTTGATGGTATT CAAAGAC C TTTG TC GGATATCAGCAGT CAGAC C CAAAG
CATCTA CATCC CCAGAGGAGTAP.AC G TMGAIFDGIQRPLSD IS SQT QS
GTGICTGCTCTTAGCAGAGATATCAAATGGGACTITACACCTIGCAAAAACCTACGGGTTGGTAGTCATATCACTGGCG
GAGACATT IYIPRGVNVSALS RD IKWD FTPC
TATGGAATTGICAGTGAGAACTCGCTTATCAAACACP_A_AATCATGTTACCCCCACGAAACAGAGGAACTGTAACTTA
CAn'TGCTCCA KNLRVGSH I TGGD IYGIVS ENS L
CCTGGGAATTATGATP_CCTCTGATGTTGTCTTGGAGCTIGAATTTGAAGGIGT.A_A_A_GGAGAAGTTCACCATGGT
GCAAGTATGGCCT IKHKIML PPRNRGPVTYTAPPGN
GTACGTCAAGTTCGAC CTGTCACTGAGAAGCTGC CAGCCP_ATCATCCTCTGTTGACTGG
CCAGAGAGTCCTTGATG CCCTTTTTCCG YDTSDVVLELEFEGVKEKFTMVQ
TGTGICCAGGGAGGAACTP_CTGCTATCCCTGGAGCCITTGGCTGIGGAAAGACAGTGATATCACAGTCTCTATCCAAG
TATTCTAAC VWPVRQVRPVTE.KLPANHPLLTG
cn =
AGTGATGTAATCATCTATGTAC-GATGTGGTGAAAGAGGAAATGAGATGICTGAAGTCCTCCGGGACTICCCAGAGCTCACAAT.GGAG
QRVLDALFPCVQGGTTAI PGAFG n.) CO
GTTGATGGTAAGGTAGAGTCAP.TTATGAAGAGGACAGCTTTGGTAGCCAATACCTCCAATATGCCTGTTGCTGCTAGA
GAAGCCTCT CGKTVIS QS LS KYSNSDVT IYVG
co (I) ATTTATACTGGAATCACACTGICAGAGTACTICCGTGACATGGGCTATCATGTCAGTATGATGGCTGACTCTACCTCTA
GAGGCCCTTAGAGAAATCTCTG GTCGTTTAGCTGAAATGCC TGCAGATAGTGGAT ATCCAG
CCIATCTIGGTGCCCGTCTGGCCT CG GKVES IMKRIALvANTSNmPVAA
TITTATGP_ACGAGCAGGCAGGGTGAAATGTCTIGGAAATCCTGAAAGAGAAGGGAGTGTCAGCATTGTP.C-GAGCAGTTICTCCACCT HEASIYTGI TLSEYFRDMGYHVS
-GGIGGTGATT'ITTCTGATCCAGTTACATCTGCCACTCTIGGTATCGTTCAGGTGITCTGOGC3CTTAGATAAGAAACT
AGCTCAACGT MMADSTSRWAEALREISGRLAEM n.) AAGCATTTC CCCTCTGT CAATTGGC TCATCAG CTACAG CAAG TATATGCG TGCC TTGGATG
P_ATACTATGACAAA CACTTCACAGAG PADS GYPAYLGARLAS FYERAGR
cn =
TTCG TTC C TCTGAGGA
CGAAAGCTAAGGAAATTCTG CAGGAAGAAGAAGAC CTGGCAGAAA TTGTACAGCT TGTGGGAAAGG CTTCT
VKCLGNPEREGSvS IVGAvS PPG n.) TIGGCAGAAACAGATAAAATCACTCTGGAGGTAGCAAAACTTATCAAAGATGATTTCCTACAACAAAATGC-ATATACTCCTTATGAC GDFSD PVTSATLGIVQVFWGLDK
co ¨1 AGGTTCTGCCCATTCTACAAGACAGTAGGGATGCTGICC_AACATGATTGCATTTTATGATATGGCTCGTP.GAGCTGT
TGAAACCACT KLAQRKTIFPSVNWLISYSKYMRA
GCCCAGAGTGACAATAAAAT CACATGGTCCATTATTCGTGAGCACATGGGAC-ACATC
CTCTATAAACTTTCCTCCATGAAATTCAAG LDEYYDKHFTEFVPLRTKAICEIL
n.) GATCCACTGAAAGATGGTGAGGCAAAGATCAAAAGCGACTATGCACAACTTCTTGAAGACATGCAGAATG
CATTCCGTAG CCTTGAA QE EEDLAE VQLVGKAS LAETDK
r"
GATTP_GAAGCCITGAAGATTACP.ACTGTGATTTCCTITTCCTCAGCAAGCTCCIATGTGTATATTTTCCTGAATTTC
TCATCTCAAA ITLEVAKL I KDDFLQQNGYT PYD
CCCITTGCTICITTATTGTGCAGCTTTGAGACTAGTGCCTATGTGTGTTATTTGITTCCcTOTTTTITTGGTAGGICTT
ATATAAAA RFC P FYKTVGMLSNMIAFYDMAR
cr) CAAACATTC CTT TGTTCTAGTGTTGTGAAG GGC CT CCCICTT CCTT
TATCTGAAGT GG TGAATATAGTAAATATACATTCTGGT TAC RAVETTAQSDNKITWS I IRE HMG
ACTACTGTAAACTIGTATGTAGGGTGATGACCCTCTTIGTCCTAGGTGTACCCITTCCICATCTCTATTXL.ATTGTAA
A.CAGGACTA DILYKLSSMKFKD PLKDGEAKIK
CTGCATGTACTCTCTTTGCAGTGAATTIGGAAIGGAAGGCCAGGTTTCTATP.ACTTTTGAACAGGTACTITGTGAAAT
GACTCAATT SDYAQLLEDmQNAFRs LED
TCTATTGTGGTAAGCTCATTGGCAGCTTAGCATTTTGCAP.AGGAATTGCTTTGCAGGAAATATTTAATTITCAAAAAC
ATAATGATT
PATGTTCCAATTATGCATCACTTC
CCCCAGTATAAATCAGGAATGTTTGTGAGAAACCATTGGGAACTATACTCTTTTTATTTTTAT
TTITTATTTITTTTATTATTTITTITTIGGGGA_CGGAGTGICCCTCTTGTTGCCCAGGCTGGAGTGCAATGGCGTGAT
CTTGGCTCA
.75 t7.-J
, EJ 0 0 4, u E. H Er.
8 [5 8 41 0 g il 8 [5 u 8 8 8 6' il 8' 0 8 El ri [5 '.; f5 1 1 0 8 6 r r 5 P, f-J1.1 E. E::
0 Eg-44 OH
CJEDg4Pgra: CD E.HC9Lio.E.0 C.74000H
El ii [5 P El [5 UHEH5 0 F.' 0 0 1 El CJ 0 E. L9 F. C9 E. Eq E. E.4 H C7 g4 CJ
KJ H
8 8 0 f5 8 L7 g g .c) [; I?: Et4 F13 g 8 f5 P. il r i HUHry E4 El, U 8 tl 0 CJ C., ,4 o c!.! u, u o o c-, -' ..
',;., El 8 0 2 6' 8 2 E= 6 g 0 0 0 E. Eg' g E: [5 H El HUH
HHKDKJHULDg4C7 g/LJCDOC9 g ,gc o E. E--.
8 8 8 0 ,t fl 2 6' 6 ' 8,-, [5 0 82 `.0 EY, 8 El [5 [5 il N 8 E. F.' EH F7' El El El P. El 0 8 U 8 U
`-' ' " E' C.) 2. El E-4 El Eg EL1 C?) 5 r.,. r, (9tr...
(ii,..! (6. (,,i v_..
V El u c) E. F E4 rg 0 U
UH
U (.7 E.
UH 0 E. E. EA CD Pc E, CJ 611 g 0 0 F. F, F.
IJ gE.E.E.UHC9gL7 gc .0 p o . 5 b ii 8u r; V' g c[i r4' ri E ([ 3E, r5 P, '[:.5 3-, !'-' 1 000 ,0000.4 i -,¶.E--.E-.-0¶-,u,cHuL) U g `d 6'. ,E 0 0 HHH0 !i 8 0 El _ Ei Eluur E-'1uf81.ur,E'E(2, oci -,7 ' CJ 0 u (7 K../ H E. E. 0 F.
C-) V, 0 cA i E r fl ,'-Z E, 0 'i 1 El fl 8 E( 0 0 H u C.) CJ (9U U F, E. 0 E. 0 CD 0 H U E. H E.
E. H H E. 0 EA g g g EA C7 cn rc H O. ., ,H,. P EL1 E.-, El g E. H 04 gli i. li Pi g..., gS2C1 EHgC7HHHH,Uoiti Hti gHg4HP_P
,E1, ii E-.' P 8 P. E E.'; t', 8 r r, v, 8, ' ;!,c' kJ V, ri 0 E.
8 8 2 il t5 g/ E. E.
E' " '' t-' 8 5 'r. F4 V., E-2 P. r ..4 6' 8 1 8" " " E'. 1 cõ 0 8 8 0 E5 2 El 0 1 E5 E5 g ';-4' ;5. El E.
., 0 8., .2 õ Eõ E.
HEC), Et.., ,F"-, __ , tj,.! CH, " r,4. [5 1 [5 i4 EE3 r ',c. g g U 'El r, r 4 g ,, , ,-, r, ti 0 0 CD KC E4 rg Ch rg 0 F. Cp 0 Ch E" F.
ii KJ E.
F?-:, ,t...;
b`'E----:Eirs,n_i8,`,-4-'E--:.nr-90E100E-.01-50 $) R 8, [5 t; EJEc.3.
/
4) ,e, u g g !-. Ch CJ gi CJ CJ tJ C) C..) u E. 19 H
C7 E4 CD 0 H E, E. 0 CD U E. E. 0 g F. U E6. 1 ,(.1,1 .4 El 8 2 EI [5 .' 1 8 . EE--,' fl 8 8 ',;.!. `E-4 u 4 ' SUBSTITUTE SHEET (RULE 26) SEQIDNO . :19 SEQIDNO . 166 0 1,0 CTGCGTCCG MIRQERS TS YQELS EELVQVVES
TGCGCCGCGGGCTGGGGCGGTCTCAGGTGTGCCGPAGCTCTGGTCAGTGCCATGATCCGGCAGGAGCGCTCCP_CATCC
TACCAGGAG SELADEQDKETVRVQGPGILPGL
C TGAGTGAGGAGTTGGTC CAGGTGGTTGAGAGCTCAGAG CTGGCAGACGAG
CAGGACAAGGAGACGGTCAGAGTCCAAGG TCCGGGT DSESASSS IRF S KACLICNVESVL
ATCTTACCAGGCCTGGACAGCGAGTCCGCCTCCAGCAGCATCGGCTICAGCAAGGCCTGCCTGAAGAACGTCTTCTCGG
TCCTACTC LIFTYLLLMAVAVELVYRTITDF
AT.CTTCATCTACCTGCTGCTCATGGCTGTGGCCGTCTTCCTGGTCTACCGGACCATCAC.AGACTTTCGTGAGAAACT
CAAGCACC CT . REKLKHPVMSVSYICEVDRYDAPG
GTCATGTCTGTGTCTTACAAGGAAGTGGATCC-CTATGA.TGCCCCAGGTATTGCCTTGTACC
CCGGTCAGGCCCAGTTGCTCAGCTGT IALYPGQAQLLSCKHHYEVTPPL
AAGCACCATTACGAGGTCATTCCTCCTCTGACAAGCCCTGGCCAC-CCGGGTGACATGAATTGCACCACCCAGAGGATCAACTACACG TS PGQPGDMNCTTQRINYTDPFS
GACCCCTTCTCCAATCAGACTGTGAAATCTGCCCTGATTGTCCAGGGGCCCCGGGAAGTGAAAAAGCGGGAGCTGG'TC
TTCCTCCAG NQTVKSALIVQGPREVKKRFLVF
TTCCGCCTGAACAAGAGTAGTGAGGACTTCAGCGCCATTGATTAGCTCCTCTTCTCTTCTTTCCAGGAGTTCCTGCAAA
GCCCAAAC LQFRLNKS SED FSAIDYLLFS S F
AGGGTAGGCTTCATGCAGGCCTGTGAGAGTGCCTGTTCCAGCTGGAAGTTCTCTGGGGGCTTCCGCACCTGGGTCAAGA
TGTCACTG QEFLQS PNRVGFMQACESACSSW
GTAAAGACCAAGGAGGAGGATGGGCGGGAAGCAGTGGAGTTCCGGCAGGAGACAAGTGTGGTTAACTACATTGACCAGA
GCCAAAA.AAAGTGCTCA_ATTGTTTTTTGTGGTCTTTGAATGGAAAGATCCTTTCATCCAGAAAGTCCAAGATATAGT
CACTGCC_AAT EAVEFRQETSVVNYIDQRPAAKK
cn CC TTGGAACACAAT TGCTGTT CTCTGTGG CG C CTTCTTGG CAT TATTTAAAG CAGCAGAGTTTG C
CO
ATCAAAATTAGAAAGAGATACCTTAPAAGAAG.AGGTCAGGCAACGP.GCCACATAAGCTGAAGTCACCTCGCGTTGTT
TAGAGAACTC- TANPWNTIALLCGAFLALFKAAE n.) cn co TCCACATCAATGGGAGCTGTCATCACTTCCACTTTGTAP-ACGGAGCTATCAACAATCCTGTACTCACTTGAAGAAATGGGGCCTTGC MIMS I KWMI KIRKRYLKRRGQA
tri 7:1 TGGGAGGAACAGCATGTAAAACTGGAACTTCTAACCCCGTCCCAPAAGAGGCGGTGTAGAGCCTAATAGAAGAGACTAA
TGGATAAA TSHIS op CCTACAAGTTATTTAAATATTTAAATTATTAATAAACTTTTTAAAGAGCTGGCCAATGACTTTTGAATAGGGTTTGTAG
AAGATG CC
TTTCTTCCTGTTTGGTTCATTGTATTGTATTAGGTTAAGCTCTACTAGGGTAATC-PAGGCTCTACTTTTCACTTTTTAAAAGTGGAC n.) cn AAAAGAGTGTGATITTc7rmccAAAAATTccrGAGTATcAAGAcGTGcAGGTcATGcrrTGGAGccTATccAcTGTAcA
cAATGG
CAAAACCGTATGACTTTGGCATCATCTG CCATTGATG
TCCAGCCTCTGACATGCTCTTTGATTTGTTAAATGTTAAATGAGACTTTA
n.) AGGCTACTAGAAACTAGTAATTAAGTTTCTTAATGGACTGAGTAGCCACCTACTTGTCCGGCTAGAATGTTTGTTGATG
TATGAGTT
TAGATTAACACTCAAAAGCACTAGGACAGATGTACATAGAAGGTGCCTACTCATTGTATTTTGATGATTTCATTAACAG
GTAAATAA co AAGTTAATACAAAAGGAACGAGTGTGACAATATGAATATCTGCTCAATCATCGGGCACAATTACTTTCATTTGGTGACT
TCCAAGGA
CAAAAAGGTAGTATGAGTCTGGACTCCCAAGATGGATCTAACTCTCAAGGTATGTTCTAACTGCTTCCAGGGAAGGGTT
TGTTAGGC
ATGGCAACTGATGGCAGGTGTCCAGAAAGAGTGACCTGGTGTCCCCGAGGAAGCTGGGTTPACTCTTTACTGTGTCCAC
AAAACTAC
CCATCATATGAGGAAGGGGTATACGCAGTGTGACCCTCAAAAAG
CTTTTAGCCTAGCCTTTGACAGAAATGAGTATGCATTAAAAAA
=
cr) AAGTCTATTTTTCACATTAAGGTTCTAAAAATTGTTTCCAGAGTTTTAAATTATTTATGTGCCTGTTGCTTCAAAGAGG
ACTTGGTA
GCATTTCCTAAATTTTGTAATCTGGCTTCCGATAATCCAAAGGGP.ATAACTCAAATGTATGAATAGGCATTTTAAATG
GGAAGPAAC
TGTTTTTTGGATGAATGATTAAAAGTGAACTGTATAAAG
SEOIDNO : 2 0 SEQIDNO . 67 GCGGACGTGGGCAGGAGGGCTGGAAAAGCCGGCGCTGGAGCGGGAACGGGAGTAGCTGCCTGGGCGCCAAAGGCCGCGG
CACTCCCA MFRKGKKRHSSSSSQSSEISTKS
CGCGGACCCCGAAGTC
CGCAACCCGGGGATGGGCCCGCGGCTGCGAGGGGATCTTCTCTGGATCAAGCAATGGTGGTGAAAAATG TT
KSVDSSLGGLSRSSTVASLDTDS
TCGCAAGGGCAAAAAACGACACAGTAGTAGCAGTTCCCAAAGTAGCGAAATCAGTACTAAGAGCAAGTCTGTGGATTCT
AGCCTTGG TKS S GQSNNNSDTCAS FRI KYVG
GGGTCTTTCACGATCCAGCACTGTGGCCAGCCICGACACAGATTCCACCAAAAGCTCAGGACAAAGCAACAATAATTCA
GALACCTG AIEKLKLSGKGLEGPLDLINYI
TGCAGAATTTCGAATAAAATATGTTGGTGCCATTGAGAAACTGAAACTCTCCGAGGGAAAP.GGCCTTGAAGGGCCATT
AGACCTGAT DvAQQDGKLPFVPPEEEFIMGVS
AAATTATATAGACGTTGCCCAGCP_AGATSGMAGTTGCCTITTGTTCCTCCGGAGGAAGA_a_TTTATTATGGGAGTTT
CCA.2-.' GTATGG KYGIKVSTSDQYDVLERIGILLYLI
CATAAAAGTATCAACATCAGATCAATATGAIGTTTTGCACAGGC.ATGCTCTCTACTTAATAATCCGGATGGTGTGTTA
CGP.TGACGG IPMVCYDDGLGAGKSLLALKTTD
TCTGGGGGCGGGAAAAAGCTTACTGGCTCTGAAGACCACAGATGCAP_CCAATGAGGAATAC.11_GCCTGTGGGTTTA
TCP_GTCCAACAG ASNEEYSLIWY. QCNSLEQAQAIC
CCTGGAACA.AGCACAAGCCATTTGCAAGGTTTTATCCACCGCTTTTGACTCTGTATTAACATCTGAGAAACCCTGAAT
CCTGCAATC KVLSTAFDSVLTSEKP
AAGTAGAAGTCAACTTCATCTGAAAGTTCAGCTGTTTTCAAACTGCAATGCTGAAATGTTATGCAAATAATGAAGTTAT
CCCTTGCT
CTAGATITTCTGAAGAAAATGGATTGTOTAAAATGCTGATCATTTGTTTATTAAAATGTGTCCTATTACACAGTGAGTT
ATGAAGTCATCTATITTCTGGGCTACTTCATTTC-TCITTTTCAACTTCTAATAAGCTTAACCTAAGTGTCP_CGAAGACGAGA
cn TGTCACAGAGGTCCACTCAGTGACAAACACACACTGAP.GGCCTGAGGGAAGACTGAGGACATGGGCTCAGTGGTGGCT
TCCCAGTCA
N.) CO TGGTATCACTGGCATGGACCTCTGTCCGGCAGAGGTC-TGGACTGGP_GACCAGGATTCATGCTGGTCTGGAACAATGACATTGCCAAC
cn co TTAAGACACACAAAGCAGATTTTCAGAAGTGTCTGGTCAP.GATAP_CATGCIGGCCAACCACAATTCCTAGAGTTAII
GAGAACCTTAA tri AAGATTACCGCTCATGCTAAAAGTATGTAAAGATCCCATGTACAGTATGATAGTGTACTTTTITTAAAGGACTC-TC.AATATACAAAA
CT T TAAAGATTAPAAACATTAAAAATAA.AARAA
rrl N.) cn SEQIDNO.:21 SEQIDNO.:68 N.) CCTCGCCCCGCCTACGCGGGAAC CC.AACCGCGGCGACCGGACGTGCACTCCTCCAGTAGCGOCTGCACGT
CCTGCAATGGC CCGCTA MARYEEVSVSGFEEFHRAVEQIIN
co TGAGGAGGTGAGCGTGTCCGGCTTCGAGGAGTTCCACCGGGCCGTGGAACAGCACAATGGCAAGACCATTTTCGCCTAC
TITAcGGG GKTIFAYFTGSKDAGGKSWCPDC
=
TTCTAAGGACGCCG-GGGCGAAA_AGCTCGTSCCCCGACTGCGTC-CAGGCTGP.ACCAGTCGTACGAGAGGGGCTGRAGCACATTP-GTGA
VQAEPVVREGLKIIISEGCVFIYC N.) AGGATGTGTGTTCATCTACTCCCAAGTAGGAGAAAAGCCTTATTGGAAAGATCCAAATAATGACTTCAGAAAAAACTTG
AAAGTAAC QVGEKPYWKDPNNDFRKNLKVTA
rn AGCAGTGCCTACACTACTTAAGTATGGAACACCTCAAAAACTGGTAGAATCTGAGTGTCTTCAGGCCAACCTOGTGGAA
ATGTTGTT VPTLLKYGTPQIGIATESECLQ.ANL
cr) CTCTGAAGATTAAGATTTTAGGATGGCAATCATgTCTTGATSTCCTGATTTGTTCTAGTATCAATAP_ACTGTATACTT
GCTTTGAAT VEMLFS ED
TCATGTTAGCAATAAATCATGTTAAP_AP_P_ACTGGCATGTGTCTAAACAATAGAGTGCTATTAAMTGCCCATGP.AC
CTTTAGTTTGC
CTGTAATACATGGATATTTTTAAGATATAP
kGAAGTCTTCAGAAATAGCAGTAAAGGCTCAAAGGAACGTGATTCTTGAAGGTGACG
GTAATACCTA.A.AAACTCCTAAAGGTGCAGAGC
r) ___________________________________ _ ______________________________________________________ a E., >4 >4 4 tee en pao z 14' 2 6 [:4, ,t1 EF, Fi 'tin' ,Z' [I 8" CE!: 6 f=1 ' ix, E-0 tx4 P-I Cil Eir o 0 UHIZC.1U fe.1M
0 or 4 u F Cil 0 P4 Cf) 4 F F 4 al (.1/-14./0/-14e0tZ cc) P ,, .` ' c3 CO rar 0 H 41 0 ... ..., Z
H
or co>crrucni-raNzH
E.) 440E-.04E.E.rPCJ004U4U0H4E. 4 U
00E-ruEruo4 UHHOHUCJOHE.0440H
4E-.00H000 UE.E.C.DHHOC.DE.40E.U<C) CD C..) u 4 H /4 0 U E. U E. 4 /4 C./ E. E-. Ei E. U E. 4 4 E. H
OPCDCDP0H4 4 404 rt. C-, (..) 4 4UHUE.C.DHE-e 4 0 Er Kg U o 4 u 4 u 4 o o o Er u U F K4 F E.
8 E-, 2: /,Yt r g g 8 8 6 8 0... * 00 8 2 r 04 8 4E); 4444 E
04 u u u c.9 o E-r 4 u 4 ,r, 4 E--.00U0 u U, 4 4 --r) -..r, g cE?, p, t 8 4 '6 8 ( 9=5 r, 'd 6 i:: 8 EU (0) (,- )4 8 [Ell UP EreE.C./ 4CDUCDE-1 .e,CD O Ce 44,HUCDUH u E.
4 U El 0 C., 4 4 H 4 H E. 0 4 C9 E. H 4 H C, C.) el. 4 C/E.H HE.CJC540 E.C..1.0 4 r, E. C.) CDUUU
ti El r.i 8482 ,1 4, v6P r, EY. b" 'E5. .1 8Ø184V-.1-1 1 E. u 0 4 , 0 0 0 u Er , 4 ci 4 Er E. Er 4 or Er 0 0 .,0, U.OgFUUF 4 E. (9 -4 4 4 E.HPHUHH/4/4E-14 Ig6c,..),4H/E,c9CJE.U. UU. C) 4 E.H4E.HU0 4H
C1E.CJE.1E.V. 8 Et, 2 f,-:: 8 6 c,,-49r-18ggreE/:: 8 8 8 ,'¶ 8 8 8 8 2 0. '6 5 c,' Ft: 8' 0 6 8 8 8 Et: 8 El '' ',.-4 Et: * E,"El '6 r-: 8 8 8 8 '6 cE.--.9 8 8 [--: 8' 2 .), " 2 8 V. , c jr- :
Ec : .1 8 ii: E;;; ._,;) ,v ,,E.. [11 0 _,,., U 0 E-, 0 0 E-. E- , H E-/
E. i...,,1 t-j, ,4 0 0 E. E. U U 4 E. 0 r.E.--/) 1 Eli (C-.).1 (5 E-.) Er-/) E. 0. * 2 ..=; E.
.er, 4 H CD -4 Ce KJ U. E. CD, A. 0 0 E. C., C.) U E. E. ,-,q CD C..1 H 0 0 0 (-) 4 4 4 KI, Kg E4 0 0 U F F. 0 4 04 E. U U E.
H40 CDUC.D. Pr F H44E.UUHHHE-.4E.E.Ch .4) Ell 8 Pi 6 .,L3 , ,&' LI 2 t; - L ) , 5 gu pu f=-,.F3: 9.() r Et: g: .), EE:: r_: i:i ,e,' ,,:,), O00 H0E-e4 .44.')FUOF t-'0,-,P 40H0E.UH
E. 4 E. CD U 0 0 0 0 H E. E. CD (9 E. 4 U 4 Er E. 0 . 0 E. 0 4 f'- .) /L) '6 :4, 8 8, 8 8 8 0, 4';
.,,,,(1 n''. 8 44) fl 8 8 :2 8 ,Ejii E,="g` L'D t i H00E/U040040E. ll , C.J E.U00,,H g4CIE.0 4 C.1 0 4 E-/ E. 0 4 E. el, 4 E. 4 CD E. U 0 4 0 o Er E. 4 0 4 Ej, el..! F.) E.:C' il 8 8 V. 6 4 8 8 El 8 b? 8 8 8 8 6 8 8 8 6 E -. E. 0 U C ./ E . CD 0 H 4 4 e5 0 E . E . 0 , r_ ." 1 [7 : !,. , [_q, ,E7gi r, 8, 8 rE--.) 2 'E-4, $ 8' u. i-4 r6 8' 4 8, 8 o E. E. u R ED u .
I
* u 111 8 8. 'C.' 8 u 8 8 8 8 V-.4 -,' 8 8 (c)D E;t' id CEi E4' ELIE ECDPSFE4'E 6680,868E,A;.8i--1288E.
1--,' 0 8 'E--: 8, 8' .-', 8 8 ''. r-: 8 ',-3 '' 8 8 8 t.-: ,c.-Z f.. Ec-,' E,;'4 ,1 6 8 'El u t".' * 6 8 6 * -.' r. u Eg C,4) ,Ei 8 8 2 8 8 8 ,,c ., 0 E., 0 0 /4 U E. CD U 4 CD 4 U E. U 0 E. U E. KC 0 H H
r E -.) E4 ,?4 E- .- : t5 E: : . .7 i [ 7 '6 8 8 8 2 Et 6 8 8 flt' -.91 01 E-' CDHU,-, 000.cCJE-.4E.E.U0E.E.E.CDULeHE.
I
CD 4 0 0 H E. El La (.1 A -4 0 Er p. sd. o 4 ce.-15 u 6 6, c-.-! ,,,,, ,,E,9 E=;-c`
HCDH00ETE-..De44H Liu 44 õ.c-.1. . _ ' 0 4 C./ E. 4 E. CD E. 0 4 E. E. E. E. U 6 t, r..., 6 re, ,t--,,. t., ,._.,., / it'u EE -,/ t' H E. F EE-4 1(Ch ECY') E )/ 8 [1 EC ', tin H) (E 2, CE '8 E' 4 F.9 /L,-11 8 tl: 8 8 u 8 8 8 6 EE---'. 6 '0' 8 il E-. 2 V-.' 4 r, 8 O440 4. CD CD CD E. H E. E. , c[....), EE.3 E. E,o.-, E., ,c..-4, 0 Ec-,, Ec-jr Ec:., cc!, o 0 E. 0 0 4 0 0 H 0 4 C. V, Fi ,f:) 8 6 E. 0 (.7) H rõ
ci: El 0 0 ., 4 ' 0 , 6' ' 2 8H 81 ' - '8 . 4 .1 . 8 .-.4 ! -, 3 1E - ' r.
7 EC- :( 9 r ,E ) 8H UC 9 ' -. . I .0 6H X * - ' I : 1H SH H8 .*E I
u 0 u E. E. Ci C.) 0 El 4 E. H 0 4 E. I ET, C..1 0 C.1 4 0 E-e E.
EJ 0 4 0 4 u 4 Er 4 0 ,E,. E.' CJE1HHE.Et,.(2 f -I 2 ,F,- Et: V-: 8 -,' 1 w &: 8 4 8 u El u r: 6 8 8) 2 E-1 E. n C4 5 y,, ku k" E,:4' -). B E 8 E;r:., ii 8 Ec-_,"E-4 Eg 8 E,--: b' 8 V ', 6' `E-_,) CV ,-, c-4, ...= %, CJ U E. 4 E. 4 4 CD 41040E-ruE-1 E. F 4 (5 0 004UE.004CJE.E.40 0040U 4H4E.
. E-14H4HOU4E-144 4H00_4440HUE.00 c)C.)Q00E.E.CDHpUL)C.)4E-, 4pOrEc, Z
O P4 '6 c; 8 6 P-, 8 6 i--: 8 8' 8 r. 8 ',J. ',=-'t `,4 8, 8 8 8 r: 1-_.= .A
H
a 8 0 6 8 8 8 * `,,) 6 b' 8 E' Vc V: Et: 8 8 Cf.) [7 r7 'E4.: 6 Et: '6 2 E4 `E--,) 1 Pi 8 4 8 8 6 8 8 ,,.. ,E.t 6 8 `..": 2 8 8 8 8 8 r, 2 O _ SUBSTITUTE SHEET (RULE 26) SEQIDNO : 7 0 1,4 CCTCCTCTCCCTGG CTTTTGTGTTGGTGCCTCCGAGCTGCAAGGAGGGTGCGCTGGAGGAGGAGGAGGGG
GGCCCGGAGTGAGAGGC MAQP ILGHGS LQPASAAGLAS LE
ACCCCCTTCACGCGCGCGCGCGCACAcGGTGCCGGCGCACGCACACACGGGCGGACACACACACACGCGCGCACACACA
CACGCACA LDS S LDQvVQTRIFKI I VIGDSN
GAGCTCGCTCGCCTCGAGCGCACGAACGTGGACGTTCTCTTTGTGTGGAGCCCTCAAGGGC-GGTTGGGGCCCCGGTTCGGTCCGGGG VGKTCLTFRFCGGTFPD KTEAT I 1,4 GAGATGGCGCAGCCCATCCTGGGccATGGGAGcCTGcAcCcCGCCTCGGccGCTGGCCTGGCGTCCCTGGAGCTcGAcT
CGTCGcTG GVDFREKTvEIEGERTKvQviNDT
GACCAGTACGTGCAGATTCGCATCTTCAAAATAATCGTGATTGGGGACTCCAACGTGGGCA.AGACCTGCCTC-ACCTTCCGCTTCTGC AC-QERFRKSMvERyyRNvRAvvF
GGGGGTACCTTCCCAGACAAGACTGAAGCCACCATCGGCGTGGACTTCAGGGAGAAGACCGTGGAAATCGAGGGCGAGA
AGATCAAG VYDVTKMTS FTNLKMWTQECNGH
GTTCAGGTGTGGGACACAGCAGGTCAGGAACGTTTCCGCAAAAGCATGDTCGAC-CATTACTACCGCAACGTACATGCCGTGGTCTTC AVPPLVPKVLVGNKCDLREQIQV
GTCTATGACGTCACCAAGATGACATCTTTCACCAACCTCAAAATGTGGATCCAAGAATGCAATGGGCATGCTGTGCCCC
CACTAGTC PSNLALKFADAHNMLLFETSAKD
CCCAAAGTGCTTGTGGGCAACAAGTGTGACTTGAGGGAACAGATCCAGGTGCCCTCCAACTTAGCCCTGAAATTTGCTG
ATGCCCAC PKESQNVESIFMCLAcRLKAQKS 0 AACATGCTCTTGTTTGAGACATCGGCCAAGGACCCCAAAGAGAGCCAGAACGTGGAGTCC-ATTTTCATGTGCTTC-GCTTGCCGATTG LLYRDAERQQGKVQKLEFPQRAN
cn AAGGCCCAGAAATCCCTGCTGTATCGTGATGCTGAGAGGCAGCAGGGGAAGGTGCAGAPACTGGAGTTCCCACAGGAAG
CTAACAGT S KTS C PC
n.) AAAACTTCCTGTCCTTGTTGAAACCAAACGAT.ATAAATACAAGATAAATTATCACTGGAGTTTTTTCTTTCCCTTTTT
TCTGTGcCT
CO GCATAATGCTGACACCTGCTTGTTTCCATAC_P.AATTGATATCAAAATAAAATTTGTATAGATT
.AAAAAAA co cn ¨4 rn Cl) rn rn co n.) r¨
k.4 SEQIDNO . : 2 4 SEQIDNO . :71 GGAGCGCGTGAGGCTCCGGCGCGCAAGCCCGGAGCAGCCCGCTGGGGCGcAcAGGGTCGCGcGGGCGCGGGGATC-GAGGACGGCGTG NEDGVAGPQLGAAAEAARAP...EAR
GCCGGTCCCCAGCT.
CGGGGCCGCGGCGGAGGCGGCGGAGGCGGCCGAGGCGCGAGCGCGGCCCGGGGTGACGCTGcGGCC CTTCGCG
ARPGVTLAP FA PLSGAAEADEGG
CC
CCTCTCGGGGGCGGCCGAGGCGGACGAGGGCGGCGGCGACTGGAGCTTCATTGACIGCGAGATGGAGGAGGTGGACCTG
CRGGAC GEMS FIDCENEEVDLQDLPSATI
CTGCCCAGCGCCACCATCGCCTGTCACCIGGACCCGCGCGTGITCGTGGACGGCCTGTGCCGGGCCAAATTTGAGTCCC
TCTITAGG ACHTZPRVFVDGLCRAKFESI,FR
ACGTATGACAP.GGACATCACCTITCAGTATITTAAGAGCTTCAA.ACGAGTCACAATAAACTICAGCAACCCCITCTC
CGCAGCAGAT TYDKDITFQYFKS FKRVRINFSN
GCCAGGCTCCAGCTOCATAAGACTGAGITTCTGGGAAAGGAAATCAAGTTATATTITGCTCAGACCTTACACATAGGAA
GCTCACAC PFSAADARLQL.HKTEFT,GICEMICI, CIGGCTCCGCCAAATCCAGACAAGCAGITTCTGATCTOCCCTCCCGCCTCTCCC-CCAGTGGGATGGAAACA_kC-TGGAAGATGCGACC YFAQTLH GS S HLAP PNPD KQFL
CCAGTCATAAACTATGATCTCTTATATGCCATCTCCAAGCTGGGGCCAGGGGAAAAGTATGAATTGCACGCAGCGACTG
ACACCACT IS PPAS PPVGWKQVEDATPVINY
CCCAGCGTGC-TGGTCCATGTAIGTGAGAGTGATCAAGAGAAGGAGGAAGAAGAGGAAATGGAAAGANTGAGGAGACCTAAGCCAAAA
ATTATCCAGACCAGGAGGCCGGAGTACACGCCGATCCACCTCAGCTGAA.CTGGCACGCGACGAGGACGCATTCCAAAT
CATACTCAC TPSVVW11.7CESDQEKEEEEEMER
GGGAGGAATCTT
TTACTGTGGAGGIGCCIGGTCACGACTTCTICGGAGGIGGCAGCCGAGATCGGGGIGGCAGRAATQCCAGTICAT
MRRPKPKI/QTRRPF,YT.PIIILS
GTTGCTCAGAAGAGAATCAAGGCCGTGICCCCTTGTTCTAATGCTGCACACCAGTTACTGITCATGGCACCCGGGAATG
ACTTGGGC
CAATCACTGAGTTIGTGGTGATCGCACAAGGACATTTGGGACTGICTTGAGA.AAACAGATP.ATGATAGTGITTTGTA
CTIGTTCTIT
TCTGGIAGGTTCTGICTGIGCCAACGGCAGGITGATCAGTGAGCTCAGGAGAGAGCTTCCTGITTCTAAGTGGCCTGCA
GGGGCCAC n.) CO
TCICTACTGGTAGGAAGAGGTACCACAGGAAGCCGCCTAGTGCAGAGAGGTTGTGAA.P.ACAGCAGCAATGCAATGIG
GAAATTGTAG El) CO
=ITC CTI'T
CTICCCTCATGITCTCATGITTGTGCATGTATATTACTGATTTACAAGP_CTAACCITIGTTCGTATATAAAGTTACA
tri CCGTTGTTGTT'ITACATCTITTGGGAAGCCAGGAAAGCGTTIGGAAAACGTATCACCTTICCCAGATTCTCGGATTCT
CGACTCTTT
GCAACAGCACTTGCTTGCGGAACTCTTCCTGGA.ATGCATTCACTCAGC.ATCCCCAACCGTGCAACGTGTAACTTGTG
CTITTGCAAA
M
AGAAGTIGATCTGAPIATTCCTCTSTAGAATTTAGCTTATACAATTCAGAGAATAGCAGTTTCACTGCCAACTTTTAGT
GGGTGAGA.A n.) ATITTAGTTTAGGTGTTTC-GGATCGGACCTCAGTTTCTGTTGTTTCTTTTATGIGGTGGTTTCTATACATGAATCATAGCCAAAAAC
TTITTIGGAAACTGTTGGTTGAGATAGTTGGTTCTTTTACCCCACGAAGACATCAAGATACACTTGTAAATAAAGCTGA
TAGCATAT n.) ATTCATACC7GTTGTACACTTGGGTGAAAAGTATGGCAGTGGGAGACT.AAGATGTATTAACCTACCTC-TGAATCATATGTTCTAGGA
AA.A.GCTGTTCCCATGTCTAACAGGACTTGAATTCAAAGCATGTCAAGIGGATAGTAGATCTGTGGCGATATGAGAGG
GATGCAGTGC .. co CTITCCCCATTCATICCIGATGGAATTGTTATACTAGGTTAACATTTGTAATTTITTTCTAGTTGTAATGTGTATGICT
GGTAAATA .. n.) C GGTATTATATTTTGGCCTTACAATACCGTAAC_.kATTITTC-TCATTITGAAATACTTAATGCCAAGTAACAATGCATGCTTIGGAAAT
r-m TTGGAAGATGOTTTTATTCTTTGAGPAGCAAATATGTTTGCATTARATGCTTTGATTGTTCATATCAAGAAATTGATTG
AACGTTCT
CAAACCCTGTTTACGGTACTTGGTAAGAGGGAGCCGGTTIGGGAGAGACCATTGCATCGCTGICCAAGTGTTTCTTGTT
AAGTGCTT
*-7-;
TTAAACTGGAGAGGCTAACCTCAAAATATITTIITTP_A-CTGCATTCTATAATAAATOGGCACAGTATGCTCCTTACAGAAAAAAAAA
A A AW IA ARA AAAAAAP..21_ AAA
;==
SEQIDNO . :25 SE Q IDNO . :72 14 ..., GATTGCGAGCCAGGAGGAGGAAGCC GGCGGTGGC CCCGTCAGCAGCCGGCTGCTGAGAGGCCGGTAGGCGGCC-GCGGTCCCGAGGGG
--, CGGCGGCCGCGCTOCTCCCTGAGAACGC-GTCC CGCAGCTGGGCAGGCGGGCGOCCTGAGC-GCGCGGAGCCATGAAGCTGTACAG CC T MKS, YS LSVIZYKGEAKVIILLKAAY 'a CAGCGTCCTCTACAAAGGCGAGGCCAAGGTGGTGCTGCTCAAAGCCGCATACGATGTGTCTTCCTICAGCTITTTC
DVS S FS FFQRSSVQEFMTFTSQLCAGAGATCCAG Co4 IVERSSKGTRASVKEQDYLCHVY
COTTCAGGAATTCATGACCTTCACGAGTCAACIGP_TTOTGGAGCGCTCATCGAAAGGCACTAGAGCTTCTGTCAAAGA
ACA.AGACTA 4=
TCTGTGcc P.CGTCTACGICCGGAATGATAGTCTIGCAGGTOTGGICATTGCTGACAATGAATACCCATCCCGGGIGGCCTITACCT
T VRNDSLAGVVIADNEYPSRVAFT
GCTGGAGAAGGTACTAGATGANITCTCCAAGCAAGICGACAGGATAGACTGGCCAGTAGGATCCCCIGCTACAATCCAT
TACCcAGC LLEKVLD E FS KQVDRIDWPVGSP
CCTGGATGGTCACCTCAGTAGATACCAGAACCCACGAGAAGCTGATCCCATGACTAAAGTGCAGGCCGA_ACTAGATC-AGP_CCAAAAT ATIHYPALDGELSRYQNPREADP
MTKVQAELDETKIILHNTMESLL
CATTCTGCACAACACCATGGAC-TCTCTGTTAGAGCGAGGTGAGAAGCTAGATGACTTGGTOTCCAAATCCGAGGTGCTGGGAACACA
GTCTAAAGCCTICTATAA.b_ACTGCCCGSAAACAAAACTCATGCTGTGCCATCATOTGATGC2-,' GCCTGCCAGAGGCCCAATGCTGGAA ERCEKLDDLVSKSEVLGTQSKAF
TCGCAC CAT CATTCACATCAGAACTGCAGCCCCTGGA.AAAGAAGAGACAGCCATAC-ACGAGGAGCr=AGAGTGGGGGCAGACTCGC CA YKTARXQNS CCAIM
TTTITATITTGAAGTTCCTOCGAGAAATGGATGGTGGAAGGGTGGCC-AATTTGAGGTCCCCAAAGGIGTATTITTOGGCAAATGAAACCATAAACTCCGACTGGCTTCTGTAGATGCCAAAGGCCT
CTITTTCA
Cl) GCTAACCCTOGGAAGGCTCTGIGGGAGGGAGGTCGGAGCCAGCTGTTICTCCATCITTGGTATATCTITGGATCTTATT
TGTACATT o C
tv CO
AATGATATTAACACTCCAGTGGGGGGTC-GGGAGTCCCTGATGCTAGGGCTGGGGIGOGTGGAGTTTGAAGACTCTTGGGAAAGCCTC ...1 Cl) TCC
TGGGGCCACTGTTGGGGGIGGGAGTGAGCCCACCACAGAGGCCACAGGCAGGCCCCCACTTCAGGCCCAAGGC
CTGGGGCGGGG .. _ co GOAACAGTCACTGOGTCTCAGATTCTGAGACTGTTOTTTAGCTTACCTTICTGCTAGGATIGC-CTICCCGCAGAGGGCAGGGCCCAT (V
.) G
o.
C
CCTAAGCAGCTTCCAAGTCCCACAAAGGTGGCTTGTGGGAGGATITGGRAGGAGCTGCATTGIGGGCGC-GGAGTGIGTGGGTTGGGT cn ¨I
TCGTACCAGCAAGTAGACTAGGAACTGAGCCCAGGAA.AGGGGGATGTITTCCTGGTGTTTGGATGGTCAGCTOGGAGT
GICCATCAT
M
n.) CAGGGGAAGATCAAACACAGGTGCACTCAGCTGCCCAGGGCCTCTOGGACACTTGCCTTGACTTGCAACTTGCCTTGAA
Cl) 1-, TCARAGCAGCAGGIGCTGIGGTCTCTCAUATTGATITTTATTTGACTCTGTGGCTCTAAGACTGCCITGA.A.CCGCCT
GAGGCCTAT tv M
GCATcTGAACAAGTGGGTCTCTCCCTTGAGC_ACCAGGAGTGGOTGCCAGCCGGCCCCGAGGATTCCCAGCACCCCACC
TATGGTCIT I
o M
GCCAGCATAGGCTTGCTAGTTCCTTCTTGOTCAGAGGTAGCTGCAGAOGGGGGAGGCCAAGGOTTTGGTCTAAGCTGTG
CCCTGCCA co I
CCTGGCAGGAGGCCCACTCACTGCCCAAGTCATGGCAACAGGCTGGAGCAGCCCAGGAGATGGGCCTP_AAATGTTCTC
GATCCCTTG o X c GGTCCTAGTGTTATGTTCCAGTCTGCCCACCTGTGCTCAGGATGCAGCCCTGGGATCCAGCACCCATGGAAGCTTCTGC
TGGGATGG tv r TGICACCTATGGGITTTGAACC_AGTGIGGTATGGICCTTGGGAGCTCTGCTCTGAGCTTGCCACACTGCTGAGAGCAC
CCACTOTCC
rn TGACCAGAGICTCAGTGGTCCTGACCCCCAATGTGGGCAGGGGCTGGGCAGGAGGGTGGGGICTGCTGTGGGTTCAGAG
GACTCCAC
ry cn CTCCTGGCTGGTTTACCTGCTGCTGCCCATTTT CTCTGGGTACTCCEGGCCAGAGGAC
TTTAGCCTACCCCTGAAGAG CCTGTCCAT
.....
GTCATTTTCCTACTGCCATAGATACCCTAAGCCCAGGOCCCCTTG.AGGCCCAGACTCAOCCTGCCCACTGGTOCCGGA
GACGGAGTO
GAGTGGGCCTGGATCCGAGGGATGCTACCTCTCCCTTTC
CCACTTGAGGACCCTGGOGAGAGATGGGGGCGGGGAAAATGGAGGTAT
GAATTTGOGGTAAGAGGAAGTGAGATCTCCGCTTGCAGGTCAGCCCCTGCCTTGCAGGGCC-GC-CTGGCTTGACTCAGGCCCTGTGAG *10 n ATAGAGGGCCCAGCCCAGCCCCACCCACAGATCCCCTGCTCCIGTTGIGTTCTGTTGTAAAICATTTGGCGAGACTCTA
TTTTAG TA
-i ACTGCTGCCTAACTTCCCTr2TGTTCTATTTGAGAGGCGCCTGTCTGGATAAAGTTGICTTGAAATTTCAAAAAAAPAA
-AAAAAP.A n - -_______________________________________________________________________________ __________ k=J
--A
kJ
...6 =
(9z 9-mH) 133HS 3iniusens anan9n0o4392,nn9n.30nnon9n9009,annnn in 2,99,0n0 9.- CI H 0n09-9.3n9,009nnn02,9,02,no9,0 oi na0onn02.002,n0.30(30annn.3>nopaponan o . (.70oP ,.c)onaa.35,A.an,b,n6-)a)...- anaPP:'06)apna H
0 .--3n0.39(30.3n.--399.-309.3909-n0an.3n9innna o an0nnnhnonnroonann=00nno.--3n9,annn.--3 9.30.30nnnnnn nn9-na9-02,nn2,9,-36)o6).3 ,,c.) o paanr).,,,>a,,o, aap>6)6) a 0 0 0 a.. na a> a.3o6) =
nnnnnoci)oonanoonnnnon, narann =
a .- a anan2,02,9029,- 0 H 9.-nny,n "D, 0 0 0 n H 0 P= n n NJ
al OH annanonanoo.3nonn00,3nHpn00.3n -,06).,->c.,a,-3n.-36).-.3nacinnnaanolopn.-6,n H b, x..po. 0 0 4) a. .4 Is Is a ,-, 4, n Is a 0 0 0 Is H 0 Is 0 Is 0 ),,, --3nn 0 r) a n a a n o a .p.. a a 0 o o n n n a a n a a a a a n a a 2,.--3nn2.nnann.-390.00.30009,909,-n09-onnn0 n.-3n2,009,009.3.3n996)9,n0n 99,099 02,92,n9 nonnonnnfrInna.-3.30a0.309.00.3n90n0o0no 9, 2, OH 9. 9 n 9 n a 9 a n o n 2. .3 0 n ). 0 =., 6) oaaonaan a ona ananon000nnaonnnob.nnnonno0nn O0/000.3no2,906)6).-3000.39,n0ao0n9:0n2,0nn 9n02,90000>ono2,n0 ,.--3tapnann.-3 a> :0,- a4),.,nn C) 0 y, o 0 o 0 0 0 .3 n 0 0 y, n n 6) n 6) o o n .3 n 6) 6) n a Is a Is a onenonnn09,9,annnon9n.30)-30n509, H 0 H
D. 0 D. 0 H D. :D., 0 > .3nn6)e32,0.3 H n a n a a a a .-3 a ,r, 0 4) n nr-32.0JJnonnannnonnanoonn .3 .3 n o n o a a n a naoc)6),a0non2,92,99=0nnn09.- nan9pns.nno .3 =,n)=,,,PP6-ipn,-3.-3no6)10'bnnaaa>nan;0.-anca a6).-3 anao .- anon.3.-05,A0n6)n6)n0onnn9a09 C) 2. n n - '0 0 9 0 a n n o a 0 0 o .3 2. 0 y, J, 0 0 0 n 'p 9 0 n 0 a oo,_3000y,,n9-*ppn.3aoap.-3ar)n n :r. n n o anan .3 o a n n a a .3 a as n .3 o a a a a o n n .p.
naaann>nna6-19-nopon9n-309,-loon9 90 a nan:p.p .,.2,0n 91-30.32,09.9.9(3.300n0nno 0 nnanonaaanan, 0410000000).-3000ann0 06-)00:,.>a=,4.> anra).,nonnooann>nno>xi-n 1, .:naanonn2,0,--3 nn0002,09,- ,-3)=. .-3.-3.3..- an annnnnnnanno naaannaa oonoononna n=,(-)5.D=,anannnon,..6.1a>,..a,n):,,an.-iann Onan09,-399.19.9.36)nano>apnPaoa:roao6)6) C) - 0 Is 0 n r) 0 4-) 0 0 0 0 a n c) o a 0 a n a a Isb 00063.3.3a no9n9002,00 -9na.--3onn2,9no9,anb, F-1.-34-).-3,-3,An C) Is a .3 n H .3 Is > S). ),, > 0 P 0 1-3 ,-3 a , , , r ) ) 0 Is 15p a a 13 a Is 6) 0 =,.-3nonnvonapannoomnonnnoonoanna n>2,0 n9 ar06.).too.onnoaaanann.bbabb.-ib 1 nn.ana r) > Jr,(33-nn 99 ..-36-)p> a aonnagb 0 I-) n:0(,).-3annoa ,=,-6)nn 000nnoonno>n nna ,n ant0(30:0.30oD,,na>o 6) nanbnaanna):,.3non )nonp,..-3 .,nn6),--3.3 ,. .oc) b.a:l..-,on.-3no-3()15,A6) C) Is n n H 0 0 a 0 0 n n a n n 0 D. 0 0 0 .3 n 0 0 0 n n n n 0 0 0 no2,00a9-9n9n909nonan99,09,0n99.3nn90 99,32,(39,906).-3.3.3-3a)%.-1.-3na.-3>n,--3annon anaanoannaannananonannaannbnpba C)06)6) o n .0(300n2,00n0o0o2,a2,a3ann.-305,:'000y.0 *1 .v 0 0 4") rt 1,. nonnna,--30.3nno.332,10 up.3n9-on ann.-302, Jr,nn9nn000(-3(30.3 9 nannn.30 =,ap,--3 6-1.3 aHnf-3,,-=,,,a,,PPaP) .3 a a a .+- 6,6)6) annpnn 0 ra 6) annonnan n n H n 0 C) .4 0 n 2, o n c-3 0 -39n 2-,n:02,nnn>onn9np63.-3.---39,0 00(3'002.9 :00n -,.-30-3.-3:0;0.-in>'.0pnap,0n;pna,.0,-3,-3ob'paa nonp 0 .3 .3 nnoonnoonaannn00000n o anon aaaacia),,a.-3)=onaa.36-)anaaaroa96-3 009 n 0 09,n92. a 0 .-3 a annn .-.3 .3 >, a a > a n H 0 0 P= ,,, 1 C) 9 n nn00n.30n.lon.3n2,nr3002,0nnn o (73'30 9.0n0n0n9o2,9ann02,009n2,0aa9-2,no G/n On06-32,02.09.3-3 :09nn2.0J,,209,02,09- 0 a n x, n nnnnan 0H0r00000000D.00H00000 0 0 oannaano> naapon ,- oPnnno - no2,9n0o noaaPaa>41 >>5,,pnaa0 6-)c-Y.3PnP a> apnana C) n a n a 0 0 0 r.,) 9no99nn a n a 0 0 0 0 0 0 (2, G) 0 :?=, 0 r) n npa>c)06).nap->ana:,.-3.31-3nbab,annnynnr) a)..aa:r9>'pt-3.-36)Pan.-3.-3n a 6).36,n)d .,.,a o, ,nn>>can aaononao>nanpanannoa 0 (739- annn9on9n 2,909,2,nonnrn.06)aannnn:woon'ivbb 6-) > nno .-3.3.36) a x, c) ;w 4-) > H' ..- on:00.3Paana b.-3.3),a ann on>noonan 0000:voaoaoaanannnononn onatapnnov.-loano0naG)044.3,-Ionana),, 0 H )-3 a -,a>6--..,6) .3 0 0 0 :v H (-,, P' tap ana6....3>a 06) a a a a 0 0 6) 0 0 H 0 0 0 0 0 0 0 0 H 0 n GI 0 0 >pr 0 0 0 r) O cl, a (-,) n n > n a a n ono>. 2,n2,0n9onnaaay,nnn 00no9.--3:0nHnana:t. - P ,,,:l.,,--3n.-3P>oantn,..--3p n na=pannnnanna a:Nana/Dana =,..3.-)nonnnanP
aoa,aa:onnanb)Japo.na oona.3 ono ,,a6". , 0 0 0 > 0 .-3 Han'pa.3>nrinannal-3.3.--3n02.02,99.32.nn nOn0nn00.3non90nnno6)na9J.9 ,-3 =,Øi-annan - ________________________________________________________ Al 1.1 r z x pi CA 10 tn H 0 0 0 r a '4 tol p r<<
V 0 0 a on a < p 0630 r tri 21 r tyi z ,t, pi pi H ti < ,-ti tn V' Y...) Cn .3 .ti .. H
tn H Pi 0 0 ..3 to to o ).. o zt x z x 'to, toi :b' Pi H PI t. a to > a b to to o x ..., r ar rltitoiko<arNNtxtro.-3 tpit-tzto z 0 En 1-C t=i z to ..zt 41 Pi a . 0 Col En 70 XP P.HZ
tr1 õrt,, 0 0 C b toi tri Pi 0 H tC 70 )-4 hri N ,,i Pi i, ,-.3Hxf--iN < azx .1,,v] tri'xi 63.-4z63 .<xpqr ,-1 H 0 0 0) ED, M A htl H )0 1-4 trs n r n a to a H Pi co to Pi to -4 H.41-1PdPotong .,--3, W CO toPNni orator ..1-ico6)xxl-Eit.18 ,,, 61 <H H t-' to .--. 2, pi H li apoiroirtotri H <ro 63<663HatoitoN-4 ri n) H X
).) ).< H 0 +el H tn ,ro 0 D. < En H 0 Pi H 0 H =
0 ,r.-.3 ow..1 10 H . :.,q c=16-), Hi 0 tn En 64 6') 0 X 4 tn PI .< 0 0 0 H tg. H hi '4 ;-3 ,o 9 ad hi i--. ,o rd n o I-I C,J < 'n 0 Pri I.<
0 0, 0 H < PD D:, t=1 Pi :4 x ,o a .- tr, a H )0 H P. tu En X ..n .3 to ),,,- ql G) 10 t, tn t-f t=i <.4Hor a or, tIN =Z H b .3 7d1-101 1=1 t-I,vP;) Ai HcNn ti V) .3 t7 ,-3 > HHH )--4). H7J1-10C).ti tianx.oior zz z z o r r H Ea toi r n H r lo xt z to .- z rol o H z p .3 N X Cfl tl 0 1.i riPit-taa= .,=at-.ti-.Norz .3 7elt,00ct. r .1-tt.i.-ir x r-Ixtqtiapitri x?.,colotaNxt4 o,xPz1 En 0 D=, 0 H ND 0 moor 0 0H0011:100<trIXH z Pi t.i w Z1-060/LOOZ OA%
01Z000/L00ZVJ/Icl [1,1 P `), 0 .4 H 01 a a, g 1.71 H Q E'1, 2 HP4>-.00:rEo HEXION01-10M,-4>a) ;110 1.,..UEnE.H.a,a1 U/9.E.1.4...x0r1.,rot-I r:14 Q N
rCli col Evl 6' 'Eli Z' 2 N
Walt...WED.-4H '-N 0 ;.. `j)" N '3 1 5 2 q Di 2J`-', ,n)g; .: ,(:), c,4 ,1 iu r' ., c' p 8 6 8 P. 2' ill 8" nF.. .7._ Cil E 2 3 P r.... 6 8 ai I E. HUUUHUU
U E..) E. < el 8 6 El 8 8 8 El 8 8 ..e 6 8 6 6 8 6 8 b' '6 8 6 8 8 L') 6' U E. t", E-, E-. U 0 g H u 0 F Er H F. i6 U(.UU ' 8 ,V, '6 6 8 b' .e) t.", t.; E,-e' 6 U(.90,0 0 E.) E. 0 H u E.
U U04:0 (<; rl. E. 1-' E.E' 2 4E-ic.2u C., .1: () C.) . 0 0 CJE.U0E.cieUt. H0000 0 HI V F i) (E 2, t - .7 , uE.0E.NUU0<E-.HbrdHOS,C?E-j'!'j U U..Ale.,..1;"E-.'3; 8 .`' 0 0 6" E-.00E.HH
V. EC.) EET 1 rY' H 8 ' 8 8 E... 8." ..,- 8 6 E. E. 0 < < 0:
< H E-, < HO
U 0 < 0 < 0 < ,t.4 80,`,-e'',-,i'ElaltLe) 6,t10.68,1Te:,,1 E--).
E.... 0 E. < E. E. 0 0 E. < E. 0 u 0 E. 0 0 (-. 8 8 6 8 '1 l E 4 .()=
;..0 5 = g," '6 8 8 8 0 8 0 0 < 0 0 U.) . Rp -..) 6. 6 -; rõ , , ,. ,,, ,., 1 F. E. 0 0 E. U 0 < < U <
.-4) 8 8 8,te'888 El086168818 '.',-,'8.'6""..;
0HUUUHE.
U E. " " EE-_.,..,=6..E6.NE1E6-3,8,- , .9t-f_i . = C.> E. E. U H E.-, UU= HU= O ., E. ' , , , u E- .
0 U < U 0 0 0 0 <
U 0 E. 0 0 < a' 0 < (11 E. < 0 gi, UUHHUUHHHHA
8 b. 8 8 . `,1i 8 ,, p4 u, [-_! u 0 E. A r; t-,¶0"6 0 i'-', b ;11 . 0 E
El.) 6 EE.. 8 ECD. (S. F.:0Ha,UU00,4,0 rt, U 1 E-7 EiC1 P. Er , E. -. -4' ) 000 8 8 f,-"q '' 8 8 r-, 8 8' '' L?
E. < E. 1,4 E-, U (..) = 8 866E86 EU' E. U H. 8El0888-itiu8 u u CI E-, < H p (.9 (D U E. E-. q u F. CD E-, 0 E. 0 E. 0 g C.) F4 p k_,,, 8 8 8 8 8 u 0 E.-. u 0 E.- L=e u,:c ,H El _=), F,' ,c? EP., `- =Z E.
888,08 t_') EY180.i.708.0E.00000E-,<OUUE.90,<
U u U U E. E. E. y g ei E-4 E,r-t. E,'5, Cp t1,4 0.
4' 8 8 Pe 8 n (V '1.
U r..) 0 0 [.. E. C.:.
U . 8 r-% 8 ,t,l, 'd 6 P4 ', * (E?, 8 P A F, ,$) (E2, r(-4) U c... g ., E.
E. 0 0 E. 0 E. u 886V-D,rl.`-'8H6,6",te' 68$'6",e88 u U E. < < E. 0 E.U0H0E--,< 86:80186808,e8i-,8 Elt;86886 E.E.UHU<E. 0H000,0u0U00UU0OHL.90 cp g (.../
u cl C.) r, C 7 = U CI
O 0 H E. E. H (9 (9 "E'ElE16%-lEt;ii8 66[1 6 ",,C, t;il `1 :t 8 8, 8 8 ,'el 8 R i.i-) !4._: Eq'4 s'-.J.) 0 < < 0 L.)L.... U Pa; L-, t. 0 E.. <PH .o.q c E.E.E.000 = 0, E. E. E. H E. H
i-j (.;rj, 6 8 2 8 6 8 8 WV ))0U 8 .18U 6 '0" 0 ',', u E-, u E,E.E.F.
<UU<HU0 E:). Hb' El 8 r4 0 6 6V661868`8E,,[483, E. u E. U 0 0 E.
00<<E.E.0 8 6 1E-4 8 8 8 8 ,Ee" ("- 8 `,= 6 6 u 8 8 ''c 8 E. : r 4 < u E.E. u E. g H 0H E. <PUUK.) E.C..) HHO00E. 0 HU
OCJOUL)E.0 0 0 0 0 0 r.-) E. u F=C 0 F. u c.D o o .1. g u u E. Kr q 8 8 8 t -,' 6 8 i s..). c? EC-; t P :<( 5 , .5E- ' 0 EP, 59 ((i 'k' 'd b' i"-: gi 8 8 8 8 q 8 ',i u 0 C.1 E. U E.
UE. 0e. FA:U L--,-. 8 El ,E,-" 8 'Et O 0 0 0 E.
H0000HH 00<< HARI. E,:,-. (i.) tE....% E, .6. ,E,-if, E--,, cc.-= 8 (,-_,., '.g.
00UUUU Ft: E.' ti CD el r2) (t=. CD E, c.) E. g 0 (.3 cD 0 E. E-, H EA
O u y < U E. U ''' u . ,I= p= c ' 0000<00 0 cDUE.,<U0 6 HD 8 g t 6 "i-9 6 t.>" 8p 0 u E. E. 0 H U E. u ,i, E--. < E.
< E. H < E.., 0 0 A
8 8 8 8 8 8 ocu<000[900000000UOU g u 0, OU 8 8 8 1 8 El r. h9 ri E,E, 8 0E.E.
O= 0U 8 8 0 8' (,: E;e" ,e 6 `,'e 8' 8 8 `,e) 8 ?-.. 8 E;e1 V: 6 c., E--. g (9 g E-.
CJOCUHE.
E,E,,e0E.-,, 8' 8 8 6, 8 6 8 8 6 8 ., 6 r," ri 8 0 8 8" 6) ) tj 8 r." 8 8 " < 1 " < ,9 " 6 5 tl 8 1 8 6 . 8 8 8 O000HHH s '4" uPu H K.
...)z) <U00000 8 8 8 re ' 8 EC', I `'. b' 8 8 8 8 8 8 8 ' U u u L) H H 6 (Du 8 6_, '6 QPI: 0 r 8 6" 6 `c-,) 8 CE.-.7 6 8 6 6 8 El u 8 8E, .)CE_, .
000 PPE. H OHHOOUE.0< 8 E.- p., i. (F_D 0 H U U E. 0 U 0 E. (W.' 04i:0 0 (C) 880PeEl88 rii SUBSTITUTE SHEET (RULE 26) H X a H >.;> z z H g a o w ul w p4 ;=4 (:)1 rK al z a a x 0 cn g ,-1 n....õNp gt=21E--,owz a, a al 1:14 T4 H p ral Z A z ,-1 X rc. E. E. a Z
E. a r4 f4 En n, z 1-1 0 En 0 in pi ,--1 fri z ,-.4 z a Cn C/3 0 E. Z 0 0 Si 0 fi= cn Er] p HOO N Ln ri-4X01X>Ent.DEn>
01 rri > x 1.-a OHH R - pHarlac_9>Ø-1 ,-1 X C9 q 0, q = 0 a 4 4 ,-.1 W X E, }-1 C4 E. P E. En ..4 A 0 C.1 En f4 a, H 1:4 n 01 >-, 0 4 a H pi X E4 cn CI Ex. 14 a >4 fat H XrdcncnzMar.n..1.-10g a q r4 0 En ac q P-, 0 01 :4 E4 a al Ea a g A 0 > La z t4 cn 0 09 PE4 la 0 H
4: 0 Z E4 GI crE
U E. E. E. E. CD4HE,<<OU40004H440 U 4 c9UONHHHUgUHFH
H u ED U E. 0 u CD u 0 u u E. 0 E.
E. 4 E. H g OHHHUUN H4E.HEDHHOE-, H Ft CD 0 E.
H u 0 0 g E-.0000(90H0c.DE. CDE.OHE.<
u H H a; g OUP NOHuOugOEHUE.gH0 E-I= ggUE. E. u o 0 U 0 u 0 A U F. .6 EH 0 CD 4 UOHHH
CDOE,E.H u 0 a, H u U E. g U E.
U U H U H U U U u 0 E. 0 0 c...1 E. u 0 0 0 0 g 404 E-1 E.
4 U 4 H HOUF4UH4E.CDOE.OHEAU 0E.
E. E. 0 5 C9HUUgH uguE.HE-ogy E. at coq 4 4 t g (-1 g F. 0 t..9 C.) 0 F00 0 U 0 H 0 H 0 g u g g 0 E. 0 E. g UUOUUNgE-.0 UHHHEHHOU
E. g U E. A g E. g 4 g: ED g (.1) C.) CD E. u 0 g g E.
0 0 0 ci E. tH E, u U A d H Eg E-, E-, E.9 E. u ri, E-, E, 0 0 OuucDCDCDOcJa,a,004 ,,;0 U 0 U E. E. A E.E.UULDH40H
0 0 U fa: Kr: HOUE.E.E.E.E.00 E--.
u U H A H g U H ., 1= ": U 0= 0 UU4E.OUOUUpt0E-, UPC 00uUUE-,HH44 V. E. E. U
E.../ U g UQUAUOUE.U00A H4HE.
gc9C9UF1,000:000gH ,AE-,ci UHUU 00A gq0c...90,,,,IgHHAa.OH E.
E.HgEHU U A U 0 U g g A U 4 0 E. g 4 u g u H Ft OUE. 6,ANg ONUCJO,AE. E. H
U U g 0 g 0 Cy E. 4 c.910U/gE-.AgUONON
4 U E. H 0 E.HHOOE. Augu0E.OggH 4 E. UE-,4p,4E-,4 UHAEHEHAHNE.C.../0 u 4E.400 HE-,u40<0 N E. 4 UgHg A 0000 E, E.H0gc..90E-.00 Ougul. 0 0 U E. u u E. 0 E. E. EH H
HUH0U1Uc1HHH
UUHOUUH
U Ci g o c.) c..) E. E. 0 < HNO0UuHUHAC9E.ga,C9 0 H
CDU4,HE-, HUHO
u E. E. E. E.
UOCDE,E. c90E-,0C9UOE.OAHHc_9gHHOH
uHEHHE, cic_90AgOc9000uUE-.0HE-4r4 0 A u E-, 0 0 A u al 0 o E. 0 g u H U H H 0 g E.
gg0u0 000 0000E-100HgE.E.0 gE-, c.9 u g g H C./000AEHLYUc9u0E-, g E. g OHuHU
g g E. 0 a; a.,E.Auu 0HguuNgUE-.00H
000 H. A 0 E. H u E.U05HgEDUE.00d0g00 = g 0 A g 000H(9000,ACDHHgE.A,Agg 000 U E. EH E. 0 u A C.7 E-, N U E-, E-, U pc q E. A A u OguggE.E.HH0HUogUE-,gH
AH0H0 U0E-.019HOU0U0,110U0gHg 0 E. E. E. 1 U U u 0 E. E. (.9 g E-. H U
CD E.', CD ED H OUU,AE.g U01..90Hgg0 4 4 E-, E. E. 1.9 g A UUUOU0 HgUOUNOE, E. 4 4 HHOH u g u E. La; 0 0 g u 0 E. H E. E. E. H 0 E. 1 0 g H u 0 E. g A 0 H U E. Pt 0E-, < I
.=-1 E-, E-4 ED Ci C., E. H (.7 U 0 a; H c) E. 0 0 E. H E. I
co OHUHU ru OOHUUUHOHOH ac I
E. U U 0 0 = = g g E-, 0 0 E. U U U g A E. H 0 A g U
U
U u 0 H EH
0 044E-104CDHa,<H004<0UU
Z. UUAL9E-.4.0000.guHH.a;HE.g g H 0 U c_i 0 u.__,UUUUU0c9acCJEDOUH U
H
H 0 0 c.., g 0 g 0 g g g g r4 OuguHuguU0 7gE.c-)0C.91-.0 cn SUBSTITUTE SHEET (RULE 26) Cr4 S4 i,..1 E al E. I4 CD
PC CI 0 CI (11 H = re) D/ 0 4 cn RI '04 U CJ Op U) D4 a .4 4 cil C11 Z 0 Z C4 DI CD E./
E, n4 2 0 E. Z ch a X !-I LE. .1 CI X cn C4 > H DI .4 U) C) , ID
r...
ts1 , F4 6 0, tc A E
= c,1 c) . cl, C) cn H H C.;
C> HK,..1[401.4C10 Z 0 >. iZ rs) 4 4 rs1 2 A 0 DI Kr) H
a ca.U01.1:4tagcn rsi rs, Fs, tr) ',>
U) _ ___________________________________________________ Uuu5C) 40EDUU E. E.E.HUE.E.H05E,E.H.45HE.0 f .4 L) E. I. .g cb c) kDi.-. 5HOHHOUHE.H05H1.55E.E.E.E.H
u u e.) E. 5 0 1-, 4 L) C..7 (.7 50000E.4,0Upcur.)0.4000HHOH5H5E.5 r.J U E.E.)044 rJ CJ H C.) / a' H H
6 0 CI E. U g .4 E. CD U
C.) EH E. E. E. t) 4 , 4 0 .4 E. / E. U 4 E-, EA EA
E. E. 0 C9 .4 E. 4 U
0 HOH0000,4505E.E.OH<H050.4H5.4E-1555 1, UUE-.0045HUE.54.E.5H0H5,400-5555HH, u a U)0 0 H E, 5 5 u .4 E. 4, 4 E. C) CD E. 0 a 0 4 E. L) CD E. CD E. a 4F-.
E. C) .4 .4 C) 0 CD C.) cD c) C) E. C) a A E.4 U E. CD .4 c) .4 E. E. C) 0 0 4 U 0 0 5 LI E. H (J 0 a: E. E. E. u E. U 5 0 CJ 5 0 E. E. E. H
4. 0 I. 0 E. E. CJ H 5 E. 5 1. E. E. H U 4 E, t.) (.7 f4 E. u H 5 0 E. 5 0 U 0 rt E. 0 E. E. 0 u u E. E. EA F, 5 (9 0 u H 5 0 E. H U rai L.7 E. E.
H'-)a, 00 H 5. 0 0 .4 0 5 E. / 0 0 0 5 F4 g 0 E, H H (.3 5 E. 5 H U ei E.
O 0 5 H E. 0 CD<Ha H0r<cDUE.HaV.,<H4a 4 u H 4 4 UUAU 5 .4 4. ED0 4 0 u u E.C.> 5. r.) 0 u C.) < u 0 H < E. a CD CD 0 C) 4 U 0 Pk C.) E. 4 E. 0 E. U FQ E. 4 0 E. C) 5 E, CJ
= 0.1 O C) 4,, E. ,4 0 0 E. CD
C.) 0 / a 0 E, A E. E. U 0 CC 4 U A 0, E. U 0, 9 O (i l'1,4 6t U U H 0 E. 5. ,4 4 .5 g Fl. 0 E./ CI 9 Ply A ec 5. U 5 CD 0 0 4 KC CD 1, 0 E. ,4 i-, E-, (7 CD C) 4 0 0 t9 U E. E. CD CD A U E. () .4 F. E. E. E. E. A 0 E. E. E.
E.
0 (.) ,4 t-i E. E. U E. E. C.) E. C9 E. E. E. CJ E. CD KC E-, 4 E, 4 E.
0 cD to 0 0 cD E.1 E4 E. 4 .4 E. E. E. u gq CJ 0 44 0 E. E. C) EJ C..) Ch. E. CI cc O Ch 0 E. CD U U ED c) PC CJ 0 E. F. E. 4 E. C9 0 4 () E. CD 4 4 V. 4 CD .e C) 0 4 E. 5 0 E. . E. 0 0 U E. (.4 54 E. a C) .4 H H 5 E. 5, U 0 0 E, 4U C) 4 EH C) C) Lh 4 0 C) H U u 0 5 (I E, t) 0 0 E. 4 CD E.
CD U E. C) 0 0 u U .4 H E. E. 0 E. CD E, .4 E, E. E. t) E. g4 U E. E. (9 a g U E. g F, g g Kt 0 E. U
cJ H E. E. H E. 1 a / E. H .4 F. CD 5 E. 5 U) E. E. ED U () c) U E. 4 51 E. / 4 u 4 E. E4 E.) 4 E. 1 EH 4 9 0 0 0 E, CD () F. E. E. g V H C/ KC E. F. E. ,4 C9 0 E. .5 CD FL
CD 04 E. E4 0 CD E. E. t9 E. E. C.) 0 CD 0 1, E. E. E. C9 tJ
,..c E. 0 CD 4 .4 4: E. t) L) .4 .4 .4 U Cl) 0 4 .4 E-, L.) t) Kc E4 .4 1 4 C.) C..) 4 E.
0 gl, 0 IJ 0 E, U 44.4 Ch Pt El 0 C.) .4 C) 0C C9 E. ch 0 E. (9 (D
0 (D
CD L) a 4: E. g 0 0 <
, t, 0 a E. ch 4 Cl) 0 I, 4 F. .0 E. I, .4 E. a E. E. t) E. t. 4 0 E. A
i (9 .µ4 (9 E. 0 U 0,4 .4 a. 0 0 FC CD CI E. E. A
E'l H 0 0 E. E. t) E. E. A
KC 0 H U E, KC Cl) A U Cl) E. 0 U 0 .4 04 4-4 E--, Ei 4 0 ,4 (.1 F. E, .4 E. E. 4 CI E. 0 E. E. rC 4 0 E, E+ U .4 E, eC 0 CD P4 E. .4 C) E. E. E., 0 ,, E. C) E. E.
CD LD CD F. gC CD H ft El U U E. (.3 PC Cl) .4 (J E., E, E4 4 Ch 0 e---, A pc () 4-, 4, c) 04 E. K: 5 E. g rg. g4 u 4 E. U c) E-4 f. E-, E' E. H E. H CD a H E. .4 U 5 CD 0 0 u CD 4 0 d Cl) H L. E. U E. CD E. E. H g4 E. a < E. t) u E. E. E. E. 0 0, 0 F. U 0 ED a u E. .4 4 C., .4 E. a U E4 E, E.-, F. Ft El Ft 9 E. CJ F. U
..4 E.
O E. 0 E, ,4 ll.0 E4 0 E.
0 E. E. E. .4 .4 0 .4 4 E. CD .4 Ch f,.9 ,.-oq E. E. E. E. 1-4 ED 0 E. u E. CJ E, E, E. CD i, E. (..) .4 .4 0 u U .4 C.9 E4 E. a E. 4 U Ft El HU0H5E,H um:4 5.UHE.E.05.40 -5E.ciE. E-I U E. E, Cl U E.
CD CD F. E. E. E. 0 E, CD c) u F. a t, 0 E. 0 E. E., PC .4 t) 0 .4 .4 .4 E. H
E. E.
U Ci CD C) '' E". C,. U .4 CD .4 C 0 E., .0 I, .4 gr, .4 CD gl 4.) H.4 H 0 44 E.) 4 ,4 CD 04 Cl) F., E-. ,4 E. 0 E. H, 4 4 CD E4 CD FN PC CD 44 H-4 E. E. HO 0 HO
E.. ci E. c9 4, F. E. E. .4 C) o,' C. a () a E. .4 a E. 4 0 Cl) () V E. < E.
Cl El E.
() (9 4 CD .4 C9 E. CD E. E. 5 CD CI C9 gC U E. Ch E. CD g4 E. U U U 40044 CD C./ 0 4 (7, f. E. 5 4 C./ E. H. a 4 C) 0 4 .4 CD g4 u (9 E. 0 E. L9 C) .4 .4 0 c) U E. eD Pi, CJ U 4 0 0 ,-. ,,,t: a 1-, E., E. 44 () (.9 0 E. 4 g g th PIC
E. 0 u 4 C.) 0 E. CD .4 0 .0 E, E+ .0 PC E, .4 (.7, g4 .4 0 F. .4 C. E. E. C) 0 cC 6c .4 pc c3 Ch Ch (di g ...q u) < 0 C.) 1 C) E. E. E. a E. E. H E. U A E. E. E. C) FL E. Ch cC .0 c) 0 CS K., g T., L9 g g Kt E.-, 0 PC CI U PC
Pt E. a .4 E. F. c) a 4 .4 E--, t) g (D () C'D '4 , (' 0 E. Ci E. 0 E. U .4 E. U 44, .4 E. E. .4 g .4 E. E. U c.) Ch E., C).4 E. 9 4, 04 E. E. E. C/ C) () E.
.4 a E-1 E-, 1,-, CD H.4 0 E. E. CD F.
c) 0 0 u cn A4 u U)'1 F. .4 E. c1 .4 .4 u E. E-1 E. u E. g 1-, E. ,.4 0 .4 E.
CI
Ch U) C) Ea E-4 E. (9 0 a CJ E. < FL A E. 4 4 CJ Ch E, 0 E. E.
E. U < E.
CJ U 0 E. 0 C) a 0 E. c) 0 E. E. 5 4 E. E. 4 E. E. E. a E.
CD 0 E. 4;
Cl) t) CD 4 E. F. 0 0 th / 0 H c9 LA E. 4 (9 E. F. E. U E. E. E.
E. L) 0 a 01 0 C .4 C-9 CJ 4C C El E. a 0 E. () 0 F. E. E.
0 U CJ E. HC9 cC +C gC
N CD 0 0 CD 0 U EA LI C) U 4 Ch c9 E. 4 E. .4 ft E4 r4 c) 4 E. CJ E. E.
C) 0 CD .4 E, U U E. 0 r4 .4 E. E. CD / 5 .4 E. CD CD E. 0 E. 04 u < LD
= CD (h .4 E. .4 E. c) I. E. .4 E. C5 .4 E, E.
E. u E. C.) E. E. E. C.) E. rg E. rJ E.
6 C) 0 0 0 CJ H E. E. 0 U).4 El 5 0 CD u CD E. u E. gf E. E.
E. H.4 .4.4 Z CD U 0 C) 1 0 C9 0 CD E. 0 .4 U E. .4 0 F. .4 .4 0 .4 0 E.
E. CJ 0 E.
Cl ,, 0 C.) E. 01 ii E. pc a .4 E. 0 .4 0 0 C.) E4 E. E. E, E. 4 E. CJ 1 CD
H C) 0 0 .4 c) 5 0 4 E. E4 Ch C.) , E. C) 0 E. 0 C5 CD .4 .0 al 0 01 E. a E.
ril 0 0 E, 0 E, cf 0 u p< 5 v4 E. 5 E. eD c) 5 g4 E. f. 4 U 0 04 rC 4 E.
L., FL c) _ SUBSTITUTE SHEET (RULE 26) , g N al > 01 hi t-q 0 a, __ p4 44 0 44 (0) al 01 tn R EA Z 1,4 ti3 74 4 fii U.) 0 Er, (-4 4 z 51 CD CD, 0 fl, g 0) E, r4 CY 0 014 Z pg, 4 74 0) I-. rl .4 2 r,4 H H 4 HO 2 6 c,2 .r: w P 4 P N ,.1 ',-?, f4 P
04.p.4c5r)0.0y04,-i uenci.-107E-.44y3 eip ,g0:441[01(30 ff, gi m m gl g 1 g (n P, FA e4 c, c7 O4 0 1 4,2 '1 E. 4.1 C)0 P1 CD 4 .3 C4 g ph4 w pl c.) .4 0 V4 i-, a. i-4 74 7. 4 04 ',1 1,:,1 '2 2 P R 6. ,Y, ','e: ..'," '4 g r, t=,,1 F:,,: '("l ,?,' 8:
.. (, E. E. K HZ OH g3 ,. ,-1 i9 5 oa u in pt C7 P. E.
al en 0) 0 > z a, 0 c4 01 G-I c. C.! La P. ta Pi Z P4 C) (:YE--vrgp1;,4, xa. P ':', VI Co CA CI CO olxAzxgg 1-4 til (4 E. .4 ;4 0) 0 z 44 P.; (9 r' 2 01 ?4 ka e4 Ch Pi CD Pi C7 era En VA p4 X .t ,1 y, _ CC i 11 t cn X Vi 0 .4 cy 0 4c Z A LU Fl 1-4 ,4 0 Z ?A 0 0 Ei a. pl fil E. 01 __________________________________________________ _ 0 (5 CT t9 c9 c) gS g 4 CD CT, ci g4 CD El g 0 E. E4 U 0 U E. ,. .4 0 E. u (4 (5 4 gt c) U .4 44 P4 kJ c) 0 t5 44 E4 c--) Ke, L, CD CI C/ 0 (.., 0 .1, 0 C-4 0 0, 0 0 A CD c.) 0 E. ti K4 0 U g g 0 t; g 3 59 r, 8 t; ,i): ,'-s' g 6 ES N E4 ';(1, `4 V, 8 8 4 ES
( i94 p4 0 D il ri 8 il 0, H =,,c H 0 0 0 9 c) ci u C) 4 E.
E4 (9 u g u (9 H .4 (9 PC U CD, U fa: E4 Al, Ali 0 AC) , [1 '6 t"), E7,e' q [:', ',q1 ','cli F, EE i?, 1 El N [--: 8 t-j ,1 8 8) E ,11 (3 (7 0 A Ch C9 (D Cõ) CI Ch Ch. C.) (D gl 0 rC ,C,.?, Ci p, () E4 C) 4 ..-, [5 ,T. E1 8 '6 U , () 8 ,V 'A N' ', ';;4! ES ES El El fl'. V, El i4 H q 6 E' 6 8 ES 8 0 ES E3 ". 8 E4 6 El El N 8 1-4 8 El 3 t4 C? f-J' 9 P, cry t51 ,, ,,_3. 1 tl t-D. * .1 6 8 8 8 8 õ N '4 f5 6 '4,)!.
,, ,.-- ,- ,-.. ,,, ,--. ,-, ,c, E. (9 E. E. E. 4 .t E4 4 4 E.
44 44 44 E. A, (J E--+ El C5 CD u E, 04 E, 0 FF (.7 u E. 12 1 pg., U r( 0 r( 4 ,. 0 L.) p g p (9, E., 0 0, E" 8 0 ;l E4 8 8 ' 4 'C I'S 0 il 8 E?, E4 0 6 '' 8 ES 8 ES Ea 'A g 1 t-r-i' * 0 8 1 8 t.:: cfl (VII 0. P.0 L55 (,-4. cl 8 6 ',..:-ii i--: E
, E, E. 0, C) 0: 0 E. E-, Ch 0: LJ 4. 0 rr 0: 0 0 E, rc 0 (4 E. ,4 E, (2) ,,, E.
,,, ot 8 0 8 i-9' 8 r.;i " gi 8 8 ',:' (C.)) Eg--,C g: ,-,c' g:9 8 :-T) E:1 2 fC' 1--:
g .,1, !-.4' 'icli 4'-' 'g E4 8 g t,'. Li 8 ti; E.)4 t--_,µ g, 8 L9 E; g !;
[:: t; 0 (1, ,E,t' ,.
u E. E. E. 0 E-, .4 &I E-, k-, 4 (D (9 F4 () re 0 E, ES ,4 A '.1/, 0 (h E, E.
0 -.... Al 'E.1 .( g r. El ,V1 8 8 I'D' E: 8 8 g g trj 1 g 8 8 )- ',,',.
t; 8 2, El 14 21 i(9 E.) 0 I-, Li CJ U Ch E. 0 u CD Pk E. iii t,) Cu. .4 E-,--4. ,6 ,õõ:
:õ9, 0 Eg 8 l 8 `4": El E5 E,'t 4 r) ,`µ,, 1 5 1, H 0 E. U t9 Z1,9 0 ti p cn 8 E u V,' P. ',', 8 8 8 El ,,, 0 '6' ,., 1-4 N ES 4 8 [l 8 El * Up (4, -'4 [4 8 'E1 E:' d E: 8 E, il t2, 0 8 8 0, ES
8 0 El CD E. u g E. U E. py (9 (D o< E. ci E-, C) 44 H g g g 0 44 E, E--, H 0 co E, E. 0 ... g .4 0 Ch r.) H El H c5 E. E. .t AI; 0 E. V E. ri 0 F6 r-, (1 gi H Eg- 0 E9, 8 E,-,' 8 u ',,- '2,. 8 -_1 s 1 v, il õ õ õ õ ,, õ õ ,, 4 õ E. 44 c) E. t.) Ch 0 0 CT
04 E--. Ei (9 0, g (9.(D " EC71 g"1 " ACH 8 '4" 6 :). ",,i1 6 t; ,":- 6 U t;
6 [5 tD r, i g'; L9 8 6 6 0 0 gC f-f 4 0 g E. (9 C) g 0 U E. 0 c5 EA 19 g gc Ef gC 0, F, E-, H E. 0 E. E4 4 0 E. g E. E, c, g (9 H CJ cD gs (9 (9 E.
2 8 (,-:4 5 El Eg ,'-' 8 6 -!, ?) E4 E4 N E,, g El 0, t; 'A ES 'i g ES 11 8 8 Eõ ',,'-'4 El 0 E: 6 El 6 (., El 8 El E, 0 El 6 El ',,-.4 i4 0 6 6 il E4 tri 0 ',,- E;-, F, I?, [?, g N N 0 El N P, ',.-NI 8 8 il; g E4 El H HLDHHHHU<UHH Ca H 0 Huu.Ku4p.[-,tciusrt..-2,b6 , 1.-.:4 kJ (9 PE, F, E. A CD 4 0 xl, 4 0 U, ,4 ..' 4c 0 Oc E-, E.? c7 0 E. 1 c) f, c) gs ,t- 0 / cl 8 8 6 0, 8 8 V 6 '4 F.: E., 8 El 4 1 N 8 8 i f5 E_,E, 4..E.r.,,,,g(90_0004000, g 0 g d, g 0 H 0,, il 8 E4 V. El 4 g 8 8 8 E4 V, 8 4 8 El u g 0 8 E, El 8 8 ',,i 0 f" 6 8 ES 1 8 g E4 8 8 6 () 6 6 CD E6 6 t; c=-ii i.) U
[..)) 8 E. n C) Eci'i ,1 'a 8 6 E, ES (4i ES ES g, ES 8 ES I:: 8 E. 0 E, 0 CD g4 0 E. 0 gt u c) u g 0 E. ps ch. 8 c7 g, cõD, c..3 c_.õ) (y, t5 8 E. E. 0 E. (J E, E. F. F, r g y t: El g t.,. E, 6. u 40 4 ..-..3 c, E. CJ E. C.) F. E. E, V CD U N., A 4 U E. E. 4 04 E. U 0 0 0 E., KC a, E. 4 4 .,µ ,E1 0 t,i tl tt..-; cl Ec, tr:!õ i...1 '4! ri 8. 6 8 8 6 El 8 66 ES 8 ES 2(i ', (i g E.
E.
ts r. C., ,4 a LI l..! H 04 4 U U u Kt g4 .4 44 0 41, 0 A pc gs (9 E. E. 4 E.
2 8 Ig." t'D t--1 ,'=.4 8 H EE:" tej 6 5 8 R ",-4 -*)' El E-,' 0 0, 4 8 8 Et: 8 0 -2.
.. E.-. CD E. (J CI CJ CD 0 E., I-4 f4 ,4 g4 c, 0 () E-, cl () ,4 0 k-, E. pt c? E. c) cD E.
1 H g(6 _ õ ,. õ. , õ,_ 91 E, U.C) El (9 E-f CJ 4 E, 0 C.) ,S4 E. E. 44 . y.D
t:,., t::: .02 ci-õ, , _ .s.? r.-õ, C) kJ E. E. 44 E. cD E4 CD 0 CS ki 5s 5s 5s s9 il t7., ,a ri, Lc...), D ;..f;. ,,_._ 7,1!
1-4 L) g W (2) LI (--1 () E-' 4004 Pi 8' 8 8 d E. 'A 0 1 E. 0 CJ= 0 H
O
1 V. g E.'.!).!
SUBSTITUTE SHEET (RULE 26) SEQIDNO . : 3 1 S
EQIDNO . : 7 8 ATAAATATCAGAGTGTGCTGCTGTGGCTTTGTGGAGCTGCC.AGAGTAAAGCAAAGAGAAAGGAAGCAGGCCCGTTGGA
AGTGGTTGT NWRSLGLALALCLLPSGGTESQD
GACAAOCCCAGCAATGTGGAGAAGCCIGGGGCTTGCCCTGGCTCTCTGTCTCCTCCCATCGGGAGGAACAGAGAGCCAG
GACCAAAG QS S LCKQEPAWS I RDQD PlvILNSN =.c CTCCTTATGTAAGCAACCCCCAGCCTGGAGCATAAGAGATCAAGATTCPATGCTAAACTCCAATGGTTCAGTGACTGTG
GTTGCTCT GSVTVVALLQASITYLCILQASKI, TCTTCAAGCCAGCTGATACCTGTGCATACTGCAGGCATCTAAATTAGAAGACCTGCGAGTAA.A.ACTGAAGAAAGP.A
GGATATTCIAA EDLRVKLICKEGYSNISYIVVNHQ
TATTTCT TATAT TO TTG TTAAT CATCAAGGAATCTC TTCT CGAT TAAAATA CA CACATC
TT1tAGAATAAGGTTTCAGAGCATATT CC GT S SELKYTELENICVSEHIPVYQ
TGTTTATCP.ACAAGAAGAAAACCAAPICAGATGTCTGGACTCTITTARATC-GAP..GCAAAGATGACTTCOTCATATATGATAGATGTGG QEENQTDVWTLLNGSKDDFLIYD
CCGTOTTGTATATCATCTTGGTTTC-CCTTITTCCTTCCTAACTTICCCATATGTAGAAGP.AGCCATTAAGATTGCTTACTGTGAP.AA
RCGRLVYHLGLPFSFLTFPYVEE
GAAAIGTGGP.AACTGCTCTCTCACGACTCTCAAAGATGP.AGACTITTGTAAACG
TGTATCTTTGGCTACTGTGGATAAAACAGTTGA AIKIAYCF,KKCGNCSLTTLKDED
AACTCCATCGCCTCATTACCATCATGAGCATCATCACAATCATG'GACATCAGCACCTTGGCAGCAGTGAGCTTICAGA
GAATC.AGCA PCKRVSLATVDKTVETPSEHY1111 ACCAGGAGCACCAAATGCTCCTACTCATCCTGCTCCTCCAGGCCITCATCACCACCATAAGCACAAGGGTCAGCATAGG
CAGGGICA EHBHNHGFIQHLGSSELSENQQPG C) CCCAGAGAACCGAGATATGOCAGCAAGTGAAGATTTACAAGATTTACAAAAGAAGCTCTGTCGAAAGAGATGTATA_kA
TCAATTACT APNAPTH PAP PGLEHHHEEKGQH
cn CTGIA.AATTGCCCAOP_GATTCAGAGTTGGCTCCTAGGAGCTGATGCTGCCATTc.;TCGP.CATCTGATATTTGAAA
AAACAGGGTCTGC RQGHPENRDMPASEDLQDLQICKL
AATCACTTGACAGTGTAAAGAA.A.A.ocTOcCATCTTTATGTAGCTGACAGGGACTTCGGGCAGAGGAGAACATARCT
GAATCTTGTCA CRKRCINQLLCKLPTDSELAPRS N.) GTGACGTTTGCCTCCAGCTGCCTGACAAATAAGTCAGCAGCTTATACCCACAGAAGCCAGIGCCAGTTGACGCTGAAAG
AATCAGGC UCCHCRHLIFEKTGSAITUQCKE co cn A.kkAAP.GTGAGAATGACCTTCAAACTAAATATTTAAi% ATAGGACATP_CTCCCCAATTTAC-T
CTAGACACAATTICATTTCCAGCATT NLPSLCS UQG LRAEENITE S CQU
TTTATAAACTACCAAATTAGTGAACCAWATAGAAATTAGATTTGTGCAAACATGGAGAAATCTACTGAATTGGCTTCCA
GATTTT EL PPAALIQI S QQL IPTEASAS tiR CO
Az...kTITTATGTCATAGAAATATTGACTCAAACCATATTTTTTATGAIGGAGCF_ACTGAAAGGTGATTGCAGCTIT
TGGTTAATATGT ITKNQAKKUELTPSN
Ill N.) CITTTITTTTCTTTITCCAGTGTTCTATTTGCTTTAATGAGAATAGAPACGTAPACTATGACCTAGGGGITTCTGTTGG
ATAATTAG
Cl) CAGTTTAGAATGGAGGAAGAACAACAAAGACATGOTTTCCATTITTTICTTTAOTTATCTCTCAAAACAATATTACTTT
GTOTTTTc N.) PATCTTCTACITITAACTAATAAAATAAGTGGATTTTGTATTTTAAGATCCAGAAATAoTTAACACGTGAATATTTTGC
TAAAAAAG
CATATATAACTATTTTAAATATCCATTTATCTTTIGTATATCTAAGACTCATCCTGATTITTACTATCACACATGAATA
AAGCCTIT co GTATCTTTCTTTCTCTAATGTTGTATCATACTCTTCTAAAACTTGAGTGGCTGTCTTAAAAGATATAAGGGGAAAGATA
ATATTGTC
TGTCTCTATATTGCTTAGTAAGTATTTCCATAGTCP_ATGATGGITTAATAGGTP.P.P_CCAAACCCTATAAACCTGA
CCTCCTTTATGG N.) TTAATACTATTAAGCAAGAATGCAGTACAGAATTGGATACAGTACGGATTTGICCAAATAla_ATTCAATAAPAACCTT
AAAGCTGAAA
AAA.PAP
4A.A.A.AAAAAAAAAAAPLAWAAAAAAAAAMAAAAAAAAAAWMAP.P_AAAPAP_a_ARARAAAAAPAAAA
C) -17!
U M: CO
EC; CI, mii, P H Li H ED 11 11 µ81 R FL-). c4''. j C)) 1 0 E. fr. ii, P. ,H g r=
.--.
r4c4C.7200 c; 1 14 P., .1 f... 8, z n En H . En H P.
i, ccs , _ia ,i ,.1 , .), ) g 2r ,, 2:
u U 4 C.) ci U 0 U, a 4), 0 0 (.9 U ,4 u4 0 0 AT, A 0 0 a E. CD
CD CD 0 a 0 E. A ED H 0 H 4, 0 H 0 a EDE..) F. a a U 0E. a H
E.DaEDE.DE.ArCED ciaNgaE.HuUEDED aNaaE.AE-1 (90ag UUCDON 000euu0NrCEDgEDF.¾(900HHU
0004 r E-.00UH4e,0,E.0HauguHE-,aHqqag EiNaUUEDgE.HHE.JurcaCiUHOONOaraCiaaau U E. 0 CI, U 0 U U EJ I. a ED a E. F. a U a E. 0 F. U a E. E.-. E-. 0.1. E.
H
U F. 0 a Ei E. 0 CD E. C. E. 0 u ED CD u U a 0 0 0 E. a 0 a a ED E. 0 8o 01. 1---, 0., 3,q tici ,4ch 8E. ,c,r):Ci (E2,0 Ei, E6,E-. cti r6(.7 3. .
c Ei .,,,, . - , 8E7, 8 ,,_,,,,, Et E,5:E. E.b, ctiDN ELIE. au ,,,;.a EC:
ci 0 U a U 0 a a a 0 a E.1 E. a AUHHUHUUAH
[...E-.E.,400Uu0E-.0uUcDciUUgOtEDE.rCHE--.H.H.E.NU
u H g U E. 0 U U a 0 r1: g 0 0 a C.> E. CD E. E. 0 c..) 0 u u .=:q ,. U
H
ci U F. H. a V H E. ...4 0 0 a a a 0 E. U a E. 0 F.
UH0CDUOU,HEDaa g 4 0 NH AA 0 A EDUrc AgONE.Ha H. F. a E. 0 A A F. E. CD C.; cD U, E.... CD A U U g q g E. E. H ED F.., H 0 F. F.
UgUU00-achagUEDaE.gHaciclug00E-'00 a U 0 E. 0 E. U a E. CDUE.E.0<0000,< <UCD<CD E. a E.
rCaUOUE.iy0CDONUagE.c.DE-10 HIE-IgUaa0 , g U 0 U g 0 0 e-.. g g E. V U a F. g E-, CD E. U E. * ED 6 0 U ci CD
6 E, E-. U
o o ,.: u 6 6 6 6 6 r, ,P4 `.,-- 8 8 E,-; r, c.i CC; (..,0 8 6 q 6 8 0,0, El g 0 U U 5 U, ci U a; E. 0 E. E. A a, E-. AgAHuHr4U4,0E--,[y, ce, EE2, ,.,., EC-% t., E(.3 ,.., 0) u":" go tC).E. EC) EY< ECU r4a, - '54 ''. - A 80 t - -15 ' Ed Ef 5A
6E - µ Ec:j C9E - , 0) 8 0, 05 Hu uE, DO S. EY. 6 5 q u E . q o (5 0 u c5 r4 E... 0 N g a E.) Ci C./ ,, A E-1 * 0 E8 E-. Ea, r, Ey, < E4 C) - - 5 .0 c' '- )0 Pi rd At ' cD, N P. , ' ' - - 4, P. , 6" ) E i j- d ' 0_ , ' - " )), c (6 0, u?' 8, " "(3 0Ã ' '6' 8 8 u4 F-; gE' E.CDHOgau*.gOON ''' , YV9C-"--"-)t'5,-c) 6 '4 cr_,' i-.)., b' ri '6' Er_; r, 8 S 6 u 1:: ,E,7,1 u E9 `,J,2, 8 8 0 ri CE'l E.' El. 0 < U U a;
E E. F.
UU.,40:Na CDFE-, Er-,_,Vi.r.. cD<CDEUE.CDCDUytEicC--.CD,Api,El:
re..1) (.;- ccj7 E9 ..j.) t-; 6 u P. o ,V: '0' -)' ';5 E6 E i--.' 'E,' 8 `-',.,=c 8 `,-t' 0 A 1 '6; 0 (.6 u .. u, gr, o u E-4, i--. gc U 0 C.J C..! 0 CD gt CD o, u E--, ,.., E-, C.) < CD g, .-5 0 ,4 O ,.,. a t-j 0 ,l, '. Q Ki. fr. 0 rt. E. ri E. ET. a 0 u q E-, H GC u y * .E4;
' .4 8 `,- c' c, c. ) . i ; EY, ,V, cc:9 Ec?, b) i-- ..) ,..-.)D 8 8 1-.' 8 5 8 6 f_-.; ..',' 5 o 8 8 ..4 C!) ,4 CD 0 C. F-, E-, 0 A U U U U E. E-, a E. U El a 0 Ei 0 -a E. H c; a o F.
g U CD a U E. u ED 0 r4; u F. C.; <4 E. a; CJ H A < 0 E. U a 0 U u 0 < C., U CD < U 0 E. 0 E. a U 0 0 CD U U E. g E. CD 4. f. F A CD E. CD U < < E.
CDHACJEE<HAEC.,<E-,a:p4ue. HuciE.ciE.E.F.E.JauH
E. ci 0 H E... U 0 0 ED g g Ey a u H U 0 a CD A 0 0 E. U * (El a Ed FD 8C . D E,8 --)j,,4 114 '-''F'4 c.). rA 8 84 g 80 L"5:_) F.7 tE:'90; EE 1H .
H E 1 ---- j ' 6E - , 8E - , ', V- , Q '' E - ', r. i r (4 r. ;- .
CDONOutiE-.0gOgagE.F.agu-a0000E.PF!ED,HHC),1 O C. c.) r-, u u E-, u .< A 0 0 CJ CD 0 < U < a FI: < U E.E.00ua L,-,' '11 i E 0 (...) 0 CD E. CJ 0 0 0 C. 0 U E 0 u g 0 F, c" u ,rq ,a E-, u E. 0 E. au OCJAUCDHCJE.01EgFU,CD,CD<F<CCD.CIFEC,D,,E.10, GC E0 N Al 8 `,' , 8, 5: 84 `E. 3 8 8 o o 4, '4 6 5: , E--: Egl [7.1. .?C E. F4 8 F4 E., ,,, : o o ,s1 5, 0 E. 0 0 0 4 0, 0 g a U U < ,..., < E. U C9 0 4. < E . F. E. f. E. a: < a,, a.
ug,4E-,u5,ouo,cuuu,..,4,,,q aHUHaE.E.E.Hociuci H 0 CD E. H u U 0 A ED ED Ei ED Ei E. E. a 0 E. 0 F. E. ED H 0 A H H F. CD
U A E. CDUNE.HC/F<FEE.C.9<H<EUEUCD A E. A Cc/CD ,a.
0 CD U U 0 0 a UUAU CD u E--. 0 LI UNHU AU a E. E. u, 1.... UN
O 0 0 a a r...D Pc 0 I.) E..D < H. < 0 H g.. H g U 0 U H a H 0 0 ri. :,;,, t. EL:
Ha .: E, ,O, E. 0 E.gauCDE-..0ci,HEDHuNuE-.HHEiu ,ug, CJ v 0 U U CD < U U U a a; C--, E. a E. F. y 0 C.) E. a y A
A H ET. E-, El O00<cJVD0000,E440.< 0<ECJ<< gyE,E0,80(E-1_, l(D)t-_,,, 46 _ .> , ,I. C-. F-' H8 aU 8 '' t". ; L5 E -,Ed L') ( ), = El E5 v", . ; " 1E
. UU (E . 40 EC la . " jd 6.0 5E - , 1 Hc 9 *H 0, : E - ', 4 u' 4 ' r UOUOUNE-400E. 400UUHHE-100044 4 UNEDa U A E. E. cD H. a CD ED U
CD a E. E. H a N ED E. H. 0 _ I-4, c-2 u F. p. El CDUUF0<0000EC.1<UUCHEE 0E-..E-IA!,JEFSJI.
C., CD FC 44 :viE-,04uE,-grE-.0400,4 0(.7,.k 0 t'. a, N t' u gc9000 piaaHUcigHUEDHEJOgaH (ED. 8 p. Ev8 ,F,.
Ci CD a CJ CD E-, C., 0 Cl E. 0 0 tJ c..., 0 F C-1 E. E 0 A U , EN a 0 C.D 0 ,4 -...4 o o ., u u ,,, a: H 0 g U E-. 0 a E. q -.¶.. 0 E. H. E. E-_, H. H
,-,1 HuHga -agE-rauci HEE.C.0U FFC-JU .50_. ,-, ;, 0A0,000A001r-, A AAF. u u u E....uHaH 0 gli =
a 00 F-1 P, `,.-.Z 8 E' 8 u 8 c.) 6 ',-_), (-'4 `,-)) ,E -. 6 8 6 V, : 8 Vc E. EE-2.
2 CDU 00cDOUrCHO UN. t--, 0000E. <U<E0C-,y Ec OHOHUg., ,4uoyqc).1-,,tugug-,a,.._ C-cl < c...?, L'.. ra ,C,D, ..-), y. y o9 0 0 .. .9 A E-,,..0-..:Q1 CDHA,5. UV
1-2 ,..2 ,:...; L., -.., =3 õy4 ,E.,:, E, r,,,,, c, ,E1,. ,,,,,.
0 E--, A 0 A cJC/Cia:FE-. E-,, N ,, '41-"i'''''''' .<F E-;
PI U Ei 0 ED E. 0 H a U U 0 . u E. u H 0 u 0 H E. CD E. 1-. U 0 0 U ED E---. 0 ED H ,= A C.) N 0 U H g (9 0 E-. a E. g U g 0 0 CD 0 a a E-. 0 SUBSTITUTE SHEET (RULE 26) ()(..qggc-,u(..,E--.rigHF-toHggr-,gp.¶Jg H <U0HUHOE.E,u&-gHaHugHR.0E-E. H g U F. E. < E. CD 4 U 0 E.
C.9 1 < 4 4 u u .4 u Q.)t, E..) 4 a 0 E. EE. OUUCDOU<C9CDHUU U
E.C9H. <UU
0040E-..4U<dULDC9 L.)/auL9a 6 4 <OUHUrc 4 ciE.a:4E-,0E.0 UE.04, 0 U E. H c) C.) H C..) au,uouaHa H CD 4 CD CJ E.
U40E.C900(JaUU4C9H4f.0 0 000 4 H H g H 4 (7 U 04 H LI 0 U U U H'( ,4 a: 0 4 E.
U a, HC) < < < E. E-4 44 U < E. U UHU 1.
CD E. U 0 0 0 U H 0 E. CD L9 U F. H a.E.a:U CD L9 U
HOUC-904UUCJ<< aLpuHHa L.) ouga HuugH E. E. 4 U U u 0 E-. E. u E. 4 E. U
U 000 c,CJ44000U E. <HU4 OU 4u U < E. 0 .< 0 E. E. E. E. 4 < U E. U 4 0 4 Ui E. 0 CJO<CJOU40000044 4044400 U4 < E. E. < K4E. dup.40uouud HOHH
ChUU HQUCJE.HU < C9UU a E.I.C9C90 a 00C) UOUUE.U<HCJ0404 C.),c4 1C) 0 CJ E. 0 ci C., E. C.) U C., C.) CJ E. c..) 04 U E. u a HoHauuoHluuouaHoaugaH a ou 0 U U E. 0 u < 0 E. g C.`J E. 0 4 0 U U E. ....., F.
a, 42 u 0 a; u E. -04 0 UHU < 0 HHE.E-10C.DdCJUJOE-.0 ()C./ CDC/HOLD
H F. U 0 4 (.1 0 E. < E. 0 C9 U 0 g 4 4 U U E. E. E.
H 4 E. U 0 0 ac...),ouHE,uu U)-' E. U U 4 4 .4 CJ 0 (.9 E. 0 CD E. U V a: E. < g 4 E. E. H 0 ED E.
Ud4HUUE. U0HUE.0 U<UU00 g ouuuHaa uat-AuvougE.ogHoa C9E.CIPUUUCDULDUUL944U0C90<40 0 0 4 4 0 E. U < U 0 E. .4 0 0 0 U < 4, 0 H
E. 4 < 0 44 44 0 0 E. 4 U 44 44 4 0 4 C.) U U 0 E.
O (I 0 UUOHUU<UU0u0 E. 4UE.<0 OUrCJOHu 4 a,(JC7aLTH,ua 4 0 CD D, E. E. U 4 < 0 0 E. 0 a, 0 E. < E. C) U E.
4 a HUCDUCJ<E.HE.4)a; E.cil.ry<ci(D4., OE.OcJE.OHre.4Ur 0/4 00H0E.
0444000 <004 04 <E.000<
E.H00H4E. UCDHU 00 HUH E. <
CDE.4E.Uc9E.C9E.HUUHUD HUH4E-,.0 E.HUgU(90E-.40E.L9U<UHUUUD k.) E.
U I-. U < H < 4 4 U C.5. U H U 0 r4 0 E. E. V E. E. F.
0 4 4 0 E. E. C) 0 Ci a, E. C) H 0 0 E. U U C.!) 4 E. 0 0 H CD 4 U U H 0 U U E. 4 H. U CD U E. C) 0 < E. E. U
O d I, CJUE.C.) OU 404 <ULDHUUHC,CDUE.
4E.E.AU<<gt-.<000E-.4E-140<HE.<c) E,dr,40(.9uuE,4[-.F.Hu0E.E-,-.4 C.? a, 0 U C.) HUCJE.E.E.CDUE. E-4 44 U C901-.1.04,04 4 4 E4 0 U 4 u 4 4 rd E--, E. U qa E. 0 U U EJ U H E.
UHUUCDHUL10 HCJ aCDE-10U<HUOCJ
'CU U < 4 4 4 4 E. _ , E. E. u CD H E. E.
HO 'CU 04 0 chuUt.H0 r,,t,t / 0 E.
E. UF<U<UULDHU aoua aua u E.
C.) HU ONE.HEJ E.4 E. E--, CD < 0 CD ,...0 E-. E. 0 0 E. .-r_ , u 0 c) El u C!) E. c..) U 4 E-. E , U E. a; H 0 E. LD 0 gE4uU4HaLDOE.UUCDE.PHOUH40.<
U E-. E. 0 U 0 a E. CD E. I. 0 0 U U C9 < 4 U U < < , U4UHU406.00U<CDOPHHU040H<
E. 4 < 0 F,C 1. E. 0 E. UHU C) 'C HE. CD 4 F. E. E. 0 H
u H U E. U 0 E. gga E. U 0 U 1. E. E. CD E. E. t, E. H
CJ g U u H u E. 0 FL Pc E. E. u 0 H 4 4 F. u (.1 E. 0 UUUOU4U00,a.E.E.44HH 00U 4UE.
0E.E.000UE.<E,HUL)'0U0H HU ciU c.) E. au', E. 4 E. .4 u u u C.) E. E. E. 04 E. U 4 g 4 E.
c_) 0.4 uu00004u OH HHU E. E. u H U g 0 0 H
U0C7H<HOUUCJWUCDE. E-i g E-4 PHUO E.
<HOLJUUE.Urd 4 <1. 0 HO HiJC7E.0 0004UU0E.E. 0E.U4UHO V.)H0 '04 E.
E.E. U 0 0 4 U 4 4 u E. F. d 4 H E. 0 E-. a 4 0 UUE.C.)E.U04 E.E.E.00uU uHHOE.E.
40UOUKE.E.C.)4E.E.0000 4.4U C.)< 004 E.C.J040400000UHOHE.gouuuaH04 O4UH<H4U04 0U440E.4 HUOHO (1)U
O U U < E. 0 4 E. U 0 U < u < 0 E. H 0 E, 0 F.E.r<U4OULAUHUOLDOCJ .,.. aucauE-.
E.g<HUOUH c9CJE.00C7H E. E. < HE.
Ci c.D E. 0 0 4 0 0 E. < U CD 4 E. 0 C.9 1 a E. U 6 O < 0 E. U 0 E. H 4: CD U E. F. E. rd 0 ' E. a CD 0 pq E. u U E. 0040U <UUUU4L9E.<0 E. U PIS E.
U a' C.7 E. H E. U CD E. U E. CJ E. U U 1 H. 4 0 C.) 5 E.
C9 d E. 0 U 0U PUL)E.E.gur, HU< 4 OE.U4H(JE.u4UHE.UUU UHOE-4<.
SUBSTITUTE SHEET (RULE 26) E-, 0Z0HOC4H,p,IXO>.>.:OH>-,tncoZzi-10>aZcoE. tn H,.1>,c)11-1).4>a.riz>0000 egclizaHoolmuHw 2CD
H H H0 C.+ pr4EntAlrE.NHel0, 0 H CI) 0 (f) E. 0 0 Q4 H VI , a-, En a 4.1 0 E. 0 H rAC E. 0 E, H a, D. >. 0 0 Z 0 cn H
E.Fin >OHIZ}A 4a.rif4>44[4,--Ig .,-4x3,41.1H
,E40 t:2to, >gu2tnn pH 4 74 14 ,..1 0 a. < . CA a 44 EA, E4 M
1 a 0 X 4 U a 0 41 4 U x 0 3 z w co 3 RI z '41 a 0 3 z r4 H H z ix CD AEG E. e4 < 2 En En DJ, 5,a>. cn E4 E. H E. rAl a, 4 Cgt+ HOP-10Z 5,--1XCY cr-1 OH (11C,.->-' 00a),,CCnC.Dr4 >0.Zcon a c-1 coo q 4 >4 e, La -., ZHHHHHHO [4 a 4 u rAl H a .,4, 0 0 > 0 C
,0 00Srilr-,H .04H HCak-,Z0141440NE-40U1-1 r.,-,g >.w>4.4w ..-1E.,-.1>co3g I-1 En>H0p>Z0E400.ale4 OHEn> PI
= t9pg ,-4t0tAl Az ,,ACEnf.a. z tnala..-la-.40Ene4000,4E.
0 4 P, H CD X c4 12 41 0 E. g4 e4 (5 E. E.
FA.1 U a, (7 4 [,, 0 C4 CD Ei e4 Z
H ,.azz,41?-+H (.9010V,ZHHHENci) R
till>, E.0>HUO
H P-O F E q ril ,A4 =,=4 0 Ha,a4Ht).74E.En.-A,P,EnU PlEntina,HEacn0a EnE.N>r4 cn X cl, c4 >, En 4 a. al E. E.E., E. > 1.0 ...I CI) H x,-1C211...cr)>001gc.9 4r-Dr=1 E4 U 0 U U 0 0 < E. E. EA H r) U U g g E. 0 E. 0 E, Ch 0 F, a: < 0 U
O UUUUUUN. g A5 0 <EDUON g g ti i ,5 H
<NOLO<
HE-EL/0000U HO 0,40000000,C 4.0,400E.
uulAcDOHNE, <0 CD OUCDHE. g HUOUUUHO
H
UHOUCDUC)C) HUHOUHE.C.90g HH g E.KCUggE.E.KC
U 0 u CD .C..9 U 0 f=C CD g E. 0 0 U U U E. g 0 0 g C.) U N E. 4, 41 CD
C.) Ch 0 CD U U CD H U g E. El g 0 f-, (9 E. < U t. E. 0 El 0 Er C.) a; U
U
HOHKCHHOgg(JUUUUHUUCJUggHUHguE.L.DC)g U KC U U U u o H. Li E. CSOHHUHHHUHH U CI 0 a; a; .4 000 UUHCJgE.E.E.0,,HHHCDC.9gUOKCHE.E.C.90HE.Ua H .-1: E.
U 0 U 0 g H 0 C) KC U C.) 0 0 U g H g g g CD g E. g U Cj HHH
C.)<,CU HUCD g U gE.E.E.E.CDC)00(9g0 C.) 000 g U
l'OUC)E-',40,1A0,400,400,4F.E. E.H.NOHOE.c....CU
0 0 CD U H CD H g4 0 gt 0 C.) 0 4 C.) g g C., E-4 E.0 B 6 E. 0 rC
CDC)u0PCJ , F CDE.HgE.C.Dgc.11c9 Hga; E. PHU H CD
HUQE.C.DC9uUHUKCUCDE.E.E.HHgUE.HCDE-4u0 U E-,u .E.Duc.)40E-,HE4E-,c)c)E.E..1 0 4 U a. a4 E4 4 04;
u g< C) 0 gc u c.) U U E. E. g g U CD E. H U C.) E.-, 4 U U 0 ,..c 4 (E-,0 upc(DE.H.0,4E.H(.9E,U<NH.CDUTDUE.. UH0E.CDU00 4, 0 F-.00 UU0 0 < ,A4 < E. 0 C.) U H E. g 0 E-, < E. 0 E. U E, E. E.
H 0 CD A4 a: U 0 a: E, (D u 0 < 0 E. 0 E. 0 At E. E. 0 0 U t) 4 (9 4 0 HIDUUCJUQUg4H0 OuHUHUH E.H.400 HgCLDFu.,C
E.K4 UU E.O K4Pc .4 H0040 .4 H .4 0 E. H g C9 U U g H U
0 E.
CDHE.C9 CJUU0 00 gHHHHOHHE.HUE.H UggE.E.0 HHUH CD U> E. E. E. CD CD E. U u F. UE.HU H r,4 F E. CD U> 4 0 0 0 E, U r4 C) 0 F. (..) AC E. 0 a: Ch a: E. H < N 0 0 ,E4 U 0 4: E, F F4 0 E. 0 PHE.CDCDUC)C9C)HE. Ug4HE.HUgac F, E4 < 0 QJ E-, E-) 0 0 0 < , O E. U CD 0 C., E. A4 E. .45.4KCUUUHHAHHOgCDUC),<CDU g H KCOCD UPPUgUa,UUCJUE.4 g OH 4E--,0E.HE.C.9E.c.9 C) CD 00C-)E.U0 gOgUgt.)0E. E. E.5 0 0 < 00.4E.5005C9U
E. H U U U E. 0 E. <4 E. 0 C) g4 E. CJ 0 0 CD E, 0 E-, 0 t, (.7 E.55 E. CJ
Lir - D ,q: Q CD C9 g Ci C.) 0 g a; E. 0 g õ, F Eg4 E.. 0 u E.C.) g a, 0 E.
/
OUC)0C9tig0Hggn.HgE. CDHOUg UOggUga 0 OH UUOCDO E.E.V OUPCJI ,gUlDgQ C9g0C)C),g F4 E-O CD C) t..) C.) U 0 a; E.
g H g F, a, E. E. E. 0 0 C) UHUH < ,E4 0 CD 0 H00000E-.0g4PC0d F00r40E.r4 550E400E. E.00D
C9OUUr4UCDF 000d clE.E.CDOCIUgE.E.E.E4.4E-,E.cD 0 O CD H C.) u ,4 0 e< 0 <
KC Ci E. E. C.) E. U CD g H g g4 .--4 g4 U 0 E. U E.
U CJ C) U U Ch 0 0 E. 0 E.
C.) U 0 4 E. E. ED E. U H E. g E. 0 0 E. E. <
OgCJE.CJO a g gOUE. 4 ( ( 4 H H CDPE.HHUHUO<HaC,A4U
o PC ti (i < < (3 Q 0 E--, 5 E-, ,4 g 0 U E. AC U ED C) < < g4 0 <C CD .4 0 ,4 u0u0EØ45.5 E.a..400u0.4H,4000NON5uLDE-, UHNO,C(900,AcUULDE.c.),414E.UP,A4,4 E-4 q r4, E-= H ,14 g 0 H
CDCJE.CDE.Ha;CDE. E. AA: 0 E. AC U .A.c u < 0 a. a. 0 a, pc H 0 0 E. 0 HOHUN0,1.0HE4H .4 0 u .c. E. 5 5 0 0 d, <0E.C.)0gUU
E.HULDE. (9cD-UH,040 H -,A4UOHON,E4a4E,CDEDH<Uclac O 0 U U U E.,. E. t., E. ac, A4 PqE-,E-104,0Pc E, H QH CDOUE.a;
500E-004 E.000 ,00000.404u0u 5.4000 u5CDUO<CDUUKCH<HH g HE.E.c9H CD g C_9 U H E---, U 4: 0 4:
0 0 U U U C., L., 4G ==C C_J HHHAH U C.) E--. E-1 1...) /..0 < E. u 0 0 UHU
E. OLD (-) 0 C9 '4 4 F,F,Hor.DE.000514 OU00,4E.00 E4E4U00g00g5U0g. E.H a; E - -, 0 0 0 (-) < 4 A E U H CD CD CD u tl', 0 E. 0 0 E4 E-, gr. . U CD U (.9 0 E. H Ell 14. U H
H U Kr.
KCO00000Q E.-. HO 4 H. 0 < (9, 0 ,A4 0 ,C < HH HO 0 0 ED
9 c., E. F.
U CD U U C!) 0 0 Q E. E. H (.9 U a, E-4 CO
H U c..) E., 0 H U E. H U 0 E. < 0 c..) U C) U E. g E. E. H 0 Kt: u U 0 H H E. 0 E . < 0 E. E. c.) E.
E4 CD CD <4 U El 4 ci 4 4 4 < H c9 0 < 6 g < (9 AU 4 C7 E. 0 E. E4 ,4 U 0 0 cD E. 0 0 0 C) 0 U 0 U U C.) g E. U 0 CD HUH HA
CD CD CD C, H 0 ." E..., E. CD E. H 4 4 ,,, H E. a; H 4 g E. CD E.
C.) 0 6, CJ
O U U U U U C.9 ch U cD E.
U (5(5 a, a' C) U g CD :. E. 0 E. C7 4 U CD E, CD 4 U UU 4 CD CD 4 E. 00 E. E. F. 0, CD O. CD i. <4 4 E-' E' El E-' C.JU
E. 0 E. U 0 0 g H CD < A A g U E-4 U 0 4, c5 -. U 4 E. 4 C.) '4 4 4 U U f4 0 4 U CD CD <4 H U u .4 C. u () E. 4 E. C.) E. a, .:4 E. c9 0 E. 0 0 E-4 kJ U U F. C) CJ E. 4 C7 CD al g H a; (9 0 () U> (9 H> (9 4 4 (9 E.
E. (7 0 U c.9 u C) U g 4 0 0 G.4 P 5 < E. 4 0 .4 c) 5 E. g E. E. E. a. C5 a:
(D E. U ,24 E. < E. U E. CD 0 ( CD U r4 .4 u E4 4 0 c; E. 5 4 CD c9 4 0 cD c9 0 F.
Hc) 0 c.) (..) f.9 E. 0 E. F. E.. 0 ,c c) g U 0 .=C U 0 CD
E, E, 4..) E. <4 E, <
O (-, E' gUHUE. U U A 0 OUUcl HuF, 0 Co C, 4 E--, g4 H E. CD 5 O CD 0 E. CD g CD g 0 CD E. C.) CD U E. E-, 0 E.
.,.4 H 0.0 E. CD C5 D ET' 1 U CA F. U 0 <C 0 C.: E. H
E, F E. E. E. H E., E-, 0 CJ Pi, E. 0 U g H P,.. E. U.
.4 E-, 0 (,) H 0 E4 0 A5 U E. Z <4 F. CI U E. CD
C'J <4 H 5 E--. E. ,5 5 0 cJ U 0 U CJ 0 < 4 () (7 E-, 0 A E. 0 KC u E. 0 C) E. <C U E. CJ
KCC.100C..)00u OH E.E--gCaa,H, 4 E, g4()U0(40E,419 OC)A000UE, E-,c)E-.4.4c)cDuE,H5u0 5 0 E. E. t.c.)0 45.0)00055 E.E.HHHOUtDgH g HOE.,.¶,c) H F.E.E.
ocE.c),,CUchgcuAg4HtQg4,4g4H-pcUE.Fr.gr_Du H K4 H .-Cc7 cD
ni UCDQUChg 0E.E.E.HguE.E.E.K400CDEAu,c40 H F H U00 ol 000c)Uul.gE.C7a,004 E. 0 pc < E. 0 < U U < (el ED 04 Fs U
O CJ 0 U 0 U t.) 0 C.) 0 PC E. CD a, E. E. U a, CJ E. El 0 E. U E. < a4 0 0 E. E. U 0 U 0 E. U g4 E. U g E. H E, 0 C.) Pc 5 5 E-4 H 0 4 a, u Q c.) 0 u 0. UUUUUHUgHHE.HHrCH ggo<0 Hg HUg Ug 0 0 E.
Z < E. (9 () 0 E. E. C., E. U E. E. 1 E. E. HUH OH .4 4 OH U E. U U
LD ,4 0 uoucDpc,E-, E-4,c:E.,CE. HA OH E.-1-gc..95.00CDE.C.) gOE.0 E.
H HO HE.CAUCDC-9.4E-,.4 (94 00E-,u.40 uf.E.50E40 0) EICDOU0 EJE.E.PHUHa/U g4r44Cic.) E.004 Kt; ,C E. P
HEH gOE. E.E.Ug ga; pC <CDOUC)C9C) 9 CiUgUCDE.C) CS U U 0 0 U CD U U < g 0 0 0 0 C.9 CJ N .=4 g4 N 0 gg U 4, t.D
g C) SUBSTITUTE SHEET (RULE 26) AGAAATTCAACAGTCATGAGCAGAGCTGAAAATTTTAAACAAGTTGAGTACCTCCTTATTCATGGAACAGCAGATGATA
ACGTTCAC RAENFKQVEYLLIHGTADDNVHF
TTTCAGCAGTCAGCTCAGATCTCCAAAGCCCTGGTCGATGTTGGAGTGGATTTCCAGGCAATGTGGTATACTGATGAAG
ACCATGGA QQSAQISKALVDVGVDFQAMWYT
ATAGCTAGCAGCACAGCACACCAACATATATATACCCACATGAGCCACTTCATAAAACAATGTTTCTCTTTACCTTAGC
ACCTCAAA DEDHGIASSTAHQHIYTHMSHFI
ATACCATGCCATTTAAAGCTTATTAAAACTCATTTTTGTTTTCATTATCTCAAAACTGCACTGTCAAGATGATGATGAT
CTTTAAAA KQCFSLP
TACACACTCAAATCAAGAAACTTAAGGTTACCTTTGTTCCCAAATTTCATACCTATCATCTTAAGTAGGGACTTCTGTC
TTCACAAC
AGATTATTACCTTACAGAAGTTTGAATTATCCGGTCGGGTTTTATTGTTTAAAATCATTTCTGCATCAGCTGCTGAAAC
AACAAATA
GGAATTGTTTTTATGGAGGCTTTGCATAGATTCCCTGAGCAGGATTTTAATCTTTTTCTAArTGGAcTGGTTGAAATGT
TGTTCTC'r TCTTTAAAGGGATGGCAAGATGTGGGCAGTGATGTCACTAGGGCAGGGACAGGATAAGAGGGATTAGGGAGAGAAGATA
GCAGGGCA
TGGCTGGGAACCCAAGICCAAGCATACCAACACGAGCAGGCTACTGTCAGCTCCCCTCGGAGAAGAGCTGTTCACAGCC
AGACTGGC
ACAGTTTTCTGAGAAAGACTATTCAAACAGTCTCAGGAAATCAAATATGCAAAGCACTGACTTCTAAGTAAAACCACAG
AAGACTCCAAAGAAATGTAAGGGAAACTGCCAGCAACGCAGGCCCCCAGGTGCCAGTTATGGCTATAGGTGCTACAAAA
ACACAGCA P
cn AGGGTGATGGGAAAGCATTGTAAATGTGCTTTTAAAAAAAAATACTGATGTTCCTAGTGAAAGAGGCAGCTTGAAACTG
rs, CO
ACACATCAGCTTGCCCTGTTAAAAGATGAAAATATTTGTATCACAAATCTTAACTTGAAGGAGTCCTTGCATCAATTTT
TCTTATTT
cATTrcTTTGAGTGTcTTAATTAAAAGAATATTTTAAcTTccTTGGAcTcATTTTAAAAAATGGAAcATAApATAcAAT
eTTATGTA
TTATTATTcccATTcTAcATAcTATGGAATTTcTcccAGTcATTTRATAApaGTGccTTcATTTTTavAGALAAAAAAA
rs, cn SEQIDNO.:34 SEQIDNO.:81Ill CGCAGCGGGTCCTCTCTATCTAGCTCCAGCCTCTCGCCTGCGCCCCACTCCCCGCGTCCCGCGTCCTAGCCGACCATGG
CCGGGCCC MAGPLRAPLLLLAILAVALAVSP
CTGCGCGCCCCGCTGCTCCTGCTGGCCATCCTGGCCGTGGCCCTGOCCGTGAGCCCCGCGGCCGGCTCCAGTCCCGGCA
rs, CGCCTGGTGGGAGGCCCCATGGACGCCAGCGTGGAGGAGGAGGGTGTGCGGCGTGCACTGGACTTTGCCGTCGGCGAGT
ACAACAAA EGVRRALDFAVGEYNKASNDMYH
GCCAGCAACGACATGTACCACAGCCGCGCGCTGCAGGTGGTGCGCGCCCGCAAGCAGATCGTAGCTGGGGTGAACTACT
TCTTGGAC SRALQVVRARKQIVAGVNYFLDV
GTGGAGCTGGGCCGAACCACGTGTACCAAGACCCAGCCCAACTTGGACAACTGCCCCTTCCATGACCAGCCACATCTGA
AAAGGAAA ELGRTTCTKTQPNLDNCPFHDQP
cs) GCATTCTGCTCTTTCCAGATCTACGCTGTGCCTTGGCAGGGCACAATGACCTTGTCGAAATCCACCTGTCAGGACGCCT
AGGGGTCT HLKRKAFCSFQIYAVPWQGTNTL
GTACCGGGCTGGCCTGTGCCTATCACCTCTTATGCACACCTCCCACCCCCTGTATTCCCACCCCTGGACTGGTGGCCCC
TGCCTTGG SKSTCQDA
GGAAGGTCTCCCCATGTGCCTGCACCAGGAGACAGACAGAGAAGGCAGCAGGCGGCCTTTGTTGCTCAGCAAGGGGCTC
TGCCCTCC
CTCCTTCCTTCTTGCTTCTCATAGCCCCGGTGTGCGGTGCATACACCCCCACCTCCTGCAATAAAATAGTAGCATCGGC
AAAAAAAA
pokkAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
17.1 SEQIDNO.:35 SEQIDNO.:82 CCCAGCGGCCCTGCAGACTTGGCACAGAGCACACCCACCTGCCTTTGTCACAGCACACTAAGAAGGTTCTCTGTGGTGA
CCAGGCTG MEGSLQLLACLACVLQMGSLVKT (.=
GGTAGAGGGCTGCTGGGTCTGCAGGCGTCAGAGCATGGAGGGGTCCCTCCAACTCCTGGCCTGCTTGGCCTGTGTGCTC
CAGATGGG RRDASGDLLNTEAHSAPAQRWSM
ATCCCTTGTGAAAACTAGAAGAGACGCTTCGGGGGATCTGCTCAACACAGAGGCGCACAGTGCCCCGGCGCAGCGCTGG
TCCATGCA QVPAEVNAEAGDAAVLPCTFTHP
GGTGCCCGCGGAGGTGAACGCGGAGGCTGGCGACGCGGCGGTGCTGCCCTGCACCTTCACGCACCCGCACCGCCACTAC
GACGGGCC HRHYDGPLTAIWRSGEPYAGPQV
GCTGACGGCCATCTGGCGCTCGGGCGAGCCGTACGCOGGCCCGCAGGTGTTCCGCTGCACCGCGGCGCCGGGCAGCGAG
CTGTGCCA FRCTAAPGSELCQTALSLHGRFR
GACGGCGCTGAGCCTGCACGGCCGCTTCCGCCTGCTGGGCAACCCGCGCCGCAACGACCTGTCCCTGCGCGTCGAGCGC
CTCGCCCT LLGNPRRNDLSLRVERLALADSG
GGCGGACAGCGGCCGCTACTTCTGCCGCGTGGAGTTCACCGGCGACGCCCACGATCGCTATGAGAGTCGCCATGGGGTC
CGTCMCG RYFCRVEFTGDAHDRYESRHGVR.
CGTGACTGCTGCGCCGCGGATCGTCAACATCTCGGTGCTGCCGGGCCCCGCGCACGCCTTCCGCGCGCTCTGCACCGCC
GAGGGGGA LRVTAAPRIVNISVLPGPAHAFR
GCCCCCGCCCGCCCTCGCCTGGTCGGGTCCCGCCCCAGGCAACAGCTCCGCTGCCCTGCAGGGCCAGGGTCACGGCTAC
CGCCGAGTTGCCCGCGCTGACCCGCGACGGCCGCTACACGTGCACGGCGGCCAATAGCCTGGGCCGCGCCGAGGCCAGC
GTCTACCT SAALQGQGHGYQVTAELPALTRD
GTTCCGCTTCCACGGCGCCCCCGGAACCTCGACCCTAGCGCTCCTGCTGGGCGCGCTGGGCCTCAAGGCCTTGCTGCTG
CTTGGCAT GRYTCTAANSLGRAEASVYLERE
TCTGGGAGCGCGTGCCACCCGACGCCGACTAGATCACCTGGTCCCCCAGGACACCCCTCCACGTGCGGACCAGGACACT
TCACCTAT RGAPGTSTLALLLGAILLKALLL N.) CO CTGGGGCTGAGCTGAAGAAATAGAAGATCTGAAAGACCTGCATAAACTCCAACGCTAG
LGILGARATRRRLDHLVPOTPP
cn RADQDTSPIWGSAEEIEDLIOLH
KLQR
N.) co n.) .00 t.) ___________________________________________________ , ___________________________________________________ , 8 8 ,E,' El El 8 ,' 8 8 8 (5C) 2 6 El 8 24 El El 4 4 El 8 Et: 6 4 6 L
E. 0 c9 .4 E. A4 C) E. gg (7 CI L9 0 H c) c) c) g (9 E, E.
(5 0 y E, E. 4 E. E. .4 () (7 E., 0 (7 .., r4 0 p (7 4 (5.4 CD r4 U U .0 C) (50 g4 y a C) CD a .8 P. Et. r) E4 8 8 ,',,', 6 8 8 El 8 8 8 ;1 8 Ll Et.' 6 8 tl 8 8 8 4 ,'-4' 8 ti, E.4 0 4 0 (7 0 E-, .4 H 0 0 E. 0 E4 E., CY 0 .4 E. 0 E. CY H E, gg H.4 0 E,'- El 8 '6''' 8 8 8 El El 8 E3 El 2 6 8 El 8 " 6 El El 6 2 8 2 8 0 E. Cy E. E. 0 0 U c.) Cc 0 .4 0 LD .4 .4 ,1 0 E. t) 6. (9 4) E. Ed= Ei t-I gq CD E.
0 .4 .4 EA (5 g C.) (7 C) K1: E, L3 E. CY H E. C9 E. C) .4 0 (7 E. (7 E.
El E. a 0 u E. C.) E. E. E. L7 0 CD 0 0 EA E. .4 (9 E. E., c9 ,r, u u t4 (7 (9 (9 E, E. c) c..?
8 El 5 8 8 E4 2 8 8 8 El 2 2 6 ," 8 El 8 8 0 8 S () 2 "..1 F-,' E-ii 8 8' g E. 4 E, EA 0 < .4 E. Cy AII S4 E. E.
(9 E. E. c9 E. r. AcJgL9U E. 0 c) ED c, (9 E. E. ,4 y : .1; Ei E. .4 L7 y c) E-4 .4 (9 u 4 fg E. ci .4 E4 E, 4 EJ CY
,i34 (5' 6 1 6 8 g 8 Cj U 8 61 .4( u,5 (g9c I; Eci; r.
6 U i% 0 t; o [1 o 8, tl 0 (D E, E. CD E. C) (7 I. < L9 E. ., L3 0 o.C, ,,t I) E. CD I. (9 E. c9 E, CY CD .0 C.3 E.
6 El 8 E, 8 El E1 0 " 8 8 8 8 8 2 6 E4 ,`,4) 8 6 EI [5 2 El 6 [5 El g) F. 8 El il 1 E4' 8 El 8 El f4 El ',- 6 LS 6 El '8 ',-'4 8 4 6 8 ': 6 El 6 E.- g [5 f 2 4 8 E--,,' E P. 6 6' ';',1 Z5 6 8 El f4 El 8 1 '-i 8, 8 i4 8 8 6 '<' 8 '4. '.' 68 0 E. U CD U 0 (9 U CD U U ,,,: t. E. .1, E7 (9 .4 E.
u H f', 0 b; 0 .-4 n.: E4 8 8 F' E f. 8 .-_' E4 6 El 8 f4 2: S 8 6 g 8 8 El E':-8 El 8 El u H t-.4' P. t;
'6 EC-1 P. U ': 8 'il' 8 8 8 8 8 F:.' il t.
(-:, 8 '6'i?, i P4 6 El 6 8 8 8 < 6 u E. c9 C) U 4 = 0 E. E. F. .4 EA EA .1, E. < r4 (7 E. .4 EA 0 0 ,q CD ge si, (7 [1 t7 8 F.% E-61 8 P. g; Ed 8 8 E, ,HUH 8 EE.--1 4 8 6 E--,' 6 -?. Z5 6 Z'3 8 '.'4 8 .4 U C9 CD E. E. E, C) c9 C) 04 Ci (J c,C FC E. E. E. C) .e L7 C9 Al C) E, i1 U CD gg (9 .., C9 E-2. i-l; Cl E4 8 8 6 8 6 u '2 8 r3 8 2 6' 6' 6 6 [2, [1 6 gll Eil c' P .',4! 6 E., _ k4 4 4 El! CD E.
B 8 6 El P-: 8 2 8 El El 8 '4 El El El 6 8 t1 El 6 g fl 8' 8 EY. r, 8 0 (2 E. 0 0 .4 E.) (7 Cy 0 L3 L) .., E, 0 0 E.
.4 (5 0 _ , u I. .4 .4 U Ot .() 0 0 L9 F. (-4 u .4 u u U E. E. U CJ 0 LI H .4 c) L) gq ID E. E. (J (9 CD a < < < --_, (...! C), 0 i'!.'5 r, p."r, p.r,õ ,<L) ti 6 El 8 8 0 8 8 2 6 j 8 2 'i 8 El 8 2 4 8 8 6 '6 8 .õ ., u c7 (9 E. 0 E4 E. p; E. E. ,4 .4 u L9 4 u U C7 L3 E.
(-4 (.4 (5 E. (J c9 0 0 L9 0 E. (9 L9 E, E. E-, 0 0 0 U oe C3 C.) 0 E. C3 U .4 (7 E. 0 4 C.) .4 ,4 U L9 o Cy C.) 0 0 Li CD .4 E. 0 C7 4. ,' 0 EA E. H 0 .4 E. E. t7 EA .4 .4 0 H
0 0 () HUH U E. U CD C9 .4 El E.7 0 cl CI L9 E. T.? E. y U y E. < p (q Ei 8 E, 8 ..g.
?.-2 !I, E., 4 8 CY cc?, C) Ei.J, CJUnUOUy CD y y 5 1;-. QD U c,,. 0 ko. i..; .3 r_.
0 ,....; c(-:11 Lc..., E4 < u 2 CD il CY -.3 up fr"... up _-.4 2 f--! E.% S E.
0 E. ,- E. 0 c9 C. c) CD 0 ,C u H Pc C9 u u CD ci u E, Ll 0 Pt; tC4 . E. (9 U C9 !dc H
E. Li E. 0 0 C7 (7 C) C) E4 ' E. CJ 0 U 0 4 4 Ft E, U E, 0 ,C CI E. 0 0 6 s_,,. ,õ, g il 2. 6 6 g g El 0 t--: ,' 8 ri!
6 8 8 8, El 6 6 8 El 8 (;.i El 8 () 8 ',' 3 6 ,, 0 , E. C3 0 ,,C E. c9 4 E. H E. 0 0 ,4 .4 ,E-A S.? S2 p S2 g ,H ,, ,S.%
..,' rci! ,J 8 Fcd:
(,, FC f= E. E-. C3 E, (3 U 0 a: E. 4 0 U 5 E. u C2 .1; V ,,, c. H " " ..., a t_: 6, (J 0 P. El 6 8 S 8, 8 8 ' 8 6 El 4 (3 Vi E4-4' g EE1 8 8 El 2 (9 ..' 0 0 =....
U Cy Cy .4 El cy u E, .4 c9 CD L9 .4 L) .4 c) c9 E. C.) 0 U E.
F. L7 ,rC () C) C.) 0 rt 0 0 CD H ,,t L3 L3 E., E. E. E. 0 CD e E. xl: 0 C9 0 Ei U 0 c../ gg E. y CD UP. c9 f3 El 8 8 8 8' 6 8 Et-2 8 8 8 0 6 El 0 8 E3 il L 6 II,' g 8 8 8 6 1 8 8 F. 8 El 8 8 El EL El 8 8 4 8 El 2: 6 8 2 i- El r g t; 8 El 8 8 E, 6 4 " El t5 8 4 8 6 8 8 4 8 8 EY E. 8 0 t7 E. 8 8 8 ,, 6 i:: 8 6' 8 P. E.' 8 8 8 0 8 2 8 8 8 E., '..- 8 il El 2 8 1 8 2 2 2 11 6 t; P.
' E"' 8 ,'C E3 2 8 8 2 8 E-3 6 8 8 6 ,'' 8 E-4' '6 E5 g E.-4' ,11 El 8 4 8 8 6 E--. (2 C9 O C) _ g (.1 () CD EA (7 (7 (7 C, q CJ C5 P Kg (.9 g4 cp u Kc E. (9 A C./ 0 4 0 c9 C..9 0 CD 0 ,4 (9 E. E. c9 cy g4 u E-, gt, Ft (50 ,4 (7 6g CY 04 c7 Cy U HUH , cp Kg p p. ,.,..1 0 .Ei'-c' !c.-.!! " ,-4, (;. Pu --.F! '' " -.)..), '',6. Li Y." 8 0 8 V, 8 6' g P. g g (4 ,, ,_, ....,,,,,_,,_. E- ,,,, (il ,,. ,..., ,v li V., g Pd, e,C U E. U E. L.) C) C.) C9 CJ E, CJ a ,,, [5 8 El El 12. 8 El E. a E.-4' t.-). El 4. E-, El 4 8 ',,' 8 ,g:. El El 8 t5 El ,.., E., 0 < E4 '41 4 E. 0 0 (9 0 C9 0 E. gg 0 I) I) C9 El I) __ CD .r...p p c__, p --._. J. s.p E ! I.--!
.: 8 8 8 El 0 8 El 8 8 8 8 8 6 8, ';-4' 6 6 2 E 8 8 8 8 8 8 (.,. ;!.' -!, 0 CY 0 E. 0 CD E-4 0 t4 K4 CD CY E. CY E. E. CP E. 64 4 C.) [-", E. E.
L7 E. 0 E. E. 0 C9 CY E.
E g g il ill i,-4' ,D4 V. 6. 8 il 8 8 t; (35 !- F. ("6 Eg-4' (el Z;
ti 6 Eg t5 El CD E' " E. 0 CD E' '.' CI 09 u (9 c9 t. E. 4, F. CD ., 0 c) E. E. c9 U 0 E. C) 4 U F. 0 L.?
g Er.. t5. Eg cj '6 [7'9 t5 t5 8 8 0 8 ; 8 8 f:: ill [-p: 8 P. 8 f5 2 ?- 4 2 ,,õ ", 060E-.6uu<ugug ..õ.E.,(2.1E-. 4 CDUCDC.100E.E. .0 vi SUBSTITUTE SHEET (RULE 26) C.) CD 04 H g H 0 HE. A
U, E-.UUCD<U000U0 00CJE.E.OUHU U
< 0 g0E-'0E--'0UciatUactU< ,E.C9H<OUOU0C7E.
U U at E. U C7 E. 0 U U E. H 0 < A H 0 0 EA El at rz4 H
U H
0 cl C.JHUHOV.hat0H0C7(7< <UE.CJ<E.UHHE.E, U CJ<<HE. UE. (9HE.dUCIC7E.UUU<C7HE.0 u U 0 aCUPHOHL70 <C)(70<04 ogq. uu,,cgc...qu<
u H 8 8 (Ei 1 .2 ('-.; 8 8 8 3 8 8 fl El P, 8 E9 :2 E LI: 3 8 r, 8 8 --:
i E. C., 0 U 0 f-, 0 gq K: 0 0 0 H E-I E-+ U 0 H 0 at 0 E. 0 F.5 E. d E. I.
U UE.<0,E.CØ0d0U000L)UHdCh 0,<C7 UUHUU
C7 0 UU<NOUUUUU<U0 4 A .4 0 H
E...) H 0 A' ..., 0 E. H
0 A 00H<Chat CJOU<NUHUE.H0HU<C10a4 E-, g g u <HUal,F,(30000E.E.FtC7HHC7dLJUd E-, ...1 A 0 0 U
0 0 E. 0 0 E. U E. 0 U 0 C) 0 C) E. 0 0 at 0 E. 0 E. U 0 < U U U, C7 (Fl!) A .4 HHE.A.4 E.HA U.4..GEØ4.4E.E.OHNOHE. U
E-, E. rtE.UU<Upt 0d HOE.E.00E.E.<<UUChatH E.
0 H OH0000000 U0L7do. 6i9oPuotn E.U000 (... A; 4 0 0 0 E. 0 E. 0 0 E-. 4 0 H a, 1 < U E. (7 H 0 H (9 E.
(.9 H (70HHOE.<H<UUE.0000.< CJUUrd0d0E.<
E. U E.E.<U0ChacH(9<(.7000E.<0 UatUUE.Uat E.4 CD
0: ei CDUat.E.HOE.OHCJUE.Hat Oat E.HE.(70<<C9H<E, 0 0 0 0 u H < 0 I. U 0 E. C7 U d 0 0 C) CJ Cl rt at U H U (.7 < 0 U
d E. at HUUUU < E, E. < E-,0HuE.o<ECJC7UucJH A, Et t.
U H E-, 0 0 < E. N U 0 < U 0 U E. 0 U E. E. U E. 0 U < 0 < <
O H E.0,00<U0000U<U< NEI
FC7f4HUE,<UU
E-4 a, E. E. < U H U < g E. U U 0 CJ E, C..1 U E. N U E. 0 E. U
1.9 U .4 n. 0 U E. 0 U E, <00 HO<C7(90E.UUE.< E. C_7 E. U U
U U OUNE-,010U0UUUUUU E.01HAEØ40U0 A
U 0 UUC)<U <0.-I<U00W0E.< H H u U 0 E. E. E. U
at 0 <C70CJED UU<OE-,<H<HHat E.< -gq c.9 E-, e, E.,qc5 E. c.) HOE.00HUCha,H(J<LJHUHLDH g4 ID pc H e4 cõ, ri: 41 H
Ecu UU
?, H 0 H 0 0 E. (9 U C.9 < 0 H E. E. 0 E. H E. U E. 4... E-. 0 0 0 E. E. HO 0 UrcUU < <E-.E.E-, U < 0 0< U E. U
g4c)of--,ugot., dUdE.U(DE.E.C9HE.at H E.Hgq_. E.
0 0 CI E.E.E.CIUUUCJOUat000<00UUNHUHU
E, 0 HUOU.< HH0U0HU<OZDUP4 HOULDCDH; H a.
(2., U U(7000 OUUUE.HULJE.E.HatUE.E.U< A. E. U
E-, H. cp 0 E. 0 0 E. E., ,4 Fr CD (...1 N 4 < E--+ L7 U 0 E. 0 Ch < c9 H
0 d AF40UCJAUCh.4 UUCJUeHOWN A 00,ACJE-.4 U
O 0 0 C.)00 0UUHHUU0OH <UU ONHU 00,...
00 UE.<<OD<U<HUU<ON(.9 U0000NuCA
(FU 1-i H < < UUUUUUCFUU
HO E. U 0 0 0 d g U CD CD H CD H E-+ 4 E. E. A 0 A 0 4.qAHAZDOH00E-,E.HUEJ00 CiEJOHE.J.....<0E.
E. 4 0 A 4 U < U 0 0 U 0 < E-, 0 0 4 4 U H E-. E-. U < E-. H 0 E. < <
0 0 E. U 0 u 0 W ,r H C.7 U U C.) oc E-, CD F. L) CJ C.) H gq Ci 0 H 0 U 0 0 H 0:qt,UUL)1.)UKC U 00 U OUC1 Ea 000 0 U 0. g u r_i Ch .t (70H<U0E. E. E-, U 0 < U 0 gqou ,-quu,4 U 0 0 U H
,t 0 U d E-1000<0U<U0.<0<4,00 HH0E.<0H<E.
OH' U UUU<OO<U<E.<0000UUHUU< Kg AHOU0 0 E. 0 0000000HOHLJOL10.4.4E-40H0FAOHOUA
0 E. ,i= 0 < U 0 C9 E. L. U 0 E.
a( U < U U U U E. CJ CJ U E. U < U U CJ
A U ,= U000.4 at E. 0 < N E. E.
C7 (7 d HUOU00E-, < < 0 E.
O -..,q H 4!0oE-,ouHUU0 6tHCJOU HUOatOrt HHOUat F4 Pc 0 D 0 e. g: F-4 pg C) u CS C.) 0 U 4 t. < E. E. < H 0 u cp 0. E.
0 U 0 U 0: ,..., E. NAOHE-.0 AUCJC/HUE..40E-,..,00.110A A
E-, 0 0 4 0 0 E-, U U 0 E. .4 0 < U 0 < Q 4 0 0 HU,G0 U a. H, E. 0 U 0 H 0 0 U E.
< 0 E. (E-.) EC-7' 8 3 8 Ec2 '6 'il4 ti t-D' 8' 8 2 N it', ',." 8 8 -'. E. A H. . H
H E. 0 4 0 0 04!C7U0C74!HE.C7UUOUU0UHUUHE.0 Ch U a' E-I U < C_7 U E. 0 0 H H H 0 U
< 0 E. kJ H < U 0 0 E. H d H
H 0 d (7 0 EJ 0 u CJ U CJ H CJ H E.
E. E. 0 H at ac 0 0 < at 0 H 0 U
E. 0 H E. H HO 0-F-' ,ri:ogyugovHOK4,o,--¶--, HOU [J
g4 K4 E. EA < CJ U 0 E. 8 E. U 0 U 0 H < C.) U E. E. 0 U (9 H E-, 0 0 U
0 Ci a=C OUU0a, 2.< E. U < u 0 u H 4 Ei u r..) 4 0 A 4 0 Ft g gC
U HO ,C Ci U U ' U 0 E-. E. C.) u C./ E. g u 0 ,: E-4 0 H 4 E. U E. 0 E. E.
0 A 0 0 0 < E-, A 0 A 0 0 A E., U 0 U E-. 0 4 I. A U 0 H A A A E.
.FU C) 0 0 U U U C7H00 00000E. ..4 CD
< 0 0 d E. 0 at < U
CD Clg g 0 E.-, U H E-, 0 U g UN g g LD 0 g CD g 1 E.pc g CD 0, N U CD H C..) uHue,i,uu,-5. ouHH ust: 4000 000 r", E.U<NR00001UUUKOU UH E0E-100cy E. E. 0 == 00.4E-, UUE--..1,4.40000 < U E. CJ
E. U u c..) q A E. E. = A 0 q E-, 0 CD E. a, a, E. E. < H d E. < < 0 at 0 E. 0 <
0 +, U 0 U U fat H E. E. E. H d d U 4. 0 E. E.
I. < PC .4 E.H 4 (7 <
8 u '' z 0 ,..c EØ4 L--, 000000E-..40uU0E.L.A00U0u EJ E.-. C:1 0 0 A U 0 E. -4 0 E. U U 0 U 0 A 0 E. H A A 0 0 0 0 4..) 0 E.
H4!UNNE.4!UUUOUH00H4!p4u04!uoutpc..)u O U E. 0 E-. 01 0 0. 5--, 0 H
0 ,< 0 U H. U E.. E. 0 H < .4 0 0 H H. H 0 E, E. 0 .4 r4 [--. E. o 0 c4 E--, E-, 0 U
E. A 0 U E. 0 0 H 0 E. H C., E. E-, < H U
< 0 0 cri E. E-, E. <
U f-, .4 .4 C. 0 0 HUUE.J.:G4,4HurcuchuuE.<
, __ -SUBSTITUTE SHEET (RULE 26) E. 4 0 U U 0 0 040E.U0H00400000440E.C.)04u U U, 4 0 0 U E. U u 0 al E. E. 4 Er. C.7 E. U E. 0 4 E. U CD U U U Ff ,..0 E.
< C9 4 4 F.S.u04000E.00E.4E.0HOU 4 0 4 H 1 c.) 4 0 0 0 4 U 0 (Cl U 0 c.) 4 U 4 H H 4 H 0 4 E. 0- H. A
C.) 0 4 Ci E. U 1A HOC) 0 0 E. U 0 0 E. E. 0 H 0 E.
Cif. uUCJO H E. C.7 U H a. 0 C.) C-, CD 44 0 (Cl 0 E. U U H A E. o Er, U
El %E-41 8 i u040u0Uuuc)OuPUE.4E.E.)4000 4 0 Pi, g r , C 9 Pc r4 C ) C 2 (Cl CD OH4 E.H.C.300E.HE.
4 E. 0 E. U 3 U 0 4 U U 4 0 H E. E. 4 H. H 4 H 4 F.7 E. 4 E. 0 E., 4 U . E. 0 ( E. 0 E. U 0 4 H C.) 4 U H
0 E. 0 E. A E.7 F. 4 U (41 0, E. 4 U u F.-,00E.Ou0,40HE.E.OE.HE. Hut. U
4000000 E. E. E. U 0 C.) 4 U U 4 4 E-, E. E. U .4 0 0 4 U E.
0 4 U < c!) < U r..) 0 0 CD ft U A H U C.9 E-t E-1 0 E. E 4 H E. H 4 0 4 E. H P.< 0 E. E. 0 E. E. 4 0 U 4 0 .:Dq ill) E74 ti9 8 8 (i-_,) '65 (.1,, 8 8 '(5 EY. 8 8 t; 6' i--', t--,' 4 0 U C.) EJ E. H u ,..i E. H E. 0 Er. E-.,. C.) 4 g E, E. 4 E. El 0 4 U 4 E.) E. E. 4 rc 0 U E. u 4 E. 0 U 0 E. U y ro 0 E, 0 Li 1E1(400Ft 0 0 gt U 0 4 C i 0 U E.) 4 E. 0 0 E. 4 0 c.) 4 E.) I. 0 OUE.004 rt:HOUE.E.U000H4UU OHHU00 EA 4 u u A C.} 0 0 : C . - l',',q E.) 4 H. U (..) 4 (Cl El 0 4 A U00019HUO
0 4 0 0 E. C.7 u OU414C;Uu0u(7040 1.5 A A u A q E. A
w g E, A CD C9 C.? E.044000Ht..9E-.1.4E.E. 40404 a,C..)0 C..) 0 F', 0 E. r4 U ,,4 0 0 0 E.--.00E-,PE-,0000 UU0E.0040 r.q E-, U 0 0 -KC 4 0 ,,t 0 0 0 c.) .r E. 0 0 4 4 0 E. E. E. u 4 E. E. 0 E.
C) H H H 0 H E. 4UV004H0uuuLD HOHUCJUE.4U0H
4 E. 4 .4 0 0 E. 0 0 CJ U ci 0 4 t..) 0, u U Q.) U 0 4 Er. 0 c...D 0 0 U 4, 4:
0 .4 E. 0 U U a: Q.) E. 0 E. E. H U 0 4 CJOgc0(.744,<CDU<U000 U E. E. 4 0 0 E-, 0 0 4 0 (-) r- LI C.D rc U 4: < C.) C.9 4 H E. 0 E. 4 0 F. 4 O4400HU 40CD4U4E.60UUOUUE.uc..)44H0u O C.) E. 4 E. 4 0 HEDUUE.C9H C9U044 4HUE40 uHuu O 4 E. 0 E. 0 u 4 E. 4 0 E. 4 E. u 0 4' 4 E. U E. E. 4 4 u E. u 0 E. 0 AHAHOAH E. H E. u E.) E. 4 u g u U U 0 E. U C.) U E. U a, 0 U
4 4 U C) E. U E. 0 4 E, 0 4 E. E. E. 0 CD < / f--, u 0 u 0 0 H 4 4 0 E. 0 Ci E. cD 4 CJ 40UHuu04E.UOu E.00404E.H0U
..¶7/00C1E. U I. < U U U u c...q u 4 E. 4 H E. 4 H 0 U 0 0 E. u ga; U U 0 CD U E.<<CDNE-, 9, U UUE-UP<C9 E. < U 0 4, 0 4 0 0 r...) C.) C..)0U0E.4U C.)040400E.0 .40 00,HE, 0 40 000 4 0 CJ ' <UHE.E.NUC E-,<CDC...DCDUUOU<
0 CD < < 4: CD 0 U U 0 F E. 0 F. U CD r..) 0 4 4 E. 4 0 0 E. E, 4 E. 4 /E. 4 a. u E. CD CJ 0 a: 0 C.) 0 0 4 E. E. 0 C l 0 CD 0 C.) 0 C.) E. U C.) E. E.
e. E-, 0 E. 4 U 4 4 C., E. 0 0 E. E. E. 0 U a: 0 E. U E. 4 U 0 0 E. E.4 UCJE-.040 E. a, U U U C.) E. 0 E. H E. E-, (9 E. 4 4 0 0 4 4 0 E. 0 E.E.0U<F, E. E. 4 9, ,4 0 < C.) U < U U E. U gE CD < E. U E. CJ 0 4, U 0 0 0 CD CD ,4 E. U u E-, U CD U CD E. < U 0 F E. CD U 0 E. E. CD 0 <FUUUF 0 H 4 4 E. 0 4 0 0 C9 0 E. 4 E. U H E. 0 U 4 E. C.9 E. U
C) 0 4 4 0 0 0 V . 4 0 E. 4 U 4 0 0 0 E. 4 H 0 U 4 t7 4 4 U 4 4 o E, u u u El E. E. 4 C.) 0 E-, H Ei UUHAUCD<HCIE.,<FUE.EDE.
U E. E-, F. 0 ED 4 E. 0 4 U 4 C.9 0 4 E. U 0 U E. 0 4 E. 4 L., 0 H 4 4 4 0 4 0 A A o 0 .4 HUUE.00000U0H4,040U4H044 CD E. U 0 U U 0 40E.HuuluH440t....404010or...)Hu H F < H F 0 0 0 .4 U C--, c-, r..7 C.) Li Ft, u H H C.), 0 4 4 0 0 0 E.
10C)00H0 E.C.90000, UU040C) 4 C.) E. E. 0 C. C.) 0 CDUCDU<C9 OUU01-, ,:4 400004 4UHEJHUUU
00UUH40 4 E. U 0 H 4; E. E. 1,4 E. 4 0 E. AgoguE, 9 :=,.n t-, E. u ,,c ,,, o U U E. E-, EA E. , a: U < CD E-, E. E. <
< E. H 4 U
U u 0 E. 0 u 0 0 Ci 0 4H0 0000H4Ouu OH 400uu 8 ',-'t 6' x): 8 tj i 0 ,x, E. , u Er, (..J U 0 U 0 4, 0 E. E-. 4 .4 0 0 0 0 U U
0E,E.4UUUOUE.UCDE.44004:0E-,UOu 4 E. C.) 0 U H U C.)00E.04 4 0 U H U E. F 0 E. < < U CD E. H E. (5 44 F 0 < 0 E. CD < 0HHOU4H400H00E.C9E.E-,C) E. H 4 I.
0 H 0 C.) 0 E. 0 C., 0 U E. 4 4 E. 0 0 E. 0 U U 4 Ft E. 0 4 0 0 L.) 0 E.
0 6q u o g (9 E-, 4 UUUOU0C9HE.4E-40 OUE.E.OUUHU
< U CJ U ti r4 U 4 4 0 4404 < U 0 4 E. < < E. 0 E-. E. E.
E. 0 E.
CJOUE.0CD<E, < 0 U < < < CO 8 o (E-4 8 ,r5 8 8 `-, 8 '.,? Et?, 8 EY, ,E' E(1, 8 (C-P0' SI
rDE-.00E-400 E. E. 0 4 uguE,c9c..9(.94 upugE.-,uE.C-, f-, E. E. U 0 U U E. 0 < E.. 44 U H r E. F 4 r..) 0 0 E. Li 0 U 4 0 H E. 0 E. gC E. u 4 0 E. F. 4 c.. E. 0 0 4uo(94c.924clouguE)0A
u 4 u H EJ E. E. 0 E--µ E. E. U U 0 a; CI CO E. E. ii u 0 U H E. 4 0 E. 0 0H4HOCIU 0 et O 0 0 U 0 U U E. 0 E. 0 E. E. u E. C.) U 0 U
4HOEJE.E.0 oru,SUOUE-.4E-.00E-.'0E-.E.u04E.OE-,u 0 4 0 u .4 H 0 E. 4 4 E-.04000E.F.E.00E.040E.0 E-.4 H H U CI 0 4 4 E. OHE.E. A 0400000UUE,4000H A 40 0 8000004 U E.E.0 UUOU40C94.440HuE.0 4u 0 U 0 C./ e= E-, 0 4 Ft r.., 4 0 CD U 4 E.
U Fi 0 E. E. 0 H CJ 4 0 0 E. 0 0 CJ.40UHU co CJUE-4000C90E.E.40E.HUAU(..)4H A 4 0 El E. E. 0 4o4(9 rn H U U El CD CI C.9 CJ CD U E. 0 0 4 0 E. 0 E. [..) 0 u u U E-4 E - . U 4 4 0 0 = = 0004,004'E.FE.U.:4:0<<FUCJ u u c_q o HEØ4H0t1 = 4C.)44E.E.14U44E.U44HHOE.H0E.E.
E.H00040 0 u K.7 E-, E, 0.4 u 4 u E. 4C.,CJUE.40U4 < Hurl;
E.E.E9EHE.Uu Z UU4u40 r0E.E.00E.E.44UU04H
O004C.)E.H0 A 00u0000 U(9044,400HCIU0E.00 U U 4 E. E. 4 E. E. H E. 0 E. 0 E. 0 0 E. 4 0 E. 4 EJ U 4 0 E. 0 E, 0 E.
0 E. E. 0 0 CJ ,4 u a F. E. 0 E-. 4 E. A V U E. U 0 Ct) 0 4. U C.) C.) g 0 < 0 4E-. 40E000 ta k4000a.E.040000E-.=40 0400E+04 u 0 4 0 E. 0 U E. 0 H u E. 0 E. 0 E. U U E. E. 4 L) ,4 E. E. E. 0 0 4 4 0 F.
SUBSTITUTE SHEET (RULE 26) .. __________________________________________________ r..) 0 4 H U C.) Ci a, b) E. U a CD E. tD 0 u a a E. CD
H a 0 0 A U E. E. a 0 0 F. (--)aE. E-,q0E.00t.)E.E-i0 A .5 aE.00HE-.
ac-DaaCJOE,u CD a E. 0 a 0 a 0 a a, U E.-, (JAE, U
u CD C.) E. a E. a 0 0 CJ E. I U 0 0 E. C.) U U a 0 Ci 0 A E. 0 E. CD tJ a , F. 0 H CD CD a, U 0 0 a 0 a 0 / U U a U
E. U u 0 a 0 0 E. F. LI 0 0 C-3 F. E.
a, a a gl. U U E. CJ H H C)0000LJ U0CJHUE.CDF. E-.C.)HC) 0 H. 0 0 E. 0 A U CD0E.E.0a0CDUE.aE-.001.0E.E.U0aE, 0 a cA CJ 0 CI E---. H 0 a H E. 0 a ft 0 V ID E. E. T. ti 0 E. 0 ,a 0 E. 0 HaCJ Cit5C.D0 _____________________________ 0 0 CD a E--. E. a 0 Ft CD CJ 0 0 0 0 U E-. a 0 u t j E , 00CD C..1 /you 1. 0 U u u 0 0 4 u 0 4 Ug,A0 OU0 1 E-, 0 H 0 A u 0 u g z. C.) E.-, o I-, E. 9 H. U a 0 0 E. u 0 a A a: 0 E. E. E. E. 0 0 0 CD 0 H. F. A 0 H E. C) a 0U a E.
0 E. a 0 F. ch E.0HCJHOU000LJE-.0040E-,0E-.0cD
I
U < A 1-, 0 < U 0 < E. E. P C.) ft a ch a, a E. U C.) U
U 0 u E. 0 CD 000 a a a E. E. U 4.4 E-, U 4 < E-, E-, 0 H. E.
U E. E. cD U H. I--.HUE.E.H AcJ
UH<OU0 HachUaa (1,_ , u q 0 Ht_DHHOChE.Hrt auu a E. CJ Ci C.) E. 0 Chc-JE.HuCJuUL) 00(Daaa0CDE.000 aU0a4C2CDU PHaaE.C9HUCh A H 40E-,Kcul 4 uE., 0 E. 0 E. 0 0 0 t. E-. E-.0-aa0HaEla 0HCJ000a uCiCift 0 U E. E. E. 0 0 a CJE.aa0chaE.C.Da0000Ha0 Ugtue HuaCJAaCh C7 <000H0HOHL/CJE,H<CJAHHHOO<
.40HUOUCJC) CDE.a0a0E.C.)0E.0UKC00UuCia 4 u E-, 0 F.E.4 H E. 0 0 a 0C-A 0,< 0H E, aPIDEACJE.CD p 0 .000 UaOuth0H0 00E. E.HUclaCJOUHEDUE. a E-, (..) E-i 0 E. a 0 u 0 C.) a CD, (!) E. V a 0 0 0 U CD U Kt: ti a E. E---. a E. 0 .4 E.
H a, 0 0 0 U E-. a 0 000HaUHluaaH00C9UE. A 001) F-' F-' 0 a a E-. E. U a a 0 E.(DE-.00E-.a,CDUHCha000E.c.JCJHa' a000E-.0000 ,E.E.
Cha000CJCJ0000E.0aHal.C3 E.
0 0 El H 1=4 a 0 0 a a <UP U<Alr4U0000E-4<.4 H H U r.) 0 0 A 0/6C 0 U H H UyO<UU H, 0 a a E. E. a a E. a a CD
E. Kg E. C.) 0 0 E. CI U H U 0 0 H CJ 0 E.
C) a, 0 E. C.) E. 0 E. a 0 ...4 H
a a. E. 0 Ft CD E. 0 .4000E-, 0 0 H 0 0 CD a 0 E. E. E. 0 E. E. H
CJ E.
0 0 E. 0 U 0 E. 0 cJ U 0 E. E. E. E. E. U 0 0 a u c) rt 4 E. E. E. U a 0 0 arDaCJ0,40,Ha E. E. a 0 0 0 0 0 a 0 at E. 0 0 E. E. 0 E. E. a H E.
0 a 0 U 0 0 a, U a U C) a E-, 0 < u ci U U 0 0 A 0 0 0 < 0 0 U U H
HCJOUH0C9,AH CI C9 V E. .4 a, H E. 0 0 ID L. 0 Ft 0 0 U a E. 0 0 CD
E. ,..q.Nuugq,c0 U E, U U 0 < 0 0 CJ u H E-, U 0 E, E-, H a C.) P E. 0 0 a a E. H 0 0 U CD a; 0 0 a; U H E, < a CD C) E. C.) a E. 0 CI 0 E. C.) 0 a F-. '1. a C) CD .0 0 uucDocuuuu AE,00E-.4 00 A
U H.E.0cDCJUE. E.aE.E.chuuE.E.u00C9 E-,4uu 0 E-' Hu 0 E. a E. 0 a 0 E. E-.<0001CJ r4E-4(JuK40E,0g4 u 00,0 C.; aUHUE.E.O auE.E.U.a achCJU)0000a0 ChEt aU
U 0 E. a E. 0 0 c.) Kc ath0a0a, CJOC,DE.CDE.Hat-.E.
aC)ach a a E. 0 U Er E. CD a 00CDCJaCh0E-.0cDE.HH uucDua u 0 0E, E. 0 a 0 0 a E. C9 E. H0E-4000000aE.00a-4,0E.F.E.CiaH
E. E. E. 0 0 0 a a E. Ei E. 0 a U U c3 0 a H. 0 U U 0 a E. 0 H ci C.) CJ E.
C.)0a00000a a,00000000a0000000 E.CD0C.D
E.C9a0000,E.Ch PCU0E.00E.H.E.00a00,400 aChua 4V)uachuE.c.) 0 E. H E. ch a 0 0 a u 0 a 0 rt < 0 0 H H CD H
!.2 H E. 0 p50.-40 H U 0 U E. 0 4 CJ A H < 0 U U 0 0 0 f.-4 Li 0 a a CD CJ E. EA CJ A A U 0 CD 0 (.70554uuE-,(DHOOUC544A<HUE-, 49 54 ,,.,4 E-, 0 C..) < ,,,C T.!) H L.) < ,r4 U H a: H U 0 a a H 0 E. E. a A CJ
E-, a E. EA 0 U CD a 0 a uach(JrcHE-,00HaUatJur.JUE.ci(JyH
U E. E. ch E. H 0 0 u 0 u 0 0 E. a E. CD A E. E. E. 0 0 a A E. C.) 0 U SJ
CD
F. CD tJ 0 a U E. E. 0 1DE..100HuUcDaH000 HUChacha U Cr) U a E. F. a; H H 0 H ,,4c.),¶,v()U0c.)K4E.A
H E. a H. C;; u F. 0 H F. 0 0 (..) .4 U UEJ '0g4A(.7E,HclUUUHUH<OH<U
U < H U E, 0 CJ 0 444E-tuutiC--, 4 0 u0 AU UcDE-.0-ach ,r0U 0E-.0C)E. 0 a u a E--, a U U F. 1--. , E. E. 0 0 H < 0 0 0 u U E-, Ci C.) u 0 o U 0 H U 0 U u H L-, U H U 0 U 0 < H A (.9 0 E-, .4 U U ,=4 (D 4!) U f--, A ,:4 A Er E. a 0 0 0 0 a E. H. CD C.) U 0 U 0 CD
U E.
r. ' 6 P. 8 6 0 F. C9 U E, 0 CD E.
E., E-. CD 0 C 0 H. ci E. a U 0 HUUacJtJUUHUE.E.E.E.c7F.aaChcha 0 E. a a F. a 0 aucJaE.E.a0achauciaUUH0acD.CF.
0 E-+UE-, UUUch F. U 0 0 a E. C) 0 H C, CD U 0 E. a u C.) E. E. 0 0 O 0 E. / E. a E. 0 0 H H 0 H g H 0 at 0 0 0 0 El PCH0F.E.01-)44 0 AU 0 a a 0 E-t a u 0 0 CJ H. a, CJ <000Fla H EJ U < 0 al O HA E-, 0 H U gq E.000E. CDHE-.0C.)0F.a0C-DaHIDHaE.
Cl E, Ei ft U H 0 a; 000F E.ft U 4 00< E.-.uuu H04E-, 4(...0 H E, a E. ft 0 U a u U a a 0 U 0 E. 0 CD 0 0 CD 0 0 H a CD g 0 0, a H E. a ch U 0 0 U 0 art0HE.E.E.00 ur-140y0c0 04 0 CJ C., 0 < 0 a 0 F` C., 0 (5 C H (-) U P U 0 C,C.) 0E.E.0a am, 4 E. E. E. E. 40 E-. [-, 0 0 C.) E-, 0 r.. . .9 ( 7 CD u u 4 0 u K4 Ki (J E-, K. E.
E. a E. H a CD t) 0 FtHO C.)0lJE, 4u0c.90 .< Kcc..)E , u O 0 0 E. E. U E. cn U Ch 0 u C.) ch E. E, E.
0, E -. ..: u I -. 4 9 0 CD E. 4 E- . U C...) m E. CJ Fg 8 H. H. E-,-. E. a CJ a 0 H E. H <
E. a U a 0 - 0 0 U
EEc,,,t-i,c3., 6 6 6 ';'4 t-A 8 0 Et (i (-i 8, t8J P . 0õ' op' E t ;- , ' ' , ,H1 6' N 1 E9 (.., 8 8' rl 8 '(', -,) (E.% -'. t.," 8 6 i-', r.j4 [ ; 8 El 14 8 ti: 6 'El E. u I
o= puo,,,,,,,E,., u H HUUU E. < 4 E . 0 p E. -, c / i -_,4 ,6 t . ; g f_c, )., Ha rg E,....00 K. 4 0. E. E-E r4: E-1 v400000E-4E.
E. 0 u E. E. E. 0 E. E. v-a H 0 U U Pe, a a CD a a 0 0 E. a H 0 H E.
a E. a H a 0: 0 0 H cri E. U E. 0 a u ch a u0 00uu 40 0 to E-. E-, SUBSTITUTE SHEET (RULE 26) GTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAA
GCGGTTAG
CTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAAT
TCTCTTAC
TGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGA
CCGAGTTG
CTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCT
TCGGGGCG
AAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCT
TTTACTTT
CACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGA
ATACTCAT
ACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAG
AAAAATAA
ACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACC
TATAAAAA
TAGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAG
ACGGTCAC
AGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGG
CTTAACTA
TGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATOCGTAAGGAGAAAATAC
CGCATCAG
GCGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCG
AAAGGGGG
ATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGG
CSEQIDNO.:40 CO
Cl) AATTCTAATACGACTCACTATAGGGAGACGAGAGCACCTGGATAGGTT
SEQIDNO.:41 CAD IA
CD
GCCTGCACCAACAGTMACA
Cl) SEQIDNO.:42 rn SEQIDNO.:43 TCCCGTCTTTGGGTCANAA
r¨
SEQIDNO.:44 17.! GCGCCGCGGATCGTCAACA
SEQIDNO.:45 ACACGTGCACGGCGGC CAA
ra SEQIDNO : 4 6 TCGCGCGTTTCGGIGATGAtGGTGAAAACCTCTGACACATGCAGCTCCCC-GAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGA
GCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGICGGGGCTGGCTTAACTATGCGGCATCAGAGCAGAT
TGTACTGA
GP.GIGCACCATATGCGGIGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCCCATCAGGCGCCATTCGCCATTCA
GGCTGCGCA
ACTGTTGGGAAGGGCGATCGGTGCGGGCCICTTCGCTATTACGCCAGCTGGCGAPAGGGGGATGTGCTGCAAGGCGATT
AAGTTGGG
TAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGCCAAGCTTITCCAAAP.AACTACCGTTGTTA
TAGGTGTCT
CTTGAACACCTATA.n.CAMCGTAGTGGATCCCGCGTCCITTCCACAAGATATATILAACCLA_AGAAATCGAAATACT
TTCAAGTTACG
GTAAGCATATGATAGTCCATTITAAAACATAATTTTP_AAACTGCAPACTACCCAAGAAATTATTACTTTCTACGTCP-CGTATTTTGT
ACTA.ATATCITTGIGTTTACAGTCAR_ATTAATTCTAAITATCTCTCTAACAGCCTTGTATCGTATATGCAAATATGA
AGGAATCATG
GGAAATAGGCCCTCTICCTGCCCGACCTTGGCGCGCGCTCGGCGCGCGGTCACGCTCCGTCACGTGGTGCGTTTTGCCT
GCGCGTCT
TTCCACTGGGGAATTCATGCTTCTCCTCCCTTTAGTGAGGGTAATTCTCTCTCTCTCCCTATAGTGAGTCGTATTAATT
CCTTCTCT
TCTATAGIGTCACCTAAATCGTTGCAATTCGTAATCATGTCATACCIGTTTCCTGTGTGAAATIGTTATCCGCTCACAA
TTCCACAC
cn .RAcATAccheccGep.Accth,AAGTGTAAAeccTeGeGTGccTAATGAGTGAccTAAcTcAcATTAATTGcGTTecG
crcAcmccc GCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTG
C1:1 TCCGCTTCCTCGCTCACICACTCGCTGCGCTCGGTCGTICGGCTGCGGCGAGCGGTATCAGCTCACTCP_AAGGCGGI-zkATACGGTTA n.) cn co TC CACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGC
C.AGCAAAAGGCCAGGP.ACCGTAAAP.AGGCCGCGTTGCTG
GCGTTTITCCATAGGCTCCGCCCCCCTGACGP.GCATCACARAAATCGACGCTCAAGICAGAGOTGGCGAAACCCGACA
GGACTATAA
AGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCG
CCTTTCTC
CCTTCGGGAP,GCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTG
GGCTGTOTG n.) cn CACGAACCCCCCGTTCAGCCCGACCGCMCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGP-CTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTP
_ACTACGGC n.) TACACTAGRAGAP.CAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTICGGAWAGAGTTGGTAGCTCTTGATC
CGGCAAA .. 0 AAAACCACCGCTGGTAGCGGIGGTTTTITTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGA.AGAT
CCITTGATC co TTTICTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATITTGGTCATGAGATTATCAAAAAGGATCT
TCACCTAG
n.) C ATCCTTITAAATT
'AAAAgTGAAGTTTTAAATCAATCTAAAGTATATATGAGTAARCTTGGICTGACAGTTACCAATGCTTPLATCAGT
r-GAGGCACCTATCTCAGCGATCTGTCTATTTCGTICATCCATAGTTGCCTGACTCCCCGTCGTGTAGATPACTACGATAC
GGGAGGGC
TTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCT CAC CGGCTC
CAGATTTATCAGCAATAAACCAGCCAGCCGGA
2) AGTAGTTCG
CCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCAT
TCAGCTCC
GGTTCCCAAcGATcAAGGCGAGTTAcATGATcCCCcATGTTGTCcAAAA;U,GCGGTTAC-CTCCTTCGGTCCTCCGATCGTTGTCAGA
AGTAAGTTGGCCGCAGTGTTATCACTcATeeTTATGGCAGCACTGCATAATTcTcTTAcT=ATGccATccGTAAGATGc TTTTCT
GraAcTcGTGAGTACTrP
ACCGCGCCACATAGCAGAACTTMAA.AGTGCTCATCATTGGAAAACGTTCTTCGC-GGCGA;a-A.ACTCTCAAGGATCTTP.CCGCTGTTG
-_________________________________________________ i gur...)...quouout,opociur.
u 0 U 0; U 0 CI T.9 U U U 0 U U U EJ E. 0 E.
E?, tCjD 8 g EY, il b' ill 8 8 8 '6 8 8 ti 8 0 E. .4 0 < H UUUUUUUUUO
E.E.urJuU04.0H<E.HUQU0,0 FI E-..4UDEDE.OchouUou5440 5400 UE...4E-louour.7(.70uu0E-.
UUHUUUUU g 5 <4 E- , Ci E-, (DE.uUtD0c.DuchUuu00, -, 0 UU0000UUHrc<
HHU < H, 0 U 0 CJ U E.
u u-, 0000 0 u u u c2<UUUH 4:0c.D0c9UUFC< H
O u U E. U E. CD U ci U E. U < 0 0 <
HE--,HUrCE-, <04:0U0E-,HU UE-, UHHHHUUUUUUUUUU
E. E. UUHUUUHUHUOHU
HE-.0u0HE-,<EDUr_DU<POU Hrg PHOO<HP<UOuyCJUHUE.00;
0 CJ 0 E. CJ CJ CJ EJ 0 U 0 U E. 0 E.
U 0 E. < 0 H 0 0 0 C) 0 u E. H H
UUUUUUUUUUUOU
U= EUUUUHUUUHU
H= E, CDUUugu0,000cJEJOHuc., HUE.,<U0CDHUE3UUraciUCJ E. 4 4 (JE-, i E--.E.E-.4u540oViuvuE.uE, .4u 0, ,,,C0uE.HU .0ciu<00 E.
0 u E. U u 0 cJ 00000g E-, t-, E. < CD 0 E. U CD 0 < U U (9 t. 4.
U 0 g U U0E-14:0u0cDCJUu<HFU
E.E.E.00UHUOU(Dua, V (.7 C.!) C9 H U
g E. E-i C.9 g U E-, U U a, E. 0 u E. E. CJ E. 0 a U0E-.<<HuUUUuuLEULDUE.E.
O H < 0 4, U CD rC U E., E, U F,C CJ 0 FE.
4 E. 0 0 E. 0 CD C.J 0 0 0 0 4 E. CD 4 CI 0 U 040E.4E.uourf uouuu44 E-, H 0 E. < OUNOUHU a, U cd 04 4. 4.
E.C<UrCUOUEDuouU0,-CFUE-,E.
uchrc UHU<UU0000(DUUEJHEJ
E. = C.) 0 U 0 UOUH ED U E. C) U) OUHU<UO<UUCDUUCJOE.4HA
E. g E. 0 c-D C-) g U .: C- , U CJ E--, E. C., F, Q 0 C.>
kJ 0 F4 0 < E. H U 0 < 0 E. CD El C.) U U E. 0 0,14 UHUUUUHUUUUHH
4 0 < 0 0 0 4 U 0 ,_< CJ V CD U 0 U 4 0 0 UCDCJUO< f"UUC-1 CDC 7 0 ouout.54 u u 54 u 4 u (.7 u u u u u u u a; 4 E, H CJ
CJ 4 H CJ U CJ < LI U 0 CDOE.04044E, 44 <FOLUU<UCD<CDUOUrc pc H
UE.004000000CDUCDU4HUH
O ,uq o u u f. E-, u 4 4 E. UHUU<.CDE.
E. 4 U U U E. 0 CD CD 0 E.54E.7uouE., E.
O 0 0 U HUU CD U 0 U 0 0 U E. 4 H
UCD<QUUHUHU<<CJOH044E, E. 0 CD 0 E. gl, U C., 0 u 0 0 cD 0 0 < 0 0 ,4C
U4H Hup,c0<UULDEJCDUcDcD0E.c., < < 4(70E-.4E.704uuElugE744.7, urpCDUC90000CDUCJO <0 .5 U HO rCuHre,c_DUcicDcauurr<
u U0UuuciPE-, E. E. H 0 E. g E. 4 ,7(,1 E-,E.OU E.U000< HUCDOUEIE.0 0 0 E. U 0 U 0 CD Ca C_D 0 CD 0 U U E. < 1 E.
E.E.7E-.54 0 CJ 0 U U 0 0 0 0 < < 0 U U. CD
CDCIHHE.UOU<24HUE.00,4 al u E . CJ V 0 V C,7 0 CJ ,... 0 0 0 C..) U 0 0 u E-, 4 0 E.C1E.UOU
O E. H 4 4 H V kJ CJ0u000uucDUH
O 0 U u U E.C.DUOUCJUOU< E-, E-, u E. ouuuuu4 c940uuuUouE. C.) H C) C) 000 Oa UPCOUCD,CCJUUHU
O KCHHOU<UCDUUCDOUCDU<4 0 µCUULDCDUUU<UCDE, 4,<HOCD04 4 CD
U0E. F,000E.404000 004 4 U 49 <4 OHOHOUVIDOOUth< E. U 0 E-, < E. CD 0 < CJ < U E., g E. UUOU 4 0 .-4E-., g .K4 0 U 0 01=4 O OgUUUUg 0 0 E, 0 UN.. UOUUUU- gUOUU E-, U
1=4 0 .4 0 U E-, CJE,00,<UUCDE.4UCJ4 E.
SUBSTITUTE SHEET (RULE 26) SEQIDNO , :47 TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTA
AATGGCCC
GCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTC.AATAATGACGTATGTTCCCATAGTAACGCCAATAGGGAC
TITCCATTG
ACGTCAATGGGIGGAGTATTTACGGTMACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTA
TTGACGT
CAATGACGGTAAATGGCCCGCCTGGCATTATGcCCAGTACATGAcCTTATGGGAcTTTccTACTTGGCAGTACATCTAC
GTATTAGT
CATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCA
AGTCTCCA
CCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCA
TTGACGCA
AATGCGCGGTAGGCGTGTACGC-TGGGAGGTCTATATAAGCAGAGCTC-GTTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCA
GATCTCGAGCTCAAGCTTCGAATTCTGCAGTCGACGGTACcGcc-GGCCCGGGATCcACCGGGGCCGCGACTCTAGATCATAATCAGC
CATACCACATTTGTAGAGGTTTTAcTTGCTTTAAAMACCTCCCAcACCTCCCCCTGAACCTGAAACATAAAATGAATGC
AATTGTT
GTTGT TAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCAT CACAAATT
TCACAAATAAAGCATTT TTTTCACTG
cn CATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAAGGCGTAAATTGTAAGCGTTLATATTTTGTTAAAATTC
GCGTTAAA
ITTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAP.AATCCCTTATAAATCAAAAGAATAGACCGA
GATAGGGTT
(/) GAGTGTTGTTCCAGTTTGGAACAAGAGTC
cACTATTAAAGAAcGTGGACTccAACGTCAAAGGGcGAAAAACCGTCTATCAGGGcGA
:71 TGGCCCACTACGTGAACCATCACCCTAATCAAGTTTITTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAA
GGGAGcCC
co CCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGG
GCGCTGGC
AAGTGTAGCGGTCACGCTGCGCGTAAcCACCAcACCcGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACT
Cr) APATGTGCGCGGAACCCCTATTTGTTTATTTTTCTI4AATAcATTCAAATATGTATCCGCTCATGAGACAATAACCCTG
ATAAATGCT
TCAATAATATTGAAAAAGGAAGAGTCCTGAGGCC-GPAAC-APiccAGCTGTGGARTGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGC
n.) rn TCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAIATTAGTCAGCRACCAGGTGTGGAAAGTCcCcAGGcTCCCCA
AGTATGcAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCcCGCCCCTAACTCCGC
CCAGTTCC n.) GCCCATT CT C CGCCCCATGGCTGACTAATTT TT TTTATTTATG CAGAGGCCGAGGCCGCCT CGGCCT
CTGAGCTATTCCAGAAGTAG
TGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAGATCGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAA
CAAGATGG co r-ATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACP.P_CAGACAATCGGCTGCT
CTGATGCCGC
CGTGTTCCGGCTGTCAGCGCAGGGC- CGCCCGGTTCTT TT TGTC AAGACCGA CCTGTCCGGTGC
CCTGAATGAACTGCAAGACGAGGC n.) cr) AGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGP-AGGGACTGGCTGCT
A T TGGGCGAAGTG C CGGGGCAGGATCT CCTGT CATCT CA CCTTGC TCCT
GCCGAGAAAGTATCCATCATGGCTGAT G CAATGCGGCG
GCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGARACATCGCATCGAGCGAGCACGTACTCGGATG
GAAGCCGG
TC TTGTCGATCAGGATGATC TGGACGAAGAGC AT CAGGGGC TCGCGCCAGC C GP.AC TGTTCGC
CAGGCTCAAGGCGAGCATGCCCGA
CGGCGAGGATCTCGTCGTGACCCATGGC GATGCCTGCTT G CCGAATATCATGGTGGAAAATGGCCGCTTT
TCTGGAT T CAT CGACTG
TGGCCGGCTGGGTGTGGCC-GACCGCTATCAGGACATAGCGTTGCcTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGA
ccecrrcorccrccrrrAce-GTATcGccGcTcccGATTcGcAGcccArrcGccTTcTATceccrrctrGAccAorrcrTcreAcceGG
ACT CTGGGGTTCap 4ATOAC_'CGACCAAGCC.',ACGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCIATGAAAGGTTG
k=.) .11.,õc, flc 0 0)0E--.4a a pc 00 0 0 a.
(34; U 0 rn a. P4 ri 4 0 0 .Z
O fa4 tal a+ U) 1-1 PI U) CD 4 F.I 4 O ui 0 o=C [..1 p4 ,-1 p4 ,-4 a+En FS al ic) U .-1 H 0 cn al co a. U a, F.
H = = pt 0 51 E. En CI KS H a. [4 PC crl ri) rd = ,-1 ,-1 < ,-.1 0 2 a I:4 C.,.1 P4 E. < 41 U0 ,-IZCIlfaci 1..¶,) P. 0 a. 0 0 0 HZ VI > 0 pc a > -4 al cn F. cn 0 4 a.
4) f:) H 0 a 0 En OH EnE-. P.,>.<ZUr.(4000U
O0 V,P0..XU0F., Ug0 0 aZ
'c) Crl c4 H ri4 E-I
H ul 0 E. U u 0 0 g 0 0 0 F. 0 U H 0 0 0 U U U U 0 OUgU00 (.7 0 0 (.9 0 0 U 'H < (J c. 0 00 00000000000 OHUE-.0<<OHOE.E-.<0 0 U C.) 0 0 0 0 F. 0 cJ 0 000000u 4 (.9 0 u 0 u 0 U 0 E. 0 0 a: <0000<UUOUU
E.0:0UUUOUUUU
U<PCOPUFE <0000 HU C)U<HOKCOUOOPC
00000000HE-.<000 al 00HUPC 0 PC g 0 PC
E-c 0 0 CJ U 0 U 0 U C I 0 KCUOUE.U.PCOU04E-.00 g<00000E-.Cic.)0 0 < 0 0 < E-. C) 0 E. 4 0 0 0 < 0 0 0 C.) 0 0 H. 0 0 0 KC
U U 0 El 0 P <000000PCUPO
00000000000:
0 <000400 0 0 PC rOOP<PCDC_DO0 OHE.0100E-.00 HUH U 0 U U 0 U 0 E. 0 0 H<<OH C.,,<<0;d0<0 , 0 0 < g 0 U U < 0 0 -E. pc u 0 0 U H 0 0 u PC KC00E-.0 Ouci0r4 C.) 0 U u 0 U 0 0 0 < < 0 u U 00 0 (,) 0 0 U 0 CJ 0 0 EJ U 0 0 0 < 0 < uH01-.0000000 Fo0r3FigHU 0 <PS 0 .= a Fl 0 H EJ C) CJ c) u E. 0 E-.
0ggc0u0E-Tr_DE,0(.9E-40r-+ a. 0 U 0 0 c.7 C.) 4 LI U f-, 0 < 0 0 0 E. C.) a: 0 < H 0 0 C) El pc 0 0 1 O <KC PC g HE-.4:Hour.Dc.) goggurDc9clur.9 =
0g000 E-, OUO<E-.00 0 U U 0 u u u 0 U 0 FigUU0 HH,OU0.:< g4 E. H000400000 i 00000000E-100 H010000:0000E.
E.E.C.10 E.E.1.0000U H u U U KC 000E-.001 4,100 0000C)C.) 0 0 HU FE 0 0 KCC)guut, C./ < CJ (.1 E-c U 00000000 <000000000E, E--.U00UHC)(3000 a: UPPCJUE-cUP<CDPE
CJ 0 < U P U 0 0 0 0 0 0 P 0 P OUKCOOCJOHO Pr H0H0<0<0000 0 g E, 01.7 0 0 0 0 0 4 0 06 4 U 4 0 4 4 U E-cPCJUPU 0 KCO<H<KCE-10 HU
OKS0000000<< Uu chuucJC)UOUO=uF.
00UKCE.<FSE-.<<c) uu <0(700000000 CJ P U P C.J U t.7 Ci 0 0 U 0t-.0000040E-.<
0 P 0 u 0 u al 0 0 U F. E-4 c.) E. 0 0 El guur.90g 0 0 U 0 U 0 < U U 0 0 O (..) (..) C.7 g U C.) 0 0 0 E-. 0 u a; E--. i--.
(.., g 00 HFS
0000000 -pc El00H UE-.00c.)000c,nou (J 0UU < H<FS 400 <00 0000000000 FS 0 FS Pc HOUUHUrOU E. C') d g 0 E. 0 0: < E. U
U0U00H0U0F. 0000 00000000000 CJUOP gug FEUOPEPOP Huu000E-.00C90 F. y00 0 0 H 0 0 HOPC04000004 000FE00<0P00 C., Pc Ci 0 CJ 0 FE 0 g 0 pc: Fc 0 0 u ci cJ u u 0 u 0 U
HOOUHP c FCE--c< H <0 E. 0 < 0 0 HP40 PC 0 u FSOOHHE, UU0U0HE. 00000000C) H
O < 0 E. E-.0 0000000 0000U0UH0 0 E-c pc rc r_l g EJOUHUKC (DUE-. UU<O000 0000 <00 g 0 . P 1 0 U 0 0 PC P E-c 0 0 U U U CJ CJ 0 0 H V
CDOUPCE,E, <P0E-cOCJO 0 PC 0 00U 0000 FE
0 r., (..) U E. E. ,.= 0 c.J < 0 U C9 H E.000H000E.00 H U E. U < H U KC 0 < 0 4 E-. PC E-. 0 0 0 U FS C7 CJ 0 0 U
ugou w ch CD 0 C) E--. 0 U g U 0000000U0UPE PC
0 0 < rS H 0 H < < 0 0 g 0Ug00<000E-100 0 P 0 0 < < 0 0 E-.
U= PEPUPE-cCJUUO<OOP UCIOPCJUUOUE.CJO
U C.) P 0 0 < 0 P < H U 0000E-.,<H0gUUU
Og C_h CJ U 0 E-c E-= E-c C.) 0 0 Pc 0 0 g 4000E.C)<0.t 0 O 00c)<<C)C)<KC r-1 PE P H 0 CJ U C) 0 CJ 0 0 0 C.) U PC
FEFEOCJE-c<OOLIPFEOPP PpCHOFEOUP00PC 0 0 0 CD V FE P Pc 0 < E. E-c 0 E-c P CJOHH00000C)0E-c 0 0 CJ FE E-c Pc 0 E-c P 0 < < KC H. 000000000000 0 4 0 0 < 0 0 0 0 4 0 o 0 u F.E.00<< 0:00HUO
U g 0 0 E. U < < U P < PC 0 0 0 0 4 EJ 0:0000CJUH
c_.) 0 < U < U < g c...q gopc HU 0000000<000 0 00 pc 00E.E. E-. C..) 0 E-1 0 0 0 0 g C.) P 0 g 0 0 U E--. 0 P
H I U 0, E. E. 00011CJOUH 00E+0 000 CDFSL)FS <
HKCE-.E-.C) uchgg goo() ug UOUU00E-.000 HuuH0HUH0E.< U
0 E. E. ugogr.90c9E-, F=4 <00000HE-.00<
C.) PUE--cc.JOOFE <OOP H 0000000.00000 H PUO0P0PUCJOE.P rn 0<PPC000000E-1 0 c'500POFEUEJOPPCPEUP co H<0000 g0C/0 <E.PPrE0E-cPPU0C-IgU == 000000 L ..) 0 u U P <
i 00 H00E-.00U< <000 = E. H U < 0 0 < g E. < U
C...7 H E. E. < F. E. E. 0 E. 0 E 0 0 (J 0 U < 0 U FE E-c 0 0 Li 0<0P0UPPC/0UC)00 Z OgUUU0UU004 E-c E. 0 F4 0 P 00 0-4 E-.0(9E-1E-. .zi 0000 0E-100UKS u 00000000.4E.<< [Jo H 0P000000CJFE00 O000< F.H.E.000< ou 0 00000 000004 C) O000E--.<00,40c)HFSH al H<0CJE-+E-.E-.E.000 0 cf) g 0, CD 0 U E. 0 U 0 E. 0 <
SUBSTITUTE SHEET (RULE 26) =
Co4 SEQIDNO :84 Identical to ATGCCGGCGCTGCTGCC TGTGGCC TCCCGCC TTTTGTTGC TACCCCGAGT CT TGCTGAC
CATGGCCTCTGGAAGCC C TCCGACC CAG SEQIDNO . : 4 9 CCCTCGCCGGCCTCGGATT CCGGCTC TGGC TACGTTCCGGGCTCGGTC TC TGCAGCCTTTGTTAC
TTGCCCCAACGAGAAG GT CGCC MIGSGLAGSGGAGGPSSTVTWCA
AAGGAGATCGCCAGGG C CGTGGT GGAGAAGCGCCTAGCAG CCTGCGTCAAC C TCATC C
CTCAGATTACATC CATC TAT GAGTGGAAA LFSNHVAATQAS LLLS FVWMPAL
GGGAAGATCGAGGAAGACAGTGAGGTGCTGATGATGATTAAAAC CCAAAGTTC C TTGGT CCCAGC
TTTGACAGAT TTT GT T CGTTC T L PVASRLLLLPRVLLTMASGSPP
GTGCACCCTTACGAAGTGGC CGAGGTAATTGCATTGCCTGTGGAACAGGGGAACTTTC CG TACC TGCAGTGGG
T GC GCCAGGTCACA TOPS PASDS GS GYVPGSVSAAFV
co GAGTCAGTTTCTGACT C TAT CACAGTCCTG C CATGA
VNL I PQ I TS IYEWKGK TEED S EV
CO
cr) YEVAEVIALPVE Q GNI" P YLQWVR
QVTESVS DS I TVL P
SEQ ID NO. 85:
.A
rn CATGTGCCAACATGCAGGTTTG CTCATATNTATAC TT T TGCCATGTTGG T GTGC T GCACCCATTAACT
CGTCATTTAGCAT TAGGTA
TAT T T CTTAATGCTAT C C CTCC CCCCTCCCTC CAC C CCACAACAGTCCC CGC TGGTGTGTGAT G
TT CCCAAAT T TTTT TT T TC TCAT
rTl rrl CANCATTATCNCTAAACAACATTGAATGAAACAACATTGAGGAT
CTGCTATATTTGAAAATAAAAATATAACTAAAAATAATACAAA
TTTTAAAAATACAGTG TAACAA CTATTTACATAGAATTTACATTGTATTAGGTATTGNANGTAAT CTAGAG TT
GAT TTAAAGGAGGG
GNGT C CAAACTTTTGGC TT CCCTGGGCCACAC TGGAANAANAATTGTC TTGGGCTACCCATAAAATACAC
TAACAATAGC TGATAAC
GA
SEQ ID NO. 86 GC TGATT TACAGAGTTT CCT CCTTATAATAT TCAAATG T
CCATTTTCAATAACAGCAACAAACTACAAAGAAACAGGAAAG TAT GG T
CTACTCACAGA
"t1 =
=
REFERENCES:
PATENTS:
U.S. Patent No. 5,712,127 Malek et al.. January 27, 1998 U.S. Patent No. 6,498,024, Malek et al.. December 24, 2002 U.S. Patent Application No. 11/000,958 field on December 2, 2003 published under No. US 2005/0153333A1 on July 14, 2005 and entitled 'Selective Terminal Tagging of Nucleic Acids' US Patent 6.617 434 Duffy, September 9, 2003 US Patent 6,451,555 Duffy. September 17, 2002 OTHER REFERENCES:
1. Frost H.M., 1964 Dymanics of Bone Remodeling. In: Bone Biodynamics. Little and Brown, Boston, MA, USA pp 315:
2. Baron, R., Anatomy and Biology of Bone Matrix and Cellular Elements, In:
Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Fifth Edition 2003. American Society for Bone and Mineral Research, Washington DC.
pp 1-8, 3. Jilka, R. L. et at,, "Increased Osteoclast Development After Esgtrogen Loss:
Mediation by Interleukin-6", Science 257: 88-91 (1992) 4. Poli. V et al., "Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion", EMBO J 13 1189-1196 (1994).
5. Srivastava, S et al.. "Estrogen Blocks M-CSF Gene Expression and Osteoclast Formation by Regulating Phosphorylation of Egr-1 and Its Interaction with Sp-1", J
Olin Invest 102: 1850-1859 (1998).
6. de Vernejoul, M. C., "Dynamics of Bone Remodeling: Biochemical and Pathophysiological Basis", Eur J Olin Chem Olin Biochem 34: 729-734 (1996).
7. Netzel-Arnett. S., J. D. Hooper, et al. (2003). "Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer." Cancer Metastasis Rev 22(2-3): 237-58.
8. Shan, J.
L. Yuan, et al. (2002). "TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells."CancerRes 62(1): 290-4.
9. Yuan, L.. J. Shan, et al. (1999). "Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer." Cancer Res 59(13):
3215-21.
Nishi, T. and M. Forgac (2002). "The vacuolar (H+)-ATPases--nature's most versatile proton pumps." Nat Rev Mol Cell Biol 3(2): 94-103.
10 11. Nishi, T . S. Kawasaki-Nishi, et al (2003) "Expression and function of the mouse V-ATPase d subunit isoforms." J Biol Chem 278(47) 46396-402 12. Morello, R., L. Tonachini, et al. (1999). "cDNA cloning, characterization and chromosome mapping of Crtap encoding the mouse cartilage associated protein."
Matrix Biol 18(3): 319-24.
13. Tonachini, L., R. Morello, et al. (1999). "cDNA cloning, characterization and chromosome mapping of the gene encoding human cartilage associated protein (CRTAP)." Cytogenet Cell Genet 87(3-4): 191-4.
14. Kawai, J., A. Shinagawa, et al. (2001). "Functional annotation of a full-length mouse cDNA collection." Nature 409(6821): 685-90.
15. Strausberg, R. L.. E. A. Feingold. et al. (2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences." Proc Natl Acad Sci U S A 99(26): 16899-903.
16. Janssen.
E.. M. Zhu, et al (2003). "LAB- a new membrane-associated adaptor molecule in B cell activation." Nat lmmunol 4(2): 117-23 17. Kawaida, R.. T. Ohtsuka, et al. (2003). "Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL." J Exp Med 197(8): 1029-35.
18. Agrawal, N., P. V. Dasaradhi, et al. (2003). "RNA interference: biology, mechanism, and applications." Microbiol Mol Biol Rev 67(4): 657-85.
19. Hannon, G. J. (2002). "RNA interference." Nature 418(6894)= 244-51 20. Brummelkamp, T. R. R Bernards. et al. (2002). "A system for stable expression of short interfering RNAs in mammalian cells." Science 296(5567): 550-3 21. Elbashir, et al. (2001). "Duplexes of 21-nucleotide RNAs mediate RNA
interference in cultured mammalian cells." Nature 411(6836): 494-8.
22. Lee, J. S. Z. Hmama, et al. (2004). "Stable gene silencing in human monocytic cell lines using lentiviral-delivered small interference RNA. Silencing of the p110alpha isoform of phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1alpha,25-dihydroxycholecalciferol and bacterial lipopolysaccharide." J Biol Chem 279(10): 9379-88.
23. Rubinson, D. A. C. P. Dillon, et al. (2003). "A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference." Nat Genet 33(3)= 401-6.
24. Boyle. W J W S. Simonet, et al (2003). "Osteoclast differentiation and activation " Nature 423(6937). 337-42 25. Gee et al. In: Huber and Carr (1994) Molecular and Immunologic Approaches.
Futura Publishing Co., Mt. Kisco N.Y., pp. 163-177.
26. Smith, A. N. F. Jouret, et al. (2005). "Vacuolar H+-ATPase d2 subunit:
molecular characterization, developmental regulation. and localization to specialized proton pumps in kidney and bone." J Am Soc Nephrol 16(5): 1245-56 27. Smith, A. N.. J. Skaug, et al. (2000). "Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing." Nat Genet 26(1): 71-5.
28. Stehberger, P. A., N. Schulz, et al. (2003). "Localization and regulation of the ATP6V0A4 (a4) vacuolar H+-ATPase subunit defective in an inherited form of distal renal tubular acidosis." J Am Soc Nephrol 14(12)- 3027-38.
29. Malkin I, Dahm S. Suk A Kobyliansky E. Toliat M. Ruf N. Livshits C.
Nurnberg P
Association of ANKH gene polymorphisms with radiographic hand bone size and geometry in a Chuvasha population. Bone. 2005 Feb;36(2).365-73 30 McMahon C, VVill A, Hu P, Shah GN, Sly WS, Smith OR Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome. Blood. 2001 Apr 1:97(7).1947-50.
31. Biskobing DM, Fan D. Acid pH increases carbonic anhydrase II and calcitonin receptor mRNA expression in mature osteoclasts. Calcif Tissue Int 2000 Aug:67(2).178-83.
32. Brage M, Abrahamson M. Lindstrom V, Grubb A, Lerner UH. Different cysteine proteinases involved in bone resorption and osteoclast formation. Calcif Tissue Int. 2005 Jun;76(6):439-47. Epub 2005 May 19.
Claims (21)
1. A siRNA or a shRNA that interferes with the expression of a polypeptide set forth in SEQ ID NO: 48 or a polypeptide encoded by SEQ ID NO: 1, for use in the treatment of bone remodeling or bone loss associated with osteoclast differentiation, or for modulating osteoclast differentiation.
2. A siRNA or a shRNA that interferes with the expression of a polypeptide set forth in SEQ ID NO: 82 or a polypeptide encoded by SEQ ID NO: 35, for use in the treatment of bone remodeling or bone loss associated with osteoclast differentiation, or for modulating osteoclast differentiation.
3. Use of a siRNA or a shRNA that interferes with the expression of a polypeptide set forth in SEQ ID NO: 48 or a polypeptide encoded by SEQ ID NO:1 in the manufacture of a medicament for modulating osteoclast differentiation, for the treatment of bone remodeling or bone loss associated with osteoclast differentiation.
4. Use of a siRNA or a shRNA that interferes with the expression of a polypeptide set forth in SEQ ID NO: 82 or a polypeptide encoded by SEQ ID NO: 35 in the manufacture of a medicament for modulating osteoclast differentiation, for the treatment of bone remodeling or bone loss associated with osteoclast differentiation.
5. An in vitro method for identifying an inhibitory compound able to impair the function of a polypeptide comprising SEQ ID NO: 48, the polypeptide encoded by SEQ
ID NO.:1, or an analog having at least 70% sequence identity with SEQ ID NO:
48, wherein said polypeptide or analog induces differentiation of osteoclasts, the method comprising contacting said polypeptide, analog or a cell expressing said polypeptide or analog with a candidate compound and measuring the function of said polypeptide or analog, whereby a reduction in the ability of the polypeptide or analog to promote osteoclast differentiation positively identifies a suitable inhibitory compound.
ID NO.:1, or an analog having at least 70% sequence identity with SEQ ID NO:
48, wherein said polypeptide or analog induces differentiation of osteoclasts, the method comprising contacting said polypeptide, analog or a cell expressing said polypeptide or analog with a candidate compound and measuring the function of said polypeptide or analog, whereby a reduction in the ability of the polypeptide or analog to promote osteoclast differentiation positively identifies a suitable inhibitory compound.
6. An in vitro method for identifying an inhibitory compound able to impair the function of a polypeptide comprising SEQ ID NO: 82, the polypeptide encoded by SEQ
ID NO.:35, or an analog having at least 70% sequence identity with SEQ ID NO:
82, wherein said polypeptide or analog induces differentiation of osteoclasts, the method comprising contacting said polypeptide, analog or a cell expressing said polypeptide or analog with a candidate compound and measuring the function of said polypeptide or analog, whereby a reduction in the ability of the polypeptide or analog to promote osteoclast differentiation positively identifies a suitable inhibitory compound.
ID NO.:35, or an analog having at least 70% sequence identity with SEQ ID NO:
82, wherein said polypeptide or analog induces differentiation of osteoclasts, the method comprising contacting said polypeptide, analog or a cell expressing said polypeptide or analog with a candidate compound and measuring the function of said polypeptide or analog, whereby a reduction in the ability of the polypeptide or analog to promote osteoclast differentiation positively identifies a suitable inhibitory compound.
7. An in vitro method for identifying an inhibitory compound able to impair the expression of a polypeptide consisting of SEQ ID NO: 48, the polypeptide encoded by SEQ ID NO: 1, or an analog having at least 70% sequence identity with SEQ ID
NO: 48, wherein said polypeptide or analog induces differentiation of osteoclasts, the method comprising contacting a candidate compound with a cell expressing said polypeptide or analog and measuring the expression of said polypeptide or analog, whereby a reduction in the expression of the polypeptide or analog positively identifies a suitable inhibitory compound.
NO: 48, wherein said polypeptide or analog induces differentiation of osteoclasts, the method comprising contacting a candidate compound with a cell expressing said polypeptide or analog and measuring the expression of said polypeptide or analog, whereby a reduction in the expression of the polypeptide or analog positively identifies a suitable inhibitory compound.
8. An in vitro method for identifying an inhibitory compound able to impair the expression of a polypeptide consisting of SEQ ID NO: 82, the polypeptide encoded by SEQ ID NO: 35, or an analog having at least 70% sequence identity with SEQ ID
NO:
82, wherein said polypeptide or analog induces differentiation of osteoclasts, the method comprising contacting a candidate compound with a cell expressing said polypeptide or analog and measuring the expression of said polypeptide or analog, whereby a reduction in the expression of the polypeptide or analog positively identifies a suitable inhibitory compound.
NO:
82, wherein said polypeptide or analog induces differentiation of osteoclasts, the method comprising contacting a candidate compound with a cell expressing said polypeptide or analog and measuring the expression of said polypeptide or analog, whereby a reduction in the expression of the polypeptide or analog positively identifies a suitable inhibitory compound.
9. An in vitro method for identifying a compound able to inhibit osteoclast differentiation, the method comprising providing to an osteoclast precursor cell a candidate compound able to bind to a polypeptide consisting of SEQ ID NO: 48, the polypeptide encoded by SEQ ID NO: 1, or an analog having at least 70% sequence identity with SEQ ID NO: 48, wherein said polypeptide or analog induces differentiation of osteoclasts, and measuring osteoclast differentiation, whereby a reduction in the ability of the polypeptide or analog to promote osteoclast differentiation positively identifies a suitable inhibitory compound.
10. An in vitro method for identifying a compound able to inhibit osteoclast differentiation, the method comprising providing to an osteoclast precursor cell a candidate compound able to bind to a polypeptide consisting of SEQ ID NO: 82, the polypeptide encoded by SEQ ID NO: 35, or an analog having at least 70%
sequence identity with SEQ ID NO: 82, wherein said polypeptide or analog induces differentiation of osteoclasts, and measuring osteoclast differentiation, whereby a reduction in the ability of the polypeptide or analog to promote osteoclast differentiation positively identifies a suitable inhibitory compound.
sequence identity with SEQ ID NO: 82, wherein said polypeptide or analog induces differentiation of osteoclasts, and measuring osteoclast differentiation, whereby a reduction in the ability of the polypeptide or analog to promote osteoclast differentiation positively identifies a suitable inhibitory compound.
11. The method of any one of claims 5 to 10, wherein the polypeptide has a sequence at least 80% identical to SEQ ID NO: 48 or to SEQ ID NO: 82.
12. The method of any one of claims 5 to 11, wherein the polypeptide has a sequence at least 90% identical to SEQ ID NO: 48 or to SEQ ID NO: 82.
13. The method of any one of claims 5 to 12, wherein the polypeptide has a sequence at least 95% identical to SEQ ID NO: 48 or to SEQ ID NO: 82.
14. The method of any one of claims 5 to 13, wherein the polypeptide has a sequence identical to SEQ ID NO: 48 or SEQ ID NO: 82.
15. The method of any one of claims 5 to 14, wherein said cell does not naturally express said polypeptide or wherein the expression of a naturally expressed polypeptide analog is repressed.
16. The method of any one of claims 7 to 8, or claims 11 to 15 as dependent on claims 7 to 8, wherein said candidate compound is a siRNA or a shRNA.
17. The method of any one of claims 5 to 8 or claims 11 to 15 as dependent on any one of claims 5 to 8, or claim 16, further comprising a step of inducing osteoclast differentiation when contacting said polypeptide, analog or cell with a candidate compound.
18. A pharmaceutical composition for modulating osteoclast differentiation comprising an isolated polypeptide set forth in SEQ ID NO: 48, a polypeptide analog thereof having at least 90% sequence identity with SEQ ID NO: 48, or a polypeptide encoded by SEQ ID NO: 1, and having an activity for modulating osteoclast differentiation, and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition for modulating osteoclast differentiation comprising an isolated polypeptide set forth in SEQ ID NO: 82, a polypeptide analog thereof having at least 70% sequence identity with SEQ ID NO: 82, or a polypeptide encoded by SEQ ID NO: 35, and having an activity of modulating osteoclast differentiation, and a pharmaceutically acceptable carrier.
20. Use of an isolated polypeptide set forth in SEQ ID NO: 48, a polypeptide analog thereof having at least 70% sequence identity with SEQ ID NO: 48, or a polypeptide encoded by SEQ ID NO: 1, and having an activity for modulating osteoclast differentiation in the preparation of a medicament for modulating osteoclast differentiation or for treating bone loss associated with osteoclast differentiation.
21. Use of an isolated polypeptide set forth in SEQ ID NO: 82, a polypeptide analog thereof having at least 70% sequence identity with SEQ ID NO: 82, or a polypeptide encoded by SEQ ID NO: 35, and having an activity of modulating osteoclast differentiation in the preparation of a medicament for modulating osteoclast differentiation or for treating bone loss associated with osteoclast differentiation.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77258506P | 2006-02-13 | 2006-02-13 | |
US60/772,585 | 2006-02-13 | ||
US81685806P | 2006-06-28 | 2006-06-28 | |
US60/816,858 | 2006-06-28 | ||
CA002638823A CA2638823A1 (en) | 2006-02-13 | 2007-02-13 | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002638823A Division CA2638823A1 (en) | 2006-02-13 | 2007-02-13 | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2785046A1 CA2785046A1 (en) | 2007-08-23 |
CA2785046C true CA2785046C (en) | 2019-07-30 |
Family
ID=46754790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2785046A Active CA2785046C (en) | 2006-02-13 | 2007-02-13 | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2785046C (en) |
-
2007
- 2007-02-13 CA CA2785046A patent/CA2785046C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2785046A1 (en) | 2007-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9695419B2 (en) | Polynucleotides and polypeptide sequences involved in the process of bone remodeling | |
US20100104575A1 (en) | Polynucleotides and polypeptide sequences involved in the process of bone remodeling | |
CA2655933A1 (en) | Polynucleotides and polypeptide sequences involved in cancer | |
US8444975B2 (en) | Method for inhibiting bone resorption | |
CA2785046C (en) | Polynucleotides and polypeptide sequences involved in the process of bone remodeling | |
AU2014200123B2 (en) | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |